FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Jackson, BR Talkington, DF Pruckler, JM Fouche, MDB Lafosse, E Nygren, B Gomez, GA Dahourou, GA Archer, WR Payne, AB Hooper, WC Tappero, JW Derado, G Magloire, R Gerner-Smidt, P Freeman, N Boncy, J Mintz, ED AF Jackson, Brendan R. Talkington, Deborah F. Pruckler, James M. Fouche, M. D. Bernadette Lafosse, Elsie Nygren, Benjamin Gomez, Gerardo A. Dahourou, Georges A. Archer, W. Roodly Payne, Amanda B. Hooper, W. Craig Tappero, Jordan W. Derado, Gordana Magloire, Roc Gerner-Smidt, Peter Freeman, Nicole Boncy, Jacques Mintz, Eric D. CA Cholera Serosurvey Working Grp TI Seroepidemiologic Survey of Epidemic Cholera in Haiti to Assess Spectrum of Illness and Risk Factors for Severe Disease SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID EL-TOR CHOLERA; VIBRIO-CHOLERAE; BLOOD-GROUP; NORTH AMERICANS; INFECTION; BANGLADESH; O1; RESPONSES; DURATION; INABA AB To assess the spectrum of illness from toxigenic Vibrio cholerae 01 and risk factors for severe cholera in Haiti, we conducted a cross-sectional survey in a rural commune with more than 21,000 residents. During March 22-April 6, 2011, we interviewed 2,622 residents >= 2 years of age and tested serum specimens from 2,527 (96%) participants for vibriocidal and antibodies against cholera toxin; 18% of participants reported a cholera diagnosis, 39% had vibriocidal titers >= 320, and 64% had vibriocidal titers >= 80, suggesting widespread infection. Among seropositive participants (vibriocidal titers >= 320), 74.5% reported no diarrhea and 9.0% had severe cholera (reported receiving intravenous fluids and overnight hospitalization). This high burden of severe cholera is likely explained by the lack of pre-existing immunity in this population, although the virulence of the atypical El Tor strain causing the epidemic and other factors might also play a role. C1 Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Foodborne Waterborne & Environm Dis, Hlth Syst Reconstruct Off, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA 30333 USA. [Jackson, Brendan R.; Talkington, Deborah F.; Pruckler, James M.; Nygren, Benjamin; Gomez, Gerardo A.; Dahourou, Georges A.; Archer, W. Roodly; Payne, Amanda B.; Hooper, W. Craig; Tappero, Jordan W.; Derado, Gordana; Gerner-Smidt, Peter; Mintz, Eric D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. Minist Sante Publ & Populat, Lab Natl Sante Publ, Direct Epidemiol Labs & Rech, Port Au Prince, Haiti. [Fouche, M. D. Bernadette] Univ Quisqueya, Port Au Prince, Haiti. [Lafosse, Elsie; Magloire, Roc; Freeman, Nicole; Boncy, Jacques] Minist Sante Publ & Populat, Port Au Prince, Haiti. Ctr Dis Control & Prevent, Haiti Off, Port Au Prince, Haiti. RP Jackson, BR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30333 USA. EM brjackson1@cdc.gov; dft1@cdc.gov; jmp3@cdc.gov; mdbfouche@yahoo.com; elsielafosse@yahoo.fr; ghz8@cdc.gov; goe4@cdc.gov; jrx0@cdc.gov; wea7@cdc.gov; bvx2@cdc.gov; woh1@cdc.gov; jwt0@cdc.gov; uwx8@cdc.gov; msppdelr@gmail.com; plg5@cdc.gov; nicolemfreeman@gmail.com; jboncy2001@yahoo.fr; edm1@cdc.gov NR 36 TC 12 Z9 12 U1 0 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 654 EP 664 DI 10.4269/ajtmh.13-0208 PG 11 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100009 PM 24106192 ER PT J AU Gelting, R Bliss, K Patrick, M Lockhart, G Handzel, T AF Gelting, Richard Bliss, Katherine Patrick, Molly Lockhart, Gabriella Handzel, Thomas TI Water, Sanitation and Hygiene in Haiti: Past, Present, and Future SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PUBLIC-HEALTH; INTERVENTIONS; MEXICO AB Haiti has the lowest rates of access to improved water and sanitation infrastructure in the western hemisphere. This situation was likely exacerbated by the earthquake in 2010 and also contributed to the rapid spread of the cholera epidemic that started later that same year. This report examines the history of the water, sanitation, and hygiene (WASH) sector in Haiti, considering some factors that have influenced WASH conditions in the country. We then discuss the situation sine the earthquake and subsequent cholera epidemic, and the responses to those events. Finally, drawing on Haiti's National Plan of Action for the Elimination of Cholera in Haiti 2013-2022,we suggest some actions that could help bring about long-term WASH improvements for the future. Because the current WASH situation has evolved over decades of limited attention and resources, it will take a long-term,sustained effort to improve the situation. C1 [Gelting, Richard; Lockhart, Gabriella] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Patrick, Molly; Handzel, Thomas] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30341 USA. [Bliss, Katherine] Ctr Strateg & Int Studies, Washington, DC 20006 USA. RP Gelting, R (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Highway,Mailstop F-58, Atlanta, GA 30341 USA. EM rgelting@cdc.gov; blisskatherine227@gmail.com; vej7@cdc.gov; gabi.vanschoyck@gmail.com; tnh7@cdc.gov NR 34 TC 6 Z9 6 U1 8 U2 44 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 665 EP 670 DI 10.4269/ajtmh.13-0217 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100010 PM 24106193 ER PT J AU Jones, RT Vetter, SM Gage, KL AF Jones, Ryan T. Vetter, Sara M. Gage, Kenneth L. TI Short Report: Exposing Laboratory-Reared Fleas to Soil and Wild Flea Feces Increases Transmission of Yersinia pestis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID EARLY-PHASE TRANSMISSION; BACTERIAL COMMUNITIES; PLAGUE EPIZOOTICS; VECTOR COMPETENCE; UNBLOCKED FLEAS; PRAIRIE DOGS; SIPHONAPTERA; CERATOPHYLLIDAE; EFFICIENCY; DYNAMICS AB Laboratory-reared Oropsylla montana were exposed to soil and wild-caught Oropsylla montana feces for 1 week. Fleas from these two treatments and a control group of laboratory-reared fleas were infected with Yersinia pestis, the etiological agent of plague. Fleas exposed to soil transmitted Y. pestis to mice at a significantly greater rate (50.0% of mice were infected) than control fleas (23.3% of mice were infected). Although the concentration of Y. pestis in fleas did not differ among treatments, the minimum transmission efficiency of fleas from the soil and wild flea feces treatments (6.9% and 7.6%, respectively) were more than three times higher than in control fleas (2.2%). Our results suggest that exposing laboratory-reared fleas to diverse microbes alters transmission of Y. pestis. C1 [Jones, Ryan T.; Vetter, Sara M.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Jones, RT (reprint author), POB 173120, Bozeman, MT 59717 USA. EM DrRyanJones@gmail.com NR 22 TC 2 Z9 2 U1 3 U2 13 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 784 EP 787 DI 10.4269/ajtmh.13-0138 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100027 PM 23939709 ER PT J AU Al Awaidy, ST Bawikar, SP Al Busaidy, SS Al Mahrouqi, S Al Baqlani, S Al Obaidani, I Alexander, J Patel, MK AF Al Awaidy, Salah Thabit Bawikar, Shyam Pandurang Al Busaidy, Suleiman Salim Al Mahrouqi, Salim Al Baqlani, Said Al Obaidani, Idris Alexander, James Patel, Minal K. TI Progress toward Elimination of Hepatitis B Virus Transmission in Oman: Impact of Hepatitis B Vaccination SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID INFECTION; CHINA AB Approximately 2-7% of the Omani population has chronic hepatitis B virus (HBV) infection. To decrease this burden, universal childhood hepatitis B vaccination was introduced in Oman in 1990. The hepatitis B vaccination strategy and reported coverage were reviewed. To assess the impact of the program on chronic HBV seroprevalence, a nationally representative seroprevalence study was conducted in Oman in 2005. Since 1991, hepatitis B vaccination in Oman has reached almost every eligible child, with reported coverage of >= 97% for the birth dose and >= 94% for three doses. Of 175 children born pre-vaccine introduction, 16 (9.1%) had evidence of HBV exposure, and 4 (2.3%) had evidence of chronic infection. Of 1,890 children born after vaccine introduction, 43 (2.3%) had evidence of HBV exposure, and 10 (0.5%) had evidence of chronic infection. Oman has a strong infant hepatitis B vaccination program, resulting in a dramatic decrease in chronic HBV seroprevalence. C1 Minist Hlth, Off HE Hlth Affairs, Muscat 113, Oman. Minist Hlth, Dept Communicable Dis Surveillance & Control, Directorate Gen Hlth Affairs, Muscat 113, Oman. Minist Hlth, Cent Publ Hlth Lab, Directorate Gen Hlth Affairs, Muscat 113, Oman. Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. RP Al Awaidy, ST (reprint author), Minist Hlth, Off HE Undersecretary Hlth Affairs, Post Box 393, Muscat 113, Oman. EM Salah.awaidy@gmail.com FU World Health Organization; Omani Ministry of Health FX Funding for this seroprevalence study was provided by the World Health Organization and the Omani Ministry of Health. NR 25 TC 4 Z9 4 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2013 VL 89 IS 4 BP 811 EP 815 DI 10.4269/ajtmh.13-0333 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240UB UT WOS:000326122100033 PM 23958910 ER PT J AU Navarro-i-Martinez, L da Silva, AJ Taboada, JL del Aguila, C Pieniazek, NJ Bornay-Llinares, FJ AF Navarro-i-Martinez, Luis da Silva, Alexandre J. Llovo Taboada, Jose del Aguila, Carmen Pieniazek, Norman J. Bornay-Llinares, Fernando J. TI Molecular characterization of Cryptosporidium spp. isolated in humans in two different locations in Spain SO ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA LA Spanish DT Article DE Cryptosporidium; C. hominis; C. parvum; C. meleagridis; Cryptosporidiosis; Diagnosis; Molecular characterization; Spain ID SP APICOMPLEXA CRYPTOSPORIDIIDAE; HIV-INFECTED PATIENTS; PCR-RFLP ANALYSIS; CHILDREN; CATTLE; MICE AB Molecular PCR based diagnostic techniques have enabled us to distinguish between the different, morphologically identical, Cryptosporidium species that can infect humans. Of the 23 recognized species in the genus, at least 9 are able to infect humans. As the intensity of the clinical manifestations, pathogenicity, excretion of oocysts, and incidence, are different between this species, molecular studies are crucial for a better understanding of the epidemiology of human cryptosporidiosis. Samples form two independent studies are analyzed in this publication. One included 23 samples from Madrid, and the other, 72 samples from La Coruna. All of them positive for Cryptosporidium spp. by microscopic methods and belonging to isolated cases of human cryptosporidiosis. For the identification of the species responsible for the infection, the 18S rDNA diagnostic region and the COWP gene diagnostic regions were used. Out of the 95 samples tested, in 77 cases we were able to extract and amplify DNA. In those cases the species responsible for the infection were: C parvum (40 cases, 2 Madrid and 38 La Coruna), C hominis (30 cases, 10 Madrid and 20 La Coruna) and C. meleagridis (2 cases, 1 Madrid and 1 La Coruna). In 5 samples it was impossible to detect the species responsible for the infection, but their positivity was confirmed by PCR (4 Madrid and 1 La Coruna). The genotypes of the isolates from patients correlated well with animals from the same regions. (C) 2012 Published by Elsevier Espana, S.L. C1 [Navarro-i-Martinez, Luis; Bornay-Llinares, Fernando J.] Univ Miguel Hernandez, Div Parasitol, Alicante, Spain. [da Silva, Alexandre J.; Pieniazek, Norman J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Llovo Taboada, Jose] Univ Santiago de Compostela CHUS, Complexo Hosp, Serv Microbiol & Parasitol, La Coruna, Spain. [del Aguila, Carmen] Univ San Pablo CEU, Dept Biol, Madrid, Spain. RP Navarro-i-Martinez, L (reprint author), Univ Miguel Hernandez, Div Parasitol, Alicante, Spain. EM Inavarro@umh.es RI del Aguila, Carmen/A-6063-2016 OI del Aguila, Carmen/0000-0003-0063-7899 NR 34 TC 3 Z9 3 U1 0 U2 2 PU EDICIONES DOYMA S A PI BARCELONA PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN SN 0213-005X EI 1578-1852 J9 ENFERM INFEC MICR CL JI Enferm. Infec. Microbiol. Clin. PD OCT PY 2013 VL 31 IS 8 BP 506 EP 510 DI 10.1016/j.eimc.2012.11.005 PG 5 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 244UR UT WOS:000326416200003 PM 23273661 ER PT J AU Harley, KG Gunier, RB Kogut, K Johnson, C Bradman, A Calafat, AM Eskenazi, B AF Harley, Kim G. Gunier, Robert B. Kogut, Katherine Johnson, Caroline Bradman, Asa Calafat, Antonia M. Eskenazi, Brenda TI Prenatal and early childhood bisphenol A concentrations and behavior in school-aged children SO ENVIRONMENTAL RESEARCH LA English DT Article DE Bisphenol A; Behavior; ADHD; Anxiety; Depression; Children ID ENDOCRINE ACTIVE COMPOUNDS; SEXUAL-DIFFERENTIATION; PERINATAL EXPOSURE; NEONATAL EXPOSURE; MICE; BRAIN; ANXIETY; WOMEN; RATS; HYPERACTIVITY AB Introduction: Early life exposure to bisphenol A (BPA), an endocrine disrupting chemical used in some food and beverage containers, receipts, and dental sealants, has been associated with anxiety and hyperactivity in animal studies. A few human studies also show prenatal and childhood BPA exposure to be associated with behavior problems in children. Methods: We measured BPA in urine from mothers during pregnancy and children at 5 years of age (N=292). Child behavior was assessed by mother and teacher report at age 7 years and direct assessment at age 9 years. Results: Prenatal urinary BPA concentrations were associated with increased internalizing problems in boys, including anxiety and depression, at age 7. No associations were seen with prenatal BPA concentrations and behaviors in girls. Childhood urinary BPA concentrations were associated with increased externalizing behaviors, including conduct problems, in girls at age 7 and increased internalizing behaviors and inattention and hyperactivity behaviors in boys and girls at age 7. Conclusions: This study adds to the existing literature showing associations of early life BPA exposure with behavior problems, including anxiety, depression, and hyperactivity in children. Additional information about timing of exposure and sex differences in effect is still needed. (C) 2013 Elsevier Inc. All rights reserved. C1 [Harley, Kim G.; Gunier, Robert B.; Kogut, Katherine; Johnson, Caroline; Bradman, Asa; Eskenazi, Brenda] Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, Berkeley, CA 94704 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30333 USA. RP Harley, KG (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, 1995 Univ Ave,Suite 265, Berkeley, CA 94704 USA. EM kharley@berkeley.edu OI Gunier, Robert/0000-0001-5485-9919 FU National Institute of Environmental Health Sciences [1RC2 ES018792, PO1 ES009605]; United States Environmental Protection Agency [R82670901, RD83171001, RD83451301] FX This work was supported by Grants 1RC2 ES018792 and PO1 ES009605 from the National Institute of Environmental Health Sciences and Grants R82670901, RD83171001, and RD83451301 from the United States Environmental Protection Agency. NR 45 TC 67 Z9 70 U1 3 U2 43 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2013 VL 126 BP 43 EP 50 DI 10.1016/j.envres.2013.06.004 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 240ZC UT WOS:000326135200006 PM 23870093 ER PT J AU Alshaarawy, O Zhu, MT Ducatman, A Conway, B Andrew, ME AF Alshaarawy, Omayma Zhu, Motao Ducatman, Alan Conway, Baqiyyah Andrew, Michael E. TI Polycyclic aromatic hydrocarbon biomarkers and serum markers of inflammation. A positive association that is more evident in men SO ENVIRONMENTAL RESEARCH LA English DT Article DE Polycyclic aromatic hydrocarbons; Inflammation; Serum C-reactive protein; Total white blood cell count; NHANES ID CARDIOVASCULAR-DISEASE; RISK-ASSESSMENT; EXPOSURE; COTININE; EXPRESSION; PREVENTION; INCREASES; SMOKING; CYP1A1; PAHS AB Background: Polycyclic aromatic hydrocarbons (PAHs) are potent atmospheric pollutants, occurring from anthropogenic and natural sources. Several animal studies have reported a positive association of PAHs with inflammation. However, it is not clear if lower background exposure to PAHs is associated with inflammation in humans, independent of smoking, a major source of PAHs. Methods: We examined participants from the National Health and Nutrition Examination Survey 20012002, 2003-2004, and 2005-2006. Our exposures of interest were eight urinary monohydroxy polycyclic aromatic hydrocarbon biomarkers. Our outcomes were serum markers of inflammation; C-reactive protein (CRP) (<= 10 mg/L) and total white blood cell (WBC) count (4000-12,000 cells/mu L). Results: Compared to participants with summed biomarkers of low-molecular weight (LMW) PAHs in the lowest quartile, the multivariable odds ratios (95% confidence interval) of high serum CRP (>= 3 mg/L) and high total WBC count (defined as at or above the 95 percentile of total WBC distribution) among participants in the highest exposure quartile were 1.77 (1.13, 2.76) and 1.34 (1.12, 1.60) respectively. Urinary 1-hydroxypyrene, the biomarker of the higher molecular weight pyrene, was positively associated with total WBC count, and to lesser extent with serum CRP. In subsequent analyses, the positive association between LMW PAHs and serum CRP and total WBC count was found to be present within the stratified subgroups, independent of smoking and other potential confounders. The positive association was more evident among adult males when compared to females. Conclusions: Urinary PAH biomarkers were found to be positively associated with serum CRP and total WBC count independent of smoking and other potential confounders. The association was more evident in men. (C) 2013 Elsevier Inc. All rights reserved. C1 [Alshaarawy, Omayma; Zhu, Motao; Conway, Baqiyyah] W Virginia Univ, Sch Publ Hlth, Dept Epidemiol, Morgantown, WV 26505 USA. [Ducatman, Alan] W Virginia Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Morgantown, WV 26505 USA. [Andrew, Michael E.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. RP Alshaarawy, O (reprint author), W Virginia Univ, Sch Publ Hlth, Dept Epidemiol, Robert C Byrd Hlth Sci Ctr, 1 Med Ctr Dr,POB 9190, Morgantown, WV 26505 USA. EM oalshaarawy@mix.wvu.edu FU Intramural CDC HHS [CC999999] NR 41 TC 16 Z9 16 U1 1 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2013 VL 126 BP 98 EP 104 DI 10.1016/j.envres.2013.07.006 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 240ZC UT WOS:000326135200013 PM 23972896 ER PT J AU Gray, SC Edwards, SE Miranda, ML AF Gray, Simone C. Edwards, Sharon E. Miranda, Marie Lynn TI Race, socioeconomic status, and air pollution exposure in North Carolina SO ENVIRONMENTAL RESEARCH LA English DT Article DE Air pollution; Data fusion; Environmental justice; Exposure predictions; Socioeconomic status ID LONG-TERM EXPOSURE; ENVIRONMENTAL JUSTICE; MYOCARDIAL-INFARCTION; UNITED-STATES; BIRTH-WEIGHT; MORTALITY; HEALTH; DISPARITIES; INEQUALITY; PREGNANCY AB Background: Although studies suggest that exposure to pollutants is associated with race/ethnicity and socio-economic status (SES), many studies are limited to the geographic regions where monitoring stations are located. Objectives: This study uses modeled predictive surfaces to examine the relationship between air pollution exposure, race/ethnicity, and measures of SES across the entire State of North Carolina. Methods: The daily predictions of particulate matter <2.5 mu m in aerodynamic diameter (PM2.5) and ozone (O-3) were determined using a spatial model that fused data from two sources: point air monitoring data and gridded numerical output. These daily predicted pollution levels for 2002 were linked with Census data. We examine the relationship between the census-tract level predicted concentration measures, SES, and racial composition. Results: SES and race/ethnicity were related to predicted concentrations of both PM2.5 and O-3 for census tracts in North Carolina. Lower SES and higher proportion minority population were associated with higher levels of PM2.5. An interquartile range (IQR) increase of median household income reduced the predicted average PM2.5 level by 0.10 mu g/m(3). The opposite relationship was true for O-3. An IQR increase of median household income increased the predicted average O-3 measure by 0.11 ppb. Conclusions: The analyses demonstrate that SES and race/ethnicity are related to predicted estimates of PM2.5 and O-3 for census tracts in North Carolina. These findings offer a baseline for future exposure modeling work involving SES and air pollution for the entire state and not just among the populations residing near monitoring networks. Published by Elsevier Inc. C1 [Gray, Simone C.; Edwards, Sharon E.; Miranda, Marie Lynn] Univ Michigan, Sch Nat Resources & Environm, Childrens Environm Hlth Initiat, Ann Arbor, MI 48109 USA. [Miranda, Marie Lynn] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA. RP Gray, SC (reprint author), Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, 1600 Clifton Rd NE,Mailstop E-48, Atlanta, GA 30333 USA. EM simonegray@cdc.gov; seedward@umich.edu; mlmirand@umich.edu FU US environmental Protection Agency [RD-83329301-0] FX This work was supported by funding from the US environmental Protection Agency (RD-83329301-0). NR 53 TC 17 Z9 17 U1 7 U2 30 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2013 VL 126 BP 152 EP 158 DI 10.1016/j.envres.2013.06.005 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 240ZC UT WOS:000326135200020 PM 23850144 ER PT J AU Silva, MJ Jia, T Samandar, E Preau, JL Calafat, AM AF Silva, Manori J. Jia, Tao Samandar, Ella Preau, James L., Jr. Calafat, Antonia M. TI Environmental exposure to the plasticizer 1,2-cyclohexane dicarboxylic acid, diisononyl ester (DINCH) in US adults (2000-2012) SO ENVIRONMENTAL RESEARCH LA English DT Article DE DINCH; Plasticizers; Phthalates; Exposure; Oxidative metabolites ID PHTHALATE METABOLITES; DI(ISONONYL)CYCLOHEXANE-1,2-DICARBOXYLATE DINCH; DI(2-ETHYLHEXYL) PHTHALATE; OXIDATIVE METABOLITES; HUMAN URINE; BIOMARKERS; CHEMICALS; QUANTIFICATION; HUMANS AB 1,2-Cyclohexane dicarboxylic acid, diisononyl ester (DINCH) is a complex mixture of nine carbon branched-chain isomers. It has been used in Europe since 2002 as a plasticizer to replace phthalates such as di(2-ethylhexyl)phthalate (DEHP) and diisononyl phthalate (DINP). Urinary concentrations of the oxidative metabolites of DINCH, namely cyclohexane-1,2-dicarboxylic acid-monocarboxy isooctyl ester (MCOCH); cyclohexane-1,2-dicarboxylic acid-mono(oxo-isononyl) ester (MONCH); and cyclohexane-1,2-dicarboxylic acid-mono(hydroxy-isononyl) ester (MHNCH), can potentially be used as DINCH exposure biomarkers. The concentrations of MCOCH, MONCH and MHNCH were measured by online solid phase extraction-high performance liquid chromatography-tandem mass spectrometry in urine collected in 2000 (n=114), 2001 (n=57), 2007 (n=23), 2009 (n=118), 2011 (n=94) and 2012 (n=121) from convenience groups of anonymous U.S. adult volunteers with no known DINCH exposure. None of the DINCH metabolites were detected in samples collected in 2000 and 2001. Only one sample collected in 2007 had measureable concentrations of DINCH metabolites. The detection rate for all three metabolites increased from 2007 to 2012. The presence of oxidative metabolites of DINCH in urine suggests that these oxidative metabolites can be used as DINCH biomarkers for exposure assessment even at environmental exposure levels. Published by Elsevier Inc. C1 [Silva, Manori J.; Jia, Tao; Samandar, Ella; Preau, James L., Jr.; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Silva, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM zca2@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 22 Z9 22 U1 2 U2 31 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD OCT PY 2013 VL 126 BP 159 EP 163 DI 10.1016/j.envres.2013.05.007 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 240ZC UT WOS:000326135200021 PM 23777640 ER PT J AU Oster, ME Riehle-Colarusso, T Simeone, RM Gurvitz, M Kaltman, JR McConnell, M Rosenthal, GL Honein, MA AF Oster, Matthew E. Riehle-Colarusso, Tiffany Simeone, Regina M. Gurvitz, Michelle Kaltman, Jonathan R. McConnell, Michael Rosenthal, Geoffrey L. Honein, Margaret A. TI Public Health Science Agenda for Congenital Heart Defects: Report From a Centers for Disease Control and Prevention Experts Meeting SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article ID PEDIATRIC CARDIAC-DISEASE; 2ND NATURAL-HISTORY; BALTIMORE-WASHINGTON INFANT; UNITED-STATES; SCIENTIFIC STATEMENT; BIRTH-DEFECTS; TASK-FORCE; CARDIOVASCULAR-DISEASE; CURRENT KNOWLEDGE; VALVAR STENOSIS C1 [Oster, Matthew E.; Riehle-Colarusso, Tiffany; Simeone, Regina M.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Oster, Matthew E.; McConnell, Michael] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA. [Simeone, Regina M.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37831 USA. [Gurvitz, Michelle] Harvard Univ, Sch Med, Boston Childrens Hosp, Cambridge, MA 02138 USA. [Kaltman, Jonathan R.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20824 USA. [Rosenthal, Geoffrey L.] Univ Maryland, Sch Med, Childrens Hosp, Baltimore, MD 21201 USA. RP Oster, ME (reprint author), Childrens Healthcare Atlanta, Div Pediat Cardiol, 1405 Clifton Rd NE, Atlanta, GA 30322 USA. EM osterm@kidsheart.com FU Centers for Disease Control and Prevention FX This work was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the Centers for Disease Control and Prevention. NR 56 TC 20 Z9 21 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2013 VL 2 IS 5 AR UNSP e000256 DI 10.1161/JAHA.113.000256 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 243UL UT WOS:000326343200031 PM 23985376 ER PT J AU Baeten, LA Pappert, R Young, J Schriefer, ME Gidlewski, T Kohler, D Bowen, RA AF Baeten, Laurie A. Pappert, Ryan Young, John Schriefer, Martin E. Gidlewski, Thomas Kohler, Dennis Bowen, Richard A. TI IMMUNOLOGICAL AND CLINICAL RESPONSE OF COYOTES (CANIS LATRANS) TO EXPERIMENTAL INOCULATION WITH YERSINIA PESTIS SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Canis latrans; coyote; plague; serology; Yersinia pestis ID EXPERIMENTAL-INFECTION; HUMAN PLAGUE; MAMMALIAN CARNIVORES; DOMESTIC-ANIMALS; BUBONIC PLAGUE; VECTOR; SEROPREVALENCE; EPIDEMIOLOGY; TRANSMISSION; EXPOSURE AB Multiple publications have reported the use of coyotes (Canis latrans) in animal-based surveillance efforts for the detection of Yersinia pestis. Coyotes are likely exposed via flea bite or oral routes and are presumed to be resistant to the development of clinical disease. These historic data have only been useful for the evaluation of the geographic distribution of Y. pestis in the landscape. Because the canid immunologic response to Y. pestis has not been thoroughly characterized, we conducted experimental inoculation of captive-reared, juvenile coyotes (n=8) with Y. pestis CO92 via oral or intradermal routes. We measured the humoral response to Y. pestis fraction 1 capsular protein (anti-F1) and found a significant difference between inoculation groups in magnitude and duration of antibody production. The anti-F1 titers in animals exposed intradermally peaked at day 10 postinoculation (PI; range=1:32 to 1:128) with titers remaining stable at 1:32 through week 12. In contrast, orally inoculated animals developed higher titers (range=1:256 to 1:1,024) that remained stable at 1:256 to 1:512 through week 6. No clinical signs of disease were observed, and minimal changes were noted in body temperature, white blood cell counts, and acute phase proteins during the 7 days PI. Gross pathology was unremarkable, and minimal changes were noted in histopathology at days 3 and 7 PI. Rechallenge at 14 wk PI via similar dosage and routes resulted in marked differences in antibody response between groups. Animals in the orally inoculated group produced a striking increase in anti-F1 titers (up to 1:4,096) within 3 days, whereas there was minimal to no increase in antibody response in the intradermal group. Information gathered from this experimental trial may provide additional insight into the spatial and temporal evaluation of coyote plague serology. C1 [Baeten, Laurie A.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Pappert, Ryan; Young, John; Schriefer, Martin E.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO 80521 USA. [Gidlewski, Thomas; Kohler, Dennis] US Anim & Plant Hlth Inspect Serv, Natl Wildlife Res Ctr, Wildlife Serv, USDA, Ft Collins, CO 80521 USA. [Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80521 USA. RP Baeten, LA (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, 1644 Campus Delivery, Ft Collins, CO 80523 USA. EM Laurie.Baeten@colostate.edu FU USDA-APHIS-WS-National Wildlife Disease Program; Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention and Biomedical Research Training Grant [T32 NRSA 7072-9]; USDA-APHIS-WS-NWRC-Predator Field Station FX We are grateful to Jeret Benson, Angela Bosco-Lauth, Paul Gordy, Elisa French, Ann Tolnay, and Natalie Cleton, who provided assistance with animal care; Nicole Marlenee for technical assistance; James zumBrunnen for the statistical analysis; Sarah Bevins for the graphics; Christopher Paddock for the immunohistochemistry; Terry Spraker for his histologic expertise; and two anonymous reviewers for their helpful edits. The procedures used in the housing, handling, and sampling of coyotes were approved by the Institutional Animal Care and Use Committee at Colorado State University (protocol 10-1751). Funding for this project was provided by USDA-APHIS-WS-National Wildlife Disease Program and Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention and Biomedical Research Training Grant (T32 NRSA 7072-9). The authors extend special thanks to the USDA-APHIS-WS-NWRC-Predator Field Station for providing training, support, and the captive-bred coyotes used in this study. The opinions and assertions made in this report are solely those of the authors and do not represent those of the CDC or USDA-APHIS. Use of trade or product names does not imply endorsement by the US government. NR 30 TC 3 Z9 3 U1 2 U2 11 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD OCT PY 2013 VL 49 IS 4 BP 932 EP 939 DI 10.7589/2013-02-040 PG 8 WC Veterinary Sciences SC Veterinary Sciences GA 241WM UT WOS:000326199400015 PM 24502720 ER PT J AU Barbour, KE Hootman, JM Helmick, CG Murphy, L Renner, JB Jordan, JM AF Barbour, Kamil E. Hootman, Jennifer M. Helmick, Charles G. Murphy, Louise Renner, Jordan B. Jordan, Joanne M. TI Bone Mineral Density and the Risk of Knee Osteoarthritis: The Johnston County Osteoarthritis Project SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Barbour, Kamil E.; Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Kennesaw, GA USA. [Murphy, Louise] CDC, Atlanta, GA 30333 USA. [Renner, Jordan B.] Univ N Carolina, Chapel Hill, NC USA. [Jordan, Joanne M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 246 BP S101 EP S101 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359201245 ER PT J AU Barbour, KE Lui, LY Helmick, CG Theis, KA Nevitt, MC Lane, NE Murphy, L Hootman, JM Hochberg, MC Cauley, JA AF Barbour, Kamil E. Lui, Li-Yung Helmick, Charles G. Theis, Kristina A. Nevitt, Michael C. Lane, Nancy E. Murphy, Louise Hootman, Jennifer M. Hochberg, Marc C. Cauley, Jane A. TI Hip Osteoarthritis and Risk Of All Cause and Disease-Specific Mortality Among Older Women: A Population-Based Cohort Study SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Barbour, Kamil E.; Helmick, Charles G.; Theis, Kristina A.; Murphy, Louise] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lui, Li-Yung] Calif Pacific Med Ctr, San Francisco, CA USA. [Nevitt, Michael C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lane, Nancy E.] UC Davis Sch Med, Sacramento, CA USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Kennesaw, GA USA. [Hochberg, Marc C.] Univ Maryland, Baltimore, MD 21201 USA. [Cauley, Jane A.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 95 BP S37 EP S37 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359201094 ER PT J AU Cisternas, M Murphy, L Pasta, D Yelin, EH Helmick, CG AF Cisternas, Miriam Murphy, Louise Pasta, David Yelin, Edward H. Helmick, Charles G. TI 2010 Medical Care Expenditures Among US Adults With Arthritis. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Cisternas, Miriam] MGC Data Serv, Carlsbad, CA USA. [Murphy, Louise] CDC, Atlanta, GA 30333 USA. [Pasta, David] DMA Corp, Palo Alto, CA USA. [Yelin, Edward H.] UC San Francisco, San Francisco, CA USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 2909 BP S1248 EP S1248 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359206336 ER PT J AU Cleveland, RJ Barbour, KE Renner, JB Jordan, JM Callahan, LF AF Cleveland, Rebecca J. Barbour, Kamil E. Renner, Jordan B. Jordan, Joanne M. Callahan, Leigh F. TI Individuals With Knee Or Hip OA and Low SES Are Likely To Be Physically Active SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Cleveland, Rebecca J.; Renner, Jordan B.; Callahan, Leigh F.] Univ N Carolina, Chapel Hill, NC USA. [Barbour, Kamil E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jordan, Joanne M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1076 BP S459 EP S459 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203062 ER PT J AU Ferucci, ED Johnston, J Gaddy, J Sumner, L Posever, J Choromanski, TL Gordon, C Lim, SS Helmick, CG AF Ferucci, Elizabeth D. Johnston, Janet Gaddy, Jasmine Sumner, Lisa Posever, James Choromanski, Tammy L. Gordon, Caroline Lim, S. Sam Helmick, Charles G. TI Prevalence and Incidence of Systemic Lupus Erythematosus in a Population-Based Registry of American Indian and Alaska Native People in the United States, 2007-2009 SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Ferucci, Elizabeth D.; Choromanski, Tammy L.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Johnston, Janet] Univ Alaska Anchorage, Anchorage, AK USA. [Gaddy, Jasmine] Oklahoma City Area Indian Hlth Serv, Oklahoma City, OK USA. [Sumner, Lisa; Posever, James] Phoenix Indian Med Ctr, Phoenix, AZ USA. [Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England. [Lim, S. Sam] Emory Univ, Atlanta, GA 30322 USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1696 BP S718 EP S719 PG 2 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359204158 ER PT J AU Hootman, JM Helmick, CG Golightly, YM AF Hootman, Jennifer M. Helmick, Charles G. Golightly, Yvonne M. TI Trends In Prevalence Of Knee Pain Among US Adults, National Health Interview Survey 2002-2010 SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Kennesaw, GA USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Golightly, Yvonne M.] Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 1078 BP S460 EP S460 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359203065 ER PT J AU Theis, KA Murphy, L AF Theis, Kristina A. Murphy, Louise TI Sex-Specific Employment Participation Restriction Across Occupational Groups Among Working-Age (18-64 years) US Adults With and Without Arthritis SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT 77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals CY OCT 25-30, 2013 CL San Diego, CA SP Amer Coll Rheumatol, Assoc Rheumatol Hlth Profess C1 [Theis, Kristina A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Murphy, Louise] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2013 VL 65 SU 10 SI SI MA 898 BP S386 EP S386 PG 1 WC Rheumatology SC Rheumatology GA 230RF UT WOS:000325359202403 ER PT J AU Silva, MJ Samandar, E Ye, XY Calafat, AM AF Silva, Manori J. Samandar, Ella Ye, Xiaoyun Calafat, Antonia M. TI In Vitro Metabolites of Di-2-ethylhexyl Adipate (DEHA) as Biomarkers of Exposure in Human Biomonitoring Applications SO CHEMICAL RESEARCH IN TOXICOLOGY LA English DT Article ID HUMAN URINE; DI(2-ETHYLHEXYL)PHTHALATE DEHP; PHTHALATE; QUANTIFICATION; MIGRATION; RATS AB Di-2-ethylhexyl adipate (DEHA) is a common plasticizer used in food packaging. At high doses, DEHA can cause adverse health effects in rats. Although the potential for human exposure to DEHA is high, no DEHA specific biomarkers are identified for human biomonitoring. Using human liver microsomes, we investigated the in vitro phase I metabolism of DEHA and its hydrolytic metabolite mono-2-ethylhexyl adipate (MEHA) and, for comparison purposes, of the analogous di-2-ethylhexyl phthalate (DEHP) and its hydrolytic metabolite mono-2-ethylhexyl phthalate. We unequivocally identified MEHA, a DEHA specific biomarker, and adipic acid, a nonspecific biomarker, using authentic standards. On the basis of their mass spectrometric fragmentation patterns, we tentatively identified two other DEHA specific metabolites: mono-2-ethylhydroxyhexyl adipate (MEHHA) and mono-2-ethyloxohexyl adipate (MEOHA), analogous to the oxidative metabolites of DEHP. Interestingly, although adipic acid was the major in vitro metabolite of DEHA, the analogous phthalic add was not the major in vitro metabolite of DEHP. Our preliminary data for 144 adults with no known exposure to DEHA suggests that adipic acid is also the main in vivo urinary metabolite, while MEHA, MEHHA, and MEOHA are only minor metabolites. Therefore, the use of these specific metabolites for assessing the exposure of DEHA may be limited to highly exposed populations. C1 [Silva, Manori J.; Samandar, Ella; Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Silva, MJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM zca2@cdc.gov FU Centers for Disease Control and Prevention, U.S. Department of Health and Human Services FX This work was supported by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. NR 19 TC 3 Z9 3 U1 7 U2 24 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0893-228X EI 1520-5010 J9 CHEM RES TOXICOL JI Chem. Res. Toxicol. PD OCT PY 2013 VL 26 IS 10 BP 1498 EP 1502 DI 10.1021/tx400215z PG 5 WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology SC Pharmacology & Pharmacy; Chemistry; Toxicology GA 239ZB UT WOS:000326063400009 PM 24016063 ER PT J AU Parola, P Paddock, CD Socolovschi, C Labruna, MB Mediannikov, O Kernif, T Abdad, MY Stenos, J Bitam, I Fournier, PE Raoult, D AF Parola, Philippe Paddock, Christopher D. Socolovschi, Cristina Labruna, Marcelo B. Mediannikov, Oleg Kernif, Tahar Abdad, Mohammad Yazid Stenos, John Bitam, Idir Fournier, Pierre-Edouard Raoult, Didier TI Update on Tick-Borne Rickettsioses around the World: a Geographic Approach SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review ID SPOTTED-FEVER GROUP; RHIPICEPHALUS-SANGUINEUS TICKS; AMBLYOMMA-AMERICANUM ACARI; GULF-COAST TICKS; REAL-TIME PCR; POLYMERASE-CHAIN-REACTION; IXODES-RICINUS TICKS; LONE STAR TICK; CAPYBARAS HYDROCHOERUS-HYDROCHAERIS; SIBIRICA SUBSP MONGOLITIMONAE AB Tick-borne rickettsioses are caused by obligate intracellular bacteria belonging to the spotted fever group of the genus Rickettsia. These zoonoses are among the oldest known vector-borne diseases. However, in the past 25 years, the scope and importance of the recognized tick-associated rickettsial pathogens have increased dramatically, making this complex of diseases an ideal paradigm for the understanding of emerging and reemerging infections. Several species of tick-borne rickettsiae that were considered nonpathogenic for decades are now associated with human infections, and novel Rickettsia species of undetermined pathogenicity continue to be detected in or isolated from ticks around the world. This remarkable expansion of information has been driven largely by the use of molecular techniques that have facilitated the identification of novel and previously recognized rickettsiae in ticks. New approaches, such as swabbing of eschars to obtain material to be tested by PCR, have emerged in recent years and have played a role in describing emerging tick-borne rickettsioses. Here, we present the current knowledge on tick-borne rickettsiae and rickettsioses using a geographic approach toward the epidemiology of these diseases. C1 [Parola, Philippe; Socolovschi, Cristina; Mediannikov, Oleg; Fournier, Pierre-Edouard; Raoult, Didier] Aix Marseille Univ, Unite Rech Malad Infect & Trop Emergentes, UM63,CNRS 7278,IRD 198,Inserm 1095,Fac Med, WHO Collaborat Ctr Rickettsioses & Other Arthropo, Marseille, France. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Labruna, Marcelo B.] Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Med Vet Prevent & Saude Anim, Sao Paulo, Brazil. [Kernif, Tahar] Inst Pasteur, Serv Ecol Syst Vectoriels, Algiers, Algeria. [Abdad, Mohammad Yazid; Stenos, John] Murdoch Univ, Australian Rickettsial Reference Lab, Div Vet & Biomed Sci, Barwon Hlth, Geelong, Vic, Australia. [Bitam, Idir] Univ Boumerdes, Boumerdes, Algeria. RP Parola, P (reprint author), Aix Marseille Univ, Unite Rech Malad Infect & Trop Emergentes, UM63,CNRS 7278,IRD 198,Inserm 1095,Fac Med, WHO Collaborat Ctr Rickettsioses & Other Arthropo, Marseille, France. EM philippe.parola@univ-amu.fr RI Mediannikov, Oleg/H-4018-2015 OI Mediannikov, Oleg/0000-0001-6039-2008 NR 481 TC 199 Z9 207 U1 5 U2 49 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0893-8512 EI 1098-6618 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD OCT PY 2013 VL 26 IS 4 BP 657 EP 702 DI 10.1128/CMR.00032-13 PG 46 WC Microbiology SC Microbiology GA 229NF UT WOS:000325272500001 PM 24092850 ER PT J AU Li, W Liu, CW Yu, YQ Li, JH Gong, PT Song, MX Xiao, LH Zhang, XC AF Li, Wei Liu, Chengwu Yu, Yuqiang Li, Jianhua Gong, Pengtao Song, Mingxin Xiao, Lihua Zhang, Xichen TI Molecular characterization of Giardia duodenalis isolates from police and farm dogs in China SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Giardia duodenalis; Dog; Triosephosphate isomerase; Genotyping; Subtyping ID ZOONOTIC TRANSMISSION; FECAL SAMPLES; WATERBORNE TRANSMISSION; PROTOZOAN PARASITES; CRYPTOSPORIDIUM; GENOTYPES; CATS; PREVALENCE; ANIMALS; HUMANS AB To assess the potential zoonotic transmission of giardiasis from dogs in China, a total of 205 fecal specimens from dogs were screened for Giardia duodenalis using PCR and sequence analysis of the triosephosphate isomerase gene. The prevalence of G. duodenalis in dogs was 13.2% (27/205). The potentially zoonotic assemblage A and the dog-specific assemblage C was identified in 25 (12.2%) and two (1.0%) dogs, respectively. All assemblage A isolates belonged to sub-assemblage AI, genotype Al-1. Likewise, one subtype was found in assemblage C. The high occurrence of potentially zoonotic G. duodenalis subtype AI-1 in dogs that are in close contact with humans is of public health concern. Published by Elsevier Inc. C1 [Li, Wei; Song, Mingxin] Northeast Agr Univ, Coll Vet Med, Harbin 150030, Peoples R China. [Li, Wei; Yu, Yuqiang; Li, Jianhua; Gong, Pengtao; Zhang, Xichen] Jilin Univ, Coll Anim Sci & Vet Med, Changchun 130062, Peoples R China. [Liu, Chengwu] Shenyang Police Dog Tech Coll, Shenyang 110034, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Xiao, LH (reprint author), Northeast Agr Univ, Coll Vet Med, 59 Mucai St, Harbin 150030, Peoples R China. EM lxiao@cdc.gov; zhangxic@public.cc.jl.cn RI Xiao, Lihua/B-1704-2013; OI Xiao, Lihua/0000-0001-8532-2727; Li, Wei/0000-0002-4264-1864 FU Major Program of Preventive and Control for National Severe Infective Diseases [2008ZX10004-001]; Northeast Agricultural University [2012RCA01] FX This work was supported by Major Program of Preventive and Control for National Severe Infective Diseases (No. 2008ZX10004-001) and funds from Northeast Agricultural University (No. 2012RCA01). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 38 TC 8 Z9 8 U1 2 U2 16 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 EI 1090-2449 J9 EXP PARASITOL JI Exp. Parasitol. PD OCT PY 2013 VL 135 IS 2 BP 223 EP 226 DI 10.1016/j.exppara.2013.07.009 PG 4 WC Parasitology SC Parasitology GA 239XA UT WOS:000326058100006 PM 23891941 ER PT J AU Gurley, ES Homaira, N Salje, H Ram, PK Haque, R Petri, W Bresee, J Moss, WJ Breysse, P Luby, SP Azziz-Baumgartner, E AF Gurley, E. S. Homaira, N. Salje, H. Ram, P. K. Haque, R. Petri, W. Bresee, J. Moss, W. J. Breysse, P. Luby, S. P. Azziz-Baumgartner, E. TI Indoor exposure to particulate matter and the incidence of acute lower respiratory infections among children: A birth cohort study in urban Bangladesh SO INDOOR AIR LA English DT Article DE Respiratory infection; Particulate matter; Indoor air pollution; Incidence; Bangladesh ID AIR-POLLUTION; DEVELOPING-COUNTRIES; CHILDHOOD PNEUMONIA; RURAL BANGLADESH; TRACT DISEASE; RISK-FACTORS; MORTALITY; INFANTS; HEALTH; METAANALYSIS AB Abstract Approximately half of all children under two years of age in Bangladesh suffer from an acute lower respiratory infection (ALRI) each year. Exposure to indoor biomass smoke has been consistently associated with an increased risk of ALRI in young children. Our aim was to estimate the effect of indoor exposure to particulate matter (PM2.5) on the incidence of ALRI among children in a low-income, urban community in Bangladesh. We followed 257 children through two years of age to determine their frequency of ALRI and measured the PM2.5 concentrations in their sleeping space. Poisson regression was used to estimate the association between ALRI and the number of hours per day that PM2.5 concentrations exceeded 100 mu g/m(3), adjusting for known confounders. Each hour that PM2.5 concentrations exceeded 100 mu g/m(3) was associated with a 7% increase in incidence of ALRI among children aged 0-11 months (adjusted incidence rate ratio (IRR) 1.07, 95% CI 1.01-1.14), but not in children 12-23 months old (adjusted IRR 1.00, 95% CI 0.92-1.09). Results from this study suggest that reducing indoor PM2.5 exposure could decrease the frequency of ALRI among infants, the children at highest risk of death from these infections. C1 [Gurley, E. S.; Homaira, N.; Haque, R.; Luby, S. P.; Azziz-Baumgartner, E.] Icddr B, Dhaka 1212, Bangladesh. [Gurley, E. S.; Salje, H.; Moss, W. J.; Breysse, P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Ram, P. K.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Petri, W.] Univ Virginia, Charlottesville, VA USA. [Bresee, J.; Luby, S. P.; Azziz-Baumgartner, E.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Gurley, ES (reprint author), Icddr B, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh. EM egurley@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X; Salje, Henrik/0000-0003-3626-4254 FU United States Centers for Disease Control and Prevention (CDC) [U01/CI000628-02]; National Institutes of Health, USA (NIH) [5R01 AI043596] FX This study was funded by the United States Centers for Disease Control and Prevention (CDC), grant number U01/CI000628-02 and the National Institutes of Health, USA (NIH), grant number 5R01 AI043596. icddr,b acknowledges with gratitude the commitment of CDC and NIH to its research efforts. The authors wish to thank the children and their families for their participation in this cohort. We appreciate the efforts of study clinic staff and field workers, and the statistical assistance of Jaynal Abedin and Yushuf Sharker. NR 33 TC 25 Z9 25 U1 2 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0905-6947 EI 1600-0668 J9 INDOOR AIR JI Indoor Air PD OCT PY 2013 VL 23 IS 5 BP 379 EP 386 DI 10.1111/ina.12038 PG 8 WC Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health SC Construction & Building Technology; Engineering; Public, Environmental & Occupational Health GA 217TX UT WOS:000324385600004 PM 23906055 ER PT J AU Feng, LB Pines, JM Yusuf, HR Grosse, SD AF Feng, Lisa B. Pines, Jesse M. Yusuf, Hussain R. Grosse, Scott D. TI US Trends in Computed Tomography Use and Diagnoses in Emergency Department Visits by Patients With Symptoms Suggestive of Pulmonary Embolism, 2001-2009 SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID UTILIZATION PATTERNS; RADIATION-EXPOSURE; ANGIOGRAPHY; CT; MULTICENTER; YIELD AB ObjectivesUsing computed tomography (CT) to evaluate patients with chest symptoms is common in emergency departments (EDs). This article describes recent trends of CT use in U.S. EDs for patients presenting with symptoms common to acute pulmonary embolism (PE). MethodsThe 2001-2009 National Hospital Ambulatory Medical Care Survey (NHAMCS), a nationally representative survey of U.S. ED encounters, was used for data collection. Patients with at least one of three complaints (chest pain, dyspnea, or hemoptysis) were categorized into the chest symptom study (CSS) group. The yearly increases in CT use for the complaints were tabulated first, then linear regression analysis was used to calculate average rates of increases in CT use between 2001 and 2007, theyears where CT use increased, for the overall population and among specific subgroups. The ratios of the number of visits when CT was ordered and there was a target diagnosis relative to the total number of visits with CT in the CSS group (diagnosis/CT ratio) were calculated for PE and pneumonia. ResultsAnnual CT rates for the CSS group increased from 2.6% in 2001 to 13.2% in 2007, subsequently leveling off at approximately 12.5% in 2008 and 2009. The average growth rate of CT use for the CSS group was 28.1% (95% confidence interval [CI]=20.9% to 35.7%) per year between 2001 and 2007. Testing rates for all subgroups increased. The lowest growth rate was among Hispanic patients, whose CT rates grew 14.2% (95% CI=5.7% to 23.5%) per year. The highest growth rate was in nonurban hospitals, at 43.1% (95% CI=15.2% to 77.8%) per year. Patients triaged as nonurgent received the fewest CTs, compared to those who should be seen in 2hours or less. With regard to sources of payment, the self-pay subgroup experienced the highest rate of increase at 35.1% (95% CI=18.6% to 53.9%). The PE diagnosis/CT ratio from 2002 to 2009 was 2.7% for the CSS group. The pneumonia diagnosis/CT ratio grew from 5.8% in 2002 to 2005 to 7.8% in 2006 to 2009. ConclusionsComputed tomography use in ED visits by patients with chest symptoms increased dramatically from 2001 to 2007 and seems to have leveled off in subsequentyears. The low PE diagnosis-to-CT ratio suggests that EDs may need to promote evidence-based use of CT. C1 [Feng, Lisa B.] Amer Inst Res, Washington, DC USA. [Pines, Jesse M.] George Washington Univ, Dept Emergency Med, Washington, DC USA. [Yusuf, Hussain R.; Grosse, Scott D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Feng, LB (reprint author), Amer Inst Res, Washington, DC USA. EM lfeng@air.org FU Intramural CDC HHS [CC999999] NR 33 TC 15 Z9 15 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD OCT PY 2013 VL 20 IS 10 BP 1033 EP 1040 DI 10.1111/acem.12221 PG 8 WC Emergency Medicine SC Emergency Medicine GA 239KX UT WOS:000326023700009 PM 24127707 ER PT J AU Gunn, JP Barron, JL Bowman, BA Merritt, RK Cogswell, ME Angell, SY Bauer, UE Frieden, TR AF Gunn, Janelle P. Barron, Jessica L. Bowman, Barbara A. Merritt, Robert K. Cogswell, Mary E. Angell, Sonia Y. Bauer, Ursula E. Frieden, Thomas R. TI Sodium Reduction Is a Public Health Priority: Reflections on the Institute of Medicine's Report, Sodium Intake in Populations: Assessment of Evidence SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Review ID BLOOD-PRESSURE; DIETARY-SODIUM; UNITED-STATES; DASH DIET; HYPERTENSION; EXCRETION C1 [Gunn, Janelle P.; Bowman, Barbara A.; Merritt, Robert K.; Cogswell, Mary E.; Bauer, Ursula E.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Barron, Jessica L.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Oak Ridge Inst Sci & Educ Fellow, Atlanta, GA USA. [Angell, Sonia Y.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Frieden, Thomas R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Gunn, JP (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM bfy2@cdc.gov NR 19 TC 16 Z9 16 U1 4 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 EI 1941-7225 J9 AM J HYPERTENS JI Am. J. Hypertens. PD OCT PY 2013 VL 26 IS 10 BP 1178 EP 1180 DI 10.1093/ajh/hpt143 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 239TF UT WOS:000326047700002 PM 24042543 ER PT J AU Brophy, JT Keith, MM Park, R Watterson, A Gilbertson, M DeMatteo, R AF Brophy, James T. Keith, Margaret M. Park, Robert Watterson, Andrew Gilbertson, Michael DeMatteo, Robert TI Breast cancer and the environment: why research and preventive action are needed SO CURRENT ONCOLOGY LA English DT Letter ID EXPOSURE; RISK C1 [Brophy, James T.; Watterson, Andrew] Univ Stirling, Occupat & Environm Hlth Res Grp, Ctr Publ Hlth & Populat Hlth Res, Stirling FK9 4LA, Scotland. [Brophy, James T.; Keith, Margaret M.] Univ Windsor, Dept Sociol Anthropol & Criminol, Tecumseh, ON, Canada. [Park, Robert] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Gilbertson, Michael] Univ Stirling, Guelph, ON, Canada. [DeMatteo, Robert] Occupat Hlth Clin Ontario Workers, Campbellcroft, ON, Canada. RP Brophy, JT (reprint author), Univ Stirling, Occupat & Environm Hlth Res Grp, Ctr Publ Hlth & Populat Hlth Res, Stirling FK9 4LA, Scotland. EM jimbrophy@yahoo.com; margkeith@yahoo.com; rhp9@cdc.gov; aew1@stir.ac.uk; michael.gilbertson23@gmail.com; dematteoca@yahoo.ca NR 8 TC 0 Z9 0 U1 0 U2 6 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1198-0052 J9 CURR ONCOL JI Curr. Oncol. PD OCT PY 2013 VL 20 IS 5 BP E488 EP E490 DI 10.3747/co.20.1681 PG 3 WC Oncology SC Oncology GA 237KP UT WOS:000325868900013 PM 24155646 ER PT J AU Hirsch-Moverman, Y Wall, K Weinfurter, P Munk, E Moran, JA Maiuri, A Khan, A DeLuca, N AF Hirsch-Moverman, Yael Wall, Kirsten Weinfurter, Paul Munk, Elizabeth Moran, Joyce Ann Maiuri, Allison Khan, Amera DeLuca, Nichlas CA TB Epidemiologic Studies Consortiu TI Acceptability of interferon-gamma release assays among healthcare workers who receive routine employee tuberculosis testing SO INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Healthcare worker TB screening; Interferon-gamma release assays; QuantiFERON; T-Spot; TB testing; Tuberculosis ID LATENT TUBERCULOSIS; INFECTION; PHYSICIANS; RECOMMENDATIONS; DIAGNOSIS AB Background: Healthcare workers (HCWs) undergo annual testing for latent tuberculosis infection (LTBI). Objective: Compare acceptability of tuberculin skin test (TST) and interferon-gamma release assay (IGRA) among HCWs. Methods: HCWs at four medical centers in the US were administered an acceptability questionnaire including a brief objective description of both tests and eliciting attitudes regarding TST and IGRAs, confidence in results, and likelihood of taking LTBI treatment. Results: Of 406 participants, 75% had never heard of IGRAs. IGRAs were preferred to TST. Belief in accuracy of hypothetical positive results of TST or IGRA and willingness to accept LTBI treatment were similar across tests. When presented with hypothetical discordant results, HCWs expressed more confidence in IGRAs. Perceived accuracy of results was the most important factor in test preferences. Conclusions: Although HCWs preferred and indicated more confidence in IGRAs, the likelihood that HCWs would believe LTBI diagnosis and initiate treatment based on positive results was similar for TST and IGRAs. C1 [Hirsch-Moverman, Yael; Moran, Joyce Ann] Columbia Univ, Mailman Sch Publ Hlth, ICAP, Charles P Felton Natl TB Ctr, New York, NY 10027 USA. [Wall, Kirsten] Denver Publ Hlth & Hosp Author, Denver, CO USA. [Weinfurter, Paul] WESTAT Corp, Rockville, MD 20850 USA. [Munk, Elizabeth] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Maiuri, Allison; Khan, Amera; DeLuca, Nichlas] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hirsch-Moverman, Y (reprint author), Columbia Univ, Mailman Sch Publ Hlth, ICAP, Charles P Felton Natl TB Ctr, 215 W 125th St,1st Fl, New York, NY 10027 USA. EM yh154@columbia.edu FU CDC TBESC FX This study was supported by contracts from the CDC TBESC to the study sites. NR 17 TC 2 Z9 2 U1 0 U2 3 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1077-3525 EI 2049-3967 J9 INT J OCCUP ENV HEAL JI Int. J. Occup. Environ. Health PD OCT PY 2013 VL 19 IS 4 BP 319 EP 324 DI 10.1179/2049396713Y.0000000038 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 235XK UT WOS:000325755700007 PM 24588038 ER PT J AU Dollard, SC Roback, JD Gunthel, C Amin, MM Barclay, S Patrick, E Kuehnert, MJ AF Dollard, Sheila C. Roback, John D. Gunthel, Clifford Amin, Minal M. Barclay, Sheilagh Patrick, Ericka Kuehnert, Matthew J. TI Measurements of human herpesvirus 8 viral load in blood before and after leukoreduction filtration SO TRANSFUSION LA English DT Article ID KAPOSIS-SARCOMA; MONONUCLEAR-CELLS; DONORS; SEROPREVALENCE; TRANSMISSION; TRANSFUSION; DNA; PCR AB BackgroundHuman herpesvirus 8 (HHV-8) is likely transmitted through blood transfusion in high-prevalence areas. The efficacy of leukoreduction filtration for reducing HHV-8 in blood has not been reported. Study Design and MethodsBlood was drawn from 45 human immunodeficiency virus-positive men either with Kaposi's sarcoma (KS; n=21) or without KS (n=24) and subject to leukoreduction filtration. HHV-8 viral load was measured in plasma and in blood before and after filtration. ResultsTwelve subjects, all with KS, had detectable HHV-8 viremia before filtration with viral loads of 10(2) to 10(5) copies/mL (mean, 3x10(4) copies/mL). After filtration, seven of 12 subjects no longer had detectable HHV-8 in their blood, and five of 12 subjects had detectable HHV-8 that was 90% reduced on average from prefiltration levels. The presence of HHV-8 in the blood after filtration was strongly associated with prefiltration viral loads greater than 1000 copies/mL and the presence of cell-free virus in plasma. None of the subjects without KS had detectable levels of HHV-8 virus in blood before or after filtration. ConclusionCell-associated HHV-8 appeared to be effectively removed by leukoreduction filtration. Cell-free HHV-8 was present in 42% of subjects as 1% to 20% of the total virus which was not removed by filtration. C1 Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. Emory Univ, Sch Med, Dept Pathol & Lab Med, Ctr Transfus & Cellular Therapies, Atlanta, GA 30322 USA. Emory Univ, Sch Med, HIV AIDS Clin Trials Unit, Atlanta, GA USA. RP Dollard, SC (reprint author), 1600 Clifton Rd NE,Mailstop G18, Atlanta, GA 30333 USA. EM sdollard@cdc.gov FU Centers for Disease Control and Prevention FX This study was funded by the Centers for Disease Control and Prevention. NR 11 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2013 VL 53 IS 10 BP 2164 EP 2167 DI 10.1111/trf.12108 PG 4 WC Hematology SC Hematology GA 230WP UT WOS:000325374300013 PM 23362994 ER PT J AU Keil, SD Kiser, P Sullivan, JJ Kong, AS Reddy, HL Avery, A Goodrich, RP AF Keil, Shawn D. Kiser, Patti Sullivan, James J. Kong, Amy S. Reddy, Heather L. Avery, Anne Goodrich, Raymond P. TI Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light SO TRANSFUSION LA English DT Article ID TRANSFUSION-TRANSMITTED MALARIA; PATHOGEN INACTIVATION; BLOOD-DONORS; TRANSMISSION; REDUCTION; INFECTION; SELECTION; PARASITES; SYSTEM; RETURN AB BackgroundPhotochemical treatment of blood products could help prevent transfusion-transmitted malaria and reduce the need for donor deferrals. In this study we evaluated the effectiveness of riboflavin and ultraviolet (UV) light against both Plasmodium falciparum, which causes the most severe form of human malaria, and Plasmodium yoelii, an in vivo murine model for malaria. Study Design and MethodsPlasma and platelet (PLT) concentrates were inoculated with either P.falciparum- or P.yoelii-infected red blood cells (RBCs). Aliquots from each unit were collected after inoculation, after addition of riboflavin, and after treatment. In vitro P.falciparum growth was assessed using thin blood films of duplicate samples at 24, 48, 72, and 96 hours. P.yoelii parasitemia was followed in mice for 14 days postinoculation. ResultsIn the in vitro studies, the mean P.falciparum parasitemia increased 12- to 19-fold in pretreatment samples, both before and after addition of riboflavin, after 96-hour culture. Few parasites were observed in Mirasol-treated units at 24 hours; those that were observed were degenerating. Through the remainder of the 96-hour culture period, cultures of treated samples were negative. In the in vivo study, mouse plasma containing P.yoelii-infected RBCs had a mean starting titer of 4.6 log mouse infectious dose 50%/mL. No infectious parasite was detected in treated samples. ConclusionTreatment with riboflavin and UV light was effective at reducing viable P.falciparum in both PLT and plasma products by at least 3.2 logs. Additionally, an at least 4.4-log reduction was observed with P.yoelii. C1 Terumo BCT LLC, Lakewood, CO USA. Colorado State Univ, Ft Collins, CO 80523 USA. Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Goodrich, RP (reprint author), Terumo BCT, 10810 W Collins Ave, Lakewood, CO 80215 USA. EM ray.goodrich@terumobct.com FU US Army Medical Research and Materiel Command [W81XWH-05-2-0001]; CDC [CID-06-266-00]; Terumo BCT Biotechnologies FX This work is supported by the US Army Medical Research and Materiel Command under Contract W81XWH-05-2-0001 and through a Cooperative Research and Development Agreement (CRADA) No. CID-06-266-00 between CDC and Terumo BCT Biotechnologies. NR 40 TC 9 Z9 10 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD OCT PY 2013 VL 53 IS 10 BP 2278 EP 2286 DI 10.1111/trf.12079 PG 9 WC Hematology SC Hematology GA 230WP UT WOS:000325374300028 PM 23320495 ER PT J AU Sacks, JJ Roeber, J Bouchery, EE Gonzales, K Chaloupka, FJ Brewer, RD AF Sacks, Jeffrey J. Roeber, Jim Bouchery, Ellen E. Gonzales, Katherine Chaloupka, Frank J. Brewer, Robert D. TI State Costs of Excessive Alcohol Consumption, 2006 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID BINGE DRINKING; UNITED-STATES; US AB Background: Excessive alcohol consumption is responsible for an average of 80,000 deaths in the U.S. each year and cost $223.5 billion ($1.90/drink) in 2006. Comparable state estimates of this cost are needed to help inform prevention strategies. Purpose: The goal of the study was to estimate the economic cost of excessive drinking by state for 2006. Methods: From December 2011 to November 2012, an expert panel developed methods to allocate component costs from the 2006 national estimate to states for (1) total; (2) government; (3) binge drinking; and (4) underage drinking costs. Differences in average state wages were used to adjust productivity losses. Results: In 2006, the median state cost of excessive drinking was $2.9 billion (range: $31.9 billion [California] to $419.6 million [North. Dakota]); the median cost per drink, $1.91 (range: $2.74 [Utah] to $0.88 [New Hampshire]); and the median per capita cost, $703 (range: $1662 [District of Columbia] to $578 [Utah]). A median of 42% of state costs were paid by government (range: 45.0% [Utah] to 37.0% [Mississippi]). Binge drinking was responsible for a median of 76.6% of state costs (range: 83.1% [Louisiana] to 71.6% [Massachusetts]); underage drinking, a median of 11.2% of state costs (range: 20.0% [Wyoming] to 5.5% [District of Columbia]). Conclusions: Excessive drinking cost states a median of $2.9 billion in 2006. Most of the costs were due to binge drinking and about $2 of every $5 were paid by government. The Guide to Community Preventive Services has recommended several evidence-based strategies-including increaeing alcohol excise taxes, limiting alcohol outlet density, and commercial host liability-that can help reduce excessive alcohol use and the associated economic costs. (C) 2013 American Journal of Preventive Medicine. All rights reserved. C1 [Sacks, Jeffrey J.] Sue Binder Consulting Inc, Atlanta, GA 30319 USA. [Brewer, Robert D.] CDC, Alcohol Program, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Roeber, Jim] New Mexico Dept Hlth, Subst Abuse Epidemiol Sect, Epidemiol & Response Div, Santa Fe, NM USA. [Bouchery, Ellen E.] Math Policy Res, Washington, DC USA. [Gonzales, Katherine] Michigan Dept Community Hlth, Bur Dis Control Prevent & Epidemiol, Lansing, MI USA. [Chaloupka, Frank J.] Univ Illinois, Dept Econ, Chicago, IL 60680 USA. RP Sacks, JJ (reprint author), Sue Binder Consulting Inc, 3958 Preston Ct, Atlanta, GA 30319 USA. EM sacksj@bellsouth.net FU CDC [200-2012-M-51945, 200-2011-M-41451]; CDC Foundation FX This project was supported by Contracts 200-2012-M-51945 and 200-2011-M-41451 from the CDC to the CDC Foundation.; JJS conducted this work while an employee of Sue Binder Consulting, Inc., and received funding for this project from the CDC Foundation. Jim Roeber conducted this work while an employee of the New Mexico Department of Health. Ellen Bouchery conducted this work while an employee of Mathematica, Inc., and received funding for this project from the CDC Foundation. Katherine Gonzales conducted this work while an employee of the Michigan Department of Community Health. Frank Chaloupka conducted this work while an employee of University of Illinois at Chicago. Robert Brewer conducted this work while an employee of the CDC. NR 30 TC 16 Z9 16 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2013 VL 45 IS 4 BP 474 EP 485 DI 10.1016/j.amepre.2013.06.004 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 228NQ UT WOS:000325193900013 PM 24050424 ER PT J AU Moulton, AD Albright, AL Gregg, EW Goodman, RA AF Moulton, Anthony D. Albright, Ann L. Gregg, Edward W. Goodman, Richard A. TI Law, Public Health, and the Diabetes Epidemic SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PREVENTIVE CARE; UNITED-STATES; US; COVERAGE; ADULTS; PREVALENCE; MELLITUS; SERVICES AB The prevalence of new cases of diabetes continues to increase, and the health burden for those with diabetes remains high. This is attributable, in part, to low adoption of evidence-based interventions for diabetes prevention and control. Law is a critical tool for health improvement, yet assessments reported in this paper indicate that federal, state, and local laws give only partial support to guidelines and evidence-based interventions relevant to diabetes prevention and control. Public health practitioners and policymakers who are concerned with the human, fiscal, and economic costs of the epidemic can explore new ways to translate the evidence base for diabetes prevention and control into effective laws and policies. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Moulton, Anthony D.] CDC, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30345 USA. [Albright, Ann L.; Gregg, Edward W.] CDC, Div Diabet Translat, Atlanta, GA 30345 USA. [Goodman, Richard A.] CDC, Epidemiol & Stat Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30345 USA. [Goodman, Richard A.] CDC, DHHS Off Assistant Secretary Hlth, Atlanta, GA 30345 USA. RP Moulton, AD (reprint author), CDC, Lab Sci Policy & Practice Program Off, Off Surveillance Epidemiol & Lab Serv, 2400 Century Pkwy NE,MS E-94, Atlanta, GA 30345 USA. EM adm6@cdc.gov FU CDC FX All authors are employees of the CDC. The salary compensation they receive from the CDC is the only funding source that supported their work related to this paper. None of the authors has any commercial associations, current and over the past 5 years, that might pose a conflict of interest. NR 36 TC 4 Z9 4 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2013 VL 45 IS 4 BP 486 EP 493 DI 10.1016/j.amepre.2013.05.017 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 228NQ UT WOS:000325193900014 PM 24050425 ER PT J AU Krist, AH Shenson, D Woolf, SH Bradley, C Liaw, WR Rothemich, SF Slonim, A Benson, W Anderson, LA AF Krist, Alex H. Shenson, Douglas Woolf, Steven H. Bradley, Cathy Liaw, Winston R. Rothemich, Stephen F. Slonim, Amy Benson, William Anderson, Lynda A. TI Clinical and Community Delivery Systems for Preventive Care An Integration Framework SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEALTH-CARE; AFRICAN-AMERICAN; PUBLIC-HEALTH; PATIENT ACTIVATION; WOMEN; SERVICES; PROGRAM; INTERVENTIONS; DISPARITIES; ENGAGEMENT AB Although clinical preventive services (CPS)-screening tests, immunizations, health behavior counseling, and preventive medications-can save lives, Americans receive only half of recommended services. This "prevention gap," if closed, could substantially reduce morbidity and mortality. Opportunities to improve delivery of CPS exist in both clinical and community settings, but these activities are rarely coordinated across these settings, resulting in inefficiencies and attenuated benefits. Through a literature review, semi-structured interviews with 50 national experts, field observations of 53 successful programs, and a national stakeholder meeting, a framework to fully integrate CPS delivery across clinical and community care delivery systems was developed. The framework identifies the necessary participants, their role' in care delivery, and the infrastructure, support, and policies necessary to ensure success. Essential stakeholders in integration include clinicians; community members and organizations; spanning personnel and infrastructure; national, state, and local leadership; and funders and purchasers. Spanning personnel and infrastructure are essential to bring clinicians and communities together and to help patients navigate across care settings. The specifics of clinical-community integrations vary depending on the services addressed and the local context. Although broad establishment of effective clinical-community integrations will require substantial changes, existing clinical and community models provide an important starting point. The key policies and elements of the framework are often already in place or easily identified. The larger challenge is for stakeholders to recognize how integration serves their mutual interests and how it can be financed and sustained over time. (C) 2013 American Journal of Preventive Medicine. All rights reserved. C1 [Krist, Alex H.; Woolf, Steven H.; Rothemich, Stephen F.] Virginia Commonwealth Univ, Dept Family Med & Populat Hlth, Richmond, VA USA. [Bradley, Cathy] Virginia Commonwealth Univ, Dept Healthcare Policy & Res, Richmond, VA USA. [Liaw, Winston R.] Fairfax Family Practice Residency, Fairfax, VA USA. [Shenson, Douglas] Yale Univ, Sch Med, New Haven, CT USA. [Slonim, Amy] Natl Assoc Chron Dis Directors, Michigan Publ Hlth Inst, CDC AARP Liaison, Washington, DC USA. [Benson, William] Hlth Benefits ABCs, Silver Spring, MD USA. [Anderson, Lynda A.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. RP Krist, AH (reprint author), POB 980251, Richmond, VA 23298 USA. EM ahkrist@vcu.edu FU CDC [U58DP002759-01]; Michigan Public Health Institute (MPHI); CTSA, National Center for Advancing Translational Sciences (NCATS) [ULTR00058] FX This publication was supported by Grant/Cooperative Agreement Number U58DP002759-01 from the CDC to National Association of Chronic Disease Directors (NACDD) and Michigan Public Health Institute (MPHI). Work was also supported by the CTSA Grant Number ULTR00058 from the National Center for Advancing Translational Sciences (NCATS). Its contents are solely the responsibility of the authors and do not necessarily reflect the views of the CDC, NACDD, MPHI, or NCATS. The authors specially acknowledge Peter Briss, MD, MPH, Steven Wallace, PhD, and Kathryn Keitzman, PhD, for collaborative efforts interviewing successful clinical-community intervention participants and/or reviewing manuscripts. NR 71 TC 12 Z9 12 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2013 VL 45 IS 4 BP 508 EP 516 DI 10.1016/j.amepre.2013.06.008 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 228NQ UT WOS:000325193900017 PM 24050428 ER PT J AU LaVail, KH Kennedy, AM AF LaVail, Katherine Hart Kennedy, Allison Michelle TI The Role of Attitudes About Vaccine Safety, Efficacy, and Value in Explaining Parents' Reported Vaccination Behavior SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE vaccine confidence; vaccine efficacy; vaccine safety; value ID CLINICAL-PRACTICE; HESITANT PARENTS; CONFIDENCE; HEALTH AB Objectives. To explain vaccine confidence as it related to parents' decisions to vaccinate their children with recommended vaccines, and to develop a confidence measure to efficiently and effectively predict parents' self-reported vaccine behaviors. Method. A sample of parents with at least one child younger than 6 years (n = 376) was analyzed using data from the HealthStyles 2010 survey. Questions were grouped into block variables to create three confidence constructs: value, safety, and efficacy. Regression equations controlling for demographic characteristics were used to identify the confidence construct(s) that best predicted parents' self-reported vaccination decisions (accept all, some, or none of the recommended childhood vaccines). Results. Among the three constructs evaluated, confidence in the value of vaccines, that is the belief that vaccines are important and vaccinating one's children is the right thing to do, was the best predictor of parents' vaccine decisions, F(2, 351) = 119.199, p < .001. When combined into a block variable for analysis, two survey items measuring confidence in the value of vaccines accounted for 40% of the variance in parents' self-reported vaccine decisions. Confidence in the safety or efficacy of vaccines failed to account for additional significant variance in parent-reported vaccination behavior. Conclusions. Confidence in the value of vaccines is a helpful predictor of parent-reported vaccination behavior. Attitudinal constructs of confidence in the safety and efficacy of vaccines failed to account for additional significant variance in parents' vaccination behaviors. Future research should assess the role of vaccine knowledge and tangible barriers, such as access and cost, to further explain parents' vaccination behaviors. C1 [LaVail, Katherine Hart; Kennedy, Allison Michelle] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP LaVail, KH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A27, Atlanta, GA 30329 USA. EM vgz4@cdc.gov NR 31 TC 7 Z9 7 U1 0 U2 11 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD OCT PY 2013 VL 40 IS 5 BP 544 EP 551 DI 10.1177/1090198112463022 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 220NO UT WOS:000324591500006 PM 23104978 ER PT J AU Head, EN Stevens, JA Haileyesus, T AF Head, Elizabeth Nicole Stevens, Judy A. Haileyesus, Tadesse TI Bathroom injuries in children less than 15 years old SO INJURY PREVENTION LA English DT Article ID UNINTENTIONAL INJURY; CAREGIVER SUPERVISION; UNITED-STATES; RISK; HOME AB Objective To quantify and describe non-fatal, unintentional bathroom injuries among children less than 15 years of age treated in US hospital emergency departments (EDs). Methods This study used 2008 data from a nationally representative sample of EDs, available from the National Electronic Injury Surveillance System-All Injury Program. We examined unintentional non-fatal bathroom injuries in any setting (eg, home, school or public place) among children less than 15 years of age and identified types of injuries, major locations within the bathroom and precipitating events. Results Based on 1099 cases, an estimated 51132 non-fatal bathroom injuries in children less than 15 years of age were treated in US EDs in 2008. Most injuries (73.8%) were caused by falls. The highest rate was for injuries that occurred in or around the shower or bathtub (65.9 per 100000). Children less than 15 years of age sustained the greatest number of injuries and had the highest injury rate (151 per 100000 (95% CI 108.7 to 193.3)), while children 10-14 years of age had the lowest rate (28.7 (95% CI 20.6 to 36.8)). The rates differed significantly by age group (p<0.001). A majority of the patients (96.9%) were treated in the ED and released. Conclusions Most bathroom injuries in children occurred while they were showering or bathing and were caused by falling or hitting an object. Such injuries might be reduced by improving caregiver supervision for younger children. For older children, a combination of bathroom safety education and environmental modifications, such as installing grab bars inside and outside the shower or tub, may reduce bathroom injuries. C1 [Head, Elizabeth Nicole] Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA. [Stevens, Judy A.; Haileyesus, Tadesse] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Stevens, JA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA. EM jstevens@cdc.gov NR 23 TC 1 Z9 1 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD OCT PY 2013 VL 19 IS 5 BP 316 EP 319 DI 10.1136/injuryprev-2012-040600 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 224LX UT WOS:000324888800004 PM 23322258 ER PT J AU Hinkle, SN Sharma, AJ Kim, SY Schieve, LA AF Hinkle, S. N. o Sharma, A. J. Kim, S. Y. Schieve, L. A. TI Maternal prepregnancy weight status and associations with children's development and disabilities at kindergarten SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE pregnancy; development; disabilities; cognitive function ID BODY-MASS INDEX; INTELLECTUAL DISABILITY; CAUSAL-DIAGRAMS; PREGNANCY; OBESITY; COGNITION; RISK; COHORTS; OVERWEIGHT; BEHAVIOR AB OBJECTIVE: Obesity is prevalent among women of reproductive age, and developmental disabilities in children continue to increase. We examined associations between mother's prepregnancy body mass index (BMI) and physical and developmental disabilities, and objective measures of reading and math skills and fine and gross motor function in children. METHODS: We used the Early Childhood Longitudinal Study-Birth Cohort (ECLS-B; n=5200), a cohort of children born in 2001 and followed until kindergarten. Children were classified according to maternal prepregnancy BMI (in kg per m(2)): underweight (BMI <18.5), normal weight (BMI 18.5-24.9), overweight (BMI 25.0-29.9), obese class I (BMI 30.0-34.9) and obese class II/III (BMI >= 35.0). Parent reports of doctor-diagnosed disabilities were collected up to kindergarten and classified as learning and behavioral or physical. Children's reading and math and fine and gross motor function were assessed at kindergarten according to standardized tests. Linear and modified logistic regression models were adjusted for maternal sociodemographic variables, family enrichment variables, and children's sex, age and year of kindergarten entry. Additional adjustment for current child BMI was performed in separate models. All data are weighted to be nationally representative of the children born in 2001. RESULTS: Compared with children of normal-weight mothers, children born to obese class II/III mothers had an increased risk of learning or behavioral (risk ratio 1.67; 95% confidence interval 1.27, 2.21)), but not physical disabilities (risk ratio 0.57; 95% confidence interval 0.27, 1.22). Gross (P<0.001), but not fine (P=0.06) motor function was significantly associated with maternal BMI, but gross motor function was attenuated after adjustment for current child BMI (P=0.05). Children's reading scores (P=0.01) but not math scores (P=0.11) were significantly associated with maternal BMI. CONCLUSIONS: In this nationally representative US cohort, children born to severely obese mothers had an increased risk for diagnosed learning and behavioral but not physical disabilities by kindergarten. C1 [Hinkle, S. N. o; Sharma, A. J.; Kim, S. Y.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Sharma, A. J.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Schieve, L. A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. RP Sharma, AJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, 4770 Buford Highway NE,MS-K23, Atlanta, GA 30341 USA. EM AJSharma@cdc.gov RI Hinkle, Stefanie/F-8253-2013; OI Hinkle, Stefanie/0000-0003-4312-708X; Sharma, Andrea/0000-0003-0385-0011 FU Oak Ridge Institute for Science and Education [DE-AC05-06OR23100] FX This research was performed in part under an appointment to the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education under contract number DE-AC05-06OR23100 between the US Department of Energy and Oak Ridge Associated Universities. NR 42 TC 16 Z9 18 U1 3 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD OCT PY 2013 VL 37 IS 10 BP 1344 EP 1351 DI 10.1038/ijo.2013.128 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 233CG UT WOS:000325542200008 PM 23860335 ER PT J AU Gronborg, TK Schendel, DE Parner, ET AF Gronborg, Therese K. Schendel, Diana E. Parner, Erik T. TI Recurrence of Autism Spectrum Disorders in Full- and Half-Siblings and Trends Over Time A Population-Based Cohort Study SO JAMA PEDIATRICS LA English DT Article ID PERVASIVE DEVELOPMENTAL DISORDER; PSYCHIATRIC-DISORDERS; EPIDEMIOLOGIC SURVEY; FAMILY-HISTORY; RISK-FACTORS; TWIN PAIRS; PREVALENCE; CHILDREN AB IMPORTANCE To date, this is the first population-based study to examine the recurrence risk for autism spectrum disorders (ASDs), including time trends, and the first study to consider the ASDs recurrence risk for full-and half-siblings. OBJECTIVES To estimate the relative recurrence risk for ASDs in a Danish population, including recurrence in full-and half-siblings, and to examine time trends in ASDs relative to the recurrence risk. DESIGN, SETTING, AND PARTICIPANTS Population-based cohort study in Denmark. All children (about 1.5 million) born in Denmark between January 1, 1980, and December 31, 2004, were identified and followed up to December 31, 2010. We identified a maternal sibling subcohort derived from mothers with at least 2 children and a paternal sibling subcohort derived from fathers with at least 2 children. EXPOSURES Children having an older sibling with ASDs are compared with children not having an older sibling with ASDs. MAIN OUTCOMES AND MEASURES The adjusted hazard ratio for ASDs among children having an older sibling with ASDs compared with children not having an older sibling with ASDs. RESULTS The overall relative recurrence risk for ASDs was 6.9 (95% CI, 6.1-7.8), and it did not change significantly over time; similar risks were observed in maternal and paternal full-siblings. The relative recurrence risks were 2.4 (95% CI, 1.4-4.1) for maternal half-siblings and 1.5 (95% CI, 0.7-3.4) for paternal half-siblings. CONCLUSIONS AND RELEVANCE Our population-based recurrence risk estimate is lower than the recently reported estimates from clinical samples. Our results demonstrate no time trend in the ASDs recurrence risk as seen in the ASDs prevalence. The difference in the recurrence risk between full-and half-siblings supports the role of genetics in ASDs, while the significant recurrence risk in maternal half-siblings may support the role of factors associated with pregnancy and the maternal intrauterine environment in ASDs. C1 [Gronborg, Therese K.; Parner, Erik T.] Aarhus Univ, Dept Publ Hlth, Biostat Sect, DK-8000 Aarhus C, Denmark. [Schendel, Diana E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Gronborg, TK (reprint author), Aarhus Univ, Dept Publ Hlth, Biostat Sect, Bartholins Alle 2, DK-8000 Aarhus C, Denmark. EM therese@biostat.au.dk FU Aarhus University FX This study is funded by Aarhus University. NR 32 TC 61 Z9 62 U1 1 U2 28 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD OCT PY 2013 VL 167 IS 10 BP 947 EP 953 DI 10.1001/jamapediatrics.2013.2259 PG 7 WC Pediatrics SC Pediatrics GA 232GQ UT WOS:000325480900017 PM 23959427 ER PT J AU Thornburg, NJ Nannemann, DP Blum, DL Belser, JA Tumpey, TM Deshpande, S Fritz, GA Sapparapu, G Krause, JC Lee, JH Ward, AB Lee, DE Li, S Winarski, KL Spiller, BW Meiler, J Crowe, JE AF Thornburg, Natalie J. Nannemann, David P. Blum, David L. Belser, Jessica A. Tumpey, Terrence M. Deshpande, Shyam Fritz, Gloria A. Sapparapu, Gopal Krause, Jens C. Lee, Jeong Hyun Ward, Andrew B. Lee, David E. Li, Sheng Winarski, Katie L. Spiller, Benjamin W. Meiler, Jens Crowe, James E., Jr. TI Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID BINDING SITE; HEMAGGLUTININ; FERRETS AB Recent studies described the experimental adaptation of influenza H5 HAs that confers respiratory droplet transmission (rdt) to influenza virus in ferrets. Acquisition of the ability to transmit via aerosol may lead to the development of a highly pathogenic pandemic H5 virus. Vaccines are predicted to play an important role in H5N1 control should the virus become readily transmissible between humans. We obtained PBMCs from patients who received an A/Vietnam/1203/2004 H5N1 subunit vaccine. Human hybridomas were then generated and characterized. We identified antibodies that bound the HA head domain and recognized both WT and rdt H5 HAs. We used a combination of structural techniques to define a mechanism of antibody recognition of an H5 HA receptor-binding site that neutralized H5N1 influenza viruses and pseudoviruses carrying the HA rdt variants that have mutations near the receptor-binding site. Incorporation or retention of this critical antigenic site should be considered in the design of novel H5 HA immunogens to protect against mammalianadapted H5N1 mutants. C1 [Thornburg, Natalie J.; Blum, David L.; Deshpande, Shyam; Fritz, Gloria A.; Sapparapu, Gopal; Krause, Jens C.; Crowe, James E., Jr.] Vanderbilt Univ, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA. [Nannemann, David P.; Meiler, Jens] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA. [Belser, Jessica A.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Krause, Jens C.; Crowe, James E., Jr.] Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA. [Lee, Jeong Hyun; Ward, Andrew B.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA. [Lee, David E.; Li, Sheng] Univ Calif San Diego, Dept Med, Sch Med, San Diego, CA USA. [Lee, David E.; Li, Sheng] Univ Calif San Diego, Sch Med, Biomed Sci Grad Program, San Diego, CA USA. [Winarski, Katie L.; Spiller, Benjamin W.; Crowe, James E., Jr.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Spiller, Benjamin W.; Meiler, Jens] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA. RP Crowe, JE (reprint author), Vanderbilt Univ, Med Ctr, Vanderbilt Vaccine Ctr, 11475 MRB 4,2213 Garland Ave, Nashville, TN 37232 USA. EM james.crowe@vanderbilt.edu RI Crowe, James/B-5549-2009; Ward, Andrew/F-9203-2014; OI Crowe, James/0000-0002-0049-1079; Ward, Andrew/0000-0001-7153-3769; Meiler, Jens/0000-0001-8945-193X; Sapparapu, Gopal/0000-0001-9670-1757 FU NIH [DMID 04-062, R01 AI106002, RR017573]; NIAID [HHSN272200900047C]; Vanderbilt NIH CTSA [UL1 RR024975]; DoD [HDTRA1-10-1-0067]; US Department of Energy, Office of Stience, Office of Basic Energy Sciences [DE-AC02-06CH11357]; Michigan Economic Development Corp; Michigan Technology Tr-Corridor [085P1000817]; Scripps Research Institute FX The authors thank P. McGraw, R. Falk, and F. Smith-House for technical support, J.A. Archuleta, C. Kinnard, and J. Janssen of the Vanderbilt Clinical Trials Center for clinical support, and S.A. Smith for helpful discussions. The authors acknowledge the significant contributions of Virgil Woods, who is now deceased. The original clinical trial of the H.5 vaccine (DMID 04-062) was supported by NIH and performed in the Vanderbilt Vaccine and Treatment Evaluation Unit (PI: K.M. Edwards). This work was supported by NIH grant R01 AI106002, NIAID contract HHSN272200900047C, the Vanderbilt NIH CTSA grant UL1 RR024975, and the DoD grant HDTRA1-10-1-0067. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Stience, Office of Basic Energy Sciences, under contract No. DE-AC02-06CH11357. K.L. Winarski was supported by a Molecular Biophysics training grant at Vanderbilt (NIH T32 GM008320). Use of the LS-CAT sector 21 was supported by the Michigan Economic Development Corp. and the Michigan Technology Tr-Corridor for the support of this research program (Grant 085P1000817). The electron microscopy studies were supported by startup funds from The Scripps Research Institute (to A.B. Ward) and conducted at the National Resource for Automated Molecular Microscopy, which is supported by NIH through the NCRR P41 program (RR017573). The modeling studies were conducted using the resources of the Advanced Computing Center for Research and Education at Vanderbilt. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 13 TC 15 Z9 15 U1 0 U2 10 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD OCT PY 2013 VL 123 IS 10 BP 4405 EP 4409 DI 10.1172/JCI69377 PG 5 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 231UE UT WOS:000325443100034 PM 23999429 ER PT J AU Henning, TC Butler, K Mitchell, J Bachman, S Deyounks, F Farshy, C Phillips, C Papp, J Caldwell, H Sturdevant, G McNicholl, J Kersh, E AF Henning, Tara C. Butler, Katherine Mitchell, James Bachman, Shanon Deyounks, Frank Farshy, Carol Phillips, Christi Papp, John Caldwell, Harlan Sturdevant, Gail McNicholl, Janet Kersh, Ellen TI DEVELOPMENT OF A RECTAL SEXUALLY TRANSMITTED INFECTION (STI) - HIV COINFECTION MACAQUE MODEL UTILIZING CHLAMYDIA TRACHOMATIS AND SHIVSF162P3 SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Henning, Tara C.; Butler, Katherine; Mitchell, James; Bachman, Shanon; Deyounks, Frank; Farshy, Carol; Phillips, Christi; McNicholl, Janet; Kersh, Ellen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Papp, John] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Caldwell, Harlan; Sturdevant, Gail] NIAID, NIH, Bethesda, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 14 BP 259 EP 259 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000020 ER PT J AU Carias, AM McRaven, M Anderson, M Henning, T Kersh, E Smith, J Butler, K Vishwanathan, SA McNicholl, JM Hendry, RM Veazey, R Hope, T AF Carias, Ann M. McRaven, Michael Anderson, Meegan Henning, Tara Kersh, Ellen Smith, James Butler, Katherine Vishwanathan, S. Ajay McNicholl, Janet M. Hendry, R. Michael Veazey, Ron Hope, Thomas TI HIV-1 INTERACTIONS AND EPITHELIAL THINNING OF THE FEMALE REPRODUCTIVE TRACT IN NON-HUMAN PRIMATE MODELS SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Carias, Ann M.; McRaven, Michael; Anderson, Meegan; Hope, Thomas] Northwestern Univ, Evanston, IL 60208 USA. [Henning, Tara; Kersh, Ellen; Smith, James; Butler, Katherine; Vishwanathan, S. Ajay; McNicholl, Janet M.; Hendry, R. Michael] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 31 BP 265 EP 265 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000037 ER PT J AU Massud, I Aung, W Martin, A Bachman, S Mitchell, J Deyounks, F Kersh, E Pau, CP Heneine, W Garcia-Lerma, JG AF Massud, Ivana Aung, Wutyi Martin, Amy Bachman, Shanon Mitchell, James Deyounks, Frank Kersh, Ellen Pau, Chou-Pong Heneine, Walid Garcia-Lerma, J. Gerardo TI LACK OF PROPHYLACTIC EFFICACY OF INTERMITTENT ORAL MARAVIROC (MVC) IN MACAQUES DESPITE HIGH DRUG CONCENTRATIONS IN RECTAL TISSUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Massud, Ivana; Aung, Wutyi; Martin, Amy; Bachman, Shanon; Mitchell, James; Deyounks, Frank; Kersh, Ellen; Pau, Chou-Pong; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 34 BP 266 EP 266 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000040 ER PT J AU Garber, DA Adams, D Guenthner, P Mitchell, J Bachman, S Deyounks, F Kersh, E McNicholl, JM AF Garber, David A. Adams, Debra Guenthner, Patricia Mitchell, James Bachman, Shanon Deyounks, Frank Kersh, Ellen McNicholl, Janet M. TI EVALUATION OF REPEAT SHIV CHALLENGE MODELS VIA RECTAL, VAGINAL AND PENILE ROUTES IN CYNOMOLGUS MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Garber, David A.; Adams, Debra; Guenthner, Patricia; Mitchell, James; Bachman, Shanon; Deyounks, Frank; Kersh, Ellen; McNicholl, Janet M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 58 BP 274 EP 274 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000064 ER PT J AU Guenthner, PC Rastogi, R Sweeney, E Mitchell, J Bachman, S Luckay, A Pau, CP Holder, A Butler, SE McNicholl, JM Garber, DA Kiser, P Smith, J AF Guenthner, Patricia C. Rastogi, Rachna Sweeney, Elizabeth Mitchell, James Bachman, Shanon Luckay, Amara Pau, Chou-Pong Holder, Angela Butler, Sara E. McNicholl, Janet M. Garber, David A. Kiser, Patrick Smith, James TI PHARMACOKINETICS AFTER RECTAL APPLICATION OF A NOVEL 1% TENOFOVIR THERMOGELLING LIQUID SUPPOSITORY (TGELS) IN CYNOMOLGUS MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Guenthner, Patricia C.; Sweeney, Elizabeth; Mitchell, James; Bachman, Shanon; Luckay, Amara; Pau, Chou-Pong; Holder, Angela; Butler, Sara E.; McNicholl, Janet M.; Garber, David A.; Smith, James] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Rastogi, Rachna; Kiser, Patrick] Univ Utah, Salt Lake City, UT 84112 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 61 BP 275 EP 275 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000067 ER PT J AU Pereira, LE Clark, M Friend, D Mitchel, J Bachman, S Deyounks, F Garber, D McNicholl, J Hendry, M Smith, JM AF Pereira, Lara E. Clark, Meredith Friend, David Mitchel, James Bachman, Shanon Deyounks, Frank Garber, David McNicholl, Janet Hendry, Michael Smith, James M. TI PRELIMINARY PHARMACOKINETIC, PHARMACODYNAMICS, AND SAFETY ANALYSES OF VAGINAL TENOFOVIR TABLETS IN PIGTAIL MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Pereira, Lara E.; Friend, David; Mitchel, James; Bachman, Shanon; Deyounks, Frank; Garber, David; McNicholl, Janet; Hendry, Michael; Smith, James M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Clark, Meredith] Eastern Virginia Med Sch, CONRAD, Dept Obstet & Gynecol, Arlington, VA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 77 BP 280 EP 280 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000083 ER PT J AU Radzio, J Hanley, K Mitchell, J Bachman, S Deyounks, F Heneine, W Garcia-Lerma, JG AF Radzio, Jessica Hanley, Krisztina Mitchell, James Bachman, Shanon Deyounks, Frank Heneine, Walid Garcia-Lerma, J. Gerardo TI IDENTIFICATION OF A HUMAN-EQUIVALENT DOSE OF DEPO-PROVERA IN PIGTAIL MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Radzio, Jessica; Mitchell, James; Bachman, Shanon; Deyounks, Frank; Heneine, Walid; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hanley, Krisztina] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA. RI Hanley, Krisztina/J-8248-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 79 BP 280 EP 280 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000085 ER PT J AU Srinivasan, P Rastogi, R Teller, RS Pau, CP Martin, A Holder, A Pereira, L Mitchell, J Garber, D Dobard, C McNicholl, JM Hendry, RM Mesquita, PM Kiser, P Herold, B Smith, JM AF Srinivasan, Priya Rastogi, Rachna Teller, Ryan S. Pau, Chou-Pong Martin, Amy Holder, Angela Pereira, Lara Mitchell, James Garber, David Dobard, Charles McNicholl, Janet M. Hendry, R. Michael Mesquita, Pedro M. Kiser, Patrick Herold, Betsy Smith, James M. TI TENOFOVIR DISOPROXIL FUMARATE DELIVERED BY INTRAVAGINAL RING IN MACAQUES ACHIEVES EQUIVALENT INTRACELLULAR TENOFOVIR DIPHOSPHATE LEVELS IN VAGINAL MONOCYTES AS A 1% TFV GEL DOSAGE SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Srinivasan, Priya; Pau, Chou-Pong; Martin, Amy; Holder, Angela; Pereira, Lara; Mitchell, James; Garber, David; Dobard, Charles; McNicholl, Janet M.; Hendry, R. Michael; Smith, James M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rastogi, Rachna; Teller, Ryan S.; Kiser, Patrick] Univ Utah, Salt Lake City, UT USA. [Mesquita, Pedro M.] Albert Einstein Coll Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 78 BP 280 EP 280 PG 1 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000084 ER PT J AU Vishwanathan, SA Wolitski, RJ Rose, CE Luo, W Mitchell, J Bachman, SJ Deyounks, F Morris, MR Patton, DL Hendry, RM McNicholl, JM Kersh, EN AF Vishwanathan, Sundaram Ajay Wolitski, Richard J. Rose, Charles E. Luo, Wei Mitchell, James Bachman, Shanon J. Deyounks, Frank Morris, Monica R. Patton, Dorothy L. Hendry, R. Michael McNicholl, Janet M. Kersh, Ellen N. TI RECTAL CYTOTOXICITY EVALUATION OF A WATER-BASED HYPEROSMOLAR LUBRICANT IN CYNOMOLGUS MACAQUES SO JOURNAL OF MEDICAL PRIMATOLOGY LA English DT Meeting Abstract C1 [Vishwanathan, Sundaram Ajay; Wolitski, Richard J.; Rose, Charles E.; Luo, Wei; Mitchell, James; Bachman, Shanon J.; Deyounks, Frank; Morris, Monica R.; Hendry, R. Michael; McNicholl, Janet M.; Kersh, Ellen N.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Patton, Dorothy L.] Univ Washington, Dept Obstet & Gynecol, Sch Med, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0047-2565 EI 1600-0684 J9 J MED PRIMATOL JI J. Med. Primatol. PD OCT PY 2013 VL 42 IS 5 MA 90 BP 283 EP 284 PG 2 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 217BR UT WOS:000324332000096 ER PT J AU Caruso, B Brunetto, G Massoud, R Switzer, B Jacobson, S AF Caruso, Breanna Brunetto, Giovanna Massoud, Raya Switzer, Bill Jacobson, Steven TI Digital Droplet PCR for Precise Quantification of Human T-Lymphotropic Virus 1 SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 12th International Symposium on NeuroVirology CY OCT 29-NOV 02, 2013 CL Washington, DC C1 [Caruso, Breanna; Brunetto, Giovanna; Massoud, Raya; Jacobson, Steven] NINDS, NIB, NIH, Bethesda, MD 20892 USA. [Switzer, Bill] CDC, NCHHSTP, OID, Atlanta, GA 30333 USA. EM breanna.caruso@nih.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2013 VL 19 SU 1 MA P38 BP S19 EP S19 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 236EM UT WOS:000325777200039 ER PT J AU Jung, HS Miller, A Park, K Kittelson, DB AF Jung, Heejung S. Miller, Art Park, Kihong Kittelson, David B. TI Carbon nanotubes among diesel exhaust particles: real samples or contaminants? SO JOURNAL OF THE AIR & WASTE MANAGEMENT ASSOCIATION LA English DT Article ID TRANSMISSION ELECTRON-MICROSCOPY; FLAME SYNTHESIS; METAL PARTICLES; LARGE-SCALE; COMBUSTION; NANOPARTICLES; ADDITIVES; EMISSIONS; ENGINES; FILMS AB During three separate studies involving characterization of diesel particulate matter, carbon nanotubes (CNTs) were found among diesel exhaust particles sampled onto transmission electron microscopy (TEM) grids. During these studies, samples were collected from three different diesel engines at normal operating conditions with or without an iron catalyst (introduced as ferrocene) in the fuel. This paper is to report the authors' observation of CNTs among diesel exhaust particles, with the intent to stimulate awareness and further discussion regarding the formation mechanisms of CNTs during diesel combustion. Implications: Increased attention is being given to CNTs and other nanomaterials and a recent review paper showed that CNTs are capable of inflammation in the lung when inhaled. For this reason and because diesel engines are so common, it is important to acknowledge the existence of CNTs among diesel particles and possible regulation and online measurement method development. C1 [Jung, Heejung S.] Univ Calif Riverside, Dept Mech Engn, Riverside, CA 92521 USA. [Jung, Heejung S.] Univ Calif Riverside, Bourns Coll Engn, Ctr Environm Res & Technol CE CERT, Riverside, CA 92521 USA. [Miller, Art] NIOSH, Spokane Res Lab, Ctr Dis Control & Prevent, Spokane, WA USA. [Park, Kihong] Gwangju Inst Sci & Technol, Dept Environm Sci & Engn, Kwangju, South Korea. [Kittelson, David B.] Univ Minnesota, Dept Mech Engn, Minneapolis, MN 55455 USA. RP Jung, HS (reprint author), Univ Calif Riverside, Dept Mech Engn, 900 Univ Ave, Riverside, CA 92521 USA. EM heejung@engr.ucr.edu OI Jung, Heejung/0000-0003-0366-7284 FU National Research Foundation of Korea (NRF) [2011-0015548] FX Kihong Park acknowledges support from the National Research Foundation of Korea (NRF) (grant 2011-0015548) on this work. NR 30 TC 7 Z9 8 U1 0 U2 9 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1096-2247 EI 2162-2906 J9 J AIR WASTE MANAGE JI J. Air Waste Manage. Assoc. PD OCT 1 PY 2013 VL 63 IS 10 BP 1199 EP 1204 DI 10.1080/10962247.2013.812048 PG 6 WC Engineering, Environmental; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 218UU UT WOS:000324458800011 PM 24282972 ER PT J AU Frye, V Williams, K Bond, KT Henny, K Cupid, M Weiss, L Lucy, D Koblin, BA AF Frye, Victoria Williams, Kim Bond, Keosha T. Henny, Kirk Cupid, Malik Weiss, Linda Lucy, Debbie Koblin, Beryl A. CA Straight Talk Intervention Study TI Condom Use and Concurrent Partnering among Heterosexually Active, African American Men: A Qualitative Report SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE HIV/AIDS; Sexual risk behavior; African Americans; Heterosexual men ID SEXUALLY-TRANSMITTED INFECTIONS; UNITED-STATES; RACIAL DISPARITIES; HIV TRANSMISSION; LEVEL ANALYSES; SELF-EFFICACY; AIDS RISK; PARTNERSHIPS; BEHAVIOR; DISEASES AB African Americans are overrepresented among heterosexual cases of HIV/AIDS in the USA. Inconsistent condom use and concurrent partnering are two sexual behaviors driving the heterosexual HIV epidemic in the African American community. To inform the development of an HIV prevention behavioral intervention to decrease concurrent partnering and increase condom use among African American heterosexual men, we conducted formative research, including 61 structured interviews, 5 focus groups with 25 men, and 30 in-depth qualitative interviews between July and December 2009. We used a grounded theoretical approach and categorizing strategies to code and analyze the qualitative data. Results around condom use confirmed earlier findings among heterosexual men in general: condoms diminish pleasure, interfere with erection, and symbolize infidelity. Although valued by some as a form of disease prevention and pregnancy prevention, condoms are often used only with specific types of female partners, such as new or casual partners, or due to visual risk assessment. Sex partner concurrency was described as normative and ascribed to men's "natural" desire to engage in a variety of sexual activities or their high sex drive, with little recognition of the role it plays in the heterosexual HIV epidemic. Fatherhood emerged among many men as a crucial life event and compelling motivation for reducing sexual risk behavior. Based on these results, we conclude that existing HIV prevention efforts to improve attitudes towards and motivate use of condoms either have not reached or have not been successful with African American heterosexual men. In designing behavioral interventions to decrease concurrent partnering and increase condom use, addressing negative attitudes towards condoms and partner risk assessment is critical, as is integrating novel motivational approaches related to identity as fathers and men in the African American community. C1 [Frye, Victoria] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, New York, NY 10021 USA. [Frye, Victoria] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY USA. [Williams, Kim; Henny, Kirk] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Bond, Keosha T.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Cupid, Malik] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA. [Weiss, Linda] New York Acad Med, Ctr Evaluat & Appl Res, New York, NY USA. [Lucy, Debbie; Koblin, Beryl A.] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Infect Dis Prevent, New York, NY 10021 USA. RP Frye, V (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, New York, NY 10021 USA. EM VFrye@NYBloodCenter.org OI Henny, Kirk/0000-0002-0886-8651 FU Division of HIV/AIDS Prevention, CDC FX This study was supported by cooperative agreement from the Division of HIV/AIDS Prevention, CDC award number. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 73 TC 5 Z9 5 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 EI 1468-2869 J9 J URBAN HEALTH JI J. Urban Health PD OCT PY 2013 VL 90 IS 5 BP 953 EP 969 DI 10.1007/s11524-012-9747-x PG 17 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 234JU UT WOS:000325640400013 PM 22869516 ER PT J AU Li, R Gregg, EW Barker, LE Zhang, P Zhang, F Zhuo, XH Williams, DE Soumerai, SB AF Li, Rui Gregg, Edward W. Barker, Lawrence E. Zhang, Ping Zhang, Fang Zhuo, Xiaohui Williams, Desmond E. Soumerai, Steven B. TI Medicare Part D is Associated With Reducing the Financial Burden of Health Care Services in Medicare Beneficiaries With Diagnosed Diabetes SO MEDICAL CARE LA English DT Article DE out-of-pocket expenditure; access to health care; Medicare Part D; diabetes ID UNITED-STATES; ADULTS; TRENDS; IMPACT; COSTS; DRUGS; US AB Background:Medicare Part D, implemented in 2006, provided coverage for prescription drugs to all Medicare beneficiaries.Objective:To examine the effect of Part D on the financial burden of persons with diagnosed diabetes.Research Design, Subjects, and Outcome Measures:We conducted an interrupted time-series analysis using data from the 1996 to 2008 Medical Expenditure Panel Survey (11,178 persons with diabetes who were covered by Medicare, and 8953 persons aged 45-64 y with diabetes who were not eligible for Medicare coverage). We then compared changes in 4 outcomes: (1) annual individual out-of-pocket expenditure (OOPE) for prescription drugs; (2) annual individual total OOPE for all health care services; (3) annual total family OOPE for all health care services; and (4) percentage of persons with high family financial burden (OOPE 10% of income).Results:For Medicare beneficiaries with diabetes, Part D was associated with a 28% ($530) decrease in individual annual OOPE for prescription drugs, a 23% ($560) reduction in individual OOPE for all health care, a 23% ($863) reduction in family OOPE for all health care, and a 24% reduction in the percentage of families with high financial burden in 2006. There were similar reductions in 2007 and 2008. By 2008, the percentage of Medicare beneficiaries with diabetes living in high financial burden families was 37% lower than it would have been had Part D not been in place.Conclusions:Introduction of Part D coverage was associated with a substantial reduction in the financial burden of Medicare beneficiaries with diabetes and their families. C1 [Li, Rui; Gregg, Edward W.; Barker, Lawrence E.; Zhang, Ping; Zhuo, Xiaohui; Williams, Desmond E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. [Zhang, Fang; Soumerai, Steven B.] Harvard Univ, Sch Med, Dept Populat Med, Harvard Pilgrim Hlth Care Inst, Boston, MA USA. RP Li, R (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Highway NE,MS F-73, Atlanta, GA 30341 USA. EM eok8@cdc.gov FU Natural Experiments for Translation in Diabetes (NEXT-D) study [RFA-DP10-002]; CDC; NIDDK FX S.B.S. was partially supported by the Natural Experiments for Translation in Diabetes (NEXT-D) study, RFA-DP10-002, sponsored by CDC and NIDDK. NR 31 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD OCT PY 2013 VL 51 IS 10 BP 888 EP 893 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 222SI UT WOS:000324751000006 PM 23969594 ER PT J AU Russell, TM Johnson, BJB AF Russell, Theresa M. Johnson, Barbara J. B. TI Lyme disease spirochaetes possess an aggrecan-binding protease with aggrecanase activity SO MOLECULAR MICROBIOLOGY LA English DT Article ID BORRELIA-BURGDORFERI; HELICOBACTER-PYLORI; SERINE-PROTEASE; E-CADHERIN; PROTEOME ANALYSIS; QUALITY CONTROL; HTRA PROTEASES; ARTHRITIS; PROTEINS; GLYCOSAMINOGLYCAN AB Connective tissues are the most common area of colonization for the Lyme disease spirochaete Borrelia burgdorferi. Colonization is aided by the interaction between numerous bacterial adhesins with components of the extracellular matrix (ECM). Here we describe a novel interaction between B.burgdorferi and the major ECM proteoglycan found in joints, aggrecan. Using affinity chromatography and mass spectrometry we identify two borrelial aggrecan-binding proteins: the known ECM ligand Bgp (BB0588) and an uncharacterized protease BbHtrA (BB0104). Proteinase K studies demonstrate that BbHtrA is surface exposed. Immunoblots using sera from patients with both early and late Lyme disease establish that BbHtrA is expressed during human disease, immunogenic, and conserved in the three major Lyme disease spirochaete species. Consequences of the interaction between aggrecan and BbHtrA were examined by proteolysis assays. BbHtrA cleaves aggrecan at a site known to destroy aggrecan function and which has been previously observed in the synovial fluid of patients with Lyme arthritis. These data demonstrate that B.burgdorferi possess aggrecan-binding proteins which may provide the organism with additional capability to colonize connective tissues. Moreover, our studies provide the first evidence that B.burgdorferi possess proteolytic activity which may contribute to the pathogenesis of Lyme arthritis. C1 [Russell, Theresa M.; Johnson, Barbara J. B.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Johnson, BJB (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. EM BJohnson@cdc.gov FU CDC FX The authors would like to thank J. Bamburg, K. Luger, R. Cohen, C.J. Weeks and T. Patton for helpful suggestions and J. Prenni and J. Pohl for consultation. CDC supported this work; however, the findings and conclusions are those of the authors and do not necessarily represent the official position of the agency. NR 55 TC 19 Z9 19 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0950-382X EI 1365-2958 J9 MOL MICROBIOL JI Mol. Microbiol. PD OCT PY 2013 VL 90 IS 2 BP 228 EP 240 DI 10.1111/mmi.12276 PG 13 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 232IG UT WOS:000325486100003 PM 23710801 ER PT J AU Russell, TM Delorey, MJ Johnson, BJB AF Russell, Theresa M. Delorey, Mark J. Johnson, Barbara J. B. TI Borrelia burgdorferi BbHtrA degrades host ECM proteins and stimulates release of inflammatory cytokines in vitro SO MOLECULAR MICROBIOLOGY LA English DT Article ID LYME-DISEASE SPIROCHETE; HUMAN ARTICULAR CHONDROCYTES; MESENCHYMAL STEM-CELLS; FIBRONECTIN FRAGMENTS; CHONDROGENIC DIFFERENTIATION; EXTRACELLULAR-MATRIX; HUMAN PLASMINOGEN; ERYTHEMA MIGRANS; E-CADHERIN; ARTHRITIS AB The Lyme disease spirochaete, Borrelia burgdorferi, causes damage to diverse host tissues and induces inflammation but the mechanisms of injury are poorly understood. We recently reported that a surface-exposed B.burgdorferi protease, which is expressed during human disease and is conserved within the major Lyme disease spirochaete species, degrades the extracellular matrix proteoglycan, aggrecan. Here we demonstrate that BbHtrA also degrades fibronectin and numerous proteoglycans found in skin, joints and neural tissues. BbHtrA degradation of fibronectin released known pro-inflammatory fibronectin fragments FnIII(13-14) and Fnf-29, which may amplify the inflammatory processes triggered by the presence of the bacteria. When this hypothesis was tested directly by exposing chondrocytes to BbHtrAin vitro, inflammatory cytokines (sICAM-1 and IL-6) and chemokines (CXCL1, CCL1, CCL2 and CCL5) that are hallmarks of Lyme disease were induced. These results provide the first evidence that, by utilizing BbHtrA, B.burgdorferi may actively participate in its dissemination and in the tissue damage and inflammation observed in Lyme disease. C1 [Russell, Theresa M.; Delorey, Mark J.; Johnson, Barbara J. B.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Johnson, BJB (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. EM BJohnson@cdc.gov FU CDC FX We thank Kalanthe Horiuchi for performing the bulk of the statistical coding. Additionally, we thank J. Bamburg, K. Luger, R. Cohen, C. J. Weeks and T. Patton for helpful suggestions. CDC supported this work; however, the findings and conclusions are those of the authors and do not necessarily represent the official position of the agency. NR 62 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0950-382X EI 1365-2958 J9 MOL MICROBIOL JI Mol. Microbiol. PD OCT PY 2013 VL 90 IS 2 BP 241 EP 251 DI 10.1111/mmi.12377 PG 11 WC Biochemistry & Molecular Biology; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 232IG UT WOS:000325486100004 PM 23980719 ER PT J AU Johnson, AP MacGowan, RJ Eldridge, GD Morrow, KM Sosman, J Zack, B Margolis, A AF Johnson, A. P. MacGowan, R. J. Eldridge, G. D. Morrow, K. M. Sosman, J. Zack, B. Margolis, A. CA START Study Grp TI Cost and Threshold Analysis of an HIV/STI/Hepatitis Prevention Intervention for Young Men Leaving Prison: Project START SO AIDS AND BEHAVIOR LA English DT Article DE HIV; AIDS; Prevention; Prison; Cost ID HIV RISK BEHAVIORS; UNITED-STATES; SEXUAL-BEHAVIOR; SUBSTANCE USE; US PRISONS; STD; TRANSMISSION; INCARCERATION; PERSPECTIVES; HEPATITIS AB The objectives of this study were to: (a) estimate the costs of providing a single-session HIV prevention intervention and a multi-session intervention, and (b) estimate the number of HIV transmissions that would need to be prevented for the intervention to be cost-saving or cost-effective (threshold analysis). Project START was evaluated with 522 young men aged 18-29 years released from eight prisons located in California, Mississippi, Rhode Island, and Wisconsin. Cost data were collected prospectively. Costs per participant were $689 for the single-session comparison intervention, and ranged from $1,823 to 1,836 for the Project START multi-session intervention. From the incremental threshold analysis, the multi-session intervention would be cost-effective if it prevented one HIV transmission for every 753 participants compared to the single-session intervention. Costs are comparable with other HIV prevention programs. Program managers can use these data to gauge costs of initiating these HIV prevention programs in correctional facilities. C1 [Johnson, A. P.] Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON K7L 4V1, Canada. [MacGowan, R. J.; Margolis, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Eldridge, G. D.] Univ Alaska Anchorage, Dept Psychol, Anchorage, AK USA. [Morrow, K. M.] Miriam Hosp, Ctr Behav & Prevent Med, Providence, RI 02906 USA. [Morrow, K. M.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Sosman, J.] Univ Wisconsin, Div Gen Med & Infect Dis, Sch Med & Publ Hlth, Madison, WI USA. [Zack, B.] Bridging Grp, Oakland, CA USA. RP Johnson, AP (reprint author), Queens Univ, Dept Community Hlth & Epidemiol, 21 Arch St,Abramsky Hall,Room 311, Kingston, ON K7L 4V1, Canada. EM ana.johnson@queensu.ca NR 44 TC 5 Z9 5 U1 1 U2 1 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2013 VL 17 IS 8 BP 2676 EP 2684 DI 10.1007/s10461-011-0096-7 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 226IB UT WOS:000325027600011 PM 22124581 ER PT J AU Hebden, JN Anttila, A Allen-Bridson, K Morrell, GC Wright, MO Horan, T AF Hebden, Joan N. Anttila, Angela Allen-Bridson, Kathy Morrell, Gloria C. Wright, Marc-Oliver Horan, Teresa TI Healthcare-associated infections studies project: An American Journal of Infection Control and National Healthcare Safety Network data quality collaboration-LabID Clostridium Difficile event 2013 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article AB This is the first in a series of case studies that will be published in American Journal of Infection Control following the Centers for Disease Control and Prevention/National Healthcare Safety Network (NHSN) surveillance definition update of 2013. These cases reflect some of the complex patient scenarios infection professionals encounter during daily surveillance of health care-associated infections using NHSN definitions. Answers to the questions posed and immediate feedback in the form of answers and explanations are available at: http://www.surveymonkey.com/s/AJIC-NHSN-LbId2013. All individual participant answers will remain confidential, although it is the authors' hope to share a summary of the findings at a later date. Cases, answers, and explanations have been reviewed and approved by NHSN staff. Active participation is encouraged and recommended. Review/reference Chapter 12-Multidrug-resistant organism & C difficile infection module protocol, of the NHSN Patient Safety Component Manual (http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf), for information you may need to answer the case study questions. Copyright (C) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Hebden, Joan N.] Wolters Kluwer Hlth Sentri7, Bellevue, WA 98006 USA. [Anttila, Angela; Allen-Bridson, Kathy; Morrell, Gloria C.] Ctr Dis Control & Prevent, Natl Healthcare Safety Network, Div Healthcare Qual Promot, Atlanta, GA USA. [Wright, Marc-Oliver] North Shore Univ Hlth Syst, Dept Infect Control, Evanston, IL USA. [Horan, Teresa] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Hebden, JN (reprint author), Wolters Kluwer Hlth Sentri7, 3535 Factoria Blvd SE, Bellevue, WA 98006 USA. NR 0 TC 2 Z9 2 U1 1 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT PY 2013 VL 41 IS 10 BP 916 EP 917 DI 10.1016/j.ajic.2013.05.009 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 229HY UT WOS:000325254600017 PM 23928030 ER PT J AU Marin, M Bialek, SR Seward, JF AF Marin, Mona Bialek, Stephanie R. Seward, Jane F. TI Updated Recommendations for Use of VariZIG-United States, 2013 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID ZOSTER IMMUNE GLOBULIN; VARICELLA; PREVENTION; IMMUNOGLOBULIN; EFFICACY; CHILDREN AB VariZIG (varicella zoster immune globulin) is indicated for transplant recipients with a significant exposure to varicella who do not have demonstrated immunity to this virus. C1 [Marin, Mona; Bialek, Stephanie R.; Seward, Jane F.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Marin, M (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM mmarin@cdc.gov NR 16 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2013 VL 13 IS 10 BP 2765 EP 2767 DI 10.1111/ajt.12477 PG 3 WC Surgery; Transplantation SC Surgery; Transplantation GA 224ZN UT WOS:000324932200033 ER PT J AU Kroneman, A Vega, E Vennema, H Vinje, J White, PA Hansman, G Green, K Martella, V Katayama, K Koopmans, M AF Kroneman, Annelies Vega, Everardo Vennema, Harry Vinje, Jan White, Peter A. Hansman, Grant Green, Kim Martella, Vito Katayama, Kazuhiko Koopmans, Marion TI Proposal for a unified norovirus nomenclature and genotyping SO ARCHIVES OF VIROLOGY LA English DT Article ID NORWALK-LIKE VIRUSES; INFECTIOUS INTESTINAL DISEASE; UNITED-STATES; ACUTE GASTROENTERITIS; MOLECULAR EPIDEMIOLOGY; ENTERIC CALICIVIRUSES; MAXIMUM-LIKELIHOOD; OUTBREAKS; CLASSIFICATION; TAXONOMY AB Noroviruses belong to a genus of genetically diverse viruses within the family Caliciviridae and cause acute gastroenteritis in humans and animals. They are subdivided into genogroups, each of which further segregates into genotypes. Until recently, a new genotype was based on a defined pairwise distance cutoff of complete VP1 sequences, but with the increasing number of available norovirus sequences, this cutoff is no longer accurate, and sequences in the public database have been misclassified. In this paper, we demonstrate that the pairwise distance cutoff method can no longer be used and outline a phylogenetic approach to classify noroviruses. Furthermore, we propose a dual nomenclature using both ORF1 and VP1 sequences, as recombination is common and recognizing recombinant viruses may be relevant. With the continuing emergence of new norovirus lineages, we propose to coordinate nomenclature of new norovirus genotypes through an international norovirus working group. C1 [Kroneman, Annelies; Vennema, Harry; Koopmans, Marion] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Vega, Everardo; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA. [White, Peter A.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Fac Sci, Sydney, NSW, Australia. [Hansman, Grant] Heidelberg Univ, CHS Fdn, Heidelberg, Germany. [Green, Kim] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Green, Kim] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA. [Martella, Vito] Univ Bari Aldo Moro, Dept Vet Publ Hlth, Valenzano, Italy. [Katayama, Kazuhiko] Natl Inst Infect Dis, Dept Virol 2, Tokyo, Japan. [Koopmans, Marion] Erasmus MC, Dept Virol, Rotterdam, Netherlands. RP Kroneman, A (reprint author), Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. EM annelies.kroneman@rivm.nl RI White, Peter/C-6573-2012; Martella, Vito/K-3146-2016; OI White, Peter/0000-0002-6046-9631; Martella, Vito/0000-0002-5740-6947; Hansman, Grant/0000-0001-8735-4618; Vinje, Jan/0000-0002-1530-3675 NR 49 TC 173 Z9 183 U1 5 U2 61 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD OCT PY 2013 VL 158 IS 10 BP 2059 EP 2068 DI 10.1007/s00705-013-1708-5 PG 10 WC Virology SC Virology GA 226BA UT WOS:000325008000004 PM 23615870 ER PT J AU Bean, CJ Boulet, SL Yang, GY Payne, AB Ghaji, N Pyle, ME Hooper, WC Bhatnagar, P Keefer, J Barron-Casella, EA Casella, JF DeBaun, MR AF Bean, Christopher J. Boulet, Sheree L. Yang, Genyan Payne, Amanda B. Ghaji, Nafisa Pyle, Meredith E. Hooper, W. Craig Bhatnagar, Pallav Keefer, Jeffrey Barron-Casella, Emily A. Casella, James F. DeBaun, Michael R. TI Acute chest syndrome is associated with single nucleotide polymorphism-defined beta globin cluster haplotype in children with sickle cell anaemia SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE sickle cell anaemia; acute chest syndrome; beta-globin; genetic analysis; haplotype ID PREDICTING CLINICAL SEVERITY; FETAL-HEMOGLOBIN LEVELS; TRANSFUSION SIT TRIAL; GENE-CLUSTER; ALPHA-THALASSEMIA; DISEASE; MANIFESTATIONS; POLYMERIZATION; MODULATION; EXPRESSION AB Genetic diversity at the human beta-globin locus has been implicated as a modifier of sickle cell anaemia (SCA) severity. However, haplotypes defined by restriction fragment length polymorphism sites across the beta-globin locus have not been consistently associated with clinical phenotypes. To define the genetic structure at the beta-globin locus more thoroughly, we performed high-density single nucleotide polymorphism (SNP) mapping in 820 children who were homozygous for the sickle cell mutation (HbSS). Genotyping results revealed very high linkage disequilibrium across a large region spanning the locus control region and the HBB (beta-globin gene) cluster. We identified three predominant haplotypes accounting for 96% of the beta(S)-carrying chromosomes in this population that could be distinguished using a minimal set of common SNPs. Consistent with previous studies, fetal haemoglobin level was significantly associated with beta(S)-haplotypes. After controlling for covariates, an association was detected between haplotype and rate of hospitalization for acute chest syndrome (ACS) (incidence rate ratio 0 center dot 51, 95% confidence interval 0 center dot 29-0 center dot 89) but not incidence rate of vaso-occlusive pain or presence of silent cerebral infarct (SCI). Our results suggest that these SNP-defined beta(S)-haplotypes may be associated with ACS, but not pain or SCI in a study population of children with SCA. C1 [Bean, Christopher J.; Yang, Genyan; Payne, Amanda B.; Ghaji, Nafisa; Pyle, Meredith E.; Hooper, W. Craig] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Boulet, Sheree L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Bhatnagar, Pallav] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Keefer, Jeffrey; Barron-Casella, Emily A.; Casella, James F.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD 21205 USA. [DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Vanderbilt Meharry Matthew Walker Ctr Excellence, Nashville, TN 37232 USA. RP DeBaun, MR (reprint author), Vanderbilt Univ, Sch Med, Vanderbilt Meharry Matthew Walker Ctr Excellence, 2200 Childrens Way, Nashville, TN 37232 USA. EM m.debaun@vanderbilt.edu FU NHLBI [RO1-HL079937, 1U54HL090515]; Burroughs Wellcome Foundation; NINDS [U01-NS-042804]; CTSA [U54 HL090515, RO1 HL091759, M01-RR00052] FX The authors would like to thank the families and children with SCD who were participants, the SIT Trial study coordinators, and both past and present laboratory members in the Division of Blood Disorders (CDC) and Division of Pediatric Hematology (JHU). Support for this study included RO1-HL079937 (NHLBI) and Burroughs Wellcome Foundation for M.R.D., U01-NS-042804 (NINDS) for E.B.C., 1U54HL090515 (NHLBI) and U54 HL090515, RO1 HL091759 and M01-RR00052 (CTSA) for J.F.C. NR 47 TC 7 Z9 7 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD OCT PY 2013 VL 163 IS 2 BP 268 EP 276 DI 10.1111/bjh.12507 PG 9 WC Hematology SC Hematology GA 229HB UT WOS:000325251700015 PM 23952145 ER PT J AU Simard, EP Watson, M Saraiya, M Clarke, CA Palefsky, JM Jemal, A AF Simard, Edgar P. Watson, Meg Saraiya, Mona Clarke, Christina A. Palefsky, Joel M. Jemal, Ahmedin TI Trends in the Occurrence of High-Grade Anal Intraepithelial Neoplasia in San Francisco: 2000-2009 SO CANCER LA English DT Article DE anal cancer; anal intraepithelial neoplasia; incidence; screening ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-POSITIVE MEN; UNITED-STATES; CANCER; LESIONS; RECOMMENDATIONS; SEX; PROGRESSION; CALIFORNIA; PATHOLOGY AB BACKGROUNDAlthough screening of human immunodeficiency virus (HIV)-positive individuals for anal intraepithelial neoplasia (AIN; a precursor of anal cancer) has been practiced in San Francisco among HIV health care providers since the early 1990s, to the authors' knowledge no study to date has focused on evaluating recent AIN trends. METHODSCases of high-grade AIN 3 and invasive anal cancer from 2000 to 2009 were obtained from the San Francisco/Oakland Surveillance, Epidemiology, and End Results (SEER) population-based cancer registry. Age-standardized rates of AIN 3 and anal cancer were calculated overall and by demographic characteristics (sex, race, and age group). Log-linear regression calculated annual percent change in rates during 2000 to 2009, and rate ratios (RRs) and 95% confidence intervals (95% CIs), evaluated differences in rates during 2000 through 2004 and 2005 through 2009. RESULTSDuring 2000 through 2009, the majority of AIN 3 cases occurred among men (1152 of 1320 men; 87.3%). Rates of AIN 3 during the corresponding period increased by 11.48% per year (P<.05) among men and were stable among women. Comparing rates among men during 2000 to 2004 with those during 2005 to 2009, the largest increases were noted among those aged 50 years to 64 years (RR, 2.47; 95% CI, 1.93-3.17) and among black individuals (RR, 3.49; 95% CI, 2.14-5.85). During the same period, anal cancer rates were stable among men and women. CONCLUSIONSRates of AIN 3 increased in San Francisco during 2000 through 2009, in conjunction with an anal cytology screening program for high-risk groups, whereas rates of invasive anal cancer were unchanged. Continued surveillance is necessary to evaluate the impact of screening and human papillomavirus vaccination on the prevention of human papillomavirus-related AIN and anal cancer. Cancer 2013;119:3539-3545.. (c) 2013 American Cancer Society. Rates of high-grade anal intraepithelial neoplasia (AIN 3) increased in San Francisco between 2000 and 2009, in conjunction with an anal cytology screening program for high-risk individuals, whereas rates of invasive anal cancer were stable. Continued surveillance is necessary to evaluate the impact of screening and human papillomavirus (HPV) vaccination coverage on the prevention of HPV-related AIN and anal cancer. C1 [Simard, Edgar P.; Jemal, Ahmedin] Amer Canc Soc, Intramural Res Dept, Surveillance Res Program, Atlanta, GA 30303 USA. [Watson, Meg; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Clarke, Christina A.] Canc Prevent Inst Calif, Fremont, CA USA. [Clarke, Christina A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. [Palefsky, Joel M.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. RP Simard, EP (reprint author), Amer Canc Soc, Intramural Res Dept, Surveillance Res Program, 250 Williams St NW, Atlanta, GA 30303 USA. EM edgar.simard@cancer.org FU National Cancer Institute; Merck; Hologic FX Dr. Clarke has received a grant from the National Cancer Institute. Dr. Palefsky is a member of the boards of Merck and Company and Pharmajet, and has received travel support from Merck. He has also received grants from Merck and Hologic and has acted as a member of the Speakers' Bureau for Hologic. Dr. Palefsky also owns stock in Aura Biosciences. NR 34 TC 10 Z9 10 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2013 VL 119 IS 19 BP 3539 EP 3545 DI 10.1002/cncr.28252 PG 7 WC Oncology SC Oncology GA 224XK UT WOS:000324925500018 PM 23861091 ER PT J AU Marcinkevage, JA Alverson, CJ Narayan, KMV Kahn, HS Ruben, J Correa, A AF Marcinkevage, Jessica A. Alverson, C. J. Narayan, K. M. Venkat Kahn, Henry S. Ruben, Julia Correa, Adolfo TI Race/Ethnicity Disparities in Dysglycemia Among US Women of Childbearing Age Found Mainly in the Nonoverweight/Nonobese SO DIABETES CARE LA English DT Article ID BETA-CELL FUNCTION; INSULIN SENSITIVITY; GLYCATED HEMOGLOBIN; METABOLIC SYNDROME; AFRICAN-AMERICANS; DIABETES-MELLITUS; ADIPOSE-TISSUE; PREVALENCE; OBESITY; RISK AB OBJECTIVETo describe the burden of dysglycemiaabnormal glucose metabolism indicative of diabetes or high risk for diabetesamong U.S. women of childbearing age, focusing on differences by race/ethnicity.RESEARCH DESIGN AND METHODSUsing U.S. National Health and Nutrition Examination Survey data (1999-2008), we calculated the burden of dysglycemia (i.e., prediabetes or diabetes from measures of fasting glucose, A1C, and self-report) in nonpregnant women of childbearing age (15-49 years) by race/ethnicity status. We estimated prevalence risk ratios (PRRs) for dysglycemia in subpopulations stratified by BMI (measured as kilograms divided by the square of height in meters), using predicted marginal estimates and adjusting for age, waist circumference, C-reactive protein, and socioeconomic factors.RESULTSBased on data from 7,162 nonpregnant women, representing >59,000,000 women nationwide, 19% (95% CI 17.2-20.9) had some level of dysglycemia, with higher crude prevalence among non-Hispanic blacks and Mexican Americans vs. non-Hispanic whites (26.3% [95% CI 22.3-30.8] and 23.8% [19.5-28.7] vs. 16.8% [14.4-19.6], respectively). In women with BMI <25 kg/m(2), dysglycemia prevalence was roughly twice as high in both non-Hispanic blacks and Mexican Americans vs. non-Hispanic whites. This relative increase persisted in adjusted models (PRRadj 1.86 [1.16-2.98] and 2.23 [1.38-3.60] for non-Hispanic blacks and Mexican Americans, respectively). For women with BMI 25-29.99 kg/m(2), only non-Hispanic blacks showed increased prevalence vs. non-Hispanic whites (PRRadj 1.55 [1.03-2.34] and 1.28 [0.73-2.26] for non-Hispanic blacks and Mexican Americans, respectively). In women with BMI >30 kg/m(2), there was no significant increase in prevalence of dysglycemia by race/ethnicity category.CONCLUSIONSOur findings show that dysglycemia affects a significant portion of U.S. women of childbearing age and that disparities by race/ethnicity are most prominent in the nonoverweight/nonobese. C1 [Marcinkevage, Jessica A.; Alverson, C. J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Marcinkevage, Jessica A.] Oak Ridge Associated Univ, Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Marcinkevage, Jessica A.; Narayan, K. M. Venkat] Emory Univ, Laney Grad Sch, Grad Div Biol & Biomed Sci, Program Nutr & Hlth Sci, Atlanta, GA 30322 USA. [Kahn, Henry S.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Ruben, Julia] D Tree Int, Weston, MA USA. [Correa, Adolfo] Univ Mississippi Med Ctr, Dept Med, Jackson, MS USA. RP Marcinkevage, JA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM jmarcinkevage@cdc.gov RI Narayan, K.M. Venkat /J-9819-2012; OI Narayan, K.M. Venkat /0000-0001-8621-5405; Kahn, Henry/0000-0003-2533-1562 FU Department of Energy; Centers of Disease Control and Prevention FX This project was supported in part by an appointment to the Research Participation Program for the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an agreement between the Department of Energy and the Centers of Disease Control and Prevention. NR 38 TC 4 Z9 4 U1 0 U2 6 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD OCT PY 2013 VL 36 IS 10 BP 3033 EP 3039 DI 10.2337/dc12-2312 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 222RT UT WOS:000324749500039 PM 23780951 ER PT J AU Reuben, CA Pastor, PN AF Reuben, Cynthia A. Pastor, Patricia N. TI The effect of special health care needs and health status on school functioning SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Child health; Child disability; National Survey of Children's Health ID SELF-RATED HEALTH; CHILD HEALTH; CHRONIC ILLNESS; UNITED-STATES; OUTCOMES; IMPACT; PREVALENCE; ASTHMA; ADOLESCENTS; RISKS AB Background: Past studies have shown that specific child conditions are associated with poor school outcomes. A national health survey with noncategorical measures of health and indicators of school functioning offers the opportunity to examine this association. Objectives: To compare links between two health measures (children with special health care needs and general health status) and multiple school outcomes. Methods: The analysis was based on 59,440 children aged 6-17 years from the 2007 National Survey of Children's Health. Child health was assessed using the Children with Special Health Care Needs (CSHCN) screener and a question on general health status. CSHCN were classified by the complexity of their health care needs. Indicators of school functioning included special education use, many problem reports, repeated a grade, lack of school engagement, and many missed school days. Results: Overall 22% of children were identified as CSHCN: 13% with more complex needs (C-CSHCN) and 9% with medication use only (CSHCN-RX). Approximately 17% of children were in less than optimal health. After controlling for a child's sociodemographic characteristics C-CSHCN had an increased risk of all of the negative school outcomes compared to children without SHCN, while CSHCN-RX had an increased risk of only one school outcome (many missed school days). Children in less than optimal health were at an increased risk of all negative school outcomes compared to children in optimal health. Conclusions: The CSHCN screener and health status question identify related, but distinct, groups of children with worse outcomes on the indicators of school functioning. Published by Elsevier Inc. C1 [Reuben, Cynthia A.; Pastor, Patricia N.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Pastor, PN (reprint author), 3311 Toledo Rd,Room 6437, Hyattsville, MD 20782 USA. EM Php3@cdc.gov NR 33 TC 5 Z9 5 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD OCT PY 2013 VL 6 IS 4 BP 325 EP 332 DI 10.1016/j.dhjo.2013.03.003 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 224CJ UT WOS:000324858900008 PM 24060255 ER PT J AU Kancherla, V Braun, KV Yeargin-Allsopp, M AF Kancherla, Vijaya Braun, Kim Van Naarden Yeargin-Allsopp, Marshalyn TI Childhood vision impairment, hearing loss and co-occurring autism spectrum disorder SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Autism spectrum disorder; Children; Developmental disabilities; Hearing loss; Visually impaired ID SOCIAL COMMUNICATION DIFFICULTIES; OPTIC-NERVE HYPOPLASIA; DEVELOPMENTAL-DISABILITIES; YOUNG-CHILDREN; METROPOLITAN ATLANTA; CONGENITAL-RUBELLA; VISUAL IMPAIRMENT; BLIND-CHILDREN; BIRTH-WEIGHT; PREVALENCE AB Background: Limited population-based data on prevalence of childhood vision impairment (VI) and hearing loss (HL), and their co-occurrence with autism spectrum disorder (ASD) exists. Objective: To examine prevalence and characteristics of VI, HL and co-occurring ASD among 8-year-olds in metropolitan Atlanta 2000-2008. Methods: We used data from the population-based Metropolitan Atlanta Developmental Disabilities Surveillance Program. Prevalence, birth and parental characteristics, presence and severity of other co-occurring developmental disabilities, and age of earliest identification of ASD, were examined for children with VI and HL, by co-occurring ASD. Results: VI and HL prevalences were 1.2 and 1.3 per 1000 8-year-olds, respectively. Approximately 6-7% of children with VI or HL had co-occurring ASD. Children with VI or HL with co-occurring ASD differed from those without co-occurring ASD by select birth characteristics and the presence of other co-occurring DDs. The median age of earliest known ASD diagnosis was significantly later among children with VI and ASD compared to children with ASD without VI (79 vs. 56 months). Children with HL and ASD were first evaluated by a community provider significantly earlier than those with ASD without HL (40 vs. 50 months). Conclusions: The frequency of co-occurring ASD with VI and HL is higher than the population prevalence of ASD. The significant delays in diagnosis of ASD in children with VI and lack of earlier diagnosis of ASD among children with HL despite earlier evaluation highlight the importance of developing screening tools for early identification of ASD among children with VI and HL. Published by Elsevier Inc. C1 [Kancherla, Vijaya; Braun, Kim Van Naarden; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Kancherla, Vijaya] Assoc Univ Ctr Disabil, Silver Spring, MD 20910 USA. RP Braun, KV (reprint author), Ctr Dis Control & Prevent, Dev Disabil Branch, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd MS E-86, Atlanta, GA 30333 USA. EM kbn5@cdc.gov FU Intramural CDC HHS [CC999999] NR 49 TC 8 Z9 9 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD OCT PY 2013 VL 6 IS 4 BP 333 EP 342 DI 10.1016/j.dhjo.2013.05.003 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 224CJ UT WOS:000324858900009 PM 24060256 ER PT J AU Volberg, V Harley, K Calafat, AM Dave, V McFadden, J Eskenazi, B Holland, N AF Volberg, Vitaly Harley, Kim Calafat, Antonia M. Dave, Veronica McFadden, Jessica Eskenazi, Brenda Holland, Nina TI Maternal Bisphenol A Exposure During Pregnancy and Its Association With Adipokines in Mexican-American Children SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Article DE leptin; adiponectin; prenatal; endocrine disruptor; sex-difference ID PERINATAL EXPOSURE; METABOLIC SYNDROME; ESTROGEN-RECEPTOR; INSULIN-RESISTANCE; BIRTH COHORT; LEPTIN; ADIPONECTIN; WEIGHT; OBESITY; MICE AB Bisphenol A (BPA) is a high volume production chemical that has been detected in 93% of the United States population. It is thought to have endocrine disrupting activity but human data are limited. In this study, we examined whether prenatal or concurrent urinary BPA concentrations are associated with key metabolism-related hormones, adiponectin and leptin (adipokines), in 9-year-old children. For this analysis, we used 188 mother-child pairs from the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) prospective study. BPA was measured in urinary spot samples during early (12.6 +/- 3.9 weeks gestation) and late (26.3 +/- 2.5 weeks gestation) pregnancy and in 9-year-old children. We found that BPA concentrations during late pregnancy were associated with increased plasma leptin in boys ( = 0.06, P = 0.01), controlling for maternal prepregnancy body mass index (BMI), pregnancy soda consumption, and smoking, years in US prior to pregnancy, maternal education, household poverty status, child BMI and child soda, fast food and sweet snack consumption at 9 years. Additionally, we found that BPA concentrations during early pregnancy are directly associated with plasma adiponectin levels in girls ( = 3.71, P = 0.03). However, we did not find any significant relationships between concurrent BPA concentrations and 9-year child adiponectin or leptin. Overall, our data suggest that prenatal BPA concentrations may influence adipokine levels in 9-year-old children. Environ. Mol. Mutagen. 54:621-628, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Volberg, Vitaly; Harley, Kim; Dave, Veronica; McFadden, Jessica; Eskenazi, Brenda; Holland, Nina] Univ Calif Berkeley, Sch Publ Hlth, CERCH, Berkeley, CA 94720 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Holland, N (reprint author), Univ Calif Berkeley, Sch Publ Hlth, 733 Univ Hall, Berkeley, CA 94720 USA. EM ninah@berkeley.edu FU NIEHS NIH HHS [P01 ES009605, R01 ES021369, RC2 ES018792] NR 56 TC 13 Z9 13 U1 0 U2 28 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD OCT PY 2013 VL 54 IS 8 SI SI BP 621 EP 628 DI 10.1002/em.21803 PG 8 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA 232DD UT WOS:000325469000002 PM 23908009 ER PT J AU Golding, J Steer, CD Hibbeln, JR Emmett, PM Lowery, T Jones, R AF Golding, Jean Steer, Colin D. Hibbeln, Joseph R. Emmett, Pauline M. Lowery, Tony Jones, Robert TI Dietary Predictors of Maternal Prenatal Blood Mercury Levels in the ALSPAC Birth Cohort Study SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID UK TOTAL DIET; METHYLMERCURY EXPOSURE; CHILD-DEVELOPMENT; FISH CONSUMPTION; REACTION CELL; ICP-MS; POPULATION; CADMIUM; FOOD; AGE AB BACKGROUND: Very high levels of prenatal maternal mercury have adverse effects on the developing fetal brain. It has been suggested that all possible sources of mercury should be avoided. However, although seafood is a known source of mercury, little is known about other dietary components that contribute to the overall levels of blood mercury. OBJECTIVE: Our goal was to quantify the contribution of components of maternal diet to prenatal blood mercury level. METHODS: Whole blood samples and information on diet and sociodemographic factors were collected from pregnant women (n = 4,484) enrolled in the Avon Longitudinal Study of Parents and Children (ALSPAC). The blood samples were assayed for total mercury using inductively coupled plasma dynamic reaction cell mass spectrometry. Linear regression was used to estimate the relative contributions of 103 dietary variables and 6 sociodemographic characteristics to whole blood total mercury levels (TBM; untransformed and log-transformed) based on R-2 values. RESULTS: We estimated that maternal diet accounted for 19.8% of the total variation in ln-TBM, with 44% of diet-associated variability (8.75% of the total variation) associated with seafood consumption (white fish, oily fish, and shellfish). Other dietary components positively associated with TBM included wine and herbal teas, and components with significant negative associations included white bread, meat pies or pasties, and french fries. CONCLUSIONS: Although seafood is a source of dietary mercury, seafood appeared to explain a relatively small proportion of the variation in TBM in our UK study population. Our findings require confirmation, but suggest that limiting seafood intake during pregnancy may have a limited impact on prenatal blood mercury levels. C1 [Golding, Jean; Steer, Colin D.; Emmett, Pauline M.] Univ Bristol, Ctr Child & Adolescent Hlth, Bristol, Avon, England. [Hibbeln, Joseph R.] NIAAA, NIH, US Dept HHS, Bethesda, MD USA. [Lowery, Tony] NOAA, Natl Marine Fisheries Serv, Natl Seafood Inspect Lab, Pascagoula, MS USA. [Jones, Robert] Ctr Dis Control & Prevent, Inorgan & Radiat Analyt Toxicol Branch, Atlanta, GA USA. RP Golding, J (reprint author), Sch Social & Community Med, Ctr Child & Adolescent Hlth, Oakfield House,Oakfield Rd, Bristol BS8 2BN, Avon, England. EM jean.golding@bristol.ac.uk OI Emmett, Pauline/0000-0003-1076-4779; Golding, Jean/0000-0003-2826-3307 FU National Oceanic and Atmospheric Administration (NOAA); Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH) FX The UK Medical Research Council (MRC), the Wellcome Trust, and the University of Bristol currently provide core support for ALSPAC. The assays of the maternal blood samples were carried out at the Centers for Disease Control and Prevention with funding from the National Oceanic and Atmospheric Administration (NOAA), and the statistical analyses were carried out in Bristol with funding from NOAA and support from the Intramural Research Program of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (NIH). NR 45 TC 26 Z9 28 U1 3 U2 35 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2013 VL 121 IS 10 BP 1214 EP 1218 DI 10.1289/ehp.1206115 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227YU UT WOS:000325152400026 PM 23811414 ER PT J AU Philippat, C Wolff, MS Calafat, AM Ye, XY Bausell, R Meadows, M Stone, J Slama, R Engel, SM AF Philippat, Claire Wolff, Mary S. Calafat, Antonia M. Ye, Xiaoyun Bausell, Rebecca Meadows, Molly Stone, Joanne Slama, Remy Engel, Stephanie M. TI Prenatal Exposure to Environmental Phenols: Concentrations in Amniotic Fluid and Variability in Urinary Concentrations during Pregnancy SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID BISPHENOL-A CONCENTRATIONS; PREDICTORS; PARABENS; BIRTH; HUMANS; WOMEN; SERUM; 2ND AB BACKGROUND: Maternal urinary biomarkers are often used to assess fetal exposure to phenols and their precursors. Their effectiveness as a measure of exposure in epidemiological studies depends on their variability during pregnancy and their ability to accurately predict fetal exposure. OBJECTIVES: We assessed the relationship between urinary and amniotic fluid concentrations of nine environmental phenols, and the reproducibility of urinary concentrations, among pregnant women. METHODS: Seventy-one women referred for amniocentesis were included. Maternal urine was collected at the time of the amniocentesis appointment and on two subsequent occasions. Urine and amniotic fluid were analyzed for 2,4-and 2,5-dichlorophenols, bisphenol A, benzophenone-3, triclosan, and methyl-, ethyl-, propyl-, and butylparabens using online solid phase extraction-high performance liquid chromatography-isotope dilution tandem mass spectrometry. RESULTS: Only benzophenone-3 and propylparaben were detectable in more than half of the amniotic fluid samples; for these phenols, concentrations in amniotic fluid and maternal urine collected on the same day were positively correlated (rho = 0.53 and 0.32, respectively). Other phenols were detected infrequently in amniotic fluid (e.g., bisphenol A was detected in only two samples). The intraclass correlation coefficients (ICCs) of urinary concentrations in samples from individual women ranged from 0.48 to 0.62 for all phenols except bisphenol A (ICC = 0.11). CONCLUSION: Amniotic fluid detection frequencies for most phenols were low. The reproducibility of urine measures was poor for bisphenol A, but good for the other phenols. Although a single sample may provide a reasonable estimate of exposure for some phenols, collecting multiple urine samples during pregnancy is an option to reduce exposure measurement error in studies regarding the effects of phenol prenatal exposure on health. C1 [Philippat, Claire; Slama, Remy] INSERM, Inst Albert Bonniot U823, Team Environm Epidemiol Appl Reprod & Resp Hlth, Grenoble, France. [Philippat, Claire; Slama, Remy] Grenoble Univ, Inst Albert Bonniot, Grenoble, France. [Wolff, Mary S.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA. [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bausell, Rebecca; Meadows, Molly] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Stone, Joanne] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA. [Engel, Stephanie M.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. RP Philippat, C (reprint author), UJF Site Sante, INSERM UJF U823, Inst Albert Bonniot, Ctr Rech, BP 170, F-38042 La Tronche 9, France. EM claire.philippat@e.ujf-grenoble.fr RI Philippat, Claire/N-2423-2013; Slama, Remy/M-1755-2013 OI Slama, Remy/0000-0002-8980-8529 FU National Institute of Environmental Health Sciences [R21ES014034]; Region Rhone-Alpes FX This research was supported by funding from the National Institute of Environmental Health Sciences (R21ES014034). C.P. was supported by a grant from Region Rhone-Alpes. NR 32 TC 43 Z9 43 U1 2 U2 41 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2013 VL 121 IS 10 BP 1225 EP 1231 DI 10.1289/ehp.1206335 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227YU UT WOS:000325152400028 PM 23942273 ER PT J AU Portnoy, J Chew, GL Phipatanakul, W Williams, PB Grimes, C Kennedy, K Matsui, EC Miller, JD Bernstein, D Blessing-Moore, J Cox, L Khan, D Lang, D Nicklas, R Oppenheimer, J Randolph, C Schuller, D Spector, S Tilles, SA Wallace, D Seltzer, J Sublett, J AF Portnoy, Jay Chew, Ginger L. Phipatanakul, Wanda Williams, P. Brock Grimes, Carl Kennedy, Kevin Matsui, Elizabeth C. Miller, J. David Bernstein, David Blessing-Moore, Joann Cox, Linda Khan, David Lang, David Nicklas, Richard Oppenheimer, John Randolph, Christopher Schuller, Diane Spector, Sheldon Tilles, Stephen A. Wallace, Dana Seltzer, James Sublett, James TI Environmental assessment and exposure reduction of cockroaches: A practice parameter SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Allergy; cockroach; sensitization; disease; morbidity ID INNER-CITY ASTHMA; HOUSE-DUST MITE; INTEGRATED PEST-MANAGEMENT; NEW-YORK-CITY; INDOOR ALLERGEN SENSITIZATION; IGE-BINDING REACTIVITY; BLA G 4; GERMAN-COCKROACH; BLATTELLA-GERMANICA; LOW-INCOME AB This parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "Environmental assessment and remediation: a practice parameter.'' This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single person, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma& Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). C1 [Sublett, James] Family Allergy & Asthma, Louisville, KY USA. [Kennedy, Kevin] Childrens Mercy Hosp, Environm Hlth Program, Kansas City, MO 64108 USA. [Portnoy, Jay] Univ Missouri, Childrens Mercy Hosp, Kansas City Sch Med, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA. [Bernstein, David] Univ Cincinnati, Coll Med, Dept Clin Med & Environm Hlth, Div Allergy Immunol, Cincinnati, OH USA. [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Med & Pediat, Dept Immunol, Palo Alto, CA 94304 USA. [Khan, David] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA. [Lang, David] Cleveland Clin Fdn, Div Med, Allergy Immunol Sect, Allergy & Immunol Fellowship Training Program, Cleveland, OH 44195 USA. [Nicklas, Richard] George Washington Med Ctr, Dept Med, Washington, DC USA. [Oppenheimer, John] Pulm & Allergy Associates, New Jersey Med Sch, Dept Internal Med, Morristown, NJ USA. [Portnoy, Jay] Univ Missouri, Childrens Mercy Hosp, Kansas City Sch Med, Dept Pediat,Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA. [Randolph, Christopher] Yale Affiliated Hosp, Ctr Allergy Asthma & Immunol, Dept Pediat, Waterbury, CT USA. [Schuller, Diane] Penn State Univ, Milton S Hershey Med Coll, Dept Pediat, Hershey, PA USA. [Spector, Sheldon] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Tilles, Stephen A.] Univ Washington, Dept Med, Sch Med, Redmond, WA USA. [Wallace, Dana] Nova SE Univ, Coll Osteopath Med, Dept Med, Davie, FL USA. [Chew, Ginger L.] Ctr Dis Control & Prevent CDC, Natl Ctr Environm Hlth, Healthy Homes & Lead Poisoning Prevent Branch, Atlanta, GA USA. RP Portnoy, J (reprint author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St 3-3, Palatine, IL 60067 USA. EM grupes@jcaai.org FU National Institutes of Health (NIH); Public Health Service; TEVA; Genentech; Pfizer; Merck; Meda; GlaxoSmithKline; Array; Cephalon; MedImmune; Vanberg Family Foundation; NIH/National Institute of Mental Health; Genentech/Novartis; AstraZeneca; Novartis; Boehringer Ingelheim; Amgen; Astellas; Amphastar; Sunovion; Nutricia; Rigel FX Disclosure of potential conflict of interest: J. Portnoy is a speaker for Thermo Fisher and Mylan and has consultant arrangements with Thermo Fisher and Sanofi. W. Phipatanakul has received research support from the National Institutes of Health (NIH). C. Grimes is employed by Health Habitats LLC. K. Kennedy has received research support from Public Health Service and is an instructor for Healthy Housing Solutions and the Indoor Air Quality Training Institute. E. C. Matsui has received payment for lectures from Indoor Biotechnologies and has received the Phadia Research Foundation Award. D. Bernstein has received research support from TEVA, Genentech, Pfizer, Merck, Meda, GlaxoSmithKline, Array, Cephalon, and MedImmune and has provided legal consultation or expert witness testimony in cases related to anaphylaxis, contact dermatitis, and occupational asthma. J. Blessing-Moore has received research support and is a speaker for Meda; is a speaker for Alcon, Teva, Sunovion, Genentech/Novartis, Merck, and AstraZeneca; is a committee member of the American College of Chest Physicians, the American College of Allergy, Asthma & Immunology (ACAAI), the American Academy of Allergy, Asthma & Immunology (AAAAI), and the American Thoracic Society. L. Cox has received consulting fees from Stallergenes, has received travel support from the AAAAI, has received fees for participation in review activities from Circassia and Novartis, has received payment for writing or reviewing the manuscript from the Blue Cross Blue Shield Technology Evaluation Center, is a board member for the American Board of Allergy and Immunology, has consultant arrangements with the Food and Drug Administration Allergenic Products Advisory Committee, has provided expert testimony in cases related to chronic cinguteria, and has received payment for lectures from the Southeastern Allergy Asthma Immunology Association and Virginia AAIS. D. Khan is a speaker for Genentech, Merck, Baxter, and Viropharma; has received research support from the Vanberg Family Foundation and the NIH/National Institute of Mental Health; is the Allied Health Chair for the ACAAI; and is a member of the Joint Task Force on Practice Parameters for the Joint Council of Allergy, Asthma & Immunology. D. Lang is a speaker for Genentech/Novartis, GlaxoSmithKline, and Merck; has consultant arrangements with GlaxoSmithKline, Merck, and Aerocrine; and has received research support from Genentech/Novartis and Merck. R. Nicklas is a committee chair, volunteer, and fellow of the ACAAI. J. Oppenheimer has consultant arrangements with GlaxoSmithKline, AstraZeneca, and Mylan; has received research support from AstraZeneca, GlaxoSmithKline, Novartis, Boehringer Ingelheim, and MedImmune; has provided legal consultation/ expert witness testimony for a malpractice defense; and is a member of the American Board of Allergy and Immunology. C. Randolph is a speaker for GlaxoSmithKline, TEVA, Viropharma, Merck, and Dey; has received research support from GlaxoSmithKline, Merck, Amgen, and Genentech/Novartis; and is a consultant for AstraZeneca and Meda. S. Spector is employed by the California Allergy & Asthma Medical Group, has consultant arrangements with ISTA Pharmaceutical, is a speaker for Novartis and Merck, and has received research support from AstraZeneca, GlaxoSmithKline, Cephalon, Amgen, Sanofi, and Targacept. S. A.; Tilles has consultant arrangements with SRXA, Sunovion, and Hyrox; has received research support from Astellas, Amphastar, MedImmune, Cephalon, Genentech, Merck, TEVA, Sunovion, Boehringer Ingelheim, Nutricia, Array, Rigel, and AstraZeneca; is Associate Editor of Allergy Watch and the Annals of Allergy; is Assistant Editor of the Joint Task Force on Practice Parameters; and is on the Executive Committee for the Seattle Food Allergy Consortium. D. Wallace has received honoraria for talks from the ACAAI; is a speaker for TEVA and Myland Labs; is an advisor for Sanofi and Sunovion; is on the Executive Committee of the ACAAI; and is on the Board of Directors for the World Allergy Organization. J. Seltzer is on the speaker's bureau and has consultant arrangements with GlaxoSmithKline, is owner of Indoor Hygienic Technologies Corporation, has provided expert witness testimony/ legal consultation in cases related to indoor environmental illness, and is on the speaker's bureau for TEVA Pharmaceuticals. J. Sublett has received payment for lectures from GlaxoSmithKline, Merck, Sunovion, and Teva and has stock/ stock options with AllergyZone LLC. The rest of the authors declare that they have no relevant conflicts of interest. NR 111 TC 0 Z9 0 U1 1 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD OCT PY 2013 VL 132 IS 4 PG 25 WC Allergy; Immunology SC Allergy; Immunology GA 227FR UT WOS:000325096500004 ER PT J AU Pihoker, C Gilliam, LK Ellard, S Dabelea, D Davis, C Dolan, LM Greenbaum, CJ Imperatore, G Lawrence, JM Marcovina, SM Mayer-Davis, E Rodriguez, BL Steck, AK Williams, DE Hattersley, AT AF Pihoker, Catherine Gilliam, Lisa K. Ellard, Sian Dabelea, Dana Davis, Cralen Dolan, Lawrence M. Greenbaum, Carla J. Imperatore, Giuseppina Lawrence, Jean M. Marcovina, Santica M. Mayer-Davis, Elizabeth Rodriguez, Beatriz L. Steck, Andrea K. Williams, Desmond E. Hattersley, Andrew T. CA SEARCH Diabet Youth Study Grp TI Prevalence, Characteristics and Clinical Diagnosis of Maturity Onset Diabetes of the Young Due to Mutations in HNF1A, HNF4A, and Glucokinase: Results From the SEARCH for Diabetes in Youth SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID NUCLEAR FACTOR-1-ALPHA GENE; ALPHA-GENE; MELLITUS; CHILDREN; MODY; IDENTIFICATION; CLASSIFICATION; HYPERGLYCEMIA; MULTICENTER; ADOLESCENTS AB Aims: Our study aims were to determine the frequency of MODY mutations (HNF1A, HNF4A, glucokinase) in a diverse population of youth with diabetes and to assess how well clinical features identify youth with maturity-onset diabetes of the young (MODY). Methods: The SEARCH for Diabetes in Youth study is a US multicenter, population-based study of youth with diabetes diagnosed at age younger than 20 years. We sequenced genomic DNA for mutations in the HNF1A, HNF4A, and glucokinase genes in 586 participants enrolled in SEARCH between 2001 and 2006. Selection criteria included diabetes autoantibody negativity and fasting C-peptide levels of 0.8 ng/mL or greater. Results: We identified a mutation in one of three MODY genes in 47 participants, or 8.0% of the tested sample, for a prevalence of at least 1.2% in the pediatric diabetes population. Of these, only 3 had a clinical diagnosis of MODY, and the majority was treated with insulin. Compared with the MODY-negative group, MODY-positive participants had lower FCP levels (2.2 +/- 1.4 vs 3.2 +/- 2.1 ng/mL, P < .01) and fewer type 2 diabetes-like metabolic features. Parental history of diabetes did not significantly differ between the 2 groups. Conclusions/Interpretation: In this systematic study of MODY in a large pediatric US diabetes cohort, unselected by referral pattern or family history, MODY was usually misdiagnosed and incorrectly treated with insulin. Although many type 2 diabetes-like metabolic features were less common in the mutation-positive group, no single characteristic identified all patients with mutations. Clinicians should be alert to the possibility of MODY diagnosis, particularly in antibody-negative youth with diabetes. C1 [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98105 USA. [Gilliam, Lisa K.; Marcovina, Santica M.] Univ Washington, Dept Med, Seattle, WA 98105 USA. [Ellard, Sian; Hattersley, Andrew T.] Univ Exeter, Inst Biomed & Clin Sci, Peninsula Med Sch, Exeter EX2 5DW, Devon, England. [Dabelea, Dana] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Steck, Andrea K.] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Aurora, CO 80045 USA. [Davis, Cralen] Wake Forest Univ Hlth Sci, Dept Biostat Sci, Winston Salem, NC 27157 USA. [Dolan, Lawrence M.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH 45229 USA. [Greenbaum, Carla J.] Benaroya Res Inst, Diabet Res Program, Seattle, WA 98101 USA. [Imperatore, Giuseppina; Williams, Desmond E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. [Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Mayer-Davis, Elizabeth] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA. [Rodriguez, Beatriz L.] Kuakini Med Ctr, Honolulu, HI 96817 USA. RP Pihoker, C (reprint author), Seattle Childrens Hosp, Dept Pediat, Div Endocrinol, A5902,4800 Sand Point Way NE, Seattle, WA 98105 USA. EM catherine.pihoker@seattlechildrens.org OI Hattersley, Andrew/0000-0001-5620-473X FU Centers for Disease Control and Prevention [PAs 00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (NIH)/National Center for Research Resources [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Barbara Davis Center at the University of Colorado at Denver (DERC NIH) [P30 DK57516]; NIH/National Center for Research Resources at the University of Cincinnati [1UL1RR026314-01]; Juvenile Diabetes Research Foundation [JDRF 9-2007-1700]; FP7 Integrated Project CEED3; Madam Curie initial funding network Biology of Liver and Pancreas Development (BOLD); Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171] FX The SEARCH for Diabetes in Youth is supported by the Centers for Disease Control and Prevention (PAs 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site contract numbers included the following: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714); University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1); Kuakini Medical Center (U58CCU919256 and U01 DP000245); Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709); University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708-01), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01); and Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171).; We also acknowledge the involvement of General Clinical Research Centers at the South Carolina Clinical, Translational Research Institute, at the Medical University of South Carolina [National Institutes of Health (NIH)/National Center for Research Resources Grant UL1RR029882]; the Children's Hospital and Regional Medical Center (Grant M01RR00037); the Colorado Pediatric General Clinical Research Center (Grant M01 RR00069) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH Grant P30 DK57516); and the Institutional Clinical and Translational Science Award), NIH/National Center for Research Resources at the University of Cincinnati (Grant 1UL1RR026314-01). The Monogenic Diabetes ancillary study was supported by the Juvenile Diabetes Research Foundation (Grant JDRF 9-2007-1700). The staff at the University of Exeter were supported by the European Union funding from FP7 Integrated Project CEED3 and Madam Curie initial funding network Biology of Liver and Pancreas Development (BOLD) and the Peninsula National Institute for Health Research Clinical Research Facility. NR 31 TC 45 Z9 48 U1 1 U2 35 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2013 VL 98 IS 10 BP 4055 EP 4062 DI 10.1210/jc.2013-1279 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 230TM UT WOS:000325365900040 PM 23771925 ER PT J AU Tohme, RA Bulkow, L Homan, CE Negus, S McMahon, BJ AF Tohme, Rania A. Bulkow, Lisa Homan, Chriss E. Negus, Susan McMahon, Brian J. TI Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010 SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Hepatitis B; Reactivation of infection; Incidence; Risk factors ID TERM-FOLLOW-UP; HEPATOCELLULAR-CARCINOMA; VIRUS-INFECTION; CLINICAL-OUTCOMES; SURFACE-ANTIGEN; UNITED-STATES; CARRIERS; GENOTYPE; NATIVES; DISEASE AB Background: A high prevalence of reactivation of hepatitis B has been documented among immuno-suppressed individuals in the inactive phase of chronic hepatitis B; However, the proportion of and the risk factors for reactivation are largely unknown among non-immunosuppressed persons. Objectives: Estimate the incidence rate of and risk factors for hepatitis B reactivation in a population-based cohort of persons in the inactive phase of chronic hepatitis B in Alaska. Study design: A cohort of 414 Alaska Native Persons in the inactive phase of hepatitis B (HBV DNA < 2000 IU/mL and normal alanine aminotransferase (ALT) for 12 months) was followed-up for 10 years. Reactivation of hepatitis B was defined as HBV DNA >= 2000 IU/mL and ALT >= 40 IU/L. Cox-proportional hazards regression models were used to identify factors associated with reactivation. Results: A total of 36 (9%) persons had reactivation during 2984 person-years of follow-up, with an annual incidence of 1.2%. Persons aged >= 50 years (1.8%) at study entry had the highest incidence rates of reactivation although incidence rates were not significantly different by age group. Risk factors for hepatitis B reactivation were male sex (Hazard Ratio (HR) = 2.41; 95% Confidence Interval (CI): 1.17-4.96), HBV DNA >= 1000 IU/mL at study entry (HR = 7.61; 95% CI: 2.81-20.6), and HBV genotype B (HR = 6.08; 95% CI: 1.32-28.0). Conclusions The incidence of hepatitis B reactivation was low during the 10 years of follow-up. However, given the higher risk of reactivation than their counterparts, males, and those with HBV DNA >= 1000 IU/mL need to be followed-up more frequently. Published by Elsevier B.V. C1 [Tohme, Rania A.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Bulkow, Lisa; McMahon, Brian J.] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Homan, Chriss E.; Negus, Susan; McMahon, Brian J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. RP Tohme, RA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE,Mailstop A04, Atlanta, GA 30333 USA. EM rtohme@cdc.gov FU CDC from the Indian Health Service [U50/CCU022279, U01PS001097, 1 U26 94 00005 NARCH I] FX Funded in part by CDC Cooperative Agreement #U50/CCU022279 and U01PS001097 and 1 U26 94 00005 NARCH I from the Indian Health Service. NR 23 TC 10 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD OCT PY 2013 VL 58 IS 2 BP 396 EP 400 DI 10.1016/j.jcv.2013.08.012 PG 5 WC Virology SC Virology GA 222RY UT WOS:000324750000014 PM 24001884 ER PT J AU Holtzman, C Armon, C Tedaldi, E Chmiel, JS Buchacz, K Wood, K Brooks, JT AF Holtzman, Carol Armon, Carl Tedaldi, Ellen Chmiel, Joan S. Buchacz, Kate Wood, Kathleen Brooks, John T. CA HOPS Investigators TI Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE polypharmacy; drug interactions; HIV; aging ID ELDERLY-PATIENTS; REDUCTASE INHIBITORS; THERAPY; PREVALENCE; COHORT; MANAGEMENT; MORBIDITY; MORTALITY; ADHERENCE; OUTCOMES AB Among aging HIV-infected adults, polypharmacy and its consequences have not been well-described. To characterize the extent of polypharmacy and the risk of antiretroviral (ARV) drug interactions among persons of different ages. Cross-sectional analysis among patients within the HIV Outpatient Study (HOPS) cohort who were prescribed ARVs during 2006-2010. We used the University of Liverpool HIV drug interactions database to identify ARV/non-ARV interactions with potential for clinical significance. Of 3,810 patients analyzed (median age 46 years, 34 % a parts per thousand yen 50 years old) at midpoint of observation, 1,494 (39 %) patients were prescribed a parts per thousand yen 5 non-ARV medications: 706 (54 %) of 1,312 patients a parts per thousand yen 50 years old compared with 788 (32 %) of 2,498 patients < 50 years. During the five-year period, the number of patients who were prescribed at least one ARV/non-ARV combination that was contraindicated or had moderate or high evidence of interaction was 267 (7 %) and 1,267 (33 %), respectively. Variables independently associated with having been prescribed a contraindicated ARV/non-ARV combination included older age (adjusted odds ratio [aOR] per 10 years of age 1.17, 95 % CI 1.01-1.35), anxiety (aOR 1.78, 95 % CI 1.32-2.40), dyslipidemia (aOR 1.96, 95 % CI 1.28-2.99), higher daily non-ARV medication burden (aOR 1.13, 95 % CI 1.10-1.17), and having been prescribed a protease inhibitor (aOR 2.10, 95 % CI 1.59-2.76). Compared with patients < 50 years, older patients were more likely to have been prescribed an ARV/non-ARV combination that was contraindicated (unadjusted OR 1.44, 95 % CI 1.14-1.82), or had moderate or high evidence of interaction (unadjusted OR 1.29, 95 % CI 1.15-1.44). A substantial percentage of patients were prescribed at least one ARV/non-ARV combination that was contraindicated or had potential for a clinically significant interaction. As HIV-infected patients age and experience multiple comorbidities, systematic reviews of current medications by providers may reduce risk of such exposures. C1 [Holtzman, Carol] Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA. [Armon, Carl; Wood, Kathleen] Cerner Corp, Vienna, VA USA. [Tedaldi, Ellen] Temple Univ, Sch Med, Philadelphia, PA 19140 USA. [Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Holtzman, C (reprint author), Temple Univ, Sch Pharm, 3307 N Broad St, Philadelphia, PA 19140 USA. EM carol.holtzman@temple.edu FU Centers for Disease Control and Prevention (CDC); Cerner Corporation FX The Centers for Disease Control and Prevention (CDC) supported the HOPS data collection through a contract with the Cerner Corporation. The co-authors from the CDC participated in the design of the study and the analysis and interpretation of the data and approved the final version of the manuscript. NR 44 TC 24 Z9 25 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD OCT PY 2013 VL 28 IS 10 BP 1302 EP 1310 DI 10.1007/s11606-013-2449-6 PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 226DP UT WOS:000325015000014 PM 23605401 ER PT J AU Radcliffe, RA Bixler, D Moorman, A Hogan, VA Greenfield, VS Gaviria, DM Patel, PR Schaefer, MK Collins, AS Khudyakov, YE Drobeniuc, J Gooch, BF Cleveland, JL AF Radcliffe, Rachel A. Bixler, Danae Moorman, Anne Hogan, Vicki A. Greenfield, Vickie S. Gaviria, Diana M. Patel, Priti R. Schaefer, Melissa K. Collins, Amy S. Khudyakov, Yury E. Drobeniuc, Jan Gooch, Barbara F. Cleveland, Jennifer L. TI Hepatitis B virus transmissions associated with a portable dental clinic, West Virginia, 2009 SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Dentistry; hepatitis B virus; outbreak; infection control; portable dental equipment ID UNITED-STATES; INFECTION; RECOMMENDATIONS AB Background. Although hepatitis B virus (HBV) transmission in dental settings is rare, in 2009 a cluster of acute HBV infections was reported among attendees of a two-day portable dental clinic in West Virginia. Methods. The authors conducted a retrospective investigation by using treatment records and volunteer logs, interviews of patients and volunteers with acute HBV infection as well as of other clinic volunteers, and molecular sequencing of the virus from those acutely infected. Results. The clinic was held under the auspices of a charitable organization in a gymnasium staffed by 750 volunteers, including dental care providers who treated 1,137 adults. Five acute HBV infections-involving three patients and two volunteers-were identified by the local and state health departments. Of four viral isolates available for testing, all were genotype D. Three case patients underwent extractions; one received restorations and one a dental prophylaxis. None shared a treatment provider with any of the others. One case volunteer worked in maintenance; the other directed patients from triage to the treatment waiting area. Case patients reported no behavioral risk factors for HBV infection. The investigation revealed numerous infection control breaches. Conclusions. Transmission of HBV to three patients and two volunteers is likely to have occurred at a portable dental clinic. Specific breaches in infection control could not be linked to these HBV transmissions. Practical Implications. All dental settings should adhere to recommended infection control practices, including oversight; training in prevention of bloodborne pathogens transmission; receipt of HBV vaccination for staff who may come into contact with blood or body fluids; use of appropriate personal protective equipment, sterilization and disinfection procedures; and use of measures, such as high-volume suction, to minimize the spread of blood. C1 [Radcliffe, Rachel A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA. [Bixler, Danae] West Virginia Dept Hlth & Human Serv, Bur Publ Hlth, Off Epidemiol & Prevent Serv, Div Infect Dis Epidemiol, Charleston, SC USA. [Moorman, Anne] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30341 USA. [Hogan, Vicki A.] West Virginia Dept Hlth & Human Resources, Bur Publ Hlth, Off Epidemiol & Prevent Serv, Div STD HIV & Hepatitis, Charleston, SC USA. [Greenfield, Vickie S.; Gaviria, Diana M.] Berkeley Cty Hlth Dept, Martinsburg, WV USA. [Patel, Priti R.; Schaefer, Melissa K.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA. [Khudyakov, Yury E.] Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Branch Lab, Div Viral Hepatitis,Natl Ctr HIV AIDS Viral Hepat, Atlanta, GA 30341 USA. [Drobeniuc, Jan] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Collins, Amy S.; Gooch, Barbara F.; Cleveland, Jennifer L.] Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Cleveland, JL (reprint author), Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F-80,4770 Buford Highway, Atlanta, GA 30341 USA. EM jlc0@cdc.gov NR 23 TC 9 Z9 9 U1 1 U2 6 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD OCT PY 2013 VL 144 IS 10 BP 1110 EP 1118 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 227WN UT WOS:000325146500007 PM 24080927 ER PT J AU Boyoglu-Barnum, S Gaston, KA Todd, SO Boyoglu, C Chirkova, T Barnum, TR Jorquera, P Haynes, LM Tripp, RA Moore, ML Anderson, LJ AF Boyoglu-Barnum, Seyhan Gaston, Kelsey A. Todd, Sean O. Boyoglu, Cemil Chirkova, Tatiana Barnum, Thomas R. Jorquera, Patricia Haynes, Lia M. Tripp, Ralph A. Moore, Martin L. Anderson, Larry J. TI A Respiratory Syncytial Virus (RSV) Anti-G Protein F(ab ')(2) Monoclonal Antibody Suppresses Mucous Production and Breathing Effort in RSV rA2-line19F-Infected BALB/c Mice SO JOURNAL OF VIROLOGY LA English DT Article ID ATTACHMENT G GLYCOPROTEIN; CYSTEINE-RICH REGION; SOLUBLE G-PROTEIN; HIGH-RISK INFANTS; T-CELL RESPONSES; SUBSTANCE-P; PULMONARY EOSINOPHILIA; AIRWAY HYPERRESPONSIVENESS; IMMUNE-RESPONSES; F-GLYCOPROTEIN AB Respiratory syncytial virus (RSV) belongs to the family Paramyxoviridae and is the single most important cause of serious lower respiratory tract infections in young children, yet no highly effective treatment or vaccine is available. Increased airway resistance and increased airway mucin production are two manifestations of RSV infection in children. RSV rA2-line19F infection induces pulmonary mucous production and increased breathing effort in BALB/c mice and provides a way to assess these manifestations of RSV disease in an animal model. In the present study, we investigated the effect of prophylactic treatment with the F(ab')(2) form of the anti-G protein monoclonal antibody (MAb) 131-2G on disease in RSV rA2-line19F-challenged mice. F(ab')(2) 131-2G does not affect virus replication. It and the intact form that does decrease virus replication prevented increased breathing effort and airway mucin production, as well as weight loss, pulmonary inflammatory-cell infiltration, and the pulmonary substance P and pulmonary Th2 cytokine levels that occur in mice challenged with this virus. These data suggest that the RSV G protein contributes to prominent manifestations of RSV disease and that MAb 131-2G can prevent these manifestations of RSV disease without inhibiting virus infection. C1 [Boyoglu-Barnum, Seyhan; Gaston, Kelsey A.; Todd, Sean O.; Boyoglu, Cemil; Chirkova, Tatiana; Moore, Martin L.; Anderson, Larry J.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Boyoglu-Barnum, Seyhan; Gaston, Kelsey A.; Todd, Sean O.; Boyoglu, Cemil; Chirkova, Tatiana; Moore, Martin L.; Anderson, Larry J.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Haynes, Lia M.] CDC, NCIRD, Div Viral Dis, Atlanta, GA 30333 USA. [Jorquera, Patricia; Tripp, Ralph A.] Univ Georgia, Dept Infect Dis, Anim Hlth Res Ctr, Athens, GA 30602 USA. [Barnum, Thomas R.] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA. RP Anderson, LJ (reprint author), Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. EM larry.anderson@emory.edu FU NIH [1U19AI095227, 1R01AI087798]; Children's Healthcare of Atlanta; Immunology Core of Emory-Children's Pediatric Research Center; Emory Vaccinology Training Grant (VTP) [T32 5T32AI074492-03] FX This work was supported by NIH grant 1U19AI095227 awarded to M.L.M. and L.J.A., funding from Children's Healthcare of Atlanta, support from the Immunology Core of Emory-Children's Pediatric Research Center, and Emory Vaccinology Training Grant (VTP) T32 5T32AI074492-03. Martin L. Moore was supported by NIH 1R01AI087798 and NIH 1U19AI095227. NR 78 TC 17 Z9 17 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2013 VL 87 IS 20 BP 10955 EP 10967 DI 10.1128/JVI.01164-13 PG 13 WC Virology SC Virology GA 229OF UT WOS:000325275800004 PM 23885067 ER PT J AU Floyd, RL Johnson, KA Owens, JR Verbiest, S Moore, CA Boyle, C AF Floyd, R. Louise Johnson, Kay A. Owens, Jasmine R. Verbiest, Sarah Moore, Cynthia A. Boyle, Coleen TI A National Action Plan for Promoting Preconception Health and Health Care in the United States (2012-2014) SO JOURNAL OF WOMENS HEALTH LA English DT Article AB Preconception health and health care (PCHHC) has gained increasing popularity as a key prevention strategy for improving outcomes for women and infants, both domestically and internationally. The Action Plan for the National Initiative on Preconception Health and Health Care: A Report of the PCHHC Steering Committee (2012-2014) provides a model that states, communities, public, and private organizations can use to help guide strategic planning for promoting preconception care projects. Since 2005, a national public-private PCHHC initiative has worked to create and implement recommendations on this topic. Leadership and funding from the Centers for Disease Control and Prevention combined with the commitment of maternal and child health leaders across the country brought together key partners from the public and private sector to provide expertise and technical assistance to develop an updated national action plan for the PCHHC Initiative. Key activities for this process included the identification of goals, objectives, strategies, actions, and anticipated timelines for the five workgroups that were established as part of the original PCHHC Initiative. These are further described in the action plan. To assist other groups doing similar work, this article discusses the approach members of the PCHHC Initiative took to convene local, state, and national leaders to enhance the implementation of preconception care nationally through accomplishments, lessons learned, and projections for future directions. C1 [Floyd, R. Louise; Owens, Jasmine R.; Moore, Cynthia A.; Boyle, Coleen] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Johnson, Kay A.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat, Hanover, NH 03756 USA. [Owens, Jasmine R.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Verbiest, Sarah] Univ N Carolina, Ctr Maternal & Infant Hlth, Chapel Hill, NC USA. RP Floyd, RL (reprint author), Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, 1825 Century Blvd MS E86, Atlanta, GA 30345 USA. EM rlf3@bellsouth.net FU national Preconception Health and Health Care Initiative; Centers for Disease Control and Prevention FX This article was supported by the national Preconception Health and Health Care Initiative, the Centers for Disease Control and Prevention, and a research appointment by the Oak Ridge Institute for Science and Education. We thank those who provided comments and reviewed earlier versions of this manuscript. NR 24 TC 10 Z9 10 U1 0 U2 10 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT 1 PY 2013 VL 22 IS 10 BP 797 EP 802 DI 10.1089/jwh.2013.4505 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 227TD UT WOS:000325136500003 PM 23944970 ER PT J AU Mazher, MA Kallen, A Edwards, JR Donlan, RM AF Mazher, M. A. Kallen, A. Edwards, J. R. Donlan, R. M. TI An In Vitro evaluation of disinfection protocols used for needleless connectors of central venous catheters SO LETTERS IN APPLIED MICROBIOLOGY LA English DT Article DE chlorhexidine gluconate plus isopropanol; disinfection; isopropanol; needleless connector; povidone-iodine ID RESISTANT STAPHYLOCOCCUS-AUREUS; BLOOD-STREAM INFECTIONS; CRITICALLY-ILL PATIENTS; POVIDONE-IODINE; CHLORHEXIDINE; CONTAMINATION; ANTISEPTICS; PREVENTION; ALCOHOL; TRIAL AB A repeatable and sensitive method to evaluate the effect of three antiseptics and two disinfection techniques on viable micro-organisms on luer-activated catheter needleless connectors (NCs) was developed. NCs were inoculated with Staphylococcus epidermidis or Klebsiella pneumoniae and disinfected with 315% chlorhexidine gluconate+70% isopropanol (CGI), 70% isopropanol (IPA) or 10% PVP povidone-iodine (PI) antiseptic pads using: (i) scrubbing the NC septum and threaded external surfaces or (ii) wiping only the surface of the septum. Treatments were also evaluated against NCs pretreated with human serum and exposed for 18h to Staph.epidermidis prior to testing. Viable cells were quantified by plate count. The method for inoculation and recovery of luminal micro-organisms was repeatable (SD, 031; n=28). IPA disinfection provided an approximate 3log(10)CFU reduction; CGI and PI provided 3-4 log(10) reductions. PI and CGI were more effective than IPA (P<005), but differences between CGI and PI were not significant for either disinfection method. IPA, but not CGI and PI was also less effective (P<005) against NCs inoculated with Kl.pneumoniae than Staph.epidermidis. Pretreatment with serum and prolonged Staph.epidermidis inoculation removed the advantage seen with CGI and PI; log(10) reductions were 180, 173 and 250 for CGI, PI and IPA, respectively. PI or CGI may be more effective than IPA for NC disinfection but effectiveness may be reduced on NCs contaminated with blood or serum. Significance and Impact of the Studysensitive and repeatable protocol was developed to evaluate antiseptics for disinfecting catheter needleless connectors (NCs). Povidone-iodine (PI) and chlorhexidine gluconate plus isopropanol (CGI) were more effective than isopropanol (IPA) for reducing Staphylococcus epidermidis contamination of NCs. The effectiveness of PI and CGI was reduced on NCs pre-exposed to human serum and prolonged bacterial inoculation. IPA was also less effective against NCs contaminated with Klebsiella pneumoniae. C1 [Mazher, M. A.; Kallen, A.; Edwards, J. R.; Donlan, R. M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Donlan, RM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM rld8@cdc.gov FU Baxter Healthcare FX M. M., A. K. and J. E. report no conflict of interest relevant to this article. R. D. participated in an earlier unrelated study in collaboration with a university that was funded by Baxter Healthcare, the manufacturer of the needleless connector evaluated in this study. Baxter Healthcare had no input on the present study. Otherwise, R.D. reports no conflict of interest relevant to this article. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US CDC. NR 18 TC 3 Z9 3 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0266-8254 EI 1472-765X J9 LETT APPL MICROBIOL JI Lett. Appl. Microbiol. PD OCT PY 2013 VL 57 IS 4 BP 282 EP 287 DI 10.1111/lam.12108 PG 6 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 226KM UT WOS:000325034500004 PM 23710651 ER PT J AU Oken, E Switkowski, K Price, S Guthrie, L Taveras, EM Gillman, M Friedes, J Callaghan, W Dietz, P AF Oken, Emily Switkowski, Karen Price, Sarah Guthrie, Lauren Taveras, Elsie M. Gillman, Matthew Friedes, Jonathan Callaghan, William Dietz, Patricia TI A Qualitative Study of Gestational Weight Gain Counseling and Tracking SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Gestational weight gain; Obstetrics; Electronic medical record; Counseling ID ELECTRONIC MEDICAL-RECORD; BODY-MASS INDEX; PRIMARY-CARE; OBSTETRIC RECORD; DECISION-SUPPORT; OBESITY; DOCUMENTATION; PREVENTION; PREGNANCY; IDENTIFY AB Excessive gestational weight gain (GWG) predicts adverse pregnancy outcomes and later obesity risk for both mother and child. Women who receive GWG advice from their obstetric clinicians are more likely to gain the recommended amount, but many clinicians do not counsel their patients on GWG, pointing to the need for new strategies. Electronic medical records (EMRs) are a useful tool for tracking weight and supporting guideline-concordant care, but their use for care related to GWG has not been evaluated. We performed in-depth interviews with 16 obstetric clinicians from a multi-site group practice in Massachusetts that uses an EMR. We recorded, transcribed, coded, and analyzed the interviews using immersion-crystallization. Many respondents believed that GWG had "a lot" of influence on pregnancy and child health outcomes but that their patients did not consider it important. Most indicated that excessive GWG was a big or moderate problem in their practice, and that inadequate GWG was rarely a problem. All used an EMR feature that calculates total GWG at each visit. Many were enthusiastic about additional EMR-based supports, such as a reference for recommended GWG for each patient based on pre-pregnancy body mass index, a "growth chart" to plot actual and recommended GWG, and an alert to identify out-of-range gains, features which many felt would remind them to counsel patients about excessive weight gain. Additional decision support tools within EMRs would be well received by many clinicians and may help improve the frequency and accuracy of GWG tracking and counseling. C1 [Oken, Emily; Switkowski, Karen; Price, Sarah; Guthrie, Lauren; Taveras, Elsie M.; Gillman, Matthew] Harvard Univ, Sch Med, Obes Prevent Program, Dept Populat Med, Boston, MA 02215 USA. [Oken, Emily; Switkowski, Karen; Price, Sarah; Guthrie, Lauren; Taveras, Elsie M.; Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Switkowski, Karen] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA. [Friedes, Jonathan] Harvard Vanguard Med Associates, Boston, MA USA. [Callaghan, William; Dietz, Patricia] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Oken, E (reprint author), Harvard Univ, Sch Med, Obes Prevent Program, Dept Populat Med, 133 Brookline Ave, Boston, MA 02215 USA. EM Emily_Oken@harvardpilgrim.org FU NHLBI NIH HHS [K24 HL068041, P30 HL101312]; NICHD NIH HHS [R01 HD034568, K24 HD069408]; NIDDK NIH HHS [P30 DK092924]; PHS HHS [200-2010-M-33818] NR 34 TC 7 Z9 7 U1 1 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2013 VL 17 IS 8 BP 1508 EP 1517 DI 10.1007/s10995-012-1158-9 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 226GX UT WOS:000325024100021 PM 23065312 ER PT J AU Lockhart, SR AF Lockhart, S. R. TI CLSI vs. EUCAST breakpoints SO MYCOSES LA English DT Meeting Abstract C1 [Lockhart, S. R.] Ctr Dis Control & Prevent, Lilburn, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0933-7407 EI 1439-0507 J9 MYCOSES JI Mycoses PD OCT PY 2013 VL 56 SU 3 SI SI BP 40 EP 41 PG 2 WC Dermatology; Mycology SC Dermatology; Mycology GA 227ZX UT WOS:000325155400078 ER PT J AU Farhat, MR Shapiro, BJ Kieser, KJ Sultana, R Jacobson, KR Victor, TC Warren, RM Streicher, EM Calver, A Sloutsky, A Kaur, D Posey, JE Plikaytis, B Oggioni, MR Gardy, JL Johnston, JC Rodrigues, M Tang, PKC Kato-Maeda, M Borowsky, ML Muddukrishna, B Kreiswirth, BN Kurepina, N Galagan, J Gagneux, S Birren, B Rubin, EJ Lander, ES Sabeti, PC Murray, M AF Farhat, Maha R. Shapiro, B. Jesse Kieser, Karen J. Sultana, Razvan Jacobson, Karen R. Victor, Thomas C. Warren, Robin M. Streicher, Elizabeth M. Calver, Alistair Sloutsky, Alex Kaur, Devinder Posey, Jamie E. Plikaytis, Bonnie Oggioni, Marco R. Gardy, Jennifer L. Johnston, James C. Rodrigues, Mabel Tang, Patrick K. C. Kato-Maeda, Midori Borowsky, Mark L. Muddukrishna, Bhavana Kreiswirth, Barry N. Kurepina, Natalia Galagan, James Gagneux, Sebastien Birren, Bruce Rubin, Eric J. Lander, Eric S. Sabeti, Pardis C. Murray, Megan TI Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis SO NATURE GENETICS LA English DT Article ID INTRINSIC MULTIDRUG-RESISTANCE; COMPENSATORY MUTATIONS; 2-COMPONENT SYSTEM; RIFAMPIN-RESISTANT; ESCHERICHIA-COLI; FITNESS; GENES; SUSCEPTIBILITY; ANTIBIOTICS; EXPRESSION AB M. tuberculosis is evolving antibiotic resistance, threatening attempts at tuberculosis epidemic control. Mechanisms of resistance, including genetic changes favored by selection in resistant isolates, are incompletely understood. Using 116 newly sequenced and 7 previously sequenced M. tuberculosis whole genomes, we identified genome-wide signatures of positive selection specific to the 47 drug-resistant strains. By searching for convergent evolution-the independent fixation of mutations in the same nucleotide position or gene-we recovered 100% of a set of known resistance markers. We also found evidence of positive selection in an additional 39 genomic regions in resistant isolates. These regions encode components in cell wall biosynthesis, transcriptional regulation and DNA repair pathways. Mutations in these regions could directly confer resistance or compensate for fitness costs associated with resistance. Functional genetic analysis of mutations in one gene, ponA1, demonstrated an in vitro growth advantage in the presence of the drug rifampicin. C1 [Farhat, Maha R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pulm & Crit Care, Boston, MA 02114 USA. [Shapiro, B. Jesse; Galagan, James; Birren, Bruce; Lander, Eric S.; Sabeti, Pardis C.] Eli & Edythe L Broad Inst, Cambridge, MA USA. [Shapiro, B. Jesse; Sabeti, Pardis C.] Harvard Univ, Fac Arts & Sci, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA. [Shapiro, B. Jesse; Sabeti, Pardis C.] Harvard Univ, Sch Publ Hlth, Ctr Communicable Dis Dynam, Boston, MA 02115 USA. [Shapiro, B. Jesse] Univ Montreal, Dept Sci Biol, Montreal, PQ H3C 3J7, Canada. [Kieser, Karen J.; Rubin, Eric J.; Sabeti, Pardis C.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Sultana, Razvan] Dana Farber Canc Inst, Dept Bioinformat & Computat Biol, Boston, MA 02115 USA. [Jacobson, Karen R.] Boston Univ, Sch Med, Infect Dis Sect, Boston, MA 02118 USA. [Jacobson, Karen R.; Victor, Thomas C.; Warren, Robin M.; Streicher, Elizabeth M.] Univ Stellenbosch, Fac Med & Hlth Sci, Ctr Mol & Cellular Biol,Dept Sci & Technol,Div Mo, MRC,Natl Res Fdn Ctr Excellence Biomed IB Res, ZA-7505 Tygerberg, South Africa. [Calver, Alistair] Anglogold Ashanti Hlth West Vaal Hosp, Orkney, South Africa. [Sloutsky, Alex; Kaur, Devinder] Univ Massachusetts, Sch Med, Massachusetts Supranat TB Reference Lab, Boston, MA 02125 USA. [Posey, Jamie E.; Plikaytis, Bonnie] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Oggioni, Marco R.] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England. [Gardy, Jennifer L.] British Columbia Ctr Dis Control, Communicable Dis Prevent & Control Serv, Vancouver, BC, Canada. [Johnston, James C.] British Columbia Ctr Dis Control, Clin Prevent Serv, Vancouver, BC, Canada. [Rodrigues, Mabel; Tang, Patrick K. C.] British Columbia Ctr Dis Control, Prov Hlth Serv Author Labs, Publ Hlth Microbiol & Reference Lab, Mycobacteriol TB Lab, Vancouver, BC, Canada. [Kato-Maeda, Midori] Univ Calif San Francisco, Div Pulm & Crit Care, San Francisco, CA 94143 USA. [Muddukrishna, Bhavana] Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA. [Muddukrishna, Bhavana] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Kreiswirth, Barry N.; Kurepina, Natalia] State Univ New Jersey, Rutgers, Publ Hlth Res Inst TB Ctr, Newark, NJ USA. [Galagan, James] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Galagan, James] Boston Univ, Dept Microbiol, Boston, MA 02215 USA. [Galagan, James] Boston Univ, Bioinformat Program, Boston, MA 02215 USA. [Gagneux, Sebastien] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Gagneux, Sebastien] Univ Basel, Basel, Switzerland. [Murray, Megan] Harvard Univ, Dept Global Hlth & Social Med, Boston, MA 02115 USA. [Murray, Megan] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Farhat, MR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pulm & Crit Care, Boston, MA 02114 USA. EM mrfarhat@partners.org; mmurray@hsph.harvard.edu RI Oggioni, Marco Rinaldo/K-3839-2016; OI Rubin, Eric/0000-0001-5120-962X; Streicher, Elizabeth/0000-0003-3901-1981; Jacobson, Karen/0000-0003-4239-3685; Tang, Patrick/0000-0003-1583-5484; Oggioni, Marco Rinaldo/0000-0003-4117-793X; Farhat, Maha/0000-0002-3871-5760; Shapiro, B. Jesse/0000-0001-6819-8699 FU Senior Ellison Foundation Award; National Institute of Allergy and Infectious Diseases [HHSN266200400001C]; Department of Pulmonary and Critical Care at Massachusetts General Hospital; Harvard MIDAS Center for Communicable Disease Dynamics; Packard Foundation; Swiss National Science Foundation [PP0033_119205] FX We thank the technical staff of the British Columbia Centre for Disease Control Public Health Microbiology and Reference Mycobacteriology Laboratory in Vancouver, M. Bosman from the National Health Laboratory Service in Cape Town and L. Fattorini from the Istituto Superiore di Sanita in Rome. This work was funded by a Senior Ellison Foundation Award (M. M.) and in part by a contact from the National Institute of Allergy and Infectious Diseases (HHSN266200400001C to B. B.), the Department of Pulmonary and Critical Care at Massachusetts General Hospital (M. R. F.), a postdoctoral fellowship from the Harvard MIDAS Center for Communicable Disease Dynamics (B.J.S.) and a Packard Foundation Fellowship (P. C. S.). S. G. was supported by the Swiss National Science Foundation (PP0033_119205). NR 45 TC 104 Z9 111 U1 7 U2 82 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD OCT PY 2013 VL 45 IS 10 SI SI BP 1183 EP U320 DI 10.1038/ng.2747 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 225UQ UT WOS:000324989600014 PM 23995135 ER PT J AU Nesheim, SR Hardnett, F Wheeling, JT Siberry, GK Paul, ME Emmanuel, P Bohannon, B Dominguez, K AF Nesheim, Steven R. Hardnett, Felicia Wheeling, John T. Siberry, George K. Paul, Mary E. Emmanuel, Patricia Bohannon, Beverly Dominguez, Kenneth CA LEGACY Consortium TI Incidence of Opportunistic Illness Before and After Initiation of Highly Active Antiretroviral Therapy in Children SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE HIV infection; pediatric; immune reconstitution inflammatory syndrome; opportunistic infection; highly active antiretroviral therapy ID IMMUNE RECONSTITUTION SYNDROME; HIV-INFECTED CHILDREN; BACILLE-CALMETTE-GUERIN; INFLAMMATORY-SYNDROME; BCG; LYMPHADENITIS; MANIFESTATION; TUBERCULOSIS; DISEASE; ZOSTER AB Background: Little is known about immune reconstitution inflammatory syndrome in children in the United States. Methods: LEGACY is a longitudinal cohort study of HIV-infected participants 0-24 years at enrollment during 2005 to 2007 from 22 US clinics. For this analysis, we included participants with complete medical record abstraction from birth or time of HIV diagnosis through 2006. Opportunistic illness (OI) included AIDS-defining conditions and selected HIV-related diagnoses. We calculated the incidence (#/100 patient-years) of OI diagnosed in the months pre- and postinitiation of the first highly active antiretroviral therapy (HAART) regimen which was followed by 1 log reduction in HIV viral load. We defined OI as immune reconstitution inflammatory syndrome if an OI incidence increased after HAART initiation. Responders were defined as experiencing 1 log decline in viral load within 6 months after HAART initiation. Results: Among 575 patients with complete chart abstraction, 524 received HAART. Of these 524 patients, 343 were responders, 181 were nonresponders and 86 experienced OI. Responders accounted for 98 of 124 (79%) of OI. Pre-HAART and post-HAART OI incidences were 43.7 and 24.4 (P = 0.003), respectively, among responders and 15.9 and 9.1 (P = 0.2), respectively, among nonresponders. Overall, OI incidences among responders and nonresponders were 33.8 and 12.3, respectively (P = 0.002). Responders were more likely than nonresponders to experience herpes simplex and herpes zoster before HAART initiation (all, P < 0.002). Conclusions: The lack of immune reconstitution inflammatory syndrome in participants initiating HAART may be due to low overall OI rates. The unexpectedly higher OI prevalence comprised mainly of herpes simplex and zoster, before HAART initiation among responders, may have motivated them to better adhere to HAART. C1 [Nesheim, Steven R.] Emory Univ, Sch Med, Atlanta, GA USA. [Nesheim, Steven R.; Bohannon, Beverly; Dominguez, Kenneth] Ctr Dis Control & Prevent, Epidemiol Branch, Atlanta, GA 30333 USA. [Hardnett, Felicia] Ctr Dis Control & Prevent, Quantitat Sci & Informat Branch, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Wheeling, John T.] Northrop Grumman Inc, Atlanta, GA USA. [Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent Maternal AIDS Branch, NIH, Rockville, MD USA. [Paul, Mary E.] Baylor Coll Med, Houston, TX 77030 USA. [Emmanuel, Patricia] Univ S Florida, Sch Med, Tampa, FL 33620 USA. RP Nesheim, SR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM sxn9@cdc.gov FU Centers for Disease Control and Prevention, Atlanta, GA [200-2004-09976] FX The LEGACY project was funded by the Centers for Disease Control and Prevention, Atlanta, GA, contract number 200-2004-09976. NR 30 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2013 VL 32 IS 10 BP 1089 EP 1095 DI 10.1097/INF.0b013e31829ee893 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 224ML UT WOS:000324890500016 PM 24067552 ER PT J AU Hoiseth, SK Murphy, E Andrew, L Vogel, U Frosch, M Hellenbrand, W Abad, R Vazquez, JA Borrow, R Findlow, J Taha, MK Deghmane, AE Caugant, DA Kriz, P Musilek, M Mayer, LW Wang, X MacNeil, JR York, L Tan, CY Jansen, KU Anderson, AS AF Hoiseth, Susan K. Murphy, Ellen Andrew, Lubomira Vogel, Ulrich Frosch, Matthias Hellenbrand, Wiebke Abad, Raquel Vazquez, Julio A. Borrow, Ray Findlow, Jamie Taha, Muhamed-Kheir Deghmane, Ala-Eddine Caugant, Dominique A. Kriz, Paula Musilek, Martin Mayer, Leonard W. Wang, Xin MacNeil, Jessica R. York, Laura Tan, Charles Y. Jansen, Kathrin U. Anderson, Annaliesa S. TI A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H-Binding Proteins and Implications for Vaccine Coverage in Different Age Groups SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE factor H-binding protein; meningococcal; serogroup B vaccine; epidemiology ID MEMBRANE VESICLE VACCINE; MENINGOCOCCAL DISEASE; SEQUENCE VARIATION; POLYSIALIC ACID; HERD-IMMUNITY; CANDIDATE; TRIAL; LIPOPROTEIN; DIVERSITY; SERUM AB Background: Recombinant vaccines containing factor H-binding protein (fHBP) have been developed for the purpose of protection from invasive meningococcal serogroup B disease. Neisseria meningitidis fHBP sequences can be divided into 2 genetically and immunologically distinct subfamilies (A and B); thus, cross protection is conferred within but not between subfamilies. A comprehensive understanding of fHBP epidemiology is required to accurately assess the potential vaccine impact when considering different vaccination implementation strategies. Methods: Systematically collected invasive meningococcal serogroup B isolates from England, Wales, Northern Ireland, the United States, Norway, France and the Czech Republic were previously characterized for fHBP sequence. This study expanded the evaluation with additional meningococcal serogroup B disease isolates from Spain (n = 346) and Germany (n = 205). This expanded set (n = 1841), collected over a 6-year period (2001 to 2006), was evaluated for fHBP sequence and fHBP subfamily relative to patient age. Results: All 1841 isolates contained fhbp. fHBP sequences from Spain and Germany fell within the previously described subfamilies, with 69% of isolates belonging to subfamily B and 31% to subfamily A; prevalent sequence variants were also similar. Stratification of data by age indicated that disease in infants <1 year of age was caused by a significantly higher proportion of isolates with fHBP subfamily A variants than that seen in adolescents and young adults 11-25 years (47.7% versus 19.5%, P < 0.0001, respectively). Conclusions: These observations highlight a difference in epidemiology of fHBP subfamilies in different age groups, with fHBP subfamily A strains causing more disease in vulnerable populations, such as infants, than in adolescents. C1 [Hoiseth, Susan K.; Murphy, Ellen; Andrew, Lubomira; Tan, Charles Y.; Jansen, Kathrin U.; Anderson, Annaliesa S.] Pfizer Vaccine Res, Pearl River, NY USA. [Vogel, Ulrich; Frosch, Matthias] Univ Wurzburg, Inst Hyg & Microbiol, D-97070 Wurzburg, Germany. [Hellenbrand, Wiebke] Robert Koch Inst, Berlin, Germany. [Abad, Raquel; Vazquez, Julio A.] Natl Inst Hlth, Madrid, Spain. [Borrow, Ray; Findlow, Jamie] Manchester Royal Infirm, Hlth Protect Agcy, Manchester M13 9WL, Lancs, England. [Taha, Muhamed-Kheir; Deghmane, Ala-Eddine] Inst Pasteur, Paris, France. [Caugant, Dominique A.] Norwegian Inst Publ Hlth, Oslo, Norway. [Kriz, Paula; Musilek, Martin] Natl Inst Publ Hlth, Prague, Czech Republic. [Mayer, Leonard W.; Wang, Xin; MacNeil, Jessica R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [York, Laura] Pfizer, Collegeville, PA USA. RP Anderson, AS (reprint author), Pfizer, 401 N Middletown Rd, Pearl River, NY 10965 USA. EM annaliesa.anderson@pfizer.com RI Abad, Raquel/L-7595-2015; Krizova, Pavla/M-6120-2015 OI Abad, Raquel/0000-0002-8339-0950; FU Pfizer Inc.; Scientific Strategy Partners; Complete Healthcare Communications, Inc.; Wyeth; Pfizer Vaccine Research; Novartis Vaccines; Pfizer; Baxter; GlaxoSmithKline; Sanofi Pasteur; Esteve Laboratories FX S.K.H., E. M., R. A., J.A.V., M.-K.T., L. W. M., L.Y., K.U.J. and A. S. A. conceived and designed the study; S. K. H., E. M., L. A., U. V., M. F., W. H., R. A., J.A.V., R. B., J.F., M.-K.T., D. A. C., P. K., M. M., L. W. M., X. W., J.R.M. and A. S. A. helped in data acquisition (including enrolment and follow-up); S. K. H., E. M., L. A., U. V., M. F., W. H., M.-K.T., M. M., L. W. M., X. W., J.R.M., L.Y., C.Y.T., K.U.J. and A. S. A. analyzed and interpreted data; E. M. and C.Y.T. conducted the statistical analysis; S. K. H., E. M., U. V., M. F., W. H., R. A., J.A.V., R. B., J.F., M.-K.T., A.-E. D., D. A. C., X. W., L.Y., C.Y.T., K.U.J. and A. S. A. drafted or revised the article critically for intellectual content. This article was sponsored by Pfizer Inc. The support provided by Scientific Strategy Partners and Complete Healthcare Communications, Inc., was funded by Pfizer Inc and consisted solely of manuscript formatting; no contribution was made to editorial content. The institution of D. A. C. has received grants from Wyeth and that of M. M. received grants from Pfizer Vaccine Research. R. B. has performed consultancies and received travel support from Baxter Biosciences, GlaxoSmithKline, Novartis, Pfizer and Sanofi Pasteur and performed contract research on behalf of the Health Protection Agency for Baxter Biosciences, GlaxoSmithKline, Novartis, Merck, Pfizer and Sanofi Pasteur. J.F. has performed consultancies for Baxter, GlaxoSmithKline, Novartis and Pfizer; received travel support from Baxter Biosciences, GlaxoSmithKline, Novartis and Pfizer and performed contract research on behalf of the Health Protection Agency for Baxter Biosciences, GlaxoSmithKline, Novartis, Merck, Pfizer and Sanofi Pasteur. J.A.V. has served as a board member for Pfizer, GlaxoSmithKline, Novartis Vaccines and Sanofi Pasteur; has received travel support from Wyeth; has received payment for lectures from Novartis Vaccines, Pfizer, Baxter and GlaxoSmithKline and has received payment for article preparation from Novartis Vaccines; his institution has received grants from Wyeth, Novartis Vaccines, Sanofi Pasteur, GlaxoSmithKline, Pfizer, Esteve Laboratories and Baxter. U. V. has served as a board member and performed consultancies for Novartis and GlaxoSmithKline, has received payment for lectures from Novartis Vaccines, Baxter and GlaxoSmithKline; his institution has received grants from GlaxoSmithKline. S. K. H., E. M., L. A., L.Y., C.Y.T., K.U.J. and A. S. A. are employees of Pfizer Inc. The authors have no other funding or conflicts of interest to disclose. NR 47 TC 18 Z9 19 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD OCT PY 2013 VL 32 IS 10 BP 1096 EP 1101 DI 10.1097/INF.0b013e31829aa63b PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 224ML UT WOS:000324890500017 PM 23694830 ER PT J AU Jones, SC Budnitz, DS Sorbello, A Mehta, H AF Jones, S. Christopher Budnitz, Daniel S. Sorbello, Alfred Mehta, Hina TI US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE fluoroquinolone; hypersensitivity; allergy; moxifloxacin; ciprofloxacin; levofloxacin; pharmacoepidemiology ID MEDIATED HYPERSENSITIVITY; ALLERGIC REACTIONS; CROSS-REACTIVITY; QUINOLONES AB PurposeTo estimate the rate of hypersensitivity reactions per 100,000 prescription dispensings of fluoroquinolones based on care rendered in a nationally representative sample of US hospital emergency departments (ED). MethodsWe analyzed the frequency of fluoroquinolone-associated hypersensitivity reactions using the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance system (2004-2010) in conjunction with US retail outpatient prescription data from IMS Health (2004-2010). We further categorized reaction severity into three subgroups (mild, moderate, and severe). ResultsBased on 1422 cases of fluoroquinolone-associated hypersensitivity reactions and national drug utilization projections, we estimated risk of hypersensitivity reactions for moxifloxacin, ciprofloxacin, and levofloxacin. The absolute risk of a fluoroquinolone-related hypersensitivity reaction of any severity was low (44.0 (95% CI 34.8-53.3) ED visits/100,000 prescriptions); however, we identified a statistically significant difference in the relative risk (rate ratios) of seeking care in an ED attributed to moxifloxacin hypersensitivity compared to either levofloxacin or ciprofloxacin. For all reaction severities, the estimated ED visits/100,000 prescriptions were 141.3 (95% CI 99.9-182.7) for moxifloxacin, 40.8 (95% CI 31.5-50.0) for levofloxacin, and 26.3 (95% CI 20.8-31.9) for ciprofloxacin. When the rates were stratified by reaction severity category (mild or moderate-severe), moxifloxacin continued to be implicated in more ED visits per 100,000 prescriptions dispensed than either levofloxacin or ciprofloxacin. ConclusionFluoroquinolones may cause hypersensitivity reactions requiring care in an ED, and relative to use, the rate of moxifloxacin-related hypersensitivity reactions is higher compared to levofloxacin or ciprofloxacin. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. C1 [Jones, S. Christopher; Sorbello, Alfred; Mehta, Hina] US FDA, Off Surveillance & Epidemiol, Silver Spring, MD 20993 USA. [Budnitz, Daniel S.] US Ctr Dis & Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Jones, SC (reprint author), US FDA, Ctr Drug Evaluat & Res, Off Surveillance & Epidemiol, Div Pharmacovigilance, 10903 New Hampshire Ave Bldg 22 Room 3464, Silver Spring, MD 20993 USA. EM Steven.Jones@fda.hhs.gov FU Intramural CDC HHS [CC999999] NR 15 TC 7 Z9 7 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD OCT PY 2013 VL 22 IS 10 BP 1099 EP 1106 DI 10.1002/pds.3499 PG 8 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 227WJ UT WOS:000325146100010 PM 23963962 ER PT J AU Derrington, TM Kotelchuck, M Plummer, K Cabral, H Lin, AE Belanoff, C Shin, M Correa, A Grosse, SD AF Derrington, Taletha Mae Kotelchuck, Milton Plummer, Katrina Cabral, Howard Lin, Angela E. Belanoff, Candice Shin, Mikyong Correa, Adolfo Grosse, Scott D. TI Racial/ethnic differences in hospital use and cost among a statewide population of children with Down syndrome SO RESEARCH IN DEVELOPMENTAL DISABILITIES LA English DT Article DE Down syndrome; Congenital heart defects; Hospital use; Hospital cost; Racial/ethnic disparities ID PRIVATELY INSURED POPULATION; METROPOLITAN ATLANTA; CONGENITAL-DEFECTS; ETHNIC DISPARITIES; ASTHMA MANAGEMENT; YOUNG-CHILDREN; UNITED-STATES; MEDICAL HOME; CARE; INFANTS AB Children with Down syndrome (DS) use hospital services more often than children without DS, but data on racial/ethnic variations are limited. This study generated population-based estimates of hospital use and cost to 3 years of age by race/ethnicity among children with DS in Massachusetts using birth certificates linked to birth defects registry and hospital discharge data from 1999 to 2004. Hospital use (>= 1 post-birth hospitalization and median days hospitalized birth and post-birth) and reasons for hospitalization were compared across maternal race/ethnicity using relative risk (RR) and Wilcoxon rank sums tests, as appropriate. Costs were calculated in 2011 United States dollars. Greater hospital use was observed among children with DS with Hispanic vs. Non-Hispanic White (NHW) mothers (post-birth hospitalization: RR 1.4; median days hospitalized: 20.0 vs. 11.0, respectively). Children with DS and congenital heart defects of Non-Hispanic Black (NHB) mothers had significantly greater median days hospitalized than their NHW counterparts (24.0 vs. 16.0, respectively). Respiratory diagnoses were listed more often among children with Hispanic vs. NHW mothers (50.0% vs. 29.1%, respectively), and NHBs had more cardiac diagnoses (34.1% vs. 21.5%, respectively). The mean total hospital cost was nine times higher among children with DS ($40,075) than among children without DS ($4053), and total costs attributable to DS were almost $18 million. Median costs were $22,781 for Hispanics, $18,495 for NHBs, and $13,947 for NHWs. Public health interventions should address the higher rates of hospital use and hospitalizations for respiratory and cardiac diseases among racial/ethnic minority children with DS in Massachusetts. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Derrington, Taletha Mae; Kotelchuck, Milton; Plummer, Katrina; Belanoff, Candice] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02118 USA. [Derrington, Taletha Mae] SRI Int, Educ Div, Ctr Educ & Human Serv, Menlo Pk, CA 94025 USA. [Kotelchuck, Milton] MassGen Hosp Children, Ctr Child &Adolescent Hlth Res & Policy, Boston, MA 02114 USA. [Cabral, Howard] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Lin, Angela E.] Massachusetts Ctr Birth Defects Res & Prevent, Massachusetts Dept Publ Hlth, Boston, MA 02108 USA. [Lin, Angela E.] MassGen Hosp Children, Med Genet Unit, Boston, MA 02114 USA. [Shin, Mikyong; Correa, Adolfo] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Shin, Mikyong] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Jackson, MS 39213 USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Derrington, TM (reprint author), 333 Ravenswood Ave, Menlo Pk, CA 94025 USA. EM taletha.derrington@sri.com; mkotelchuck@partners.org; katrinaplummer@gmail.com; hjcab@bu.edu; alin@partners.org; cbelanoff@bu.edu; fqx6@cdc.org; acorrea@umc.edu; sgrosse@cdc.gov FU Intramural CDC HHS [CC999999]; PHS HHS [200-2009-31671, 200-2007-22997] NR 39 TC 5 Z9 5 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-4222 J9 RES DEV DISABIL JI Res. Dev. Disabil. PD OCT PY 2013 VL 34 IS 10 BP 3276 EP 3287 DI 10.1016/j.ridd.2013.06.022 PG 12 WC Education, Special; Rehabilitation SC Education & Educational Research; Rehabilitation GA 225NB UT WOS:000324968500026 PM 23892874 ER PT J AU Liu, Y Wheaton, AG Chapman, DP Croft, JB AF Liu, Yong Wheaton, Anne G. Chapman, Daniel P. Croft, Janet B. TI Sleep Duration and Chronic Diseases among US Adults Age 45 Years and Older: Evidence From the 2010 Behavioral Risk Factor Surveillance System SO SLEEP LA English DT Article DE Chronic disease; mental health; population-based survey; sleep duration ID PERCEIVED INSUFFICIENT SLEEP; FREQUENT MENTAL DISTRESS; HEALTH INTERVIEW SURVEY; CORONARY-HEART-DISEASE; BODY-MASS INDEX; QUALITY-OF-LIFE; CARDIOVASCULAR-DISEASE; UNITED-STATES; LONG-SLEEP; DAYTIME FATIGUE AB Study Objective: To examine the effects of obesity and frequent mental distress (FMD) on the relationship of sleep duration with coronary heart disease (CHD), stroke, and diabetes. Design: Cross-sectional study. Setting: Population-based surveillance. Participants: There were 54,269 adults age 45 y or older who completed the 2010 Behavioral Risk Factor Surveillance System survey in 14 states. Results: Nearly one third (31.1% or an estimated 11.1 million) of respondents age 45 y and older reported being short sleepers (<= 6 h), 64.8% being optimal sleepers (7-9 h), and 4.1% being long sleepers (>= 10 h) in a 24-h period. Compared with the optimal sleep duration, both short and long sleep durations were significantly associated with obesity, FMD (mental health was not good >= 14 days during the past 30 days), CHD, stroke, and diabetes after controlling for sex, age, race/ethnicity, and education. The U-shaped relationships of sleep duration with CHD, stroke, and diabetes were moderately attenuated by FMD. The relationship between sleep duration and diabetes was slightly attenuated by obesity. Conclusions: Sleep duration had U-shaped relationships with leading chronic diseases. Further prospective studies are needed to determine how mental health and maintenance of a normal weight may interact with sleep duration to prevent chronic diseases. C1 [Liu, Yong; Wheaton, Anne G.; Chapman, Daniel P.; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. RP Liu, Y (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, 4770 Buford Highway NE,Mail Stop K-67, Atlanta, GA 30341 USA. EM ikd8@cdc.gov NR 70 TC 36 Z9 36 U1 0 U2 14 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD OCT 1 PY 2013 VL 36 IS 10 BP 1421 EP 1427 DI 10.5665/sleep.3028 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 227SV UT WOS:000325135600006 PM 24082301 ER PT J AU Yaemsiri, S Sen, S Tinker, LF Robinson, WR Evans, RW Rosamond, W Wasserthiel-Smoller, S He, K AF Yaemsiri, Sirin Sen, Souvik Tinker, Lesley F. Robinson, Whitney R. Evans, Rhobert W. Rosamond, Wayne Wasserthiel-Smoller, Sylvia He, Ka TI Serum Fatty Acids and Incidence of Ischemic Stroke Among Postmenopausal Women SO STROKE LA English DT Article DE omega-3; omega-6; postmenopausal; women; serum fatty acids ID DIETARY-FAT; HEART-DISEASE; DOCOSAHEXAENOIC ACID; CEREBRAL INFARCTION; CLINICAL-TRIAL; BLOOD-PRESSURE; FISH-OIL; RISK; HEALTH; LIPIDS AB Background and Purpose Although studies have linked types of fatty acids with coronary heart disease, data on individual fatty acids and risk of ischemic stroke are limited. We aimed to examine the associations between serum fatty acid concentrations and incidence of ischemic stroke and its subtypes. Methods We conducted a prospective case-control study nested in the Women's Health Initiative Observational Study cohort of postmenopausal US women aged 50 to 79 years. Between 1993 and 2003, incident cases of ischemic stroke were matched 1:1 to controls on age, race, and length of follow-up (964 matched pairs). Conditional logistic regression was used to estimate odds ratios and 99.9% confidence intervals (CI) for ischemic stroke and its subtypes. Results The multivariable-adjusted odds ratios and 99.9% CI of ischemic stroke associated with a 1-SD increment in serum fatty acid concentration were 1.38 (99.9% CI, 1.05-1.83) for linoelaidic acid (18:2tt, SD=0.04%), 1.27 (99.9% CI, 1.06-1.51) for palmitic acid (16:0, SD=2.74%), 1.20 (99.9% CI, 1.01-1.43) for oleic acid (18:1n9, SD=2.32%), 0.72 (99.9% CI, 0.59-0.87) for docosapentaenoic acid (22:5n3, SD=0.18%), 0.72 (99.9% CI, 0.59-0.87) for docosahexaenoic acid (22:6n3, SD=0.91%), and 0.81 (99.9% CI, 0.67-0.98) for arachidonic acid (20:4n6, SD=2.02%). These associations were generally consistent for atherothrombotic and lacunar stroke but not cardioembolic stroke. Conclusions These findings suggest that individual serum trans, saturated, and monounsaturated fatty acids are positively associated with particular ischemic stroke subtypes, whereas individual n3 and n6 polyunsaturated fatty acids are inversely associated. C1 [Yaemsiri, Sirin; Robinson, Whitney R.; Rosamond, Wayne; He, Ka] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Yaemsiri, Sirin] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Sen, Souvik] Univ S Carolina, Dept Neurol, Columbia, SC 29208 USA. [Tinker, Lesley F.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Evans, Rhobert W.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Wasserthiel-Smoller, Sylvia] Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA. [He, Ka] Indiana Univ, Dept Epidemiol & Biostat, Bloomington, IN 47405 USA. RP He, K (reprint author), Indiana Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 1025 E 7th St, Bloomington, IN 47405 USA. EM kahe@indiana.edu RI He, Ka/I-9906-2014 FU US Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118 to 32119, 32122, 42107-26, 42129-32, 44221]; National Institute of Neurological Disorders and Stroke [R21NS056445]; American Heart Association; National Heart, Lung, and Blood Institute National Research Service [5-T32-HL007055-30]; National Heart, Lung, and Blood Institute, National Institutes of Health FX The Women's Health Initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, and US Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118 to 32119, 32122, 42107-26, 42129-32, and 44221. This study was supported by a grant from the National Institute of Neurological Disorders and Stroke to Dr He (R21NS056445). Dr Yaemsiri was supported by the American Heart Association Mid-Atlantic Predoctoral Fellowship and the National Heart, Lung, and Blood Institute National Research Service Award Training grant (5-T32-HL007055-30). NR 38 TC 11 Z9 12 U1 4 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD OCT PY 2013 VL 44 IS 10 BP 2710 EP 2717 DI 10.1161/STROKEAHA.111.000834 PG 8 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 223TC UT WOS:000324831900022 PM 23899914 ER PT J AU Basavaraju, SV Lohrke, B Pitman, JP Pathak, SR Meza, BPL Shiraishi, RW Wilkinson, R Bock, N Mataranyika, M Lowrance, DW AF Basavaraju, Sridhar V. Lohrke, Britta Pitman, John P. Pathak, Sonal R. Meza, Benjamin P. L. Shiraishi, Ray W. Wilkinson, Robert Bock, Naomi Mataranyika, Mary Lowrance, David W. TI Knowledge and barriers related to reporting of acute transfusion reactions among healthcare workers in Namibia SO TRANSFUSION MEDICINE LA English DT Letter ID SUB-SAHARAN AFRICA; CENTERS C1 [Basavaraju, Sridhar V.; Meza, Benjamin P. L.; Bock, Naomi] US Ctr Dis Control & Prevent, HIV Prevent Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Lohrke, Britta; Wilkinson, Robert] Blood Transfus Serv Namibia, Windhoek, Namibia. [Pitman, John P.; Lowrance, David W.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Windhoek, Namibia. [Pathak, Sonal R.] ICF Macro, Atlanta, GA USA. [Shiraishi, Ray W.] US Ctr Dis Control & Prevent, Epidemiol & Strateg Informat Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Mataranyika, Mary] Namibia Minist Hlth & Social Serv, Directorate Clin Support Serv, Windhoek, Namibia. RP Basavaraju, SV (reprint author), US Ctr Dis Control & Prevent, HIV Prevent Branch, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd NE,MS E 04, Atlanta, GA 30333 USA. EM etu7@cdc.gov OI Pitman, John/0000-0001-5983-7241 FU Intramural CDC HHS [CC999999] NR 9 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0958-7578 J9 TRANSFUSION MED JI Transfus. Med. PD OCT PY 2013 VL 23 IS 5 BP 367 EP 369 DI 10.1111/tme.12058 PG 3 WC Hematology SC Hematology GA 224WU UT WOS:000324923200011 PM 23841708 ER PT J AU Kuzmina, NA Kuzmin, IV Ellison, JA Taylor, ST Bergman, DL Dew, B Rupprecht, CE AF Kuzmina, Natalia A. Kuzmin, Ivan V. Ellison, James A. Taylor, Steven T. Bergman, David L. Dew, Beverly Rupprecht, Charles E. TI A reassessment of the evolutionary timescale of bat rabies viruses based upon glycoprotein gene sequences SO VIRUS GENES LA English DT Article DE Rabies; Virus; Glycoprotein; Viral evolution; Bat rabies; Phylogenetic analysis ID HISTORY; DYNAMICS; ORIGIN AB Rabies, an acute progressive encephalomyelitis caused by viruses in the genus Lyssavirus, is one of the oldest known infectious diseases. Although dogs and other carnivores represent the greatest threat to public health as rabies reservoirs, it is commonly accepted that bats are the primary evolutionary hosts of lyssaviruses. Despite early historical documentation of rabies, molecular clock analyses indicate a quite young age of lyssaviruses, which is confusing. For example, the results obtained for partial and complete nucleoprotein gene sequences of rabies viruses (RABV), or for a limited number of glycoprotein gene sequences, indicated that the time of the most recent common ancestor (TMRCA) for current bat RABV diversity in the Americas lies in the seventeenth to eighteenth centuries and might be directly or indirectly associated with the European colonization. Conversely, several other reports demonstrated high genetic similarity between lyssavirus isolates, including RABV, obtained within a time interval of 25-50 years. In the present study, we attempted to re-estimate the age of several North American bat RABV lineages based on the largest set of complete and partial glycoprotein gene sequences compiled to date (n = 201) employing a codon substitution model. Although our results overlap with previous estimates in marginal areas of the 95 % high probability density (HPD), they suggest a longer evolutionary history of American bat RABV lineages (TMRCA at least 732 years, with a 95 % HPD 436-1107 years). C1 [Kuzmina, Natalia A.; Kuzmin, Ivan V.; Ellison, James A.; Taylor, Steven T.; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Bergman, David L.] Wildlife Serv, USDA, APHIS, Phoenix, AZ 85021 USA. [Dew, Beverly] North Carolina Dept Hlth & Human Serv, Raleigh, NC 27609 USA. RP Kuzmina, NA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Bldg 17,MS G-33, Atlanta, GA 30333 USA. EM natakuzmina@yandex.ru RI Bergman, David/C-6874-2015; OI Bergman, David/0000-0002-6757-643X; Ellison, James/0000-0003-4492-4857 NR 23 TC 5 Z9 5 U1 0 U2 19 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0920-8569 J9 VIRUS GENES JI Virus Genes PD OCT PY 2013 VL 47 IS 2 BP 305 EP 310 DI 10.1007/s11262-013-0952-9 PG 6 WC Genetics & Heredity; Virology SC Genetics & Heredity; Virology GA 226KL UT WOS:000325034400014 PM 23839669 ER PT J AU Odewole, OA Williamson, RS Zakai, NA Berry, RJ Judd, SE Qi, YP Adedinsewo, DA Oakley, GP AF Odewole, Oluwaseun A. Williamson, Rebecca S. Zakai, Neil A. Berry, Robert J. Judd, Suzanne E. Qi, Yan Ping Adedinsewo, Demilade A. Oakley, Godfrey P., Jr. TI Near-elimination of folate-deficiency anemia by mandatory folic acid fortification in older US adults: Reasons for Geographic and Racial Differences in Stroke study 2003-2007 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID HEALTH MEASURES SURVEY; UNITED-STATES; HEMOGLOBIN CONCENTRATION; SPINA-BIFIDA; POPULATION; PREVALENCE; TRENDS; VITAMIN; IMPACT; SERUM AB Background: The United States implemented mandatory folic acid fortification of enriched cereal grains in 1998. Although several studies have documented the resulting decrease in anemia and folate deficiency, to our knowledge, no one has determined the prevalence of folate-deficiency anemia after fortification. Objective: We determined the prevalence of folate deficiency and folate-deficiency anemia within a sample of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort. Design: The REGARDS cohort is a prospective cohort of 30,239 black and white participants living in the contiguous United States. We measured serum folate concentrations in a random sample of 1546 REGARDS participants aged >= 50 y with baseline hemoglobin and red blood cell mean corpuscular volume measurements. Folate deficiency was defined as a serum folate concentration <6.6 nmol/L (<3.0 ng/mL), and anemia was defined as a hemoglobin concentration <13 g/dL in men and <12 g/dL in nonpregnant women (WHO criteria). Folate-deficiency anemia was defined as the presence of both folate deficiency and anemia. Results: The mean hemoglobin concentration was 13.6 g/dL, and 15.9% of subjects had anemia. The median serum folate concentration was 34.2 nmol/L (15.1 ng/mL), and only 2 of 1546 participants 0.1%) were folate deficient. Both subjects were African American women with markedly elevated C-reactive protein concentrations, macrocytosis, and normal serum cobalamin concentrations; only one subject was anemic. Overall, the prevalence of folate-deficiency anemia was <0.1% (1 of 1546 subjects). Conclusion: Our data suggest that, after mandatory folic acid fortification, the prevalence of folate-deficiency anemia is nearly nonexistent in a community-dwelling population in the United States. C1 [Odewole, Oluwaseun A.; Williamson, Rebecca S.; Adedinsewo, Demilade A.; Oakley, Godfrey P., Jr.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Oakley, Godfrey P., Jr.] Emory Univ, Rollins Sch Publ Hlth, Ctr Spina Bifida Res Prevent & Policy, Atlanta, GA 30322 USA. [Zakai, Neil A.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA. [Zakai, Neil A.] Univ Vermont, Coll Med, Dept Oncol, Burlington, VT USA. [Berry, Robert J.; Qi, Yan Ping] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Judd, Suzanne E.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. RP Oakley, GP (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM gpoakley@mindsping.com OI Berry, Robert/0000-0002-7162-5046; Adedinsewo, Demilade/0000-0002-8629-2029 FU CDC [U48 DP001909O] FX Supported by the CDC (Cooperative Agreement U48 DP001909O) and by unrestricted gifts from Gerry Davy and Sophie's Voice Foundation. NR 30 TC 13 Z9 13 U1 0 U2 14 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2013 VL 98 IS 4 BP 1042 EP 1047 DI 10.3945/ajcn.113.059683 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 221YF UT WOS:000324696100022 PM 23945721 ER PT J AU Tian, N Zhang, ZF Loustalot, F Yang, QH Cogswell, ME AF Tian, Niu Zhang, Zefeng Loustalot, Fleetwood Yang, Quanhe Cogswell, Mary E. TI Sodium and potassium intakes among US infants and preschool children, 2003-2010 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID USUAL NUTRIENT INTAKE; BLOOD-PRESSURE; INTAKE DISTRIBUTIONS; SALT SENSITIVITY; DIETARY-SODIUM; HYPERTENSION; TODDLERS; CHILDHOOD; RECOMMENDATIONS; COLLECTION AB Background: Data are limited on usual sodium and potassium intakes relative to age-specific recommendations and the sodium: potassium ratio in infants and preschoolers, especially among those aged <2 y, who are black or breastfed. Objective: The usual sodium intake above the Tolerable Upper Intake Levels (ULs), potassium intakes above Adequate Intakes (AIs), the sodium: potassium ratio, and sodium density (mg/kcal) among US infants and preschoolers by age group, as applicable, were estimated and compared by race-ethnicity and current breast-feeding status. Design: Data were analyzed among 3 groups of children (aged 7-11 mo, 1-3 y, and 4-5 y) from the NHANES 2003-2010 by using measurement error models. Results: Seventy-nine percent of children aged 1-3 y and 87% of those aged 4-5 y exceeded their sodium UL; among non-Hispanic black children, the estimates were 84% and 97%, respectively. For potassium, 97% of infants, 5% of children aged 1-3 y, and 0.4% aged 4-5 y met their AIs. Compared with non-Hispanic whites and Mexican Americans, non-Hispanic black infants and preschoolers had higher mean sodium density and sodium: potassium ratios. Currently breastfed infants and children consumed, on average, less sodium than those who were not breastfed (382 +/- 53 compared with 538 +/- 22 mg in those aged 7-11 mo and 1154 +/- 88 compared with 1985 +/- 24 mg in those aged 1-3 y, respectively), but the sodium: potassium ratio did not differ. Conclusions: Most US preschoolers, particularly non-Hispanic blacks, consume too much sodium, and nearly all do not consume enough potassium. Data that suggest that currently breastfed infants consume less sodium than do those who are not breastfeeding merit further investigation. C1 [Tian, Niu; Zhang, Zefeng; Loustalot, Fleetwood; Yang, Quanhe; Cogswell, Mary E.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Tian, N (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,MS-F72, Atlanta, GA 30341 USA. EM vii9@cdc.gov FU Centers for Disease Control and Prevention, US Department of Health and Human Services FX Supported by the Centers for Disease Control and Prevention, US Department of Health and Human Services. NR 44 TC 16 Z9 16 U1 0 U2 7 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD OCT PY 2013 VL 98 IS 4 BP 1113 EP 1122 DI 10.3945/ajcn.113.060012 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 221YF UT WOS:000324696100028 PM 23966425 ER PT J AU Streja, E Miller, JE Bech, BH Greene, N Pedersen, LH Yeargin-Allsopp, M Braun, KV Schendel, DE Christensen, D Uldall, P Olsen, J AF Streja, Elani Miller, Jessica E. Bech, Bodil H. Greene, Naomi Pedersen, Lars Henning Yeargin-Allsopp, Marshalyn Braun, Kim Van Naarden Schendel, Diana E. Christensen, Deborah Uldall, Peter Olsen, Jorn TI Congenital cerebral palsy and prenatal exposure to self-reported maternal infections, fever, or smoking SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE congenital cerebral palsy; maternal infections; pregnancy; smoking ID LOW-BIRTH-WEIGHT; RISK-FACTORS; PRETERM INFANTS; PERINATAL FACTORS; CHILDREN BORN; COHORT; PREVALENCE; CHILDHOOD; SWEDEN; ENCEPHALOPATHY AB OBJECTIVE: The objective of the study was to investigate the association between maternal self-reported infections, fever, and smoking in the prenatal period and the subsequent risk for congenital cerebral palsy (CP). STUDY DESIGN: We included the 81,066 mothers of singletons born between 1996 and 2003 who participated in the Danish National Birth Cohort. Children were followed up through December 2008. Information on maternal infections, fever, smoking, and other demographic and lifestyle factors during pregnancy were reported by mothers in computer-assisted telephone interviews in early and midgestation. We identified 139 CP cases including 121 cases of spastic CP (sCP) as confirmed by the Danish National Cerebral Palsy Register. Cox proportional hazards regression models were used to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs). RESULTS: Self-reported vaginal infections were associated with an increased risk of CP and sCP (aHR, 1.52; 95% CI, 1.04-2.24; and aHR, 1.73; 95% CI, 1.16-2.60, respectively) and particularly untreated vaginal infections were associated with an increased risk of sCP (aHR, 1.95; 95% CI, 1.16-3.26). Fever was associated with the risk of CP (aHR, 1.53; 95% CI, 1.06-2.21). Smoking 10 or more cigarettes per day during pregnancy was also associated with sCP (aHR, 1.80; 95% CI, 1.10-2.94). There was a modest excess in risk for children exposed to both heavy smoking and vaginal infections. No other self-reported infections were significantly associated with CP. CONCLUSION: Self-reported vaginal infections, fever, and smoking 10 or more cigarettes per day during pregnancy were associated with a higher risk of overall CP and/or sCP. C1 [Streja, Elani; Miller, Jessica E.; Greene, Naomi; Olsen, Jorn] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA. [Bech, Bodil H.; Pedersen, Lars Henning; Olsen, Jorn] Aarhus Univ Hosp, Dept Publ Hlth, Epidemiol Sect, DK-8000 Aarhus, Denmark. [Pedersen, Lars Henning] Aarhus Univ Hosp, Inst Clin Med, Dept Obstet & Gynecol, DK-8000 Aarhus, Denmark. [Uldall, Peter] Univ Southern Denmark, Natl Inst Publ Hlth, Danish Cerebral Registry, Odense, Denmark. [Olsen, Jorn] Univ Copenhagen, Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark. [Yeargin-Allsopp, Marshalyn; Braun, Kim Van Naarden; Schendel, Diana E.; Christensen, Deborah] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Streja, E (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA. RI Bech, Bodil Hammer/B-9646-2016; Miller, Jessica/I-2255-2016 FU National Center on Birth Defects and Developmental Disabilities; Centers for Disease Control and Prevention, Atlanta, GA; University of Aarhus, Aarhus, Denmark FX E.S. was supported by a grant from the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, and the University of Aarhus, Aarhus, Denmark. NR 42 TC 4 Z9 4 U1 1 U2 15 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2013 VL 209 IS 4 AR 332.e1 DI 10.1016/j.ajog.2013.06.023 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 221YY UT WOS:000324698200012 PM 23791566 ER PT J AU Gao, RB Bhatnagar, J Blau, DM Greer, P Rollin, DC Denison, AM Deleon-Carnes, M Shieh, WJ Sambhara, S Tumpey, TM Patel, M Liu, L Paddock, C Drew, C Shu, YL Katz, JM Zaki, SR AF Gao, Rongbao Bhatnagar, Julu Blau, Dianna M. Greer, Patricia Rollin, Dominique C. Denison, Amy M. Deleon-Carnes, Marlene Shieh, Wun-Ju Sambhara, Suryaprakash Tumpey, Terrence M. Patel, Mitesh Liu, Lindy Paddock, Christopher Drew, Clifton Shu, Yuelong Katz, Jacqueline M. Zaki, Sherif R. TI Cytokine and Chemokine Profiles in Lung Tissues from Fatal Cases of 2009 Pandemic Influenza A (H1N1) Role of the Host Immune Response in Pathogenesis SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID CELL-DEATH APOPTOSIS; HONG-KONG INFLUENZA; VIRUS-INFECTION; FAS LIGAND; RESPIRATORY-FAILURE; T-CELLS; EXPRESSION; DISEASE; INDUCTION; PATHOLOGY AB Pathological studies on fatal cases caused by 2009 pandemic influenza H1N1 virus (2009 pH1N1) reported extensive diffuse alveolar damage and virus infection predominantly in the lung parenchyma. However, the host immune response after severe 2009 pH1N1 infection is poorly understood. Herein, we investigated viral Load, the immune response, and apoptosis in Lung tissues from 50 fatal cases with 2009 pH1N1 virus infection. The results suggested that 7 of the 27 cytokines/chemokines showed remarkably high expression, including IL-1 receptor antagonist protein, IL-6, tumor necrosis factor-alpha, IL-8, monocyte chemoattractant protein-1, macrophage inflammatory protein 1-beta, and interferon-inducible protein-10 in lung tissues of 2009 pH1N1 fatal cases. Viral Load, which showed the highest level on day 7 of illness onset and persisted until day 17 of illness, was positively correlated with mRNA Levels of IL-1 receptor antagonist protein, monocyte chemoattractant protein-1, macrophage inflammatory protein 1-beta, interferon-inducible protein-10, and regulated on activation normal T-cell expressed and secreted. Apoptosis was evident in lung tissues stained by the TUNEL assay. Decreased Fas and elevated FasL mRNA Levels were present in lung tissues, and cleaved caspase-3 was frequently seen in pneumocytes, submucosal glands, and lymphoid tissues. The pathogenesis of the 2009 pH1N1 virus infection is associated with viral replication and production of proinflammatory mediators. FasL and caspase-3 are involved in the pathway of 2009 pH1N1 virus-induced apoptosis in lung tissues, and the disequilibrium between the Fas and FasL Level in lung tissues could contribute to delayed clearance of the virus and subsequent pathological damages. C1 [Gao, Rongbao; Shu, Yuelong; Zaki, Sherif R.] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, State Key Lab Mol Virol & Genet Engn, Dept Influenza,Chinese Natl Influenza Ctr, Beijing, Peoples R China. [Bhatnagar, Julu; Blau, Dianna M.; Greer, Patricia; Rollin, Dominique C.; Denison, Amy M.; Deleon-Carnes, Marlene; Shieh, Wun-Ju; Patel, Mitesh; Liu, Lindy; Paddock, Christopher; Drew, Clifton; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Influenza Div, Atlanta, GA 30333 USA. [Sambhara, Suryaprakash; Tumpey, Terrence M.; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Influenza Div, Atlanta, GA 30333 USA. [Sambhara, Suryaprakash; Tumpey, Terrence M.; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Immunol & Pathogenesis Branch, Influenza Div, Atlanta, GA 30333 USA. RP Zaki, SR (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, 1600 Clifton Rd,Mailstop G32, Atlanta, GA 30333 USA. EM szaki@cdc.gov NR 60 TC 28 Z9 28 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD OCT PY 2013 VL 183 IS 4 BP 1258 EP 1268 DI 10.1016/j.ajpath.2013.06.023 PG 11 WC Pathology SC Pathology GA 227MU UT WOS:000325118800021 PM 23938324 ER PT J AU Counts, JM Astles, JR Lipman, HB AF Counts, Jon M. Astles, John R. Lipman, Harvey B. TI Assessing physician utilization of laboratory practice guidelines: Barriers and opportunities for improvement SO CLINICAL BIOCHEMISTRY LA English DT Article DE Practice guidelines; Adaptation; Computerized physician order entry (CPOE); Evidence based medicine; Clinical decision support ID CLINICAL-PRACTICE GUIDELINES; BEHAVIOR; DIAGNOSIS; SYSTEMS; IMPACT; TESTS; CARE AB Objectives: To assess physician utilization of laboratory practice guidelines (LPGs)(3) to improve LPG uptake and use. Design and methods: A statewide survey of 4987 primary care physicians (PCPs) and 75 infectious disease (ID) specialists was conducted in 2005-2006 to correlate guideline source with users' awareness, utilization, and perceived usefulness of LPGs. We compared LPGs developed by the Centers for Disease Control and Prevention (CDC) to LPGs developed by the Washington State Department of Health through its Clinical Laboratory Advisory Council (CLAC). Results: Physician awareness of LPGs was a major impediment to utilization of CLAC LPGs, and they were perceived as inaccessible, too numerous and unhelpful. However, once aware, respondents tended to use LPGs and there were no important differences in impediments or the ways CDC and CLAC LPGs were used. Of the PCPs who had a computerized physician order entry system (CPOE), a majority (92%) found, or expected that they would find, the integration of guidelines into their system helpful. Conclusions: For both CDC and CLAC LPGs, the greatest impediments to uptake were awareness and familiarity, which depended upon LPG source, physician specialty, and practice setting. There was no apparent impediment to uptake of CLAC or CDC LPGs based upon their credibility. Because better promotion could increase uptake, CLAC LPGs are now promoted by the Washington State Medical Association. Integration of LPGs into CPOE and smart phone applications could address major impediments to clinician use. The Cabana paradigm would be useful for any organization seeking to improve LPG impact. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. C1 [Counts, Jon M.] Univ Washington, Fdn Hlth Care Qual, Seattle, WA 98195 USA. [Astles, John R.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA 30333 USA. RP Counts, JM (reprint author), Ctr Dis Control & Prevent, MS F-11,1600 Clifton Rd, Atlanta, GA 30333 USA. EM countsj1937@hotmail.com; JAstles@cdc.gov FU Centers for Disease Control and Prevention [HM06-60503CONT08] FX This work was supported by the Centers for Disease Control and Prevention cooperative agreement (HM06-60503CONT08). NR 31 TC 0 Z9 0 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0009-9120 J9 CLIN BIOCHEM JI Clin. Biochem. PD OCT PY 2013 VL 46 IS 15 BP 1554 EP 1560 DI 10.1016/j.clinbiochem.2013.06.004 PG 7 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 226SM UT WOS:000325056300039 PM 23791802 ER PT J AU Heimburg-Molinaro, J Priest, JW Live, D Boons, GJ Song, XZ Cummings, RD Mead, JR AF Heimburg-Molinaro, Jamie Priest, Jeffrey W. Live, David Boons, Geert-Jan Song, Xuezheng Cummings, Richard D. Mead, Jan R. TI Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Cryptosporidium parvum; Tn antigen; Glycopeptide microarrays; Toxoplasma; Plasmodium ID N-ACETYLGALACTOSAMINYLTRANSFERASE ACTIVITY; O-GLYCOSYLATION; GLYCAN MICROARRAYS; TOXOPLASMA-GONDII; PARVUM; ANTIGEN; IDENTIFICATION; EIMERIA; CLONING; GLYCOPROTEINS AB Glycoproteins expressed by Ciyptosporidium parvum are immunogenic in infected individuals but the nature of the epitopes recognised in C. parvum glycoproteins is poorly understood. Since a known immunodominant antigen of Cryptosporidium, the 17 kDa glycoprotein, has previously been shown to bind to lectins that recognise the Tn antigen (GaINAc alpha 1-Ser/Thr-R), a large number of glycopeptides with different Tn valency and presentation were prepared. In addition, glycopeptides were synthesised based on a 40 kDa cryptosporidial antigen, a polymorphic surface glycoprotein with varying numbers of serine residues, to determine the reactivity with sera from C parvum-infected humans. These glycopeptides and non-glycosylated peptides were used to generate a glycopeptide microarray to allow screening of sera from C parvum-infected individuals for the presence of IgM and IgG antibodies. IgG but not IgM in sera from C parvum-infected individuals bound to multivalent Tn antigen epitopes presented on glycopeptides, suggesting that glycoproteins from C parvum that contain the Tn antigen induce immune responses upon infection. In addition, molecular differences in glycosylated peptides (e.g. substituting Set for Thr) as well as the site of glycosylation had a pronounced effect on rpactivity. Lastly, pooled sera from individuals infected with either Toxoplasma or Plasmodium were also tested against the modified Cryptosporidiurn peptides and some sera showed specific binding to glycopeptide epitopes. These studies reveal that specific anti-glycopeptide antibodies that recognise the Tn antigen may be useful diagnostically and in defining the roles of parasite glycoconjugates in infections. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. C1 [Heimburg-Molinaro, Jamie; Song, Xuezheng; Cummings, Richard D.] Emory Univ, Dept Biochem, Atlanta, GA 30322 USA. [Priest, Jeffrey W.] Ctr Dis Control & Prevent, Div Foodbome Waterborne & Enter Dis, Decatur, GA 30033 USA. [Live, David; Boons, Geert-Jan] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA. [Mead, Jan R.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Mead, Jan R.] Atlanta VA Med Ctr, Decatur, GA 30033 USA. RP Mead, JR (reprint author), Atlanta VA Med Ctr, 1670 Clairmont Rd, Decatur, GA 30033 USA. EM jmead@emory.edu RI Boons, Geert-Jan/J-3211-2016 OI Boons, Geert-Jan/0000-0003-3111-5954 FU Emory's and Children's Pediatrics Research Center, USA; Children's Center for Immunology and Vaccines, USA; Department of Veteran's Affairs, USA; Georgia Research Alliance, USA; National Institutes of Health, USA [RO1CA088986]; National Institutes of Health [GM098791] FX This work was supported in part by Emory's and Children's Pediatrics Research Center, USA, Children's Center for Immunology and Vaccines, USA, the Department of Veteran's Affairs, USA, the Georgia Research Alliance, USA, the National Institutes of Health, USA, Grant RO1CA088986 (G.-J.B.), and the National Institutes of Health Grant GM098791 (R.D.C). We thank Hong Ju and Yi Lasanajak for technical assistance. Use of trade names is for identification only and does not imply endorsement by the Public Health Service, USA or by the U.S. Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, USA. NR 42 TC 5 Z9 5 U1 0 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 J9 INT J PARASITOL JI Int. J. Parasit. PD OCT PY 2013 VL 43 IS 11 BP 901 EP 907 DI 10.1016/j.ijpara.2013.05.012 PG 7 WC Parasitology SC Parasitology GA 225LY UT WOS:000324965600006 PM 23856596 ER PT J AU Brener, ND Eaton, DK Kann, LK McManus, TS Lee, SM Scanlon, KS Fulton, JE O'Toole, TP AF Brener, Nancy D. Eaton, Danice K. Kann, Laura K. McManus, Tim S. Lee, Sarah M. Scanlon, Kelley S. Fulton, Janet E. O'Toole, Terry P. TI Behaviors Related to Physical Activity and Nutrition Among US High School Students SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Physical activity; Dietary behaviors; High school students ID WHITE ADOLESCENT GIRLS; BODY-MASS INDEX; UNITED-STATES; DIETARY-INTAKE; NATIONAL SAMPLE; MEAL PATTERNS; WEIGHT STATUS; FAMILY MEALS; FAST-FOOD; HEALTH AB Purpose: National data related to physical activity (PA) and nutrition among adolescents are needed to help develop effective obesity prevention programs. The 2010 National Youth Physical Activity and Nutrition Study (NYPANS) was conducted to provide nationally representative data on behaviors and behavioral correlates related to healthy eating and PA. Methods: NYPANS used a three-stage cluster sample design to obtain data representative of public-and private-school students in grades 9 through 12 in the United States (n = 11,429). Students completed an anonymous, self-administered questionnaire in their classrooms during a regular class period. Trained data collectors directly measured the students' height and weight at school using a standard protocol. Results: Analyses revealed that 19.0% of students were obese and 17.8% were overweight. Students participated in a range of physical activities during the 12 months before the survey; prevalence ranged from 5.0% for ice hockey to 83.9% for walking. In addition, 52.5% of students enjoyed the physical education classes they took at school. During the 7 days before the survey, 74.8% of students ate at least one meal or snack from a fast food restaurant, with black students more likely than white and Hispanic students to have done so. Forty-one percent of students always or most of the time have a TV on while eating dinner at home. Conclusions: These and other NYPANS results can be used to develop obesity prevention programs that address specific behaviors and behavioral correlates, and target subgroups in which behaviors and behavioral correlates related to obesity are most prevalent. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Brener, Nancy D.; Kann, Laura K.; McManus, Tim S.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Eaton, Danice K.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Atlanta, GA 30341 USA. [Lee, Sarah M.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30341 USA. [Scanlon, Kelley S.; Fulton, Janet E.; O'Toole, Terry P.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Brener, ND (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, 4770 Buford Highway,NE,Mailstop K-29, Atlanta, GA 30341 USA. EM NBrener@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 10 Z9 10 U1 2 U2 28 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2013 VL 53 IS 4 BP 539 EP 546 DI 10.1016/j.jadohealth.2013.05.006 PG 8 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 221WA UT WOS:000324689500019 PM 23796969 ER PT J AU Conger, RD Schofield, TJ Neppl, TK Merrick, MT AF Conger, Rand D. Schofield, Thomas J. Neppl, Tricia K. Merrick, Melissa T. TI Disrupting Intergenerational Continuity in Harsh and Abusive Parenting: The Importance of a Nurturing Relationship With a Romantic Partner SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Abuse and violence; Domestic abuse; Parental discipline; Parenting style; Romantic relationships ID TRANSMISSION; RESILIENCE; BEHAVIOR; ADOLESCENTS; PATHWAYS; CONTEXT; MODEL AB Purpose: Harsh, abusive, and rejecting behavior by parents toward their children is associated with increased risk for many developmental problems for youth. Earlier research also shows that children raised by harsh parents are more likely to treat their own children harshly. The present study evaluated nurturing and supportive behaviors of spouses or cohabiting romantic partners hypothesized to strengthen co-parent relationships and help break this intergenerational cycle of harsh parenting. Methods: Data come from the Family Transitions Project, a 22-year, 3-generation study of a cohort of over 500 early adolescents (G2) grown to adulthood. During adolescence, observers rated G1 (parent of G2) harsh parenting to G2. Several years later, observers rated G2 harsh parenting toward their oldest child (G3). In addition, G2's romantic partner (spouse or cohabiting partner) was rated by observers on a range of behaviors expected to affect G2 harsh parenting. Results: Romantic partner warmth and positive communication with G2 were associated with less G2 harsh parenting toward G3 (a compensatory or main effect) and when these partner behaviors were high, there was no evidence of intergenerational continuity from G1 to G2 harsh parenting (a moderating or protective effect). G1 harsh parenting slightly decreased the likelihood that G2 would select a supportive spouse or romantic partner (evidence of cumulative continuity). Conclusions: Romantic partner warmth and positive communication appear to disrupt continuity in harsh and abusive parenting. As appropriate, preventive interventions designed to reduce risk for child maltreatment should include a focus on spousal or partner behaviors in their educational or treatment programs. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Conger, Rand D.] Univ Calif Davis, Family Res Grp, Davis, CA 95618 USA. [Schofield, Thomas J.; Neppl, Tricia K.] Iowa State Univ, Dept Human Dev & Family Studies, Ames, IA USA. [Merrick, Melissa T.] Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA USA. RP Conger, RD (reprint author), Univ Calif Davis, Family Res Grp, 202 Cousteau Pl,Suite 100, Davis, CA 95618 USA. EM rdconger@ucdavis.edu FU National Institute of Child Health and Human Development [HD047573, HD051746]; National Institute on Drug Abuse [DAO17902]; National Institute of Mental Health [MH051361]; Centers for Disease Control and Prevention [200-2011-F-38936] FX Support for this research was provided by grants from the National Institute of Child Health and Human Development (HD047573, HD051746), the National Institute on Drug Abuse (DAO17902), and the National Institute of Mental Health (MH051361). The analyses presented in this paper were supported by the Centers for Disease Control and Prevention (200-2011-F-38936). The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of these funders. NR 31 TC 18 Z9 18 U1 6 U2 39 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2013 VL 53 IS 4 SU S BP S11 EP S17 DI 10.1016/j.jadohealth.2013.03.014 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 221VX UT WOS:000324689200003 PM 24059934 ER PT J AU Herrenkohl, TI Klika, JB Brown, EC Herrenkohl, RC Leeb, RT AF Herrenkohl, Todd I. Klika, J. Bart Brown, Eric C. Herrenkohl, Roy C. Leeb, Rebecca T. TI Tests of the Mitigating Effects of Caring and Supportive Relationships in the Study of Abusive Disciplining Over Two Generations SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Intergenerational abuse; Protective factor; Mitigating factor; Safe, stable, nurturing, relationship ID CHILD MALTREATMENT; INTERGENERATIONAL CONTINUITY; VIOLENCE; PREVENTION; RESILIENCE; MODERATORS; PROMOTION; MEDIATORS; PATHWAYS; HEALTH AB Purpose: To examine evidence of the continuity in abusive discipline across two generations (G1 and G2) and the role of safe, stable, and nurturing relationships (SSNRs) as protective factors. Methods: Data are from the Lehigh Longitudinal Study, a prospective investigation of the causes and consequences child maltreatment that began in the 1970s with a sample of 457 children and their parents. Data were most recently collected in 2008-2010 from 80% of the original child sample (N = 357) when they were adults age 36 years on average. Of those assessed as adults, 268 participants (G2s) were parenting children and thus comprise the analysis sample. Analyses examined the association between harsh physical discipline practices by G1 parents and G2's reports of similarly severe discipline practices used in parenting their own children. Analyses also investigated the direct and interactive (protective) effects of SSNR variables that pertain to the care, warmth, and support children received from their mothers, fathers, and siblings over their lifetimes. A measure of an adult partner's warmth and support was also included. A case-level examination of G2 harsh discipliners was included to investigate other forms of past and more recent forms of abuse exposure. Results: Results show a significant predictive association between physical discipline by G1 and G2 parents (beta = .30; p < .05; odds ratio, 1.14; confidence interval, 1.04-1.26), after accounting for childhood socioeconomic status and gender. Whereas being harshly disciplined as a child was inversely related to reports of having had a caring relationship with one's mother (r = -.25; p < .01), only care and support from one's father predicted a lower risk of harsh physical discipline by G2s (beta = -.24; p < .05; odds ratio, .74; confidence interval, .59-.92). None of the SSNR variables moderated the effect of G1 discipline on G2 discipline. A case-level examination of the abusive histories of G2 harsh discipliners found they had in some instances been exposed to physical and emotional abuse by multiple caregivers and by adult partners. Conclusions: There is continuity in physical disciplining over two generations. SSNRs measured in this study did not mediate or moderate the effect of G1 on G2 harsh physical discipline, although care and support from fathers was inversely related to the likelihood of G2 harsh physical discipline. This relationship is independent of abuse in childhood. Research is needed to identify factors that interrupt the intergenerational continuity of harsh physical (abusive) disciplining so that promising interventions can be developed and implemented. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Herrenkohl, Todd I.; Klika, J. Bart; Brown, Eric C.] Univ Washington, Sch Social Work, Seattle, WA 98115 USA. [Herrenkohl, Roy C.] Lehigh Univ, Dept Sociol & Anthropol, Ctr Social Res, Bethlehem, PA 18015 USA. [Leeb, Rebecca T.] Ctr Dis Control & Prevent, Child Dev Studies Team, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Herrenkohl, TI (reprint author), Univ Washington, Sch Social Work, Social Dev Res Grp, 9725 3rd Ave NE,Suite 401, Seattle, WA 98115 USA. EM tih@u.washington.edu FU Centers for Disease Control Prevention [200-2011-F-38936]; National Institute on Child Health and Development; Office of Behavioral Social Sciences and Research [RO1 HD049767] FX This research was supported by the Centers for Disease Control Prevention (grant 200-2011-F-38936) and by grants from the National Institute on Child Health and Development and the Office of Behavioral Social Sciences and Research (RO1 HD049767). The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of these funders. NR 42 TC 12 Z9 12 U1 2 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2013 VL 53 IS 4 SU S BP S18 EP S24 DI 10.1016/j.jadohealth.2013.04.009 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 221VX UT WOS:000324689200004 PM 24059935 ER PT J AU Jaffee, SR Bowes, L Ouellet-Morin, I Fisher, HL Moffitt, TE Merrick, MT Arseneault, L AF Jaffee, Sara R. Bowes, Lucy Ouellet-Morin, Isabelle Fisher, Helen L. Moffitt, Terrie E. Merrick, Melissa T. Arseneault, Louise TI Safe, Stable, Nurturing Relationships Break the Intergenerational Cycle of Abuse: A Prospective Nationally Representative Cohort of Children in the United Kingdom SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Cycle of abuse; Maltreatment; Intergenerational transmission ID ANTISOCIAL-BEHAVIOR; PHYSICAL ABUSE; SCREENING-TEST; MALTREATMENT; RISK; CONTINUITY; CHILDHOOD; VIOLENCE; TRANSMISSION; DEPRIVATION AB Purpose: To identify contextual and interpersonal factors that distinguish families in which the inter-generational transmission of maltreatment is maintained from families in which the cycle is broken. Methods: The sample was composed of 1,116 families in the United Kingdom who participated in the Environmental Risk (E-Risk) Longitudinal Twin Study. We assessed mother's childhood history of maltreatment retrospectively with a validated and reliable interview. Prospective reports of children's physical maltreatment were collected repeatedly up to 12 years. We compared families in which mothers but not children had experienced maltreatment with families in which both mothers and children had experienced maltreatment, and with families without maltreatment, on a range of contextual and interpersonal factors known to affect child development. Results: In multivariate analyses, supportive and trusting relationships with intimate partners, high levels of maternal warmth toward children, and low levels of partner violence between adults distinguished families in which mothers but not children experienced maltreatment from families in which mothers and children experienced maltreatment. Families in which only mothers experienced maltreatment were largely similar to families in which neither generation experienced maltreatment, except that mothers belonging to the former group were more likely to have a lifetime history of depression and low levels of social support. Conclusions: Safe, stable, nurturing relationships between intimate partners and between mothers and children are associated with breaking the cycle of abuse in families. Additional research is needed to determine whether these factors have a causal role in preventing the transmission of maltreatment from one generation to the next. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Jaffee, Sara R.; Fisher, Helen L.; Moffitt, Terrie E.; Arseneault, Louise] Kings Coll London, MRC, Social Genet & Dev Psychiat Ctr, London, England. [Jaffee, Sara R.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. [Bowes, Lucy] Univ Oxford, Dept Social Policy & Intervent, Oxford, England. [Ouellet-Morin, Isabelle] Univ Montreal, Sch Criminol, Montreal, PQ, Canada. [Ouellet-Morin, Isabelle] Mental Hlth Univ Inst Montreal, Res Ctr, Montreal, PQ, Canada. [Moffitt, Terrie E.] Duke Univ, Dept Psychol & Neurosci, Durham, NC USA. [Moffitt, Terrie E.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. [Moffitt, Terrie E.] Duke Univ, Dept Behav Sci, Durham, NC USA. [Merrick, Melissa T.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Arseneault, L (reprint author), Inst Psychiat, MRC, Social Genet & Dev Psychiat Ctr, London SE5 8AF, England. EM louise.arseneault@kcl.ac.uk RI Fisher, Helen/A-7178-2010; Moffitt, Terrie/D-5295-2011 OI Fisher, Helen/0000-0003-4174-2126; Moffitt, Terrie/0000-0002-8589-6760 FU Medical Research council [UK MRC G1002190, G9806489]; Economic and Social Research Council [RES-177-25-0013]; National Institute of Child Health and Human Development grant [HD061298]; Jacobs Foundation FX The E-Risk study is funded by the Medical Research council (grants UK MRC G1002190 and G9806489). Additional support was provided by Economic and Social Research Council grant RES-177-25-0013, National Institute of Child Health and Human Development grant HD061298, and by funds from the Jacobs Foundation. The authors are grateful to the study mothers and fathers, the twins, and the twins' teachers for participation. Louise Arseneault is a British Academy Mid-Career Fellow. The authors thank Michael Rutter and Robert Plomin, Thomas Achenbach for kind permission to adapt the Child Behavior Checklist, and members of the E-Risk team for their dedication, hard work, and insights. NR 40 TC 21 Z9 21 U1 2 U2 37 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2013 VL 53 IS 4 SU S BP S4 EP S10 DI 10.1016/j.jadohealth.2013.04.007 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 221VX UT WOS:000324689200002 PM 24059939 ER PT J AU Merrick, MT Leeb, RT Lee, RD AF Merrick, Melissa T. Leeb, Rebecca T. Lee, Rosalyn D. TI Examining the Role of Safe, Stable, and Nurturing Relationships in the Intergenerational Continuity of Child Maltreatment-Introduction to the Special Issue SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID TOXIC STRESS; ABUSE; VIOLENCE; PREVENTION; ADVERSITY; NEGLECT; SAMPLE; CYCLE; RISK C1 [Merrick, Melissa T.; Lee, Rosalyn D.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Leeb, Rebecca T.] Ctr Dis Control & Prevent, Div Hlth & Human Dev, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Merrick, MT (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. NR 29 TC 11 Z9 11 U1 0 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2013 VL 53 IS 4 SU S BP S1 EP S3 DI 10.1016/j.jadohealth.2013.06.017 PG 3 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 221VX UT WOS:000324689200001 PM 24059933 ER PT J AU Schofield, TJ Lee, RD Merrick, MT AF Schofield, Thomas J. Lee, Rosalyn D. Merrick, Melissa T. TI Safe, Stable, Nurturing Relationships as a Moderator of Intergenerational Continuity of Child Maltreatment: A Meta-Analysis SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Child maltreatment; Intergenerational continuity; Buffering protective effects; Transgenerational patterns; Safe, stable nurturing relationships (SSNRs) ID PHYSICAL ABUSE; TRANSMISSION; CYCLE; PREVENTION; RESILIENCE; MECHANISMS; BEHAVIOR; FUTURE; STATES; WOMEN AB Purpose: The present paper summarizes findings of the special issue papers on the intergenerational continuity of child maltreatment and through meta-analysis explores the potential moderating effects of safe, stable, nurturing relationships (SSNRs). Methods: Studies were selected for inclusion in this meta-analysis if they (1) were published in peer-reviewed journals; (2) tested for intergenerational continuity in any form of child maltreatment, using prospective, longitudinal data; and (3) tested for moderating effects of any variable of SSNRs on intergenerational continuity of child maltreatment. The search revealed only one additional study beyond the four reports written for this special issue that met inclusion criteria for the meta-analysis. Results: Estimates of intergenerational stability of child maltreatment from the studies included in this special issue are consistent with several other studies, which find that child maltreatment in one generation is positively related to child maltreatment in the next generation. Furthermore, meta-analytic results from the five studies that met the inclusion criteria suggest a protective, moderating effect of SSNRs on intergenerational continuity of child maltreatment. The calculated fail-safe index indicated that 49 unpublished intergenerational studies with an average null effect would be required to render nonsignificant the overall moderation effect of SSNRs on child maltreatment. Conclusions: This special issue expanded the examination of SSNRs beyond the caregiver-child dyad. That is, these studies considered SSNRs in adult relationships as well as parent-child relationships. Results suggest that certain types of SSNRs between parents and other adults (e. g., romantic partner, co-parent, or adult social support resource) may decrease maltreatment continuity. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Schofield, Thomas J.] ISU, HDFS, Ames, IA 50011 USA. [Lee, Rosalyn D.; Merrick, Melissa T.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Schofield, TJ (reprint author), ISU, HDFS, 4380 Palmer,Suite 1360, Ames, IA 50011 USA. EM tommy@iastate.edu FU Centers for Disease Control and Prevention (CDC) [200-2011-F-38936] FX Publication of this article was supported by the Centers for Disease Control and Prevention (CDC; 200-2011-F-38936). The opinions or views expressed in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 45 TC 19 Z9 19 U1 5 U2 38 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2013 VL 53 IS 4 SU S BP S32 EP S38 DI 10.1016/j.jadohealth.2013.05.004 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 221VX UT WOS:000324689200006 PM 24059937 ER PT J AU Thornberry, TP Henry, KL Smith, CA Ireland, TO Greenman, SJ Lee, RD AF Thornberry, Terence P. Henry, Kimberly L. Smith, Carolyn A. Ireland, Timothy O. Greenman, Sarah J. Lee, Rosalyn D. TI Breaking the Cycle of Maltreatment: The Role of Safe, Stable, and Nurturing Relationships SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Maltreatment; Intergenerational continuity; Safe, stable, and nurturing relationships ID CHILD PHYSICAL ABUSE; INTERGENERATIONAL CONTINUITY; RISK; PREVENTION; DISORDER; VIOLENCE; NEGLECT; STRESS; IMPACT; TRIAL AB Purpose: We examine two research questions. First, does a history of child maltreatment victimization significantly increase the likelihood of maltreatment perpetration during adulthood? Second, do safe, stable, and nurturing relationships (SSNRs) during early adulthood serve as direct protective factors, buffering protective factors, or both to interrupt intergenerational continuity in maltreating behaviors? Methods: Data come from the Rochester Youth Development Study that followed a community sample from age 14 to 31 with 14 assessments. Maltreatment victimization records covering birth through age 17 were collected from Child Protective Services records as were maltreatment perpetration records from age 21 to 30. Data on five SSNRs were measured during three interviews from ages 21 to 23. Results: There is a significant relationship between maltreatment victimization and maltreatment perpetration (odds ratio = 2.57; 95% confidence interval = 1.47-4.50). Three of the five SSNRs investigated-relationship satisfaction, parental satisfaction, and attachment to child-served as direct protective factors, significantly reducing risk for those who had been maltreated. However, none of the interaction terms-between maltreatment victimization and the SSNR-was statistically significant, indicating that the SSNRs did not serve as buffering protective factors Conclusions: Although a history of maltreatment significantly increases the risk of subsequent perpetration of maltreatment, enhancing SSNRs with intimate partners and with children during early adulthood can decrease the odds that a victim of maltreatment will become a perpetrator. Mandated reporters and service providers should be aware of the risk posed by earlier maltreatment and be prepared to ameliorate that risk, in part by strengthening supportive social relationships. (C) 2013 Society for Adolescent Health and Medicine. All rights reserved. C1 [Thornberry, Terence P.; Greenman, Sarah J.] Univ Maryland, Dept Criminol & Criminal Justice, College Pk, MD 20742 USA. [Henry, Kimberly L.] Colorado State Univ, Dept Psychol, Ft Collins, CO 80523 USA. [Smith, Carolyn A.] SUNY Albany, Sch Social Welf, Albany, NY 12222 USA. [Ireland, Timothy O.] Niagara Univ, Dept Criminol & Criminal Justice, Niagara, NY USA. [Lee, Rosalyn D.] US Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. RP Thornberry, TP (reprint author), Univ Maryland, Dept Criminol & Criminal Justice, 2220 LeFrak Hall, College Pk, MD 20742 USA. EM thornbet@umd.edu FU Centers for Disease Control and Prevention [R01CE001572]; Office of Juvenile Justice and Delinquency Prevention [2006-JW-BX-0074, 86-JN-CX-0007, 96-MU-FX-0014, 2004-MU-FX-0062]; National Institute on Drug Abuse [R01DA020195, R01DA005512]; National Science Foundation [SBR-9123299, SBR-9512290]; National Institute of Mental Health [R01MH56486, R01MH63386]; National Institute of Child Health and Human Development [P30HD32041] FX Support for the Rochester Youth Development Study was provided by the Centers for Disease Control and Prevention (R01CE001572), the Office of Juvenile Justice and Delinquency Prevention (2006-JW-BX-0074, 86-JN-CX-0007, 96-MU-FX-0014, 2004-MU-FX-0062), the National Institute on Drug Abuse (R01DA020195, R01DA005512), the National Science Foundation (SBR-9123299), and the National Institute of Mental Health (R01MH56486, R01MH63386). Work on this project was also aided by grants to the Center for Social and Demographic Analysis at the University at Albany from National Institute of Child Health and Human Development (P30HD32041) and National Science Foundation (SBR-9512290). NR 39 TC 16 Z9 16 U1 0 U2 28 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD OCT PY 2013 VL 53 IS 4 SU S BP S25 EP S31 DI 10.1016/j.jadohealth.2013.04.019 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 221VX UT WOS:000324689200005 PM 24059936 ER PT J AU Lindsay, B Pop, M Antonio, M Walker, AW Mai, V Ahmed, D Oundo, J Tamboura, B Panchalingam, S Levine, MM Kotloff, K Li, S Magder, LS Paulson, JN Liu, B Ikumapayi, U Ebruke, C Dione, M Adeyemi, M Rance, R Stares, MD Ukhanova, M Barnes, B Lewis, I Ahmed, F Alam, MT Amin, R Siddiqui, S Ochieng, JB Ouma, E Juma, J Mailu, E Omore, R O'Reilly, CE Hannis, J Manalili, S DeLeon, J Yasuda, I Blyn, L Ranken, R Li, F Housley, R Ecker, DJ Hossain, MA Breiman, RF Morris, JG McDaniel, TK Parkhill, J Saha, D Sampath, R Stine, OC Nataro, JP AF Lindsay, Brianna Pop, Mihai Antonio, Martin Walker, Alan W. Mai, Volker Ahmed, Dilruba Oundo, Joseph Tamboura, Boubou Panchalingam, Sandra Levine, Myron M. Kotloff, Karen Li, Shan Magder, Laurence S. Paulson, Joseph N. Liu, Bo Ikumapayi, Usman Ebruke, Chinelo Dione, Michel Adeyemi, Mitchell Rance, Richard Stares, Mark D. Ukhanova, Maria Barnes, Bret Lewis, Ian Ahmed, Firoz Alam, Meer Taifur Amin, Ruhul Siddiqui, Sabbir Ochieng, John B. Ouma, Emmanuel Juma, Jane Mailu, Eunice Omore, Richard O'Reilly, Ciara E. Hannis, James Manalili, Sheri DeLeon, Jonna Yasuda, Irene Blyn, Lawrence Ranken, Raymond Li, Feng Housley, Roberta Ecker, David J. Hossain, M. Anowar Breiman, Robert F. Morris, J. Glenn McDaniel, Timothy K. Parkhill, Julian Saha, Debasish Sampath, Rangarajan Stine, O. Colin Nataro, James P. TI Survey of Culture, GoldenGate Assay, Universal Biosensor Assay, and 16S rRNA Gene Sequencing as Alternative Methods of Bacterial Pathogen Detection SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID DIARRHEA; CASE/CONTROL; AGREEMENT; COUNTRIES; CHILDREN AB Cultivation-based assays combined with PCR or enzyme-linked immunosorbent assay (ELISA)-based methods for finding virulence factors are standard methods for detecting bacterial pathogens in stools; however, with emerging molecular technologies, new methods have become available. The aim of this study was to compare four distinct detection technologies for the identification of pathogens in stools from children under 5 years of age in The Gambia, Mali, Kenya, and Bangladesh. The children were identified, using currently accepted clinical protocols, as either controls or cases with moderate to severe diarrhea. A total of 3,610 stool samples were tested by established clinical culture techniques: 3,179 DNA samples by the Universal Biosensor assay (Ibis Biosciences, Inc.), 1,466 DNA samples by the GoldenGate assay (Illumina), and 1,006 DNA samples by sequencing of 16S rRNA genes. Each method detected different proportions of samples testing positive for each of seven enteric pathogens, entero-aggregative Escherichia coli (EAEC), enterotoxigenic E. coli (ETEC), enteropathogenic E. coli (EPEC), Shigella spp., Campylobacter jejuni, Salmonella enterica, and Aeromonas spp. The comparisons among detection methods included the frequency of positive stool samples and kappa values for making pairwise comparisons. Overall, the standard culture methods detected Shigella spp., EPEC, ETEC, and EAEC in smaller proportions of the samples than either of the methods based on detection of the virulence genes from DNA in whole stools. The GoldenGate method revealed the greatest agreement with the other methods. The agreement among methods was higher in cases than in controls. The new molecular technologies have a high potential for highly sensitive identification of bacterial diarrheal pathogens. C1 [Lindsay, Brianna; Panchalingam, Sandra; Levine, Myron M.; Kotloff, Karen; Li, Shan; Magder, Laurence S.; Stine, O. Colin] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Pop, Mihai; Paulson, Joseph N.; Liu, Bo] Univ Maryland, College Pk, MD 20742 USA. [Antonio, Martin; Ikumapayi, Usman; Ebruke, Chinelo; Dione, Michel; Adeyemi, Mitchell; Saha, Debasish] MRC Unit, Serrekunda, Gambia. [Walker, Alan W.; Rance, Richard; Stares, Mark D.; Parkhill, Julian] Wellcome Trust Sanger Inst, Hinxton, Cambs, England. [Mai, Volker; Ukhanova, Maria; Morris, J. Glenn] Univ Florida, Gainesville, FL USA. [Ahmed, Dilruba; Ahmed, Firoz; Alam, Meer Taifur; Amin, Ruhul; Siddiqui, Sabbir; Hossain, M. Anowar] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Oundo, Joseph; Ochieng, John B.; Ouma, Emmanuel; Juma, Jane; Mailu, Eunice; Omore, Richard; Breiman, Robert F.] CDC, Kenya Med Res Inst, Res Stn, Kisumu, Kenya. [Tamboura, Boubou] Ctr Vaccine Dev, Bamako, Mali. [Barnes, Bret; Lewis, Ian; O'Reilly, Ciara E.; McDaniel, Timothy K.] Illumina, San Diego, CA USA. [Hannis, James; Manalili, Sheri; DeLeon, Jonna; Yasuda, Irene; Blyn, Lawrence; Ranken, Raymond; Li, Feng; Housley, Roberta; Ecker, David J.; Sampath, Rangarajan] Ibis, San Diego, CA USA. [Nataro, James P.] Univ Virginia, Charlottesville, VA USA. [Barnes, Bret; Lewis, Ian; O'Reilly, Ciara E.; McDaniel, Timothy K.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Lindsay, B (reprint author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA. EM blind002@umaryland.edu RI Parkhill, Julian/G-4703-2011; Pop, Mihai/A-7987-2013; OI Parkhill, Julian/0000-0002-7069-5958; Pop, Mihai/0000-0001-9617-5304; Walker, Alan/0000-0001-5099-8495 FU Bill and Melinda Gates Foundation [42917]; Illumina FX This work was supported by the Bill and Melinda Gates Foundation (grant 42917).; T.K.M., B.B., and I.L. are employees and shareholders of Illumina, the manufacturer of GoldenGate technology, one of the platforms evaluated in this study. J.H., S.M., J.D., I.Y., L.B., R.R., F.L., R.H., D.J.E., and R.S. are employees of Ibis Biosciences, the manufacturer of Universal Biosensor technology. J.P. has received funding for conference travel and accommodation from Illumina. NR 19 TC 7 Z9 7 U1 2 U2 20 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2013 VL 51 IS 10 BP 3263 EP 3269 DI 10.1128/JCM.01342-13 PG 7 WC Microbiology SC Microbiology GA 220YU UT WOS:000324624300016 PM 23884998 ER PT J AU Ramanan, P Blumberg, AK Mathison, B Pritt, BS AF Ramanan, Poornima Blumberg, Andrea K. Mathison, Blaine Pritt, Bobbi S. TI Parametrial Anisakidosis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID INTESTINAL ANISAKIASIS; GASTRIC ANISAKIASIS; MAJOR ALLERGEN; EOSINOPHILIC GASTROENTERITIS; MOLECULAR-IDENTIFICATION; PULMONARY ANISAKIASIS; PARASITIC ZOONOSES; PLEURAL EFFUSION; ACUTE ABDOMEN; SIMPLEX AB Anisakidosis is a parasitic infection caused by anisakid nematodes in the genera Anisakis and Pseudoterranova. Infection is not uncommon in the United States due to increased raw seafood consumption. We report the first known case of parametrial anisakidosis in a 42-year-old woman and review existing literature. C1 [Ramanan, Poornima] Mayo Clin, Div Infect Dis, Rochester, MN USA. [Pritt, Bobbi S.] Mayo Clin, Div Clin Microbiol, Rochester, MN 55905 USA. [Blumberg, Andrea K.] Mem Hosp West, Pembroke Pines, FL USA. [Mathison, Blaine] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Pritt, BS (reprint author), Mayo Clin, Div Clin Microbiol, Rochester, MN 55905 USA. EM Pritt.bobbi@mayo.edu OI Pritt, Bobbi/0000-0003-0261-1326 NR 57 TC 7 Z9 7 U1 2 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2013 VL 51 IS 10 BP 3430 EP 3434 DI 10.1128/JCM.01398-13 PG 5 WC Microbiology SC Microbiology GA 220YU UT WOS:000324624300043 PM 23863565 ER PT J AU Respicio-Kingry, LB Byrd, L Allison, A Brett, M Scott-Waldron, C Galliher, K Hannah, P Mead, P Petersen, JM AF Respicio-Kingry, Laurel B. Byrd, Lori Allison, Ashley Brett, Meghan Scott-Waldron, Christine Galliher, Karen Hannah, Paul Mead, Paul Petersen, Jeannine M. TI Cutaneous Infection Caused by a Novel Francisella sp. SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID FORMERLY YERSINIA-PHILOMIRAGIA; TULARENSIS; PATHOGEN AB A 69-year-old patient presented with a tender, thickly crusted skin lesion of 1 week's duration. A bacterial culture swab taken from the underlying granular tissue yielded a pure isolate of a Gram-negative coccobacillus, presumptively identified as a novel Francisella species via 16S rRNA and multilocus gene sequence analysis. C1 [Respicio-Kingry, Laurel B.; Brett, Meghan; Mead, Paul; Petersen, Jeannine M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO USA. [Byrd, Lori; Allison, Ashley] Dermatol Clin, Baton Rouge, LA USA. [Brett, Meghan] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Scott-Waldron, Christine] Louisiana Off Publ Hlth, New Orleans, LA USA. [Galliher, Karen; Hannah, Paul] Orange Cty Publ Hlth Lab, Santa Ana, CA USA. RP Petersen, JM (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO USA. EM nzp0@cdc.gov NR 18 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2013 VL 51 IS 10 BP 3456 EP 3460 DI 10.1128/JCM.01105-13 PG 5 WC Microbiology SC Microbiology GA 220YU UT WOS:000324624300049 PM 23903547 ER PT J AU Ge, BL Wang, F Sjolund-Karlsson, M McDermott, PF AF Ge, Beilei Wang, Fei Sjoelund-Karlsson, Maria McDermott, Patrick F. TI Antimicrobial resistance in Campylobacter: Susceptibility testing methods and resistance trends SO JOURNAL OF MICROBIOLOGICAL METHODS LA English DT Review DE Campylobacter; Susceptibility testing; Molecular; Antimicrobial resistance; Trend ID AGAR DILUTION METHODS; JEJUNI SUBSP JEJUNI; DISK DIFFUSION METHOD; REAL-TIME PCR; LEVEL ERYTHROMYCIN RESISTANCE; QUALITY-CONTROL RANGES; DNA-SEQUENCE ANALYSIS; CMEABC EFFLUX PUMP; LINE PROBE ASSAY; MACROLIDE RESISTANCE AB Most Campylobacter infections are self-limiting but antimicrobial treatment (e.g., macrolides, fluoroquinolones) is necessary in severe or prolonged cases. Susceptibility testing continues to play a critical role in guiding therapy and epidemiological monitoring of resistance. The methods of choice for Campylobacter recommended by the Clinical and Laboratory Standards Institute (CLSI) are agar dilution and broth microdilution, while a disk diffusion method was recently standardized by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Macrolides, quinolones, and tetracyclines are among the common antimicrobials recommended for testing. Molecular determination of Campylobacter resistance via DNA sequencing or PCR-based methods has been performed. High levels of resistance to tetracycline and ciprofloxacin are frequently reported by many national surveillance programs, but resistance to erythromycin and gentamicin in Campylobacter jejuni remains low. Nonetheless, variations in susceptibility observed over time underscore the need for continued public health monitoring of Campylobacter resistance from humans, animals, and food. Published by Elsevier B.V. C1 [Ge, Beilei; Wang, Fei; McDermott, Patrick F.] US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, Laurel, MD 20708 USA. [Wang, Fei] Univ Maryland, Dept Nutr & Food Sci, College Pk, MD 20742 USA. [Sjoelund-Karlsson, Maria] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. RP Ge, BL (reprint author), 8401 Muirkirk Rd, Laurel, MD 20708 USA. EM beilei.ge@fda.hhs.gov RI Wang, Fei/J-4353-2014 NR 104 TC 30 Z9 33 U1 3 U2 37 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-7012 EI 1872-8359 J9 J MICROBIOL METH JI J. Microbiol. Methods PD OCT PY 2013 VL 95 IS 1 SI SI BP 57 EP 67 DI 10.1016/j.mimet.2013.06.021 PG 11 WC Biochemical Research Methods; Microbiology SC Biochemistry & Molecular Biology; Microbiology GA 222GG UT WOS:000324718600008 PM 23827324 ER PT J AU Lovegrove, MC Hon, S Geller, RJ Rose, KO Hampton, LM Bradley, J Budnitz, DS AF Lovegrove, Maribeth C. Hon, Stephanie Geller, Robert J. Rose, Kathleen O. Hampton, Lee M. Bradley, Jill Budnitz, Daniel S. TI Efficacy of Flow Restrictors in Limiting Access of Liquid Medications by Young Children SO JOURNAL OF PEDIATRICS LA English DT Article ID EMERGENCY-DEPARTMENT VISITS; ORAL PRESCRIPTION DRUGS; OF-HOSPITAL MANAGEMENT; CONSENSUS GUIDELINE; MULTICENTER SURVEY; OVERDOSES; CHILDHOOD; PRODUCTS; INFANTS AB Objective To assess whether adding flow restrictors (FRs) to liquid medicine bottles can provide additional protection against unsupervised medication ingestions by young children, even when the child-resistant closure is not fully secured. Study design In April and May 2012, we conducted a block randomized trial with a convenience sample of 110 3- and 4-year-old children from 5 local preschools. Participants attempted to remove test liquid from an uncapped bottle with an FR and a control bottle without an FR (with either no cap or an incompletely closed cap). Results All but 1 (96%; 25 of 26) of the open control bottles and 82% (68 of 83) of the incompletely closed control bottles were emptied within 2 minutes. Only 6% (7 of 110) of the bottles with FRs were emptied during the 10-minute testing period, none before 6 minutes. Overall, children removed less liquid from the bottles with FRs than from the open or incompletely closed control bottles without FRs (both P < .001). All children assigned open control bottles and 90% of those assigned incompletely closed control bottles removed >= 25 mL of liquid. In contrast, 11% of children removed >= 25 mL of liquid from uncapped bottles with FRs. Older children (aged 54-59 months) were more successful than younger children at removing >= 25 mL of liquid (P = .002) from bottles with FRs. Conclusion Our findings suggest that adding FRs to liquid medicine bottles limits the accessibility of their contents to young children and could complement the safety provided by current child-resistant packaging. C1 [Lovegrove, Maribeth C.; Rose, Kathleen O.; Hampton, Lee M.; Bradley, Jill; Budnitz, Daniel S.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Rose, Kathleen O.; Bradley, Jill] CACI Int Inc, Atlanta, GA USA. [Hon, Stephanie; Geller, Robert J.] Georgia Poison Ctr, Atlanta, GA USA. [Geller, Robert J.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. RP Budnitz, DS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mailstop A-24, Atlanta, GA 30333 USA. EM dbudnitz@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 4 Z9 4 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2013 VL 163 IS 4 BP 1134 EP + DI 10.1016/j.jpeds.2013.05.045 PG 7 WC Pediatrics SC Pediatrics GA 224HM UT WOS:000324873700041 PM 23896185 ER PT J AU Presson, AP Partyka, G Jensen, KM Devine, OJ Rasmussen, SA McCabe, LL McCabe, ERB AF Presson, Angela P. Partyka, Ginger Jensen, Kristin M. Devine, Owen J. Rasmussen, Sonja A. McCabe, Linda L. McCabe, Edward R. B. TI Current Estimate of Down Syndrome Population Prevalence in the United States SO JOURNAL OF PEDIATRICS LA English DT Article ID BIRTH-DEFECTS; MATERNAL AGE; CHILDREN; RATES; ADOLESCENTS; LIVEBIRTH AB Objective To calculate a reliable estimate of the population prevalence of Down syndrome in the US. Study design The annual number of births of infants with Down syndrome were estimated by applying published birth prevalence rates of Down syndrome by maternal age to US data from the Centers for Disease Control and Prevention for the years for which births by maternal age were available (1940-2008). Death certificate data for persons with Down syndrome were available for the years 1968-2007. We estimated the number of people with Down syndrome on January 1, 2008, using a life table approach based on proportions of deaths by age. Monte Carlo sampling was used to create 90% uncertainty intervals (UIs) for our estimates. Results We estimated the January 1, 2008, population prevalence of Down syndrome as approximately 250 700 (90% UI, 185 900-321 700) based on proportions of deaths by age from the most recent 2 years (2006-2007) of death certificate data. This estimate corresponds to a prevalence of 8.27 people with Down syndrome per 10 000 population (90% UI, 6.14-10.62). Conclusion Our estimate of Down syndrome prevalence is roughly 25%-40% lower than estimates based solely on current birth prevalence. The results presented here can be considered a starting point for facilitating policy and services planning for persons with Down syndrome. C1 [Presson, Angela P.; Partyka, Ginger] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. [Presson, Angela P.] Univ Utah, Dept Internal Med, Div Epidemiol, Salt Lake City, UT 84112 USA. [Jensen, Kristin M.; McCabe, Linda L.; McCabe, Edward R. B.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Jensen, Kristin M.] Univ Colorado, Sch Med, Dept Internal Med, Aurora, CO USA. [Devine, Owen J.; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Presson, AP (reprint author), Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA. RI Jensen, Kristin/D-3478-2014 OI Jensen, Kristin/0000-0003-1352-0518 FU Intramural CDC HHS [CC999999] NR 29 TC 46 Z9 46 U1 3 U2 27 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2013 VL 163 IS 4 BP 1163 EP 1168 DI 10.1016/j.jpeds.2013.06.013 PG 6 WC Pediatrics SC Pediatrics GA 224HM UT WOS:000324873700046 PM 23885965 ER PT J AU Price, CS DeStefano, F Weintraub, ES AF Price, Cristofer S. DeStefano, Frank Weintraub, Eric S. TI Ignoring the forest and the trees: Vaccine antigen study is overmatched Reply SO JOURNAL OF PEDIATRICS LA English DT Letter C1 [Price, Cristofer S.] ABT Associates Inc, Bethesda, MD USA. [DeStefano, Frank; Weintraub, Eric S.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. RP Price, CS (reprint author), ABT Associates Inc, Bethesda, MD USA. NR 4 TC 0 Z9 0 U1 0 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD OCT PY 2013 VL 163 IS 4 BP 1231 EP 1232 DI 10.1016/j.jpeds.2013.06.002 PG 3 WC Pediatrics SC Pediatrics GA 224HM UT WOS:000324873700069 PM 23859027 ER PT J AU Brener, ND McManus, T Wechsler, H Kann, L AF Brener, Nancy D. McManus, Tim Wechsler, Howell Kann, Laura TI Trends in Professional Development for and Collaboration by Health Education Teachers-41 States, 2000-2010 SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE health educators; professional preparation of school health personnel; school health instruction ID SCHOOL-HEALTH; PREVENTION AB BACKGROUNDProfessional development (PD) and collaboration help ensure the quality of school health education. The purpose of this study was to examine trends in the percentage of lead health education teachers (LHETs) receiving PD on health topics and collaborating with other school staff on health education activities. METHODSThis study analyzed representative data from 41 states participating in School Health Profiles surveys between 2000 and 2010. Logistic regression examined linear trends in the percentage of LHETs who received PD on 12 topics and who collaborated on health education activities. RESULTSSignificant increases in the percentage of LHETs receiving PD on nutrition and physical activity and significant decreases in the percentage of LHETs receiving PD on alcohol- and other drug-use prevention and human immunodeficiency virus prevention were seen. Significant increases in the percentage of LHETs who collaborated with physical education staff and nutrition services staff were seen in 29 and 39 states, respectively. CONCLUSIONSAlthough 10-year increases in PD and collaboration in the areas of nutrition and physical activity are encouraging, PD and collaboration in other topic areas still need improvement. These results will help states target more resources toward PD and collaboration in areas where they have been decreasing. C1 [Brener, Nancy D.; McManus, Tim; Wechsler, Howell] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Wechsler, Howell] Ctr Dis Control & Prevent, Alliance Healthier Generat, Atlanta, GA 30341 USA. [Kann, Laura] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Sch Based Surveillance Branch, Atlanta, GA 30341 USA. RP Brener, ND (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Mailstop K-29,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM nbrener@cdc.gov; tsm9@cdc.gov; howell.wechsler@healthiergeneration.org; lkk1@cdc.gov FU Intramural CDC HHS [CC999999] NR 19 TC 0 Z9 1 U1 1 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD OCT PY 2013 VL 83 IS 10 BP 734 EP 742 DI 10.1111/josh.12088 PG 9 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 216RH UT WOS:000324301200008 PM 24020688 ER PT J AU Brener, ND Wechsler, H McManus, T AF Brener, Nancy D. Wechsler, Howell McManus, Tim TI How School Healthy Is Your State? A State-by-State Comparison of School Health Practices Related to a Healthy School Environment and Health Education SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE school health instruction; nutrition and diet; child and adolescent health AB BACKGROUNDSchool Health Profiles (Profiles) results help states understand how they compare to each other on specific school health policies and practices. The purpose of this study was to develop composite measures of critical Profiles results and use them to rate each state on their overall performance. METHODSUsing data from state Profiles surveys conducted in 2010, the authors examined 12 key practices: 6 related to a healthy school environment and 6 related to health education. States were divided into quartiles based on the percentage of schools in the state that engaged in the practice, and then rank-ordered based on the sum of their quartile scores. RESULTSWhereas some states have low ranks or high ranks in both sets of practices, others have a relatively low rank in one set but a high rank in the other. States with the lowest overall sums tend to be in the west and midwest, whereas states with the highest sums tend to be in the east. CONCLUSIONSThis study identifies states whose school health policies and practices should be emulated and other states whose policies and practices are in urgent need of improvement. C1 [Brener, Nancy D.; Wechsler, Howell; McManus, Tim] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Wechsler, Howell] Ctr Dis Control & Prevent, Alliance Healthier Generat, Atlanta, GA 30341 USA. RP Brener, ND (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, 4770 Buford Highway NE,Mailstop K-29, Atlanta, GA 30341 USA. EM nad1@cdc.gov; howell.wechsler@healthiergeneration.org; tsm9@cdc.gov FU Intramural CDC HHS [CC999999] NR 15 TC 2 Z9 2 U1 0 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD OCT PY 2013 VL 83 IS 10 BP 743 EP 749 DI 10.1111/josh.12089 PG 7 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 216RH UT WOS:000324301200009 PM 24020689 ER PT J AU Jones, SE Olsen, EO Michael, SL Saraiya, M AF Jones, Sherry Everett Olsen, Emily O'Malley Michael, Shannon L. Saraiya, Mona TI Association of UV Index and Sunscreen Use Among White High School Students in the United States SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE child and adolescent health; community health; environmental health ID SUN-PROTECTION; CUTANEOUS MELANOMA; SKIN-CANCER; RISK; SURVEILLANCE; BEHAVIOR; EXPOSURE; LATITUDE; TRIAL; RATES AB BACKGROUNDWhen used appropriately, sunscreen decreases the amount of ultraviolet (UV) radiation exposure to the skin and is recommended to prevent skin cancer. This study examined the association between annual average UV index and sunscreen use among White, non-Hispanic youth. METHODSThe 2007 and 2009 national Youth Risk Behavior Survey (YRBS) data were analyzed. The YRBS is a school-based, cross-sectional study that uses a 3-stage cluster sample design to obtain a nationally representative sample of public and private high school students in the United States. Overall response rates were 68% and 72% (N=14,041 and 16,410, respectively). Logistic regression analyzes, controlling for grade, examined whether annual average (mean) UV index where students attend school, a proxy measure of potential sunlight exposure, was associated with sunscreen use. RESULTSAmong White male students, as the mean UV index increased, the adjusted odds of never wearing sunscreen increased (adjusted odds ratio, AOR=1.15 [95% CI=1.04, 1.27], p<.01) and the adjusted odds of most of the time or always wearing sunscreen decreased (AOR=0.85 [0.78, 0.94], p<.01). There was no association between sunscreen use and mean UV index among White female students. CONCLUSIONThese findings suggest a need for renewed public health efforts among school, clinical, and public health professionals to promote sunscreen use as part of a comprehensive approach to prevent skin cancer. School and community approaches that passively protect young people from the sun should be considered as a complement to efforts to increase sunscreen use. C1 [Jones, Sherry Everett; Olsen, Emily O'Malley; Michael, Shannon L.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Jones, SE (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, 4770 Buford Hwy NE,MS K29, Atlanta, GA 30341 USA. EM sce2@cdc.gov; dgx1@cdc.gov; sot2@cdc.gov; yzs2@cdc.gov NR 37 TC 1 Z9 1 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD OCT PY 2013 VL 83 IS 10 BP 750 EP 756 DI 10.1111/josh.12090 PG 7 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 216RH UT WOS:000324301200010 ER PT J AU Escandon, P Lizarazo, J Agudelo, CI Chiller, T Castaneda, E AF Escandon, Patricia Lizarazo, Jairo Ines Agudelo, Clara Chiller, Tom Castaneda, Elizabeth TI Evaluation of a rapid lateral flow immunoassay for the detection of cryptococcal antigen for the early diagnosis of cryptococcosis in HIV patients in Colombia SO MEDICAL MYCOLOGY LA English DT Article DE Cryptococcosis; Colombia; AIDS; diagnosis ID INFECTED PATIENTS; MENINGITIS AB A previous study carried out in a tertiary care hospital in Colombia demonstrated the usefulness of the Cryptococcus capsular antigen detection by latex (CrAg Latex) in the early diagnosis of cryptococcosis in HIV-infected patients with low CD4(+) levels. The aim of this study was to establish the performance of a new rapid lateral flow assay (CrAg LFA) in preserved sera of those HIV-infected patients collected between 2001 and 2006. A total of 421 sera from 297 patients with a confirmed diagnosis of HIV were tested with CrAg LFA and results compared with those obtained with CrAg Latex. All patients provided informed consent for specimen collection. A concordance of 100% was found between positive results obtained by both methods. However, 13 sera that were negative by CrAg Latex, were positive by CrAg LFA (3.1%). In these positive patients, median of CD4(+) levels was 67 cells/mu l (8-608 cells/mu l), while median of viral load was 118,965 copies/ml (50-500,000 copies/ml). Patients who were negative for cryptococcosis had a median of 177 cells/mu l in CD4(+) levels (4-2516 cells/mu l) and a median of 62,318 copies/ml in viral loads (25-50,000 copies/ml). A significant statistical difference was found when comparing CD4(+) levels and viral load in patients positive for cryptococcosis and those that were proven to be negative (P < 0.0001). The use of Point-of-Care Tests (POCT) like CrAg LFA play an important role in the diagnosis of infectious diseases, especially in resource limited settings, where it will be a useful means to diagnose cryptococcosis early in HIV patients. C1 [Escandon, Patricia; Ines Agudelo, Clara; Castaneda, Elizabeth] Inst Nacl Salud, Microbiol Grp, Bogota, Colombia. [Lizarazo, Jairo] Hosp Univ Erasmo Meoz, Cucuta, Colombia. [Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Escandon, P (reprint author), Inst Nacl Salud, Microbiol Grp, Bogota, Colombia. EM pescandon@ins.gov.co FU Hospital Universitario Erasmo Meoz in Cucuta, Colombia; Instituto Nacional de Salud, Bogota, D.C., Colombia FX This work was supported by the Hospital Universitario Erasmo Meoz in Cucuta, Colombia, and the Instituto Nacional de Salud, Bogota, D.C., Colombia. NR 12 TC 9 Z9 9 U1 0 U2 17 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD OCT PY 2013 VL 51 IS 7 BP 765 EP 768 DI 10.3109/13693786.2013.781692 PG 4 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 219VK UT WOS:000324538900013 PM 23611420 ER PT J AU Stevens, JA Rudd, RA AF Stevens, J. A. Rudd, R. A. TI The impact of decreasing U.S. hip fracture rates on future hip fracture estimates SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Elderly; Falls; Hip fracture; Hip fracture projections; Trends ID UNITED-STATES; DENSITY; TRENDS; FEMUR; FALL AB We examined age- and sex-specific hip fracture hospitalization rates among people aged 65 and older using 1990-2010 National Hospital Discharge Survey data. Trends calculated using Joinpoint regression analysis suggest that future increases in hip fractures due to the aging population will be largely offset by decreasing hip fracture rates among women. However, this trend will be counterbalanced by rising numbers of hip fractures among men. Introduction From 1990 to 2006, age-adjusted U. S. hip fracture rates among people aged 65 years and older declined significantly. We wanted to determine whether decreasing age group-specific hip fracture rates might offset increases in hip fractures among the aging population over the next two decades. Methods This study used data from the National Hospital Discharge Survey, a national probability survey of inpatient discharges from nonfederal U. S. hospitals, to analyze hip fracture hospitalizations, defined as cases with first diagnosis coded ICD-9 CM820. We analyzed trends in rates by sex and 10-year age groups using Joinpoint analysis software and used the results and projected population estimates to obtain the expected number of hip fractures in 2020 and 2050. Results Based on current age-and sex-specific trends in hip fracture hospitalization rates, the number of hip fractures is projected to rise 11.9 %-from 258,000 in 2010 to 289,000 (Projection Interval [PI]=193,000-419,000) in 2030. The number of hip fractures among men is expected to increase 51.8 % (PI=15.9-119.4 %) while the number among women is expected to decrease 3.5 % (PI=-44.3-37.3 %). These trends will affect the future distribution of hip fractures among the older population. Conclusions Although the number of older people in the U. S. A. will increase appreciably over the next 20 years, the expected increase in the total number of hip fractures will be largely offset by decreasing hip fracture rates among women. However, this trend will be counterbalanced by rising numbers of hip fractures among men. C1 [Stevens, J. A.; Rudd, R. A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Stevens, JA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-62, Atlanta, GA 30341 USA. EM jas2@cdc.gov; rvr2@cdc.gov FU Intramural CDC HHS [CC999999] NR 21 TC 40 Z9 40 U1 0 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD OCT PY 2013 VL 24 IS 10 BP 2725 EP 2728 DI 10.1007/s00198-013-2375-9 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 219UN UT WOS:000324536200020 PM 23632827 ER PT J AU Simon, AE Driscoll, A Gorina, Y Parker, JD Schoendorf, KC AF Simon, Alan E. Driscoll, Anne Gorina, Yelena Parker, Jennifer D. Schoendorf, Kenneth C. TI A Longitudinal View of Child Enrollment in Medicaid SO PEDIATRICS LA English DT Article DE Medicaid enrollment; children; insurance ID INSURANCE; COVERAGE; SCHIP AB BACKGROUND: Although national cross-sectional estimates of the percentage of children enrolled in Medicaid are available, the percentage of children enrolled in Medicaid over longer periods of time is unknown. Also, the percentage and characteristics of children who rely on Medicaid throughout childhood, rather than transiently, are unknown. METHODS: We performed a longitudinal examination of Medicaid coverage among children across a 5-year period. Children 0 to 13 years of age in the 2004 National Health Interview Survey file were linked to Medicaid Analytic eXtract files from 2004 to 2008. The percentage of children enrolled in Medicaid at any time during the 5-year observation period and the number of years during which children were enrolled in Medicaid were calculated. Duration of Medicaid enrollment was compared across sociodemographic characteristics by using chi(2) tests. RESULTS: Forty-one percent of all US children were enrolled in Medicaid at least some time during the 5-year period, compared with a single-year estimate of 32.8% in 2004 alone. Of enrolled children, 51.5% were enrolled during all 5 years. Children with lower parental education, with lower household income, of minority race or ethnicity, and in suboptimal health were more likely to be enrolled in Medicaid during all 5 years. CONCLUSIONS: Longitudinal data reveal higher percentages of children with Medicaid insurance than shown by cross-sectional data. Half of children enrolled in Medicaid are enrolled during at least 5 consecutive years, and these children have higher risk sociodemographic profiles. C1 [Simon, Alan E.; Driscoll, Anne; Schoendorf, Kenneth C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Infant Child & Womens Hlth Stat Branch, Hyattsville, MD 20782 USA. [Gorina, Yelena] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Aging & Chron Dis Branch, Hyattsville, MD 20782 USA. [Parker, Jennifer D.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Special Projects Branch, Hyattsville, MD 20782 USA. [Schoendorf, Kenneth C.] US PHS, Rockville, MD USA. RP Simon, AE (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6122, Hyattsville, MD 20782 USA. EM fpa8@cdc.gov NR 25 TC 2 Z9 2 U1 0 U2 1 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD OCT PY 2013 VL 132 IS 4 BP 656 EP 662 DI 10.1542/peds.2013-1544 PG 7 WC Pediatrics SC Pediatrics GA 227FI UT WOS:000325095400044 PM 24062367 ER PT J AU Wang, WC Oyeku, SO Luo, Z Boulet, SL Miller, ST Casella, JF Fish, B Thompson, BW Grosse, SD AF Wang, Winfred C. Oyeku, Suzette O. Luo, Zhaoyu Boulet, Sheree L. Miller, Scott T. Casella, James F. Fish, Billie Thompson, Bruce W. Grosse, Scott D. CA Baby Hug Investigators TI Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia SO PEDIATRICS LA English DT Article DE hydroxyurea; medical costs; young children; sickle cell anemia ID HEALTH-CARE; BABY HUG; DISEASE; TOXICITY; TRIAL; HOSPITALIZATION; EXPENDITURES; FREQUENCY; EFFICACY; IMPACT AB BACKGROUND AND OBJECTIVE: In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care in treated versus untreated children. METHODS: The BABY HUG database was used to compare inpatient events in subjects receiving hydroxyurea with those receiving placebo. Unit costs were estimated from the 2009 MarketScan Multi-state Medicaid Database for children with sickle cell disease, aged 1 to 3 years. Inpatient costs were based on length of hospital stay, modified by the occurrence of acute chest syndrome, splenic sequestration, or transfusion. Outpatient expenses were based on the schedule required for BABY HUG and a "standard" schedule for 1- to 3-year-olds with sickle cell anemia. RESULTS: There were 232 hospitalizations in the subjects receiving hydroxyurea and 324 in those on placebo; length of hospital stay was similar in the 2 groups. Estimated outpatient expenses were greater in those receiving hydroxyurea, but these were overshadowed by inpatient costs. The total estimated annual cost for those on hydroxyurea ($11 072) was 21% less than the cost of those on placebo ($13 962; P = .038). CONCLUSIONS: Savings on inpatient care resulted in a significantly lower overall estimated medical care cost for young children with sickle cell anemia who were receiving hydroxyurea compared with those receiving placebo. Because cost savings are likely to increase with age, these data provide additional support for broad use of hydroxyurea treatment in this population. C1 [Wang, Winfred C.] St Jude Childrens Res Hosp, Dept Hematol, Memphis, TN 38105 USA. [Oyeku, Suzette O.] Montefiore Med Ctr, Dept Pediat, Bronx, NY 10467 USA. [Luo, Zhaoyu; Thompson, Bruce W.] Clin Trials & Surveys Corp, Owings Mills, MD USA. [Boulet, Sheree L.] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Grosse, Scott D.] Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control, Div Blood Disorders, Atlanta, GA USA. [Grosse, Scott D.] Natl Ctr Birth Defects & Dev Disabil, Ctr Prevent, Div Blood Disorders, Atlanta, GA USA. [Miller, Scott T.] Suny Downstate Med Ctr, Kings Cty Hosp Ctr, Brooklyn, NY 11203 USA. [Casella, James F.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Wang, WC (reprint author), St Jude Childrens Res Hosp, Dept Hematol, 262 Danny Thomas Pl, Memphis, TN 38105 USA. EM winfred.wang@stjude.org FU National Heart, Lung and Blood Institute; National Institute of Child Health and Human Development FX Supported by the National Heart, Lung and Blood Institute and the National Institute of Child Health and Human Development. NR 20 TC 13 Z9 13 U1 0 U2 10 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD OCT PY 2013 VL 132 IS 4 BP 677 EP 683 DI 10.1542/peds.2013-0333 PG 7 WC Pediatrics SC Pediatrics GA 227FI UT WOS:000325095400047 PM 23999955 ER PT J AU Iwamoto, M Mu, Y Lynfield, R Bulens, SN Nadle, J Aragon, D Petit, S Ray, SM Harrison, LH Dumyati, G Townes, JM Schaffner, W Gorwitz, RJ Lessa, FC AF Iwamoto, Martha Mu, Yi Lynfield, Ruth Bulens, Sandra N. Nadle, Joelle Aragon, Deborah Petit, Susan Ray, Susan M. Harrison, Lee H. Dumyati, Ghinwa Townes, John M. Schaffner, William Gorwitz, Rachel J. Lessa, Fernanda C. TI Trends in Invasive Methicillin-Resistant Staphylococcus aureus Infections SO PEDIATRICS LA English DT Article DE Staphylococcus aureus infection; methicillin resistance; children; infants; epidemiology ID INTENSIVE-CARE-UNIT; BLOOD-STREAM INFECTIONS; RISK-FACTORS; COLONIZATION; SURVEILLANCE; INFANTS; RATES; PREVENTION; HOSPITALS; EMERGENCE AB OBJECTIVE: To describe trends in the incidence of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections in children during 2005-2010. METHODS: We evaluated reports of invasive MRSA infections in pediatric patients identified from population-based surveillance during 2005-2010. Cases were defined as isolation of MRSA from a normally sterile site and classified on the basis of the setting of the positive culture and presence or absence of health care exposures. Estimated annual changes in incidence were determined by using regression models. National age- and race-specific incidences for 2010 were estimated by using US census data. RESULTS: A total of 876 pediatric cases were reported; 340 (39%) were among infants. Overall, 35% of cases were hospital-onset, 23% were health care-associated community-onset, and 42% were community-associated (CA). The incidence of invasive CA-MRSA infection per 100 000 children increased from 1.1 in 2005 to 1.7 in 2010 (modeled yearly increase: 10.2%; 95% confidence interval: 2.7%-18.2%). No significant trends were observed for health care-associated community-onset and hospital-onset cases. Nationally, estimated invasive MRSA incidence in 2010 was higher among infants aged <90 days compared with older infants and children (43.9 vs 2.0 per 100 000) and among black children compared with other races (6.7 vs 1.6 per 100 000). CONCLUSIONS: Invasive MRSA infection in children disproportionately affects young infants and black children. In contrast to reports of declining incidence among adults, there were no significant reductions in health care-associated MRSA infections in children. Concurrently, the incidence of CA-MRSA infections has increased, underscoring the need for defining optimal strategies to prevent MRSA infections among children with and without health care exposures. C1 [Iwamoto, Martha; Mu, Yi; Bulens, Sandra N.; Gorwitz, Rachel J.; Lessa, Fernanda C.] Ctr Dis Control, Atlanta, GA 30333 USA. [Iwamoto, Martha; Mu, Yi; Bulens, Sandra N.; Gorwitz, Rachel J.; Lessa, Fernanda C.] Ctr Prevent, Atlanta, GA USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Nadle, Joelle] California Emerging Infect Program, Oakland, CA USA. [Aragon, Deborah] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Petit, Susan] Connecticut Dept Hlth, Hartford, CT USA. [Ray, Susan M.] Georgia Emerging Infect Program, Atlanta, GA USA. [Ray, Susan M.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. [Harrison, Lee H.] Maryland Emerging Infect Program, Baltimore, MD USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Dumyati, Ghinwa] Univ Rochester, Dept Med Infect Dis, Rochester, NY USA. [Townes, John M.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. RP Iwamoto, M (reprint author), Ctr Dis Control, 1600 Clifton Rd NE,Mailstop C-09, Atlanta, GA 30333 USA. EM miwamoto@cdc.gov FU Centers for Disease Control and Prevention FX Supported through a cooperative agreement with the Emerging Infections Program of the Centers for Disease Control and Prevention. NR 37 TC 41 Z9 46 U1 0 U2 18 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD OCT PY 2013 VL 132 IS 4 BP E817 EP E824 DI 10.1542/peds.2013-1112 PG 8 WC Pediatrics SC Pediatrics GA 227FI UT WOS:000325095400002 PM 24062373 ER PT J AU Smith, JM Rastogi, R Teller, RS Srinivasan, P Mesquita, PMM Nagaraja, U McNicholl, JM Hendry, RM Dinh, CT Martin, A Herold, BC Kiser, PF AF Smith, James M. Rastogi, Rachna Teller, Ryan S. Srinivasan, Priya Mesquita, Pedro M. M. Nagaraja, Umadevi McNicholl, Janet M. Hendry, R. Michael Dinh, Chuong T. Martin, Amy Herold, Betsy C. Kiser, Patrick F. TI Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE controlled drug delivery; PrEP; nonhuman primate; pharmacokinetics ID HUMAN-IMMUNODEFICIENCY-VIRUS; NONHUMAN-PRIMATES; DELIVERY; PHARMACOKINETICS; PROPHYLAXIS; PREVENTION; INFECTION; ADHERENCE; GEL; DAPIVIRINE AB Topical preexposure prophylaxis interrupts HIV transmission at the site of mucosal exposure. Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application. However, modest or no protection was observed in clinical trials. Intravaginal rings (IVRs) may improve efficacy by providing long-term sustained drug delivery leading to constant mucosal antiretroviral concentrations and enhancing adherence. Although a few IVRs have entered the clinical pipeline, 100% efficacy in a repeated macaque vaginal challenge model has not been achieved. Here we describe a reservoir IVR technology that delivers the tenofovir prodrug tenofovir disoproxil fumarate (TDF) continuously over 28 d. With four monthly ring changes in this repeated challenge model, TDF IVRs generated reproducible and protective drug levels. All TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly vaginal exposures to 50 tissue culture infectious dose SHIV162p3. In contrast, 11/12 control macaques became infected, with a median of four exposures assuming an eclipse of 7 d from infection to virus RNA detection. Protection was associated with tenofovir levels in vaginal fluid [mean 1.8 x 10(5) ng/mL (range 1.1 x 104 to 6.6 x 10(5) ng/mL)] and ex vivo antiviral activity of cervicovaginal lavage samples. These observations support further advancement of TDF IVRs as well as the concept that extended duration drug delivery devices delivering topical antiretrovirals could be effective tools in preventing the sexual transmission of HIV in humans. C1 [Smith, James M.; Srinivasan, Priya; McNicholl, Janet M.; Hendry, R. Michael; Dinh, Chuong T.; Martin, Amy] Ctr Dis Control & Prevent, Lab Branch, Div HIV AIDS Prevent,Coordinating Ctr Infect Dis, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA 30333 USA. [Rastogi, Rachna; Teller, Ryan S.; Nagaraja, Umadevi; Kiser, Patrick F.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA. [Mesquita, Pedro M. M.; Herold, Betsy C.] Albert Einstein Coll Med, Dept Pediat & Microbiol Immunol, Bronx, NY 10461 USA. [Kiser, Patrick F.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA. RP Kiser, PF (reprint author), Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA. EM patrick.kiser@northwestern.edu RI Kiser, Patrick/C-2843-2014; OI Kiser, Patrick/0000-0002-3868-7122; Mesquita, Pedro/0000-0002-6591-4896 FU National Institutes of Health [U19 AI076980] FX We thank David Garber, James Mitchell, Frank Deyounks, Shanon Ellis, and Leecresia Jenkins for all animal procedures; Chou-Pong Pao for analysis of drug levels; and Gerardo Garcia-Lerma and Jessica Radzio for providing the historical macaque control data. We acknowledge Gilead Sciences for providing tenofovir disoproxil fumarate. This work was supported by the National Institutes of Health Grant U19 AI076980. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 41 TC 46 Z9 46 U1 0 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD OCT 1 PY 2013 VL 110 IS 40 BP 16145 EP 16150 DI 10.1073/pnas.1311355110 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 227II UT WOS:000325105500071 PM 24043812 ER PT J AU Pearce, BD Hubbard, S Rivera, HN Wilkins, PP Fisch, MC Hopkins, MH Hasenkamp, W Gross, R Bliwise, N Jones, JL Duncan, E AF Pearce, Bradley D. Hubbard, Sydney Rivera, Hilda N. Wilkins, Patricia P. Fisch, Marylynn C. Hopkins, Myfanwy H. Hasenkamp, Wendy Gross, Robin Bliwise, Nancy Jones, Jeffrey L. Duncan, Erica TI Toxoplasma gondii exposure affects neural processing speed as measured by acoustic startle latency in schizophrenia and controls SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Toxoplasma gondii; Acoustic startle; Latency ID PREPULSE INHIBITION; TRAFFIC ACCIDENTS; REFLEX; INFECTION; RATS; HABITUATION; PERFORMANCE; DEFICITS; RODENTS; NORMALS AB The prevalence of Toxoplasma gondii (TOXO) infection in schizophrenia (SCZ) is elevated compared to controls (odds ratio = 2.73). TOXO infection is associated with psychomotor slowing in rodents and non-psychiatric humans. Latency of the acoustic startle response, an index of neural processing speed, is the time it takes for a startling stimulus to elicit the reflexive response through a three-synapse subcortical circuit. We report a significant slowing of latency in TOXO seropositive SCZ vs. seronegative SCZ, and in TOXO seropositive controls vs. seronegative controls. Latency was likewise slower in SCZ subjects than in controls. These findings indicate a slowing of neural processing speed with chronic TOXO infection; the slowest startle latency was seen in the TOXO seropositive SCZ group. Published by Elsevier B.V. C1 [Pearce, Bradley D.; Hubbard, Sydney; Fisch, Marylynn C.; Hopkins, Myfanwy H.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30329 USA. [Rivera, Hilda N.; Wilkins, Patricia P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Hasenkamp, Wendy; Gross, Robin; Duncan, Erica] Emory Univ, Sch Med, Atlanta VA Med Ctr, Decatur, GA 30033 USA. [Hasenkamp, Wendy; Gross, Robin; Duncan, Erica] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Decatur, GA 30033 USA. [Bliwise, Nancy] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. [Jones, Jeffrey L.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Duncan, E (reprint author), Vet Affairs Med Ctr, Atlanta Dept, 1670 Clairmont Rd,MHSL 116A, Decatur, GA 30033 USA. EM bpearce@emory.edu; sydney.hubbard@gmail.com; igi2@cdc.gov; pma1@cdc.gov; MFisch@live.com; myfanwy.hopkins@emory.edu; whasenk@gmail.com; regross@emory.edu; nbliwis@emory.edu; JLJ1@CDC.GOV; erica.duncan@va.gov RI Duncan, Erica/B-1671-2016 FU Department of Veterans Affairs Merit Review Program; NIDA [R01DA018294-01A2]; NIMH [1R21MH083138-01A1] FX This paper was funded by the Department of Veterans Affairs Merit Review Program (ED). Additional salary support was provided to ED from NIDA (R01DA018294-01A2) and to BDP from (NIMH (1R21MH083138-01A1)). NR 32 TC 10 Z9 10 U1 2 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD OCT PY 2013 VL 150 IS 1 BP 258 EP 261 DI 10.1016/j.schres.2013.07.028 PG 4 WC Psychiatry SC Psychiatry GA 216OZ UT WOS:000324294700043 PM 23953218 ER PT J AU Mao, SH Goodrich, RJ Hauser, R Schrader, SM Chen, Z Krawetz, SA AF Mao, Shihong Goodrich, Robert J. Hauser, Russ Schrader, Steven M. Chen, Zhen Krawetz, Stephen A. TI Evaluation of the effectiveness of semen storage and sperm purification methods for spermatozoa transcript profiling SO SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE LA English DT Article DE mitochondrial RNA; preferentially isolated transcripts; stable transcript pairs ID RNAS; IDENTIFICATION; FERTILIZATION; FERTILE; FRESH AB Different semen storage and sperm purification methods may affect the integrity of isolated spermatozoa! RNA. RNA-Seq was applied to determine whether semen storage methods (pelleted vs. liquefied) and somatic cell lysis buffer (SCLB) vs. PureSperm (PS) purification methods affect the quantity and quality of sperm RNA. The results indicate that the method of semen storage does not markedly impact RNA profiling whereas the choice of purification can yield significant differences. RNA-Seq showed that the majority of mitochondrial and mid-piece associated transcripts were lost after SCLB purification, which indicated that the mid-piece of spermatozoa may have been compromised. In addition, the number of stable transcript pairs from SCLB-samples was less than that from the PS samples. This study supports the view that PS purification better maintains the integrity of spermatozoal RNAs. C1 [Mao, Shihong; Goodrich, Robert J.; Krawetz, Stephen A.] Wayne State Univ, Dept Obstet & Gynecol, Ctr Mol Med & Genet, Detroit, MI 48201 USA. [Hauser, Russ] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Mem Obstet & Gynecol Serv, Boston, MA USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Schrader, Steven M.] NIOSH, Cincinnati, OH 45226 USA. [Schrader, Steven M.; Chen, Zhen] NIH, LIFE Study Team, Bethesda, MD 20892 USA. [Chen, Zhen] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. RP Krawetz, SA (reprint author), Wayne State Univ, Dept Obstet & Gynecol, 271 CS Mott Ctr,275 E Hancock Ave, Detroit, MI 48201 USA. EM steve@compbio.med.wayne.edu FU Charlotte B. Failing Professorship; Harvard School of Public Health; National Institute of Environmental Health Sciences [ES017285]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [25PM6]; LIFE Study Working Group, Division of Epidemiology, Statistics, and Prevention Research FX The authors declare no conflicts of interest. This work was supported in part by the Charlotte B. Failing Professorship to SAK, a GENI pilot grant to SAK and RH from Harvard School of Public Health; National Institute of Environmental Health Sciences (Grant Number ES017285) to RH and SAK and in part by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Contract 25PM6 in collaboration with the LIFE Study Working Group, Division of Epidemiology, Statistics, and Prevention Research who provided semen samples for analysis. NR 27 TC 7 Z9 7 U1 0 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1939-6368 J9 SYST BIOL REPROD MED JI Syst. Biol. Reprod. Med. PD OCT PY 2013 VL 59 IS 5 BP 287 EP 295 DI 10.3109/19396368.2013.817626 PG 9 WC Andrology; Reproductive Biology SC Endocrinology & Metabolism; Reproductive Biology GA 221OQ UT WOS:000324668600009 PM 23869956 ER PT J AU Vemula, SV Pandey, A Singh, N Katz, JM Donis, R Sambhara, S Mittal, SK AF Vemula, Sai V. Pandey, Aseem Singh, Neetu Katz, Jacqueline M. Donis, Ruben Sambhara, Suryaprakash Mittal, Suresh K. TI Adenoviral vector expressing murine beta-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice SO VIRUS RESEARCH LA English DT Article DE Vaccine for elderly; Immunostimulation; Adenovirus vector-based vaccines; Influenza; Aged mice; Murine beta-defensin 2 ID INNATE IMMUNE-RESPONSE; ANTITUMOR IMMUNITY; DENDRITIC CELLS; PANDEMIC INFLUENZA; RETROVIRUS INFECTION; PROTECTION; TARGET; VIRUS; ACTIVATION; CHEMOKINES AB The ability to resist infections and respond to vaccinations is greatly reduced in the older adult population owing to a general decline in innate and adaptive immune functions with aging. Over the years several strategies such as increasing the vaccine dose, number of immunizations and using adjuvants have been evaluated to improve the immunogenicity and efficacy of vaccines in the older adult population. Murine beta-defensin 2 (Mbd2) has been shown to function as a molecular adjuvant by recruiting and activating immature dendritic cells (DCs), professional antigen-presenting cells (APC), to the site of the immunization. In this study, we evaluated the potential utility of Mbd2 to enhance the efficacy of an adenoviral vector-based H5N1 influenza vaccine expressing hemagglutinin (HA) and nucleoprotein (NP) (HAd-HA-NP) in an aged mouse model. Our results indicated that immunostimulation with an adenoviral vector expressing Mbd2 (HAd-Mbd2) activated DCs and significantly enhanced the humoral and cellular immune responses induced by HAd-HA-NP. Furthermore, immunostimulation with HAd-Mbd2 followed by immunization with HAd-HA-NP resulted in significantly lower virus titers in the lungs following challenge with a H5N1 influenza virus compared to the group immunized with HAd-HA-NP without immunostimulation. Overall, our results highlight the potential utility of Mbd2 as a molecular adjuvant to enhance the immunogenicity and protective efficacy of vaccines for the elderly. (C) 2013 Elsevier B.V. All rights reserved. C1 [Vemula, Sai V.; Pandey, Aseem; Singh, Neetu; Mittal, Suresh K.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. [Vemula, Sai V.; Pandey, Aseem; Singh, Neetu; Mittal, Suresh K.] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA. [Katz, Jacqueline M.; Donis, Ruben; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Mittal, SK (reprint author), Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA. EM ssambhara@cdc.gov; mittal@purdue.edu FU Public Health Service from the National Institute of Allergy and Infectious Diseases [AI059374]; Showalter Award FX This work was supported by a Public Health Service grant AI059374 from the National Institute of Allergy and Infectious Diseases and a Showalter Award. We are thankful to J. Kovach for her excellent secretarial assistance. NR 36 TC 1 Z9 2 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD OCT PY 2013 VL 177 IS 1 BP 55 EP 61 DI 10.1016/j.virusres.2013.07.008 PG 7 WC Virology SC Virology GA 225PF UT WOS:000324974100006 PM 23892144 ER PT J AU Safaeian, M Rajaraman, P Hartge, P Yeager, M Linet, M Butler, MA Ruder, AM Purdue, MP Hsing, A Beane-Freeman, L Hoppin, JA Albanes, D Weinstein, SJ Inskip, PD Brenner, A Rothman, N Chatterjee, N Gillanders, EM Chanock, SJ Wang, SS AF Safaeian, Mahboobeh Rajaraman, Preetha Hartge, Patricia Yeager, Meredith Linet, Martha Butler, Mary Ann Ruder, Avima M. Purdue, Mark P. Hsing, Ann Beane-Freeman, Laura Hoppin, Jane A. Albanes, Demetrius Weinstein, Stephanie J. Inskip, Peter D. Brenner, Alina Rothman, Nathaniel Chatterjee, Nilanjan Gillanders, Elizabeth M. Chanock, Stephen J. Wang, Sophia S. TI Joint effects between five identified risk variants, allergy, and autoimmune conditions on glioma risk SO CANCER CAUSES & CONTROL LA English DT Article DE Single-nucleotide polymorphisms; Glioma; Allergies; Autoimmune conditions; Gene-environment interaction ID GENOME-WIDE ASSOCIATION; HIGH-GRADE GLIOMA; BRAIN-TUMORS; 1ST-DEGREE RELATIVES; AGRICULTURAL HEALTH; SUSCEPTIBILITY LOCI; NERVOUS-SYSTEM; CANCER; HISTORY; ADULTS AB Common variants in two of the five genetic regions recently identified from genome-wide association studies (GWAS) of risk of glioma were reported to interact with a history of allergic symptoms. In a pooled analysis of five epidemiologic studies, we evaluated the association between the five GWAS implicated gene variants and allergies and autoimmune conditions (AIC) on glioma risk (851 adult glioma cases and 3,977 controls). We further evaluated the joint effects between allergies and AIC and these gene variants on glioma risk. Risk estimates were calculated as odds ratios (OR) and 95 % confidence intervals (95 % CI), adjusted for age, gender, and study. Joint effects were evaluated by conducting stratified analyses whereby the risk associations (OR and 95 % CI) with the allergy or autoimmune conditions for glioma were evaluated by the presence or absence of the 'at-risk' variant, and estimated p interaction by fitting models with the main effects of allergy or autoimmune conditions and genotype and an interaction (product) term between them. Four of the five SNPs previously reported by others were statistically significantly associated with increased risk of glioma in our study (rs2736100, rs4295627, rs4977756, and rs6010620); rs498872 was not associated with glioma in our study. Reporting any allergies or AIC was associated with reduced risks of glioma (allergy: adjusted OR = 0.71, 95 % CI 0.55-0.91; AIC: adjusted OR = 0.65, 95 % CI 0.47-0.90). We did not observe differential association between allergic or autoimmune conditions and glioma by genotype, and there were no statistically significant p interactions. Stratified analysis by glioma grade (low and high grade) did not suggest risk differences by disease grade. Our results do not provide evidence that allergies or AIC modulate the association between the four GWAS-identified SNPs examined and risk of glioma. C1 [Safaeian, Mahboobeh; Rajaraman, Preetha; Hartge, Patricia; Linet, Martha; Purdue, Mark P.; Hsing, Ann; Beane-Freeman, Laura; Albanes, Demetrius; Weinstein, Stephanie J.; Inskip, Peter D.; Brenner, Alina; Rothman, Nathaniel; Chatterjee, Nilanjan] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Safaeian, Mahboobeh] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA. [Yeager, Meredith; Weinstein, Stephanie J.] NCI, Core Genom Res, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Butler, Mary Ann; Ruder, Avima M.] NIOSH, Ctr Dis Control & Prevent, Atlanta, GA USA. [Hoppin, Jane A.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC USA. [Gillanders, Elizabeth M.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Wang, Sophia S.] City Hope Natl Med Ctr, Div Etiol, Dept Populat Sci, Duarte, CA USA. RP Safaeian, M (reprint author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA. EM safaeianm@mail.nih.gov RI Albanes, Demetrius/B-9749-2015; Purdue, Mark/C-9228-2016; Beane Freeman, Laura/C-4468-2015 OI Purdue, Mark/0000-0003-1177-3108; Beane Freeman, Laura/0000-0003-1294-4124 FU National Cancer Institute; National Institute for Occupational Safety and Health; National Cancer Institute [N01-CO-12400]; NIEHS FX The study was funded by Intramural Research Program of the National Cancer Institute and the National Institute for Occupational Safety and Health. It was been funded in whole or in part with federal funds from the National Cancer Institute under contract N01-CO-12400. The funding source for AHS is from the Intramural Program of NIEHS. AHS Data release P1REL0506_02. We are indebted to the scientific and field efforts of Tim Sheehy, Laurie Burdette, Aurelie Vogt, Annelie Landgren, Zhaoming Wang, Arti Aranasi, Michelle Brotzman, Lisa Newman, and Peter Hui. NR 27 TC 11 Z9 11 U1 0 U2 8 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD OCT PY 2013 VL 24 IS 10 BP 1885 EP 1891 DI 10.1007/s10552-013-0244-7 PG 7 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 216AF UT WOS:000324252500012 PM 23903690 ER PT J AU Wheeler, MW Bailer, AJ AF Wheeler, Matthew W. Bailer, A. John TI An empirical comparison of low-dose extrapolation from points of departure (PoD) compared to extrapolations based upon methods that account for model uncertainty SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Benchmark doses; Cancer risk estimation; Dose-response data; Linear extrapolation; Model averaging; Semi parametric methods AB Experiments with relatively high doses are often used to predict risks at appreciably lower doses. A point of departure (PoD) can be calculated as the dose associated with a specified moderate response level that is often in the range of experimental doses considered. A linear extrapolation to lower doses often follows. An alternative to the PoD method is to develop a model that accounts for the model uncertainty in the dose-response relationship and to use this model to estimate the risk at low doses. Two such approaches that account for model uncertainty are model averaging (MA) and semi-parametric methods. We use these methods, along with the PoD approach in the context of a large animal (40,000+ animal) bioassay that exhibited sub-linearity. When models are fit to high dose data and risks at low doses are predicted, the methods that account for model uncertainty produce dose estimates associated with an excess risk that are closer to the observed risk than the PoD linearization. This comparison provides empirical support to accompany previous simulation studies that suggest methods that incorporate model uncertainty provide viable, and arguably preferred, alternatives to linear extrapolation from a PoD. Published by Elsevier Inc. C1 [Wheeler, Matthew W.] NIOSH, Risk Evaluat Branch, Cincinnati, OH 45226 USA. [Bailer, A. John] Miami Univ, Dept Stat, Oxford, OH 45056 USA. RP Wheeler, MW (reprint author), NIOSH, Risk Evaluat Branch, 4626 Columbia Pkwy, Cincinnati, OH 45226 USA. EM mwheeler@cdc.gov; baileraj@MiamiOH.edu FU Intramural CDC HHS [CC999999] NR 17 TC 2 Z9 2 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD OCT PY 2013 VL 67 IS 1 BP 75 EP 82 DI 10.1016/j.yrtph.2013.06.006 PG 8 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA 218PA UT WOS:000324443400007 PM 23831127 ER PT J AU Trivers, KF Patterson, JR Roland, KB Rodriguez, JL AF Trivers, Katrina F. Patterson, Jennifer Rees Roland, Katherine B. Rodriguez, Juan L. TI Issues of ovarian cancer survivors in the USA: a literature review SO SUPPORTIVE CARE IN CANCER LA English DT Review DE Ovarian neoplasms; Survival; Treatment; Financial; End of life; Fertility; Sexual health ID QUALITY-OF-LIFE; GYNECOLOGIC-ONCOLOGY-GROUP; CELL TUMOR SURVIVORS; PSYCHOLOGICAL DISTRESS; BREAST/OVARIAN CANCER; SEXUAL FUNCTION; WOMEN; CHEMOTHERAPY; PREDICTORS; ADJUSTMENT AB As the number of ovarian cancer survivors increases, so does the need for appropriate intervention and care. A literature review was conducted to assess the issues affecting ovarian cancer survivors in the USA, including the needs of younger survivors. Articles on six topics (finances/employment, reproductive and sexual health, treatment effects, information needs, genomics, and end-of-life/palliative care) among ovarian cancer survivors were identified through comprehensive database searches. Abstracts for all citations were reviewed to determine relevancy. Data from relevant articles, defined as including a sample size of a parts per thousand yen20, published in English, involving human subjects in the USA, and published between 2000 and 2010, were abstracted. Thirty-four articles were relevant. Common, but often unaddressed, treatment side effects included infertility and issues with sexual health. Survivors reported not receiving adequate information about their disease. Hereditary cancer can lead to concern for family members. End-of-life/palliative care was often not addressed by physicians. Most of the studies used a cross-sectional design and lacked control groups. Participants were primarily recruited from academic medical centers or clinical trials and tended to be White. Few studies specifically addressed young survivors; however, reproductive health issues are common. Ovarian cancer has wide-ranging impacts. This review emphasizes the need for more research among ovarian cancer survivors, particularly related to finances, reproductive and sexual health, information, genomics, and end-of-life care. Issues specific to young survivors also deserve more attention. Direction for future research and clinical implications are discussed. C1 [Trivers, Katrina F.; Roland, Katherine B.; Rodriguez, Juan L.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Patterson, Jennifer Rees] SciMetrika LLC, Durham, NC USA. RP Trivers, KF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F76, Atlanta, GA 30341 USA. EM fph1@cdc.gov FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. NR 44 TC 6 Z9 7 U1 0 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD OCT PY 2013 VL 21 IS 10 BP 2889 EP 2898 DI 10.1007/s00520-013-1893-5 PG 10 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 214DB UT WOS:000324109900029 PM 23846493 ER PT J AU Feng, YF Wu, SY Varma, JK Klena, JD Angulo, FJ Ran, L AF Feng, Yanfang Wu, Shuyu Varma, Jay K. Klena, John D. Angulo, Frederick J. Ran, Lu TI Systematic review of human listeriosis in China, 1964-2010 SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE Listeriosis; China; review; clinical features; epidemiology ID RISK-FACTORS; MONOCYTOGENES INFECTION; FOODBORNE LISTERIOSIS; EPIDEMIOLOGY; FOODS AB OBJECTIVES Listeria is an important foodborne pathogen with severe manifestations and high case-fatality rate. However, listeriosis is not yet a notifiable disease in China, and there is no national monitoring system for cases. We conducted a systematic review to better understand the clinical and epidemiologic features of listeriosis in China. METHODS Both electronic and manual retrieval systems were used to search Chinese literature for cases and isolates of human listeriosis reported between 1964 and 2010. We recorded and analysed demographic, clinical and laboratory information available for reported cases. RESULTS A total of 147 clinical cases, 479 Listeria isolates and 82 outbreak-related cases were reported in 28 (90%) provinces in China from January 1964 to December 2010. Of the clinical cases, 45 (31%) were central nervous system infections, 68 (46%) were septicaemia and 34 (23%) were focal infections or gastroenteritis. The overall case-fatality rate was 26% (34/130) among clinical cases with known outcomes and 46% (21/46) among neonatal cases. CONCLUSION Listeriosis cases occurred in China throughout the study period between 1964 and 2010. Case-fatality was similar to published data from other countries. China should consider requiring notification of listeriosis cases to improve estimates of incidence, identification of risk factors and design of preventive measures. C1 [Feng, Yanfang; Ran, Lu] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing 102206, Peoples R China. [Feng, Yanfang] Univ Amsterdam, Swammerdam Inst Life Sci, Dept Mol Biol & Microbial Food Safety, Amsterdam, Netherlands. [Wu, Shuyu; Varma, Jay K.; Klena, John D.; Angulo, Frederick J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ran, L (reprint author), Chinese Ctr Dis Control & Prevent, Div Infect Dis Prevent & Control, 155 Changbai Rd, Beijing 102206, Peoples R China. EM ranlu@chinacdc.cnm FU WHO Global Foodborne Infections Network program; China - US Collaborative Program on Emerging and Re-emerging Infectious Diseases FX This study was supported by WHO Global Foodborne Infections Network program and the China - US Collaborative Program on Emerging and Re-emerging Infectious Diseases. NR 36 TC 3 Z9 7 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2013 VL 18 IS 10 BP 1248 EP 1256 DI 10.1111/tmi.12173 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213PC UT WOS:000324069100012 PM 24016031 ER PT J AU Bruxvoort, K Kalolella, A Nchimbi, H Festo, C Taylor, M Thomson, R Cairns, M Thwing, J Kleinschmidt, I Goodman, C Kachur, SP AF Bruxvoort, Katia Kalolella, Admirabilis Nchimbi, Happy Festo, Charles Taylor, Mark Thomson, Rebecca Cairns, Matthew Thwing, Julie Kleinschmidt, Immo Goodman, Catherine Kachur, S. Patrick TI Getting antimalarials on target: impact of national roll-out of malaria rapid diagnostic tests on health facility treatment in three regions of Tanzania SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE malaria; malaria rapid diagnostic test; implementation; artemisinin-based combination therapie; Tanzania; drug stock-outs; antibiotic use ID DAR-ES-SALAAM; RANDOMIZED-TRIAL; ARTEMETHER-LUMEFANTRINE; COMBINATION THERAPY; FEBRILE ILLNESS; MANAGEMENT; IMPLEMENTATION; CHILDREN; FEVER; OVERDIAGNOSIS AB OBJECTIVES Parasitological confirmation of malaria prior to treatment is recommended for patients of all ages, with malaria rapid diagnostic tests (mRDTs) an important tool to target artemisinin-based combination therapies (ACTs) to patients with malaria. To evaluate the impact on case management practices of routine government implementation of mRDTs, we conducted large-scale health facility surveys in three regions of Tanzania before and after mRDT roll-out. METHODS Febrile patients at randomly selected health facilities were interviewed about care received at the facility, and blood samples were collected for reference blood smears. Health facility staff were interviewed about their qualifications and availability of malaria diagnostics and drugs. RESULTS The percentage of febrile patients tested for malaria at the facility increased from 15.8% in 2010 to 54.9% in 2012. ACTs were obtained by 65.8% of patients positive by reference blood smear in 2010 and by 50.2% in 2012 (P = 0.0675); no antimalarial was obtained by 57.8% of malaria-negative patients in 2010 and by 82.3% in 2012 (P < 0.0001). Overall, ACT use decreased (39.9-21.3%, P < 0.0001) and antibiotic use increased (31.2-48.5%, P < 0.0001). CONCLUSION Roll-out of mRDTs in Tanzania dramatically improved diagnostic testing for malaria and reduced overuse of ACTs for patients without parasitemia. However, post-roll-out almost 50% of febrile patients did not receive a diagnostic test, and almost 50% of patients testing positive did not receive ACTs. Stock-outs of ACTs and mRDTs were important problems. Further investigation is needed to determine reasons for not providing ACTs to patients with malaria and potential for inappropriate antibiotic use. C1 [Bruxvoort, Katia; Taylor, Mark; Thomson, Rebecca; Cairns, Matthew; Kleinschmidt, Immo; Goodman, Catherine] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [Bruxvoort, Katia; Kalolella, Admirabilis; Nchimbi, Happy; Festo, Charles; Taylor, Mark; Thomson, Rebecca] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Thwing, Julie; Kachur, S. Patrick] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. RP Bruxvoort, K (reprint author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England. EM katia.bruxvoort@lshtm.ac.uk OI Taylor, Mark/0000-0002-7646-7905 FU Bill and Melinda Gates Foundation, through the ACT Consortium; European Regional Development Fund; European Social Fund Convergence Programme for Cornwall and the Isles of Scilly FX The authors would like to thank Adam Wolkon for training and advice on PDA programming and Eugenie Poirot and Bhargavi Rao for assistance during training, piloting and start of field work. Many thanks to the field teams, regional and district health officers and study participants. This work was funded by the Bill and Melinda Gates Foundation, through the ACT Consortium. Mark Taylor is now employed by The European Centre for Environment and Human Health (part of the University of Exeter Medical School), which is supported by investment from the European Regional Development Fund and the European Social Fund Convergence Programme for Cornwall and the Isles of Scilly. NR 42 TC 25 Z9 25 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD OCT PY 2013 VL 18 IS 10 BP 1269 EP 1282 DI 10.1111/tmi.12168 PG 14 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213PC UT WOS:000324069100015 PM 23937722 ER PT J AU Stormo, AR Espey, D Glenn, J Lara-Prieto, E Moreno, A Nunez, F Padilla, H Waxman, A Flowers, L Santos, C Soria, M Luciani, S Saraiya, M AF Stormo, A. R. Espey, D. Glenn, J. Lara-Prieto, E. Moreno, A. Nunez, F. Padilla, H. Waxman, A. Flowers, L. Santos, C. Soria, M. Luciani, S. Saraiya, M. TI Findings and lessons learned from a multi-partner collaboration to increase cervical cancer prevention efforts in Bolivia SO RURAL AND REMOTE HEALTH LA English DT Article DE capacity building; cervical cancer; cryotherapy; global health; Latin America; visual inspection with acetic acid; women's health ID CRYOTHERAPY AB Cervical cancer is a leading cause of cancer death among women in Bolivia, where cytology based screening has not performed well due to health-systems constraints. In response, the Centers for Disease Control and Prevention and the Pan American Health Organization partnered with the Bolivian Ministry of Health and the Peruvian Cancer Institute (INEN) to build capacity in Bolivia for the use of visual inspection of the cervix with acetic acid (VIA) and cryotherapy. Four 5-day courses on basic clinical skills to perform these procedures, provide related counseling, and manage side effects and infections were conducted from September 2010 to December 2012 for 61 Bolivian nurses and physicians. Of these courses, two were conducted by Bolivian trainers that were certified through a Training-of-Trainers course taught by the INEN. Classroom didactic sessions included lectures and practice with anatomic models followed by clinical practice sessions to provide trainees with practical experience in VIA and cryotherapy. Pre- and post-training evaluations were administered to ascertain knowledge gained. Evaluation of competency was conducted during simulation exercises in the classroom and during supervised performances of procedures in clinical settings. This report summarizes findings and lessons learned that will be useful for planning the supervision and monitoring phase of this project as well as for future partnerships in the Latin American and the Caribbean region. C1 [Stormo, A. R.; Espey, D.; Glenn, J.; Saraiya, M.] CDC, Atlanta, GA 30333 USA. [Lara-Prieto, E.; Luciani, S.] Pan Amer Hlth Org, Washington, DC USA. [Moreno, A.] Hosp Japones, Beni, Bolivia. [Nunez, F.; Padilla, H.] Pan Amer Hlth Org, La Paz, Bolivia. [Waxman, A.] Univ New Mexico, Alburqueque, NM USA. [Flowers, L.] Emory Univ, Atlanta, GA 30322 USA. [Santos, C.] Peruvian Natl Canc Inst, Lima, Peru. [Soria, M.] Bolivian Minist Hlth, La Paz, Bolivia. RP Stormo, AR (reprint author), CDC, Atlanta, GA 30333 USA. FU US Department of Energy; CDC FX This research was supported by an appointment to CDC's Research Participation Program administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the US Department of Energy and CDC. ORISE had no involvement in the study design; collection, analysis, and interpretation of data; the writing of the manuscript; or the decision to submit this manuscript for publication. NR 26 TC 2 Z9 2 U1 0 U2 3 PU AUSTRALIAN RURAL HEALTH EDUC NETWORK PI DEAKIN WEST PA PO BOX 242, DEAKIN WEST, ACT 2600, AUSTRALIA SN 1445-6354 J9 RURAL REMOTE HEALTH JI Rural Remote Health PD OCT-DEC PY 2013 VL 13 IS 4 AR 2595 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AR3WW UT WOS:000343520700018 PM 24245564 ER PT J AU Boore, AL Jungk, J Russo, ET Redd, JT Angulo, FJ Williams, IT Cheek, JE Gould, LH AF Boore, A. L. Jungk, J. Russo, E. T. Redd, J. T. Angulo, F. J. Williams, I. T. Cheek, J. E. Gould, L. H. TI Added value of a household-level study during an outbreak investigation of Salmonella serotype Saintpaul infections, New Mexico 2008 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Epidemiology; foodborne infections; investigation; Salmonella; salmonellosis ID UNITED-STATES; RAW PRODUCE AB In 2008, nationwide investigations of a Salmonella serotype Saintpaul outbreak led first to consumer warnings for Roma and red round tomatoes, then later for jalapeno and serrano peppers. In New Mexico, where there were a large number of cases but no restaurant-based clusters, the NM Department of Health and the Indian Health Service participated with CDC in individual-level and household-level case-control studies of infections in New Mexico and the Navajo Nation. No food item was associated in the individual-level study. In the household-level study, households with an ill member were more likely to have had jalapeno peppers present during the exposure period and to have reported ever having serrano peppers in the household. This report illustrates the complexity of this investigation, the limitations of traditional individual-level case-control studies when vehicles of infection are ingredients or commonly eaten with other foods, and the added value of a household-level study. C1 [Boore, A. L.; Russo, E. T.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30329 USA. [Boore, A. L.; Russo, E. T.; Angulo, F. J.; Williams, I. T.; Gould, L. H.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Jungk, J.] New Mexico Dept Hlth, Epidemiol & Response Div, Santa Fe, NM USA. [Redd, J. T.; Cheek, J. E.] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Albuquerque, NM USA. RP Boore, AL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30329 USA. EM amyboore@gmail.com RI Jungk, Jessica/A-9958-2015 OI Jungk, Jessica/0000-0001-7087-7623 FU Department of Health and Human Services, Centers for Disease Control and Prevention FX This work was supported by government funding through the Department of Health and Human Services, Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 9 TC 1 Z9 1 U1 0 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2013 VL 141 IS 10 BP 2068 EP 2073 DI 10.1017/S0950268812002877 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 211EH UT WOS:000323887200008 PM 23228507 ER PT J AU Cartwright, EJ Patel, MK Mbopi-Keou, FX Ayers, T Haenke, B Wagenaar, BH Mintz, E Quick, R AF Cartwright, E. J. Patel, M. K. Mbopi-Keou, F. X. Ayers, T. Haenke, B. Wagenaar, B. H. Mintz, E. Quick, R. TI Recurrent epidemic cholera with high mortality in Cameroon: persistent challenges 40 years into the seventh pandemic SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Cholera; diarrhoea; Vibrio cholerae; water (safe) ID ORAL REHYDRATION SOLUTIONS; WATER-TREATMENT; AFRICA; TRANSMISSION; BANGLADESH; OUTBREAK; DIARRHEA; HEALTH; ZAMBIA; RISK AB Cameroon has experienced recurrent cholera epidemics with high mortality rates. In September 2009, epidemic cholera was detected in the Far North region of Cameroon and the reported case-fatality rate was 12%. We conducted village-, healthcare facility- and community-level surveys to investigate reasons for excess cholera mortality. Results of this investigation suggest that cholera patients who died were less likely to seek care, receive rehydration therapy and antibiotics at a healthcare facility, and tended to live further from healthcare facilities. Furthermore, use of oral rehydration salts at home was very low in both decedents and survivors. Despite the many challenges inherent to delivering care in Cameroon, practical measures could be taken to reduce cholera mortality in this region, including the timely provision of treatment supplies, training of healthcare workers, establishment of rehydration centres, and promotion of household water treatment and enhanced handwashing with soap. C1 [Cartwright, E. J.; Patel, M. K.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Epidem Intelligence Serv, Atlanta, GA USA. [Cartwright, E. J.; Patel, M. K.; Ayers, T.; Mintz, E.; Quick, R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Mbopi-Keou, F. X.] Minist Publ Hlth, Yaounde, Cameroon. [Mbopi-Keou, F. X.] Univ Yaounde I, Yaounde, Cameroon. [Haenke, B.; Wagenaar, B. H.] Far North Reg Cameroon, Community Hlth Volunteer, Washington, DC USA. [Haenke, B.; Wagenaar, B. H.] United States Peace Corps, Washington, DC USA. RP Cartwright, EJ (reprint author), Emory Univ, Div Infect Dis, 49 Jesse Hill Dr, Atlanta, GA 30303 USA. EM ejcartwright@gmail.com OI Ayers, Tracy/0000-0003-4140-3263 FU United States Centers for Disease Control and Prevention FX This work was supported by the United States Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 37 TC 3 Z9 3 U1 3 U2 26 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2013 VL 141 IS 10 BP 2083 EP 2093 DI 10.1017/S0950268812002932 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 211EH UT WOS:000323887200010 PM 23290586 ER PT J AU Harris, C Shuster, DZ Gomez, RR Sant, KE Reed, MS Pohl, J Hansen, JM AF Harris, Craig Shuster, Daniel Z. Gomez, Rosaicela Roman Sant, Karilyn E. Reed, Matthew S. Pohl, Jan Hansen, Jason M. TI Inhibition of glutathione biosynthesis alters compartmental redox status and the thiol proteome in organogenesis-stage rat conceptuses SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Glutathione; Cysteine; Redox status; Thiol proteome; Organogenesis; Conceptus; Embryo; Visceral yolk sac; Spliceosome; Redox potential; Amniotic fluid; Yolk sac fluid; Developmental signalling ID NF-KAPPA-B; VISCERAL YOLK-SAC; OXIDATIVE STRESS; THIOL/DISULFIDE REDOX; EMBRYONIC-DEVELOPMENT; CANCER; CELLS; PROLIFERATION; TERATOGENESIS; TRANSCRIPTION AB Developmental signals that control growth and differentiation are regulated by environmental factors that generate reactive oxygen species (ROS) and alter steady-state redox environments in tissues and fluids. Protein thiols are selectively oxidized and reduced in distinct spatial and temporal patterns in conjunction with changes in glutathione/glutathione disulfide (GSH/GSSG) and cysteine/cystine (Cys/CySS) redox potentials (E-h) to regulate developmental signaling. The purpose of this study was to measure compartment-specific thiol redox status in cultured organogenesis-stage rat conceptuses and to evaluate the impact of thiol oxidation on the redox proteome. The visceral yolk sac (VYS) has the highest initial (0 h) total intracellular GSH (GSH+2GSSG) concentration (5.5 mM) and the lowest E-h (-223 mV) as determined by HPLC analysis. Total embryo (EMB) GSH concentrations ranged lower (3.2 mM) and were only slightly more oxidized than the VYS. Total GSH concentrations in yolk sac fluid (YSF) and amniotic fluid (AF) are >500-fold lower than in tissues and are highly oxidized (YSF E-h=-121 my and AF E-h=-49 mV). Steady-state total Cys concentrations (Cys+2CySS) were significantly lower than GSH in tissues but were otherwise equal in VYS and EMB near 0.5 mM. On gestational day 11, total GSH and Cys concentrations in EMB and VYS increase significantly over the 6 h time course while E-h remains relatively constant. The E-h (GSH/GSSG) in YSF and AF become more reduced over time while E-h (Cys/CySS) become more oxidized. Addition of L-buthionine-S,R-sulfoximine (BSO) to selectively inhibit GSH synthesis and mimic the effects of some GSH-depleting environmental chemicals significantly decreased VYS and EMB GSH and Cys concentrations and increased E-h over the 6 h exposure period, showing a greater overall oxidation. In the YSF, BSO caused a significant increase in total Cys concentrations to 1.7 mM but did not significantly change the E-h for Cys/CySS. A significant net oxidation was seen in the BSO-treated AF compartment after 6 h. Biotinylated iodoacetamide (BIAM) labeling of proteins revealed the significant thiol oxidation of many EMB proteins following BSO treatment. Quantitative changes in the thiol proteome, associated with developmentally relevant pathways, were detected using isotope coded affinity tag (ICAT) labeling and mass spectroscopy. Adaptive pathways were selectively enriched with increased concentrations of proteins involved in mRNA processing (splicesome) and mRNA stabilization (glycolysis, GAPDH), as well as protein synthesis (aminoacyl-tRNA) and protein folding (antigen processing, Hsp70, protein disulfide isomerase). These results show the ability of chemical and environmental modulators to selectively alter compartmental intracellular and extracellular GSH and Cys concentrations and change their corresponding E-h within the intact viable conceptus. The altered E-h were also of sufficient magnitude to alter the redox proteome and change relative protein concentrations, suggesting that the mechanistic links through which environmental factors inform and regulate developmental signaling pathways may be discovered using systems developmental biology techniques. (C) 2013 Elsevier Inc. All rights reserved. C1 [Harris, Craig; Shuster, Daniel Z.; Gomez, Rosaicela Roman; Sant, Karilyn E.] Univ Michigan, Dept Environm Hlth Sci, Dev Toxicol Lab, Ann Arbor, MI 48109 USA. [Reed, Matthew S.; Pohl, Jan] Ctr Dis Control, Biotechnol Core Facil Branch, DSR, Atlanta, GA 30333 USA. [Hansen, Jason M.] Emory Univ, Emory Med Sch, Div Pulm Allergy Immunol Cyst Fibrosis & Sleep, Dept Pediat,Emory Childrens Ctr cyct Fibrosis Res, Atlanta, GA 30322 USA. RP Harris, C (reprint author), Univ Michigan, Dept Environm Hlth Sci, Dev Toxicol Lab, 1420 Washington Hts, Ann Arbor, MI 48109 USA. EM charris@umich.edu OI Sant, Karilyn/0000-0001-8565-2072 FU University of Michigan's Office of the Vice President for Research (OVPR); Bill and Melinda Gates Foundation; Children's Health Care of Atlanta; Emory +Children's Center for Cystic Fibrosis Research; NIEHS/NIH [T32 ES007062] FX This work was funded with generous support by grants from the University of Michigan's Office of the Vice President for Research (OVPR) and the Bill and Melinda Gates Foundation (C. H.), as well as, the Children's Health Care of Atlanta and the Emory +Children's Center for Cystic Fibrosis Research (J.M.H.). Graduate student support was provided by an NIEHS/NIH training grant, T32 ES007062 (R.R.G. and K.E.S.). "The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention." NR 67 TC 6 Z9 6 U1 1 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD OCT PY 2013 VL 63 SI SI BP 325 EP 337 DI 10.1016/j.freeradbiomed.2013.05.040 PG 13 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 200TV UT WOS:000323094700031 PM 23736079 ER PT J AU Bhatnagar, P Keefer, JR Casella, JF Barron-Casella, EA Bean, CJ Hooper, CW Payne, AB Arking, DE Debaun, MR AF Bhatnagar, Pallav Keefer, Jeffrey R. Casella, James F. Barron-Casella, Emily A. Bean, Christopher J. Hooper, Craig W. Payne, Amanda B. Arking, Dan E. Debaun, Michael R. TI Association between baseline fetal hemoglobin levels and incidence of severe vaso-occlusive pain episodes in children with sickle cell anemia SO PEDIATRIC BLOOD & CANCER LA English DT Article DE fetal hemoglobin; sickle cell anemia; vaso-occlusive pain ID RISK-FACTORS; DISEASE; HYDROXYUREA; FREQUENCY; ADULTS; DESIGN; TRIAL AB The ameliorating effect of high fetal hemoglobin (HbF) levels on the incidence of pain episodes in sickle cell anemia (SCA) is well-known; however, in children this relationship is less clearly established. We hypothesized that higher HbF levels in children with SCA are associated with fewer severe pain episodes. A meta-analysis of data from the Silent Infarct Transfusion Trial (n=456) and the Cooperative Study of Sickle Cell Disease (n=764), demonstrated that baseline HbF levels were associated with the incidence of severe pain, commonly defined across studies as an event requiring hospitalization (P-value=0.02). Pediatr Blood Cancer 2013;60:E125-E127. (c) 2013 Wiley Periodicals, Inc. C1 [Bhatnagar, Pallav; Arking, Dan E.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Sch Med, Baltimore, MD 21205 USA. [Keefer, Jeffrey R.; Casella, James F.; Barron-Casella, Emily A.] Johns Hopkins Univ, Dept Pediat, Sch Med, Div Pediat Hematol, Baltimore, MD 21205 USA. [Bean, Christopher J.; Hooper, Craig W.; Payne, Amanda B.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Debaun, Michael R.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. RP Arking, DE (reprint author), Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Sch Med, 733 N Broadway,Room 447, Baltimore, MD 21205 USA. EM arking@jhmi.edu; m.debaun@vanderbilt.edu FU National Heart, Lung and Blood Institute (NHLBI) [U54HL090515, 5R01HL091759]; National Institute of Neurological Disorders and Stroke (NINDS) [NIH-NINDS 5U01-NS042804-03]; Burroughs Wellcome Foundation FX Grant sponsor: National Heart, Lung and Blood Institute (NHLBI); Grant numbers: U54HL090515; 5R01HL091759; Grant sponsor: National Institute of Neurological Disorders and Stroke (NINDS); Grant number: NIH-NINDS 5U01-NS042804-03; Grant sponsor: Burroughs Wellcome Foundation NR 14 TC 3 Z9 3 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD OCT PY 2013 VL 60 IS 10 BP E125 EP E127 DI 10.1002/pbc.24588 PG 3 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 197XG UT WOS:000322885200005 PM 23677903 ER PT J AU Akinyi, S Hayden, T Gamboa, D Torres, K Bendezu, J Abdallah, JF Griffing, SM Quezada, WM Arrospide, N De Oliveira, AM Lucas, C Magill, AJ Bacon, DJ Barnwell, JW Udhayakumar, V AF Akinyi, Sheila Hayden, Tonya Gamboa, Dionicia Torres, Katherine Bendezu, Jorge Abdallah, Joseph F. Griffing, Sean M. Marquino Quezada, Wilmer Arrospide, Nancy De Oliveira, Alexandre Macedo Lucas, Carmen Magill, Alan J. Bacon, David J. Barnwell, John W. Udhayakumar, Venkatachalam TI Multiple genetic origins of histidine-rich protein 2 gene deletion in Plasmodium falciparum parasites from Peru SO SCIENTIFIC REPORTS LA English DT Article ID RAPID DIAGNOSTIC-TESTS; MULTILOCUS GENOTYPE DATA; AMAZON REGION; MICROSATELLITE MARKERS; MALARIA PARASITES; PFHRP2; RESISTANCE; INFERENCE; BREAKAGE; POLICY AB The majority of malaria rapid diagnostic tests (RDTs) detect Plasmodium falciparum histidine-rich protein 2 (PfHRP2), encoded by the pfhrp2 gene. Recently, P. falciparum isolates from Peru were found to lack pfhrp2 leading to false-negative RDT results. We hypothesized that pfhrp2-deleted parasites in Peru derived from a single genetic event. We evaluated the parasite population structure and pfhrp2 haplotype of samples collected between 1998 and 2005 using seven neutral and seven chromosome 8 microsatellite markers, respectively. Five distinct pfhrp2 haplotypes, corresponding to five neutral microsatellite-based clonal lineages, were detected in 1998-2001; pfhrp2 deletions occurred within four haplotypes. In 2003-2005, outcrossing among the parasite lineages resulted in eight population clusters that inherited the five pfhrp2 haplotypes seen previously and a new haplotype; pfhrp2 deletions occurred within four of these haplotypes. These findings indicate that the genetic origin of pfhrp2 deletion in Peru was not a single event, but likely occurred multiple times. C1 [Akinyi, Sheila; Hayden, Tonya; Abdallah, Joseph F.; Griffing, Sean M.; De Oliveira, Alexandre Macedo; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Gamboa, Dionicia; Torres, Katherine; Bendezu, Jorge] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt IMTAvH, Lima 100, Peru. [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Ciencias Celulares & Mol, Lima 31, Peru. [Marquino Quezada, Wilmer; Arrospide, Nancy] Inst Nacl Salud, Lima, Peru. RP Udhayakumar, V (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM vxu0@cdc.gov RI maria, ana /G-8106-2014; OI ARROSPIDE, NANCY/0000-0001-5031-5850 FU Amazon Malaria Initiative; U.S. Agency for International Development; American Society of Microbiology/CDC Postdoctoral Fellowship Program; DGCD [95502]; Peru/Brazil International Center of Excellence in Malaria Research [U19AI089681]; NIH/Fogarty International Center Global Infectious Diseases Training Grant [D43TW007120] FX We wish to thank all members of the study team who originally contributed to the collection of samples and study participants for their permission to use these samples. We acknowledge funding support from the Amazon Malaria Initiative which is supported by the U.S. Agency for International Development. S. A. and T. H. were supported by the American Society of Microbiology/CDC Postdoctoral Fellowship Program. D. G. is supported by DGCD (Framework Agreement 03, 2008-2013, Project 95502); D. G. and J.B. are supported by the Peru/Brazil International Center of Excellence in Malaria Research U19AI089681 (NIH/NIAID, United States Public Health Service, USA). K. T. is supported by the NIH/Fogarty International Center Global Infectious Diseases Training Grant D43TW007120 (IMTAvH-UCSD). A.M.O., C. L., J.W.B. and V. U. are employees of the U.S. Government and D.J.B. is a military service member. This work was prepared as part of their official duties. We thank Dr. Fredrik Vannberg of the Georgia Institute of Technology and Mr. Ira F. Goldman of the Centers for Disease Control and Prevention for critical review of the manuscript. NR 27 TC 12 Z9 13 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD SEP 30 PY 2013 VL 3 AR 2797 DI 10.1038/srep02797 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 225UI UT WOS:000324988400006 PM 24077522 ER PT J AU Abrams, B Anderson, H Blackmore, C Bove, FJ Condon, SK Eheman, CR Fagliano, J Haynes, LB Lewis, LS Major, J McGeehin, MA Simms, E Sircar, K Soler, J Stanbury, M Watkins, SM Wartenberg, D AF Abrams, Beth (Vivi) Anderson, Henry Blackmore, Carina Bove, Frank J. Condon, Suzanne K. Eheman, Christie R. Fagliano, Jerald Haynes, Lorena Barck Lewis, Lauren S. Major, Jennifer McGeehin, Michael A. Simms, Erin Sircar, Kanta Soler, John Stanbury, Martha Watkins, Sharon M. Wartenberg, Daniel TI Investigating Suspected Cancer Clusters and Responding to Community Concerns Guidelines from CDC and the Council of State and Territorial Epidemiologists SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID PUBLIC-HEALTH AB This report augments guidelines published in 1990 for investigating clusters of health events (CDC. Guidelines for investigating clusters of health events. MMWR 1990; 39[No. RR-11]). The 1990 Guidelines considered any noninfectious disease cluster, injuries, birth defects, and previously unrecognized syndromes or illnesses. These new guidelines focus on cancer clusters. State and local health departments can use these guidelines to develop a systematic approach to responding to community concerns regarding cancer clusters. The guidelines are intended to apply to situations in which a health department responds to an inquiry about a suspected cancer cluster in a residential or community setting only. Occupational or medical treatment-related clusters are not included in this report. Since 1990, many improvements have occurred in data resources, investigative techniques, and analytic/statistical methods, and much has been learned from both large-and small-scale cancer cluster investigations. These improvements and lessons have informed these updated guidelines. These guidelines utilize a four-step approach (initial response, assessment, major feasibility study, and etiologic investigation) as a tool for managing a reported cluster. Even if a cancer cluster is identified, there is no guarantee that a common cause or an environmental contaminant will be implicated. Identification of a common cause or an implicated contaminant might be an expected outcome for the concerned community. Therefore, during all parts of an inquiry, responders should be transparent, communicate clearly, and explain their decisions to the community. C1 [Abrams, Beth (Vivi); Lewis, Lauren S.; Sircar, Kanta] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Anderson, Henry] Wisconsin Dept Hlth Serv, Madison, WI USA. [Blackmore, Carina; Watkins, Sharon M.] Florida Dept Hlth, Tallahassee, FL USA. [Bove, Frank J.] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Condon, Suzanne K.] Massachusetts Dept Publ Hlth, Boston, MA USA. [Eheman, Christie R.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Fagliano, Jerald] New Jersey Dept Hlth & Sr Serv, Trenton, NJ USA. [Haynes, Lorena Barck; Major, Jennifer] Haynes Ross Strateg, Seattle, WA USA. [McGeehin, Michael A.] Res Triangle Inst, Res Triangle Pk, NC USA. [Simms, Erin] Council State & Terr Epidemiologists, Atlanta, GA USA. [Soler, John] Minnesota Dept Hlth, St Paul, MN USA. [Stanbury, Martha] Michigan Dept Community Hlth, Lansing, MI USA. [Wartenberg, Daniel] Rutgers State Univ, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA. RP Sircar, K (reprint author), CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM ddq0@cdc.gov NR 65 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD SEP 27 PY 2013 VL 62 IS 8 BP 1 EP 24 PG 24 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 242JM UT WOS:000326236300001 ER PT J AU Berlin, D Farmer, BM Rao, RB Rella, J Kunins, H Dowell, D Graber, N Hoffman, RS Karpati, A Weiss, D Jones, C Toprani, A Ridpath, A AF Berlin, David Farmer, Brenna M. Rao, Rama B. Rella, Joseph Kunins, Hillary Dowell, Deborah Graber, Nathan Hoffman, Robert S. Karpati, Adam Weiss, Don Jones, Christopher Toprani, Amita Ridpath, Alison TI Deaths and Severe Adverse Events Associated with Anesthesia-Assisted Rapid Opioid Detoxification - New York City, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID MAINTENANCE; TRIAL C1 [Berlin, David; Farmer, Brenna M.; Rao, Rama B.; Rella, Joseph] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA. [Kunins, Hillary; Dowell, Deborah; Graber, Nathan; Hoffman, Robert S.; Karpati, Adam; Weiss, Don] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Jones, Christopher] Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA. [Toprani, Amita; Ridpath, Alison] CDC, Atlanta, GA 30333 USA. RP Toprani, A (reprint author), CDC, Atlanta, GA 30333 USA. EM vij2@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 27 PY 2013 VL 62 IS 38 BP 777 EP 780 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WS UT WOS:000326057300001 ER PT J AU Ball, SW Donahue, SMA Izrael, D Walker, DK DiSogra, C Martonik, R Greby, SM Srivastav, A Zhang, J Lu, PJ Williams, WW Lindley, MC Graitcer, SB Bridges, CB Singleton, JA de Perio, MA Laney, AS AF Ball, Sarah W. Donahue, Sara M. A. Izrael, David Walker, Deborah K. DiSogra, Charles Martonik, Rachel Greby, Stacie M. Srivastav, Anup Zhang, Jun Lu, Peng-jun Williams, Walter W. Lindley, Megan C. Graitcer, Samuel B. Bridges, Carolyn B. Singleton, James A. de Perio, Marie A. Laney, A. Scott TI Influenza Vaccination Coverage Among Health-Care Personnel - United States, 2012-13 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LONG-TERM-CARE; ELDERLY-PEOPLE; HOME STAFF; RESIDENTS; MORTALITY C1 [Ball, Sarah W.; Donahue, Sara M. A.; Izrael, David; Walker, Deborah K.] ABT Associates Inc, Cambridge, MA 02138 USA. [DiSogra, Charles; Martonik, Rachel] Abt SRBI, New York, NY USA. [Greby, Stacie M.; Srivastav, Anup; Zhang, Jun; Lu, Peng-jun; Williams, Walter W.; Lindley, Megan C.; Graitcer, Samuel B.; Bridges, Carolyn B.; Singleton, James A.] Natl Ctr Immunizat & Resp Dis, Immunizat Svcs Div, Atlanta, GA USA. [de Perio, Marie A.] CDC, Div Surveillance Hazard Evaluat & Field Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. [Laney, A. Scott] CDC, Div Resp Dis Studies, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. RP Greby, SM (reprint author), Natl Ctr Immunizat & Resp Dis, Immunizat Svcs Div, Atlanta, GA USA. EM sgreby@cdc.gov; asrivastav@cdc.gov NR 10 TC 23 Z9 23 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 27 PY 2013 VL 62 IS 38 BP 781 EP 786 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WS UT WOS:000326057300002 ER PT J AU Ball, S Donahue, S Izrael, D Walker, DK Martonik, R DiSogra, C Ding, H Greby, SM Kahn, K Lu, PJ Williams, WW Singleton, JA Kennedy, ED Bridges, CB Grohskopf, LA Jamieson, DJ Ahluwalia, I AF Ball, Sarah Donahue, Sara Izrael, David Walker, Deborah K. Martonik, Rachel DiSogra, Charles Ding, Helen Greby, Stacie M. Kahn, Katherine Lu, Peng-Jun Williams, Walter W. Singleton, James A. Kennedy, Erin D. Bridges, Carolyn B. Grohskopf, Lisa A. Jamieson, Denise J. Ahluwalia, Indu TI Influenza Vaccination Coverage Among Pregnant Women - United States, 2012-13 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ball, Sarah; Donahue, Sara; Izrael, David; Walker, Deborah K.] ABT Associates Inc, Cambridge, MA 02138 USA. [Martonik, Rachel; DiSogra, Charles] Abt SRBI, New York, NY USA. [Ding, Helen; Greby, Stacie M.; Kahn, Katherine; Lu, Peng-Jun; Williams, Walter W.; Singleton, James A.; Kennedy, Erin D.; Bridges, Carolyn B.] Natl Ctr Immunizat & Resp Dis, Immunizat Svcs Div, Atlanta, GA USA. [Grohskopf, Lisa A.] Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. [Jamieson, Denise J.; Ahluwalia, Indu] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Ding, H (reprint author), Natl Ctr Immunizat & Resp Dis, Immunizat Svcs Div, Atlanta, GA USA. EM hding@cdc.gov NR 10 TC 40 Z9 40 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 27 PY 2013 VL 62 IS 38 BP 787 EP 792 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WS UT WOS:000326057300003 ER PT J AU Langley, G AF Langley, Gayle TI Updated Information on the Epidemiology of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection and Guidance for the Public, Clinicians, and Public Health Authorities, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Langley, Gayle] Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Div Healthcare Qual Promot, Atlanta, GA USA. [Langley, Gayle] Ctr Global Hlth, Div Global Hlth Protect Proposed, Atlanta, GA USA. [Langley, Gayle] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Langley, G (reprint author), Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Div Healthcare Qual Promot, Atlanta, GA USA. EM glangley@cdc.gov NR 10 TC 12 Z9 13 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 27 PY 2013 VL 62 IS 38 BP 793 EP 796 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WS UT WOS:000326057300004 ER PT J AU Turner, K Hamilton, J Hall, CJ Pinner, RW Gallagher, K Conn, L AF Turner, Kathryn Hamilton, Janet Hall, C. Jason Pinner, Robert W. Gallagher, Kathy Conn, Laura TI Progress in Increasing Electronic Reporting of Laboratory Results to Public Health Agencies - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Hall, C. Jason] Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Pinner, Robert W.] Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Gallagher, Kathy] CDC, Div Hlth Informat & Surveillance, Ctr Surveillance Epidemiol & Lab, Atlanta, GA 30333 USA. [Conn, Laura] CDC, Off Publ Hlth Sci Svcs, Atlanta, GA 30333 USA. RP Hall, CJ (reprint author), Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. EM cjhall@cdc.gov NR 9 TC 3 Z9 3 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 27 PY 2013 VL 62 IS 38 BP 797 EP 799 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WS UT WOS:000326057300005 ER PT J AU Shore, DA Yang, H Balish, AL Shepard, SS Carney, PJ Chang, JC Davis, CT Donis, RO Villanueva, JM Klimov, AI Stevens, J AF Shore, David A. Yang, Hua Balish, Amanda L. Shepard, Samuel S. Carney, Paul J. Chang, Jessie C. Davis, Charles T. Donis, Ruben O. Villanueva, Julie M. Klimov, Alexander I. Stevens, James TI Structural and Antigenic Variation among Diverse Clade 2 H5N1 Viruses SO PLOS ONE LA English DT Article ID RECEPTOR-BINDING SPECIFICITY; MULTIPLE SEQUENCE ALIGNMENT; INFLUENZA-A VIRUSES; TO-PERSON TRANSMISSION; HUMAN AIRWAY; HEMAGGLUTININ; VACCINE; EVOLUTION; SELECTION; FERRETS AB Antigenic variation among circulating H5N1 highly pathogenic avian influenza A viruses mandates the continuous production of strain-specific pre-pandemic vaccine candidates and represents a significant challenge for pandemic preparedness. Here we assessed the structural, antigenic and receptor-binding properties of three H5N1 HPAI virus hemagglutinins, which were recently selected by the WHO as vaccine candidates [A/Egypt/N03072/2010 (Egypt10, clade 2.2.1), A/Hubei/1/2010 (Hubei10, clade 2.3.2.1) and A/Anhui/1/2005 (Anhui05, clade 2.3.4)]. These analyses revealed that antigenic diversity among these three isolates was restricted to changes in the size and charge of amino acid side chains at a handful of positions, spatially equivalent to the antigenic sites identified in H1 subtype viruses circulating among humans. All three of the H5N1 viruses analyzed in this study were responsible for fatal human infections, with the most recently-isolated strains, Hubei10 and Egypt10, containing multiple residues in the receptor-binding site of the HA, which were suspected to enhance mammalian transmission. However, glycan-binding analyses demonstrated a lack of binding to human alpha 2-6-linked sialic acid receptor analogs for all three HAs, reinforcing the notion that receptor-binding specificity contributes only partially to transmissibility and pathogenesis of HPAI viruses and suggesting that changes in host specificity must be interpreted in the context of the host and environmental factors, as well as the virus as a whole. Together, our data reveal structural linkages with phylogenetic and antigenic analyses of recently emerged H5N1 virus clades and should assist in interpreting the significance of future changes in antigenic and receptor-binding properties. C1 [Shore, David A.; Yang, Hua; Balish, Amanda L.; Shepard, Samuel S.; Carney, Paul J.; Chang, Jessie C.; Davis, Charles T.; Donis, Ruben O.; Villanueva, Julie M.; Klimov, Alexander I.; Stevens, James] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. RP Stevens, J (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. EM fwb4@cdc.gov FU Centers for Disease Control and Prevention; U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]; Centers for Disease Control by the Consortium for Functional Glycomics (CFG); National Institute of General Medical Sciences [GM62116] FX This work was funded by the Centers for Disease Control and Prevention. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. Use of the Advanced Photon Source at Argonne National Laboratory was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. Glycan microarrays were produced under contract for the Centers for Disease Control by the Consortium for Functional Glycomics (CFG) funded by National Institute of General Medical Sciences Grant GM62116. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 84 TC 9 Z9 9 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 27 PY 2013 VL 8 IS 9 AR UNSP e75209 DI 10.1371/journal.pone.0075209 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 228WY UT WOS:000325223900038 PM 24086467 ER PT J AU Belser, JA Gustin, KM Pearce, MB Maines, TR Zeng, H Pappas, C Sun, XJ Carney, PJ Villanueva, JM Stevens, J Katz, JM Tumpey, TM AF Belser, Jessica A. Gustin, Kortney M. Pearce, Melissa B. Maines, Taronna R. Zeng, Hui Pappas, Claudia Sun, Xiangjie Carney, Paul J. Villanueva, Julie M. Stevens, James Katz, Jacqueline M. Tumpey, Terrence M. TI Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice SO NATURE LA English DT Article ID H5N1 VIRUSES; INCREASED VIRULENCE; RECEPTOR-BINDING; HUMAN INFECTION; HEMAGGLUTININ; SPECIFICITY; INTERFERON; TROPISM; VACCINE; MODEL AB On 29 March 2013, the Chinese Center for Disease Control and Prevention confirmed the first reported case of human infection with an avian influenza A (H7N9) virus(1). The recent human infections with H7N9 virus, totalling over 130 cases with 39 fatalities to date, have been characterized by severe pulmonary disease and acute respiratory distress syndrome (ARDS)(2). This is concerning because H7 viruses have typically been associated with ocular disease in humans, rather than severe respiratory disease(3). This recent outbreak underscores the need to better understand the pathogenesis and transmission of these viruses in mammals. Here we assess the ability of A/Anhui/1/2013 and A/Shanghai/1/2013 (H7N9) viruses, isolated from fatal human cases, to cause disease in mice and ferrets and to transmit to naive animals. Both H7N9 viruses replicated to higher titre in human airway epithelial cells and in the respiratory tract of ferrets compared to a seasonal H3N2 virus. Moreover, the H7N9 viruses showed greater infectivity and lethality in mice compared to genetically related H7N9 and H9N2 viruses. The H7N9 viruses were readily transmitted to naive ferrets through direct contact but, unlike the seasonal H3N2 virus, did not transmit readily by respiratory droplets. The lack of efficient respiratory droplet transmission was corroborated by low receptor-binding specificity for human-like alpha 2,6-linked sialosides. Our results indicate that H7N9 viruses have the capacity for efficient replication in mammals and human airway cells and highlight the need for continued public health surveillance of this emerging virus. C1 [Belser, Jessica A.; Gustin, Kortney M.; Pearce, Melissa B.; Maines, Taronna R.; Zeng, Hui; Pappas, Claudia; Sun, Xiangjie; Carney, Paul J.; Villanueva, Julie M.; Stevens, James; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tft9@cdc.gov FU National Institute of General Medical Sciences [GM62116] FX We thank the China CDC as part of the WHO Global Influenza Surveillance and Response System (GISRS) for facilitating access to viruses and A. Balish for preparation of viruses. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agency. Glycan microarray slides were produced under contract for the CDC using a glycan library generously provided by the Consortium for Functional Glycomics, funded by National Institute of General Medical Sciences Grant GM62116. NR 28 TC 150 Z9 159 U1 6 U2 67 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD SEP 26 PY 2013 VL 501 IS 7468 BP 556 EP + DI 10.1038/nature12391 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 223RP UT WOS:000324826300060 PM 23842497 ER PT J AU Petrie, JG Ohmit, SE Cowling, BJ Johnson, E Cross, RT Malosh, RE Thompson, MG Monto, AS AF Petrie, Joshua G. Ohmit, Suzanne E. Cowling, Benjamin J. Johnson, Emileigh Cross, Rachel T. Malosh, Ryan E. Thompson, Mark G. Monto, Arnold S. TI Influenza Transmission in a Cohort of Households with Children: 2010-2011 SO PLOS ONE LA English DT Article ID PANDEMIC INFLUENZA; UNITED-STATES; A H1N1; VACCINE EFFECTIVENESS; VIRUS; ILLNESS; INFECTION; SEASON; CIRCULATION; PREVENTION AB Background: Households play a major role in community spread of influenza and are potential targets for mitigation strategies. Methods: We enrolled and followed 328 households with children during the 2010-2011 influenza season; this season was characterized by circulation of influenza A (H3N2), A (H1N1)pdm09 and type B viruses. Specimens were collected from subjects with acute respiratory illnesses and tested for influenza in real-time reverse transcriptase polymerase chain reaction (RT-PCR) assays. Influenza cases were classified as community-acquired or household-acquired, and transmission parameters estimated. Results: Influenza was introduced to 78 (24%) households and transmission to exposed household members was documented in 23 households. Transmission was more likely in younger households (mean age <22 years) and those not reporting home humidification, but was not associated with household vaccination coverage. The secondary infection risk (overall 9.7%) was highest among young children (<9 years) and varied substantially by influenza type/subtype with the highest risk for influenza A (H3N2). The serial interval (overall 3.2 days) also varied by influenza type and was longest for influenza B. Duration of symptomatic illness was shorter in children compared with adults, and did not differ by influenza vaccination status. Discussion: Prospective study of households with children over a single influenza season identified differences in household transmission by influenza type/subtype, subject age, and home humidification, suggesting possible targets for interventions to reduce transmission. C1 [Petrie, Joshua G.; Ohmit, Suzanne E.; Johnson, Emileigh; Cross, Rachel T.; Malosh, Ryan E.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Cowling, Benjamin J.] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China. [Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Ohmit, SE (reprint author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. EM sohmit@umich.edu RI Cowling, Benjamin/C-4263-2009 OI Cowling, Benjamin/0000-0002-6297-7154 FU Centers for Disease Control and Prevention; University of Michigan [U01 IP000170] FX This work was supported by the Centers for Disease Control and Prevention through a cooperative agreement with the University of Michigan (U01 IP000170). NR 31 TC 15 Z9 16 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 25 PY 2013 VL 8 IS 9 AR e75339 DI 10.1371/journal.pone.0075339 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 228VC UT WOS:000325218700078 PM 24086511 ER PT J AU Kobau, R Bann, C Lewis, M Zack, MM Boardman, AM Boyd, R Lim, KC Holder, T Hoff, AKL Luncheon, C Thompson, W Horner-Johnson, W Lucas, RE AF Kobau, Rosemarie Bann, Carla Lewis, Megan Zack, Matthew M. Boardman, Angela M. Boyd, Renee Lim, Kim C. Holder, Tommy Hoff, Anastacia K. L. Luncheon, Cecily Thompson, William Horner-Johnson, Willi Lucas, Richard E. TI Mental, social, and physical well-being in New Hampshire, Oregon, and Washington, 2010 Behavioral Risk Factor Surveillance System: implications for public health research and practice related to Healthy People 2020 foundation health measures on well-being SO POPULATION HEALTH METRICS LA English DT Article ID CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; POSITIVE EMOTIONS; UNITED-STATES; SATISFACTION; HAPPINESS; SUPPORT; PROMOTION; BENEFITS; ADULTS AB Background: Well-being is now accepted as one of four cross-cutting measures in gauging progress for Healthy People 2020. This shift to population indicators of well-being redresses notions of health that have focused on absence of illness (negative health) as a primary or sufficient indicator of positive functioning. The purpose of this study was to estimate mental, social, and physical well-being in three US states using new measures piloted on the 2010 Behavioral Risk Factor Surveillance Survey System (BRFSS). Baseline estimates were provided for states overall, and within states for demographic subgroups, those with chronic health conditions or disabilities, and those with behavioral risk factors. Methods: Ten validated questions designed to assess mental (e. g., satisfaction with life, satisfaction with life domains, happiness), physical (e. g., satisfaction with energy level), and social dimensions (e. g., frequency of social support) of well-being were selected with state input for inclusion on BRFSS. 18,622 individuals responded to the BRFSS surveys administered by New Hampshire (N = 3,139), Oregon (N = 2,289), and Washington (N = 13,194). Multivariate adjusted proportions of positive responses to well-being items were examined. Results: After adjustment for confounders, about 67% of adults in these states had high levels of well-being, including > 80% reporting experiencing happiness. Most adults were satisfied with their work, neighborhood, and education, but significant differences were seen in subgroups. Well-being differed by demographic characteristics such as marital status, health behaviors, chronic conditions, and disability status, with those who reported a disability and smokers consistently experiencing the worst well-being. Conclusions: Well-being is accepted as one of four cross-cutting measures in gauging progress for Healthy People 2020. Well-being differs by important sociodemographic factors and health conditions (e. g., age, employment, smoking, disability status). These findings provide baseline estimates for the three states to use in gauging improvements in wellbeing and can serve as a model for other state-level or national surveillance systems. These findings also assist states in identifying vulnerable subgroups who may benefit from potential interventions such as those in the National Prevention Strategy that focus on enhancing well-being where such disparities exist. C1 [Kobau, Rosemarie; Zack, Matthew M.; Luncheon, Cecily; Thompson, William] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Bann, Carla; Lewis, Megan; Holder, Tommy] RTI Int, Res Triangle Pk, NC 27709 USA. [Boardman, Angela M.; Hoff, Anastacia K. L.] Washington State Dept Hlth, Data Qual & Stat Serv DQSS Ctr Hlth Stat, Olympia, WA 98504 USA. [Boyd, Renee] Oregon Hlth Author, Off Dis Prevent & Epidemiol, Ctr Hlth Stat, Survey Unit, Portland, OR 97232 USA. [Lim, Kim C.] Bur Publ Hlth Stat & Informat, New Hampshire Div Publ Hlth Serv, Concord, NH 03301 USA. [Horner-Johnson, Willi] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Portland, OR 97239 USA. [Lucas, Richard E.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. RP Kobau, R (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS K78, Atlanta, GA 30341 USA. EM rkobau@cdc.gov NR 64 TC 4 Z9 5 U1 2 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-7954 J9 POPUL HEALTH METR JI Popul. Health Metr. PD SEP 24 PY 2013 VL 11 AR 19 DI 10.1186/1478-7954-11-19 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245PS UT WOS:000326476500001 PM 24063647 ER PT J AU Haynes, CA Guerra, SL Fontana, JC DeJesus, VR AF Haynes, Christopher A. Guerra, Stephanie L. Fontana, Jessalyn C. DeJesus, Victor R. TI HPLC-ESI-MS/MS analysis of hemoglobin peptides in tryptic digests of dried-blood spot extracts detects HbS, HbC, HbD, HbE, HbO-Arab, and HbG-Philadelphia mutations SO CLINICA CHIMICA ACTA LA English DT Article DE Dried-blood spot; Hemoglobinopathies; HPLC-ESI-MS/MS ID SICKLE-CELL-DISEASE; TANDEM MASS-SPECTROMETRY; LIQUID-CHROMATOGRAPHY; ALPHA-THALASSEMIA; LC-MS/MS; VARIANTS; IDENTIFICATION; MORTALITY AB Background: Hemoglobinopathies are mutations resulting in abnormal globin chain structure; some have clinically significant outcomes such as anemia or reduced lifespan. Five beta-globin mutations are (c.20A>T, p.E6V), (c.19G>A, p. E6K), (c.79G>A, p.E26K), (c.364G>C, p.E121Q), and (c.364G>A, p.E121K), resulting in HbS (sickle-cell hemoglobin), HbC, HbE, HbD-Los Angeles, and HbO-Arab, respectively. One alpha-globin mutation is (c.[207C>G or 207C>A], p.N68K), resulting in HbG-Philadelphia. Methods: HPLC-ESI-MS/MS analysis of dried-blood spot (DBS) punches from newborns extracted with a trypsin-containing solution provides greater than 90% coverage of alpha-, beta-, and gamma-globin amino acid sequences. Because the (c.20A>T, p.E6V), (c.19G>A, p. E6K), (c.79G>A, p.E26K), (c.364G>C, p.E121Q), (c.364G>A, p.E121K), and (c.[207C>G or 207C>A], p.N68K) mutations generate globin peptides with novel amino acid sequences, detecting one of these peptides in DBS extracts is indicative of the presence of a hemoglobinopathy in the newborn. Results: The method described here can distinguish normal beta-globin peptides from the mutant HbS, HbC, HbE, HbD-Los Angeles and HbO-Arab peptides, as well as normal alpha-globin peptide from the mutant HbG-Philadelphia peptide, allowing the identification of unaffected heterozygotes such as HbAS, and of compound heterozygotes such as HbASG-Philadelphia. Conclusions: This HPLC-ESI-MS/MS analytical approach provides information that is not available from traditional hemoglobin analyses such as isoelectric focusing and HPLC-UV. It is also capable of determining the amino acid sequence of hemoglobin peptides, potentially allowing the detection of numerous hemoglobinopathies resulting from point mutations. Published by Elsevier B.V. C1 [Haynes, Christopher A.; DeJesus, Victor R.] Ctr Dis Control & Prevent, Biochem Mass Spectrometry Lab, Atlanta, GA 30341 USA. [Guerra, Stephanie L.] Harvard Univ, Div Med Sci, Cambridge, MA 02138 USA. [Fontana, Jessalyn C.] Univ Illinois, Springfield, IL 62703 USA. RP Haynes, CA (reprint author), Ctr Dis Control & Prevent, Biochem Mass Spectrometry Lab, 4770 Buford Hwy NE,Mail Stop F-19, Atlanta, GA 30341 USA. EM cph7@cdc.gov NR 39 TC 11 Z9 12 U1 1 U2 24 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD SEP 23 PY 2013 VL 424 BP 191 EP 200 DI 10.1016/j.cca.2013.06.007 PG 10 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 226NH UT WOS:000325042600037 PM 23796846 ER PT J AU Juliao, PC Sosa, S Gonzalez, LD Padilla, N Ortiz, L Goldman, I Udhayakumar, V Lindblade, KA AF Juliao, Patricia C. Sosa, Silvia Gonzalez, Luis D. Padilla, Norma Ortiz, Lucia Goldman, Ira Udhayakumar, Venkatachalam Lindblade, Kim A. TI Importation of chloroquine-resistant Plasmodium falciparum by Guatemalan peacekeepers returning from the Democratic Republic of the Congo SO MALARIA JOURNAL LA English DT Article DE Malaria; Malaria elimination; Chloroquine resistance; Imported malaria; Guatemala; Military; Central America; Latin America; Democratic Republic of the Congo ID POLYMERASE-CHAIN-REACTION; ANOPHELES-ALBIMANUS; MALARIA PARASITES; IMPORTED MALARIA; DRUG-RESISTANCE; CENTRAL-AMERICA; PFCRT; MUTATIONS; SURVEILLANCE; VIVAX AB Background: Malaria elimination is being pursued in five of seven Central American countries. Military personnel returning from peacekeeping missions in sub-Saharan Africa could import chloroquine-resistant Plasmodium falciparum, posing a threat to elimination and to the continued efficacy of first-line chloroquine (CQ) treatment in these countries. This report describes the importation of P. falciparum from among 150 Guatemalan army special forces and support staff who spent ten months on a United Nations' peacekeeping mission in the Democratic Republic of the Congo (DRC) in 2010. Methods: Investigators reviewed patients' medical charts and interviewed members of the contingent to identify malaria cases and risk factors for malaria acquisition. Clinical specimens were tested for malaria; isolated parasites were characterized molecularly for CQ resistance. Results: Investigators identified 12 cases (8%) of laboratory-confirmed P. falciparum infection within the contingent; one case was from a soldier infected with a CQ-resistant pfcrt genotype resulting in his death. None of the contingent used an insecticide-treated bed net (ITN) or completely adhered to malaria chemoprophylaxis while in the DRC. Conclusion: This report highlights the need to promote use of malaria prevention measures, in particular ITNs and chemoprophylaxis, among peacekeepers stationed in malaria-endemic areas. Countries attempting to eliminate malaria should consider appropriate methods to screen peacekeepers returning from endemic areas for malaria infections. Cases of malaria in travellers, immigrants and soldiers returning to Central America from countries with CQ-resistant malaria should be assumed to be carry resistant parasites and receive appropriate anti-malarial therapy to prevent severe disease and death. C1 [Juliao, Patricia C.; Lindblade, Kim A.] US Ctr Dis Control & Prevent, Int Emerging Infect Program, Reg Off Cent Amer & Panama, Guatemala City 01015, Guatemala. [Sosa, Silvia; Padilla, Norma; Ortiz, Lucia] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City 01015, Guatemala. [Gonzalez, Luis D.] Mil Med Ctr Guatemala, Guatemala City, Guatemala. [Goldman, Ira; Udhayakumar, Venkatachalam; Lindblade, Kim A.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30030 USA. RP Juliao, PC (reprint author), US Ctr Dis Control & Prevent, Int Emerging Infect Program, Reg Off Cent Amer & Panama, 18 Ave 11-95 Zona 15,Vista Hermosa 3, Guatemala City 01015, Guatemala. EM pcjuliao@gmail.com FU US Centers for Disease Control and Prevention [UO1 GH000028-02] FX We would like to thank the Military Health Services from the Guatemalan Army (Fabiola Enriquez, Mario Roberto Perez Franco, and Harold Garcia), the Guatemala Military Medical Center (Sergio Fernando Nitsch Montiel and Mario Luis Ovalle Figuero), the Vectors Program of the Ministry of Public Health and Social Welfare of Guatemala (I Gongora and A Sanchez), the National Center of Epidemiology of Guatemala (A Miranda), and the National Health Laboratory of Guatemala (S Diaz). Control of this outbreak would not have been possible without the investigative team from the Center for Health Studies, Universidad del Valle de Guatemala (G Abdala, A Estevez, J Garcia, S Hernandez, G Lopez, M Lopez, A Paniagua, O Paniagua, J Paniagua, L Pilona, B Molina, E Molina, A Morales, D Mozon, F Munoz, M Castellanos, G Rivera). S Patrick Kachur and Laurence Slutsker from the CDC Malaria Branch provided important advice on treatment and the investigation. We thank A Primeau for her editorial help with this manuscript. We are especially grateful to the patients, family members and the health care professionals involved in their care. This work was supported in part by Cooperative Agreement Number UO1 GH000028-02 from the US Centers for Disease Control and Prevention. NR 29 TC 8 Z9 8 U1 2 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD SEP 23 PY 2013 VL 12 AR 344 DI 10.1186/1475-2875-12-344 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 227JP UT WOS:000325109200001 PM 24060234 ER PT J AU Baroudi, D Khelef, D Goucem, R Adjou, KT Adamu, H Zhang, HW Xiao, LH AF Baroudi, Djamel Khelef, Djamel Goucem, Rachid Adjou, Karim T. Adamu, Haileeyesus Zhang, Hongwei Xiao, Lihua TI Common occurrence of zoonotic pathogen Cryptosporidium meleagridis in broiler chickens and turkeys in Algeria SO VETERINARY PARASITOLOGY LA English DT Article DE Cryptosporidium; Cryptosporidiosis; Diagnosis; C meleagridis; GP60; Chickens; Turkeys; Genotyping; Algeria ID SMALL-INTESTINAL CRYPTOSPORIDIOSIS; PUBLIC-HEALTH SIGNIFICANCE; MOLECULAR CHARACTERIZATION; PHYLOGENETIC ANALYSIS; GALLINACEOUS BIRDS; DOMESTIC-ANIMALS; SPP.; GENOTYPE; FARM; APICOMPLEXA AB Only a small number of birds have been identified by molecular techniques as having Cryptosporidium meleagridis, the third most important species for human cryptosporidiosis. In this study, using PCR-RFLP analysis of the small subunit (SSU) rRNA gene, we examined the ileum of 90 dead chickens from 23 farms and 57 dead turkeys from 16 farms in Algeria for Cryptosporidium spp. C meleagridis-positive specimens were subtyped by sequence analysis of the 60 kDa glycoprotein gene. Cryptosporidium infection rates were 34% and 44% in chickens and turkeys, respectively, with all positive turkeys (25) and most positive chickens (26/31) having C meleagridis. All C meleagridis specimens belonged to a new subtype family. The frequent occurrence of C meleagridis in chickens and turkeys illustrates the potential for zoonotic transmission of cryptosporidiosis in Algeria. Published by Elsevier B.V. C1 [Baroudi, Djamel; Khelef, Djamel; Goucem, Rachid] Ecole Natl Super Vet, Algiers, Algeria. [Adjou, Karim T.] ANSES ENVA, UMR BIPAR, Paris, France. [Adamu, Haileeyesus; Zhang, Hongwei; Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Zhang, Hongwei] Henan Ctr Dis Prevent & Control, Inst Parasite Dis Prevent & Control, Zhengzhou, Peoples R China. RP Xiao, LH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Mail Stop D66,1600 Clifton Rd, Atlanta, GA 30329 USA. EM lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; OI Xiao, Lihua/0000-0001-8532-2727; Adamu, Haileeyesus/0000-0003-2998-5977 FU High National Veterinary School (ENSV), Algiers, Algeria; Centers for Disease Control and Prevention (CDC), Atlanta GA, USA FX This work was conducted with support from the High National Veterinary School (ENSV), Algiers, Algeria, and the Centers for Disease Control and Prevention (CDC), Atlanta GA, USA. NR 49 TC 12 Z9 14 U1 1 U2 24 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 J9 VET PARASITOL JI Vet. Parasitol. PD SEP 23 PY 2013 VL 196 IS 3-4 BP 334 EP 340 DI 10.1016/j.vetpar.2013.02.022 PG 7 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA 210WC UT WOS:000323864500014 PM 23498647 ER PT J AU Harris, N Johnson, C Sionean, C Ivy, W Singh, S Wei, S Mizuno, N Lansky, A AF Harris, Norma Johnson, Christopher Sionean, Catlainn Ivy, Wade Singh, Sonia Wei, Stanley Mizuno, Niko Lansky, Amy TI Estimated Percentages and Characteristics of Men Who Have Sex with Men and Use Injection Drugs - United States, 1999-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PREEXPOSURE PROPHYLAXIS; INTERIM GUIDANCE; PREVENTION C1 [Harris, Norma; Johnson, Christopher; Sionean, Catlainn; Ivy, Wade; Singh, Sonia; Wei, Stanley; Mizuno, Niko; Lansky, Amy] CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Harris, N (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. EM nharris@cdc.gov NR 10 TC 5 Z9 5 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 20 PY 2013 VL 62 IS 37 BP 757 EP 762 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WR UT WOS:000326057200002 ER PT J AU Bright, MA Davis, K Babb, S Bunnelh, R Rodes, R Alexander, R Coln, C Zhang, L Beistk, D Mitchko, J McAfee, T AF Bright, Mary Anne Davis, Kevin Babb, Stephen Bunnelh, Rebecca Rodes, Robert Alexander, Robert Coln, Caryn Zhang, Lei Beistk, Diane Mitchko, Jane McAfee, Timothy TI Impact of a National Tobacco Education Campaign on Weekly Numbers of Quitline Calls and Website Visitors - United States, March 4-June 23, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID SMOKING-CESSATION C1 [Bright, Mary Anne] NCI, Bethesda, MD 20892 USA. [Davis, Kevin] RTI Int, Res Triangle Pk, NC USA. [Babb, Stephen; Bunnelh, Rebecca; Rodes, Robert; Alexander, Robert; Coln, Caryn; Zhang, Lei; Beistk, Diane; Mitchko, Jane; McAfee, Timothy] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Babb, S (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM sbabb@cdc.gov NR 9 TC 11 Z9 11 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 20 PY 2013 VL 62 IS 37 BP 763 EP 767 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WR UT WOS:000326057200003 ER PT J AU Andre, M AF Andre, McKenzie TI Assessing the Risks for Poliovirus Outbreaks in Polio-Free Countries - Africa, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ERADICATION; POLIOMYELITIS; PROGRESS C1 CDC, WHO, Reg Off Africa, Global Immunizat Div,Ctr Global Hlth, Atlanta, GA 30333 USA. RP Andre, M (reprint author), CDC, WHO, Reg Off Africa, Global Immunizat Div,Ctr Global Hlth, Atlanta, GA 30333 USA. EM aandre@cdc.gov NR 10 TC 6 Z9 7 U1 1 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 20 PY 2013 VL 62 IS 37 BP 768 EP 772 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WR UT WOS:000326057200004 ER PT J AU Grohskopf, LA Shay, DK Shimabukuro, TT Sokolow, LZ Keitel, WA Bresee, JS Cox, NJ AF Grohskopf, Lisa A. Shay, David K. Shimabukuro, Tom T. Sokolow, Leslie Z. Keitel, Wendy A. Bresee, Joseph S. Cox, Nancy J. TI Prevention and Control of Seasonal Influenza with Vaccines Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014 SO MMWR RECOMMENDATIONS AND REPORTS LA English DT Article ID GUILLAIN-BARRE-SYNDROME; HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS; RANDOMIZED CONTROLLED-TRIAL; A H1N1 2009; LABORATORY-CONFIRMED INFLUENZA; THIMEROSAL-CONTAINING VACCINES; LIVER-TRANSPLANT RECIPIENTS; SAFETY DATALINK PROJECT AB This report updates the 2012 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccines for the prevention and control of seasonal influenza (CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2012; 61:613-8). Routine annual influenza vaccination is recommended for all persons aged >= 6 months. For the 2013-14 influenza season, it is expected that trivalent live attenuated influenza vaccine (LAIV3) will be replaced by a quadrivalent LAIV formulation (LAIV4). Inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Vaccine virus strains included in the 2013-14 U. S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)-like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and a B/Massachusetts/2/2012-like virus. Quadrivalent vaccines will include an additional influenza B virus strain, a B/Brisbane/60/2008-like virus, intended to ensure that both influenza B virus antigenic lineages (Victoria and Yamagata) are included in the vaccine. This report describes recently approved vaccines, including LAIV4, IIV4, trivalent cell culture-based inactivated influenza vaccine (ccIIV3), and trivalent recombinant influenza vaccine (RIV3). No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one product is otherwise appropriate. This information is intended for vaccination providers, immunization program personnel, and public health personnel. These recommendations and other information are available at CDC's influenza website (http://www.cdc.gov/flu); any updates also will be found at this website. Vaccination and health-care providers should check the CDC influenza website periodically for additional information. C1 [Grohskopf, Lisa A.; Shay, David K.; Sokolow, Leslie Z.; Bresee, Joseph S.; Cox, Nancy J.] CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Shimabukuro, Tom T.] CDC, Natl Ctr Emerging & Zoonot Dis, Immunizat Safety Off, Atlanta, GA 30333 USA. [Sokolow, Leslie Z.] Battelle Mem Inst, Atlanta, GA USA. [Keitel, Wendy A.] Baylor Coll Med, Houston, TX 77030 USA. RP Grohskopf, LA (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. EM lgrohskopf@cdc.gov NR 374 TC 57 Z9 58 U1 3 U2 8 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 1057-5987 EI 1545-8601 J9 MMWR RECOMM REP JI MMWR Recomm. Rep. PD SEP 20 PY 2013 VL 62 IS 7 BP 1 EP 43 PG 43 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 234IQ UT WOS:000325636900001 ER PT J AU Xu, ST Zhang, Y Zhu, Z Liu, CY Mao, NY Ji, YX Wang, HL Jiang, XH Li, CS Tang, W Feng, DX Wang, CY Zheng, L Lei, Y Ling, H Zhao, CF Ma, Y He, JL Wang, Y Li, P Guan, RH Zhou, SJ Zhou, JH Wang, S Zhang, H Zheng, HY Liu, L Ma, HMT Guan, J Lu, PS Feng, Y Zhang, YJ Zhou, SD Xiong, Y Ba, ZM Chen, H Yang, XH Bo, F Ma, YJ Liang, Y Lei, YK Gu, SY Liu, W Chen, M Featherstone, D Jee, Y Bellini, WJ Rota, PA Xu, W AF Xu, Songtao Zhang, Yan Zhu, Zhen Liu, Chunyu Mao, Naiying Ji, Yixin Wang, Huiling Jiang, Xiaohong Li, Chongshan Tang, Wei Feng, Daxing Wang, Changyin Zheng, Lei Lei, Yue Ling, Hua Zhao, Chunfang Ma, Yan He, Jilan Wang, Yan Li, Ping Guan, Ronghui Zhou, Shujie Zhou, Jianhui Wang, Shuang Zhang, Hong Zheng, Huanying Liu, Leng Ma, Hemuti Guan, Jing Lu, Peishan Feng, Yan Zhang, Yanjun Zhou, Shunde Xiong, Ying Ba, Zhuoma Chen, Hui Yang, Xiuhui Bo, Fang Ma, Yujie Liang, Yong Lei, Yake Gu, Suyi Liu, Wei Chen, Meng Featherstone, David Jee, Youngmee Bellini, William J. Rota, Paul A. Xu, Wenbo TI Genetic Characterization of the Hemagglutinin Genes of Wild-Type Measles Virus Circulating in China, 1993-2009 SO PLOS ONE LA English DT Article ID REPUBLIC-OF-CHINA; B-CELL RESPONSE; MOLECULAR EPIDEMIOLOGY; MONOCLONAL-ANTIBODIES; PROTEIN; RECEPTOR; IDENTIFICATION; ANTIGENICITY; EVOLUTION; GENOTYPES AB Background: China experienced several large measles outbreaks in the past two decades, and a series of enhanced control measures were implemented to achieve the goal of measles elimination. Molecular epidemiologic surveillance of wild-type measles viruses (MeV) provides valuable information about the viral transmission patterns. Since 1993, virologic surveillnace has confirmed that a single endemic genotype H1 viruses have been predominantly circulating in China. A component of molecular surveillance is to monitor the genetic characteristics of the hemagglutinin (H) gene of MeV, the major target for virus neutralizing antibodies. Principal Findings: Analysis of the sequences of the complete H gene from 56 representative wild-type MeV strains circulating in China during 1993-2009 showed that the H gene sequences were clustered into 2 groups, cluster 1 and cluster 2. Cluster1 strains were the most frequently detected cluster and had a widespread distribution in China after 2000. The predicted amino acid sequences of the H protein were relatively conserved at most of the functionally significant amino acid positions. However, most of the genotype H1 cluster1 viruses had an amino acid substitution (Ser240Asn), which removed a predicted N-linked glycosylation site. In addition, the substitution of Pro397Leu in the hemagglutinin noose epitope (HNE) was identified in 23 of 56 strains. The evolutionary rate of the H gene of the genotype H1 viruses was estimated to be approximately 0.76x10(-3) substitutions per site per year, and the ratio of dN to dS (dN/dS) was <1 indicating the absence of selective pressure. Conclusions: Although H genes of the genotype H1 strains were conserved and not subjected to selective pressure, several amino acid substitutions were observed in functionally important positions. Therefore the antigenic and genetic properties of H genes of wild-type MeVs should be monitored as part of routine molecular surveillance for measles in China. C1 [Xu, Songtao; Zhang, Yan; Zhu, Zhen; Mao, Naiying; Ji, Yixin; Wang, Huiling; Jiang, Xiaohong; Xu, Wenbo] China Ctr Dis Control & Prevent, Reg Reference Measles Lab WHO Western Pacific Reg, Key Lab Med Virol, Minist Hlth,Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China. [Liu, Chunyu; Bellini, William J.; Rota, Paul A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Li, Chongshan; Tang, Wei] Shanghai Ctr Dis Control & Prevent, Shanghai, Peoples R China. [Feng, Daxing] Henan Ctr Dis Control & Prevent, Zhengzhou, Henan Province, Peoples R China. [Wang, Changyin] Shandong Ctr Dis Control & Prevent, Jinan, Shandong, Peoples R China. [Zheng, Lei] Shanxi Ctr Dis Control & Prevent, Taiyuan, Shanxi Province, Peoples R China. [Lei, Yue] Tianjin Ctr Dis Control & Prevent, Tianjin, Peoples R China. [Ling, Hua; Zhao, Chunfang] Chongqing Ctr Dis Control & Prevent, Chongqing, Peoples R China. [Ma, Yan] Hainan Ctr Dis Control & Prevent, Haikou, Hainan Province, Peoples R China. [He, Jilan] Sichuan Ctr Dis Control & Prevent, Chengdu, Sichuan Provinc, Peoples R China. [Wang, Yan] Liaoning Ctr Dis Control & Prevent, Shenyang, Liaoning Provin, Peoples R China. [Li, Ping; Guan, Ronghui] Shaanxi Ctr Dis Control & Prevent, Xian, Shannxi Provinc, Peoples R China. [Zhou, Shujie] Anhui Ctr Dis Control & Prevent, Hefei, Anhui, Peoples R China. [Zhou, Jianhui; Wang, Shuang] Jilin Ctr Dis Control & Prevent, Changchun, Jilin Province, Peoples R China. [Zhang, Hong] Hunan Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China. [Zheng, Huanying; Liu, Leng] Guangdong Ctr Dis Control & Prevent, Guangzhou, Guangzhou Provi, Peoples R China. [Ma, Hemuti; Guan, Jing] Xinjiang Ctr Dis Control & Prevent, Urumchi City, Xinjiang Provin, Peoples R China. [Lu, Peishan] Jiangsu Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China. [Feng, Yan; Zhang, Yanjun] Zhejiang Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China. [Zhou, Shunde; Xiong, Ying] Jiangxi Ctr Dis Control & Prevent, Nanchang City, Jiangxi, Peoples R China. [Ba, Zhuoma] Qinghai Ctr Dis Control & Prevent, Xining, Qinghai Provinc, Peoples R China. [Chen, Hui] Ningxia Ctr Dis Control & Prevent, Yinchuan City, Ningxia Provinc, Peoples R China. [Yang, Xiuhui] Fujian Ctr Dis Control & Prevent, Fuzhou, Fujian Province, Peoples R China. [Bo, Fang; Ma, Yujie] Heilongjiang Ctr Dis Control & Prevent, Harbin, Heilongjiang Pr, Peoples R China. [Liang, Yong] Hebei Ctr Dis Control & Prevent, Shijiazhuang, Hebei Province, Peoples R China. [Lei, Yake] Hubei Ctr Dis Control & Prevent, Wuhan, Hunan, Peoples R China. [Gu, Suyi] Inner Mongolia Ctr Dis Control & Prevent, Hohhot City, Inner Mongolia, Peoples R China. [Liu, Wei] Guangxi Ctr Dis Control & Prevent, Nanning, Guangxi Provinc, Peoples R China. [Chen, Meng] Beijing Ctr Dis Control & Prevent, Beijing, Peoples R China. [Featherstone, David] WHO, CH-1211 Geneva, Switzerland. [Jee, Youngmee] WHO, Western Pacific Reg Off, Manila, Philippines. RP Xu, W (reprint author), China Ctr Dis Control & Prevent, Reg Reference Measles Lab WHO Western Pacific Reg, Key Lab Med Virol, Minist Hlth,Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China. EM wenbo_xu1@yahoo.com.cn FU Key Technologies R&D Program of National Ministry of Science [2013ZX10004-202, 2012ZX10004215, 2013ZX10004-101, 2012ZX10004401, 2012ZX10004201-003]; WHO Measles Regional Reference Laboratory; WHO [WP CHN AAA 011 XZ 08] FX This work is supported by the Key Technologies R&D Program of National Ministry of Science (2013ZX10004-202, 2012ZX10004215, 2013ZX10004-101, 2012ZX10004401, 2012ZX10004201-003), WHO Measles Regional Reference Laboratory funding and WHO funding (number WP CHN AAA 011 XZ 08). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 39 TC 8 Z9 11 U1 2 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 20 PY 2013 VL 8 IS 9 AR e73374 DI 10.1371/journal.pone.0073374 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 222YC UT WOS:000324768000003 PM 24073194 ER PT J AU Hicks, LA Taylor, TH Hunkler, RJ AF Hicks, Lauri A. Taylor, Thomas H., Jr. Hunkler, Robert J. TI More on US Outpatient Antibiotic Prescribing, 2010 REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID UNITED-STATES C1 [Hicks, Lauri A.; Taylor, Thomas H., Jr.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hunkler, Robert J.] IMS Hlth, Plymouth Meeting, PA USA. RP Hicks, LA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM lhicks@cdc.gov NR 4 TC 4 Z9 5 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 19 PY 2013 VL 369 IS 12 BP 1175 EP 1176 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 220BD UT WOS:000324554800029 PM 24047077 ER PT J AU Person, B Schilling, K Owuor, M Ogange, L Quick, R AF Person, Bobbie Schilling, Katharine Owuor, Mercy Ogange, Lorraine Quick, Rob TI A Qualitative Evaluation of Hand Drying Practices among Kenyans SO PLOS ONE LA English DT Article ID SYSTEMATIC ANALYSIS; HYGIENE; DISEASE; RISK AB Background: Recommended disease prevention behaviors of hand washing, hygienic hand drying, and covering one's mouth and nose in a hygienic manner when coughing and sneezing appear to be simple behaviors but continue to be a challenge to successfully promote and sustain worldwide. We conducted a qualitative inquiry to better understand current hand drying behaviors associated with activities of daily living, and mouth and nose covering practices, among Kenyans. Methods and Findings: We conducted 7 focus group discussions; 30 in-depth interviews; 10 structured household observations; and 75 structured observations in public venues in the urban area of Kisumu; rural communities surrounding Kisumu; and a peri-urban area outside Nairobi, Kenya. Using a grounded theory approach, we transcribed and coded the narrative data followed by thematic analysis of the emergent themes. Hand drying, specifically on a clean towel, was not a common practice among our participants. Most women dried their hands on their waist cloth, called a leso, or their clothes whether they were cooking, eating or cleaning the nose of a young child. If men dried their hands, they used their trousers or a handkerchief. Children rarely dried their hands; they usually just wiped them on their clothes, shook them, or left them wet as they continued with their activities. Many people sneezed into their hands and wiped them on their clothes. Men and women used a handkerchief fairly often when they had a runny nose, cold, or the flu. Most people coughed into the air or their hand. Conclusions: Drying hands on dirty clothes, rags and lesos can compromise the benefits of handwashing. Coughing and sneezing in to an open hand can contribute to spread of disease as well. Understanding these practices can inform health promotion activities and campaigns for the prevention and control of diarrheal disease and influenza. C1 [Person, Bobbie] Ctr Dis Control & Prevent, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Schilling, Katharine; Quick, Rob] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Owuor, Mercy; Ogange, Lorraine] Kenya Govt Med Res Ctr, Kisumu, Kenya. RP Person, B (reprint author), Ctr Dis Control & Prevent, Off Director, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. EM bperson@cdc.gov FU Vestergaard Frandsen SA FX This qualitative inquiry was funded by Vestergaard Frandsen SA(http://www.vestergaard-frandsen.com/) as part of a larger hand hygiene investigation but they had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 3 Z9 3 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 19 PY 2013 VL 8 IS 9 AR UNSP e74370 DI 10.1371/journal.pone.0074370 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 223BC UT WOS:000324777300033 PM 24069302 ER PT J AU Gregg, EW Boyle, JP Thompson, TJ Barker, LE Albright, AL Williamson, DF AF Gregg, Edward W. Boyle, James P. Thompson, Theodore J. Barker, Lawrence E. Albright, Ann L. Williamson, David F. TI Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030 SO POPULATION HEALTH METRICS LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTIONS; CORONARY-HEART-DISEASE; PUBLIC-HEALTH; CARDIOVASCULAR-DISEASE; RISK-FACTORS; US; MORTALITY; MELLITUS; POPULATION AB Background: Although diabetes is one of the most costly and rapidly increasing serious chronic diseases worldwide, the optimal mix of strategies to reduce diabetes prevalence has not been determined. Methods: Using a dynamic model that incorporates national data on diabetes prevalence and incidence, migration, mortality rates, and intervention effectiveness, we project the effect of five hypothetical prevention policies on future US diabetes rates through 2030: 1) no diabetes prevention strategy; 2) a "high-risk" strategy, wherein adults with both impaired fasting glucose (IFG) (fasting plasma glucose of 100-124 mg/dl) and impaired glucose tolerance (IGT) (2-hour post-load glucose of 141-199 mg/dl) receive structured lifestyle intervention; 3) a "moderate-risk" strategy, wherein only adults with IFG are offered structured lifestyle intervention; 4) a "population-wide" strategy, in which the entire population is exposed to broad risk reduction policies; and 5) a "combined" strategy, involving both the moderate-risk and population-wide strategies. We assumed that the moderate- and high-risk strategies reduce the annual diabetes incidence rate in the targeted subpopulations by 12.5% through 2030 and that the population-wide approach would reduce the projected annual diabetes incidence rate by 2% in the entire US population. Results: We project that by the year 2030, the combined strategy would prevent 4.6 million incident cases and 3.6 million prevalent cases, attenuating the increase in diabetes prevalence by 14%. The moderate-risk approach is projected to prevent 4.0 million incident cases, 3.1 million prevalent cases, attenuating the increase in prevalence by 12%. The high-risk and population approaches attenuate the projected prevalence increases by 5% and 3%, respectively. Even if the most effective strategy is implemented (the combined strategy), our projections indicate that the diabetes prevalence rate would increase by about 65% over the 23 years (i.e., from 12.9% in 2010 to 21.3% in 2030). Conclusions: While implementation of appropriate diabetes prevention strategies may slow the rate of increase of the prevalence of diabetes among US adults through 2030, the US diabetes prevalence rate is likely to increase dramatically over the next 20 years. Demand for health care services for people with diabetes complications and diabetes-related disability will continue to grow, and these services will need to be strengthened along with primary diabetes prevention efforts. C1 [Gregg, Edward W.; Boyle, James P.; Thompson, Theodore J.; Barker, Lawrence E.; Albright, Ann L.; Williamson, David F.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM edg7@cdc.gov NR 51 TC 12 Z9 12 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-7954 J9 POPUL HEALTH METR JI Popul. Health Metr. PD SEP 18 PY 2013 VL 11 AR 18 DI 10.1186/1478-7954-11-18 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 245PQ UT WOS:000326476300001 PM 24047329 ER PT J AU Lol, JC Castellanos, ME Liebman, KA Lenhart, A Pennington, PM Padilla, NR AF Lol, Juan C. Castellanos, Maria E. Liebman, Kelly A. Lenhart, Audrey Pennington, Pamela M. Padilla, Norma R. TI Molecular evidence for historical presence of knock-down resistance in Anopheles albimanus, a key malaria vector in Latin America SO PARASITES & VECTORS LA English DT Article DE Anopheles albimanus; Pyrethroid resistance; Voltage-gated sodium channel gene; kdr mutations ID GATED SODIUM-CHANNEL; ARABIENSIS DIPTERA-CULICIDAE; INSECTICIDE RESISTANCE; PYRETHROID RESISTANCE; IMPREGNATED BEDNETS; MITOCHONDRIAL-DNA; MOSQUITO-CONTROL; KDR MUTATION; GAMBIAE; POPULATIONS AB Background: Anopheles albimanus is a key malaria vector in the northern neotropics. Current vector control measures in the region are based on mass distributions of long-lasting insecticidal nets (LLINs) and focal indoor residual spraying (IRS) with pyrethroids. Resistance to pyrethroid insecticides can be mediated by increased esterase and/or multi-function oxidase activity and/or mutations in the voltage-gated sodium channel gene. The aim of this work was to characterize the homologous kdr region of the voltage-gated sodium channel gene in An. albimanus and to conduct a preliminary retrospective analysis of field samples collected in the 1990's, coinciding with a time of intense pyrethroid application related to agricultural and public health insect control in the region. Methods: Degenerate primers were designed to amplify the homologous kdr region in a pyrethroid-susceptible laboratory strain (Sanarate) of An. albimanus. Subsequently, a more specific primer pair was used to amplify and sequence the region that contains the 1014 codon associated with pyrethroid resistance in other Anopheles spp. (L1014F, L1014S or L1014C). Results: Direct sequencing of the PCR products confirmed the presence of the susceptible kdr allele in the Sanarate strain (L1014) and the presence of homozygous-resistant kdr alleles in field-collected individuals from Mexico (L1014F), Nicaragua (L1014C) and Costa Rica (L1014C). Conclusions: For the first time, the kdr region in An. albimanus is described. Furthermore, molecular evidence suggests the presence of kdr-type resistance in field-collected An. albimanus in Mesoamerica in the 1990s. Further research is needed to conclusively determine an association between the genotypes and resistant phenotypes, and to what extent they may compromise current vector control efforts. C1 [Lol, Juan C.; Castellanos, Maria E.; Pennington, Pamela M.; Padilla, Norma R.] Univ Valle Guatemala, Ct Estudios Salud, Guatemala City, Guatemala. [Liebman, Kelly A.; Lenhart, Audrey] Ctr Dis Control & Prevent, CDC, Ctr Global Hlth, Div Parasit Dis & Malaria,Entomol Branch, Atlanta, GA 30329 USA. RP Padilla, NR (reprint author), Univ Valle Guatemala, Ct Estudios Salud, 18 Ave 11-95 Zona 15 Vista Hermosa 3, Guatemala City, Guatemala. EM npadilla@ces.uvg.edu.gt OI Lol Chiguil, Juann Carlos/0000-0002-7799-9495 FU US Agency for International Development (USAID) under Amazon Malaria Initiative, Cooperative Agreement Guatemala Public Health [1U51GH000011]; Center for Health Studies, Universidad del Valle de Guatemala FX Partial funding for this work was provided by the US Agency for International Development (USAID) under Amazon Malaria Initiative, Cooperative Agreement Guatemala Public Health/No. 1U51GH000011 and the Center for Health Studies, Universidad del Valle de Guatemala. Ana Maria de Merida and Alvaro Molina for providing historic mosquito samples. We also thank Ellen Dotson from CDC (MR4) for providing the kdr positive controls and primers, and William Brogdon for his helpful comments. NR 50 TC 6 Z9 6 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD SEP 18 PY 2013 VL 6 AR 268 DI 10.1186/1756-3305-6-268 PG 7 WC Parasitology SC Parasitology GA 224KK UT WOS:000324883900001 PM 24330978 ER PT J AU Wheaton, AG Ford, ES Thompson, WW Greenlund, KJ Presley-Cantrell, LR Croft, JB AF Wheaton, Anne G. Ford, Earl S. Thompson, William W. Greenlund, Kurt J. Presley-Cantrell, Letitia R. Croft, Janet B. TI Pulmonary function, chronic respiratory symptoms, and health-related quality of life among adults in the United States - National Health and Nutrition Examination Survey 2007-2010 SO BMC PUBLIC HEALTH LA English DT Article DE Chronic respiratory disease; Spirometry; FEV1; Activity limitation; Frequent mental distress; Wellbeing ID COPD PATIENTS; SURVEILLANCE; POPULATION; DISEASE; DETERMINANTS; SEVERITY; SAMPLE; ASTHMA AB Background: We examined the association of impaired lung function and respiratory symptoms with measures of health status and health-related quality of life (HRQOL) among US adults. Methods: The sample included 5139 participants aged 40-79 years in the National Health and Nutrition Examination Survey 2007-2010 who underwent spirometric testing and responded to questions about respiratory symptoms, health status, and number of physically unhealthy, mentally unhealthy, or activity limitation days in the prior 30 days. Results: Among these adults, 7.2% had restrictive impairment (FEV1/FVC >= 70%; FVC < 80% of predicted), 10.9% had mild obstruction (FEV1/FVC < 70%; FEV1 >= 80% predicted), and 9.0% had moderate-severe obstruction (FEV1/FVC < 70%; FEV1 < 80% predicted). Individuals with restrictive impairment or moderate-severe obstruction were more likely to report fair/poor health compared to those with normal lung function (prevalence ratio (PR) =1.5 [95% CI: 1.2-1.9] and 1.5 [1.3-1.8]), after controlling for sociodemographics, non-respiratory chronic diseases, body mass index, smoking, and respiratory symptoms. Frequent mental distress (FMD; >= 14 mentally unhealthy days), frequent physical distress (FPD; >= 14 physically unhealthy days), and frequent activity limitation (FAL; >= 14 activity limitation days) did not differ by lung function status. Adults who reported any respiratory symptoms (frequent cough, frequent phlegm, or past year wheeze) were more likely to report fair/poor health (PR = 1.5 [1.3-1.7]), FPD (PR = 1.6 [1.4-1.9]), FMD (PR = 1.8 [1.4-2.2]), and FAL (PR = 1.4 [1.1-1.9]) than those with no symptoms. Conclusions: These results suggest the importance of chronic respiratory symptoms as potential risk factors for poor HRQOL and suggest improved symptom treatment and prevention efforts would likely improve HRQOL. C1 [Wheaton, Anne G.; Ford, Earl S.; Thompson, William W.; Greenlund, Kurt J.; Presley-Cantrell, Letitia R.; Croft, Janet B.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30341 USA. RP Wheaton, AG (reprint author), Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, 4770 Buford Highway,Mailstop K67, Atlanta, GA 30341 USA. EM awheaton@cdc.gov NR 26 TC 8 Z9 8 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD SEP 17 PY 2013 VL 13 AR 854 DI 10.1186/1471-2458-13-854 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 220XI UT WOS:000324620200003 PM 24040892 ER PT J AU Rabe, IB Schwartz, BS Farnon, EC Josephson, SA Webber, AB Roberts, JP de Mattos, AM Gallay, BJ van Slyck, S Messenger, SL Yen, CJ Bloch, EM Drew, CP Fischer, M Glaser, CA AF Rabe, Ingrid B. Schwartz, Brian S. Farnon, Eileen C. Josephson, S. Andrew Webber, Allison B. Roberts, John Paul de Mattos, Angelo M. Gallay, Brian J. van Slyck, Sean Messenger, Sharon L. Yen, Cynthia J. Bloch, Evan M. Drew, Clifton P. Fischer, Marc Glaser, Carol A. CA WNV Transplant Invest Team TI Fatal Transplant-Associated West Nile Virus Encephalitis and Public Health Investigation-California, 2010 SO TRANSPLANTATION LA English DT Article DE West Nile virus; Transplant-associated transmission; Encephalitis ID UNITED-STATES; ORGAN-TRANSPLANTATION; INFECTION; TRANSMISSION; ANTIBODIES; RECIPIENTS; DISEASE; DONOR AB Background. In December 2010, a case of West Nile virus (WNV) encephalitis occurring in a kidney recipient shortly after organ transplantation was identified. Methods. A public health investigation was initiated to determine the likely route of transmission, detect potential WNV infections among recipients from the same organ donor, and remove any potentially infected blood products or tissues. Available serum, cerebrospinal fluid, and urine samples from the organ donor and recipients were tested for WNV infection by nucleic acid testing and serology. Results. Two additional recipients from the same organ donor were identified, their clinical and exposure histories were reviewed, and samples were obtained. WNV RNA was retrospectively detected in the organ donor's serum. After transplantation, the left kidney recipient had serologic and molecular evidence of WNV infection and the right kidney recipient had prolonged but clinically inapparent WNV viremia. The liver recipient showed no clinical signs of infection but had flavivirus IgG antibodies; however, insufficient samples were available to determine the timing of infection. No remaining infectious products or tissues were identified. Conclusions. Clinicians should suspect WNV as a cause of encephalitis in organ transplant recipients and report cases to public health departments for prompt investigation of the source of infection. Increased use of molecular testing and retaining pretransplantation sera may improve the ability to detect and diagnose transplant-associated WNV infection in organ transplant recipients. C1 [Rabe, Ingrid B.; Farnon, Eileen C.; Drew, Clifton P.; Fischer, Marc] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Rabe, Ingrid B.; Farnon, Eileen C.; Drew, Clifton P.; Fischer, Marc] Ctr Dis Control & Prevent, Atlanta, GA USA. [Schwartz, Brian S.; Josephson, S. Andrew; Webber, Allison B.; Roberts, John Paul] Univ Calif San Francisco, San Francisco, CA 94143 USA. [de Mattos, Angelo M.; Gallay, Brian J.] Univ Calif Davis, Davis, CA 95616 USA. [van Slyck, Sean] Calif Transplant Donor Network, Oakland, CA USA. [Messenger, Sharon L.; Yen, Cynthia J.; Glaser, Carol A.] Calif Dept Publ Hlth, Richmond, CA USA. [Bloch, Evan M.] Blood Syst Res Inst, San Francisco, CA USA. RP Rabe, IB (reprint author), 3156 Rampart Rd,Mail Stop P-02, Ft Collins, CO 80521 USA. EM IRabe@cdc.gov NR 29 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD SEP 15 PY 2013 VL 96 IS 5 BP 463 EP 468 DI 10.1097/TP.0b013e31829b4142 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 299FX UT WOS:000330382400011 PM 23823653 ER PT J AU Dyer, JL Wallace, R Orciari, L Hightower, D Yager, P Blanton, JD AF Dyer, Jessie L. Wallace, Ryan Orciari, Lillian Hightower, Dillon Yager, Pamela Blanton, Jesse D. TI Rabies surveillance in the United States during 2012 SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article ID POSTEXPOSURE PROPHYLAXIS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; RECOMMENDATIONS; PREVENTION AB During 2012, 49 states and Puerto Rico reported 6,162 rabid animals and 1 human rabies case to the CDC, representing a 2.1% increase from the 6,031 rabid animals and 6 human cases reported in 2011. Approximately 92% of reported rabid animals were wildlife. Relative contributions by the major animal groups were as follows: 1,953 raccoons (31.7%), 1,680 bats (27.3%), 1,539 skunks (25.0%), 340 foxes (5.5%), 257 cats (4.2%), 115 cattle (1.9%), and 84 dogs (1.4%). Compared with 2011, there was a substantial increase in the number of rabid cattle reported. One case of rabies involving a human was reported from California after the patient died abroad. The infection was determined to be a result of a rabies virus variant associated with Tadarida brasiliensis, with exposure occurring in California. C1 [Dyer, Jessie L.; Wallace, Ryan; Orciari, Lillian; Hightower, Dillon; Yager, Pamela; Blanton, Jesse D.] CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Blanton, JD (reprint author), CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM asi5@cdc.gov NR 23 TC 16 Z9 16 U1 0 U2 27 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD SEP 15 PY 2013 VL 243 IS 6 BP 805 EP 815 PG 11 WC Veterinary Sciences SC Veterinary Sciences GA 255HL UT WOS:000327229900011 PM 24004227 ER PT J AU Ortiz, JR Neuzil, KM Rue, TC Zhou, H Shay, DK Cheng, PY Cooke, CR Goss, CH AF Ortiz, Justin R. Neuzil, Kathleen M. Rue, Tessa C. Zhou, Hong Shay, David K. Cheng, Po-Yung Cooke, Colin R. Goss, Christopher H. TI Population-based Incidence Estimates of Influenza-associated Respiratory Failure Hospitalizations, 2003 to 2009 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE epidemiology; respiratory tract infections; critical care; artificial respiration; state inpatient database ID IMMUNIZATION PRACTICES ACIP; UNITED-STATES; SYNCYTIAL VIRUS; VACCINE EFFECTIVENESS; ADVISORY-COMMITTEE; OLDER-ADULTS; MORTALITY; RECOMMENDATIONS; BIAS AB Rationale: The incidence of influenza-associated acute respiratory failure is unknown. Objectives: To estimate the population-based incidence of influenza-associated acute respiratory failure hospitalizations. Methods: This is a cohort study from January 2003 through March 2009 using hospitalization databases for Arizona, California, and Washington from the Healthcare Cost and Utilization Project and influenza surveillance data for regions encompassing these states. Acute respiratory failure requiring mechanical ventilation was defined by International Classification of Diseases-9-CMcode. We used negative-binomial regression modeling to estimate the incidence of influenza-associated events. Measurements and Main Results: The incidence of influenza-associated acute respiratory failure was 2.7 per 100,000 person-years (95% confidence interval, 0.2-23.5), and during the influenza season, 3.8% of all respiratory failure hospitalizations were attributable to influenza. Compared with adults aged 18-49 years, the incidence rate ratio for influenza-associated acute respiratory failure was lower among children aged 1-4 (0.9) and 5-17 years (0.3); however, it was higher among adults aged 50-64 (4.8), 65-74 (10.4), 75-84 (19.9), and 85 years and older (33.7). Results were similar with more sensitive and specific outcome definitions and in a sensitivity analysis using only Arizona-specific outcome and surveillance data. Conclusions: Our data indicate that influenza was an important contributor to respiratory failure hospitalizations during 2003-2009. Clinicians should maintain a high index of suspicion for influenza among hospitalized patients with acute respiratory illness when influenza is circulating in a community. Influenza has a greater effect on respiratory failure in the elderly, for whom better prevention measures are needed. C1 [Ortiz, Justin R.; Neuzil, Kathleen M.; Goss, Christopher H.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Ortiz, Justin R.; Neuzil, Kathleen M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Rue, Tessa C.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Ortiz, Justin R.; Neuzil, Kathleen M.] PATH, Vaccine Access & Delivery Global Program, Seattle, WA USA. [Zhou, Hong; Shay, David K.; Cheng, Po-Yung] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Cooke, Colin R.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. RP Ortiz, JR (reprint author), Univ Washington, Med Ctr, Div Pulm & Crit Care Med, Box 356522,1959 NE Pacific St, Seattle, WA 98195 USA. EM jrortiz@uw.edu OI Cooke, Colin/0000-0001-9713-5371; Shay, David/0000-0001-9619-4820 FU Robert Wood Johnson Harold Amos Medical Faculty Development Program; University of Washington Housestaff Association John B. Coombs Research Award; Robert Wood Johnson Foundation Clinical Scholars program FX Supported by the Robert Wood Johnson Harold Amos Medical Faculty Development Program and the University of Washington Housestaff Association John B. Coombs Research Award (J.R.O.), and Robert Wood Johnson Foundation Clinical Scholars program (C.R.C.). The funders had no role in preparation of the manuscript or in the decision to submit the manuscript for publication. No additional external funding was received for this manuscript. NR 40 TC 10 Z9 10 U1 1 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD SEP 15 PY 2013 VL 188 IS 6 BP 710 EP 715 DI 10.1164/rccm.201212-2341OC PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 219OI UT WOS:000324516100015 PM 23855650 ER PT J AU Gutman, J Mwandama, D Wiegand, RE Ali, D Mathanga, DP Skarbinski, J AF Gutman, Julie Mwandama, Dyson Wiegand, Ryan E. Ali, Doreen Mathanga, Don P. Skarbinski, Jacek TI Effectiveness of Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine During Pregnancy on Maternal and Birth Outcomes in Machinga District, Malawi SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE malaria; pregnancy; intermittent preventive treatment; sulfadoxine-pyrimethamine; Malawi ID PLASMODIUM-FALCIPARUM MALARIA; PLACENTAL MALARIA; HIGH PREVALENCE; WOMEN; INFECTION; EFFICACY; RESISTANCE; REGRESSION; THERAPY; AFRICA AB Background. Malaria during pregnancy is associated with low birth weight and increased perinatal mortality, especially among primigravidae. Despite increasing prevalence of malarial parasite resistance to sulfadoxine-pyrimethamine (SP), SP continues to be recommended for intermittent preventive treatment in pregnancy (IPTp). Methods. Women without human immunodeficiency virus infection were enrolled upon delivery. Data on the number of SP doses received during pregnancy were recorded. The primary outcome was placental infection demonstrated by histologic analysis. Secondary outcomes included malaria parasitemia (in peripheral, placental, cord blood specimens) at delivery and composite birth outcome (small for gestational age, preterm delivery, or low birth weight). Results. Of 703 women enrolled, 22% received <2 SP doses. Receipt of >= 2 SP doses had no impact on histologically confirmed placental infection. IPTp-SP was associated with a dose-dependent protective effect on composite birth outcome in primigravidae, with an adjusted prevalence ratio of 0.50 (95% confidence interval [CI], .30-.82), 0.30 (95% CI, .19-.48), and 0.18 (95% CI, .05-.61) for 1, 2, and >= 3 doses, respectively, compared with 0 doses. Conclusions. IPTp-SP did not reduce the frequency of placental infection but was associated with improved birth outcomes. Few women received no SP, so the true effect of IPTp-SP may be underestimated. Malawian pregnant women should continue to receive IPTp-SP, but alternative strategies and antimalarials for preventing malaria during pregnancy should be investigated. C1 [Gutman, Julie; Wiegand, Ryan E.; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30322 USA. [Mwandama, Dyson; Mathanga, Don P.] Univ Malawi, Coll Med, Malaria Alert Ctr, Blantyre, Malawi. [Ali, Doreen] Coll Med, Natl Malaria Control Program, Lilongwe, Malawi. [Mathanga, Don P.] Coll Med, Malawi & Dept Community Hlth, Lilongwe, Malawi. RP Gutman, J (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30322 USA. EM jgutman@cdc.gov FU US President's Malaria Initiative, US Agency for International Development; CDC [5 U01 CI000189]; Malaria Alert Centre, College of Medicine [5 U01 CI000189] FX This work was supported by the US President's Malaria Initiative, US Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC), and through a cooperative agreement (5 U01 CI000189) between the CDC and the Malaria Alert Centre, College of Medicine. NR 38 TC 23 Z9 23 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 15 PY 2013 VL 208 IS 6 BP 907 EP 916 DI 10.1093/infdis/jit276 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 219MD UT WOS:000324510200006 PM 23801600 ER PT J AU Falsey, RR Kinzer, MH Hurst, S Kalus, A Pottinger, PS Duchin, JS Zhang, J Noble-Wang, J Shinohara, MM AF Falsey, Ryan R. Kinzer, Michael H. Hurst, Stanley Kalus, Andrea Pottinger, Paul S. Duchin, Jeffrey S. Zhang, Jiong Noble-Wang, Judith Shinohara, Michi M. TI Cutaneous Inoculation of Nontuberculous Mycobacteria During Professional Tattooing: A Case Series and Epidemiologic Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE nontuberculous mycobacteria (NTM); antibiotic resistance; tattoo ID CHELONAE INFECTION; SKIN INFECTION; OUTBREAK; ABSCESSUS; COMPLICATIONS; INK AB Background. The increase in popularity of tattoos has coincided with an increase in reports of cutaneous inoculation of nontuberculous (atypical) mycobacteria (NTM) during the tattooing process. We report 3 NTM infections in otherwise healthy persons who received tattoos, which prompted a multiagency epidemiologic investigation. Methods. Tattoo artists involved were contacted and interviewed regarding practices, ink procurement and use, and other symptomatic clients. Additional patients were identified from their client lists with an Internet survey. Results. Thirty-one cases of suspected or confirmed NTM inoculation from professional tattooing were uncovered, including 5 confirmed and 26 suspected cases. Clinical biopsy specimens from 3 confirmed infections grew Mycobacterium abscessus strains that were indistinguishable by pulsed-field gel electrophoresis testing. Another 2 skin specimens grew Mycobacterium chelonae, which also grew from a bottle of graywash ink obtained from the tattoo artist. Conclusions. The pathogenicity and antibiotic resistance patterns of certain NTM isolates highlight the importance of correct diagnosis and potential difficulty in treating infections. Enforcement of new standards for the regulation and use of tattoo inks should be considered. C1 [Falsey, Ryan R.; Hurst, Stanley; Kalus, Andrea; Shinohara, Michi M.] Univ Washington, Div Dermatol, Seattle, WA 98195 USA. [Pottinger, Paul S.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA. [Zhang, Jiong] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Kinzer, Michael H.; Duchin, Jeffrey S.] Publ Hlth Seattle & King Cty, Communicable Dis Epidemiol & Immunizat Sect, Washington, DC USA. [Noble-Wang, Judith] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Falsey, RR (reprint author), Univ Washington, Div Dermatol, 1959 NE Pacific St,Box 356524, Seattle, WA 98195 USA. EM rfalsey@gmail.com NR 23 TC 14 Z9 15 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 15 PY 2013 VL 57 IS 6 BP E143 EP E147 DI 10.1093/cid/cit347 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 212YF UT WOS:000324018100005 PM 23704119 ER PT J AU Black, CL Yankey, D Kolasa, M AF Black, Carla L. Yankey, David Kolasa, Maureen TI National, State, and Local Area Vaccination Coverage Among Children Aged 19-35 Months-United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Black, Carla L.; Yankey, David; Kolasa, Maureen] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Black, CL (reprint author), CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM cblack2@cdc.gov NR 8 TC 54 Z9 55 U1 1 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 13 PY 2013 VL 62 IS 36 BP 733 EP 740 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 275JY UT WOS:000328673300001 ER PT J AU Wallace, G Redd, S Rota, J Rota, P Bellini, W Lebo, E AF Wallace, Gregory Redd, Susan Rota, Jennifer Rota, Paul Bellini, William Lebo, Emmaculate TI Measles-United States, January 1-August 24, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Wallace, Gregory; Redd, Susan; Rota, Jennifer; Rota, Paul; Bellini, William] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Lebo, Emmaculate] CDC, EIS, Atlanta, GA 30333 USA. RP Lebo, E (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM elebo@cdc.gov NR 10 TC 30 Z9 30 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 13 PY 2013 VL 62 IS 36 BP 741 EP 743 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 275JY UT WOS:000328673300002 ER PT J AU Smith, MJ McFalls, D Hendricks, J Watkins, J Moore, C Peacock, G de Coteau, A AF Smith, Michael J. McFalls, Deborah Hendricks, Jennifer Watkins, Janice Moore, Cynthia Peacock, Georgina de Coteau, Adina TI Influenza Vaccination Practices of Physicians and Caregivers of Children with Neurologic and Neurodevelopmental Conditions-United States, 2011-12 Influenza Season SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Smith, Michael J.] Univ Louisville, Sch Med, Louisville, KY 40292 USA. [McFalls, Deborah; Hendricks, Jennifer; Watkins, Janice] Oak Ridge Associated Univ, Oak Ridge, TN USA. [Moore, Cynthia; Peacock, Georgina; de Coteau, Adina] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Peacock, G (reprint author), CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM ghn3@cdc.gov NR 6 TC 3 Z9 3 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 13 PY 2013 VL 62 IS 36 BP 744 EP 746 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 275JY UT WOS:000328673300003 ER PT J AU Adekoya, N Roberts, H AF Adekoya, Nelson Roberts, Henry TI Comparison of Provisional with Final Notifiable Disease Case Counts-National Notifiable Diseases Surveillance System, 2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ABERRATIONS C1 [Adekoya, Nelson] CDC, Div Notifiable Dis & Healthcare Informat, Publ Hlth Surveillance & Informat Program Off, Atlanta, GA 30333 USA. [Roberts, Henry] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Adekoya, N (reprint author), CDC, Div Notifiable Dis & Healthcare Informat, Publ Hlth Surveillance & Informat Program Off, Atlanta, GA 30333 USA. EM nba7@cdc.gov NR 8 TC 1 Z9 1 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 13 PY 2013 VL 62 IS 36 BP 747 EP 751 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 275JY UT WOS:000328673300004 ER PT J AU Arciuolo, RJ Brantley, TR Asfaw, MM Jablonski, RR Fu, J Giancotti, FR Rosen, JB Zucker, JR AF Arciuolo, Robert J. Brantley, Tamara R. Asfaw, Mekete M. Jablonski, Rachel R. Fu, Jie Giancotti, Francesca R. Rosen, Jennifer B. Zucker, Jane R. TI Measles Outbreak Among Members of a Religious Community-Brooklyn, New York, March-June 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Arciuolo, Robert J.; Brantley, Tamara R.; Asfaw, Mekete M.; Jablonski, Rachel R.; Fu, Jie; Giancotti, Francesca R.; Rosen, Jennifer B.] CDC, New York City Dept Hlth & Mental Hyg, Atlanta, GA 30333 USA. [Zucker, Jane R.] CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Arciuolo, RJ (reprint author), CDC, New York City Dept Hlth & Mental Hyg, Atlanta, GA 30333 USA. EM rarciuolo@health.nyc.gov NR 3 TC 11 Z9 11 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 13 PY 2013 VL 62 IS 36 BP 752 EP 753 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 275JY UT WOS:000328673300005 ER PT J AU Sullivan, K Moore, ZS Fleischauer, AT AF Sullivan, Kristin Moore, Zack S. Fleischauer, Aaron T. TI Measles Outbreak Associated with a Traveler Returning from India-North Carolina, April-May 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Sullivan, Kristin; Moore, Zack S.] CDC, North Carolina Div Publ Hlth, Atlanta, GA 30333 USA. [Fleischauer, Aaron T.] CDC, Career Epidemiol Field, Atlanta, GA 30333 USA. RP Fleischauer, AT (reprint author), CDC, Career Epidemiol Field, Atlanta, GA 30333 USA. EM afleischauer@cdc.gov NR 2 TC 7 Z9 7 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 13 PY 2013 VL 62 IS 36 BP 753 EP 753 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 275JY UT WOS:000328673300006 ER PT J AU Yolton, K Xu, YY Sucharew, H Succop, P Altaye, M Popelar, A Montesano, MA Calafat, AM Khoury, JC AF Yolton, Kimberly Xu, Yingying Sucharew, Heidi Succop, Paul Altaye, Mekibib Popelar, Ann Montesano, M. Angela Calafat, Antonia M. Khoury, Jane C. TI Impact of low-level gestational exposure to organophosphate pesticides on neurobehavior in early infancy: a prospective study SO ENVIRONMENTAL HEALTH LA English DT Article DE NNNS; Organophosphates; Pesticides; Neurobehavior; Infancy; Prenatal exposure ID NEONATAL BEHAVIORAL-ASSESSMENT; MEXICAN-AMERICAN CHILDREN; ASSESSMENT SCALE NBAS; PRENATAL EXPOSURE; SUBSTANCE EXPOSURE; VEGETABLE INTAKE; PREGNANCY; PERFORMANCE; COCAINE; ALCOHOL AB Background: National data suggest widespread gestational exposure to organophosphate pesticides (OPs) based on the detection of OP metabolites in the urine of pregnant women. Associations with early infant neurobehavior are largely understudied, with only two studies reporting abnormal reflexes in newborns in association with gestational exposure to OPs. Our objective was to utilize biological markers of OP metabolites in pregnant women and a comprehensive assessment of infant neurobehavior to determine the association of gestational exposure to OPs with neurobehavioral outcomes during early infancy. Methods: Among a cohort of 350 mother/infant pairs, we measured six common dialkylphosphate metabolites of OP pesticides in maternal urine, at two times during pregnancy (16 w & 26 w gestation), then calculated aggregate concentrations of diethylphosphate, dimethylphosphate, and total dialkyphosphate metabolites. We measured infant neurobehavior at about five weeks of age using the NICU Network Neurobehavioral Scale (NNNS), a comprehensive assessment of neurobehavior in young infants. Analyses of associations between gestational exposure to OPs and neurobehavior at five weeks included multiple linear and logistic regression. Results: After adjustment for covariates, higher creatinine-corrected urinary concentrations of diethylphosphate metabolites were associated with improved attention and reduced lethargy and hypotonia in young infants. Higher creatinine-corrected urinary concentrations of total dialkylphosphate metabolites were associated with fewer signs of autonomic stress. Women who were white, married, had advanced education, and reported more frequent consumption of fresh fruits and vegetables had higher concentrations of OP metabolites during pregnancy. Conclusions: In this sample of pregnant women whose urinary concentrations of dialkylphosphate metabolites are representative of national exposure levels, we found no detrimental effects of gestational exposure to OPs on neurobehavioral outcomes among young infants. These results are important as they suggest there may be minimal to no detectable adverse impact of low level prenatal OP exposure on the neurobehavior of young infants. C1 [Yolton, Kimberly; Xu, Yingying; Popelar, Ann] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Gen & Community Pediat, Cincinnati, OH 45229 USA. [Sucharew, Heidi; Altaye, Mekibib; Khoury, Jane C.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. [Succop, Paul] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Montesano, M. Angela; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. RP Yolton, K (reprint author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Gen & Community Pediat, Cincinnati, OH 45229 USA. EM kimberly.yolton@cchmc.org RI Sucharew, Heidi/M-4338-2015; Altaye, Mekibib/N-5274-2015; Khoury, Jane/O-2068-2015 FU National Institute of Environmental Health Sciences; Environmental Protection Agency [R01 ES015517, P01 ES11261] FX This work was partially supported by grants from the National Institute of Environmental Health Sciences and Environmental Protection Agency (R01 ES015517, P01 ES11261). The study sponsors made no contributions to study design, data collection, analysis, interpretation, authorship, or decisions to submit for publication. We appreciate the support and guidance of Dr. Bruce Lanphear. We acknowledge the technical assistance of C. Chambers, C. Fernandez, D.G. Kim, M. Odetokun, P. Olive and T. Bernert (Centers for Disease Control and Prevention, Atlanta, GA) in measuring the urinary concentrations of organophosphate pesticide metabolites, creatinine, and serum cotinine. NR 50 TC 8 Z9 8 U1 2 U2 34 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD SEP 13 PY 2013 VL 12 AR 79 DI 10.1186/1476-069X-12-79 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 227RQ UT WOS:000325131900001 PM 24034442 ER PT J AU Bhatnagar, P Barron-Casella, E Bean, CJ Milton, JN Baldwin, CT Steinberg, MH DeBaun, M Casella, JF Arking, DE AF Bhatnagar, Pallav Barron-Casella, Emily Bean, Christopher J. Milton, Jacqueline N. Baldwin, Clinton T. Steinberg, Martin H. DeBaun, Michael Casella, James F. Arking, Dan E. TI Genome-Wide Meta-Analysis of Systolic Blood Pressure in Children with Sickle Cell Disease SO PLOS ONE LA English DT Article ID ASSOCIATION; HYPERTENSION; RECEPTOR; DOPAMINE; LOCI; VARIANTS; INFARCTS; LINKAGE; DESIGN; ANEMIA AB In pediatric sickle cell disease (SCD) patients, it has been reported that higher systolic blood pressure (SBP) is associated with increased risk of a silent cerebral infarction (SCI). SCI is a major cause of neurologic morbidity in children with SCD, and blood pressure is a potential modulator of clinical manifestations of SCD; however, the risk factors underlying these complications are not well characterized. The aim of this study was to identify genetic variants that influence SBP in an African American population in the setting of SCD, and explore the use of SBP as an endo-phenotype for SCI. We conducted a genome-wide meta-analysis for SBP using two SCD cohorts, as well as a candidate screen based on published SBP loci. A total of 1,617 patients were analyzed, and while no SNP reached genome-wide significance (P-value<5.0x10(-8)), a number of suggestive candidate loci were identified. The most significant SNP, rs7952106 (P-value=8.57x10(-7)), was in the DRD2 locus on chromosome 11. In a gene-based association analysis, MIR4301 (micro-RNA4301), which resides in an intron of DRD2, was the most significant gene (P-value=5.2x10(-5)). Examining 27 of the previously reported SBP associated SNPs, 4 SNPs were nominally significant. A genetic risk score was constructed to assess the aggregated genetic effect of the published SBP variants, demonstrating a significant association (P=0.05). In addition, we also assessed whether these variants are associated with SCI, validating the use of SBP as an endo-phenotype for SCI. Three SNPs were nominally associated, and only rs2357790 (5' CACNB2) was significant for both SBP and SCI. None of these SNPs retained significance after Bonferroni correction. Taken together, our results suggest the importance of DRD2 genetic variation in the modulation of SBP, and extend the aggregated importance of previously reported SNPs in the modulation of SBP in an African American cohort, more specifically in children with SCD. C1 [Bhatnagar, Pallav; Arking, Dan E.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA. [Barron-Casella, Emily; Casella, James F.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Hematol, Baltimore, MD 21205 USA. [Bean, Christopher J.] Ctr Dis Control & Prevent, Clin & Mol Hemostasis Lab Branch, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Milton, Jacqueline N.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Baldwin, Clinton T.; Steinberg, Martin H.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [DeBaun, Michael] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA. RP Casella, JF (reprint author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Hematol, Baltimore, MD 21205 USA. EM jcasella@jhmi.edu; arking@jhmi.edu FU National Heart, Lung and Blood Institute (NHLBI) [U54HL090515, 5R01HL091759]; National Institute of Neurological Disorders and Stroke (NINDS) [NIH-NINDS 5U01-NS042804-03]; [5T32 HL007501]; [R01 HL 87681]; [R01 068970]; [RC2 HL 101212] FX This study was supported by the National Heart, Lung and Blood Institute (NHLBI) (Award Number: U54HL090515, 5R01HL091759) and the National Institute of Neurological Disorders and Stroke (NINDS) (NIH-NINDS 5U01-NS042804-03). This work was also supported by 5T32 HL007501 (J.N.M.) and R01 HL 87681, R01 068970 and RC2 HL 101212 (M. H. S.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 5 Z9 5 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 13 PY 2013 VL 8 IS 9 AR UNSP e74193 DI 10.1371/journal.pone.0074193 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 218BU UT WOS:000324408400054 PM 24058526 ER PT J AU Sheffield, JS Munoz, FM Beigi, RH Rasmussen, SA Edwards, KM Read, JS Heine, RP Ault, KA Swamy, GK Jevaji, I Spong, CY Fortner, KB Patel, SM Nesin, M AF Sheffield, Jeanne S. Munoz, Flor M. Beigi, Richard H. Rasmussen, Sonja A. Edwards, Kathryn M. Read, Jennifer S. Heine, R. Phillips Ault, Kevin A. Swamy, Geeta K. Jevaji, Indira Spong, Catherine Y. Fortner, Kimberly B. Patel, Shital M. Nesin, Mirjana TI Research on vaccines during pregnancy: Reference values for vital signs and laboratory assessments SO VACCINE LA English DT Article DE Laboratory assessment; Toxicity grading scale; Maternal immunization AB The Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health organized a series of conferences, "Enrolling Pregnant Women in Clinical Trials of Vaccines and Therapeutics", to discuss enrollment and safety assessments of pregnant women in clinical trials of vaccines. Experts in obstetrics, maternal fetal medicine, infectious diseases, pediatrics, neonatology, genetics, vaccinology and clinical trial design were charged with identifying normal ranges for vital signs and laboratory assessments in pregnancy. A grading system for adverse events was then developed (C) 2013 Elsevier Ltd. All rights reserved. C1 [Sheffield, Jeanne S.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Div Maternal Fetal Med, Dallas, TX 75390 USA. [Munoz, Flor M.] Baylor Coll Med, Dept Pediat Mol Virol & Microbiol, Houston, TX 77030 USA. [Beigi, Richard H.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Dept Pediat, Vanderbilt Vaccine Res Program, Nashville, TN 37232 USA. [Read, Jennifer S.] US Dept HHS, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Off Secretary, Washington, DC 20201 USA. [Heine, R. Phillips; Swamy, Geeta K.] Duke Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Durham, NC 27710 USA. [Ault, Kevin A.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30303 USA. [Ault, Kevin A.] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30303 USA. [Ault, Kevin A.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30303 USA. [Jevaji, Indira] NIH, USA Div ESRD Populat & Community Hlth DEPCH, Ctr Medicare & Medicaid Serv CMS, Qual Improvement Grp,Ctr Clin Stand & Qual,Off Re, Bethesda, MD 20817 USA. [Spong, Catherine Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA. [Fortner, Kimberly B.] Vanderbilt Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Nashville, TN 37232 USA. [Patel, Shital M.] Baylor Coll Med, Dept Med Mol Virol & Microbiol, Houston, TX 77030 USA. [Nesin, Mirjana] NIAID, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20817 USA. RP Nesin, M (reprint author), 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM jeanne.sheffield@utsouthwestern.edu NR 9 TC 14 Z9 14 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 13 PY 2013 VL 31 IS 40 BP 4264 EP 4273 DI 10.1016/j.vaccine.2013.07.031 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 219MG UT WOS:000324510500002 PM 23906887 ER PT J AU Munoz, FM Sheffield, JS Beigi, RH Read, JS Swamy, GK Jevaji, I Rasmussen, SA Edwards, KM Fortner, KB Patel, SM Spong, CY Ault, K Heine, RP Nesin, M AF Munoz, Flor M. Sheffield, Jeanne S. Beigi, Richard H. Read, Jennifer S. Swamy, Geeta K. Jevaji, Indira Rasmussen, Sonja A. Edwards, Kathryn M. Fortner, Kimberly B. Patel, Shital M. Spong, Catherine Y. Ault, Kevin Heine, R. Philips Nesin, Mirjana TI Research on vaccines during pregnancy: Protocol design and assessment of safety SO VACCINE LA English DT Article DE Safety; Maternal immunization; Adverse events; Pregnancy studies; Definitions; Clinical trials ID NEWBORN-INFANTS; MALFORMATIONS; IMMUNIZATION; PREVENTION AB The Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health organized a series of conferences, entitled "Enrolling Pregnant Women in Clinical Trials of Vaccines and Therapeutics", to discuss study design and the assessment of safety in clinical trials conducted in pregnant women. A panel of experts was charged with developing guiding principles for the design of clinical trials and the assessment of safety of vaccines during pregnancy. Definitions and a grading system to evaluate local and systemic reactogenicity, adverse events, and other events associated with pregnancy and delivery were developed. The purpose of this report is to provide investigators interested in vaccine research in pregnancy with a basic set of tools to design and implement maternal immunization studies which may be conducted more efficiently using consistent definitions and grading of adverse events to allow the comparison of safety reports from different trials. These guidelines and safety assessment tools may be modified to meet the needs of each particular protocol based on evidence collected as investigators use them in clinical trials in different settings and share their findings and expertise. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Munoz, Flor M.] Baylor Coll Med, Dept Pediat Mol Virol & Microbiol, Houston, TX 77030 USA. [Sheffield, Jeanne S.] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Div Maternal Fetal Med, Dallas, TX 75390 USA. [Beigi, Richard H.] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA. [Read, Jennifer S.] US Dept HHS, Natl Vaccine Program Off, Off Assistant Secretary Hlth, Off Secretary, Washington, DC 20201 USA. [Swamy, Geeta K.; Heine, R. Philips] Duke Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Durham, NC 27710 USA. [Jevaji, Indira] NIH, Off Res Womens Hlth, Off Director, Bethesda, MD 20817 USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Dept Pediat, Vanderbilt Vaccine Res Program, Nashville, TN 37232 USA. [Fortner, Kimberly B.] Vanderbilt Univ, Dept Obstet & Gynecol, Div Maternal Fetal Med, Nashville, TN 37232 USA. [Patel, Shital M.] Baylor Coll Med, Dept Med Mol Virol & Microbiol, Houston, TX 77030 USA. [Spong, Catherine Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA. [Ault, Kevin] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30303 USA. [Ault, Kevin] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30303 USA. [Ault, Kevin] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30303 USA. [Nesin, Mirjana] NIAID, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20817 USA. RP Munoz, FM (reprint author), Baylor Coll Med, 1 Baylor Plaza,Suite 221-D,BCM 280, Houston, TX 77030 USA. EM florm@bcm.edu; nesinm@gmail.com NR 43 TC 15 Z9 15 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 13 PY 2013 VL 31 IS 40 BP 4274 EP 4279 DI 10.1016/j.vaccine.2013.07.042 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 219MG UT WOS:000324510500003 PM 23906888 ER PT J AU Nguyen, YT Graitcer, SB Nguyen, TH Tran, DN Pham, TD Le, MTQ Tran, HN Bui, CT Dang, DT Nguyen, LT Uyeki, TM Dennis, D Kile, JC Kapella, BK Iuliano, AD Widdowson, MA Nguyen, HT AF Nguyen, Yen T. Graitcer, Samuel B. Nguyen, Tuan H. Tran, Duong N. Pham, Tho D. Le, Mai T. Q. Tran, Huu N. Bui, Chien T. Dang, Dat T. Nguyen, Long T. Uyeki, Timothy M. Dennis, David Kile, James C. Kapella, Bryan K. Iuliano, A. D. Widdowson, Marc-Alain Nguyen, Hien T. TI National surveillance for influenza and influenza-like illness in Vietnam, 2006-2010 SO VACCINE LA English DT Article DE Influenza; Southeast Asia; Influenza A (H1N1) subtype; Influenza A (H3N2) subtype; Influenza B; Pandemic influenza; Vietnam ID THAILAND; VACCINATION; VIRUSES; HEALTH; COST AB Influenza virus infections result in considerable morbidity and mortality both in the temperate and tropical world. Influenza surveillance over multiple years is important to determine the impact and epidemiology of influenza and to develop a national vaccine policy, especially in countries developing influenza vaccine manufacturing capacity, such as Vietnam. We conducted surveillance of influenza and influenza-like illness in Vietnam through the National Influenza Surveillance System during 2006-2010. At 15 sentinel sites, the first two patients presenting each weekday with influenza-like illness (ILI), defined as fever and cough and/or sore throat with illness onset within 3 days, were enrolled and throat specimens were collected and tested for influenza virus type and influenza A subtype by RT-PCR. De-identified demographic and provider reported subsequent hospitalization information was collected on each patient. Each site also collected information on the total number of patients with influenza-like illness evaluated per week. Of 29,804 enrolled patients presenting with influenza-like illness, 6516(22%) were influenza positive. Of enrolled patients, 2737 (9.3%) were reported as subsequently hospitalized; of the 2737, 527 (19%) were influenza positive. Across all age groups with ILI, school-aged children had the highest percent of influenza infection (29%) and the highest percent of subsequent hospitalizations associated with influenza infection (28%). Influenza viruses co-circulated throughout most years in Vietnam during 2006-2010 and often reached peak levels multiple times during a year, when >20% of tests were influenza positive. Influenza is an important cause of all influenza-like illness and provider reported subsequent hospitalization among outpatients in Vietnam, especially among school-aged children. These findings may have important implications for influenza vaccine policy in Vietnam. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Graitcer, Samuel B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Graitcer, Samuel B.; Uyeki, Timothy M.; Dennis, David; Kile, James C.; Kapella, Bryan K.; Iuliano, A. D.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Tran, Huu N.; Nguyen, Long T.] Inst Pasteur, Ho Chi Minh City, Vietnam. [Bui, Chien T.] Inst Pasteur, Nha Trang, Vietnam. [Dang, Dat T.] Inst Pasteur, Tay Nguyen, Vietnam. RP Graitcer, SB (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd,MS A-19, Atlanta, GA 30333 USA. EM SGraitcer@cdc.gov OI Widdowson, Marc-Alain/0000-0002-0682-6933 NR 24 TC 13 Z9 13 U1 0 U2 10 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD SEP 13 PY 2013 VL 31 IS 40 BP 4368 EP 4374 DI 10.1016/j.vaccine.2013.07.018 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 219MG UT WOS:000324510500016 PM 23911781 ER PT J AU Dodd, CN Romio, SA Black, S Vellozzi, C Andrews, N Sturkenboom, M Zuber, P Hua, W Bonhoeffer, J Buttery, J Crawford, N Deceuninck, G de Vries, C De Wals, P Gutierrez-Gimeno, MV Heijbel, H Hughes, H Hur, K Hviid, A Kelman, J Kilpi, T Chuang, SK Macartney, K Rett, M Lopez-Callada, VR Salmon, D Sanchez, FG Sanz, N Silverman, B Storsaeter, J Thirugnanam, U van der Maas, N Yih, K Zhang, T Izurieta, H AF Dodd, Caitlin N. Romio, Silvana A. Black, Steven Vellozzi, Claudia Andrews, Nick Sturkenboom, Miriam Zuber, Patrick Hua, Wei Bonhoeffer, Jan Buttery, Jim Crawford, Nigel Deceuninck, Genevieve de Vries, Corinne De Wals, Philippe Gutierrez-Gimeno, M. Victoria Heijbel, Harald Hughes, Hayley Hur, Kwan Hviid, Anders Kelman, Jeffrey Kilpi, Tehri Chuang, S. K. Macartney, Kristine Rett, Melisa Lopez-Callada, Vesta Richardson Salmon, Daniel Sanchez, Francisco Gimenez Sanz, Nuria Silverman, Barbara Storsaeter, Jann Thirugnanam, Umapathi van der Maas, Nicoline Yih, Katherine Zhang, Tao Izurieta, Hector CA Global H1N1 GBS Consortium TI International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines SO VACCINE LA English DT Article DE Guillain Barre Syndrome (GBS); Monovalent H1N1 Vaccine (H1N1); Self-controlled case-series method (SCCS); International; Adjuvant; Adverse events following immunization (AEFI) ID CONTROLLED CASE SERIES; UNITED-KINGDOM; ADJUVANTED VACCINE; ADVERSE EVENTS; SAFETY; IMMUNIZATION; LICENSURE; SURVEILLANCE; ASSOCIATION; PROGRAM AB Background: The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barre syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination. Methods: The primary analysis used the self-controlled case series (SCCS) design to estimate the relative incidence (RI) of GBS in the 42 days following vaccination with pH1N1 vaccine in a pooled analysis across databases and in analysis using a meta-analytic approach. Results: We found a relative incidence of GBS of 2.42(95% CI 1.58-3.72) in the 42 days following exposure to pH1N1 vaccine in analysis of pooled data and 2.09(95% CI 1.28-3.42) using the meta-analytic approach. Conclusions: This study demonstrates that international collaboration to evaluate serious outcomes using a common protocol is feasible. The significance and consistency of our findings support a conclusion of an association between 2009 H1N1 vaccination and GBS. Given the rarity of the event the relative incidence found does not provide evidence in contradiction to international recommendations for the continued use of influenza vaccines. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Dodd, Caitlin N.] Cincinnati Childrens Hosp Med Ctr, Dept Biostat & Epidemiol, Cincinnati, OH 45229 USA. [Romio, Silvana A.; Sturkenboom, Miriam] Erasmus Univ, Med Ctr, Dept Med Informat, Rotterdam, Netherlands. [Black, Steven] Cincinnati Childrens Hosp Med Ctr, Dept Global Child Hlth, Cincinnati, OH 45229 USA. [Vellozzi, Claudia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Andrews, Nick] Hlth Protect Agcy, London, England. [Zuber, Patrick] WHO, Dept Immunizat Vaccines & Biol IVB, CH-1211 Geneva, Switzerland. [Hua, Wei; Izurieta, Hector] US FDA, Ctr Biol Evaluat & Res, Off Biost & Epidemiol, Rockville, MD 20857 USA. [Bonhoeffer, Jan] Brighton Collaborat Fdn, Basel, Switzerland. [Bonhoeffer, Jan] Univ Childrens Hosp, Basel, Switzerland. [Buttery, Jim] Monash Univ, Dept Paediat, Murdoch Childrens Res Inst, Clayton, Vic 3800, Australia. [Crawford, Nigel] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia. [Deceuninck, Genevieve; De Wals, Philippe] Quebec Univ Hosp, Res Ctr, Publ Hlth Res Unit, Quebec City, PQ, Canada. [de Vries, Corinne] Univ Bath, Dept Pharm & Pharmacol, Bath, Avon, England. [Gutierrez-Gimeno, M. Victoria] Ctr Publ Hlth Res CSISP FISABIO, Vaccine Dept, Valencia, Spain. [Heijbel, Harald] Swedish Inst Infect Dis, Lund, Sweden. [Hughes, Hayley] US Dept Def, Washington, DC 20305 USA. [Hur, Kwan] Hines Vet Affairs Hosp, Pharm Benefit Management Serv, Ctr Med Safety, Hines, IL USA. [Hviid, Anders] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark. [Kelman, Jeffrey] Ctr Medicare Serv, Ctr Drug & Hlth Plan Choice, Baltimore, MD USA. [Kelman, Jeffrey] Ctr Medicaid Serv, Baltimore, MD USA. [Kilpi, Tehri] Natl Inst Hlth & Welf, Helsinki, Finland. [Chuang, S. K.] Ctr Hlth Protect, Dept Hlth, Hong Kong, Hong Kong, Peoples R China. [Macartney, Kristine] Childrens Hosp Westmead, Westmead, NSW, Australia. [Rett, Melisa; Yih, Katherine] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Rett, Melisa; Yih, Katherine] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Lopez-Callada, Vesta Richardson] Natl Ctr Child & Adolescent Hlth, Mexico City, DF, Mexico. [Salmon, Daniel] US Dept Hlth & Human Serv, Off Assistant Secretary Hlth, Natl Vaccine Program Off, Washington, DC USA. [Salmon, Daniel] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Salmon, Daniel] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD USA. [Sanchez, Francisco Gimenez] Torrecardenas Hosp, Dept Pediat, Almeria, Spain. [Sanz, Nuria] Hosp Clin & Prov Barcelona SCReN, Barcelona, Spain. [Silverman, Barbara] Maccabi Healthcare Serv, Tel Aviv, Israel. [Storsaeter, Jann] Norwegian Inst Publ Hlth, Oslo, Norway. [Thirugnanam, Umapathi] Natl Neurosci Inst, Singapore, Singapore. [van der Maas, Nicoline] RIVM, Bilthoven, Netherlands. Fudan Univ, Dept Epidemiology, Sch Publ Hlth, Key Lab Publ Hlth Safety,Minist Educ, Shanghai 200433, Peoples R China. RP Dodd, CN (reprint author), Cincinnati Childrens Hosp Med Ctr, Dept Biostat & Epidemiol, Cincinnati, OH 45229 USA. EM c.dodd@erasmusmc.nl RI Bonhoeffer, Jan/E-5903-2014; Sammon, Cormac/B-7340-2015; Addis, Antonio/J-7894-2016; CPRD, CPRD/B-9594-2017; OI Sammon, Cormac/0000-0002-7921-4858; Addis, Antonio/0000-0003-0962-9959; Kulldorff, Martin/0000-0002-5284-2993; Clothier, Hazel Joanne/0000-0001-7594-0361; Silverman, Barbara/0000-0002-0337-4919; Cheng, Allen/0000-0003-3152-116X FU World Health Organization; US Food and Drug Administration FX Minimal funding was provided by the World Health Organization and by the US Food and Drug Administration for creation and maintenance of an online workspace as well as travel for group statisticians to conduct data analysis. No funding was provided to investigators for their participation. NR 46 TC 29 Z9 29 U1 8 U2 194 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 13 PY 2013 VL 31 IS 40 BP 4448 EP 4458 DI 10.1016/j.vaccine.2013.06.032 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 219MG UT WOS:000324510500027 PM 23770307 ER PT J AU Mao, B Patel, MK Hennessey, K Duncan, RJW Wannemuehler, K Soeung, SC AF Mao, Bunsoth Patel, Minal K. Hennessey, Karen Duncan, Richard J. W. Wannemuehler, Kathleen Soeung, Sann Chan TI Prevalence of chronic hepatitis B virus infection after implementation of a hepatitis B vaccination program among children in three provinces in Cambodia SO VACCINE LA English DT Article DE Hepatitis B virus; Cambodia; Seroprevalence; Vaccine ID COLD-CHAIN; SURFACE-ANTIGEN; IMMUNIZATION; EPIDEMIOLOGY; INDONESIA; DELIVERY; VIETNAM; INFANTS; DEVICE; CHINA AB Background: Hepatitis B virus (HBV) is highly endemic in Cambodia with an estimated pre-vaccine hepatitis B surface antigen (HBsAg) prevalence of 9%. By 2005, a hepatitis B vaccination program was implemented to decrease infection rates in children. We conducted a serosurvey to evaluate the impact of the vaccination program in 2011. Methods: A cross-sectional two-stage cluster survey was conducted to estimate HBsAg prevalence among children born from 2006 to 2007 in three provinces: Phnom Penh (urban), Kratie (rural), and Ratanakiri (remote). Demographic data, as well as written or oral vaccination history were collected. Children were tested for HBsAg. Factors associated with undervaccination and HBsAg positivity were modeled. Results: Coverage of timely hepatitis B vaccine birth dose (administered at <= 24 h) was 55% in Phnom Penh, 36% in Kratie, and 22% in Ratanakiri. Coverage with >= 3 hepatitis B vaccine doses (HepB3) was 91% in Phnom Penh, 82% in Kratie, and 64% in Ratanakiri. When compared with children who were born in health facilities with a skilled birth attendant (SBA), children born at home without a SBA were more likely not to have received a timely BD (adjusted relative risk [aRR] = 1.94; 95% CI = 1.75-2.15) as were children born at home with an SBA (aRR = 1.54; 95% CI = 1.32-1.80). The proportion of children who tested positive for HBsAg was 0.33% in Phnom Penh, 1.41% in Kratie, and 3.45% in Ratanakiri. In all three provinces, children who received their first dose after 7 days of life and children who never received hepatitis B vaccine had the highest HBsAg prevalence. Conclusions: Progress has been made in Cambodia in decreasing the burden of chronic HBV infection among children. Improvements in vaccination coverage will further decrease the burden of disease. (C) 2013 World Health Organization. Published by Elsevier Ltd. All rights reserved. C1 [Mao, Bunsoth] Univ Hlth Sci, Phnom Penh, Cambodia. [Patel, Minal K.; Wannemuehler, Kathleen] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Hennessey, Karen] WHO, Reg Off Western Pacific, Expanded Programme Immunizat, Manila 1000, Philippines. [Duncan, Richard J. W.] WHO, Expanded Programme Immunizat, Phnom Penh, Cambodia. [Soeung, Sann Chan] Minist Hlth, Natl Immunizat Program, Phnom Penh, Cambodia. RP Mao, B (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM maobunsoth888@yahoo.com; hgo9@cdc.gov; hennesseyk@wpro.who.int; duncanr@wpro.who.int; kpw9@cdc.gov; workmoh@gmail.com FU World Health Organization's Regional Office for the Western Pacific FX This work was supported by the World Health Organization's Regional Office for the Western Pacific. NR 34 TC 6 Z9 6 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD SEP 13 PY 2013 VL 31 IS 40 BP 4459 EP 4464 DI 10.1016/j.vaccine.2013.05.009 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 219MG UT WOS:000324510500028 PM 23684825 ER PT J AU Roellig, DM Gomez-Puerta, LA Mead, DG Pinto, J Ancca-Juarez, J Calderon, M Bern, C Gilman, RH Cama, VA AF Roellig, Dawn M. Gomez-Puerta, Luis A. Mead, Daniel G. Pinto, Jesus Ancca-Juarez, Jenny Calderon, Maritza Bern, Caryn Gilman, Robert H. Cama, Vitaliano A. CA Chagas Disease Workgrp Arequipa TI Hemi-Nested PCR and RFLP Methodologies for Identifying Blood Meals of the Chagas Disease Vector, Triatoma infestans SO PLOS ONE LA English DT Article ID POLYMERASE-CHAIN-REACTION; TRYPANOSOMA-CRUZI; FEEDING PATTERNS; REDUVIIDAE; HEMIPTERA; IDENTIFICATION; TRANSMISSION; ARGENTINA; INFECTION; AREQUIPA AB Trypanosoma cruzi, the etiologic agent of Chagas disease, is transmitted by hematophagous reduviid bugs within the subfamily Triatominae. These vectors take blood meals from a wide range of hosts, and their feeding behaviors have been used to investigate the ecology and epidemiology of T. cruzi. In this study we describe two PCR-based methodologies that amplify a fragment of the 16S mitochondrial rDNA, aimed to improve the identification of blood meal sources for Triatoma infestans: a.-Sequence analyses of two heminested PCRs that allow the identification of mammalian and avian species, and b.-restriction fragment length polymorphism (RFLP) analysis from the mammalian PCR to identify and differentiate multi-host blood meals. Findings from both methodologies indicate that host DNA could be detected and the host species identified in samples from laboratory reared and field collected triatomines. The implications of this study are two-fold. First, these methods can be used in areas where the fauna diversity and feeding behavior of the triatomines are unknown. Secondly, the RFLP method led to the identification of multi-host DNA from T. infestans gut contents, enhancing the information provided by this assay. These tools are important contributions for ecological and epidemiological studies of vector-borne diseases. C1 [Roellig, Dawn M.; Bern, Caryn; Cama, Vitaliano A.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Gomez-Puerta, Luis A.] Univ Nacl Mayor San Marcos, Lima 14, Peru. [Mead, Daniel G.] Univ Georgia, Southeastern Cooperat Wildlife Dis Study, Athens, GA 30602 USA. [Pinto, Jesus; Ancca-Juarez, Jenny; Calderon, Maritza] Univ Peruana Cayetano Heredia, Lima, Peru. [Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Cama, VA (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. EM vec5@cdc.gov OI Gomez-Puerta, Luis/0000-0002-7909-979X FU National Institute of Allergy and Infectious Diseases [5P50 AI074285-03, 04, 1K01AI079162-03, 3K01AI079162-02S1]; DPDM PDB Centers for Disease Control and Prevention (CDC); Emerging Infectious Diseases (EID); CDC FX This work was supported in part by the National Institute of Allergy and Infectious Diseases projects 5P50 AI074285-03 and 04, 1K01AI079162-03 and 3K01AI079162-02S1, DPDM PDB Centers for Disease Control and Prevention (CDC), and by an appointment (DMR) to the Emerging Infectious Diseases (EID) Fellowship Program administered by the Association of Public Health Laboratories (APHL) and funded by CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 1 Z9 1 U1 1 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 11 PY 2013 VL 8 IS 9 AR e74713 DI 10.1371/journal.pone.0074713 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 248VW UT WOS:000326734500117 PM 24040328 ER PT J AU Jorquera, PA Choi, Y Oakley, KE Powell, TJ Boyd, JG Palath, N Haynes, LM Anderson, LJ Tripp, RA AF Jorquera, Patricia A. Choi, Youngjoo Oakley, Katie E. Powell, Thomas J. Boyd, James G. Palath, Naveen Haynes, Lia M. Anderson, Larry J. Tripp, Ralph A. TI Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease SO PLOS ONE LA English DT Article ID ATTACHMENT G-GLYCOPROTEIN; T-CELL RESPONSES; G FUSION PROTEIN; BALB/C MICE; DENDRITIC CELLS; F-GLYCOPROTEIN; SEROPOSITIVE CHILDREN; ACID) NANOPARTICLES; ANTIBODY-RESPONSE; SUBUNIT VACCINE AB Nanoparticle vaccines were produced using layer-by-layer fabrication and incorporating respiratory syncytial virus (RSV) G protein polypeptides comprising the CX3C chemokine motif. BALB/c mice immunized with G protein nanoparticle vaccines produced a neutralizing antibody response that inhibited RSV replication in the lungs following RSV challenge. ELISPOT analysis showed that G nanoparticle vaccinated mice had increased levels of RSV G protein-specific IL-4 and IFN-gamma secreting cells compared to controls following RSV challenge. Remarkably, RSV challenge of G protein nanoparticle vaccinated mice resulted in increased RSV M2-specific IL-4 and IFN-gamma secreting T cells, and increased M2-specific H-2Kd-tetramer positive CD8(+) T cells in the lungs compared to controls. Cell type analysis showed vaccination was not associated with increased pulmonary eosinophilia following RSV challenge. These results demonstrate that vaccination of mice with the RSV G protein nanoparticle vaccines induces a potent neutralizing antibody response, increased G protein-and M2- specific T cell responses, and a reduction in RSV disease pathogenesis. C1 [Jorquera, Patricia A.; Choi, Youngjoo; Oakley, Katie E.; Tripp, Ralph A.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. [Powell, Thomas J.; Boyd, James G.; Palath, Naveen] Artificial Cell Technol, New Haven, CT USA. [Haynes, Lia M.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Anderson, Larry J.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. RP Tripp, RA (reprint author), Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. EM ratripp@uga.edu OI Tripp, Ralph/0000-0002-2924-9956 FU National Institutes of Health [5 R01 AI 99744-3]; Georgia Research Alliance FX This research was supported in part by the National Institutes of Health (5 R01 AI 99744-3) and through the Georgia Research Alliance to RT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 84 TC 20 Z9 20 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 10 PY 2013 VL 8 IS 9 AR e74905 DI 10.1371/journal.pone.0074905 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 259PK UT WOS:000327538600120 PM 24040360 ER PT J AU Jafri, RZ Ali, A Messonnier, NE Tevi-Benissan, C Durrheim, D Eskola, J Fermon, F Klugman, KP Ramsay, M Sow, S Shao, ZJ Bhutta, ZA Abramson, J AF Jafri, Rabab Z. Ali, Asad Messonnier, Nancy E. Tevi-Benissan, Carol Durrheim, David Eskola, Juhani Fermon, Florence Klugman, Keith P. Ramsay, Mary Sow, Samba Shao Zhujun Bhutta, Zulfiqar A. Abramson, Jon TI Global epidemiology of invasive meningococcal disease SO POPULATION HEALTH METRICS LA English DT Review DE Meningococcus; Neisseria meningitidis; Invasive meningococcal disease; Meningitis; Epidemiology; Meningitis belt ID NEISSERIA-MENINGITIDIS; BACTERIAL-MENINGITIS; SEROGROUP W135; AFRICA; EMERGENCE; VACCINE; RISK; PREVENTION; IMPACT; CANADA AB Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other manifestations. In countries with high endemic rates, the disease burden places an immense strain on the public health system. The worldwide epidemiology of invasive meningococcal disease (IMD) varies markedly by region and over time. This review summarizes the burden of IMD in different countries and identifies the highest-incidence countries where routine preventive programs against Neisseria meningitidis would be most beneficial in providing protection. Available epidemiological data from the past 20 years in World Health Organization and European Centre for Disease Prevention and Control collections and published articles are included in this review, as well as direct communications with leading experts in the field. Countries were grouped into high-, moderate-, and low-incidence countries. The majority of countries in the high-incidence group are found in the African meningitis belt; many moderate-incidence countries are found in the European and African regions, and Australia, while low-incidence countries include many from Europe and the Americas. Priority countries for vaccine intervention are high-and moderate-incidence countries where vaccine-preventable serogroups predominate. Epidemiological data on burden of IMD are needed in countries where this is not known, particularly in South-East Asia and Eastern Mediterranean regions, so evidence-based decisions about the use of meningococcal vaccines can be made. C1 [Jafri, Rabab Z.; Ali, Asad; Bhutta, Zulfiqar A.] Aga Khan Univ, Div Women & Child Hlth, Dept Pediat & Child Hlth, Karachi, Pakistan. [Messonnier, Nancy E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Tevi-Benissan, Carol] World Hlth Org, Geneva, Switzerland. [Durrheim, David] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia. [Durrheim, David] Hunter New England Area, Wallsend, Tyne & Wear, Australia. [Eskola, Juhani] Finnish Natl Inst Hlth & Welf THL, Helsinki, Finland. [Fermon, Florence] Med Sans Frontieres, Internat Vaccinat Working Grp, Paris, France. [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Klugman, Keith P.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Klugman, Keith P.] MRC, Johannesburg, South Africa. [Ramsay, Mary] Ctr Infect Colindale, Immunisat Dept, Hlth Protect Agcy, London, England. [Sow, Samba] Minist Hlth, Ctr Vaccine Dev, Bamako, Mali. [Sow, Samba] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Shao Zhujun] Inst Communicable Dis Control & Prevent, Beijing, Peoples R China. [Abramson, Jon] Wake Forest Sch Med, Winston Salem, NC USA. RP Ali, A (reprint author), Aga Khan Univ, Div Women & Child Hlth, Dept Pediat & Child Hlth, Stadium Rd, Karachi, Pakistan. EM asad.ali@aku.edu NR 51 TC 61 Z9 65 U1 1 U2 30 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-7954 J9 POPUL HEALTH METR JI Popul. Health Metr. PD SEP 10 PY 2013 VL 11 AR 17 DI 10.1186/1478-7954-11-17 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 223PU UT WOS:000324819600001 PM 24016339 ER PT J AU Brown, KK Shaw, PB Mead, KR Kovein, RJ Voorhees, RT Brandes, AR AF Brown, Kenneth K. Shaw, Peter B. Mead, Kenneth R. Kovein, Ronald J. Voorhees, Robert T. Brandes, Adam R. TI Chemical exposure monitor with indoor positioning (CEMWIP) SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 246th National Meeting of the American-Chemical-Society (ACS) CY SEP 08-12, 2013 CL Indianapolis, IN SP Amer Chem Soc C1 [Brown, Kenneth K.; Shaw, Peter B.; Mead, Kenneth R.; Kovein, Ronald J.] NIOSH, Div Appl Res & Technol, Chem Exposure Monitoring Branch, Cincinnati, OH 45226 USA. [Voorhees, Robert T.] Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA. [Brandes, Adam R.] MeasureNet Technol Ltd, Cincinnati, OH 45226 USA. EM krb1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD SEP 8 PY 2013 VL 246 MA 246-ENVR PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 288NJ UT WOS:000329618403706 ER PT J AU Brown, KK Mead, KR Shaw, PB Kovein, RJ Voorhees, RT Brandes, AR AF Brown, Kenneth K. Mead, Kenneth R. Shaw, Peter B. Kovein, Ronald J. Voorhees, Robert T. Brandes, Adam R. TI Personal PID chemical sensor coupled with a real-time location system to create a novel direct-reading exposure assessment method SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 246th National Meeting of the American-Chemical-Society (ACS) CY SEP 08-12, 2013 CL Indianapolis, IN SP Amer Chem Soc C1 [Brown, Kenneth K.; Mead, Kenneth R.; Shaw, Peter B.; Kovein, Ronald J.] NIOSH, Div Appl Res & Technol, Chem Exposure Monitoring Branch, Cincinnati, OH 45226 USA. [Voorhees, Robert T.] Univ Cincinnati, Dept Chem, Cincinnati, OH 45221 USA. [Brandes, Adam R.] MeasureNet Technol Ltd, Cincinnati, OH 45226 USA. EM krb1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD SEP 8 PY 2013 VL 246 MA 104-ENVR PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 288NJ UT WOS:000329618403576 ER PT J AU Geraci, C Hodson, L AF Geraci, Charles Hodson, Laura TI New horizons, emerging technologies, converging safety cultures? Learning from the challenges of nanotechnology SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 246th National Meeting of the American-Chemical-Society (ACS) CY SEP 08-12, 2013 CL Indianapolis, IN SP Amer Chem Soc C1 [Geraci, Charles; Hodson, Laura] NIOSH, Nanotechnol Res Ctr, Cincinnati, OH 45226 USA. EM cgeraci@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD SEP 8 PY 2013 VL 246 MA 8-CHAS PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 288NJ UT WOS:000329618401389 ER PT J AU Hodson, LL Geraci, C AF Hodson, Laura L. Geraci, Charles TI New horizons, lessons from the Nanotechnology Research Center: Understanding and managing laboratory health and safety of a new or emerging technology SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 246th National Meeting of the American-Chemical-Society (ACS) CY SEP 08-12, 2013 CL Indianapolis, IN SP Amer Chem Soc C1 [Hodson, Laura L.; Geraci, Charles] NIOSH, Nanotechnol Res Ctr, Cincinnati, OH 45226 USA. EM lhodson@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD SEP 8 PY 2013 VL 246 MA 7-CHAS PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 288NJ UT WOS:000329618401388 ER PT J AU Kanitz, MH AF Kanitz, Mary Helen TI Analysis of a serum biomarker of exposure to chemical toxicants SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY LA English DT Meeting Abstract CT 246th National Meeting of the American-Chemical-Society (ACS) CY SEP 08-12, 2013 CL Indianapolis, IN SP Amer Chem Soc C1 [Kanitz, Mary Helen] NIOSH, Cincinnati, OH 45226 USA. EM mhk2@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0065-7727 J9 ABSTR PAP AM CHEM S JI Abstr. Pap. Am. Chem. Soc. PD SEP 8 PY 2013 VL 246 MA 78-TOXI PG 1 WC Chemistry, Multidisciplinary SC Chemistry GA 288NJ UT WOS:000329618407256 ER PT J AU Wegayehu, T Adamu, H Petros, B AF Wegayehu, Teklu Adamu, Haileeyesus Petros, Beyene TI Prevalence of Giardia duodenalis and Cryptosporidium species infections among children and cattle in North Shewa Zone, Ethiopia SO BMC INFECTIOUS DISEASES LA English DT Article DE Giardia duodenalis; Cryptosporidium; Prevalence; Zoonotic transmission ID DAIRY CALVES; EPIDEMIOLOGY; DIARRHEA; HUMANS AB Background: Giardia and Cryptosporidium are the most common causes of protozoan diarrhea that lead to significant morbidity and mortality worldwide. The purpose of this study was to determine the prevalence of Giardia duodenalis and Cryptosporidium species infections among children and cattle, and to assess the potential risk of zoonotic transmission. Methods: This cross-sectional study was conducted between January and April 2009 in Girar Jarso and Dera Districts of North Shewa Zone, Oromia Region, Ethiopia. A total of 768 stool specimens were collected and examined for intestinal parasites using direct wet mount with saline and formalin ether concentration methods. The modified Ziehl-Neelsen staining method was used for the detection of Cryptosporidium species. Statistical analysis was performed using SPSS software version 15. Results: Out of 384 children examined, 53 (13.8%) and 28 (7.3%) were positive for Giardia and Cryptosporidium infections, respectively. Similarly, of the total 384 cattle examined, 9 (2.3%) were positive for Giardia duodenalis and 30 (7.8%) were positive for Cryptosporidium infection. The prevalence of giardiasis was significantly higher among children who had close contact with cattle 33 (18.7%) compared to children who had no contact with cattle 20 (9.6%) (P < 0.05). Higher number of Cryptosporidium infection was also recorded in children who had close contact with cattle 15 (8.5%). Difference in prevalence of giardiasis and cryptosporidiosis among children was not statistically significant between males and females. On the other hand, difference in the prevalence of giardiasis among children was statistically significant between age groups. Conclusions: Higher prevalence of Giardia duodenalis infection detected among children was significantly associated with contact with cattle and manure that the children had. Further analysis using molecular techniques is needed to explain the existence of zoonotic transmission in the study area. C1 [Wegayehu, Teklu] Arba Minch Univ, Dept Biol, Coll Nat Sci, Arba Minch, Ethiopia. [Wegayehu, Teklu] Univ Addis Ababa, Aklilu Lemma Inst Pathobiol, Addis Ababa, Ethiopia. [Adamu, Haileeyesus] Ctr Dis Control & Prevent CDC, Atlanta, GA 30329 USA. [Adamu, Haileeyesus; Petros, Beyene] Univ Addis Ababa, Coll Nat Sci, Dept Microbial Cellular & Mol Biol, Addis Ababa, Ethiopia. RP Wegayehu, T (reprint author), Arba Minch Univ, Dept Biol, Coll Nat Sci, Arba Minch, Ethiopia. EM tekluweg2007@yahoo.com OI Adamu, Haileeyesus/0000-0003-2998-5977 FU Addis Ababa University; North Shewa Zone FX We duly acknowledge Addis Ababa University for the financial support. We are also grateful to the support of North Shewa Zone and the respective district administrators. Our special thanks go to Mr. Tesfaye Habtemariam and Mr. Simon Shibru for their language edition, and to the data collectors for their contribution. NR 35 TC 19 Z9 19 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD SEP 8 PY 2013 VL 13 AR 419 DI 10.1186/1471-2334-13-419 PG 7 WC Infectious Diseases SC Infectious Diseases GA 235NU UT WOS:000325726900001 PM 24010794 ER PT J AU Choopanya, K Martin, M Vanichseni, S Mock, PA Suntharasamai, P Sangkum, U AF Choopanya, Kachit Martin, Michael Vanichseni, Suphak Mock, Philip A. Suntharasamai, Pravan Sangkum, Udomsak TI HIV antiretroviral prophylaxis for injecting drug users Reply SO LANCET LA English DT Letter C1 [Choopanya, Kachit; Vanichseni, Suphak; Suntharasamai, Pravan; Sangkum, Udomsak] Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Martin, Michael; Mock, Philip A.] Thailand Minist Publ Hlth US CDC Collaborat, Nonthaburi 11000, Thailand. [Martin, Michael] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Martin, M (reprint author), Thailand Minist Publ Hlth US CDC Collaborat, Nonthaburi 11000, Thailand. EM znd9@cdc.gov NR 5 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD SEP 7 PY 2013 VL 382 IS 9895 BP 855 EP 855 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 215WE UT WOS:000324240700019 PM 24012264 ER PT J AU Cotter, C Sturrock, HJW Hsiang, MS Liu, J Phillips, AA Hwang, J Gueye, CS Fullman, N Gosling, RD Feachem, RGA AF Cotter, Chris Sturrock, Hugh J. W. Hsiang, Michelle S. Liu, Jenny Phillips, Allison A. Hwang, Jimee Gueye, Cara Smith Fullman, Nancy Gosling, Roly D. Feachem, Richard G. A. TI The changing epidemiology of malaria elimination: new strategies for new challenges SO LANCET LA English DT Review ID PLASMODIUM-FALCIPARUM INFECTIONS; SOUTH-AFRICA; VIVAX MALARIA; KNOWLESI MALARIA; RISK-FACTORS; PERSONAL PROTECTION; HIDDEN POPULATIONS; INTEGRATED CONTROL; COUNTRY EMBARKING; VECTOR DENSITIES AB Malaria-eliminating countries achieved remarkable success in reducing their malaria burdens between 2000 and 2010. As a result, the epidemiology of malaria in these settings has become more complex. Malaria is increasingly imported, caused by Plasmodium vivax in settings outside sub-Saharan Africa, and clustered in small geographical areas or clustered demographically into subpopulations, which are often predominantly adult men, with shared social, behavioural, and geographical risk characteristics. The shift in the populations most at risk of malaria raises important questions for malaria-eliminating countries, since traditional control interventions are likely to be less effective. Approaches to elimination need to be aligned with these changes through the development and adoption of novel strategies and methods. Knowledge of the changing epidemiological trends of malaria in the eliminating countries will ensure improved targeting of interventions to continue to shrink the malaria map. C1 [Cotter, Chris; Sturrock, Hugh J. W.; Hsiang, Michelle S.; Liu, Jenny; Phillips, Allison A.; Hwang, Jimee; Gueye, Cara Smith; Fullman, Nancy; Gosling, Roly D.; Feachem, Richard G. A.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94105 USA. [Hsiang, Michelle S.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94105 USA. [Hwang, Jimee] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. RP Cotter, C (reprint author), Univ Calif San Francisco, Global Hlth Grp, 50 Beale St,Suite 1200, San Francisco, CA 94105 USA. EM cotterc@globalhealth.ucsf.edu FU Bill & Melinda Gates Foundation FX The work of the Global Health Group on malaria elimination is supported by a grant from the Bill & Melinda Gates Foundation. We thank the reviewers of this paper, including Patrick Kachur and John MacArthur of the CDC malaria branch, for their helpful comments; and Saehee Lee, Kelly Sanders, Kerstin Svendsen, and Hyun-Ju Woo for their assistance in data collection and preparation of the report. NR 142 TC 188 Z9 192 U1 7 U2 84 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD SEP 7 PY 2013 VL 382 IS 9895 BP 900 EP 911 DI 10.1016/S0140-6736(13)60310-4 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 215WE UT WOS:000324240700032 PM 23594387 ER PT J AU Leidel, L Groseclose, SL Burney, B Navin, P Wooster, M AF Leidel, Laura Groseclose, Samuel L. Burney, Bruce Navin, Phil Wooster, Mark TI CDC's Emergency Management Program Activities-Worldwide, 2003-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Leidel, Laura; Groseclose, Samuel L.] CDC, Off Sci & Publ Hlth Practice, Atlanta, GA 30333 USA. [Burney, Bruce; Navin, Phil; Wooster, Mark] CDC, Div Emergency Operat, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP Leidel, L (reprint author), CDC, Off Sci & Publ Hlth Practice, Atlanta, GA 30333 USA. EM lleidel@cdc.gov NR 3 TC 6 Z9 6 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 6 PY 2013 VL 62 IS 35 BP 709 EP 713 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WQ UT WOS:000326057100001 ER PT J AU Hilborn, ED Wade, TJ Hicks, L Garrison, L Carpenter, J Adam, E Mull, B Yoder, J Roberts, V Gargano, JW AF Hilborn, Elizabeth D. Wade, Timothy J. Hicks, Lauri Garrison, Laurel Carpenter, Joe Adam, Elizabeth Mull, Bonnie Yoder, Jonathan Roberts, Virginia Gargano, Julia W. TI Surveillance for Waterborne Disease Outbreaks Associated with Drinking Water and Other Nonrecreational Water - United States, 2009-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID QUALITY C1 [Hilborn, Elizabeth D.; Wade, Timothy J.] US EPA, Washington, DC USA. [Hicks, Lauri; Garrison, Laurel] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Carpenter, Joe] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Adam, Elizabeth; Mull, Bonnie; Yoder, Jonathan; Roberts, Virginia; Gargano, Julia W.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Gargano, JW (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM jgargano@cdc.gov NR 10 TC 38 Z9 38 U1 1 U2 21 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 6 PY 2013 VL 62 IS 35 BP 714 EP 720 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WQ UT WOS:000326057100003 ER PT J AU Schieb, LJ Greer, SA Ritchey, MD George, MG Casper, ML AF Schieb, Linda J. Greer, Sophia A. Ritchey, Matthew D. George, Mary G. Casper, Michele L. TI Vital Signs: Avoidable Deaths from Heart Disease, Stroke, and Hypertensive Disease - United States, 2001-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTH; CARE; MORTALITY; ADULTS AB Background: Deaths attributed to lack of preventive health care or timely and effective medical care can be considered avoidable. In this report, avoidable causes of death are either preventable, as in preventing cardiovascular events by addressing risk factors, or treatable, as in treating conditions once they have occurred. Although various definitions for avoidable deaths exist, studies have consistently demonstrated high rates in the United States. Cardiovascular disease is the leading cause of U.S. deaths (approximately 800,000 per year) and many of them (e.g., heart disease, stroke, and hypertensive deaths among persons aged <75 years) are potentially avoidable. Methods: National Vital Statistics System mortality data for the period 2001-2010 were analyzed. Avoidable deaths were defined as those resulting from an underlying cause of heart disease (ischemic or chronic rheumatic), stroke, of hypertensive disease in decedents aged <75 years. Rates and trends by age, sex, race/ethnicity, and place were calculated. Results: In 2010, an estimated 200,070 avoidable deaths from heart disease, stroke, and hypertensive disease occurred in the United States, 56% of which occurred among persons aged <65 years. The overall age-standardized death rate was 60.7 per 100,000. Rates were highest in the 65-74 years age group, among males, among non-Hispanic blacks, and in the South. During 2001-2010, the overall rate declined 29%, and rates of decline varied by age. Conclusions: Nearly one fourth of all cardiovascular disease deaths are avoidable. These deaths disproportionately occurred among non-Hispanic blacks and residents of the South. Persons aged <65 years had lower rates than those aged 65-74 years but still accounted for a considerable share of avoidable deaths and demonstrated less improvement. Implications for Public Health Practice: National, state, and local initiatives aimed at improving health-care systems and supporting healthy behaviors are essential to reducing avoidable heart disease, stroke, and hypertensive disease deaths. Strategies include promoting the ABCS (aspirin when appropriate, blood pressure control, cholesterol management, and smoking cessation), reducing sodium consumption, and creating healthy environments. C1 [Schieb, Linda J.; Greer, Sophia A.; Ritchey, Matthew D.; George, Mary G.; Casper, Michele L.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Schieb, LJ (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM lschieb@cdc.gov NR 22 TC 24 Z9 25 U1 0 U2 12 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 6 PY 2013 VL 62 IS 35 BP 721 EP 727 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WQ UT WOS:000326057100004 ER PT J AU Person, A Spitters, C Patrick, G Wasserman, C Vander Kelen, P VanEenwyk, J Gilboa, S Kucik, J Sorenson, R Ailes, E Stahre, M AF Person, Amy Spitters, Chris Patrick, Glen Wasserman, Cathy Vander Kelen, Patrick VanEenwyk, Juliet Gilboa, Suzanne Kucik, James Sorenson, Reed Ailes, Elizabeth Stahre, Mandy TI Investigation of a Cluster of Neural Tube Defects - Central Washington, 2010-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Spitters, Chris] Yakima Hlth Dist, Yakima, WA USA. [Patrick, Glen; Wasserman, Cathy; Vander Kelen, Patrick; VanEenwyk, Juliet] Washington State Dept Hlth, Washington, DC USA. [Gilboa, Suzanne; Kucik, James] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Sorenson, Reed] CDC, Council State & Territorial Epidemiologists, Atlanta, GA 30333 USA. [Ailes, Elizabeth; Stahre, Mandy] CDC, EIS, Atlanta, GA 30333 USA. RP Stahre, M (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM mstahre@cdc.gov NR 3 TC 5 Z9 7 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 6 PY 2013 VL 62 IS 35 BP 728 EP 728 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WQ UT WOS:000326057100005 ER PT J AU Corey, C Wang, BG Johnson, SE Apelberg, B Husten, C King, BA McAfee, TA Bunnell, R Arrazola, RA Dube, SR AF Corey, Catherine Wang, Baoguang Johnson, Sarah E. Apelberg, Benjamin Husten, Corinne King, Brian A. McAfee, Tim A. Bunnell, Rebecca Arrazola, Rene A. Dube, Shanta R. TI Electronic Cigarette Use Among Middle and High School Students - United States, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Corey, Catherine; Wang, Baoguang; Johnson, Sarah E.; Apelberg, Benjamin; Husten, Corinne] US FDA, Ctr Tobacco Prod, Rockville, MD 20857 USA. [King, Brian A.; McAfee, Tim A.; Bunnell, Rebecca; Arrazola, Rene A.; Dube, Shanta R.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP King, BA (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM baking@cdc.gov NR 4 TC 205 Z9 205 U1 3 U2 33 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD SEP 6 PY 2013 VL 62 IS 35 BP 729 EP 730 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 239WQ UT WOS:000326057100006 ER PT J AU Nakazawa, Y Lash, RR Carroll, DS Damon, IK Karem, KL Reynolds, MG Osorio, JE Rocke, TE Malekani, JM Muyembe, JJ Formenty, P Peterson, AT AF Nakazawa, Yoshinori Lash, R. Ryan Carroll, Darin S. Damon, Inger K. Karem, Kevin L. Reynolds, Mary G. Osorio, Jorge E. Rocke, Tonie E. Malekani, Jean M. Muyembe, Jean-Jacques Formenty, Pierre Peterson, A. Townsend TI Mapping Monkeypox Transmission Risk through Time and Space in the Congo Basin SO PLOS ONE LA English DT Article ID SPECIES DISTRIBUTION MODELS; ECOLOGICAL NICHE; GEOGRAPHIC-DISTRIBUTION; CLIMATE-CHANGE; UNITED-STATES; NORTH-AMERICA; VIRUS; DISTRIBUTIONS; NDVI; PREDICTION AB Monkeypox is a major public health concern in the Congo Basin area, with changing patterns of human case occurrences reported in recent years. Whether this trend results from better surveillance and detection methods, reduced proportions of vaccinated vs. non-vaccinated human populations, or changing environmental conditions remains unclear. Our objective is to examine potential correlations between environment and transmission of monkeypox events in the Congo Basin. We created ecological niche models based on human cases reported in the Congo Basin by the World Health Organization at the end of the smallpox eradication campaign, in relation to remotely-sensed Normalized Difference Vegetation Index datasets from the same time period. These models predicted independent spatial subsets of monkeypox occurrences with high confidence; models were then projected onto parallel environmental datasets for the 2000s to create present-day monkeypox suitability maps. Recent trends in human monkeypox infection are associated with broad environmental changes across the Congo Basin. Our results demonstrate that ecological niche models provide useful tools for identification of areas suitable for transmission, even for poorly-known diseases like monkeypox. C1 [Nakazawa, Yoshinori; Lash, R. Ryan; Carroll, Darin S.; Damon, Inger K.; Karem, Kevin L.; Reynolds, Mary G.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Nakazawa, Yoshinori] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Osorio, Jorge E.] Univ Wisconsin, Sch Vet Med, Dept Pathol Sci, Madison, WI 53706 USA. [Rocke, Tonie E.] USGS Natl Wildlife Hlth Ctr, Madison, WI USA. [Malekani, Jean M.] Univ Kinshasa, Kinshasa, Congo. [Muyembe, Jean-Jacques] Inst Natl Rech Biomed, Kinshasa, Congo. [Formenty, Pierre] WHO, Dept Communicable Dis Surveillance & Response, CH-1211 Geneva, Switzerland. [Peterson, A. Townsend] Univ Kansas, Biodivers Inst, Lawrence, KS 66045 USA. RP Nakazawa, Y (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ynakazawa@cdc.gov OI Peterson, A. Townsend/0000-0003-0243-2379; Rocke, Tonie/0000-0003-3933-1563 FU National Institutes of Health [1R01TW008859-01] FX This research was supported by the National Institutes of Health grant 1R01TW008859-01 ("Sylvatic Reservoirs of Human Monkeypox"). Use of trade, product, or firm names does not imply endorsement by the United States Government. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 3 Z9 3 U1 2 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 5 PY 2013 VL 8 IS 9 AR e74816 DI 10.1371/journal.pone.0074816 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 219CG UT WOS:000324481600147 PM 24040344 ER PT J AU Nasreen, S Khan, SU Azziz-Baumgartner, E Hancock, K Veguilla, V Wang, D Rahman, M Alamgir, ASM Sturm-Ramirez, K Gurley, ES Luby, SP Katz, JM Uyeki, TM AF Nasreen, Sharifa Khan, Salah Uddin Azziz-Baumgartner, Eduardo Hancock, Kathy Veguilla, Vic Wang, David Rahman, Mahmudur Alamgir, A. S. M. Sturm-Ramirez, Katharine Gurley, Emily S. Luby, Stephen P. Katz, Jacqueline M. Uyeki, Timothy M. TI Seroprevalence of Antibodies against Highly Pathogenic Avian Influenza A (H5N1) Virus among Poultry Workers in Bangladesh, 2009 SO PLOS ONE LA English DT Article ID RISK-FACTORS; HONG-KONG; INFECTION; MARKETS; INDONESIA; RESPONSES; VIETNAM; VACCINE; CHINA AB We conducted a cross-sectional study in 2009 to determine the seroprevalence and risk factors for highly pathogenic avian influenza A (H5N1) [HPAI H5N1] virus antibodies among poultry workers at farms and live bird markets with confirmed/suspected poultry outbreaks during 2009 in Bangladesh. We tested sera by microneutralization assay using A/Bangladesh/207095/2008 (H5N1; clade 2.2.2) virus with confirmation by horse red blood cell hemagglutination inhibition and H5-specific Western blot assays. We enrolled 212 workers from 87 farms and 210 workers from three live bird markets. One hundred and two farm workers (48%) culled poultry. One hundred and ninety-three farm workers (91%) and 178 market workers (85%) reported direct contact with poultry that died during a laboratory confirmed HPAI H5N1 poultry farm outbreak or market poultry die-offs from suspected HPAI H5N1. Despite exposure to sick poultry, no farm or market poultry workers were seropositive for HPAI H5N1 virus antibodies (95% confidence interval 0-1%). C1 [Nasreen, Sharifa; Khan, Salah Uddin; Sturm-Ramirez, Katharine; Gurley, Emily S.; Luby, Stephen P.] Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, Dhaka 1000, Bangladesh. [Azziz-Baumgartner, Eduardo; Hancock, Kathy; Veguilla, Vic; Wang, David; Sturm-Ramirez, Katharine; Luby, Stephen P.; Katz, Jacqueline M.; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rahman, Mahmudur; Alamgir, A. S. M.] Govt Bangladesh, Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. RP Nasreen, S (reprint author), Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, GPO Box 128, Dhaka 1000, Bangladesh. EM drsharifa74@gmail.com RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Khan, M. Salah Uddin Khan/0000-0001-5928-9257 FU Centers for Disease Control and Prevention (CDC) [5U51CI000298] FX This research study was funded by the Centers for Disease Control and Prevention (CDC) through their cooperative agreement with icddr, b (CA/Grant#5U51CI000298). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. CDC provided technical support for testing of the specimens. Eight co-authors of this manuscript are CDC employees who have contributed significantly and fulfill authorship criteria. NR 44 TC 6 Z9 6 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 5 PY 2013 VL 8 IS 9 AR UNSP e73200 DI 10.1371/journal.pone.0073200 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 219CG UT WOS:000324481600057 PM 24039887 ER PT J AU McCollum, JT Cronquist, AB Silk, BJ Jackson, KA O'Connor, KA Cosgrove, S Gossack, JP Parachini, SS Jain, NS Ettestad, P Ibraheem, M Cantu, V Joshi, M DuVernoy, T Fogg, NW Gorny, JR Mogen, KM Spires, C Teitell, P Joseph, LA Tarr, CL Imanishi, M Neil, KP Tauxe, RV Mahon, BE AF McCollum, Jeffrey T. Cronquist, Alicia B. Silk, Benjamin J. Jackson, Kelly A. O'Connor, Katherine A. Cosgrove, Shaun Gossack, Joe P. Parachini, Susan S. Jain, Neena S. Ettestad, Paul Ibraheem, Mam Cantu, Venessa Joshi, Manjiri DuVernoy, Tracy Fogg, Norman W., Jr. Gorny, James R. Mogen, Kathryn M. Spires, Charlotte Teitell, Paul Joseph, Lavin A. Tarr, Cheryl L. Imanishi, Maho Neil, Karen P. Tauxe, Robert V. Mahon, Barbara E. TI Multistate Outbreak of Listeriosis Associated with Cantaloupe SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID SURVEILLANCE NETWORK FOODNET; UNITED-STATES; FRESH PRODUCE; MONOCYTOGENES VIRULENCE; FOODBORNE ILLNESS; PULSENET; DISEASES; ESTABLISHMENT; EVOLUTION; PATHOGENS AB BACKGROUND Although new pathogen-vehicle combinations are increasingly being identified in produce-related disease outbreaks, fresh produce is a rarely recognized vehicle for listeriosis. We investigated a nationwide listeriosis outbreak that occurred in the United States during 2011. METHODS We defined an outbreak-related case as a laboratory-confirmed infection with any of five outbreak-related subtypes of Listeria monocytogenes isolated during the period from August 1 through October 31, 2011. Multistate epidemiologic, trace-back, and environmental investigations were conducted, and outbreak-related cases were compared with sporadic cases reported previously to the Listeria Initiative, an enhanced surveillance system that routinely collects detailed information about U.S. cases of listeriosis. RESULTS We identified 147 outbreak-related cases in 28 states. The majority of patients (127 of 147, 86%) were 60 years of age or older. Seven infections among pregnant women and newborns and one related miscarriage were reported. Of 145 patients for whom information about hospitalization was available, 143 (99%) were hospitalized. Thirty-three of the 147 patients (22%) died. Patients with outbreak-related illness were significantly more likely to have eaten cantaloupe than were patients 60 years of age or older with sporadic illness (odds ratio, 8.5; 95% confidence interval, 1.3 to infinity). Cantaloupe and environmental samples collected during the investigation yielded isolates matching all five outbreak-related subtypes, confirming that whole cantaloupe produced by a single Colorado farm was the outbreak source. Unsanitary conditions identified in the processing facility operated by the farm probably resulted in contamination of cantaloupes with L. monocytogenes. CONCLUSIONS Raw produce, including cantaloupe, can serve as a vehicle for listeriosis. This outbreak highlights the importance of preventing produce contamination within farm and processing environments. C1 [McCollum, Jeffrey T.; O'Connor, Katherine A.; Jain, Neena S.; Ibraheem, Mam; Imanishi, Maho] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Silk, Benjamin J.; Jackson, Kelly A.; O'Connor, Katherine A.; Joseph, Lavin A.; Tarr, Cheryl L.; Imanishi, Maho; Neil, Karen P.; Tauxe, Robert V.; Mahon, Barbara E.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [McCollum, Jeffrey T.; Cronquist, Alicia B.; Cosgrove, Shaun; Gossack, Joe P.; Parachini, Susan S.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Ettestad, Paul; Ibraheem, Mam] New Mexico Dept Hlth, Santa Fe, NM USA. [Cantu, Venessa] Dept State Hlth Serv, Austin, TX USA. [Joshi, Manjiri] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA. [DuVernoy, Tracy; Fogg, Norman W., Jr.; Gorny, James R.; Mogen, Kathryn M.; Spires, Charlotte; Teitell, Paul] US FDA, Silver Spring, MD USA. RP McCollum, JT (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. EM jeffrey.mccollum@us.army.mil NR 35 TC 70 Z9 73 U1 6 U2 84 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD SEP 5 PY 2013 VL 369 IS 10 BP 944 EP 953 DI 10.1056/NEJMoa1215837 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 211KV UT WOS:000323906900011 PM 24004121 ER PT J AU Arinaitwe, E Ades, V Walakira, A Ninsiima, B Mugagga, O Patil, TS Schwartz, A Kamya, MR Nasr, S Chang, M Filler, S Dorsey, G AF Arinaitwe, Emmanuel Ades, Veronica Walakira, Andrew Ninsiima, Boaz Mugagga, Olive Patil, Teja S. Schwartz, Alanna Kamya, Moses R. Nasr, Sussann Chang, Michelle Filler, Scott Dorsey, Grant TI Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy: A Cross-Sectional Study from Tororo, Uganda SO PLOS ONE LA English DT Article ID PLACEBO-CONTROLLED TRIAL; INSECTICIDE-TREATED NETS; LOW-BIRTH-WEIGHT; PLASMODIUM-FALCIPARUM; DRUG-RESISTANCE; HIGH PREVALENCE; WOMEN; EFFICACY; INFECTION; PARASITES AB Background: Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is widely recommended in sub-Saharan Africa to reduce the risk of malaria and improve birth outcomes. However, there are reports that the efficacy of IPTp with SP is waning, especially in parts of Africa where antimalarial resistance to this drug has become widespread. Methodology/Principal Findings: We conducted a cross-sectional study of 565 HIV-uninfected women giving birth at Tororo District Hospital in southeastern Uganda. The primary objective of the study was to measure associations between use of SP during pregnancy from antenatal records and the risk of adverse outcomes including placental malaria, low birth weight, maternal parasitemia and maternal anemia. The proportion of women who reported taking 0, 1, 2, and 3 doses of SP during pregnancy was 5.7%, 35.8%, 56.6% and 2.0% respectively. Overall, the prevalence of placental malaria was 17.5%, 28.1%, and 66.2% by placental smear, PCR, and histopathology, respectively. In multivariate analyses controlling for potential confounders, >= 2 doses of SP was associated with non-significant trends towards lower odds of placental malaria by placental smear (OR = 0.75, p = 0.25), placental malaria by PCR (OR = 0.93, p = 0.71), placental malaria by histopathology (OR = 0.75, p = 0.16), low birth weight (OR = 0.63, p = 0.11), maternal parasitemia (OR = 0.88, p = 0.60) and maternal anemia (OR = 0.88, p = 0.48). Using a composite outcome, >= 2doses of SP was associated with a significantly lower odds of placental malaria, low birth weight, maternal parasitemia, or maternal anemia (OR = 0.52, p = 0.01). Conclusions/Significance: In this area of Uganda with intense malaria transmission, the prevalence of placental malaria by histopathology was high even among women who reported taking at least 2 doses of SP during pregnancy. The reported use of >= 2 doses of SP was not associated with protection against individual birth and maternal outcome measures but did protect against a composite measure of any adverse outcome. C1 [Arinaitwe, Emmanuel; Walakira, Andrew; Ninsiima, Boaz; Mugagga, Olive] Infect Dis Res Collaborat, Kampala, Uganda. [Ades, Veronica] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA USA. [Patil, Teja S.; Schwartz, Alanna; Dorsey, Grant] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Nasr, Sussann; Chang, Michelle] Ctr Dis Control & Prevent, Atlanta, GA USA. [Filler, Scott] Global Fund Fight Acquired Immune Deficiency Synd, Geneva, Switzerland. RP Dorsey, G (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM gdorsey@medsfgh.ucsf.edu OI Ades, Veronica/0000-0002-9163-7511 FU U.S. President's Malaria Initiative [1U51CK000117] FX This work was supported by the U.S. President's Malaria Initiative through a cooperative agreement with the Centers for Disease Control and Prevention (1U51CK000117). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 13 Z9 13 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 4 PY 2013 VL 8 IS 9 AR e73073 DI 10.1371/journal.pone.0073073 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 219OE UT WOS:000324515600065 PM 24023811 ER PT J AU Bristow, CC Podewils, LJ Bronner, LE Bantubani, N van der Walt, M Peters, A Mametja, D AF Bristow, Claire C. Podewils, Laura Jean Bronner, Liza Ellen Bantubani, Nonkqubela van der Walt, Martie Peters, Annatjie Mametja, David TI TB tracer teams in South Africa: knowledge, practices and challenges of tracing TB patients to improve adherence SO BMC PUBLIC HEALTH LA English DT Article DE Tuberculosis; Default tracing; Treatment management; KAP; Treatment adherence; Community outreach ID MULTIDRUG-RESISTANT TUBERCULOSIS; DRUG-RESISTANCE; OUTCOMES; THERAPY; LIMA; PERU AB Background: In 2008-2009 the South African National Tuberculosis (TB) Program (NTP) implemented a national pilot project, the TB Tracer Project, aiming to decrease default rates and improve patient outcomes. The current study aimed to inform the NTP by describing the knowledge, attitudes, and practices of TB program personnel involved with tracing activities. Methods: A self-administered written questionnaire was sent to TB staff, managers and tracer team leaders to assess basic TB knowledge, attitudes and practices. Descriptive statistics were used to summarize results and the chi-squared statistic was used to compare responses of staff at facilities that participated in the TB Tracer Project (tracer) and those that followed standard NTP care (non-tracer). Results: Of 560 total questionnaires distributed, 270 were completed and returned (response rate 48%). Total TB knowledge ranged from 70.8-86.3% correct across all response groups. However, just over half (range 50-59.3%) of each respondent group was able to correctly identify the four components of a DOT encounter. A patient no longer feeling sick was cited by 72.1% of respondents as the reason patients fail to adhere to treatment. Tracer teams were viewed as an effective means to get patients to return to treatment by 96.3% of health facility level respondents. Tracer team leaders reported concerns including lack of logistical support (41.7%), insufficient physical safety precautions (41.7%), and inadequate protection from contracting TB (39.1%). Upon patients returning to treatment at the clinic, facilities included in the TB Tracer Project were significantly more likely to discuss alternate DOTS arrangements than non-tracer facilities (79.2 vs. 66.4%, p = 0.03). Conclusions: This study identified key components of knowledge, attitudes, and practices regarding TB patient tracing activities in South Africa. Educating patients on the essential need to complete treatment irrespective of clinical symptoms may help improve treatment adherence. Future scale-up and integration of TB tracing activities as part of standard TB management should include provisions for standardized training of personnel on the critical elements of DOTS, and for ensuring appropriate supervision, logistical support, and physical safety and TB transmission protection of tracing teams. C1 [Bristow, Claire C.; Peters, Annatjie] Ctr Dis Control & Prevent CDC, Global AIDS Program South Africa, Pretoria, South Africa. [Podewils, Laura Jean; Bronner, Liza Ellen] Ctr Dis Control & Prevent CDC, Div TB Eliminat, Atlanta, GA 30333 USA. [Bronner, Liza Ellen; Bantubani, Nonkqubela; van der Walt, Martie] South African Med Res Council MRC, Western Cape, South Africa. [Mametja, David] Republ South Africa Natl Dept Hlth, TB Unit, Pretoria, South Africa. RP Podewils, LJ (reprint author), Ctr Dis Control & Prevent CDC, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM lpp8@cdc.gov FU South African national Departments of Health; South African provincial Departments of Health; South African local Departments of Health; Centers for Disease Control and Prevention South Africa Global AIDS Program; South African Medical Research Council [5 U51 PS000729-05, PA PS07-006]; European Union FX We would like to thank the South African national, provincial and local Departments of Health for their support and approval for this study. Additionally, we would like to acknowledge all members of the tracer teams and clinical staff at the health facilities involved in this study for all of their dedication and tireless efforts. We would also like to give special appreciation to Thandiwe Busie Mncwabe, who was responsible for the coordination and administrative aspects of sending and receiving the questionnaires. Evaluation of the project was made possible through the support of the Centers for Disease Control and Prevention South Africa Global AIDS Program, and through funding and collaboration with the South African Medical Research Council (Cooperative Agreement 5 U51 PS000729-05, PA PS07-006). We would also like to thank the European Union for financing the planning, implementation and monitoring of the Tracer Project. NR 16 TC 0 Z9 0 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD SEP 4 PY 2013 VL 13 AR 801 DI 10.1186/1471-2458-13-801 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 216BH UT WOS:000324255300001 PM 24007294 ER PT J AU Lockhart, SR Iqbal, N Harris, JR Grossman, NT DeBess, E Wohrle, R Marsden-Haug, N Vugia, DJ AF Lockhart, Shawn R. Iqbal, Naureen Harris, Julie R. Grossman, Nina T. DeBess, Emilio Wohrle, Ron Marsden-Haug, Nicola Vugia, Duc J. TI Cryptococcus gattii in the United States: Genotypic Diversity of Human and Veterinary Isolates SO PLOS ONE LA English DT Article ID NEOFORMANS VAR GATTII; EPIDEMIOLOGIC CUTOFF VALUES; IN-VITRO SUSCEPTIBILITIES; BRITISH-COLUMBIA; VANCOUVER-ISLAND; PACIFIC-NORTHWEST; 2 VARIETIES; SEROTYPE-B; CLINICAL-MANIFESTATIONS; EMERGING PATHOGEN AB Background: Cryptococcus gattii infections are being reported in the United States (US) with increasing frequency. Initially, US reports were primarily associated with an ongoing C. gattii outbreak in the Pacific Northwest (PNW) states of Washington and Oregon, starting in 2004. However, reports of C. gattii infections in patients from other US states have been increasing since 2009. Whether this is due to increasing frequency of disease, greater recognition within the clinical community, or both is currently unknown. Methodology/Principal Findings: During 2005-2013, a total of 273 C. gattii isolates from human and veterinary sources in 16 US states were collected. Of these, 214 (78%) were from the Pacific Northwest (PNW) and comprised primarily the clonal C. gattii genotypes VGIIa (64%), VGIIc (21%) and VGIIb (9%). The 59 isolates from outside the PNW were predominantly molecular types VGIII (44%) and VGI (41%). Genotyping using multilocus sequence typing revealed small clusters, including a cluster of VGI isolates from the southeastern US, and an unrelated cluster of VGI isolates and a large cluster of VGIII isolates from California. Most of the isolates were mating type MAT alpha, including all of the VGII isolates, but one VGI and three VGIII isolates were mating type MATa. Conclusions/Significance: We provide the most comprehensive report to date of genotypic diversity of US C. gattii isolates both inside and outside of the PNW. C. gattii may have multiple endemic regions in the US, including a previously-unrecognized endemic region in the southeast. Regional clusters exist both in California and the Southeastern US. VGII strains associated with the PNW outbreak do not appear to have spread substantially beyond the PNW. C1 [Lockhart, Shawn R.; Iqbal, Naureen; Harris, Julie R.; Grossman, Nina T.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30329 USA. [DeBess, Emilio] Oregon Dept Human Serv, Portland, OR USA. [Wohrle, Ron; Marsden-Haug, Nicola] Washington State Dept Hlth, Tumwater, WA USA. [Vugia, Duc J.] Calif Dept Publ Hlth, Richmond, CA USA. RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30329 USA. EM gyi2@cdc.gov NR 65 TC 24 Z9 24 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 3 PY 2013 VL 8 IS 9 AR e74737 DI 10.1371/journal.pone.0074737 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 217DY UT WOS:000324338200122 PM 24019979 ER PT J AU Oster, AM Russell, K Wiegand, RE Valverde, E Forrest, DW Cribbin, M Le, BC Paz-Bailey, G AF Oster, Alexandra M. Russell, Kate Wiegand, Ryan E. Valverde, Eduardo Forrest, David W. Cribbin, Melissa Le, Binh C. Paz-Bailey, Gabriela CA NHBS Study Grp TI HIV Infection and Testing among Latino Men Who Have Sex with Men in the United States: The Role of Location of Birth and Other Social Determinants SO PLOS ONE LA English DT Article ID VIRAL-HEPATITIS; HEALTH-CARE; BLACK-MEN; YOUNG MEN; SURVEILLANCE; PREVENTION; PREVALENCE; IMPACT; GAY; DISPARITIES AB Background: In the United States, Latino men who have sex with men (MSM) are disproportionately affected by HIV. Latino MSM are a diverse group who differ culturally based on their countries or regions of birth and their time in the United States. We assessed differences in HIV prevalence and testing among Latino MSM by location of birth, time since arrival, and other social determinants of health. Methods: For the 2008 National HIV Behavioral Surveillance System, a cross-sectional survey conducted in large US cities, MSM were interviewed and tested for HIV infection. We used generalized estimating equations to test associations between various factors and 1) prevalent HIV infection and 2) being tested for HIV infection in the past 12 months. Results: Among 1734 Latino MSM, HIV prevalence was 19%. In multivariable analysis, increasing age, low income, and gay identity were associated with HIV infection. Moreover, men who were U.S.-born or who arrived >= 5 years ago had significantly higher HIV prevalence than recent immigrants. Among men not reporting a previous positive HIV test, 63% had been tested for HIV infection in the past 12 months; recent testing was most strongly associated with having seen a health care provider and disclosing male-male attraction/sexual behavior to a health care provider. Conclusions: We identified several social determinants of health associated with HIV infection and testing among Latino MSM. Lower HIV prevalence among recent immigrants contrasts with higher prevalence among established immigrants and suggests a critical window of opportunity for HIV prevention, which should prioritize those with low income, who are at particular risk for HIV infection. Expanding health care utilization and encouraging communication with health care providers about sexual orientation may increase testing. C1 [Oster, Alexandra M.; Russell, Kate; Wiegand, Ryan E.; Valverde, Eduardo; Cribbin, Melissa; Le, Binh C.; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Forrest, David W.] Univ Miami, Miami, FL USA. RP Oster, AM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM AOster@cdc.gov OI Russell, Kate/0000-0001-9343-3355 FU Centers for Disease Control and Prevention (CDC) FX The National HIV Behavioral Surveillance System is funded by the Centers for Disease Control and Prevention (CDC). Study design and data collection are conducted by funded sites in accordance with a standardized protocol developed by CDC. Data analysis and preparation of the manuscript were conducted by CDC staff. NR 26 TC 13 Z9 13 U1 2 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD SEP 3 PY 2013 VL 8 IS 9 AR e73779 DI 10.1371/journal.pone.0073779 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 217DY UT WOS:000324338200079 PM 24147151 ER PT J AU Ngo-Metzger, Q Ward, JW Valdiserri, RO AF Ngo-Metzger, Quyen Ward, John W. Valdiserri, Ronald O. TI Expanded Hepatitis C Virus Screening Recommendations Promote Opportunities for Care and Cure SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID UNITED-STATES; PERSONS BORN; INFECTION C1 [Ngo-Metzger, Quyen] Agcy Healthcare Res & Qual, Rockville, MD 20850 USA. [Ward, John W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Valdiserri, Ronald O.] US Dept HHS, Washington, DC 20201 USA. RP Ngo-Metzger, Q (reprint author), Agcy Healthcare Res & Qual, 540 Gaither Rd, Rockville, MD 20850 USA. NR 8 TC 12 Z9 12 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD SEP 3 PY 2013 VL 159 IS 5 BP 364 EP + DI 10.7326/0003-4819-159-5-201309030-00675 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 215YA UT WOS:000324245900010 PM 23797155 ER PT J AU Blanchard, JF Thompson, LH Aral, SO AF Blanchard, James F. Thompson, Laura H. Aral, Sevgi O. TI Second generation HIV surveillance in Pakistan: evidence for understanding the epidemic and planning a response SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Editorial Material C1 [Blanchard, James F.; Thompson, Laura H.] Univ Manitoba, Ctr Global Publ Hlth, Dept Community Hlth Sci, Winnipeg, MB R3E 0T6, Canada. [Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Blanchard, JF (reprint author), Univ Manitoba, Ctr Global Publ Hlth, Dept Community Hlth Sci, R070-771 McDermot Ave, Winnipeg, MB R3E 0T6, Canada. EM james_blanchard@umanitoba.ca NR 12 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 EI 1472-3263 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD SEP PY 2013 VL 89 SU 2 BP 1 EP 3 DI 10.1136/sextrans-2013-051297 PG 3 WC Infectious Diseases SC Infectious Diseases GA AI0FR UT WOS:000336522100001 PM 23956339 ER PT J AU Dale, AM Harris-Adamson, C Rempel, D Gerr, F Hegmann, K Silverstein, B Burt, S Garg, A Kapellusch, J Merlino, L Thiese, MS Eisen, EA Evanoff, B AF Dale, Ann Marie Harris-Adamson, Carisa Rempel, David Gerr, Fred Hegmann, Kurt Silverstein, Barbara Burt, Susan Garg, Arun Kapellusch, Jay Merlino, Linda Thiese, Matthew S. Eisen, Ellen A. Evanoff, Bradley TI Prevalence and incidence of carpal tunnel syndrome in US working populations: pooled analysis of six prospective studies SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Article DE CTS; epidemiology; industry; longitudinal study; median nerve; MSD; musculoskeletal disorder; nerve compression; occupational injury; surveillance; work-related injury ID RISK-FACTORS; GENERAL-POPULATION; HAND DIAGRAMS; MUSCULOSKELETAL DISORDERS; INDUSTRIAL-WORKERS; MEDIAN NEUROPATHY; NERVE-CONDUCTION; WASHINGTON-STATE; CASE DEFINITIONS; SYMPTOM DIAGRAM AB Objectives Most studies of carpal tunnel syndrome (CTS) incidence and prevalence among workers have been limited by small sample sizes or restricted to a small subset of jobs. We established a common CTS case definition and then pooled CTS prevalence and incidence data across six prospective studies of musculoskeletal outcomes to measure CTS frequency and allow better studies of etiology. Methods Six research groups collected prospective data at >50 workplaces including symptoms characteristic of CTS and electrodiagnostic studies (EDS) of the median and ulnar nerves across the dominant wrist. While study designs and the timing of data collection varied across groups, we were able to create a common CTS case definition incorporating both symptoms and EDS results from data that were collected in all studies. Results At the time of enrollment, 7.8% of 4321 subjects met our case definition and were considered prevalent cases of CTS. During 8833 person-years of follow-up, an additional 204 subjects met the CTS case definition for an overall incidence rate of 2.3 CTS cases per 100 person-years. Conclusions Both prevalent and incident CTS were common in data pooled across multiple studies and sites. The large number of incident cases in this prospective study provides adequate power for future exposure response analyses to identify work- and non-work-related risk factors for CTS. The prospective nature allows determination of the temporal relations necessary for causal inference. C1 [Dale, Ann Marie; Evanoff, Bradley] Washington Univ, Sch Med, Div Gen Med Sci, St Louis, MO 63110 USA. [Harris-Adamson, Carisa] Samuel Merritt Univ, Dept Phys Therapy, Oakland, CA USA. [Rempel, David] Univ Calif San Francisco, Div Occupat & Environm Med, San Francisco, CA 94143 USA. [Gerr, Fred; Merlino, Linda] Univ Iowa, Dept Occupat & Environm Hlth, Coll Publ Hlth, Iowa City, IA USA. [Gerr, Fred; Merlino, Linda] Univ Utah, Mt Ctr Occupat & Environm Hlth RMCOEH, Salt Lake City, UT USA. [Hegmann, Kurt; Thiese, Matthew S.] Washington State Dept Labor & Ind, Safety & Hlth Assessment & Res Prevent SHARP Prog, Olympia, WA 98504 USA. [Silverstein, Barbara] NIOSH, Cincinnati, OH 45226 USA. [Burt, Susan] Univ Wisconsin, Ctr Ergon, Milwaukee, WI 53201 USA. [Garg, Arun; Kapellusch, Jay] Univ Calif Berkeley, UC Berkeley Sch Publ Hlth, Berkeley, CA 94720 USA. RP Dale, AM (reprint author), Washington Univ, Sch Med, 660 South Euclid Ave,Campus Box 8005, St Louis, MO 63110 USA. EM adale@dom.wustl.edu RI Dale, Ann Marie/P-1382-2014; OI Dale, Ann Marie/0000-0002-5624-8967; Burt, Susan/0000-0002-4353-9773; Evanoff, Bradley A./0000-0003-0085-333X; Thiese, Matthew/0000-0003-4505-2907 FU Center for Disease Control / NIOSH [5R01OH009712]; National Center for Research Resources (NCRR) of the National Institutes of Health (NIH); NIH Roadmap for Medical Research [UL1 RR024992] FX This study was supported by research funding from the Center for Disease Control / NIOSH (5R01OH009712) and from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research (UL1 RR024992). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of NIOSH. We would like to acknowledge the efforts of the large number of research technician, assistants, and any other personnel from each of the research study groups that made the collection of the data presented in this manuscript possible. NR 53 TC 37 Z9 38 U1 0 U2 13 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 EI 1795-990X J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PD SEP PY 2013 VL 39 IS 5 BP 495 EP 505 DI 10.5271/sjweh.3351 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD0IC UT WOS:000332916700008 PM 23423472 ER PT J AU Dorner, B Kull, S Schulz, M Strotmeier, J Kirchner, S Schreiber, T Dabrowski, W Nitsche, A Kalb, S Dorner, M Barr, J Rummel, A AF Dorner, B. Kull, S. Schulz, M. Strotmeier, J. Kirchner, S. Schreiber, T. Dabrowski, W. Nitsche, A. Kalb, S. Dorner, M. Barr, J. Rummel, A. TI Isolation and functional characterization of a novel C. botulinum type A neurotoxin subtype SO INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Meeting Abstract CT 65th Annual Meeting of the German-Society-for-Hygiene-and-Microbiology (DGHM) e V / Annual Meeting of the German-Society-for-Infectious-Diseases (DGI) e V CY SEP 22-25, 2013 CL Univ Rostock, Rostock, GERMANY SP German Soc Hyg & Microbiol e V, German Soc Infect Dis e V, SIEMENS HO Univ Rostock C1 [Dorner, B.; Kull, S.; Schulz, M.; Kirchner, S.; Schreiber, T.; Dorner, M.] Robert Koch Inst, Biol Toxine ZBS3, Berlin, Germany. [Strotmeier, J.; Rummel, A.] Hannover Med Sch, Inst Toxikol, D-30623 Hannover, Germany. [Dabrowski, W.; Nitsche, A.] Robert Koch Inst, Hochpathogene Virale Erreger ZBS1, Berlin, Germany. [Kalb, S.; Barr, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4221 EI 1618-0607 J9 INT J MED MICROBIOL JI Int. J. Med. Microbiol. PD SEP PY 2013 VL 303 SU 1 BP 62 EP 62 PG 1 WC Microbiology; Virology SC Microbiology; Virology GA AB0QQ UT WOS:000331497600212 ER PT J AU Plescia, M White, MC AF Plescia, Marcus White, Mary C. TI The National Prevention Strategy and Breast Cancer Screening: Scientific Evidence for Public Health Action SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID EARLY-DETECTION PROGRAM; AFRICAN-AMERICAN WOMEN; UNITED-STATES; MAMMOGRAPHY USE; FOLLOW-UP; CARE; RECOMMENDATION; DISPARITIES; ADHERENCE; ACCESS AB Mammography screening rates in the United States have remained fairly stable over the past decade, and screening rates remain low for some groups. We examined insights from recent public health research on breast cancer screening to identify promising new approaches to improve screening rates and address persistent health disparities in mammography use. We considered this research in the context of the four strategic directions of the National Prevention Strategy: elimination of health disparities, empowered people, healthy and safe community environments, and clinical and community preventive services. This research points to the value of direct outreach and case management services, interventions to support more patient-centered models of care, and more organized, population-based approaches to identify women who are eligible to be screened, encourage participation, and monitor results. C1 [Plescia, Marcus; White, Mary C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Plescia, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, NCCDPHP, 4770 Buford Highway,MS F-76, Atlanta, GA 30341 USA. EM mplescia@cdc.gov RI White, Mary /C-9242-2012 OI White, Mary /0000-0002-9826-3962 NR 50 TC 6 Z9 6 U1 0 U2 11 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2013 VL 103 IS 9 BP 1545 EP 1548 DI 10.2105/AJPH.2013.301305 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3NB UT WOS:000330998200022 PM 23865665 ER PT J AU Maalouf, J Cogswell, ME Gunn, JP Curtis, CJ Rhodes, D Hoy, K Pehrsson, P Nickle, M Merritt, R AF Maalouf, Joyce Cogswell, Mary E. Gunn, Janelle P. Curtis, Christine J. Rhodes, Donna Hoy, Kathy Pehrsson, Pamela Nickle, Melissa Merritt, Robert TI Monitoring the Sodium Content of Restaurant Foods: Public Health Challenges and Opportunities SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Review ID TAKE-AWAY FOODS; AUSTRALIAN FOODS; NUTRITIONAL PROFILE; MINERAL-CONTENT; PROXIMATE; MEALS; BAHRAIN; ENERGY; CHAINS; MENU AB We reviewed methods of studies assessing restaurant foods' sodium content and nutrition databases. We systematically searched the 1964-2012 literature and manually examined references in selected articles and studies. Twenty-six (5.2%) of the 499 articles we found met the inclusion criteria and were abstracted. Five were conducted nationally. Sodium content determination methods included laboratory analysis (n = 15), point-of-purchase nutrition information or restaurants' Web sites (n = 8), and menu analysis with a nutrient database (n = 3). There is no comprehensive data system that provides all information needed to monitor changes in sodium or other nutrients among restaurant foods. Combining information from different sources and methods may help inform a comprehensive system to monitor sodium content reduction efforts in the US food supply and to develop future strategies. C1 [Maalouf, Joyce; Cogswell, Mary E.; Gunn, Janelle P.; Merritt, Robert] Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Maalouf, Joyce] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Curtis, Christine J.] New York City Dept Hlth & Mental Hyg, Nutr Strategy Program, New York, NY USA. [Rhodes, Donna; Hoy, Kathy] ARS, USDA, Beltsville Human Nutr Res Ctr, Food Surveys Res Grp, Beltsville, MD USA. [Pehrsson, Pamela; Nickle, Melissa] ARS, USDA, Beltsville Human Nutr Res Ctr, Nutrient Data Lab, Beltsville, MD USA. RP Maalouf, J (reprint author), Ctr Dis Control & Prevent, Epidemiol & Surveillance Branch, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop F72, Atlanta, GA 30341 USA. EM vjh6@cdc.gov FU Oak Ridge Institute for Science and Education Research Participation Programs at the Centers for Disease Control and Prevention (CDC) FX J. Maalouf was supported by the Oak Ridge Institute for Science and Education Research Participation Programs at the Centers for Disease Control and Prevention (CDC). NR 54 TC 1 Z9 2 U1 0 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD SEP PY 2013 VL 103 IS 9 BP E21 EP E30 DI 10.2105/AJPH.2013.301442 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3NB UT WOS:000330998200010 PM 23865701 ER PT J AU Tangka, FK Trogdon, JG Nwaise, I Ekwueme, DU Guy, GP Orenstein, D AF Tangka, Florence K. Trogdon, Justin G. Nwaise, Isaac Ekwueme, Donatus U. Guy, Gery P., Jr. Orenstein, Diane TI State-Level Estimates of Cancer-Related Absenteeism Costs SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID SHORT-TERM DISABILITY; UNITED-STATES; BREAST-CANCER; IMPACT; WORK; BURDEN; CARE AB Background: Cancer is one of the top five most costly diseases in the United States and leads to substantial work loss. Nevertheless, limited state-level estimates of cancer absenteeism costs have been published. Methods: In analyses of data from the 2004-2008 Medical Expenditure Panel Survey, the 2004 National Nursing Home Survey, the U. S. Census Bureau for 2008, and the 2009 Current Population Survey, we used regression modeling to estimate annual state-level absenteeism costs attributable to cancer from 2004 to 2008. Results: We estimated that the state-level median number of days of absenteeism per year among employed cancer patients was 6.1 days and that annual state-level cancer absenteeism costs ranged from $14.9 million to $915.9 million (median = $115.9 million) across states in 2010 dollars. Absenteeism costs are approximately 6.5% of the costs of premature cancer mortality. Conclusions: The results from this study suggest that lost productivity attributable to cancer is a substantial cost to employees and employers and contributes to estimates of the overall impact of cancer in a state population. C1 [Tangka, Florence K.; Ekwueme, Donatus U.; Guy, Gery P., Jr.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Trogdon, Justin G.] RTI Int, Durham, NC USA. [Nwaise, Isaac] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Orenstein, Diane] Ctr Dis Control & Prevent, Div Community Hlth, Atlanta, GA 30341 USA. RP Tangka, FK (reprint author), Ctr Dis Control & Prevent, DCPC EARB, 4770 Buford Highway NE,MS F-76, Atlanta, GA 30341 USA. EM ftangka@cdc.gov FU Centers for Disease Control and Prevention [200-2008-27958] FX Funding for this study was provided by the Centers for Disease Control and Prevention (Contract No. 200-2008-27958, Task Order 0015). NR 29 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2013 VL 55 IS 9 BP 1015 EP 1020 DI 10.1097/JOM.0b013e3182a2a467 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300EY UT WOS:000330448400004 PM 23969498 ER PT J AU Bang, KM Syamlal, G Mazurek, JM Wassell, JT AF Bang, Ki Moon Syamlal, Girija Mazurek, Jacek M. Wassell, James T. TI Chronic Obstructive Pulmonary Disease Prevalence Among Nonsmokers by Occupation in the United States SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; CHRONIC-BRONCHITIS; NEVER SMOKERS; LUNG-DISEASE; COPD; POPULATION; BURDEN; EXPOSURES; SMOKING AB Objective: To examine the prevalence of chronic obstructive pulmonary disease (COPD) among nonsmokers by occupation in the United States. Methods: The 1997 to 2004 National Health Interview Survey data for working adults aged 25 years or more were used to estimate the COPD prevalence and to examine change in COPD prevalence between 1997 to 2000 and 2001 to 2004 by occupational groups. Results: During 1997 to 2004, COPD prevalence was 2.8%. The COPD prevalence was highest in financial records processing (4.6%) occupations. There was a slight increase in COPD prevalence during the two survey periods from 2.8% during 1997 to 2000 compared with 2.9% during 2001 to 2004. Conclusions: No significant changes in the COPD prevalence between the two periods were found. Nevertheless, the elevated COPD prevalence in certain occupational groups suggests that other risk factors play a role in developing COPD. C1 [Bang, Ki Moon; Syamlal, Girija; Mazurek, Jacek M.; Wassell, James T.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Bang, KM (reprint author), NIOSH, Div Resp Dis Studies, CDC, RM H-G900-2,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM kmb2@cdc.gov NR 57 TC 8 Z9 9 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2013 VL 55 IS 9 BP 1021 EP 1026 DI 10.1097/JOM.0b013e31829baa97 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300EY UT WOS:000330448400005 PM 23969499 ER PT J AU Luckhaupt, SE Cohen, MA Calvert, GM AF Luckhaupt, Sara E. Cohen, Martha A. Calvert, Geoffrey M. TI Concordance Between Current Job and Usual Job in Occupational and Industry Groupings Assessment of the 2010 National Health Interview Survey SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID HEALTH INTERVIEW SURVEY; US AB Objective: To determine whether current job is a reasonable surrogate for usual job. Methods: Data from the 2010 National Health Interview Survey were utilized to determine concordance between current and usual jobs for workers employed within the past year. Concordance was quantitated by kappa values for both simple and detailed industry and occupational groups. Good agreement is considered to be present when kappa values exceed 60. Results: Overall kappa values +/- standard errors were 74.5 +/- 0.5 for simple industry, 72.4 +/- 0.5 for detailed industry, 76.3 +/- 0.4 for simple occupation, 73.7 +/- 0.5 for detailed occupation, and 80.4 +/- 0.6 for very broad occupational class. Sixty-five of 73 detailed industry groups and 78 of 81 detailed occupation groups evaluated had good agreement between current and usual jobs. Conclusions: Current job can often serve as a reliable surrogate for usual job in epidemiologic studies. C1 [Luckhaupt, Sara E.; Cohen, Martha A.; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studi, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Luckhaupt, SE (reprint author), NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM pks8@cdc.gov FU US government FX The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health, or the National Center for Health Statistics. All authors are federal government employees, and the NHIS and preparation of this manuscript were completely funded by the US government. NR 11 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2013 VL 55 IS 9 BP 1074 EP 1090 DI 10.1097/JOM.0b013e318297321d PG 17 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300EY UT WOS:000330448400012 PM 23969506 ER PT J AU Chen, ZQ Chakrabarty, S Levine, RS Aliyu, MH Ding, T Jackson, LL AF Chen, Zhiqiang Chakrabarty, Sangita Levine, Robert S. Aliyu, Muktar H. Ding, Tan Jackson, Larry L. TI Work-Related Knee Injuries Treated in US Emergency Departments SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID OCCUPATIONAL INJURIES; RISK-FACTORS; MUSCULOSKELETAL INJURIES; UNITED-STATES; OSTEOARTHRITIS; DISORDERS; SLIP; PAIN; HIP; CONSTRUCTION AB Objective: To characterize work-related knee injuries treated in US emergency departments (EDs). Methods: We characterized work-related knee injuries treated in EDs in 2007 and examined trends from 1998 to 2007 by using the National Electronic Injury Surveillance System-occupational supplement. Results: In 2007, 184,300 (+/- 54,000; 95% confidence interval) occupational knee injuries were treated in US EDs, accounting for 5% of the 3.4 (+/- 0.9) million ED-treated occupational injuries. The ED-treated knee injury rate was 13 (+/- 4) injuries per 10,000 full-time equivalent workers. Younger workers and older female workers had high rates. Strains/sprains and contusions/abrasions were common-frequently resulting from falls and bodily reaction/overexertion events. Knee injury rates declined from 1998 through 2007. Conclusions: Knee injury prevention should emphasize reducing falls and bodily reaction/overexertion events, particularly among all youth and older women. C1 [Chen, Zhiqiang; Chakrabarty, Sangita; Levine, Robert S.; Aliyu, Muktar H.] Meharry Med Coll, Div Prevent & Occupat Med, Nashville, TN 37208 USA. [Ding, Tan] Meharry Med Coll, Dept Family & Community Med, Nashville, TN 37208 USA. [Chen, Zhiqiang] Kaiser Permanente, Dept Occupat Med, Manteca, CA USA. [Jackson, Larry L.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Jackson, LL (reprint author), NIOSH, Div Safety Res, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS1808, Morgantown, WV 26505 USA. EM LLJackson@cdc.gov FU National Institute on Minority Health and Health Disparities [5P20MD000516]; National Institute for Occupational Safety and Health [T03OH009406-04] FX Funding for this activity was made possible, in part, by award 5P20MD000516 from the National Institute on Minority Health and Health Disparities and award T03OH009406-04 from the National Institute for Occupational Safety and Health. NR 65 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD SEP PY 2013 VL 55 IS 9 BP 1091 EP 1099 DI 10.1097/JOM.0b013e31829b27bf PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300EY UT WOS:000330448400013 PM 23969507 ER PT J AU Grohskopf, LA Chillag, KL Gvetadze, R Liu, AY Thompson, M Mayer, KH Collins, BM Pathak, SR O'Hara, B Ackers, ML Rose, CE Grant, RM Paxton, LA Buchbinder, SP AF Grohskopf, Lisa A. Chillag, Kata L. Gvetadze, Roman Liu, Albert Y. Thompson, Melanie Mayer, Kenneth H. Collins, Brandi M. Pathak, Sonal R. O'Hara, Brandon Ackers, Marta L. Rose, Charles E. Grant, Robert M. Paxton, Lynn A. Buchbinder, Susan P. TI Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE PrEP; preexposure prophylaxis; prevention and control; HIV; antiretroviral agents; tenofovir; clinical trial; phase 2 ID POSTEXPOSURE PROPHYLAXIS; PREEXPOSURE PROPHYLAXIS; RENAL-FAILURE; FANCONI-SYNDROME; NEPHROTOXICITY; PREVENTION; INFECTION; ABNORMALITIES; EMTRICITABINE; TRANSMISSION AB Objectives: To evaluate the clinical safety of daily tenofovir disoproxil fumarate (TDF) among HIV-negative men who have sex with men. Design: Randomized, double-blind, placebo-controlled trial. Participants were randomized 1: 1: 1: 1 to immediate or delayed study drug (TDF, 300 mg orally per day, or placebo). Methods: Four hundred healthy HIV-uninfected men who have sex with men reporting anal sex with another man within the previous 12 months enrolled in Atlanta, Boston, and San Francisco. HIV serostatus, clinical and laboratory adverse events (AEs), adherence (pill count, Medication Event Monitoring System, and self-report), and sexual and other sociobehavioral data were assessed at 3-month intervals for 24 months. Primary outcomes were clinical safety, assessed by incidence of AEs and laboratory abnormalities. Results: Study drug was initiated by 373 (93%) participants (186 TDF and 187 placebo), of whom 325 (87%) completed the final study visit. Of 2428 AEs reported among 334 (90%) participants, 2366 (97%) were mild or moderate in severity. Frequencies of commonly reported AEs did not differ significantly between TDF and placebo arms. In multivariable analyses, back pain was more likely among TDF recipients (P = 0.04); these reports were not associated with documented fractures or other objective findings. There were no grade >= 3 creatinine elevations; grades 1 and 2 creatinine increases were not associated with TDF receipt. Estimated percentage of study drug doses taken was 92% by pill count and 77% by Medication Event Monitoring System. Seven seroconversions occurred: 4 on placebo and 3 among delayed arm participants not yet on study drug. Conclusions: Daily oral TDF was well tolerated, with reasonable adherence. No significant renal concerns were identified. C1 [Grohskopf, Lisa A.; Chillag, Kata L.; Ackers, Marta L.; Paxton, Lynn A.] Ctr Dis Control & Prevent, Epidemiol Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Gvetadze, Roman; Rose, Charles E.] Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Liu, Albert Y.; Buchbinder, Susan P.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA. [Thompson, Melanie] AIDS Res Consortium Atlanta, Atlanta, GA USA. [Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Fenway Hlth, Boston, MA 02215 USA. [Collins, Brandi M.; Pathak, Sonal R.; O'Hara, Brandon] Northrop Grumman Corp, Falls Church, VA USA. [Grant, Robert M.] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94143 USA. [Grant, Robert M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Grohskopf, LA (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-20, Atlanta, GA 30333 USA. EM lkg6@cdc.gov FU US Department of Health and Human Services, Centers for Disease Control and Prevention [200-2003-03003, 200-2003-03007, 2002004-09853.] FX Supported by US Department of Health and Human Services, Centers for Disease Control and Prevention, Contracts # 200-2003-03003, # 200-2003-03007, and # 2002004-09853. NR 35 TC 39 Z9 43 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2013 VL 64 IS 1 BP 79 EP 86 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300GE UT WOS:000330451600015 PM 23466649 ER PT J AU Liu, AY Vittinghoff, E Chillag, K Mayer, K Thompson, M Grohskopf, L Colfax, G Pathak, S Gvetadze, R O'Hara, B Collins, B Ackers, M Paxton, L Buchbinder, SP AF Liu, Albert Y. Vittinghoff, Eric Chillag, Kata Mayer, Kenneth Thompson, Melanie Grohskopf, Lisa Colfax, Grant Pathak, Sonal Gvetadze, Roman O'Hara, Brandon Collins, Brandi Ackers, Marta Paxton, Lynn Buchbinder, Susan P. TI Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE risk compensation; behavioral disinhibition; sexual risk behavior; PrEP; MSM ID MALE CIRCUMCISION; COST-EFFECTIVENESS; INTERIM GUIDANCE; INFECTION RISK; PREVENTION; IMPACT; INTERVENTION; TRANSMISSION; AFRICA; WOMEN AB Objective: To evaluate for changes in sexual behaviors associated with daily pill use among men who have sex with men (MSM) participating in a preexposure prophylaxis trial. Design: Randomized, double-blind, placebo-controlled trial. Participants were randomized 1: 1: 1: 1 to receive tenofovir disoproxil fumarate or placebo at enrollment or after a 9-month delay and followed for 24 months. Methods: Four hundred HIV-negative MSM reporting anal sex with a man in the past 12 months and meeting other eligibility criteria enrolled in San Francisco, Atlanta, and Boston. Sexual risk was assessed at baseline and quarterly visits using Audio Computer-Assisted Self-Interview. The association of pill taking with sexual behavior was evaluated using logistic and negative-binomial regressions for repeated measures. Results: Overall indices of behavioral risk declined or remained stable during follow-up. Mean number of partners and proportion reporting unprotected anal sex declined during follow-up (P < 0.05), and mean unprotected anal sex episodes remained stable. During the initial 9 months, changes in risk practices were similar in the group that began pills immediately vs. those in the delayed arm. These indices of risk did not differ significantly after initiation of pill use in the delayed arm or continuation of study medication in the immediate arm. Use of poppers, amphetamines, and sexual performance-enhancing drugs were independently associated with one or more indices of sexual risk. Conclusions: There was no evidence of risk compensation among HIV-uninfected MSM in this clinical trial. Monitoring for risk compensation should continue now that preexposure prophylaxis has been shown to be efficacious in MSM and other populations and will be provided in open-label trials and other contexts. C1 [Liu, Albert Y.; Buchbinder, Susan P.] San Francisco Dept Publ Hlth, Bridge HIV, San Francisco, CA USA. [Liu, Albert Y.; Colfax, Grant] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Chillag, Kata; Grohskopf, Lisa; Ackers, Marta; Paxton, Lynn] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Mayer, Kenneth] Fenway Hlth, Boston, MA USA. [Thompson, Melanie] AIDS Res Consortium Atlanta, Atlanta, GA USA. [Pathak, Sonal; O'Hara, Brandon; Collins, Brandi] Northrop Grumman Corp, Falls Church, VA USA. [Vittinghoff, Eric; Buchbinder, Susan P.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Mayer, Kenneth] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Mayer, Kenneth] Harvard Univ, Sch Med, Boston, MA USA. [Colfax, Grant] San Francisco Dept Publ Hlth, HIV Prevent Sect, San Francisco, CA USA. [Gvetadze, Roman] Ctr Dis Control & Prevent, Quantitat Sci & Data Management Branch, Div HIV AIDS Prevent, Atlanta, GA USA. RP Liu, AY (reprint author), 25 Van Ness Ave,Suite 100, San Francisco, CA 94102 USA. EM albert.liu@sfdph.org FU US Department of Health and Human Services, Centers for Disease Control and Prevention [200-2003-03003, 200-2003-03007, 200-2004-09853] FX Supported by funds from the US Department of Health and Human Services, Centers for Disease Control and Prevention, Contracts #200-2003-03003, #200-2003-03007, and #200-2004-09853. Study drug was supplied by Gilead Sciences. NR 31 TC 35 Z9 36 U1 3 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2013 VL 64 IS 1 BP 87 EP 94 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300GE UT WOS:000330451600016 PM 23481668 ER PT J AU Taylor, MM Schillinger, JA Furness, BW Brewer, T Newman, DR Pathela, P Skinner, J Braunstein, S Shepard, C Ahmed, T Griffin, A Blank, S Peterman, TA AF Taylor, Melanie M. Schillinger, Julia A. Furness, Bruce W. Brewer, Toye Newman, Daniel R. Pathela, Preeti Skinner, Julia Braunstein, Sarah Shepard, Colin Ahmed, Tashrik Griffin, Angelique Blank, Susan Peterman, Thomas A. TI Gonorrhea Infections Diagnosed Among Persons Living With HIV/AIDS: Identifying Opportunities for Integrated Prevention Services in New York City, Washington, DC, Miami/Dade County, and Arizona SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE STD; gonorrhea; HIV; AIDS; persons living with HIV/AIDS; STD/HIV coinfection; men who have sex with men ID MULTICLINIC ASSESSMENT; SAFER-SEX; HIV; STD; SURVEILLANCE; PROVIDERS; MEN AB Persons living with HIV/AIDS who acquire new sexually transmitted diseases (STDs) pose a risk for enhanced transmission of both HIV and STDs. To describe the frequency of HIV coinfection among gonorrhea cases (GC), HIV and GC surveillance databases (2000-2008) were cross-matched in New York City (NYC), Washington, DC (DC), Miami/Dade County (MDC), and Arizona (AZ). During 2000-2008, 4.6% (9471/205,689) of reported GCs occurred among persons with previously diagnosed HIV: NYC (5.5%), DC (7.3%), MDC (4%), and AZ (2%). The overall HIV-GC coinfection rates increased over the study period in all 4 sites. Real-time data integration could allow for enhanced prevention among persons with HIV infection and acute STDs. C1 [Taylor, Melanie M.; Schillinger, Julia A.; Furness, Bruce W.; Brewer, Toye; Newman, Daniel R.; Blank, Susan; Peterman, Thomas A.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, Melanie M.; Skinner, Julia] Arizona Dept Hlth Serv, STD Program, Phoenix, AZ 85007 USA. [Schillinger, Julia A.; Pathela, Preeti; Braunstein, Sarah; Shepard, Colin; Blank, Susan] New York City Dept Hlth & Mental Hyg, Long Isl City, NY USA. [Furness, Bruce W.] Dist Columbia Dept Hlth, HIV AIDS Hepatitis STD & TB Adm, Washington, DC USA. [Brewer, Toye; Ahmed, Tashrik; Griffin, Angelique] Miami Dade Cty Dept Hlth, Miami, FL USA. RP Taylor, MM (reprint author), CDC NCHHSTP DSTDP, Phoenix, AZ 85006 USA. EM mdt7@cdc.gov NR 29 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD SEP 1 PY 2013 VL 64 IS 1 BP 115 EP 120 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300GE UT WOS:000330451600019 PM 23945254 ER PT J AU Haarbauer-Krupa, J Parks, SE AF Haarbauer-Krupa, Juliet Parks, Sharyn E. TI Abusive Head Trauma in Young Children: Descriptive Factors and Outcomes SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Haarbauer-Krupa, Juliet; Parks, Sharyn E.] Ctr Dis Control & Prevent, Div Unintent Injury, Atlanta, GA USA. Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD SEP-OCT PY 2013 VL 28 IS 5 MA 0054 BP E52 EP E52 PG 1 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 298ZU UT WOS:000330364600051 ER PT J AU Haarbauer-Krupa, J Lionbarger, M McGuire, L AF Haarbauer-Krupa, Juliet Lionbarger, Michael McGuire, Lisa TI Evidence-Based Review of Youth Concussion Guidelines SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Meeting Abstract C1 [Haarbauer-Krupa, Juliet; Lionbarger, Michael; McGuire, Lisa] Ctr Dis Control & Prevent, TBI Team, Div Unintent Injury Response, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD SEP-OCT PY 2013 VL 28 IS 5 MA 0052 BP E51 EP E52 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 298ZU UT WOS:000330364600049 ER PT J AU Stoto, MA Nelson, C Higdon, MA Kraemer, J Singleton, CM AF Stoto, Michael A. Nelson, Christopher Higdon, Melissa A. Kraemer, John Singleton, Christa-Marie TI Learning About After Action Reporting From the 2009 H1N1 Pandemic: A Workshop Summary SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE after action reports; H1N1; quality improvement; root cause analysis AB Objective: To analyze key variations in the after action report/improvement plan (AAR/IP) process used by state and local health departments following the 2009 H1N1 pandemic and identify ideas for improving that process. Design: Workshop participants discussed their AAR findings and the methods used to prepare their reports and implications for improving the AAR/IP process in future events. Participants: Workshop participants included state and local health department personnel who had submitted AAR/IPs to the Centers for Disease Control and Prevention (CDC) for review. Measures: Workshop participants were asked to consider the question: On the basis of what you heard in this workshop, what would you do differently if you could redo your 2009 H1N1 AAR/IP? Results: Workshop discussions revealed wide differences in the participants' understanding of the intended uses and users of the AAR/IPs, their scope, timing, and format, and the use of external consultants in their preparation, and on the strengths and weaknesses of various approaches. The AAR/IPs also varied in the extent to which they sought to identify root causes and the methods they used to do so. Conclusions: The AAR/IPs can be useful for both accountability and quality improvement, but these objectives require different foci and methodological approaches. Notably, the AAR/IPs can also be used as an opportunity to hold health departments accountable for conducting root cause analyses and making the improvements that follow from them. Federal agencies requiring the AAR/IPs should clarify the purpose and issues of scope and timing; develop training materials and exemplary cases of effective AAR/IPs, particularly of root cause analysis applied to public health emergency preparedness, professional guidelines, and standards for consultants; and consider developing a peer model for preparing AAR/IPs. C1 [Stoto, Michael A.; Kraemer, John] Georgetown Univ, Sch Nursing & Hlth Studies, Dept Hlth Syst Adm, Washington, DC 20057 USA. [Nelson, Christopher] RAND Corp, Santa Monica, CA USA. [Higdon, Melissa A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Kraemer, John] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20057 USA. [Singleton, Christa-Marie] Ctr Dis Control & Prevent, Div State & Local Readiness, Atlanta, GA USA. RP Stoto, MA (reprint author), Georgetown Univ, Sch Nursing & Hlth Studies, Dept Hlth Syst Adm, 3700 Reservoir Rd NW,Room 236, Washington, DC 20057 USA. EM stotom@georgetown.edu FU OPHPR CDC HHS [5P01TP000307-01] NR 6 TC 7 Z9 7 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2013 VL 19 IS 5 BP 420 EP 427 DI 10.1097/PHH.0b013e3182751d57 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300DU UT WOS:000330445400009 PM 23518591 ER PT J AU Stoto, MA Nelson, C Higdon, MA Kraemer, J Hites, L Singleton, CM AF Stoto, Michael A. Nelson, Christopher Higdon, Melissa A. Kraemer, John Hites, Lisle Singleton, Christa-Marie TI Lessons About the State and Local Public Health System Response to the 2009 H1N1 Pandemic: A Workshop Summary SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE countermeasure distribution and administration; H1N1; incident management; public health emergency preparedness; situational awareness AB Objective: Identify lessons about the public health emergency preparedness system from after action report/improvement plans (AAR/IPs) authored by state and local health departments following the 2009 H1N1 influenza pandemic. Design: Potentially generalizable findings were collected during a workshop attended by representatives from the Centers for Disease Control and Prevention (CDC), state and local public health departments, and other organizations that prepared 2009 H1N1 AAR/IPs. Participants: Workshop participants included state and local health department personnel who had submitted AAR/IPs to the CDC for review. Measures: Workshop participants were asked to consider the question: What did you hear from other jurisdictions that resonated with your own experience and could be a generalized finding? Results: Workshop discussions revealed potential lessons concerning: (1) situational awareness during the initial response; (2) resource mobilization and legal authority; (3) the complexity of vaccine distribution and administration; (4) balancing emergency response and routine operations; (5) communication and coordination among the many independent actors in the public health system; and (6) incident management in a long-duration incident. Conclusions: The response to the 2009 H1N1 influenza pandemic provides an opportunity to learn about the public health system's emergency response capabilities and to identify ways to improve preparedness for future events. Perhaps the most important lessons from the 2009 H1N1 response reveal the complexity of coordinating actions among the many different actors, institutions, sectors, and disciplines involved in the public health system. While the response to the pandemic engendered creative "on the spot" solutions, continued effort is needed to better understand and manage the identified challenges. C1 [Stoto, Michael A.; Kraemer, John] Georgetown Univ, Sch Nursing & Hlth Studies, Dept Hlth Syst Adm, Washington, DC 20057 USA. [Nelson, Christopher] RAND Corp, Santa Monica, CA USA. [Higdon, Melissa A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Kraemer, John] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20057 USA. [Hites, Lisle] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL USA. [Singleton, Christa-Marie] Ctr Dis Control & Prevent, Div State & Local Readiness, Atlanta, GA USA. RP Stoto, MA (reprint author), Georgetown Univ, Sch Nursing & Hlth Studies, Dept Hlth Syst Adm, 3700 Reservoir Rd NW,Room 236, Washington, DC 20057 USA. EM stotom@georgetown.edu FU OPHPR CDC HHS [5P01TP000307-01] NR 14 TC 8 Z9 8 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2013 VL 19 IS 5 BP 428 EP 435 DI 10.1097/PHH.0b013e3182751d3e PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300DU UT WOS:000330445400010 PM 23892378 ER PT J AU Baty, SA Ayala, A Odish, M Cadwell, BL Schumacher, M Sunenshine, RH AF Baty, Steven A. Ayala, Aurimar Odish, Mazen Cadwell, Betsy L. Schumacher, Mare Sunenshine, Rebecca H. TI Factors Associated With Receipt of 2009 Pandemic Influenza A (H1N1) Monovalent and Seasonal Influenza Vaccination Among School-Aged Children: Maricopa County, Arizona, 2009-2010 Influenza Season SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE H1N1 subtype; human; immunization programs; influenza; influenza A virus; school health services ID UNITED-STATES; VIRUS INFECTIONS; IMMUNIZATION; PREDICTORS; COVERAGE; SCHOOLCHILDREN; ABSENTEEISM; EPIDEMIC; FAMILIES; DEATHS AB Context: To target school-aged children (SAC), who were identified as a priority for pandemic 2009 Influenza A (pH1N1) vaccination, Maricopa County (MC) initiated school-based influenza vaccination in 69% of its 706 schools during the 2009-2010 influenza season. Objective: To determine factors associated with receipt of pH1N1 monovalent and 2009-2010 seasonal influenza vaccination among SAC and evaluate the association of school-based vaccination with vaccination status of SAC. Design: Random-digit dialing was used to survey 600 MC households with willing adult participants and children grades K-12. Logistic regression was used to identify factors associated with pH1N1 and seasonal vaccine receipt. Setting: Arizona. Participants: Household adults with children grades K-12. Main Outcome Measure: Characteristics of children, parents, and households were obtained. Results: Among 909 SAC, 402 (44%) received pH1N1 and 436 (48%) received seasonal vaccination. Factors associated with pH1N1 vaccination included vaccine availability at school (adjusted odds ratio [AOR]: 1.6; 95% confidence interval [CI]: 1.0-2.7), high-risk medical condition in child (AOR: 2.4; 95% CI: 1.4-4.0), elementary versus high school attendance (AOR: 1.6; 95% CI: 1.0-2.7), and seasonal influenza vaccination (AOR: 10.0; 95% CI: 6.4-15.6). Factors associated with seasonal vaccination included Hispanic ethnicity (AOR: 2.2; 95% CI: 1.1-4.2), health insurance coverage (AOR: 4.8; 95% CI: 1.7-13.7), elementary versus high school attendance (AOR: 1.5; 95% CI: 1.0-2.5), and pH1N1 vaccination (AOR: 10.5; 95% CI: 6.7-16.6). Conclusions: Availability of pH1N1 vaccine at school was independently associated with pH1N1 vaccination of MC school-aged children. School-based influenza vaccination campaigns should be considered to increase vaccination among this population. C1 [Baty, Steven A.] Ctr Dis Control & Prevent, Arizona Dept Hlth Serv, Epidem Intelligence Serv Field Assignments Branch, Atlanta, GA 30333 USA. [Cadwell, Betsy L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Field Assignments Branch, Phoenix, AZ USA. [Ayala, Aurimar] Maricopa Cty, Off Epidemiol, Phoenix, AZ USA. [Odish, Mazen] Univ Arizona, Coll Med, Phoenix, AZ USA. [Schumacher, Mare] Maricopa Cty, Dept Publ Hlth, Off Epidemiol, Phoenix, AZ USA. [Sunenshine, Rebecca H.] Ctr Dis Control & Prevent, Dept Publ Hlth, Maricopa Cty, Phoenix, AZ USA. RP Baty, SA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM steven.baty@us.army.mil NR 27 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2013 VL 19 IS 5 BP 436 EP 443 DI 10.1097/PHH.0b013e3182751d1c PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300DU UT WOS:000330445400011 PM 23549371 ER PT J AU Stanley, S Arriola, KJ Smith, S Hurlbert, M Ricci, C Escoffery, C AF Stanley, Sandte Arriola, Kimberly Jacob Smith, Shakiyla Hurlbert, Marc Ricci, Carolyn Escoffery, Cam TI Reducing Barriers to Breast Cancer Care Through Avon Patient Navigation Programs SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE Avon Foundation for Women; breast cancer; health disparities; patient navigation ID DIAGNOSIS; WOMEN; POPULATION; OUTREACH; PROTOCOL; SCIENCE; TRIAL; STATE; TIME AB Context: Avon Foundation for Women grantees provide breast cancer services through patient navigation (PN) in an effort to alleviate barriers to care among underserved women. Objective: To gain a better understanding of how PN programs function, this study explores variations in the use of navigators, types of services offered, description of clients they serve, tracking of treatment completion, and evaluation mechanisms. Participants: Fifty-six Avon PN programs funded since 2008 throughout the United States were contacted. Design: An online survey was distributed to the grantees of which 44 (81%) complete responses were collected and analyzed. Results: Clients were racially and ethnically diverse, mostly in the 40- to 64-year old age range (64%) and 91.6% with an average income of less than $ 30 000. Women were either uninsured (50.7%) or receiving Medicaid (32.4%). PN programs were both community and hospital-based (22.5%); many hospitals (35.2%) were described as safety nets (eg, provide a significant level of care to low-income, uninsured, vulnerable populations). On-site services included breast screening (eg, mammography and breast ultrasound) and treatment (eg, breast surgery and radiation therapy). Some barriers to care identified by the programs included transportation, access to appointments, language, and financial issues (eg, cost of screening and treatment specifically for those uninsured). More than 39% of programs provided care across the cancer continuum. Conclusions: Many Avon PN programs incorporated navigation services that span the cancer care continuum. They addressed disparities by offering navigation and on-site medical services to reduce multiple systems barriers and social issues related to breast care. C1 [Stanley, Sandte] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Smith, Shakiyla] Emory Ctr Injury Control, Atlanta, GA USA. [Stanley, Sandte; Arriola, Kimberly Jacob; Escoffery, Cam] Emory Univ, Atlanta, GA 30322 USA. [Hurlbert, Marc; Ricci, Carolyn] Avon Fdn Women, New York, NY USA. RP Stanley, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-07, Atlanta, GA 30333 USA. EM sstanley@cdc.gov OI Hurlbert, Marc/0000-0003-3301-3572 NR 31 TC 5 Z9 5 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2013 VL 19 IS 5 BP 461 EP 467 DI 10.1097/PHH.0b013e318276e272 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300DU UT WOS:000330445400014 PM 23266756 ER PT J AU Dunet, DO Losby, JL Tucker-Brown, A AF Dunet, Diane O. Losby, Jan L. Tucker-Brown, Aisha TI Using Evaluability Assessment to Support the Development of Practice-Based Evidence in Public Health SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE evaluability assessment; evaluation; evidence-informed public health practice; practice-based evidence; program evaluation AB Practice-based evidence arises from programs implemented in real-world settings. Program success may be judged on the basis of experience; however, formal evaluation studies of methodological rigor can provide a high level of credible evidence to inform public health practice. Such studies can be lengthy and expensive. Furthermore, even well-designed studies may not reach conclusive findings, for example, when a program lacks full implementation, when data systems do not have capacity to collect evaluation data, or when program implementation has not attained stability. An evaluability assessment is used to determine the capacity and readiness of a program for full-scale effectiveness evaluation. Evaluators at the Centers for Disease Control and Prevention use evaluability assessment as a preevaluation consisting of brief, focused, criteria-based assessments, document review, and a site visit. Evaluability assessment is used to guide investments in subsequent rigorously designed evaluations that yield conclusive findings to build strong and credible practice-based evidence. C1 [Dunet, Diane O.; Losby, Jan L.; Tucker-Brown, Aisha] Ctr Dis Control & Prevent, Appl Res & Evaluat Branch, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Dunet, DO (reprint author), Ctr Dis Control & Prevent, Appl Res & Evaluat Branch, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy NE,MS F-72, Atlanta, GA 30341 USA. EM ddunet@cdc.gov NR 10 TC 4 Z9 4 U1 5 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2013 VL 19 IS 5 BP 479 EP 482 DI 10.1097/PHH.0b013e318280014f PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300DU UT WOS:000330445400017 PM 23287816 ER PT J AU Christensen, J Gronborg, TK Sorensen, MJ Schendel, D Parner, ET Pedersen, LH Vestergaard, M AF Christensen, Jakob Gronborg, Therese Koops Sorensen, Merete Juul Schendel, Diana Parner, Erik Thorlund Pedersen, Lars Henning Vestergaard, Mogens TI Prenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material ID OUTCOMES C1 [Christensen, Jakob] Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark. [Christensen, Jakob] Aarhus Univ Hosp, Dept Clin Pharmacol, DK-8000 Aarhus, Denmark. [Gronborg, Therese Koops; Parner, Erik Thorlund] Aarhus Univ, Dept Biostat, Aarhus, Denmark. [Pedersen, Lars Henning] Aarhus Univ, Dept Epidemiol, Aarhus, Denmark. [Pedersen, Lars Henning] Aarhus Univ, Inst Publ Hlth, Inst Clin Med, Dept Obstet & Gynaecol, Aarhus, Denmark. [Vestergaard, Mogens] Aarhus Univ, Inst Publ Hlth, Res Unit, Aarhus, Denmark. [Vestergaard, Mogens] Aarhus Univ, Inst Publ Hlth, Sect Gen Practice, Aarhus, Denmark. [Sorensen, Merete Juul] Aarhus Univ Hosp, Reg Ctr Child & Adolescent Psychiat, Risskov, Denmark. [Schendel, Diana] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Christensen, J (reprint author), Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark. NR 5 TC 0 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD SEP PY 2013 VL 68 IS 9 BP 613 EP 614 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 301DM UT WOS:000330513000003 ER PT J AU Terranella, A Asay, GRB Messonnier, ML Clark, TA Liang, JL AF Terranella, Andrew Asay, Garrett R. Beeler Messonnier, Mark L. Clark, Thomas A. Liang, Jennifer L. TI Pregnancy Dose Tdap and Postpartum Cocooning to Prevent Infant Pertussis: A Decision Analysis EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Terranella, Andrew] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Epidem Intelligence Serv, Sci Educ & Profess Dev Off, Atlanta, GA 30333 USA. [Terranella, Andrew; Clark, Thomas A.; Liang, Jennifer L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA USA. [Asay, Garrett R. Beeler; Messonnier, Mark L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA. RP Terranella, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Epidem Intelligence Serv, Sci Educ & Profess Dev Off, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD SEP PY 2013 VL 68 IS 9 BP 615 EP 616 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 301DM UT WOS:000330513000004 ER PT J AU Tatti, KM Martin, SW Boney, KO Brown, K Clark, TA Tondella, ML AF Tatti, Kathleen M. Martin, Stacey W. Boney, Kathryn O. Brown, Kristin Clark, Thomas A. Tondella, Maria Lucia TI Qualitative Assessment of Pertussis Diagnostics in United States Laboratories SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE proficiency panels; pertussis diagnostics; polymerase chain reaction; Bordetella spp. ID REAL-TIME PCR; BORDETELLA-PERTUSSIS; RAPID DETECTION; ASSAY; HOLMESII; STANDARDIZATION; SPECIMENS; PERTACTIN; STRAINS; DNA AB Background: United States national surveillance data show that the use of culture for pertussis diagnostics has sharply declined, whereas polymerase chain reaction (PCR) is now the most common testing method. PCR testing for pertussis is rapid and sensitive, but the lack of standardization and variable specificity is concerning. Methods: A web-based survey containing 12 questions was sent to public health, commercial and hospital-based US laboratories performing clinical diagnostics to determine the pertussis diagnostics used. An extensive realtime PCR (RT-PCR) questionnaire accompanied a proficiency panel assessing the types of extraction methods, RT-PCR methods and current quality control in place at the laboratories. The proficiency panel of 12 specimens containing Bordetella pertussis at various concentrations and negative controls was created to detect cross-contamination and assess the lower limit of detection. Results: One hundred twenty-three (35%) of 355 respondents from the web-based survey performed diagnostic tests for the presence of B. pertussis. Eighty-three (71%) labs reported performing culture, whereas 67 (54%) labs used PCR. All 41 laboratories that consented to participate in the proficiency exercise used the IS481 RT-PCR target; however, a variety of extraction and RT-PCR methods were employed. The laboratories correctly identified 92% of the B. pertussis specimens, and 5% of the laboratories (1.8% of the panel specimens) reported at least 1 false-positive. Conclusions: The small percentage of false-positives suggests that adequate procedures are in place to prevent cross-contamination. Differing extraction and PCR methods as well as variable analytic sensitivity emphasize the necessity for an external well-defined quality control program and interlaboratory pertussis PCR harmonization. C1 [Tatti, Kathleen M.; Martin, Stacey W.; Boney, Kathryn O.; Brown, Kristin; Clark, Thomas A.; Tondella, Maria Lucia] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. RP Tatti, KM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE,Mailstop D11, Atlanta, GA 30333 USA. EM ket2@cdc.gov NR 24 TC 11 Z9 11 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD SEP PY 2013 VL 32 IS 9 BP 942 EP 945 DI 10.1097/INF.0b013e3182947ef8 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 301IH UT WOS:000330525500011 PM 23587980 ER PT J AU Neely, M Rutstein, R Del Bianco, G Heresi, G Barton, T Wiznia, A Wiegand, R Wheeling, T Bohannon, B Dominguez, K AF Neely, Michael Rutstein, Richard Del Bianco, Gabriela Heresi, Gloria Barton, Theresa Wiznia, Andrew Wiegand, Ryan Wheeling, Travis Bohannon, Beverly Dominguez, Kenneth CA LEGACY Consortium TI Use of Nucleoside Reverse Transcriptase Inhibitor-only Regimens in HIV-infected Children and Adolescents SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE HIV; reverse transcriptase inhibitors; therapy ID ACTIVE ANTIRETROVIRAL THERAPY; LAMIVUDINE MONOTHERAPY; HIV-1-INFECTED PATIENTS; EQUIVALENCE TRIAL; INITIAL TREATMENT; FOLLOW-UP; ABACAVIR; EFFICACY; ADULTS; VIRUS AB Objective: In adults, nucleoside reverse transcriptase inhibitor-only antiretroviral regimens (NOARs) with >= 3 nucleoside reverse transcriptase inhibitors are less potent than highly active antiretroviral therapy (HAART). Published pediatric experience with NOARs is limited; thus, we wished to better define the virological, immunological and toxicological effects of NOARs in children and adolescents. Methods: We analyzed data from NOAR-treated participants in LEGACY, a multicenter observational cohort study of HIV-infected children and adolescents. NOAR-treated case-participants were matched to participants without prior NOAR who initiated HAART during the same year for comparison. Results: Of 575 participants with data from time of HIV diagnosis through 2006, 67 (12%) received NOARs for at least 24 weeks; most (46%) received the fixed dose combination of zidovudine/lamivudine/abacavir. NOAR use peaked in 2001 to 2002. NOAR-treated participants were significantly older and more treatment experienced than HAART-treated participants. Virologic outcomes, including the percentage of participants with a plasma HIV RNA viral load <400 copies/mL at week 24 (47% versus 34%) and the mean 24-week change in log 10 plasma HIV RNA viral load from baseline (-0.63 versus -1.02), were similar between NOAR- and HAART-treated participants, but virologic rebound was more likely in NOAR-treated participants (77% versus 54%, P = 0.02). Increase in CD4 percentage points from baseline to 24 weeks was negligible in NOAR-treated participants compared with HAART-treated participants (0.95% versus 10.1%, P < 0.001). Anemia and leukopenia were more commonly reported with NOARs than HAART. Discussion: Week 24 virologic outcomes were similar between NOAR- and HAART-treated participants, but NOAR durability was poorer and their use was associated with less immunologic reconstitution. NOARs should play a limited role in pediatric and adolescent antiretroviral therapy. C1 [Neely, Michael] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA. [Rutstein, Richard] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Del Bianco, Gabriela; Heresi, Gloria] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Barton, Theresa] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Wiznia, Andrew] Jacobi Med Ctr, Bronx, NY USA. [Wiegand, Ryan; Bohannon, Beverly; Dominguez, Kenneth] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wheeling, Travis; LEGACY Consortium] Northrop Grumman, Atlanta, GA USA. RP Neely, M (reprint author), Lab Appl Pharmacokinet, 2250 Alcazar St CSC 134B, Los Angeles, CA 90033 USA. EM mneely@usc.edu FU Centers for Disease Control and Prevention, Atlanta, GA [200-2004-09976] FX The LEGACY project was funded by the Centers for Disease Control and Prevention, Atlanta, GA, contract number 200-2004-09976. NR 25 TC 1 Z9 1 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD SEP PY 2013 VL 32 IS 9 BP E370 EP E376 DI 10.1097/INF.0b013e31828e8c09 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 301IH UT WOS:000330525500005 PM 24008749 ER PT J AU Spaulding, AC Miller, J Trigg, BG Braverman, P Lincoln, T Reams, PN Staples-Horne, M Sumbry, A Rice, D Satterwhite, CL AF Spaulding, Anne C. Miller, Jamie Trigg, Bruce G. Braverman, Paula Lincoln, Thomas Reams, Patricia N. Staples-Horne, Michelle Sumbry, Anitra Rice, Dana Satterwhite, Catherine Lindsey TI Screening for Sexually Transmitted Diseases in Short-Term Correctional Institutions: Summary of Evidence Reviewed for the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines SO SEXUALLY TRANSMITTED DISEASES LA English DT Review ID RISK BEHAVIORS; UNITED-STATES; INCARCERATED ADOLESCENTS; PSYCHIATRIC-DISORDERS; SAN-FRANCISCO; CHLAMYDIA; HEALTH; PREVALENCE; GONORRHEA; INFECTION AB Young persons entering US jails and youth detention facilities have high rates of sexually transmitted diseases (STDs). The Centers for Disease Control and Prevention added STD screening guidelines specific to correctional settings to the 2010 STD Treatment Guidelines. This article summarizes published evidence from 1990 to 2009 used to develop the recommendations. The literature supports routine screening of adolescents and young women (aged <= 35 years, or on the basis of local institutional prevalence data) for chlamydia and gonorrhea because of high prevalence and the subsequent risk of adverse reproductive outcomes. Chlamydia positivity among young women (aged <20 years) in juvenile detention facilities and adult facilities is more than 14%. Men in correctional settings are also at high risk for chlamydia and gonorrhea. Among boys in juvenile detention facilities, chlamydia positivity is estimated at 6.6%; among young men in adult facilities, positivity is 16.6%. Screeningmen (to reduce sequelae among women) should be considered based on local epidemiology and resource availability. Syphilis screening is not strongly supported in published literature because of low prevalence and is not routinely recommended; however, some screening may be warranted based on local prevalence. Although there is a great diversity in the organization of correctional facilities, implementation of screening recommendations is possible owing to improvements in test technology (urine specimens) and through integration of a standard screening protocol. Based on the high burden of disease and substantial opportunities to reach a high-risk population, correctional facilities are important venues to target efforts to control STDs. C1 [Spaulding, Anne C.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Miller, Jamie] Natl Coalit STD Directors, Washington, DC USA. [Trigg, Bruce G.] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Braverman, Paula] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45267 USA. [Lincoln, Thomas] Tufts Univ, Sch Med, Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA. [Reams, Patricia N.] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pediat, Richmond, VA 23298 USA. [Staples-Horne, Michelle] Georgia Dept Juvenile Justice, Decatur, GA USA. [Sumbry, Anitra] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Rice, Dana] Wayne State Univ, Sch Med, Dept Family Med, Detroit, MI USA. [Rice, Dana] Wayne State Univ, Sch Med, Dept Publ Hlth Sci, Detroit, MI USA. [Satterwhite, Catherine Lindsey] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Spaulding, AC (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd,Room 3033, Atlanta, GA 30322 USA. EM ASpauld@emory.edu OI Lincoln, Thomas/0000-0002-4956-1226 NR 40 TC 8 Z9 8 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD SEP PY 2013 VL 40 IS 9 BP 679 EP 684 DI 10.1097/01.olq.0000431353.88464.ab PG 6 WC Infectious Diseases SC Infectious Diseases GA 297FJ UT WOS:000330240800001 PM 23945422 ER PT J AU Introcaso, CE Gruber, D Bradley, H Peterman, TA Ewell, J Wendell, D Foxhood, J Su, JR Weinstock, HS Markowitz, LE AF Introcaso, Camille E. Gruber, DeAnn Bradley, Heather Peterman, Thomas A. Ewell, Joy Wendell, Debbie Foxhood, Joseph Su, John R. Weinstock, Hillard S. Markowitz, Lauri E. TI Challenges in Congenital Syphilis Surveillance: How Are Congenital Syphilis Investigations Classified? SO SEXUALLY TRANSMITTED DISEASES LA English DT Article AB Background: Congenital syphilis is a serious, preventable, and nationally notifiable disease. Despite the existence of a surveillance case definition, congenital syphilis is sometimes classified differently using an algorithm on the Centers for Disease Control and Prevention's case reporting form. Methods: We reviewed Louisiana's congenital syphilis electronic reporting system for investigations of infants born from January 2010 to October 2011, abstracted data required for classification, and applied the surveillance definition and the algorithm. We calculated the sensitivities and specificities of the algorithm and Louisiana's classification using the surveillance definition as the surveillance gold standard. Results: Among 349 congenital syphilis investigations, the surveillance definition identified 62 cases. The algorithm had a sensitivity of 91.9% and a specificity of 64.1%. Louisiana's classification had a sensitivity of 50% and a specificity of 91.3% compared with the surveillance definition. Conclusions: The differences between the algorithm and the surveillance definition led to misclassification of congenital syphilis cases. The algorithm should match the surveillance definition. Other state and local health departments should assure that their reported cases meet the surveillance definition. C1 [Introcaso, Camille E.; Bradley, Heather; Peterman, Thomas A.; Su, John R.; Weinstock, Hillard S.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30329 USA. [Gruber, DeAnn; Ewell, Joy; Wendell, Debbie; Foxhood, Joseph] Louisiana Off Publ Hlth STD, HIV Program, New Orleans, LA USA. RP Introcaso, CE (reprint author), Ctr Dis Control & Prevent, Corp Sq Bldg 10,MS E-02, Atlanta, GA 30329 USA. EM vie4@cdc.gov NR 9 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD SEP PY 2013 VL 40 IS 9 BP 695 EP 699 DI 10.1097/01.olq.0000431352.50346.fb PG 5 WC Infectious Diseases SC Infectious Diseases GA 297FJ UT WOS:000330240800004 PM 23949584 ER PT J AU Kidd, S Lee, MVC Maningas, E Komeya, A Kunimoto, G O'Connor, N Katz, AR Wasserman, GM Kirkcaldy, RD Whelen, AC AF Kidd, Sarah Lee, Maria V. C. Maningas, Eloisa Komeya, Alan Kunimoto, Gail O'Connor, Norman Katz, Alan R. Wasserman, Glenn M. Kirkcaldy, Robert D. Whelen, A. Christian TI Gonococcal Susceptibility to Cephalosporins-Hawaii, 2003 to 2011 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID DISEASES-TREATMENT-GUIDELINES; NEISSERIA-GONORRHOEAE; DECREASED SUSCEPTIBILITY; ORAL CEPHALOSPORINS; UNITED-STATES; NO LONGER; INFECTIONS; FLUOROQUINOLONES; UPDATE AB Among gonococcal isolates examined at the Hawaii State Laboratory Division from 2003 to 2011, the prevalence of elevated cefixime minimum inhibitory concentrations (MICs; >= 0.064 mu g/mL) and elevated cefpodoxime MICs (>= 0.19 mu g/mL) increased over time. In contrast, few isolates exhibited elevated ceftriaxone MICs (> 0.094 mu g/mL), and the prevalence of elevated ceftriaxone MICs did not change. C1 [Kidd, Sarah; Kirkcaldy, Robert D.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Lee, Maria V. C.; Maningas, Eloisa; Komeya, Alan; Kunimoto, Gail; O'Connor, Norman; Katz, Alan R.; Wasserman, Glenn M.; Whelen, A. Christian] Hawaii State Dept Hlth, Honolulu, HI USA. [Katz, Alan R.; Whelen, A. Christian] Univ Hawaii Manoa, Honolulu, HI 96822 USA. RP Kidd, S (reprint author), 1600 Clifton Rd NE,MS-E02, Atlanta, GA 30333 USA. EM HGK9@cdc.gov FU Intramural CDC HHS [CC999999] NR 11 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD SEP PY 2013 VL 40 IS 9 BP 756 EP 759 DI 10.1097/01.olq.0000431357.18959.30 PG 4 WC Infectious Diseases SC Infectious Diseases GA 297FJ UT WOS:000330240800015 PM 23949591 ER PT J AU Williams, AJK Lampasona, V Schlosser, M Mueller, PW Pittman, D Winter, WE Wyatt, R Akolkar, B Bingley, PJ Achenbach, P AF Williams, A. J. K. Lampasona, V. Schlosser, M. Mueller, P. W. Pittman, D. Winter, W. E. Wyatt, R. Akolkar, B. Bingley, P. J. Achenbach, P. TI N-terminally truncated GAD discriminates progression in GAD antibody positive relatives of patients with type 1 diabetes SO DIABETOLOGIA LA English DT Meeting Abstract CT 49th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) CY SEP 23-27, 2013 CL Barcelona, SPAIN SP European Assoc Study Diabet C1 [Williams, A. J. K.; Wyatt, R.; Bingley, P. J.] Univ Bristol, Sch Clin Sci, Bristol BS8 1TH, Avon, England. [Lampasona, V.] Ist Sci San Raffaele, Ctr Translat Genom & Bioinformat, I-20132 Milan, Italy. [Schlosser, M.] Ernst Moritz Arndt Univ Greifswald, Dept Med Biochem & Mol Biol, Karlsburg, Germany. [Mueller, P. W.] Ctr Dis Control & Prevent, Mol Risk Assessment Lab, Atlanta, GA USA. [Pittman, D.; Winter, W. E.] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA. [Akolkar, B.] NIDDK, Div Diabet Endocrinol & Metab, Bethesda, MD 20892 USA. [Achenbach, P.] Helmholtz Ctr Munich, Diabet Res Inst, Neuherberg, Germany. RI Achenbach, Peter/M-9867-2014 OI Achenbach, Peter/0000-0001-6720-2684 NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD SEP PY 2013 VL 56 SU 1 MA 25 BP S17 EP S17 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 282TQ UT WOS:000329196900026 ER PT J AU Carter, M Kraft, JM Hock-Long, L Hatfield-Timajchy, K AF Carter, Marion Kraft, Joan M. Hock-Long, Linda Hatfield-Timajchy, Kendra TI Relationship Characteristics and Feelings About Pregnancy Among Black and Puerto Rican Young Adults SO PERSPECTIVES ON SEXUAL AND REPRODUCTIVE HEALTH LA English DT Article ID AFRICAN-AMERICAN WOMEN; UNINTENDED PREGNANCY; INTENTIONS; HEALTH; CONTEXT; COUPLES; MATTER; DESIRE; BABY; MEN AB CONTEXT: Unintended pregnancy is common among black and Hispanic young adults in the United States. How pregnancy intentions form and change is poorly understood, although research indicates that intentions and attitudes are dependent on partners' views and other relationship factors, and are different by gender. METHODS: A sample of black and Puerto Rican men and women aged 18-25 from low-income neighborhoods in two cities were surveyed in 2007-2008. Using data on 520 serious and casual sexual relationships reported by 460 respondents, generalized ordered logistic regression analysis was conducted to identify individual-and relationship-level correlates of how respondents would feel if they became involved in a pregnancy with a particular partner. RESULTS: About one-quarter of respondents reported each of four possibilities of how they would feel about a pregnancy with a particular partner-very upset, a little upset, a little pleased and very pleased. In 45% of relationships, respondents believed that their partners would be very pleased about a pregnancy, whereas they themselves would be very pleased in only one-quarter of cases. Overall, women were less likely to feel positive about a pregnancy than were men (odds ratio, 0.3). Respondents' positive feelings about their relationships were associated with a strong tendency toward more positive feelings about a pregnancy (2.1), as was a measure of how positive respondents thought their partners would feel (1.5-2.6). The latter association was particularly strong among women (1.7). CONCLUSIONS: Relationship characteristics were associated with feelings about pregnancy for both genders. Future research should utilize a more comprehensive framework for conceptualizing and examining sexual relationships. C1 [Carter, Marion; Kraft, Joan M.; Hatfield-Timajchy, Kendra] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30329 USA. [Hock-Long, Linda] Family Planning Council Southeast Penn, Philadelphia, PA USA. RP Carter, M (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30329 USA. EM MCarter1@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 5 Z9 5 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-6341 EI 1931-2393 J9 PERSPECT SEX REPRO H JI Perspect. Sex Reprod. Health PD SEP PY 2013 VL 45 IS 3 BP 148 EP 156 DI 10.1363/4514813 PG 9 WC Demography; Family Studies SC Demography; Family Studies GA 213XO UT WOS:000324094100004 PM 24020776 ER PT J AU Barile, JP Thompson, WW Zack, MM Krahn, GL Horner-Johnson, W Bowen, SE AF Barile, John P. Thompson, William W. Zack, Matthew M. Krahn, Gloria L. Horner-Johnson, Willi Bowen, Sonya E. TI Multiple Chronic Medical Conditions and Health-Related Quality of Life in Older Adults, 2004-2006 SO PREVENTING CHRONIC DISEASE LA English DT Article ID FUNCTIONAL LIMITATIONS; DISABILITY; OUTCOMES; DISEASE AB Introduction Understanding longitudinal relationships among multiple chronic conditions, limitations in activities of daily living, and health-related quality of life is important for identifying potential opportunities for health promotion and disease prevention among older adults. Methods This study assessed longitudinal associations between multiple chronic conditions and limitations in activities of daily living on health-related quality of life among older adults (years) from 2004 through 2006, using data from the Medicare Health Outcomes Survey (N = 27,334). Results Using a longitudinal path model, we found the numbers of chronic conditions at baseline and 2-year follow-up were independently associated with more limitations in activities of daily living at 2-year follow-up. In addition, more limitations in activities of daily living at 2-year follow-up were associated with worse health-related quality of life during the follow-up time period. The association between multiple chronic conditions and indices of health-related quality of life was mediated by changes in limitations in activities of daily living. Conclusion Both baseline and new multiple chronic conditions led to worse health in terms of activities of daily living and health-related quality of life and should be considered important outcomes to intervene on for improved long-term health. In addition, public health practitioners should consider addressing classes of multiple chronic conditions by using interventions designed to reduce the emergence of multiple chronic conditions, such as physical activity, reductions in smoking rates, and improved and coordinated access to health care services. C1 [Barile, John P.] Univ Hawaii Manoa, Honolulu, HI 96822 USA. [Thompson, William W.; Zack, Matthew M.; Krahn, Gloria L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Horner-Johnson, Willi] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bowen, Sonya E.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. RP Barile, JP (reprint author), Univ Hawaii Manoa, 2530 Dole St,Sakamaki Hall,C404, Honolulu, HI 96822 USA. EM Barile@Hawaii.edu RI Barile, John/F-9456-2015; OI Barile, John/0000-0003-4098-0640; Horner-Johnson, Willi/0000-0003-3568-1400 NR 29 TC 5 Z9 5 U1 3 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2013 VL 10 AR UNSP 120282 DI 10.5888/pcd10.120282 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KS UT WOS:000329393500015 ER PT J AU Fan, AZ Rock, V Zhang, XP Li, Y Elam-Evans, L Balluz, L AF Fan, Amy Z. Rock, Valerie Zhang, Xuanping Li, Yan Elam-Evans, Laurie Balluz, Lina TI Trends in Cigarette Smoking Rates and Quit Attempts Among Adults With and Without Diagnosed Diabetes, United States, 2001-2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; CESSATION; RISK; INTERVENTION; PREDICTORS; REDUCTION; MELLITUS; PROGRAM; TOBACCO; DISEASE AB Introduction Quitting smoking is a critical step toward diabetes control. It is not known whether smoking rates in adults with diabetes are similar to rates among adults who do not have the disease or whether people with diabetes have increased motivation to quit. We examined prevalence trends of current smoking and quit attempts among US adults with and without diagnosed diabetes from 2001 through 2010. Methods We used data from the 2001 through 2010 Behavioral Risk Factor Surveillance System, a state-based telephone survey of noninstitutionalized US adults, and conducted linear trend analysis and log linear regression. Results The adjusted prevalence of cigarette smoking among adults with diagnosed diabetes was 9% less than adults without diagnosed diabetes (adjusted prevalence ratio [APR], 0.91; 99% confidence interval [CI], 0.89-0.93). Declines in smoking prevalence were greater among adults without diabetes than adults with diagnosed diabetes (P < .001). Among smokers, the adjusted prevalence of quit attempts among adults with diagnosed diabetes was 13% higher than among adults without diagnosed diabetes (APR, 1.13; 99% CI, 1.11-1.15). Among adult smokers with diagnosed diabetes, quit attempts were stable over time for those aged 18 to 44 years and those with a high school education or less. Quit attempts were also stable for older smokers, non-Hispanic African Americans, and Hispanic smokers, regardless of diagnosed diabetes status. Conclusion A large proportion of smokers with diagnosed diabetes seemed to have quit smoking, but more research is needed to confirm success and how difficult it was to achieve. C1 [Fan, Amy Z.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Rock, Valerie; Zhang, Xuanping; Elam-Evans, Laurie; Balluz, Lina] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Li, Yan] Georgia Dept Community Hlth, Atlanta, GA USA. RP Fan, AZ (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, 1600 Clifton Rd,MS E97, Atlanta, GA 30333 USA. EM afan@cdc.gov NR 31 TC 2 Z9 2 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2013 VL 10 AR UNSP 120259 DI 10.5888/pcd10.120259 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KS UT WOS:000329393500013 ER PT J AU Fox, MH Reichard, A AF Fox, Michael H. Reichard, Amanda TI Disability, Health, and Multiple Chronic Conditions Among People Eligible for Both Medicare and Medicaid, 2005-2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID DUAL ELIGIBLES; UNITED-STATES; ADULTS; CARE; BENEFICIARIES; INDIVIDUALS; DISPARITIES; CHALLENGES; SERVICES AB Introduction People who are eligible for both Medicare and Medicaid (dual eligibles) and who have disabilities and multiple chronic conditions (MCC) present challenges for treatment, preventive services, and cost-effective access to care within the US health system. We sought to better understand dual eligibles and their association with MCC, accounting for sociodemographic factors inclusive of functional disability category. Methods Medical Expenditure Panel Survey (MEPS) data for 2005 through 2010 were stratified by ages 18 to 64 and 65 or older to account for unique subsets of dual eligibles. Prevalence of MCC was calculated for those with physical disabilities, physical plus cognitive disabilities, and all others, accounting for sociodemographic and health-related factors. Adjusted odds for having MCC were calculated by using logistic regression. Results Of dual eligibles aged 18 to 64, 53% had MCC compared with 73.5% of those aged 65 or older. Sixty-five percent of all dual eligibles had 2 or more chronic conditions, and among dual eligibles aged 65 or older with physical disabilities and cognitive limitations, 35% had 4 or more, with hypertension and arthritis the most common conditions. Dual eligibles aged 18 to 64 who had a usual source of medical care had a 127% increased likelihood of having MCC compared with those who did not have a usual source of care. Conclusion Attention to disability can be a component to helping further understand the relationship between health and chronic conditions for dual eligible populations and other segments of our society with complex health and medical needs. C1 [Fox, Michael H.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Reichard, Amanda] Univ Kansas, Lawrence, KS 66045 USA. RP Fox, MH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, 1600 Clifton Rd,Mailstop E-88, Atlanta, GA 30333 USA. EM mhfox@cdc.gov NR 29 TC 2 Z9 2 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2013 VL 10 AR UNSP 130064 DI 10.5888/pcd10.130064 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KS UT WOS:000329393500010 ER PT J AU Gibbert, WS Keating, SM Jacobs, JA Dodson, E Baker, E Diem, G Giles, W Gillespie, KN Grabauskas, V Shatchkute, A Brownson, RC AF Gibbert, Wesley S. Keating, Shannon M. Jacobs, Julie A. Dodson, Elizabeth Baker, Elizabeth Diem, Gunter Giles, Wayne Gillespie, Kathleen N. Grabauskas, Vilius Shatchkute, Aushra Brownson, Ross C. TI Training the Workforce in Evidence-Based Public Health: An Evaluation of Impact Among US and International Practitioners SO PREVENTING CHRONIC DISEASE LA English DT Article ID DECISION-MAKING; EDUCATION; BARRIERS AB Introduction The Prevention Research Center in St. Louis developed a course on evidence-based public health in 1997 to train the public health workforce in implementation of evidence-based public health. The objective of this study was to assess use and benefits of the course and identify barriers to using evidence-based public health skills as well as ways to improve the course. Methods We used a mixed-method design incorporating on-site pre- and post-evaluations among US and international course participants who attended from 2008 through 2011 and web-based follow-up surveys among course participants who attended from 2005 through 2011 (n = 626). Respondents included managers, specialists, and academics at state health departments, local health departments, universities, and national/regional health departments. Results We found significant improvement from pre- to post-evaluation for 11 measures of knowledge, skill, and ability. Follow -up survey results showed at least quarterly use of course skills in most categories, majority endorsement of most course benefits, and lack of funding and coworkers who do not have evidence-based public health training as the most significant barriers to implementation of evidence-based public health. Respondents suggested ways to increase evidence-based decision making at their organization, focusing on organizational support and continued access to training Conclusion Although the evidence-based public health course is effective in improving self-reported measures of knowledge, skill, and ability, barriers remain to the implementation of evidence-based decision making, demonstrating the importance of continuing to offer and expand training in evidence-based public health. C1 [Keating, Shannon M.] Hlth Capital Consultants, St Louis, MO USA. [Jacobs, Julie A.; Dodson, Elizabeth] Washington Univ, Prevent Res Ctr St Louis, Brown Sch, St Louis, MO USA. [Baker, Elizabeth] Prevent Res Ctr St Louis, St Louis, MO USA. [Baker, Elizabeth] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA. [Diem, Gunter] Vorarlberg Publ Hlth Soc, Vorarlberg, Austria. [Giles, Wayne] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gillespie, Kathleen N.] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA. [Grabauskas, Vilius] Lithuanian Univ Hlth Sci, Kaunas, Lithuania. [Grabauskas, Vilius] WHO, Countrywide Integrated Noncommunicable Dis Interv, Copenhagen, Denmark. [Brownson, Ross C.] Washington Univ, Prevent Res Ctr St Louis, Brown Sch, St Louis, MO USA. [Brownson, Ross C.] Washington Univ, Sch Med, St Louis, MO USA. RP Gibbert, WS (reprint author), Prevent Res Ctr St Louis, 621 N Skinker Blvd, St Louis, MO 63130 USA. EM wsgibbert@gmail.com RI yan, liu/A-1822-2015 OI yan, liu/0000-0001-8517-1084 FU National Association of Chronic Disease Directors [482012]; Centers for Disease Control and Prevention, Prevention Research Centers Program [U48/DP001903] FX This study was made possible by the contributions of EBPH course faculty members, including Dr Claudia Campbell, Dr Sylvie Stachenko, Dr Erkki Vartiainen, and Dr Jozica Maucek Zakotnic. We are also grateful to Carol Brownson and to Ellen Jones and Chuck Gollmar of the National Association of Chronic Disease Directors. The EBPH training program was supported in part by the National Association of Chronic Disease Directors contract no. 482012; cooperative agreement no. U48/DP001903 from the Centers for Disease Control and Prevention, Prevention Research Centers Program. NR 33 TC 4 Z9 4 U1 2 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2013 VL 10 AR UNSP 130120 DI 10.5888/pcd10.130120 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KS UT WOS:000329393500001 ER PT J AU Giang, KB Minh, HV Nga, PQ Hai, PT Quan, NT Tong, VT Xuan, LTT Hsia, J AF Kim Bao Giang Hoang Van Minh Pham Quynh Nga Phan Thi Hai Nguyen The Quan Tong, Van T. Le Thi Thanh Xuan Hsia, Jason TI Factors Associated With Exposure to Antismoking Information Among Adults in Vietnam, Global Adult Tobacco Survey, 2010 SO PREVENTING CHRONIC DISEASE LA English DT Article AB Introduction The media play a critical role in tobacco control. Knowledge about the exposure of a population to antismoking information can provide information for planning communication activities in tobacco control. We examined exposure to antismoking information associated with socioeconomic and demographic factors among adults (15 years) in Vietnam. Methods The Global Adult Tobacco Survey (GATS) is a nationally representative household survey of noninstitutionalized men and women aged 15 years or older and was conducted in Vietnam in 2010 (N = 9,925). We used GATS data on exposure to sources of antismoking information and analyzed associations among socioeconomic and demographic groups. Results An estimated 91.6% of the adult population was exposed to at least 1 source of antismoking information, and the mean number of sources of exposure was 3.7. Compared with their counterparts, respondents who were older, had higher education levels, higher economic status, and higher knowledge levels about the health consequences of smoking were more likely to be exposed to any source of antismoking information and to more informational sources. The most common source of exposure was television (85.9%). Respondents of higher social class (education, occupation, wealth) had more exposure through modern media sources (television), and respondents of lower social class were exposed to more traditional sources such as radio or loudspeakers. Conclusion Exposure to at least 1 source of antismoking information is high in Vietnam, and the number and type of source varied by sociodemographic group. Use of multiple communication channels is recommended to reinforce antismoking messages and to reach different groups in the population. C1 [Kim Bao Giang; Hoang Van Minh; Le Thi Thanh Xuan] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam. [Pham Quynh Nga] WHO, Off Vietnam, Hanoi, Vietnam. [Phan Thi Hai] Vietnam Steering Comm Smoking & Hlth VINACOSH, Hanoi, Vietnam. [Nguyen The Quan] Gen Stat Off, Hanoi, Vietnam. [Tong, Van T.; Hsia, Jason] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Minh, HV (reprint author), Hanoi Med Univ, Inst Prevent Med & Publ Hlth, 1 Ton That Tung, Hanoi, Vietnam. EM hoangvanminh@hmu.edu.vn OI Tong, Van/0000-0002-3970-1440 FU Bloomberg Philanthropies FX This study was funded by the Bloomberg Philanthropies. We appreciate the contributions to the success of the survey made by the Centers for Disease Control and Prevention (CDC), the CDC Foundation, the World Health Organization, the General Statistics Office of Vietnam, and Hanoi Medical University. NR 19 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2013 VL 10 AR UNSP 120348 DI 10.5888/pcd10.120348 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KS UT WOS:000329393500006 ER PT J AU Posner, SF AF Posner, Samuel F. TI PCD Recognizes Outstanding Student Research: Patel et al on Emergency Medical Services Capacity for Prehospital Stroke Care in North Carolina SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Posner, SF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mail Stop F-68, Atlanta, GA 30341 USA. EM shp5@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 2 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2013 VL 10 AR UNSP 130247 DI 10.5888/pcd10.130247 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KS UT WOS:000329393500003 ER PT J AU Yeoman, K Safranek, T Buss, B Cadwell, BL Mannino, D AF Yeoman, Kristin Safranek, Thomas Buss, Bryan Cadwell, Betsy L. Mannino, David TI Adverse Childhood Experiences and Adult Smoking, Nebraska, 2011 SO PREVENTING CHRONIC DISEASE LA English DT Article ID RANDOMIZED-TRIAL; HOME VISITATION; SEXUAL-ABUSE; LIFE-COURSE; 5 STATES; HEALTH; DEATH; CONSEQUENCES; MALTREATMENT; ASSOCIATION AB Introduction Smoking is a public health risk; the prevalence of smoking among adults in Nebraska is 18.4%. Studies indicate that maltreatment of children alters their brain development, possibly increasing risk for tobacco use. Previous studies have documented associations between childhood maltreatment and adult health behaviors, demonstrating the influence of adverse experiences on tobacco use. We examined prevalence and associations between adverse childhood experiences and smoking among Nebraskans. Methods We analyzed 2011 Nebraska Behavioral Risk Factor Surveillance System (Adverse Childhood Experience module) data, defining adverse childhood experience exposures as physical, sexual, and verbal abuse (ie, direct exposures), and household dysfunction associated with mental illness, substance abuse, divorce, domestic violence, and living with persons with incarceration histories (ie, environmental exposures). We estimated prevalence of exposures, taking into account the complex survey design. We used logistic regression with predicted margins to estimate adjusted relative risk for smoking by direct or environmental exposure. Results Approximately 51% of Nebraskans experienced 1 or more adverse childhood events; 7% experienced 5 or more. Prevalence of environmental exposures (42%) was significantly higher than that of direct exposures (31%). Prevalence of individual exposures ranged from 6% (incarceration of a household member) to 25% (verbal abuse). Adjusted relative risks of smoking for direct and environmental exposures were 1.5 and 1.8, respectively. Conclusion We present a new method of evaluating adverse childhood experience data. Prevalence of adverse childhood experiences is high among Nebraskans, and these exposures are associated with smoking. State-specific strategies to monitor adverse events among children and provide interventions might help to decrease the smoking rate in this population. C1 [Yeoman, Kristin; Safranek, Thomas] Nebraska Dept Hlth & Human Serv, Lincoln, NE 68509 USA. [Buss, Bryan; Cadwell, Betsy L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mannino, David] Univ Kentucky, Coll Publ Hlth, Lexington, KY USA. RP Yeoman, K (reprint author), Nebraska Dept Hlth & Human Serv, 301 Centennial Mall South,POB 95026, Lincoln, NE 68509 USA. EM kyeoman@cdc.gov OI Mannino, David/0000-0003-3646-7828 NR 29 TC 2 Z9 2 U1 2 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD SEP PY 2013 VL 10 AR UNSP 130009 DI 10.5888/pcd10.130009 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KS UT WOS:000329393500012 ER PT J AU Hu, DJ Xing, J Tohme, RA Liao, YL Pollack, H Ward, JW Holmberg, SD AF Hu, Dale J. Xing, Jian Tohme, Rania A. Liao, Youlian Pollack, Henry Ward, John W. Holmberg, Scott D. TI Hepatitis B Testing and Access to Care Among Racial and Ethnic Minorities in Selected Communities Across the United States, 2009-2010 SO HEPATOLOGY LA English DT Article ID VIRUS INFECTION; LIVER-CANCER; CAMBODIAN-AMERICANS; CHINESE-AMERICANS; ASIAN-AMERICANS; 2008 UPDATE; VACCINATION; PREVALENCE; MANAGEMENT; KNOWLEDGE AB Hepatitis B virus (HBV) infection is widely prevalent among racial and ethnic minorities in the United States; however, few data have been available regarding HBV testing and referral to care for these populations. Using survey data collected in 2009-2010 from the Racial and Ethnic Approaches to Community Health (REACH) across the U.S., we assessed rates and determinants of hepatitis B testing and access to care in 28 minority communities in the U.S. Of 53,896 respondents, 21,129 (39.2%) reported having been tested for hepatitis B. Of the 1,235 who reported testing positive, 411 (33.3%) reported currently receiving specialty care. After controlling for demographic and socioeconomic characteristics, the likelihood of having been tested for hepatitis B and receiving care if infected was higher among males, non-English speaking persons, and those having health insurance compared to their counterparts. Compared to college graduates, respondents without a college education were less likely to get tested for hepatitis B. Conclusion: These data indicate that more than half of racial/ethnic minority persons in these communities had not been tested for hepatitis B, and only about one-half of those who tested positive had ever received treatment. More state and federal efforts are needed to screen racial/ethnic minorities, especially foreign-born persons, for HBV and link those with infection to care. (Hepatology 2013;53:856-862) C1 [Hu, Dale J.; Xing, Jian; Tohme, Rania A.; Ward, John W.; Holmberg, Scott D.] Natl Ctr HIV Viral Hepatitis STDs & TB Prevent NC, Div Viral Hepatitis, Atlanta, GA USA. [Liao, Youlian] Ctr Dis Control & Prevent CDC, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot NCCDPHP, Atlanta, GA USA. [Pollack, Henry] NYU, Med Ctr, Bellevue Hosp, New York, NY USA. RP Holmberg, SD (reprint author), CDC Mailstop G-37,1600 Clifton Rd, Atlanta, GA 30333 USA. EM sdh1@cdc.gov NR 32 TC 17 Z9 17 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD SEP PY 2013 VL 58 IS 3 BP 856 EP 862 DI 10.1002/hep.26286 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 283YX UT WOS:000329284000006 PM 23359276 ER PT J AU Backer, LC Landsberg, JH Miller, M Keel, K Taylor, TK AF Backer, Lorraine C. Landsberg, Jan H. Miller, Melissa Keel, Kevin Taylor, Tegwin K. TI Canine Cyanotoxin Poisonings in the United States (1920s-2012): Review of Suspected and Confirmed Cases from Three Data Sources SO TOXINS LA English DT Article DE anatoxin; dog; canine; cyanotoxin; hepatotoxin; microcystin; neurotoxin poisoning; cyanobacteria; blue-green algae ID ANABAENA-FLOS-AQUAE; HARMFUL ALGAL BLOOMS; MICROCYSTIN-LR; CYANOBACTERIAL TOXINS; GLOBAL EXPANSION; CLIMATE-CHANGE; NORTH-AMERICA; FRESH; DOGS; BIOACCUMULATION AB Cyanobacteria (also called blue-green algae) are ubiquitous in aquatic environments. Some species produce potent toxins that can sicken or kill people, domestic animals, and wildlife. Dogs are particularly vulnerable to cyanotoxin poisoning because of their tendency to swim in and drink contaminated water during algal blooms or to ingestalgal mats.. Here, we summarize reports of suspected or confirmed canine cyanotoxin poisonings in the U.S. from three sources: (1) The Harmful Algal Bloom-related Illness Surveillance System (HABISS) of the National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC); (2) Retrospective case files from a large, regional veterinary hospital in California; and (3) Publicly available scientific and medical manuscripts; written media; and web-based reports from pet owners, veterinarians, and other individuals. We identified 231 discreet cyanobacteria harmful algal bloom (cyanoHAB) events and 368 cases of cyanotoxinpoisoning associated with dogs throughout the U.S. between the late 1920s and 2012. The canine cyanotoxin poisoning events reviewed here likely represent a small fraction of cases that occur throughout the U.S. each year. C1 [Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Landsberg, Jan H.] Florida Fish & Wildlife Conservat Commiss, Fish & Wildlife Res Inst, St Petersburg, FL 33701 USA. [Miller, Melissa; Taylor, Tegwin K.] Dept Fish & Wildlife, Marine Wildlife Vet Care & Res Ctr, Off Spill Prevent & Response, Santa Cruz, CA 95060 USA. [Miller, Melissa; Keel, Kevin] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA. RP Backer, LC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, 4770 Buford Highway NE,MS F-60, Chamblee, GA 30341 USA. EM lfb9@cdc.gov; jan.landsberg@myfwc.com; melissa.miller@wildlife.ca.gov; mkkeel@ucdavis.edu; tktdvm@gmail.com FU [CDC-RFA-EH08-801] FX Florida, Iowa, Maryland, Minnesota, New York, North Carolina, Oregon, Virginia, Wisconsin were funded to conduct HAB-related surveillance through the Cooperative Agreement to Enhance Surveillance of Risk Factors and Health Effects Related to Harmful Algal Blooms; Funding Opportunity Number CDC-RFA-EH08-801. NR 189 TC 20 Z9 20 U1 3 U2 37 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2072-6651 J9 TOXINS JI Toxins PD SEP PY 2013 VL 5 IS 9 BP 1597 EP 1628 DI 10.3390/toxins5091597 PG 32 WC Toxicology SC Toxicology GA 274TI UT WOS:000328628700007 PM 24064718 ER PT J AU Gilbert, AT Fooks, AR Hayman, DTS Horton, DL Muller, T Plowright, R Peel, AJ Bowen, R Wood, JLN Mills, J Cunningham, AA Rupprecht, CE AF Gilbert, Amy T. Fooks, A. R. Hayman, D. T. S. Horton, D. L. Mueller, T. Plowright, R. Peel, A. J. Bowen, R. Wood, J. L. N. Mills, J. Cunningham, A. A. Rupprecht, C. E. TI Deciphering Serology to Understand the Ecology of Infectious Diseases in Wildlife SO ECOHEALTH LA English DT Review DE antibody prevalence; epidemiological models; immunity; surveillance; wildlife disease ID BIG BROWN BATS; CLASSICAL SWINE-FEVER; WEST NILE VIRUS; RABIES VIRUS; MATERNAL ANTIBODIES; IMMUNE-RESPONSES; ANTIGENIC RELATIONSHIPS; CANINE-DISTEMPER; DOMESTIC DOGS; TADARIDA-BRASILIENSIS AB The ecology of infectious disease in wildlife has become a pivotal theme in animal and public health. Studies of infectious disease ecology rely on robust surveillance of pathogens in reservoir hosts, often based on serology, which is the detection of specific antibodies in the blood and is used to infer infection history. However, serological data can be inaccurate for inference to infection history for a variety of reasons. Two major aspects in any serological test can substantially impact results and interpretation of antibody prevalence data: cross-reactivity and cut-off thresholds used to discriminate positive and negative reactions. Given the ubiquitous use of serology as a tool for surveillance and epidemiological modeling of wildlife diseases, it is imperative to consider the strengths and limitations of serological test methodologies and interpretation of results, particularly when using data that may affect management and policy for the prevention and control of infectious diseases in wildlife. Greater consideration of population age structure and cohort representation, serological test suitability and standardized sample collection protocols can ensure that reliable data are obtained for downstream modeling applications to characterize, and evaluate interventions for, wildlife disease systems. C1 [Gilbert, Amy T.; Rupprecht, C. E.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Fooks, A. R.; Hayman, D. T. S.; Horton, D. L.] Anim Hlth & Vet Labs Agcy, Wildlife Zoonoses & Vector Borne Dis Grp, Weybridge KT15 3NB, Surrey, England. [Fooks, A. R.] Univ Liverpool, Natl Consortium Zoonosis Res, Neston CH64 7TE, England. [Hayman, D. T. S.; Peel, A. J.; Wood, J. L. N.] Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Cambridge CB3 0ES, England. [Hayman, D. T. S.; Peel, A. J.; Cunningham, A. A.] Zool Soc London, Inst Zool, London NW1 4RY, England. [Hayman, D. T. S.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Mueller, T.] Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, D-16868 Wusterhausen, Germany. [Plowright, R.] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA. [Bowen, R.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. [Mills, J.] Emory Univ, Populat Biol Ecol & Evolut Program, Atlanta, GA 30322 USA. [Gilbert, Amy T.] USDA, Natl Wildlife Res Ctr, Ft Collins, CO 80521 USA. [Rupprecht, C. E.] Global Alliance Rabies Control, Manhattan, KS USA. RP Gilbert, AT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM Amy.T.Gilbert@aphis.usda.gov RI Horton, Daniel/D-9909-2011; APHA, Staff publications/E-6082-2010; Peel, Alison/I-3202-2012; Cunningham, Andrew/E-7536-2010; Wood, James/A-1626-2008; Fooks, Anthony/F-5418-2010 OI Horton, Daniel/0000-0002-9126-2756; Peel, Alison/0000-0003-3538-3550; Wood, James/0000-0002-0258-3188; FU David H. Smith Fellowship in Conservation Research; Wellcome Trust; Royal Society Wolfson Research Merit award; UK Department for Environment, Food and Rural Affairs (DEFRA) [SV3500, SV3034]; Alborada Trust FX The authors thank the working group of Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate, Department of Homeland Security and the Rabies program at CDC-Atlanta, specifically Richard Franka and Michael Niezgoda, for insightful discussions of serologic testing and interpretation. AG was supported by an Oak Ridge Institute for Science and Education (ORISE) fellowship. DTSH acknowledges support from the David H. Smith Fellowship in Conservation Research and the Wellcome Trust. AAC was supported by a Royal Society Wolfson Research Merit award. ARF and DLH are supported by the UK Department for Environment, Food and Rural Affairs (DEFRA) projects SV3500 and SV3034. JLNW was supported by the Alborada Trust. The findings and conclusions in this report are those of the authors only, and do not necessarily reflect the views of their institutions. NR 90 TC 29 Z9 29 U1 3 U2 60 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1612-9202 EI 1612-9210 J9 ECOHEALTH JI EcoHealth PD SEP PY 2013 VL 10 IS 3 BP 298 EP 313 DI 10.1007/s10393-013-0856-0 PG 16 WC Biodiversity Conservation; Ecology; Environmental Sciences SC Biodiversity & Conservation; Environmental Sciences & Ecology GA 270ST UT WOS:000328339700011 PM 23918033 ER PT J AU Ampofo, WK Baylor, N Cobey, S Cox, NJ Daves, S Edwards, S Ferguson, N Grohmann, G Hay, A Katz, J Kullabutr, K Lambert, L Levandowski, R Mishra, AC Monto, A Siqueira, M Tashiro, M Waddell, AL Wairagkar, N Wood, J Zambon, M Zhang, WQ AF Ampofo, William K. Baylor, Norman Cobey, Sarah Cox, Nancy J. Daves, Sharon Edwards, Steven Ferguson, Neil Grohmann, Gary Hay, Alan Katz, Jacqueline Kullabutr, Kornnika Lambert, Linda Levandowski, Roland Mishra, A. C. Monto, Arnold Siqueira, Marilda Tashiro, Masato Waddell, Anthony L. Wairagkar, Niteen Wood, John Zambon, Maria Zhang, Wenqing CA WHO Writing Grp TI Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE influenza vaccine viruses; vaccine virus selection; WHO recommendations C1 [Ampofo, William K.] Natl Influenza Ctr, Accra, Ghana. [Baylor, Norman] Food & Drug Adm, Rockville, MA USA. [Cobey, Sarah] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Cox, Nancy J.; Katz, Jacqueline] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Daves, Sharon] NAMRU 3, Cairo, Egypt. [Edwards, Steven] Network Expertise Anim Influenzas OFFLU Steering, Hereford, England. [Ferguson, Neil] Imperial Coll Sch Med St Marys, London, England. [Grohmann, Gary] Therapeut Goods Adm Labs, Symonston, Australia. [Hay, Alan] Natl Inst Med Res, London NW7 1AA, England. [Kullabutr, Kornnika] Minist Publ Hlth, Nonthaburi, Thailand. [Lambert, Linda] NIH, Bethesda, MD 20892 USA. [Mishra, A. C.] Natl Influenza Ctr, Pune, Maharashtra, India. [Monto, Arnold] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Siqueira, Marilda] Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil. [Tashiro, Masato] WHO Collaborating Ctr Reference & Res Influenza, Tokyo, Japan. [Wairagkar, Niteen; Zhang, Wenqing] WHO, CH-1211 Geneva, Switzerland. [Wood, John] NIBSC, Potters Bar, Herts, England. [Zambon, Maria] Hlth Protect Agcy, London, England. RP Zhang, WQ (reprint author), WHO, CH-1211 Geneva, Switzerland. EM zhangw@who.int RI Ferguson, Neil/B-8578-2008 OI Ferguson, Neil/0000-0002-1154-8093 NR 2 TC 3 Z9 3 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2013 VL 7 SU 2 SI SI BP 52 EP 53 DI 10.1111/irv.12081 PG 2 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 265KE UT WOS:000327949400008 PM 24034484 ER PT J AU Santesso, N Hsu, J Mustafa, R Brozek, J Chen, YL Hopkins, JP Cheung, A Hovhannisyan, G Ivanova, L Flottorp, SA Saeterdal, I Wong, AD Tian, JH Uyeki, TM Akl, EA Alonso-Coello, P Smaill, F Schunemann, HJ AF Santesso, Nancy Hsu, Jonathan Mustafa, Reem Brozek, Jan Chen, Yao Long Hopkins, Jessica P. Cheung, Adrienne Hovhannisyan, Gayane Ivanova, Liudmila Flottorp, Signe A. Saeterdal, Ingvil Wong, Arthur D. Tian, Jinhui Uyeki, Timothy M. Akl, Elie A. Alonso-Coello, Pablo Smaill, Fiona Schuenemann, Holger J. TI Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Review DE antiviral; influenza; M2 ion channel blocker; neuraminidase inhibitor; observational study ID CLINICAL EFFECTIVENESS; OSELTAMIVIR-RESISTANT; VIRUS-INFECTIONS; UNITED-STATES; CHILDREN; OUTCOMES; COMPLICATIONS; MULTICENTER; ZANAMIVIR; THERAPY AB Despite the use of antivirals to treat patients with severe influenza, questions remain with respect to effects and safety. Although a recent systematic review has provided some indication of benefit, the analysis is limited by the quality of the available evidence from randomized controlled trials. To supplement the existing information, the authors conducted a systematic review of observational studies of antiviral treatment for influenza. This report summarises the findings of that review. Similar to the randomised trials, the confidence in the estimates of the effects for decision-making is low to very low primarily due to the risk of selection and publication bias in the observational studies. From these observational studies, the summary estimates suggest that oseltamivir may reduce mortality, hospitalisation and duration of symptoms compared with no treatment. Inhaled zanamivir may also reduce symptom duration and hospitalisations, but patients may experience more complications compared with no treatment. Earlier treatment with antivirals is generally associated with better outcomes than later treatment. Further high-quality evidence is needed to inform treatment guidelines because of the overall low to very low quality of evidence. C1 [Santesso, Nancy; Hsu, Jonathan; Mustafa, Reem; Brozek, Jan; Hopkins, Jessica P.; Cheung, Adrienne; Hovhannisyan, Gayane; Ivanova, Liudmila; Akl, Elie A.; Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada. [Chen, Yao Long; Tian, Jinhui] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China. [Hopkins, Jessica P.] Niagara Reg Publ Hlth, Thorold, ON, Canada. [Flottorp, Signe A.; Saeterdal, Ingvil] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway. [Flottorp, Signe A.] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway. [Wong, Arthur D.] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON L8N 3Z5, Canada. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Akl, Elie A.] SUNY Buffalo, Dept Med, Buffalo, NY 14260 USA. [Alonso-Coello, Pablo] CIBERESP IIB St Pau, Iberoamer Cochrane Ctr, Barcelona, Spain. [Smaill, Fiona] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada. [Schuenemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada. RP Schunemann, HJ (reprint author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Michael Gent Chair Healthcare Res, Room 2C10B,1200 Main St West, Hamilton, ON L8N 3Z5, Canada. EM schuneh@mcmaster.ca OI Flottorp, Signe/0000-0003-2961-7461; Mustafa, Reem/0000-0002-2091-0875 FU World Health Organization; McMaster University FX World Health Organization and McMaster University NR 42 TC 10 Z9 10 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2013 VL 7 SU 2 SI SI BP 76 EP 81 DI 10.1111/irv.12085 PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 265KE UT WOS:000327949400013 PM 24034489 ER PT J AU Fowlkes, A Dasgupta, S Chao, E Lemmings, J Goodin, K Harris, M Martin, K Feist, M Wu, W Boulton, R Temte, J Brammer, L Finelli, L AF Fowlkes, Ashley Dasgupta, Sharoda Chao, Edward Lemmings, Jennifer Goodin, Kate Harris, Meghan Martin, Karen Feist, Michelle Wu, Winfred Boulton, Rachelle Temte, Jonathan Brammer, Lynnette Finelli, Lyn TI Estimating influenza incidence and rates of influenza-like illness in the outpatient setting SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Epidemiology; H1N1; influenza; pandemic ID PANDEMIC INFLUENZA; DIAGNOSTIC-TESTS; YOUNG-CHILDREN; INFECTION; SURVEILLANCE; DISEASE; BURDEN; VIRUS; TIME; AGE AB Background: Estimating influenza incidence in outpatient settings is challenging. We used outpatient healthcare practice populations as a proxy to estimate community incidence of influenza-like illness (ILI) and laboratory-confirmed influenza-associated ILI. Methods: From October 2009 to July 2010, 38 outpatient practices in seven jurisdictions conducted surveillance for ILI (fever with cough or sore throat for patients >= 2 years; fever with >= 1 respiratory symptom for patients <2 years). From a sample of patients with ILI, respiratory specimens were tested for influenza. Results: During the week of peak influenza activity (October 24, 2009), 13% of outpatient visits were for ILI and influenza was detected in 72% of specimens. For the 10-month surveillance period, ILI and influenza-associated ILI incidence were 20.0 (95% CI: 19.7, 20.4) and 8.7/1000 (95% CI: 8.2, 9.2) persons, respectively. Influenza-associated ILI incidence was highest among children aged 2-17 years. Observed trends were highly correlated with national ILI and virologic surveillance. Conclusions: This is the first multistate surveillance system demonstrating the feasibility of using outpatient practices to estimate the incidence of medically attended influenza at the community level. Surveillance demonstrated the substantial burden of pandemic influenza in outpatient settings and especially in children aged 2-17 years. Observed trends were consistent with established syndromic and virologic systems. C1 [Fowlkes, Ashley; Dasgupta, Sharoda; Brammer, Lynnette; Finelli, Lyn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. [Chao, Edward; Lemmings, Jennifer] Council State & Terr Epidemiologists, Atlanta, GA USA. [Goodin, Kate] Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. [Harris, Meghan] Iowa Dept Publ Hlth, Ctr Acute Dis Epidemiol, Des Moines, IA 50319 USA. [Martin, Karen] Minnesota Dept Hlth, St Paul, MN USA. [Feist, Michelle] North Dakota Dept Hlth, Div Dis Control, Bismarck, ND USA. [Wu, Winfred] New York City Dept Hlth & Mental Hyg, Primary Care Informat Project, New York, NY USA. [Boulton, Rachelle] Utah Dept Hlth, Div Dis Control & Prevent, Salt Lake City, UT 84116 USA. [Temte, Jonathan] Univ Wisconsin Sch Med & Publ Hlth, Dept Family Med, Madison, WI USA. RP Fowlkes, A (reprint author), 1600 Clifton Rd,NE MS A32, Atlanta, GA 30333 USA. EM afowlkes@cdc.gov FU Centers for Disease Control and Prevention (CDC) [5U38HM000414-04] FX This publication was supported by Cooperative Agreement Number 5U38HM000414-04 from the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. The use of trade names is for identification only and does not imply endorsement by the Department of Health and Human Services or the CDC. NR 23 TC 17 Z9 17 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2013 VL 7 IS 5 BP 694 EP 700 DI 10.1111/irv.12014 PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 268HZ UT WOS:000328162300004 PM 22984820 ER PT J AU Kennedy, ED Roy, M Norris, J Fry, AM Kanzaria, M Blau, DM Shieh, WJ Zaki, SR Waller, K Kamimoto, L Finelli, L Jhung, MA AF Kennedy, Erin D. Roy, Monika Norris, Jeffrey Fry, Alicia M. Kanzaria, Mitul Blau, Dianna M. Shieh, Wun-Ju Zaki, Sherif R. Waller, Kirsten Kamimoto, Laurie Finelli, Lyn Jhung, Michael A. CA 2009 Pandemic H1N1 Influenza-Assoc TI Lower respiratory tract hemorrhage associated with 2009 pandemic influenza A (H1N1) virus infection SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Hemorrhage; influenza; pH1N1; viral pneumonia AB Please cite this paper as: Kennedy etal. for the 2009 Pandemic H1N1 Influenza-Associated Lower Respiratory Tract Hemorrhage Working Group. (2012) Lower respiratory tract hemorrhage associated with 2009 pandemic influenza A (H1N1) virus infection. Influenza and Other Respiratory Viruses DOI: 10.1111/irv.12022. Background Influenza-associated lower respiratory tract hemorrhage (LRTH) has been reported in previous pandemics and is a rare complication of seasonal influenza virus infection. We describe patients with LRTH associated with 2009 pandemic influenza A (H1N1) (pH1N1) virus infection identified from April 2009 to April 2010 in the United States. Methods We ascertained patients with pH1N1-associated LRTH through state and local surveillance, the Emerging Infections Program, and CDCs Infectious Diseases Pathology Branch. All patients had influenza A, evidence of pneumonia, and evidence of LRTH. Results We identified 44 cases; the median number of days from illness onset to clinical signs of LRTH was one. Hemoptysis or respiratory tract bleeding was documented in 40% of pH1N1-associated LRTH cases, often present early during the course of illness. Twenty-one (48%) patients with LRTH had no other hemorrhagic diatheses. Seven (23%) patients with LRTH received antiviral treatment within two days of illness onset. Conclusions During influenza season, clinicians should consider influenza infection in the differential diagnosis for patients presenting with hemoptysis or other signs or symptoms of LRTH. While the impact of timing of antiviral therapy on this complication has not been studied, the rapid progression of LRTH may support use of early empiric therapy. Continued investigation is necessary to betterdefine the clinical spectrum of both seasonal influenza- and pH1N1-associated LRTH. C1 [Kennedy, Erin D.; Fry, Alicia M.; Kanzaria, Mitul; Kamimoto, Laurie; Finelli, Lyn; Jhung, Michael A.] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA 30333 USA. [Kennedy, Erin D.; Roy, Monika] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Roy, Monika] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA. [Norris, Jeffrey] CDC Experience Appl Epidemiol Fellowship, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Kanzaria, Mitul] Ctr Dis Control & Prevent, Epidemiol Elect Program, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Blau, Dianna M.; Shieh, Wun-Ju; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Waller, Kirsten] Penn Dept Hlth, Harrisburg, PA 17108 USA. RP Kennedy, ED (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM EDKennedy@cdc.gov FU Pfizer, Inc.; CDC Foundation FX The authors would like to acknowledge all of the state and local health departments, hospital infection preventionists, and surveillance officers from the Emerging Infections Program Influenza Network for submitting case report forms. Jeffrey Norris's CDC Experience Fellowship stipend was paid for by Pfizer, Inc. through a partnership with the CDC Foundation. NR 10 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2013 VL 7 IS 5 BP 761 EP 765 DI 10.1111/irv.12026 PG 5 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 268IE UT WOS:000328162800002 PM 23279922 ER PT J AU Fitter, DL Freeman, NM Buteau, J Magloire, R Sessions, WM Guo, LZ Katz, MA Boncy, J AF Fitter, David L. Freeman, Nicole M. Buteau, Josiane Magloire, Roc Sessions, Wendy M. Guo, Lizheng Katz, Mark A. Boncy, Jacques TI Pandemic H1N1 influenza surveillance in Haiti, July-December 2009 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Haiti; influenza; surveillance ID SEASONAL INFLUENZA; INFECTIONS; BURDEN AB Please cite this paper as: Fitter etal. (2012) Pandemic H1N1 influenza surveillance in Haiti, July-December 2009. Influenza and Other Respiratory Viruses DOI: 10.1111/irv.12060. From June 2009 through December 2009, Haiti conducted sentinel surveillance for influenza. 499 samples were collected and tested using real-time RT-PCR. 197 (39.5%) were positive for influenza, including 95 (48%) pandemic (H1N1) 2009, 57 (29%) seasonal influenza A and 45 (23%) influenza B. The median age of pandemic (H1N1) 2009 cases was 21.7; two-thirds of pandemic (H1N1) 2009 cases were in patients aged 6years - 35years. Pandemic activity peaked in September and co-circulated with other influenza subtypes. The age distribution and seasonality of pandemic (H1N1) 2009 in Haiti were similar to other countries in the Caribbean region. C1 [Fitter, David L.; Sessions, Wendy M.; Guo, Lizheng] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Freeman, Nicole M.; Boncy, Jacques] Natl Publ Hlth Lab, Port Au Prince, Haiti. [Buteau, Josiane; Magloire, Roc] Minist Publ Hlth & Populat, Port Au Prince, Haiti. [Katz, Mark A.] Ctr Dis Control & Prevent, Port Au Prince, Haiti. RP Fitter, DL (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-05, Atlanta, GA 30333 USA. EM dfitter@cdc.gov NR 15 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2013 VL 7 IS 5 BP 772 EP 775 DI 10.1111/irv.12060 PG 4 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 268IE UT WOS:000328162800004 PM 23199103 ER PT J AU Khaokham, CB Selent, M Loustalot, FV Zarecki, SM Harrington, D Hoke, E Faix, DJ Ortiguerra, R Alvarez, B Almond, N McMullen, K Cadwell, B Uyeki, TM Blair, PJ Waterman, SH AF Khaokham, Christina B. Selent, Monica Loustalot, Fleetwood V. Zarecki, Shauna Mettee Harrington, Douglas Hoke, Eileen Faix, Dennis J. Ortiguerra, Ryan Alvarez, Bryan Almond, Nathaniel McMullen, Kellie Cadwell, Betsy Uyeki, Timothy M. Blair, Patrick J. Waterman, Stephen H. TI Seroepidemiologic investigation of an outbreak of pandemic influenza A H1N1 2009 aboard a US Navy Vessel-San Diego, 2009 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Disease outbreaks; epidemiology; H1N1 subtype; influenza A virus; military personnel ID VIRUS; SHIP; CHEMOPROPHYLAXIS; INFECTION; CHILDREN; ADULTS AB Background During summer 2009, a US Navy ship experienced an influenza-like illness outbreak with 126 laboratory-confirmed cases of pandemic influenza A (H1N1) 2009 virus among the approximately 2000-person crew. Methods During September 24-October 9, 2009, a retrospective seroepidemiologic investigation was conducted to characterize the outbreak. We administered questionnaires, reviewed medical records, and collected post-outbreak sera from systematically sampled crewmembers. We used real-time reverse transcription-PCR or microneutralization assays to detect evidence of H1N1 virus infection. Results Retrospective serologic data demonstrated that the overall H1N1 virus infection attack rate was 32%. Weighted H1N1 virus attack rates were higher among marines (37%), junior-ranking personnel (34%), and persons aged 19-24 years (36%). In multivariable analysis, a higher risk of illness was found for women versus men (odds ratio [OR]=2.2; 95% confidence interval [CI]: 1.1-4.4), marines versus navy personnel (OR=1.7; 95% CI, 1.0-2.9), and those aged 19-24 versus >= 35 years (OR=3.9; 95% CI, 1.2-12.8). Fifty-three percent of infected persons did not recall respiratory illness symptoms. Among infected persons, only 35% met criteria for acute respiratory illness and 11% for influenza-like illness. Conclusions Approximately half of H1N1 infections were asymptomatic, and thus, the attack rate was higher than estimated by clinical illness alone. Enhanced infection control measures including pre-embarkation illness screening, improved self-reporting of illness, isolation of ill and quarantine of exposed contacts, and prompt antiviral chemoprophylaxis and treatment might be useful in controlling shipboard influenza outbreaks. C1 [Khaokham, Christina B.; Selent, Monica; Loustalot, Fleetwood V.; Zarecki, Shauna Mettee] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Harrington, Douglas; Alvarez, Bryan; Almond, Nathaniel; McMullen, Kellie] Navy Environm & Prevent Med Unit Five, San Diego, CA USA. [Hoke, Eileen] Navy Med Corps, San Diego, CA USA. [Faix, Dennis J.; Ortiguerra, Ryan; Blair, Patrick J.] Naval Hlth Res Ctr, San Diego, CA USA. [Cadwell, Betsy; Uyeki, Timothy M.; Waterman, Stephen H.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Khaokham, CB (reprint author), Ctr Dis Control & Prevent, Hlth Human Serv Agcy, 3851 Rosecrans St MS-P572, San Diego, CA 92110 USA. EM igc9@cdc.gov FU US Department of Defense's Armed Forces Health Surveillance Center, Division of the Global Emerging Infections Surveillance and Response System FX This work was funded in part by a grant from the US Department of Defense's Armed Forces Health Surveillance Center, Division of the Global Emerging Infections Surveillance and Response System. NR 22 TC 9 Z9 9 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD SEP PY 2013 VL 7 IS 5 BP 791 EP 798 DI 10.1111/irv.12100 PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 268IE UT WOS:000328162800007 PM 23496798 ER PT J AU Bagamian, KH Towner, JS Mills, JN Kuenzi, AJ AF Bagamian, Karoun H. Towner, Jonathan S. Mills, James N. Kuenzi, Amy J. TI Increased Detection of Sin Nombre Hantavirus RNA in Antibody-Positive Deer Mice from Montana, USA: Evidence of Male Bias in RNA Viremia SO VIRUSES-BASEL LA English DT Article DE Sin Nombre hantavirus; deer mouse; Peromyscus maniculatus; transmission; viral RNA; RT-PCR ID MOUSE PEROMYSCUS-MANICULATUS; VOLES CLETHRIONOMYS-GLAREOLUS; VIRUS-INFECTION; SEOUL VIRUS; NORWAY RATS; IMMUNE-RESPONSES; ETIOLOGIC AGENT; SEX-DIFFERENCES; UNITED-STATES; MODEL AB Hantaviruses are widespread emergent zoonotic agents that cause unapparent or limited disease in their rodent hosts, yet cause acute, often fatal pulmonary or renal infections in humans. Previous laboratory experiments with rodent reservoir hosts indicate that hantaviruses can be cleared from host blood early in the infection cycle, while sequestered long term in various host organs. Field studies of North American deer mice (Peromyscus maniculatus), the natural reservoir of Sin Nombre hantavirus, have shown that viral RNA can be transiently detected well past the early acute infection stage, but only in the minority of infected mice. Here, using a non-degenerate RT-PCR assay optimized for SNV strains known to circulate in Montana, USA, we show that viral RNA can be repeatedly detected on a monthly basis in up to 75% of antibody positive deer mice for periods up to 3-6 months. More importantly, our data show that antibody positive male deer mice are more than twice as likely to have detectable SNV RNA in their blood as antibody positive females, suggesting that SNV-infected male deer mice are more likely to shed virus and for longer periods of time. C1 [Bagamian, Karoun H.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30033 USA. [Bagamian, Karoun H.; Kuenzi, Amy J.] Univ Montana, Montana Tech, Dept Biol, Butte, MT 59701 USA. [Mills, James N.] Emory Univ, Populat Biol Ecol & Evolut Program, Atlanta, GA 30322 USA. RP Bagamian, KH (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30033 USA. EM karoun11@gmail.com; jit8@cdc.gov; wildlifedisease@gmail.com; akuenzi@mtech.edu FU National Institute of General Medical Sciences of the National Institutes of Health [P20GM103474]; Viral Special Pathogens Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA FX Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM103474 and the Viral Special Pathogens Branch, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA. NR 26 TC 2 Z9 2 U1 0 U2 11 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD SEP PY 2013 VL 5 IS 9 BP 2320 EP 2328 DI 10.3390/v5092320 PG 9 WC Virology SC Virology GA 274NZ UT WOS:000328614500016 PM 24064796 ER PT J AU Lopiano, KK Young, LJ Gotway, CA AF Lopiano, Kenneth K. Young, Linda J. Gotway, Carol A. TI Estimated generalized least squares in spatially misaligned regression models with Berkson error SO BIOSTATISTICS LA English DT Article DE Geostatistics; Kriging; Measurement error AB In environmental studies, relationships among variables that are misaligned in space are routinely assessed. Because the data are misaligned, kriging is often used to predict the covariate at the locations where the response is observed. Using kriging predictions to estimate regression parameters in linear regression models introduces a Berkson error, which induces a covariance structure that is challenging to estimate. In addition, if the parameters associated with kriging (e.g. trend surface parameters and spatial covariance parameters) are estimated, then an additional uncertainty is introduced. We characterize the total measurement error as part of a broader class of Berkson error models and develop an estimated generalized least squares estimator using estimated covariance parameters. In working with the induced model, we fully account for the error structure and estimate the covariance parameters using likelihood-based methods. We provide insight into when it is important to fully account for the covariance structure induced from the different error sources. We assess the performance of the estimators using simulation and illustrate the methodology using publicly available data from the US Environmental Protection Agency. C1 [Lopiano, Kenneth K.] Stat & Appl Math Sci Inst, Res Triangle Pk, NC 27709 USA. [Young, Linda J.] Univ Florida IFAS, Dept Stat, Gainesville, FL 32611 USA. [Gotway, Carol A.] CDC, Atlanta, GA 30333 USA. RP Lopiano, KK (reprint author), Stat & Appl Math Sci Inst, 19 TW Alexander Dr, Res Triangle Pk, NC 27709 USA. EM klopiano@gmail.com FU National Aeronautical and Space Administration (NASA) [NNX10AO08G]; Florida Department of Health, Division of Environmental Health; Centers for Disease Control and Prevention (CDC) [1 U38 EH000941-01]; National Science Foundation under Quantitative Spatial Ecology, Evolution, and Environment Program at the University of Florida [0801544] FX The work of the first two authors was supported by the National Aeronautical and Space Administration (NASA) Applied Sciences Public Health Program's grant award number NNX10AO08G and by the Florida Department of Health, Division of Environmental Health, and Grant/Cooperative Agreement Number 1 U38 EH000941-01 from the Centers for Disease Control and Prevention (CDC). The work of the first author was partially supported by the National Science Foundation under Grant No. 0801544 in the Quantitative Spatial Ecology, Evolution, and Environment Program at the University of Florida. NR 10 TC 7 Z9 7 U1 0 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1465-4644 EI 1468-4357 J9 BIOSTATISTICS JI Biostatistics PD SEP PY 2013 VL 14 IS 4 BP 737 EP 751 DI 10.1093/biostatistics/kxt011_online PG 15 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 269ZZ UT WOS:000328285800010 PM 23568241 ER PT J AU Dowell, SF Sejvar, JJ Riek, L Vandemaele, KAH Lamunu, M Kuesel, AC Schmutzhard, E Matuja, W Bunga, S Foltz, J Nutman, TB Winkler, AS Mbonye, AK AF Dowell, Scott F. Sejvar, James J. Riek, Lul Vandemaele, Katelijn A. H. Lamunu, Margaret Kuesel, Annette C. Schmutzhard, Erich Matuja, William Bunga, Sudhir Foltz, Jennifer Nutman, Thomas B. Winkler, Andrea S. Mbonye, Anthony K. TI Nodding Syndrome SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CLINICAL-CHARACTERISTICS; ONCHOCERCA-VOLVULUS; EPILEPTIC SEIZURES; SYDENHAMS CHOREA; SOUTHERN SUDAN; WEST UGANDA; FOLLOW-UP; CLASSIFICATION; METAANALYSIS; ASSOCIATION AB An epidemic illness characterized by head nodding associated with onchocerciasis has been described in eastern Africa since the early 1960s; we summarize published reports and recent studies. Onset of nodding occurs in previously healthy 5-15-year-old children and is often triggered by eating or cold temperatures and accompanied by cognitive impairment. Its incidence has increased in Uganda and South Sudan over the past 10 years. Four case control studies identified modest and inconsistent associations. There were nonspecific lesions seen by magnetic resonance imaging, no cerebrospinal fluid inflammation, and markedly abnormal electroencephalography results. Nodding episodes are atonic seizures. Testing has failed to demonstrate associations with trypanosomiasis, cysticercosis, loiasis, lymphatic filariasis, cerebral malaria, measles, prion disease, or novel pathogens; or deficiencies of folate, cobalamin, pyridoxine, retinol, or zinc; or toxicity from mercury, copper, or homocysteine. There is a consistent enigmatic association with onchocerciasis detected by skin snip or serologic analysis. Nodding syndrome is an unexplained epidemic epilepsy. C1 [Dowell, Scott F.; Sejvar, James J.; Bunga, Sudhir; Foltz, Jennifer] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Riek, Lul] Minist Hlth, Juba, Sudan. [Vandemaele, Katelijn A. H.; Lamunu, Margaret; Kuesel, Annette C.] World Hlth Org, Geneva, Switzerland. [Schmutzhard, Erich] Univ Innsbruck, A-6020 Innsbruck, Austria. [Matuja, William] Muhimbili Univ, Dar Es Salaam, Tanzania. [Nutman, Thomas B.] NIH, Bethesda, MD 20892 USA. [Winkler, Andrea S.] Tech Univ Munich, D-80290 Munich, Germany. [Mbonye, Anthony K.] Minist Hlth, Kampala, Uganda. [Mbonye, Anthony K.] Makerere Univ, Kampala, Uganda. RP Dowell, SF (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D69, Atlanta, GA 30333 USA. EM sfd2@cdc.gov OI Kuesel, Annette C./0000-0002-1696-1784 NR 40 TC 26 Z9 26 U1 0 U2 15 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1374 EP 1384 DI 10.3201/eid1909.130401 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800003 PM 23965548 ER PT J AU Zhang, LJ Peng, ZB Ou, JM Zeng, G Fontaine, RE Liu, MB Cui, FQ Hong, RT Zhou, H Huai, Y Chuang, SK Leung, YH Feng, YX Luo, Y Shen, T Zhu, BP Widdowson, MA Yu, HJ AF Zhang, Lijie Peng, Zhibin Ou, Jianming Zeng, Guang Fontaine, Robert E. Liu, Mingbin Cui, Fuqiang Hong, Rongtao Zhou, Hang Huai, Yang Chuang, Shuk-Kwan Leung, Yiu-Hong Feng, Yunxia Luo, Yuan Shen, Tao Zhu, Bao-Ping Widdowson, Marc-Alain Yu, Hongjie TI Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on Trans-Pacific Passenger Aircraft, 2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HEALTH-CARE WORKERS; A H1N1 VIRUS; RANDOMIZED-TRIAL; NONPHARMACEUTICAL INTERVENTIONS; INFECTIOUS-DISEASES; PANDEMIC INFLUENZA; SURGICAL MASK; AIR-TRAVEL; TRANSMISSION; HOUSEHOLDS AB In response to several influenza A(H1N1)pdnn09 infections that developed in passengers after they traveled on the same 2 flights from New York, New York, USA, to Hong Kong, China, to Fuzhou, China, we assessed transmission of influenza A(H1N1)pdm09 virus on these flights. We defined a case of infection as onset of fever and respiratory symptoms and detection of virus by PCR in a passenger or crew member of either flight. Illness developed only in passengers who traveled on the New York to Hong Kong flight. We compared exposures of 9 case-passengers with those of 32 asymptomatic control-passengers. None of the 9 case-passengers, compared with 47% (15/32) of control-passengers, wore a face mask for the entire flight (odds ratio 0, 95% CI 0-0.71). The source case-passenger was not identified. Wearing a face mask was a protective factor against influenza infection. We recommend a more comprehensive intervention study to accurately estimate this effect. C1 [Zhang, Lijie] Chinese Ctr Dis Control & Prevent, Chinese Field Epidemiol Training Program, Beijing 102206, Peoples R China. [Zhang, Lijie; Peng, Zhibin; Zeng, Guang; Liu, Mingbin; Cui, Fuqiang; Zhou, Hang; Feng, Yunxia; Luo, Yuan; Shen, Tao; Zhu, Bao-Ping; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China. [Ou, Jianming; Hong, Rongtao] Fujian Ctr Dis Control & Prevent, Fuzhou, Peoples R China. [Liu, Mingbin] Nanchang Ctr Dis Control & Prevent, Nanchang, Peoples R China. [Fontaine, Robert E.; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Atlanta, GA USA. [Huai, Yang] China US Collaborat Program Emerging & Reemerging, Beijing, Peoples R China. [Chuang, Shuk-Kwan; Leung, Yiu-Hong] Hong Kong Dept Hlth, Hong Kong, Hong Kong, Peoples R China. RP Yu, HJ (reprint author), Chinese Ctr Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China. EM yuhj@chinacdc.cn OI Widdowson, Marc-Alain/0000-0002-0682-6933 NR 40 TC 2 Z9 2 U1 2 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1403 EP 1410 DI 10.3201/eid1909.121765 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800006 ER PT J AU Fiebelkorn, AP Lawler, J Curns, AT Brandeburg, C Wallace, GS AF Fiebelkorn, Amy Parker Lawler, Jacqueline Curns, Aaron T. Brandeburg, Christina Wallace, Gregory S. TI Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; OUTBREAK; EPIDEMIOLOGY; POPULATION; ISLAND AB Although the measles-mumps-rubella (MMR) vaccine is not recommended for mumps postexposure prophylaxis (PEP), data on its effectiveness are limited. During the 2009-2010 mumps outbreak in the northeastern United States, we assessed effectiveness of PEP with a third dose of MMR vaccine among contacts in Orthodox Jewish households who were given a third dose. within 5 days of mumps onset in the household's index patient. During the first incubation period after onset in the index patient, mumps attack rates were compared between persons who received a third MMR dose and 2-dose-vaccinated persons who had not. Twenty-eight (11.7%) of 239 eligible household members received a third MMR dose as PEP. Mumps attack rates were 0% among third-dose recipients versus 5.2% among 2-dose recipients without PEP (p = 0.57). Although a third MMR dose administered as PEP did not have a significant effect, it may offer some benefits in specific outbreak contexts. C1 [Fiebelkorn, Amy Parker] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Curns, Aaron T.; Wallace, Gregory S.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Lawler, Jacqueline; Brandeburg, Christina] Orange Cty Hlth Dept, Goshen, NY USA. RP Fiebelkorn, AP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30333 USA. EM AFiebelkorn@cdc.gov NR 26 TC 6 Z9 6 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1411 EP 1417 DI 10.3201/eid1909.130299 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800007 PM 23965729 ER PT J AU Condori-Condori, RE Streicker, DG Cabezas-Sanchez, C Velasco-Villa, A AF Edgar Condori-Condori, Rene Streicker, Daniel G. Cabezas-Sanchez, Cesar Velasco-Villa, Andres TI Enootic and Epizootic Rabies Associated with Vampire Bats, Peru SO EMERGING INFECTIOUS DISEASES LA English DT Article ID GENETIC-CHARACTERIZATION; DESMODUS-ROTUNDUS; VIRUS VARIANT; SAO-PAULO; BRAZIL; POLYMORPHISM; DIVERSITY; INFECTION; COUNTRIES; EXPOSURE AB During the past decade, incidence of human infection with rabies virus (RABV) spread by the common vampire bat (Desmodus rotundus) increased considerably in South America, especially in remote areas of the Amazon rainforest, where these bats commonly feed on humans. To better understand the epizootiology of rabies associated with vampire bats, we used complete sequences of the nucleoprotein gene to infer phylogenetic relationships among 157 RABV isolates collected from humans, domestic animals, and wildlife, including bats, in Peru during 2002-2007. This analysis revealed distinct geographic structuring that indicates that RABVs spread gradually and involve different vampire bat subpopulations with different transmission cycles. Three putative new RABV lineages were found in 3 non vampire bat species that may represent new virus reservoirs. Detection of novel RABV variants and accurate identification of reservoir hosts are critically important for the prevention and control of potential virus transmission, especially to humans. C1 [Edgar Condori-Condori, Rene; Streicker, Daniel G.] Univ Georgia, Athens, GA 30602 USA. [Edgar Condori-Condori, Rene; Streicker, Daniel G.; Velasco-Villa, Andres] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Edgar Condori-Condori, Rene; Cabezas-Sanchez, Cesar] Ctr Nacl Salud Publ, Inst Nacl Salud, Lima, Peru. RP Condori-Condori, RE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G33, Atlanta, GA 30333 USA. EM hws5@cdc.gov FU Centers for Disease Control and Prevention, Atlanta GA, USA; Instituto Nacional de Salud in Lima, Peru; American Fellow's program, Partners of the Americas of the USA government FX This study was sponsored by the Centers for Disease Control and Prevention, Atlanta GA, USA; Instituto Nacional de Salud in Lima, Peru; and the American Fellow's program, Partners of the Americas of the USA government. NR 39 TC 12 Z9 12 U1 0 U2 28 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1463 EP 1469 DI 10.3201/eid1909.130083 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800013 ER PT J AU Griese, SE Fleischauer, AT MacFarquhar, JK Moore, Z Harrelson, C Valiani, A Morrison, SE Sweat, D Maillard, JM Griffin, D Springer, D Mikoleit, M Newton, AE Jackson, B Nguyen, TA Bosch, S Davies, M AF Griese, Stephanie E. Fleischauer, Aaron T. MacFarquhar, Jennifer K. Moore, Zackary Harrelson, Cris Valiani, Anita Morrison, Sue Ellen Sweat, David Maillard, Jean-Marie Griffin, Denise Springer, Debra Mikoleit, Matthew Newton, Anna E. Jackson, Brendan Thai-An Nguyen Bosch, Stacey Davies, Megan TI Gastroenteritis Outbreak Associated with Unpasteurized Tempeh, North Carolina, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID CROSS-CONTAMINATION; FOODBORNE DISEASE; STAINLESS-STEEL; UNITED-STATES; CAMPYLOBACTER; SALMONELLA; SURFACES; PATHOGENS; SURVIVAL; HEALTH AB During an investigation of an outbreak of gastroenteritis caused by Salmonella enterica serovar Paratyphi B variant L(+) tartrate(+), we identified unpasteurized tempeh as a novel food vehicle and Rhizopus spp. starter culture as the source of the contamination. Safe handling of uncooked, unpasteurized tempeh should be emphasized for prevention of foodborne illnesses. C1 [Griese, Stephanie E.; Fleischauer, Aaron T.; MacFarquhar, Jennifer K.; Mikoleit, Matthew; Newton, Anna E.; Jackson, Brendan; Thai-An Nguyen; Bosch, Stacey] Ctr Dis Control & Prevent, Atlanta, GA USA. [Griese, Stephanie E.; Fleischauer, Aaron T.; MacFarquhar, Jennifer K.; Moore, Zackary; Harrelson, Cris; Valiani, Anita; Sweat, David; Maillard, Jean-Marie; Griffin, Denise; Springer, Debra; Davies, Megan] North Carolina Div Publ Hlth, Raleigh, NC 27699 USA. [Morrison, Sue Ellen] Buncombe Cty Dept Hlth, Asheville, NC USA. RP Griese, SE (reprint author), North Carolina Div Publ Hlth, 1902 Mail Serv Ctr, Raleigh, NC 27699 USA. EM ftw4@cdc.gov OI Mikoleit, Matthew/0000-0002-4582-6733 NR 13 TC 0 Z9 0 U1 3 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1514 EP 1517 DI 10.3201/eid1909.130334 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800025 PM 23965530 ER PT J AU Blau, DM Rabe, IB Bhatnagar, J Civen, R Trivedi, KK Rollin, D Hocevar, SN Kuehnert, M Staples, JE Zaki, SR Fischer, M AF Blau, Dianna M. Rabe, Ingrid B. Bhatnagar, Julu Civen, Rachel Trivedi, Kavita K. Rollin, Dominique Hocevar, Susan N. Kuehnert, Matthew Staples, J. Erin Zaki, Sherif R. Fischer, Marc CA W Nile Virus Transplant-Associated TI West Nile Virus RNA in Tissues from Donor Associated with Transmission to Organ Transplant Recipients SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; PCR AB We identified West Nile virus (WNV) RNA in skin, fat, muscle, tendon, and bone marrow from a deceased donor associated with WNV transmission through solid organ transplantation. WNV could not be cultured from the RNA-positive tissues. Further studies are needed to determine if WNV can be transmitted from postmortem tissues. C1 [Blau, Dianna M.; Bhatnagar, Julu; Rollin, Dominique; Hocevar, Susan N.; Kuehnert, Matthew; Zaki, Sherif R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Rabe, Ingrid B.; Staples, J. Erin; Fischer, Marc] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Civen, Rachel] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Trivedi, Kavita K.] Calif Dept Publ Hlth, Richmond, CA USA. RP Blau, DM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G32, Atlanta, GA 30333 USA. EM dblau@cdc.gov NR 15 TC 8 Z9 8 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1518 EP 1520 DI 10.3201/eid1909.130365 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800026 PM 23965573 ER PT J AU Sleeman, K Guo, Z Barnes, J Shaw, M Stevens, J Gubareva, LV AF Sleeman, Katrina Guo, Zhu Barnes, John Shaw, Michael Stevens, James Gubareva, Larisa V. TI R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses SO EMERGING INFECTIOUS DISEASES LA English DT Article ID NEURAMINIDASE ACTIVE-SITE; A H7N9 VIRUS; RESISTANCE; INHIBITORS; SENSITIVITY; MUTATIONS; FERRETS AB Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered. C1 [Sleeman, Katrina; Guo, Zhu; Barnes, John; Shaw, Michael; Stevens, James; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G16, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov NR 15 TC 39 Z9 42 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1521 EP 1524 DI 10.3201/eid1909.130724 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800027 PM 23965618 ER PT J AU Dai, X Dong, C Zhou, ZX Liang, JH Dong, M Yang, Y Fu, JG Tian, H Wang, S Fan, J Meng, JH Purdy, MA AF Dai, Xing Dong, Chen Zhou, Zhenxian Liang, Jiuhong Dong, Min Yang, Yan Fu, Jianguang Tian, Hua Wang, Song Fan, Jie Meng, Jihong Purdy, Michael A. TI Hepatitis E Virus Genotype 4, Nanjing, China, 2001-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTION; RISK AB During 2001-2011, hepatitis E virus (HEV) was found in the blood of patients in Nanjing, China. All HEV-positive patients had virus genotype 4; subgenotype 4a was predominant. The effective population of HEV in Nanjing increased in approximate to 1980 and continued until approximate to 2003 when it plateaued. C1 [Dai, Xing; Dong, Chen; Zhou, Zhenxian; Liang, Jiuhong; Dong, Min; Yang, Yan; Fu, Jianguang; Tian, Hua; Wang, Song; Fan, Jie; Meng, Jihong] Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China. [Zhou, Zhenxian] Nanjing Second Hosp, Nanjing, Jiangsu, Peoples R China. [Purdy, Michael A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Meng, JH (reprint author), Southeast Univ, Sch Med, 87 Dingjiaqiao Rd, Manjing 210009, Jiangsu, Peoples R China. EM jihongmeng@163.com FU National High Technology Research and Development Program (863 Program) of China [2006AA02A235]; Natural Science Foundation [BK2006098]; Science and Technology Support Program of Jiangsu Province, China [BE2009664] FX This study was supported by the National High. Technology Research and Development Program (863 Program 2006AA02A235) of China, the Natural Science Foundation (BK2006098), and the Science and Technology Support Program (BE2009664) of Jiangsu Province, China. NR 15 TC 12 Z9 12 U1 0 U2 9 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1528 EP 1530 DI 10.3201/eid1909.130013 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800029 PM 23965731 ER PT J AU Lopez-Martinez, I Balish, A Barrera-Badillo, G Jones, J Nunez-Garcia, TE Jang, Y Aparicio-Antonio, R Azziz-Baumgartner, E Belser, JA Ramirez-Gonzalez, JE Pedersen, JC Ortiz-Alcantara, J Gonzalez-Duran, E Shu, B Emery, SL Poh, MK Reyes-Teran, G Vazquez-Perez, JA Avila-Rios, S Uyeki, T Lindstrom, S Villanueva, J Tokars, J Ruiz-Matus, C Gonzalez-Roldan, JF Schmitt, B Klimov, A Cox, N Kuri-Morales, P Davis, CT Diaz-Quinonez, JA AF Lopez-Martinez, Irma Balish, Amanda Barrera-Badillo, Gisela Jones, Joyce Nunez-Garcia, Tatiana E. Jang, Yunho Aparicio-Antonio, Rodrigo Azziz-Baumgartner, Eduardo Belser, Jessica A. Ramirez-Gonzalez, Jose E. Pedersen, Janice C. Ortiz-Alcantara, Joanna Gonzalez-Duran, Elizabeth Shu, Bo Emery, Shannon L. Poh, Mee K. Reyes-Teran, Gustavo Vazquez-Perez, Joel A. Avila-Rios, Santiago Uyeki, Timothy Lindstrom, Stephen Villanueva, Julie Tokars, Jerome Ruiz-Matus, Cuitlahuac Gonzalez-Roldan, Jesus F. Schmitt, Beverly Klimov, Alexander Cox, Nancy Kuri-Morales, Pablo Davis, C. Todd Diaz-Quinonez, Jose Alberto TI Highly Pathogenic Avian Influenza A(H7N3) Virus in Poultry Workers, Mexico, 2012 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BRITISH-COLUMBIA; HUMAN ILLNESS; H7N3; INFECTION; RECOMBINATION; OUTBREAK AB We identified 2 poultry workers with conjunctivitis caused by highly pathogenic avian influenza A(H7N3) viruses in Jalisco, Mexico. Genomic and antigenic analyses of 1 isolate indicated relatedness to poultry and wild bird subtype H7N3 viruses from North America. This isolate had a multibasic cleavage site that might have been derived from redombination with host rRNA. C1 [Lopez-Martinez, Irma; Barrera-Badillo, Gisela; Nunez-Garcia, Tatiana E.; Aparicio-Antonio, Rodrigo; Ramirez-Gonzalez, Jose E.; Ortiz-Alcantara, Joanna; Gonzalez-Duran, Elizabeth; Diaz-Quinonez, Jose Alberto] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico. [Balish, Amanda; Jones, Joyce; Jang, Yunho; Azziz-Baumgartner, Eduardo; Belser, Jessica A.; Shu, Bo; Emery, Shannon L.; Poh, Mee K.; Uyeki, Timothy; Lindstrom, Stephen; Villanueva, Julie; Tokars, Jerome; Klimov, Alexander; Cox, Nancy; Davis, C. Todd] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Pedersen, Janice C.; Schmitt, Beverly] USDA, Ames, IA USA. [Reyes-Teran, Gustavo; Vazquez-Perez, Joel A.; Avila-Rios, Santiago] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico. [Ruiz-Matus, Cuitlahuac; Gonzalez-Roldan, Jesus F.] Direcc Gen Epidemiol, Mexico City, DF, Mexico. [Kuri-Morales, Pablo] Subsecretaria Prevenc & Promoc Salud, Mexico City, DF, Mexico. RP Davis, CT (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D30, Atlanta, GA 30333 USA. EM ctdavis@cdc.gov OI Diaz-Quinonez, Jose Alberto/0000-0002-3503-7079 NR 15 TC 24 Z9 25 U1 1 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1531 EP 1534 DI 10.3201/eid1909.130087 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800030 PM 23965808 ER PT J AU Potter, P AF Potter, Polyxeni TI When at night I go to sleep/Fourteen angels watch do keep SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material ID SAINT-VITUS; DANCE C1 [Potter, Polyxeni] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, EID Journal, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD SEP PY 2013 VL 19 IS 9 BP 1554 EP 1555 DI 10.3201/eid1909.AC1909 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268MB UT WOS:000328173800041 ER PT J AU Rhoden, E Liu, HM Wang-Chern, SW Oberste, MS AF Rhoden, Eric Liu, Hong-Mei Wang-Chern, Shur-wern Oberste, M. Steven TI Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds (vol 98, pg 186, 2013) SO ANTIVIRAL RESEARCH LA English DT Correction C1 [Rhoden, Eric; Liu, Hong-Mei; Wang-Chern, Shur-wern; Oberste, M. Steven] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Div Viral Dis, Atlanta, GA USA. RP Oberste, MS (reprint author), 1600 Clifton Rd NE,Mailstop G-17, Atlanta, GA 30333 USA. EM erhoden@cdc.gov; hliu@cdc.gov; schern@cdc.gov; soberste@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 EI 1872-9096 J9 ANTIVIR RES JI Antiviral Res. PD SEP PY 2013 VL 99 IS 3 BP 436 EP 436 DI 10.1016/j.antiviral.2013.08.011 PG 1 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 253RZ UT WOS:000327108300027 ER PT J AU Nesheim, S Harris, LF Lampe, M AF Nesheim, Steven Harris, Lauren Fitz Lampe, Margaret TI Elimination of perinatal HIV infection in the USA and other high-income countries: achievements and challenges SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE elimination; human immunodeficiency virus; mother-to-child transmission; perinatal; prevention ID TO-CHILD TRANSMISSION; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; PREGNANT-WOMEN; HEPATITIS-C; UNITED-KINGDOM; VIRAL LOAD; REPRODUCTIVE AGE; POSITIVE WOMEN; PUERTO-RICO AB Purpose of reviewTo describe progress and challenges to elimination of mother-to-child HIV transmission (EMCT) in high-income countries.Recent findingsDespite ongoing declines in the number of perinatally HIV-infected infants in most high-income countries, the number of HIV-infected women delivering may be increasing, accompanied by apparent changes in this population, including higher percentages with antiretroviral pretreatment' (with possible antiretroviral resistance), other coinfections, mental health diagnoses, and recent immigration. The impact of antiretroviral resistance on mother-to-child transmission is yet to be defined. A substantial minority of infant HIV acquisitions occurs in the context of maternal acute HIV infection during pregnancy. Some infant infections occur after pregnancy, for example, by premastication of food, or breastfeeding (perhaps by an uninfected woman who acquires HIV while breastfeeding).SummaryThe issues of EMCT are largely those of providing proper care for HIV-infected women. Use of combination ART by increasing proportions of the infected population may function as a structural intervention important to achieving this goal. Providers and public health systems need to be alert for HIV-serodiscordant couples in which the woman is uninfected and for changes in the population of HIV-infected pregnant women. Accurate data about HIV-exposed pregnancies are vital to monitor progress toward EMCT. C1 [Nesheim, Steven; Harris, Lauren Fitz; Lampe, Margaret] Ctr Dis Control & Prevent, Epidemiol Branch, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis Sexually Transmitted, Atlanta, GA 30333 USA. [Harris, Lauren Fitz] ICF Int, Atlanta, GA USA. RP Nesheim, S (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop E-45, Atlanta, GA 30333 USA. EM sxn9@cdc.gov FU Intramural CDC HHS [CC999999] NR 65 TC 15 Z9 15 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X EI 1746-6318 J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD SEP PY 2013 VL 8 IS 5 BP 447 EP 456 DI 10.1097/COH.0b013e3283636ccb PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 248US UT WOS:000326730500012 PM 23925002 ER PT J AU Whitfield, GP Gabriel, KKP Kohl, HW AF Whitfield, Geoffrey P. Gabriel, Kelley K. Pettee Kohl, Harold W., III TI Assessing Sitting Across Contexts: Development of the Multicontext Sitting Time Questionnaire SO RESEARCH QUARTERLY FOR EXERCISE AND SPORT LA English DT Article DE accelerometers; endurance athletes; epidemiology; sedentary; validation ID PHYSICAL-ACTIVITY; SEDENTARY BEHAVIORS; UNITED-STATES; ADULTS; RISK; ACCELEROMETER; OBESITY; WOMEN AB Purpose: To describe the development and preliminary evaluation of the Multicontext Sitting Time Questionnaire (MSTQ). Method: During development of the MSTQ, contexts and domains of sitting behavior were utilized as recall cues to improve the accuracy of sitting assessment. The terms workday and nonworkday were used to disambiguate occupational and discretionary sitting. An expert panel evaluated content validity. Among 25 participants, test-retest reliability of the MSTQ items was assessed with intraclass correlation coefficients (ICCs). Convergent validity was assessed versus relative and absolute accelerometer-estimated sedentary time and activity log using Pearson (r) or Spearman () correlation coefficients where appropriate. Results: Pilot testing revealed Web-based MSTQ administration was rapid, scalable, and inexpensive. Most items in the MSTQ demonstrated acceptable reliability (ICCs>.70). Compared with accelerometer-estimated sedentary time relative to total wear time, the MSTQ exhibited a low correlation on workdays (r=.34) and a moderately high correlation on nonworkdays (r=.61). Conclusions: The systematic development of the MSTQ resulted in several improvements over previous tools and may serve as a model for purpose-driven questionnaire design. Additional validation is needed to conclusively determine the utility of the MSTQ. C1 [Kohl, Harold W., III] Univ Texas Austin, Austin, TX 78712 USA. RP Whitfield, GP (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM geofwhitfield@yahoo.com FU Cancer Education and Career Development Program, National Institutes of Health [2 R25 CA57712] FX The authors would like to thank the members of the Physical Activity and Public Health Working Group at the Austin Regional Campus of the University of Texas School of Public Health for their support and ideas throughout this process. The first author (GPW) is partially supported by the Cancer Education and Career Development Program, National Institutes of Health Grant NO. 2 R25 CA57712. There were no other sources of funding for this research. NR 18 TC 3 Z9 3 U1 0 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0270-1367 EI 2168-3824 J9 RES Q EXERCISE SPORT JI Res. Q. Exerc. Sport PD SEP 1 PY 2013 VL 84 IS 3 BP 323 EP 328 DI 10.1080/02701367.2013.814041 PG 6 WC Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences SC Social Sciences - Other Topics; Psychology; Sport Sciences GA 218KG UT WOS:000324430700006 PM 24261011 ER PT J AU Koster, J Ramazani, SY AF Koster, J. Ramazani, S. Y. TI Piloting an Instrument to Understand the Knowledge, Attitude, and Perceptions toward Blood Donation in The Democratic Republic of Congo SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting and CTTXPO CY OCT 12-15, 2013 CL Denver, CO SP AABB C1 [Koster, J.] Safe Blood Africa Fdn, Johannesburg, South Africa. [Ramazani, S. Y.] Natl Blood Serv, Kinshasa, Zaire. [Koster, J.; Ramazani, S. Y.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM juliettekoster@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2013 VL 53 SU 2 SI SI BP 99A EP 100A PG 2 WC Hematology SC Hematology GA 218CA UT WOS:000324409000208 ER PT J AU Harvey, A Chung, K Kuehnert, MJ AF Harvey, A. Chung, K. Kuehnert, M. J. TI Hemovigilance Data Reported to the National Healthcare Safety Network, 2010-2012 SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting and CTTXPO CY OCT 12-15, 2013 CL Denver, CO SP AABB C1 [Harvey, A.; Chung, K.; Kuehnert, M. J.] Ctr Dis Control & Prevent, Off Blood Organ & Other Tissue Safety, Atlanta, GA USA. EM fom7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2013 VL 53 SU 2 SI SI BP 134A EP 135A PG 2 WC Hematology SC Hematology GA 218CA UT WOS:000324409000299 ER PT J AU Stramer, SL Foster, GA Brodsky, J Munoz-Jordan, JL Hunsperger, E Lanteri, MC Anez, G Rios, M Cory, R Linnen, JM AF Stramer, S. L. Foster, G. A. Brodsky, J. Munoz-Jordan, J. L. Hunsperger, E. Lanteri, M. C. Anez, G. Rios, M. Cory, R. Linnen, J. M. TI Investigational Dengue Testing Yields High Rates of Ribonucleic acid (RNA)-Positive Donors in Puerto Rico SO TRANSFUSION LA English DT Meeting Abstract CT AABB Annual Meeting and CTTXPO CY OCT 12-15, 2013 CL Denver, CO SP AABB C1 [Stramer, S. L.; Foster, G. A.] Amer Red Cross, Biomed Serv, Sci Support Off, Gaithersburg, MD USA. [Brodsky, J.] Qual Analyt Inc, Riverwoods, IL USA. [Munoz-Jordan, J. L.; Hunsperger, E.] Ctr Dis Control & Prevent CDC, San Juan, PR USA. [Lanteri, M. C.] Blood Syst Res Inst, San Francisco, CA USA. [Anez, G.; Rios, M.] US FDA, DETTD, OBRR, CBER, Bethesda, MD 20014 USA. [Cory, R.; Linnen, J. M.] Hol Gen Probe, San Diego, CA USA. EM susan.stramer@redcross.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2013 VL 53 SU 2 SI SI BP 216A EP 216A PG 1 WC Hematology SC Hematology GA 218CA UT WOS:000324409000507 ER PT J AU Aidoo, M AF Aidoo, Michael TI Factoring Quality Laboratory Diagnosis into the Malaria Control Agenda for Sub-Saharan Africa SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CASE-MANAGEMENT; FEBRILE ILLNESS; TANZANIA; MICROSCOPY; CHILDREN; ZAMBIA; TESTS; KENYA; CHLOROQUINE; ETHIOPIA AB Recent progress in malaria control in sub-Saharan Africa has been achieved primarily through provision of insecticide-treated nets, indoor residual spraying, and antimalarial drugs. Although these interventions are important, proper case identification and accurate measurement of their impact depend on quality diagnostic testing. Current availability of diagnostic testing for malaria in sub-Saharan Africa is inadequate to support disease management, prevention programs, and surveillance needs. Challenges faced include a dearth of skilled workforce, inadequate health systems infrastructure, and lack of political will. A coordinated approach to providing pre-service clinical and laboratory training together with systems that support a scale-up of laboratory services could provide means not only for effective malaria case management but also, management of non-malaria febrile illnesses, disease surveillance, and accurate control program evaluation. A synthesis of the challenges faced in ensuring quality malaria testing and how to include this information in the malaria control and elimination agenda are presented. C1 [Aidoo, Michael] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Aidoo, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop A06, Atlanta, GA 30333 USA. EM maidoo@cdc.gov NR 37 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2013 VL 89 IS 3 BP 403 EP 406 DI 10.4269/ajtmh.13-0108 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240XB UT WOS:000326129900002 PM 24006294 ER PT J AU Savage, HM Godsey, MS Lambert, A Panella, NA Burkhalter, KL Harmon, JR Lash, RR Ashley, DC Nicholson, WL AF Savage, Harry M. Godsey, Marvin S., Jr. Lambert, Amy Panella, Nicholas A. Burkhalter, Kristen L. Harmon, Jessica R. Lash, R. Ryan Ashley, David C. Nicholson, William L. TI First Detection of Heartland Virus (Bunyaviridae: Phlebovirus) from Field Collected Arthropods SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID MISSOURI; IXODIDAE; ACARI; FEVER; PHYLOGENY; NYMPHS; CHINA; TREES; KEY AB Heartland virus (HRTV), the first pathogenic Phlebovirus (Family: Bunyaviridae) discovered in the United States, was recently described from two Missouri farmers. In 2012, we collected 56,428 ticks representing three species at 12 sites including both patients' farms. Amblyomma americanum and Dermacentor variabilis accounted for nearly all ticks collected. Ten pools composed of deplete nymphs of A. americanum collected at a patient farm and a nearby conservation area were reverse transcription-polymerase chain reaction positive, and eight pools yielded viable viruses. Sequence data from the nonstructural protein of the Small segment indicates that tick strains and human strains are very similar, >= 97.6% sequence identity. This is the first study to isolate HRTV from field-collected arthropods and to implicate ticks as potential vectors. Amblyomma americanum likely becomes infected by feeding on viremic hosts during the larval stage, and transmission to humans occurs during the spring and early summer when nymphs are abundant and actively host seeking. C1 [Savage, Harry M.] Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. [Ashley, David C.] Missouri Western State Univ, Dept Biol, St Joseph, MO USA. RP Savage, HM (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM HMS1@cdc.gov; mjg9@cdc.gov; ahk7@cdc.gov; nap4@cdc.gov; ktb3@cdc.gov; jharmon@cdc.gov; rlash@cdc.gov; ashley@missouriwestern.edu; wnicholson@cdc.gov FU Division of Vector-Borne Diseases of the Centers for Disease Control and Prevention FX This project was supported by the Division of Vector-Borne Diseases of the Centers for Disease Control and Prevention. Local collection assistance was supported by county and state health departments and MWSU. NR 32 TC 64 Z9 65 U1 3 U2 22 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2013 VL 89 IS 3 BP 445 EP 452 DI 10.4269/ajtmh.13-0209 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240XB UT WOS:000326129900008 PM 23878186 ER PT J AU Billeter, SA Colton, L Sangmaneedet, S Suksawat, F Evans, BP Kosoy, MY AF Billeter, Sarah A. Colton, Leah Sangmaneedet, Somboon Suksawat, Fanan Evans, Brian P. Kosoy, Michael Y. TI Short Report: Molecular Detection and Identification of Bartonella Species, in Rat Fleas from Northeastern Thailand SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PREVALENCE; RICKETTSIA; RODENTS; CATS; DOGS; DNA; ECTOPARASITES; ANAPLASMA; EHRLICHIA; BANGKOK AB The presence of Bartonella species in Xenopsylla cheopis fleas collected from Rattus spp. (R. exulans;. R. norvegicus, and R. rattus) in Khon Kaen Province, Thailand was investigated. One hundred ninety-three fleas obtained from 62 rats, were screened by polymerase chain reaction using primers specific for the 16S-23S,intergenic spacer region, and the presence of Bartonella DNA was confirmed by using the citrate synthase gene. Bartonella DNA: was detected in 59.1%,(114 of 193) of fleas examined. Sequencing demonstrated the presence of Bartonella spp. similar to B. elizabethae, B. rattimassiliensis, B. rochalimae, and B. tribocorum in the samples tested with a cutoff for sequence similarity >= 96% and 4 clustered together with the closest match with B. grahamii (95.5% identity). If X. cheopis proves to be a competent vector of these species, our results suggest that humans and animals residing in this area may be at risk for infection by several zoonotic Bartonella species. C1 [Billeter, Sarah A.; Colton, Leah; Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Sangmaneedet, Somboon; Suksawat, Fanan] Khon Kaen Univ, Fac Vet Med, Khon Kaen, Thailand. [Evans, Brian P.] Armed Forces Res Inst Med Sci, Dept Entomol, Bangkok 10400, Thailand. RP Kosoy, MY (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM ina8@cdc.gov; ant6@cdc.gov; sombn_sa@kku.ac.th; jsvetmed@yahoo.com; brian.patrick.evans@us.army.mil; mck3@cdc.gov FU American Society of Tropical Medicine and Hygiene Robert E. Shope International Fellowship FX This study was supported by an American Society of Tropical Medicine and Hygiene Robert E. Shope International Fellowship to Sarah A. Billeter. NR 26 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2013 VL 89 IS 3 BP 462 EP 465 DI 10.4269/ajtmh.12-0483 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240XB UT WOS:000326129900011 PM 23836577 ER PT J AU Komar, N Panella, NA Young, GR Brault, AC Levy, CE AF Komar, Nicholas Panella, Nicholas A. Young, Ginger R. Brault, Aaron C. Levy, Craig E. TI Avian Hosts of West Nile Virus in Arizona SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID LOUIS-ENCEPHALITIS-VIRUS; DIPTERA-CULICIDAE; INFECTION; DISEASE; CALIFORNIA; BIRDS; EPIDEMIOLOGY; TRANSMISSION; COMPETENCE; MOSQUITOS AB West Nile virus (WNV) causes sporadic outbreaks of human encephalitis in Phoenix, Arizona. To identify amplifying hosts of WNV in the Phoenix area, we blood-sampled resident birds and measured antibody prevalence following an outbreak in the East Valley of metropolitan Phoenix during summer, 2010. House sparrow (Passer, domesticus), house finch (Haemorhous mexicanus), great-tailed grackle (Quiscalus mexicanus), and mourning dove. (Zenaida macroura) accounted for most WNV infections among locally resident birds. These species roost communally after early summer breeding. In September 2010, Culex vector-avian host contact was 3-fold greater at communal bird roosts compared with control sites, as determined. by densities of resting mosquitoes with previous vertebrate contact (i.e., blood-engorged or gravid mosquitoes). Because of the low competence of mourning doves, these were considered weak amplifiers but potentially effective free-ranging sentinels. Highly competent sparrows, finches, and grackles were predicted to be key amplifying hosts for WNV in suburban Phoenix. C1 [Komar, Nicholas; Panella, Nicholas A.; Young, Ginger R.; Brault, Aaron C.] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Ft Collins, CO USA. [Levy, Craig E.] Arizona Dept Hlth Serv Epidemiol, Phoenix, AZ USA. RP Komar, N (reprint author), CDC DVBD ADB, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM NKomar@cdc.gov; nap4@cdc.gov; gyoung527@gmail.com; acbrault1@mac.com; CraigLevy@mail.maricopa.gov FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. NR 27 TC 4 Z9 4 U1 1 U2 26 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD SEP PY 2013 VL 89 IS 3 BP 474 EP 481 DI 10.4269/ajtmh.13-0061 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 240XB UT WOS:000326129900013 PM 23857022 ER PT J AU Inandi, T Caman, OK Aydin, N Onal, AE Kaypmaz, A Turhan, E Erguder, T Warren, WC AF Inandi, Tacettin Caman, Ozge Karadag Aydin, Neriman Onal, Ayse Emel Kaypmaz, Ayse Turhan, Ebru Erguder, Toker Warren, Wick C. TI GLOBAL HEALTH PROFESSIONS STUDENT SURVEY - TURKEY: SECOND-HAND SMOKE EXPOSURE AND OPINIONS OF MEDICAL STUDENTS ON ANTI-TOBACCO LAW SO CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE second-hand smoke; tobacco; legislation; medical students; medical schools ID TOBACCO; COUNTRIES AB Aim: This study, as a part of "the Global Health Professions Student Survey" (GHPSS), aimed to assess medical students' tobacco use, exposure to second-hand tobacco smoke (SHS), and opinions as well as smoking policies at medical faculties in Turkey. Methods: The study was conducted in 2010 as a school-based survey of third-year students in 12 medical schools. GHPSS uses a standardised methodology for selecting schools (probability proportional to student enrolment size) and data processing. In total, data from 1,217 of third year medical students were analysed. Results: Prevalence of current tobacco use among participating students was 28.5%. Exposure to SHS in the last seven days was 46.9% at home, and 42.2% in other places. Among smokers, over 7 in 10 students reported smoking on medical school premises during the past 30 days and the past year. Conclusion: Medical students' exposure to SHS is common and smoking on medical school premises/buildings constitutes a problem. Turkey passed an anti-tobacco law in 2008, yet enforcement of the law must be stronger. In addition, medical schools must evaluate, and likely revise their education curricula to better prepare medical students to advocate tobacco control. C1 [Inandi, Tacettin; Turhan, Ebru] Mustafa Kemal Univ, Fac Med, Dept Publ Hlth, Antakya, Turkey. [Caman, Ozge Karadag] Hacettepe Univ, Fac Med, Dept Publ Hlth, TR-06100 Ankara, Turkey. [Aydin, Neriman] Gaziantep Univ, Fac Med, Dept Publ Hlth, Gaziantep, Turkey. [Onal, Ayse Emel] Istanbul Univ, Istanbul Fac Med, Dept Publ Hlth, Istanbul, Turkey. [Kaypmaz, Ayse] Istanbul Univ, Cerrahpasa Med Fac, Dept Publ Hlth, Istanbul, Turkey. [Erguder, Toker] WHO Country Off, Bloomberg Initiat, Natl Tobacco Control Programme, Ankara, Turkey. [Warren, Wick C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Caman, OK (reprint author), Hacettepe Univ, Tip Fak, Halk Sagligi Anabilim Dali, TR-06100 Ankara, Turkey. EM ozgecaman@hacettepe.edu.tr FU World Health Organization Regional Office for Europe [EU/09/110846] FX This work was supported by the World Health Organization Regional Office for Europe (Grant number EU/09/110846) NR 26 TC 4 Z9 4 U1 1 U2 4 PU NATL INST PUBLIC HEALTH PI PRAGUE 10 PA DEPT SCIENTIFIC INFORMATION, SROBAROVA 48, PRAGUE 10, 100 42, CZECH REPUBLIC SN 1210-7778 EI 1803-1048 J9 CENT EUR J PUBL HEAL JI Cent. Eur. J. Public Health PD SEP PY 2013 VL 21 IS 3 BP 134 EP 139 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 238NR UT WOS:000325955200005 PM 24344536 ER PT J AU Nix, WA Khetsuriani, N Penaranda, S Maher, K Venczel, L Cselko, Z Freire, MC Cisterna, D Lema, CL Rosales, P Rodriguez, JR Rodriguez, W Halkyer, P Ronveaux, O Pallansch, MA Oberste, MS AF Nix, W. Allan Khetsuriani, Nino Penaranda, Silvia Maher, Kaija Venczel, Linda Cselko, Zsuzsa Cecilia Freire, Maria Cisterna, Daniel Lema, Cristina L. Rosales, Patricia Rodriguez, Jacqueline R. Rodriguez, Wilma Halkyer, Percy Ronveaux, Olivier Pallansch, Mark A. Oberste, M. Steven TI Diversity of picornaviruses in rural Bolivia SO JOURNAL OF GENERAL VIROLOGY LA English DT Article ID ACUTE FLACCID PARALYSIS; SOUTH ASIAN CHILDREN; CAPSID PROTEIN VP1; KARWINSKIA-HUMBOLDTIANA; SAFFOLD CARDIOVIRUS; CLINICAL SPECIMENS; PCR AMPLIFICATION; STOOL SAMPLES; IDENTIFICATION; ENTEROVIRUSES AB The family Picornaviridae is a large and diverse group of viruses that infect humans and animals. Picornaviruses are among the most common infections of humans and cause a wide spectrum of acute human disease. This study began as an investigation of acute flaccid paralysis (AFP) in a small area of eastern Bolivia, where surveillance had identified a persistently high AFP rate in children. Stools were collected and diagnostic studies ruled out poliovirus. We tested stool specimens from 51 AFP cases and 34 healthy household or community contacts collected during 2002-2003 using real-time and semi-nested reverse transcription polymerase chain reaction assays for enterovirus, parechovirus, cardiovirus, kobuvirus, salivirus and cosavirus. Anecdotal reports suggested a temporal association with neurological disease in domestic pigs, so six porcine stools were also collected and tested with the same set of assays, with the addition of an assay for porcine teschovirus. A total of 126 picornaviruses were detected in 73 of 85 human individuals, consisting of 53 different picornavirus types encompassing five genera (all except Kobuvirus). All six porcine stools contained porcine and/or human picornaviruses. No single virus, or combination of viruses, specifically correlated with AFP; however, the study revealed a surprising complexity of enteric picornaviruses in a single community. C1 [Nix, W. Allan; Khetsuriani, Nino; Penaranda, Silvia; Maher, Kaija; Venczel, Linda; Cselko, Zsuzsa; Pallansch, Mark A.; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Cecilia Freire, Maria; Cisterna, Daniel; Lema, Cristina L.] Inst Nacl Enfemedades Infecciosos C Malbran, Buenos Aires, DF, Argentina. [Rosales, Patricia; Rodriguez, Wilma] Minist Hlth & Sports, La Paz, Bolivia. [Rodriguez, Jacqueline R.] Pediat Hosp San Antonio Sauces, Monteagudo, Bolivia. [Halkyer, Percy; Ronveaux, Olivier] Pan Amer Hlth Org, La Paz, Bolivia. RP Oberste, MS (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM soberste@cdc.gov FU Hungarian-American Enterprise Scholarship Fund, Budapest, Hungary FX We thank the staff of the Bolivia EPI program for their work on identification and investigation of the APP cases and support of the study specimen collection; Dr Ramon D. Ibanez Calderon of LIDIVET, Santa Cruz, for his assistance in exploring potential aetiologies of pig diseases in Hernando Siles; Dr Noemi Waksman de Torres for discussions of Karwinskia toxicology and assistance with exploring its role in APP in Bolivia; Z. C. was supported by a fellowship from the Hungarian-American Enterprise Scholarship Fund, Budapest, Hungary. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of CDC. NR 44 TC 21 Z9 21 U1 0 U2 5 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-1317 EI 1465-2099 J9 J GEN VIROL JI J. Gen. Virol. PD SEP PY 2013 VL 94 BP 2017 EP 2028 DI 10.1099/vir.0.053827-0 PN 9 PG 12 WC Biotechnology & Applied Microbiology; Virology SC Biotechnology & Applied Microbiology; Virology GA 243GJ UT WOS:000326304600009 PM 23804569 ER PT J AU Lobelo, F de Quevedo, IG Holub, CK Nagle, BJ Arredondo, EM Barquera, S Elder, JP AF Lobelo, Felipe de Quevedo, Isabel Garcia Holub, Christina K. Nagle, Brian J. Arredondo, Elva M. Barquera, Simon Elder, John P. TI School-Based Programs Aimed at the Prevention and Treatment of Obesity: Evidence-Based Interventions for Youth in Latin America SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE obesity; school-based interventions; children; Latin America ID PHYSICAL-ACTIVITY INTERVENTIONS; RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR RISK-FACTORS; DEVELOPING-COUNTRIES; CHILDHOOD OBESITY; NUTRITION TRANSITION; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; LIFE-STYLE; OVERWEIGHT AB BACKGROUNDRapidly rising childhood obesity rates constitute a public health priority in Latin America which makes it imperative to develop evidence-based strategies. Schools are a promising setting but to date it is unclear how many school-based obesity interventions have been documented in Latin America and what level of evidence can be gathered from such interventions. METHODSWe performed a systematic review of papers published between 1965 and December 2010. Interventions were considered eligible if they had a school-based component, were done in Latin America, evaluated an obesity related outcome (body mass index [BMI], weight, %body fat, waist circumference, BMIz-score), and compared youth exposed vs not exposed. RESULTSTen studies were identified as having a school-based component. Most interventions had a sample of normal and overweight children. The most successful interventions focused on prevention rather than treatment, had longer follow-ups, a multidisciplinary team, and fewer limitations in execution. Three prevention and 2 treatment interventions found sufficient improvements in obesity-related outcomes. CONCLUSIONSWe found sufficient evidence to recommend school-based interventions to prevent obesity among youth in Latin America. Evidence-based interventions in the school setting should be promoted as an important component for integrated programs, policies, and monitoring frameworks designed to reverse the childhood obesity in the region. C1 [Lobelo, Felipe; de Quevedo, Isabel Garcia] Ctr Dis Control & Prevent, Global Hlth Promot Off, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Holub, Christina K.; Nagle, Brian J.; Arredondo, Elva M.] San Diego State Univ, Inst Behav & Community Hlth, San Diego, CA 92123 USA. [Barquera, Simon] Natl Inst Publ Hlth, Ctr Nutr & Hlth, Dept Nutr Policies & Programs, Cuemavaca 62100, Mor, Mexico. [Elder, John P.] San Diego State Univ, San Diego, CA 92123 USA. RP Lobelo, F (reprint author), Ctr Dis Control & Prevent, Global Hlth Promot Off, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K40, Atlanta, GA 30341 USA. EM rlobelo@cdc.gov; vpr5@cdc.gov; cholub@projects.sdsu.edu; naglebj@gmail.com; earredondo@projects.sdsu.edu; sbarquera@insp.mx; jelder@mail.sdsu.edu OI Lobelo, Felipe/0000-0003-4185-7193 FU CDC [1U48DP001917] FX This study was approved by the Institutional Review Board of San Diego State University and was funded by the CDC 1U48DP001917. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 57 TC 8 Z9 8 U1 3 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4391 EI 1746-1561 J9 J SCHOOL HEALTH JI J. Sch. Health PD SEP PY 2013 VL 83 IS 9 BP 668 EP 677 DI 10.1111/josh.12080 PG 10 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 241HV UT WOS:000326158000010 PM 23879787 ER PT J AU Sweeney, P Gardner, LI Buchacz, K Garland, PM Mugavero, MJ Bosshart, JT Shouse, RL Bertolli, J AF Sweeney, Patricia Gardner, Lytt I. Buchacz, Kate Garland, Pamela Morse Mugavero, Michael J. Bosshart, Jeffrey T. Shouse, R. Luke Bertolli, Jeanne TI Shifting the Paradigm: Using HIV Surveillance Data as a Foundation for Improving HIV Care and Preventing HIV Infection SO MILBANK QUARTERLY LA English DT Article DE ethical data use; HIV treatment; HIV prevention; HIV surveillance ID ACTIVE ANTIRETROVIRAL THERAPY; PUBLIC-HEALTH INFORMATION; MEDICAL-CARE; VIRAL LOAD; SAN-FRANCISCO; UNITED-STATES; PARTNER NOTIFICATION; INHIBITOR THERAPY; LIFE EXPECTANCY; ADHERENCE AB Context Reducing HIV incidence in the United States and improving health outcomes for people living with HIV hinge on improving access to highly effective treatment and overcoming barriers to continuous treatment. Using laboratory tests routinely reported for HIV surveillance to monitor individuals' receipt of HIV care and contacting them to facilitate optimal care could help achieve these objectives. Historically, surveillance-based public health intervention with individuals for HIV control has been controversial because of concerns that risks to privacy and autonomy could outweigh benefits. But with the availability of lifesaving, transmission-interrupting treatment for HIV infection, some health departments have begun surveillance-based outreach to facilitate HIV medical care. Methods Guided by ethics frameworks, we explored the ethical arguments for changing the uses of HIV surveillance data. To identify ethical, procedural, and strategic considerations, we reviewed the activities of health departments that are using HIV surveillance data to contact persons identified as needing assistance with initiating or returning to care. Findings Although privacy concerns surrounding the uses of HIV surveillance data still exist, there are ethical concerns associated with not using HIV surveillance to maximize the benefits from HIV medical care and treatment. Early efforts to use surveillance data to facilitate optimal HIV medical care illustrate how the ethical burdens may vary depending on the local context and the specifics of implementation. Health departments laid the foundation for these activities by engaging stakeholders to gain their trust in sharing sensitive information; establishing or strengthening legal, policy and governance infrastructure; and developing communication and follow-up protocols that protect privacy. Conclusions We describe a shift toward using HIV surveillance to facilitate optimal HIV care. Health departments should review the considerations outlined before implementing new uses of HIV surveillance data, and they should commit to an ongoing review of activities with the objective of balancing beneficence, respect for persons, and justice. C1 [Sweeney, Patricia; Gardner, Lytt I.; Buchacz, Kate; Garland, Pamela Morse; Bosshart, Jeffrey T.; Shouse, R. Luke; Bertolli, Jeanne] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Mugavero, Michael J.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. RP Sweeney, P (reprint author), Ctr Dis Control & Prevent, HIV Incidence & Case Surveillance Branch, Div HIV AIDS Prevent, 1600 Clifton Rd,Mailstop E-47, Atlanta, GA 30333 USA. EM PSweeney@cdc.gov NR 105 TC 17 Z9 17 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0887-378X EI 1468-0009 J9 MILBANK Q JI Milbank Q. PD SEP PY 2013 VL 91 IS 3 BP 558 EP 603 DI 10.1111/milq.12018 PG 46 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 217DC UT WOS:000324335900007 PM 24028699 ER PT J AU Wilcox, S Altpeter, M Anderson, LA Belza, B Bryant, L Jones, DL Leith, KH Phelan, EA Satariano, WA AF Wilcox, Sara Altpeter, Mary Anderson, Lynda A. Belza, Basia Bryant, Lucinda Jones, Dina L. Leith, Katherine H. Phelan, Elizabeth A. Satariano, William A. CA Hlth Aging Res Network Writing Grp TI The Healthy Aging Research Network: Resources for Building Capacity for Public Health and Aging Practice SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article ID PHYSICAL-ACTIVITY AB There is an urgent need to translate science into practice and help enhance the capacity of professionals to deliver evidence-based programming. We describe contributions of the Healthy Aging Research Network in building professional capacity through online modules, issue briefs, monographs, and tools focused on health promotion practice, physical activity, mental health, and environment and policy. We also describe practice partnerships and research activities that helped inform product development and ways these products have been incorporated into real-world practice to illustrate possibilities for future applications. Our work aims to bridge the research-to-practice gap to meet the demands of an aging population. C1 [Wilcox, Sara] Univ S Carolina, Arnold Sch Publ Hlth, Dept Exercise Sci, Columbia, SC 29208 USA. [Wilcox, Sara] Univ S Carolina, Arnold Sch Publ Hlth, Prevent Res Ctr, Columbia, SC 29208 USA. [Leith, Katherine H.] Univ S Carolina, DeSaussure Coll, Coll Social Work, Columbia, SC 29208 USA. [Altpeter, Mary] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC USA. [Anderson, Lynda A.] Ctr Dis Control & Prevent, Hlth Aging Program, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Belza, Basia] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Phelan, Elizabeth A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA. [Bryant, Lucinda] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Aurora, CO USA. [Bryant, Lucinda] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Hlth Syst Management & Policy, Aurora, CO USA. [Jones, Dina L.] W Virginia Univ, Dept Orthopaed, Morgantown, WV 26506 USA. [Jones, Dina L.] W Virginia Univ, Sch Med, Div Phys Therapy, Morgantown, WV 26506 USA. [Satariano, William A.] Univ Calif Berkeley, Sch Publ Hlth, Dept Epidemiol & Community Hlth, Berkeley, CA 94720 USA. RP Wilcox, S (reprint author), Univ S Carolina, Arnold Sch Publ Hlth, Dept Exercise Sci, 921 Assembly St,PHRC 1st Floor, Columbia, SC 29208 USA. EM wilcoxs@mailbox.sc.edu FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [U48 DP001911] NR 15 TC 1 Z9 1 U1 1 U2 6 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD SEP-OCT PY 2013 VL 28 IS 1 BP 2 EP 6 DI 10.4278/ajhp.121116-CIT-564 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 224AZ UT WOS:000324854900007 PM 24000962 ER PT J AU MacDorman, MF Declercq, E Mathews, TJ AF MacDorman, Marian F. Declercq, Eugene Mathews, T. J. TI Recent Trends in Out-of-Hospital Births in the United States SO JOURNAL OF MIDWIFERY & WOMENS HEALTH LA English DT Article DE birth centers; home birth; midwifery workforce ID HOME BIRTHS AB IntroductionAlthough out-of-hospital births are still relatively rare in the United States, it is important to monitor trends in these births, as they can affect patterns of facility usage, clinician training, and resource allocation, as well as health care costs. Trends and characteristics of home and birth center births are analyzed to more completely profile contemporary out-of-hospital births in the United States. MethodsNational birth certificate data were used to examine a recent increase in out-of-hospital births. ResultsAfter a gradual decline from 1990 to 2004, the number of out-of-hospital births increased from 35,578 in 2004 to 47,028 in 2010. In 2010, 1 in 85 US infants (1.18%) was born outside a hospital; about two-thirds of these were born at home, and most of the rest were born in birth centers. The proportion of home births increased by 41%, from 0.56% in 2004 to 0.79% in 2010, with 10% of that increase occurring in the last year. The proportion of birth center births increased by 43%, from 0.23% in 2004 to 0.33% in 2010, with 14% of the increase in the last year. About 90% of the total increase in out-of hospital births from 2004 to 2010 was a result of increases among non-Hispanic white women, and 1 in 57 births to non-Hispanic white women (1.75%) in 2010 was an out-of-hospital birth. Most home and birth center births were attended by midwives. DiscussionHome and birth center births in the United States are increasing, and the rate of out-of-hospital births is now at the highest level since 1978. There has been a decline in the risk profile of out-of-hospital births, with a smaller proportion of out-of-hospital births in 2010 than in 2004 occurring to adolescents and unmarried women and fewer preterm, low-birth-weight, and multiple births. (C) 2013 This article is a U.S. Government work and is in the public domain in the United States. C1 [MacDorman, Marian F.; Mathews, T. J.] Ctr Dis Control & Prevent, Reprod Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Atlanta, GA USA. [Declercq, Eugene] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA 02215 USA. RP MacDorman, MF (reprint author), Natl Ctr Hlth Stat, Div Vital Stat, 3311 Toledo Rd,Room 7318, Hyattsville, MD 20782 USA. EM mfm1@cdc.gov NR 20 TC 17 Z9 17 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-9523 EI 1542-2011 J9 J MIDWIFERY WOM HEAL JI J. Midwifery Women Health PD SEP PY 2013 VL 58 IS 5 BP 494 EP 501 DI 10.1111/jmwh.12092 PG 8 WC Nursing SC Nursing GA 230WE UT WOS:000325373200003 PM 26055924 ER PT J AU Hoelzer, K Chen, Y Dennis, S Evans, P Pouillot, R Silk, BJ Walls, I AF Hoelzer, K. Chen, Y. Dennis, S. Evans, P. Pouillot, R. Silk, B. J. Walls, I. TI New Data, Strategies, and Insights for Listeria monocytogenes Dose-Response Models: Summary of an Interagency Workshop, 2011 SO RISK ANALYSIS LA English DT Article DE risk assessment; Dose-response; Listeria monocytogenes ID TO-EAT FOODS; QUANTITATIVE RISK-ASSESSMENT; NONHUMAN PRIMATE MODEL; PREGNANT GUINEA-PIGS; KNOCK-OUT MICE; INDUCED STILLBIRTHS; GENETIC-CONTROL; ANIMAL-MODELS; UNITED-STATES; A/J MICE AB Listeria monocytogenes is a leading cause of hospitalization, fetal loss, and death due to foodborne illnesses in the United States. A quantitative assessment of the relative risk of listeriosis associated with the consumption of 23 selected categories of ready-to-eat foods, published by the U.S. Department of Health and Human Services and the U.S. Department of Agriculture in 2003, has been instrumental in identifying the food products and practices that pose the greatest listeriosis risk and has guided the evaluation of potential intervention strategies. Dose-response models, which quantify the relationship between an exposure dose and the probability of adverse health outcomes, were essential components of the risk assessment. However, because of data gaps and limitations in the available data and modeling approaches, considerable uncertainty existed. Since publication of the risk assessment, new data have become available for modeling L. monocytogenes dose-response. At the same time, recent advances in the understanding of L. monocytogenes pathophysiology and strain diversity have warranted a critical reevaluation of the published dose-response models. To discuss strategies for modeling L. monocytogenes dose-response, the Interagency Risk Assessment Consortium (IRAC) and the Joint Institute for Food Safety and Applied Nutrition (JIFSAN) held a scientific workshop in 2011 (details available at http://foodrisk.org/irac/events/). The main findings of the workshop and the most current and relevant data identified during the workshop are summarized and presented in the context of L. monocytogenes dose-response. This article also discusses new insights on dose-response modeling for L. monocytogenes and research opportunities to meet future needs. C1 [Hoelzer, K.; Chen, Y.; Dennis, S.; Evans, P.; Pouillot, R.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. [Evans, P.] US Food Safety & Inspect Serv, Microbiol Issues Branch, Off Publ Hlth Sci, USDA, Washington, DC 20250 USA. [Silk, B. J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Walls, I.] Natl Inst Food & Agr, USDA, Washington, DC USA. RP Hoelzer, K (reprint author), US FDA, Ctr Food Safety & Appl Nutr HFS 005, College Pk, MD USA. EM Karin.Hoelzer@fda.hhs.gov RI Pouillot, Regis/E-8103-2010; OI Pouillot, Regis/0000-0002-6107-5212; Walls, Isabel/0000-0002-9643-8845 FU Research Participation Program at the Center for Food Safety and Applied Nutrition; U.S. Department of Energy; U.S. Food and Drug Administration FX This work was supported, in part, by appointments to the Research Participation Program at the Center for Food Safety and Applied Nutrition administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. NR 86 TC 5 Z9 5 U1 0 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0272-4332 EI 1539-6924 J9 RISK ANAL JI Risk Anal. PD SEP PY 2013 VL 33 IS 9 BP 1568 EP 1581 DI 10.1111/risa.12005 PG 14 WC Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods SC Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences GA 217VV UT WOS:000324391400002 PM 23311571 ER PT J AU Kasolo, F Yoti, Z Bakyaita, N Gaturuku, P Katz, R Fischer, JE Perry, HN AF Kasolo, Francis Yoti, Zabulon Bakyaita, Nathan Gaturuku, Peter Katz, Rebecca Fischer, Julie E. Perry, Helen N. TI IDSR AS A PLATFORM FOR IMPLEMENTING IHR IN AFRICAN COUNTRIES SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Article AB Of the 46 countries in the World Health Organization (WHO) African region (AFRO), 43 are implementing Integrated Disease Surveillance and Response (IDSR) guidelines to improve their abilities to detect, confirm, and respond to high-priority communicable and noncommunicable diseases. IDSR provides a framework for strengthening the surveillance, response, and laboratory core capacities required by the revised International Health Regulations [IHR (2005)]. In turn, IHR obligations can serve as a driving force to sustain national commitments to IDSR strategies. The ability to report potential public health events of international concern according to IHR (2005) relies on early warning systems founded in national surveillance capacities. Public health events reported through IDSR to the WHO Emergency Management System in Africa illustrate the growing capacities in African countries to detect, assess, and report infectious and noninfectious threats to public health. The IHR (2005) provide an opportunity to continue strengthening national IDSR systems so they can characterize outbreaks and respond to public health events in the region. C1 [Kasolo, Francis; Yoti, Zabulon; Bakyaita, Nathan; Gaturuku, Peter] World Hlth Org Reg Off Africa, Brazzaville, Congo. [Katz, Rebecca; Fischer, Julie E.] George Washington Univ, Dept Hlth Policy, Washington, DC USA. [Perry, Helen N.] Ctr Dis Control & Prevent, IDSR, Div Global Hlth & Protect, Atlanta, GA USA. RP Perry, HN (reprint author), CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. EM hap5@cdc.gov NR 13 TC 13 Z9 13 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 EI 1557-850X J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD SEP 1 PY 2013 VL 11 IS 3 BP 163 EP 169 DI 10.1089/bsp.2013.0032 PG 7 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA 218JL UT WOS:000324428600001 PM 24041192 ER PT J AU Lopez, W Kershner, SP Penn, MS AF Lopez, Wilfredo Kershner, Stacie P. Penn, Matthew S. TI EMAC VOLUNTEERS: LIABILITY AND WORKERS' COMPENSATION SO BIOSECURITY AND BIOTERRORISM-BIODEFENSE STRATEGY PRACTICE AND SCIENCE LA English DT Article ID CROSS-JURISDICTIONAL COORDINATION; EMERGENCY LEGAL PREPAREDNESS AB Legal Perspectives is aimed at informing healthcare providers, emergency planners, and other decision makers about important legal issues related to public health and healthcare preparedness and response. The articles describe these potentially challenging topics and conclude with the authors' suggestions for further action. The articles do not provide legal advice. Therefore, those affected by the issues discussed in this column should seek further guidance from legal counsel. Readers may submit topics of interest to the column's editor, Ryan Morhard, JD, through the Journal's editorial office at jjfox@upmc.edu.The Emergency Management Assistance Compact (EMAC) provides a mechanism for states to assist each other during natural disasters and other emergencies. Congress ratified EMAC in 1996, and all 50 states and 3 territories have adopted it. EMAC allows a state affected by a disaster to request personnel and materiel from another state. For personnel requests, EMAC provides that the requesting state cover the tort liability and the responding state cover the workers' compensation liability. This article discusses the limitations of EMAC in deploying volunteers and how the Uniform Emergency Volunteer Health Practitioners Act and other provisions address those limitations. C1 [Lopez, Wilfredo] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Kershner, Stacie P.] Georgia State Univ, Ctr Law Hlth & Soc, Atlanta, GA 30303 USA. [Penn, Matthew S.] CDC, Publ Hlth Law Program, Atlanta, GA 30341 USA. RP Penn, MS (reprint author), CDC, Publ Hlth Law Program, OSTLTS, 4770 Buford Hwy,MS E-70, Atlanta, GA 30341 USA. EM mpenn@cdc.gov FU Intramural CDC HHS [CC999999] NR 7 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1538-7135 EI 1557-850X J9 BIOSECUR BIOTERROR JI Biosecur. Bioterror. PD SEP 1 PY 2013 VL 11 IS 3 BP 217 EP 225 DI 10.1089/bsp.2013.0040 PG 9 WC Public, Environmental & Occupational Health; International Relations SC Public, Environmental & Occupational Health; International Relations GA 218JL UT WOS:000324428600005 PM 24041195 ER PT J AU Zhang, XZ Beckles, GL Chou, CF Saaddine, JB Wilson, MR Lee, PP Parvathy, N Ryskulova, A Geiss, LS AF Zhang, Xinzhi Beckles, Gloria L. Chou, Chiu-Fang Saaddine, Jinan B. Wilson, M. Roy Lee, Paul P. Parvathy, Nair Ryskulova, Asel Geiss, Linda S. TI Socioeconomic Disparity in Use of Eye Care Services Among US Adults With Age-Related Eye Diseases National Health Interview Survey, 2002 and 2008 SO JAMA OPHTHALMOLOGY LA English DT Article ID BLUE MOUNTAINS EYE; VISUAL IMPAIRMENT; UNITED-STATES; OLDER-ADULTS; MACULAR DEGENERATION; SOCIAL DETERMINANTS; 2020 VISION; PREVALENCE; PEOPLE; RISK AB IMPORTANCE Individuals with age-related eye disease (ARED) need to use eye care services for detection, assessment, and care at regular intervals. OBJECTIVE To explore the association between socioeconomic position (SEP) and use of eye care services among US adults with self-reported ARED during 2002 and 2008. DESIGN Data were from the National Health Interview Survey 2002 and 2008. We used multiple logistic regression to estimate predictive margins, controlling for other factors, and we used the slope index of inequality to measure the relationship between SEP and use of eye care services across the entire distributions of poverty-income ratio (PIR) and educational attainment. SETTING A cross-sectional, nationally representative sample of adults, with prevalence estimates weighted to represent the civilian, noninstitutionalized US population. PARTICIPANTS The sample included US participants in the 2002 (n = 3586) and the 2008 (n = 3104) National Health Interview Survey who were at least 40 years old and reported any ARED (age-related macular degeneration, cataract, diabetic retinopathy, or glaucoma). MAIN OUTCOMES AND MEASURES Use of eye care services; SEP was measured by the PIR and educational attainment. RESULTS In 2002, persons with ARED and a PIR of less than 1.50 were significantly less likely than those with a PIR of at least 5 to report visiting an eye care provider (62.7% vs 80.1%; P < .001) or undergoing a dilated eye examination in the past 12 months (64.3% vs 80.4%; P < .001), after adjustment for other factors. Similarly, persons with less than a high school education were less likely than those with at least a college education to report a visit to an eye care provider (62.9% vs 80.8%; P < .001) or dilated eye examination (64.8% vs 81.4%; P < .001). In 2002, the slope index of inequality showed statistically significant differences for eye care provider visits across the levels of education (24.4; P = .006), and in 2008, it showed a significant difference for eye care provider visits across the levels of educational attainment (25.2; P = .049) and PIR (21.8; P = .01). CONCLUSIONS AND RELEVANCE Significant differences in the use of eye care services by SEP persist among US adults with eye diseases. C1 [Zhang, Xinzhi; Wilson, M. Roy] Natl Inst Minor Hlth & Hlth Dispar, NIH, Bethesda, MD 20892 USA. [Beckles, Gloria L.; Chou, Chiu-Fang; Saaddine, Jinan B.; Parvathy, Nair; Geiss, Linda S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Lee, Paul P.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA. [Ryskulova, Asel] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Zhang, XZ (reprint author), Natl Inst Minor Hlth & Hlth Dispar, Div Data Management & Sci Reporting, NIH, 6707 Democracy Blvd,Ste 800, Bethesda, MD 20892 USA. EM xinzhi.zhang@nih.gov FU National Center for Health Statistics, Centers for Disease Control and Prevention FX This study was supported by the National Center for Health Statistics, Centers for Disease Control and Prevention. NR 52 TC 12 Z9 12 U1 1 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD SEP PY 2013 VL 131 IS 9 BP 1198 EP 1206 DI 10.1001/jamaophthalmol.2013.4694 PG 9 WC Ophthalmology SC Ophthalmology GA 232HC UT WOS:000325482400012 PM 23868137 ER PT J AU Honeycutt, AA Segel, JE Zhuo, XH Hoerger, TJ Imai, K Williams, D AF Honeycutt, Amanda A. Segel, Joel E. Zhuo, Xiaohui Hoerger, Thomas J. Imai, Kumiko Williams, Desmond TI Medical Costs of CKD in the Medicare Population SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; RENAL-DISEASE; UNITED-STATES; PREVALENCE; MODELS; RISK AB Estimates of the medical costs associated with different stages of CKD are needed to assess the economic benefits of interventions that slow the progression of kidney disease. We combined laboratory data from the National Health and Nutrition Examination Survey with expenditure data from Medicare claims to estimate the Medicare program's annual costs that were attributable to CKD stage 1-4. The Medicare costs for persons who have stage 1 kidney disease were not significantly different from zero. Per person annual Medicare expenses attributable to CKD were $1700 for stage 2, $3500 for stage 3, and $12,700 for stage 4, adjusted to 2010 dollars. Our findings suggest that the medical costs attributable to CKD are substantial among Medicare beneficiaries, even during the early stages; moreover, costs increase as disease severity worsens. These cost estimates may facilitate the assessment of the net economic benefits of interventions that prevent or slow the progression of CKD. C1 [Honeycutt, Amanda A.; Hoerger, Thomas J.] Res Triangle Int, Res Triangle Pk, NC 27709 USA. [Segel, Joel E.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Zhuo, Xiaohui; Williams, Desmond] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Honeycutt, AA (reprint author), Res Triangle Int, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM honeycutt@rti.org FU Centers of Excellence in Health Promotion Economics [1 P30 CD000138] FX We would also like to acknowledge support from the Centers of Excellence in Health Promotion Economics, grant #1 P30 CD000138. NR 18 TC 33 Z9 34 U1 2 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD SEP PY 2013 VL 24 IS 9 BP 1478 EP 1483 DI 10.1681/ASN.2012040392 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 227EO UT WOS:000325092900019 PM 23907508 ER PT J AU Flegal, KM Kalantar-Zadeh, K AF Flegal, Katherine M. Kalantar-Zadeh, Kamyar TI Overweight, Mortality and Survival SO OBESITY LA English DT Editorial Material ID BODY-MASS INDEX; OBESITY PARADOX; METAANALYSIS; RISK; OUTCOMES; ILLNESS; CANCER; IMPACT C1 [Flegal, Katherine M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Med Ctr, Harold Simmons Ctr Chron Dis Res & Epidemiol, Orange, CA USA. RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM kmf2@cdc.gov OI Flegal, Katherine/0000-0002-0838-469X; Kalantar-Zadeh, Kamyar/0000-0002-8666-0725 FU NCATS NIH HHS [UL1 TR000124]; NIDDK NIH HHS [R01 DK078106] NR 15 TC 24 Z9 25 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD SEP PY 2013 VL 21 IS 9 BP 1744 EP 1745 DI 10.1002/oby.20588 PG 2 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 231ON UT WOS:000325426600028 PM 23929522 ER PT J AU Johnson, D Lynch, R Marshall, C Mead, K Hirst, D AF Johnson, David Lynch, Robert Marshall, Charles Mead, Kenneth Hirst, Deborah TI Aerosol Generation by Modern Flush Toilets SO AEROSOL SCIENCE AND TECHNOLOGY LA English DT Article ID WATER TREATMENT PLANTS; TO-AIR TRANSFER; AIRBORNE TRANSMISSION; MICROBIAL AEROSOLS; DROPLET PRODUCTION; BURSTING BUBBLES; BACTERIA; ENRICHMENT; INFECTION; VIRUS AB A microbe-contaminated toilet will produce bioaerosols when flushed. We assessed toilet plume aerosol from high efficiency (HET), pressure-assisted high efficiency (PAT), and flushometer (FOM) toilets with similar bowl water and flush volumes. Total and droplet nuclei bioaerosols were assessed. Monodisperse 0.25-1.9-m fluorescent microspheres served as microbe surrogates in separate trials in a mockup 5m(3) water closet (WC). Bowl water seeding was approximately 10(12) particles/mL. Droplet nuclei were sampled onto 0.2-m pore size mixed cellulose ester filters beginning 15 min after the flush using open-face cassettes mounted on the WC walls. Pre- and postflush bowl water concentrations were measured. Filter particle counts were analyzed via fluorescent microscopy. Bowl headspace droplet count size distributions were bimodal and similar for all toilet types and flush conditions, with 95% of droplets <2 m diameter and >99% <5m. Up to 145,000 droplets were produced per flush, with the high-energy flushometer producing over three times as many as the lower energy PAT and over 12times as many as the lowest energy HET despite similar flush volumes. The mean numbers of fluorescent droplet nuclei particles aerosolized and remaining airborne also increased with flush energy. Fluorescent droplet nuclei per flush decreased with increasing particle size. These findings suggest two concurrent aerosolization mechanismssplashing for large droplets and bubble bursting for the fine droplets that form droplet nuclei. Copyright 2013 American Association for Aerosol Research C1 [Johnson, David; Lynch, Robert; Marshall, Charles] Univ Oklahoma, Hlth Sci Ctr, Dept Occupat & Environm Hlth, Oklahoma City, OK 73126 USA. [Mead, Kenneth; Hirst, Deborah] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH USA. RP Johnson, D (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Occupat & Environm Hlth, POB 26901,CHB Room 139E, Oklahoma City, OK 73126 USA. EM david-johnson@ouhsc.edu FU Intramural CDC HHS [CC999999] NR 47 TC 7 Z9 7 U1 5 U2 23 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0278-6826 EI 1521-7388 J9 AEROSOL SCI TECH JI Aerosol Sci. Technol. PD SEP 1 PY 2013 VL 47 IS 9 BP 1047 EP 1057 DI 10.1080/02786826.2013.814911 PG 11 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 222IZ UT WOS:000324725700011 PM 26635429 ER PT J AU Guerra, MA AF Guerra, Marta A. TI Leptospirosis: Public health perspectives SO BIOLOGICALS LA English DT Article DE Leptospirosis; Public health; Epidemiology zoonosis; Diagnosis; Vaccines ID PARTICIPANTS; EFFICACY; OUTBREAK; TRIAL AB Leptospirosis, caused by a spirochete of genus Leptospira, is considered the most widespread zoonosis in the world. It has a global distribution with a higher incidence in the tropics and subtropics, ranging from 10 to 100 human cases per 100,000 individuals. Leptospirosis is considered an "emerging" zoonosis due to increased contact between animals and humans and the resulting human encroachment into wildlife habitat. Climate change and its associated environmental shifts can affect the degree of transmission of leptospirosis. Surveillance for leptospirosis is important for early detection of cases because early treatment is crucial to decrease morbidity and mortality. In June 2012, the Council of State and Territorial Epidemiologists approved reinstatement of leptospirosis as a Nationally Notifiable Condition. Reinstatement of national surveillance will facilitate the assessment of the incidence, geographic distribution, trends, and risk factors associated with human cases and the identification of outbreaks and potential new animal reservoirs. Published by Elsevier Ltd on behalf of The International Alliance for Biological Standardization. C1 Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA 30329 USA. RP Guerra, MA (reprint author), Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Atlanta, GA 30329 USA. EM hzg4@CDC.GOV FU Intramural CDC HHS [CC999999] NR 23 TC 11 Z9 14 U1 0 U2 15 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1045-1056 J9 BIOLOGICALS JI Biologicals PD SEP PY 2013 VL 41 IS 5 SI SI BP 295 EP 297 DI 10.1016/j.biologicals.2013.06.010 PG 3 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Pharmacology & Pharmacy GA 231VU UT WOS:000325447300002 PM 23850378 ER PT J AU Hayman, DTS McDonald, KD Kosoy, MY AF Hayman, David T. S. McDonald, Katherine D. Kosoy, Michael Y. TI Evolutionary history of rat-borne Bartonella: the importance of commensal rats in the dissemination of bacterial infections globally SO ECOLOGY AND EVOLUTION LA English DT Article DE Bayesian inference; emerging pathogens; invasive species; phylogeography; Rattus; reservoir host ID HOST-SPECIFICITY; WOODLAND RODENTS; SOUTHERN CHINA; SMALL MAMMALS; OLD-WORLD; PREVALENCE; STRAINS; SPP.; POPULATION; TRIBOCORUM AB Emerging pathogens that originate from invasive species have caused numerous significant epidemics. Some bacteria of genus Bartonella are rodent-borne pathogens that can cause disease in humans and animals alike. We analyzed gltA sequences of 191 strains of rat-associated bartonellae from 29 rodent species from 17 countries to test the hypotheses that this bacterial complex evolved and diversified in Southeast Asia before being disseminated by commensal rats Rattus rattus (black rat) and Rattus norvegicus (Norway rat) to other parts of the globe. The analysis suggests that there have been numerous dispersal events within Asia and introductions from Asia to other regions, with six major clades containing Southeast Asian isolates that appear to have been dispersed globally. Phylogeographic analyses support the hypotheses that these bacteria originated in Southeast Asia and commensal rodents (R. rattus and R. norvegicus) play key roles in the evolution and dissemination of this Bartonella complex throughout the world. C1 [Hayman, David T. S.; McDonald, Katherine D.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Hayman, David T. S.] Univ Florida, Dept Biol, Gainesville, FL 32611 USA. [Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Hayman, DTS (reprint author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. EM davidtshayman@gmail.com FU Cedar Tree Foundation through a David H. Smith Fellowship in Conservation Research; Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate, Department of Homeland Security, Fogarty International Center, National Institutes of Health; Global Diseases Detection Program of the CDC Center of Global Health FX Support for this study was provided by the Cedar Tree Foundation through a David H. Smith Fellowship in Conservation Research (D. T. S. H.), and the Research and Policy for Infectious Disease Dynamics program of the Science and Technology Directorate, Department of Homeland Security, Fogarty International Center, National Institutes of Health (D. T. S. H.) and the Global Diseases Detection Program of the CDC Center of Global Health (M. Y. K.). NR 44 TC 10 Z9 11 U1 3 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7758 J9 ECOL EVOL JI Ecol. Evol. PD SEP PY 2013 VL 3 IS 10 BP 3195 EP 3203 DI 10.1002/ece3.702 PG 9 WC Ecology; Evolutionary Biology SC Environmental Sciences & Ecology; Evolutionary Biology GA 224ZR UT WOS:000324932600001 PM 24223261 ER PT J AU Quiros-Alcala, L Eskenazi, B Bradman, A Ye, XY Calafat, AM Harley, K AF Quiros-Alcala, Lesliam Eskenazi, Brenda Bradman, Asa Ye, Xiaoyun Calafat, Antonia M. Harley, Kim TI Determinants of urinary bisphenol A concentrations in Mexican/Mexican-American pregnant women SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Bisphenol A; Prenatal; Pregnancy; Mexican-American ID 24-HOUR CREATININE CLEARANCE; MEXICAN DESCENT; BIRTH OUTCOMES; HUMAN EXPOSURE; UNITED-STATES; VARIABILITY; POPULATION; PHENOLS; CITY; PREDICTORS AB Prenatal exposure to bisphenol A (BPA) may be associated with adverse health effects in the developing fetus; however, little is known about predictors of BPA exposure during pregnancy. We examined BPA exposure in 491 pregnant women from the Center for the Health Assessment of Mothers and Children of Salinas (CHAMACOS) cohort and explored the role of living in the United States on significant dietary predictors of BPA exposure. Women provided urine samples up to two times during pregnancy (n = 866 total samples). We computed the intraclass correlation coefficient (ICC) to evaluate variability in concentrations between collections and used generalized estimating equation (GEE) models to assess predictors of exposure. Geometric mean (GSD) BPA concentrations were 0.9 (2.8) mu g/L and 1.0 (2.6) mu g/L at the first and second prenatal visits, respectively. We observed greater within- than between-woman variability in urinary BPA concentrations (ICC = 0.22). GEE models suggest that women who lived in the United States their entire life had 38% (CI: -0.1, 89.3) higher urinary BPA concentrations compared with other immigrant women. Additionally, women who consumed >= 3 sodas per day or hamburgers three times a week or more had 58% (CI: 18.0, 112.1) and 20% (CI: -0.2, 45.2) higher urinary BPA concentrations, respectively, compared with women who consumed no sodas or hamburgers. A higher percentage of women who lived their entire life in the United States reported increased consumption of sodas and hamburgers compared with other immigrant women. Independent of other factors, BPA urinary concentrations were slightly higher when the sample was collected later in the day. As in previous studies, high within-woman variability in urinary BPA concentrations confirms that several samples are needed to properly characterize exposure during pregnancy. Results also suggest that some factors could be modified to minimize exposures during pregnancy in our study participants (e.g., reducing soda and hamburger intake) and that factors associated with acculturation might increase BPA concentrations. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved. C1 [Quiros-Alcala, Lesliam; Eskenazi, Brenda; Bradman, Asa; Harley, Kim] Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, Berkeley, CA 94704 USA. [Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Quiros-Alcala, L (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Ctr Environm Res & Childrens Hlth, 1995 Univ Ave,Suite 265, Berkeley, CA 94704 USA. EM lquiros@berkeley.edu; eskenazi@berkeley.edu; abradman@berkeley.edu; xay5@cdc.gov; aic7@cdc.gov; kharley@berkeley.edu RI Quiros-Alcala, Lesliam /Q-4928-2016 OI Quiros-Alcala, Lesliam /0000-0002-6600-7227 FU U.S. EPA [RD 83171001]; NIEHS [RC ES018792, P01 ES009605] FX This publication was supported by grant numbers: RD 83171001 from the U.S. EPA, and RC ES018792 and P01 ES009605 from NIEHS. This work is solely the responsibility of the authors and does not necessarily represent the official views of the funders or CDC. We gratefully acknowledge the study participants; community partners, and our field and Center staff for their contributions to this work. We would also like to thank Xiaoliu Zhou, Tao Jia, and Ryan Hennings for measuring the urinary BPA concentrations. NR 65 TC 29 Z9 30 U1 1 U2 25 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 J9 ENVIRON INT JI Environ. Int. PD SEP PY 2013 VL 59 BP 152 EP 160 DI 10.1016/j.envint.2013.05.016 PG 9 WC Environmental Sciences SC Environmental Sciences & Ecology GA 224PQ UT WOS:000324901000018 PM 23816546 ER PT J AU Cupul-Uicab, LA Klebanoff, MA Brock, JW Longnecker, MP AF Cupul-Uicab, Lea A. Klebanoff, Mark A. Brock, John W. Longnecker, Matthew P. TI Prenatal Exposure to Persistent Organochlorines and Childhood Obesity in the US Collaborative Perinatal Project SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID BODY-MASS INDEX; ENDOCRINE-DISRUPTING CHEMICALS; POLYCHLORINATED-BIPHENYLS; CAUSAL-DIAGRAMS; IN-UTERO; GROWTH; OVERWEIGHT; CHILDREN; BIRTH; RISK AB Background: In some previous studies, prenatal exposure to persistent organochlorines such as 1,1,-dichloro-2,2-bis(p-chlorophenyl) ethylene (p,p' -DDE), polychlorinated biphenyls (PCBs), and hexachlorobenzene (HCB) has been associated with higher body mass index (BMI) in children. Objective: Our goal was to evaluate the association of maternal serum levels of beta-hexachlorocyclohexane (beta-HCH), p,p' -DDE, dichlorodiphenyltrichloroethane (p,p' -DDT), dieldrin, heptachlor epoxide, HCB, trans-nonachlor, oxychlordane, and PCBs with offspring obesity during childhood. Methods: The analysis was based on a subsample of 1,915 children followed until 7 years of age as part of the U.S. Collaborative Perinatal Project (CPP). The CPP enrolled pregnant women in 1959-1965; exposure levels were measured in third-trimester maternal serum that was collected before these organochlorines were banned in the United States. Childhood overweight and obesity were defined using age-and sex-specific cut points for BMI as recommended by the International Obesity Task Force. Results: Adjusted results did not show clear evidence for an association between organochlorine exposure and obesity; however, a suggestive finding emerged for dieldrin. Compared with those in the lowest quintile (dieldrin, <0.57 mu g/L), odds of obesity were 3.6 (95% CI: 1.3, 10.5) for the fourth and 2.3 (95% CI: 0.8, 7.1) for the highest quintile. Overweight and BMI were unrelated to organochlorine exposure. Conclusions: In this population with relatively high levels of exposure to organochlorines, no clear associations with obesity or BMI emerged. C1 [Cupul-Uicab, Lea A.; Longnecker, Matthew P.] Natl Inst Environm Hlth Sci, NIH, Dept Hlth & Human Serv, Epidemiol Branch, Res Triangle Pk, NC USA. [Cupul-Uicab, Lea A.] Natl Inst Publ Hlth, Ctr Populat Hlth Res, Cuernavaca 62100, Morelos, Mexico. [Klebanoff, Mark A.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Klebanoff, Mark A.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA. [Brock, John W.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Cupul-Uicab, LA (reprint author), Natl Inst Publ Hlth, Ctr Populat Hlth Res, Ave Univ 655, Cuernavaca 62100, Morelos, Mexico. EM lea.cupul@insp.mx RI CUPUL UICAB, LEA/C-8699-2014; OI CUPUL UICAB, LEA/0000-0001-6190-4474; Longnecker, Matthew/0000-0001-6073-5322 FU National Institute of Environmental Health Sciences; National Institutes of Health FX This research was supported by the Intramural Research Program of the National Institute of Environmental Health Sciences, National Institutes of Health. NR 41 TC 19 Z9 19 U1 1 U2 12 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD SEP PY 2013 VL 121 IS 9 BP 1103 EP 1109 DI 10.1289/ehp.1205901 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 227XS UT WOS:000325149600027 PM 23799652 ER PT J AU Salmon, DA Vellozzi, C Chen, RT Halsey, NA AF Salmon, Daniel A. Vellozzi, Claudia Chen, Robert T. Halsey, Neal A. TI Did the influenza A (H1N1) 2009 monovalent inactivated vaccines increase the risk for Guillain-Barre syndrome? SO EXPERT REVIEW OF CLINICAL IMMUNOLOGY LA English DT Editorial Material DE Guillain-Barre syndrome; immunization safety; influenza; influenza vaccine; vaccine safety ID ANTIGANGLIOSIDE ANTIBODIES; UNITED-STATES; IMMUNIZATION; VACCINATION C1 [Salmon, Daniel A.; Halsey, Neal A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Vellozzi, Claudia] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual & Promot, Atlanta, GA 30333 USA. [Chen, Robert T.] Ctr Dis Control & Prevent, Clin Trials Team, Epidemiol Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Salmon, DA (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. EM dsalmon@jhsph.edu NR 20 TC 0 Z9 0 U1 0 U2 2 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1744-666X J9 EXPERT REV CLIN IMMU JI Expert Rev. Clin. Immunol. PD SEP PY 2013 VL 9 IS 9 BP 795 EP 797 DI 10.1586/1744666X.2013.824686 PG 3 WC Immunology SC Immunology GA 224MB UT WOS:000324889200002 PM 24070041 ER PT J AU Braden, CR Tauxe, RV AF Braden, Christopher R. Tauxe, Robert V. TI Emerging Trends in Foodborne Diseases SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Foodborne infections; Outbreak investigations; Laboratory diagnosis; Molecular subtyping; Trends; Imports; Burden of illness; Food poisoning ID UNITED-STATES; CHAGAS-DISEASE; FOOD SAFETY; INFECTIONS; ILLNESS; PATHOGENS; OUTBREAKS; RESISTANCE; TAIWAN; SURVEILLANCE AB New foodborne pathogens continue to emerge, and the globalization of the food supply means that the safety of our food depends on policies and practices in many countries. Public health surveillance of foodborne bacterial pathogens depends on culture, isolation, and subtyping. New diagnostic strategies that bypass culture threaten public health surveillance in the short-term but offer the potential for more refined and rapid outbreak detection in the future. Infectious disease clinicians play a critical role in diagnosis and reporting because they may be the first to suspect a new problem and often link clinical and public health communities. C1 [Braden, Christopher R.; Tauxe, Robert V.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Braden, CR (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Mailstop C-09,1600 Clifton Rd Northeast, Atlanta, GA 30333 USA. EM crb5@cdc.gov NR 60 TC 10 Z9 10 U1 1 U2 56 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD SEP PY 2013 VL 27 IS 3 BP 517 EP + DI 10.1016/j.idc.2013.06.001 PG 18 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 228MN UT WOS:000325191000003 PM 24011828 ER PT J AU Medina-Marino, A Reynolds, D Finley, C Hays, S Jones, J Soyemi, K AF Medina-Marino, Andrew Reynolds, Debra Finley, Carol Hays, Susan Jones, Jane Soyemi, Kenneth TI Communication and Mass Vaccination Strategies After Pertussis Outbreak in Rural Amish Communities-Illinois, 2009-2010 SO JOURNAL OF RURAL HEALTH LA English DT Article DE Amish community; epidemiology; health promotion; mass vaccination; Pertussis outbreak ID INFANT PERTUSSIS; WHOOPING-COUGH; IMMUNIZATION; DISEASE; RISK; RECOMMENDATIONS; POPULATION; EXEMPTIONS; RUBELLA; MEASLES AB PurposeDuring January 2010, 2 infants from an Amish community in east-central Illinois were hospitalized with pertussis. The local health department (LDH) intervened to control disease transmission, identify contributing factors, and determine best communications methods to improve vaccination coverage. MethodsA retrospective cohort study was conducted using public health surveillance data to determine the extent of the outbreak; the standard Centers for Disease Control and Prevention and Council of State and Territorial Epidemiologists case definition for pertussis was used. The standardized Illinois Department of Public Health pertussis patient interview form was used to collect demographic, symptom, vaccination history, and treatment history information. To control disease transmission, LDH staff worked with the Amish community to promote a vaccination campaign during February 6-April 30, 2010. FindingsForty-seven cases were identified, with onsets during December 2009-March 2010. Median age was 7 (interquartile range 1-12) years. Nineteen (40%) patients were male; 39 (83%) were aged <18 years; 37 (79%) had not received any pertussis-containing vaccine. Presenting symptoms did not differ substantially between vaccinated and unvaccinated patients. Duration of cough was longer among unvaccinated than vaccinated patients (32 vs 15.5 days, P = .002). Compared with vaccinated patients, proportionately more unvaccinated patients reported secondary household transmission (30% vs 72%; P = .012). Through enhanced vaccination campaigns, 251 (approximate to 10%) Amish community members were administered 254 pertussis-containing vaccines. ConclusionsTargeted health communication and outreach resulted in a successful vaccine campaign and long-running monthly vaccination clinic. Amish do not universally reject vaccines, and their practices regarding vaccination are not static. C1 [Medina-Marino, Andrew; Reynolds, Debra; Finley, Carol; Soyemi, Kenneth] Illinois Dept Publ Hlth, Chicago, IL 60303 USA. [Medina-Marino, Andrew] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA. [Hays, Susan; Jones, Jane] Douglas Cty Hlth Dept, Tuscola, IL USA. RP Medina-Marino, A (reprint author), Illinois Dept Publ Hlth, 122 South Michigan Ave 7th Floor, Chicago, IL 60303 USA. EM andrewmedinamarino@gmail.com; Kenneth.soyemi@illinois.gov NR 29 TC 3 Z9 3 U1 4 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0890-765X J9 J RURAL HEALTH JI J. Rural Health PD SEP PY 2013 VL 29 IS 4 BP 413 EP 419 DI 10.1111/jrh.12019 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 229MX UT WOS:000325271500009 PM 24088215 ER PT J AU Daelmans, B Ferguson, E Lutter, CK Singh, N Pachon, H Creed-Kanashiro, H Woldt, M Mangasaryan, N Cheung, E Mir, R Pareja, R Briend, A AF Daelmans, Bernadette Ferguson, Elaine Lutter, Chessa K. Singh, Neha Pachon, Helena Creed-Kanashiro, Hilary Woldt, Monica Mangasaryan, Nune Cheung, Edith Mir, Roger Pareja, Rossina Briend, Andre TI Designing appropriate complementary feeding recommendations: tools for programmatic action SO MATERNAL AND CHILD NUTRITION LA English DT Article DE infant and young child feeding; complementary feeding; ProPAN; Optifood; infant and young child nutrition ID CHILDREN; FOOD; GROWTH AB Suboptimal complementary feeding practices contribute to a rapid increase in the prevalence of stunting in young children from age 6 months. The design of effective programmes to improve infant and young child feeding requires a sound understanding of the local situation and a systematic process for prioritizing interventions, integrating them into existing delivery platforms and monitoring their implementation and impact. The identification of adequate food-based feeding recommendations that respect locally available foods and address gaps in nutrient availability is particularly challenging. We describe two tools that are now available to strengthen infant and young child-feeding programming at national and subnational levels. ProPAN is a set of research tools that guide users through a step-by-step process for identifying problems related to young child nutrition; defining the context in which these problems occur; formulating, testing, and selecting behaviour-change recommendations and nutritional recipes; developing the interventions to promote them; and designing a monitoring and evaluation system to measure progress towards intervention goals. Optifood is a computer-based platform based on linear programming analysis to develop nutrient-adequate feeding recommendations at lowest cost, based on locally available foods with the addition of fortified products or supplements when needed, or best recommendations when the latter are not available. The tools complement each other and a case study from Peru illustrates how they have been used. The readiness of both instruments will enable partners to invest in capacity development for their use in countries and strengthen programmes to address infant and young child feeding and prevent malnutrition. C1 [Daelmans, Bernadette] WHO, Dept Maternal Newborn Child & Adolescent Hlth, CH-1211 Geneva 27, Switzerland. [Ferguson, Elaine; Singh, Neha] London Sch Hyg & Trop Med, Dept Populat Hlth, London WC1, England. [Lutter, Chessa K.] Pan Amer Hlth Org, Dept Family Gender & Life Course, Washington, DC USA. [Pachon, Helena] Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Creed-Kanashiro, Hilary; Pareja, Rossina] Inst Invest Nutr, Lima, Peru. [Woldt, Monica] FHI 360, Food & Nutr Tech Assistance Project FANTA 3, Washington, DC USA. [Mangasaryan, Nune; Cheung, Edith] United Nations Childrens Fund, Nutr Sect, New York, NY USA. [Mir, Roger] Ctr Dis Control & Prevent, Div Epidemiol & Analyt Methods Populat Hlth, Atlanta, GA USA. [Briend, Andre] Univ Tampere, Dept Int Hlth, Sch Med, FIN-33101 Tampere, Finland. RP Daelmans, B (reprint author), WHO, Dept Maternal Newborn Child & Adolescent Hlth, CH-1211 Geneva 27, Switzerland. EM daelmansb@who.int OI Singh, Neha/0000-0003-0057-121X FU US Agency for International Development (USAID) through the Food and Nutrition Technical Assistance III Project (FANTA) [AID-OAA-A-12-00005]; UBS Optimus Foundation; WHO Headquarters; WHO Regional Office for the Western Pacific; Global Alliance for Improved Nutrition (GAIN) FX Funding for the development of Optifood was provided through the US Agency for International Development (USAID) under terms of Cooperative Agreement No. AID-OAA-A-12-00005, through the Food and Nutrition Technical Assistance III Project (FANTA), managed by FHI 360, with additional funding from the UBS Optimus Foundation, WHO Headquarters and the WHO Regional Office for the Western Pacific.; Funding for ProPAN was provided in part by the Global Alliance for Improved Nutrition (GAIN). Helena Pachon's time was supported by an appointment to the Research Participation Program at the US Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 43 TC 18 Z9 18 U1 5 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1740-8695 J9 MATERN CHILD NUTR JI Matern. Child Nutr. PD SEP PY 2013 VL 9 SU 2 SI SI BP 116 EP 130 DI 10.1111/mcn.12083 PG 15 WC Nutrition & Dietetics; Pediatrics SC Nutrition & Dietetics; Pediatrics GA 226EK UT WOS:000325017100009 PM 24074322 ER PT J AU Dawson, AL Cassell, CH Riehle-Colarusso, T Grosse, SD Tanner, JP Kirby, RS Watkins, SM Correia, JA Olney, RS AF Dawson, April L. Cassell, Cynthia H. Riehle-Colarusso, Tiffany Grosse, Scott D. Tanner, Jean Paul Kirby, Russell S. Watkins, Sharon M. Correia, Jane A. Olney, Richard S. TI Factors Associated With Late Detection of Critical Congenital Heart Disease in Newborns SO PEDIATRICS LA English DT Article DE congenital heart disease; neonatal screening ID PULSE OXIMETRY; BIRTH-DEFECTS; UNITED-STATES; FEASIBILITY; STRATEGIES; MORTALITY; PROGRAMS; GEORGIA AB OBJECTIVES: Critical congenital heart disease (CCHD) was recently added to the US Recommended Uniform Screening Panel for newborns. This study assessed whether maternal/household and infant characteristics were associated with late CCHD detection. METHODS: This was a statewide, population-based, retrospective, observational study of infants with CCHD born between 1998 and 2007 identified by using the Florida Birth Defects Registry. We examined 12 CCHD conditions that are primary and secondary targets of newborn CCHD screening using pulse oximetry. We used Poisson regression models to analyze associations between selected characteristics (eg, CCHD type, birth hospital nursery level [highest level available in the hospital]) and late CCHD detection (defined as diagnosis after the birth hospitalization). RESULTS: Of 3603 infants with CCHD and linked hospitalizations, CCHD was not detected during the birth hospitalization for 22.9% (n = 825) of infants. The likelihood of late detection varied by CCHD condition. Infants born in a birth hospital with a level I nursery only (adjusted prevalence ratio: 1.9 [95% confidence interval: 1.6-2.2]) or level II nursery (adjusted prevalence ratio: 1.5 [95% confidence interval: 1.3-1.7]) were significantly more likely to have late-detected CCHD compared with infants born in a birth hospital with a level III (highest) nursery. CONCLUSIONS: After controlling for the selected characteristics, hospital nursery level seems to have an independent association with late CCHD detection. Thus, perhaps universal newborn screening for CCHD could be particularly beneficial in level I and II nurseries and may reduce differences in the frequency of late diagnosis between birth hospital facilities. C1 [Dawson, April L.; Cassell, Cynthia H.; Riehle-Colarusso, Tiffany; Grosse, Scott D.; Olney, Richard S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Dawson, April L.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Tanner, Jean Paul; Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Birth Defects Surveillance Program, Tampa, FL USA. [Watkins, Sharon M.; Correia, Jane A.] Florida Birth Defects Registry Bur Epidemiol, Dept Hlth, Div Dis Control & Hlth Protect, Tallahassee, FL USA. RP Dawson, AL (reprint author), CDC, NCBDDD, 1600 Clifton Rd,MS-E86, Atlanta, GA 30333 USA. EM isp3@cdc.gov FU March of Dimes Foundation [5-FY09-533] FX A research grant (5-FY09-533) from the March of Dimes Foundation supported various aspects of this project, including database development. This study was also supported by appointments to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the Centers for Disease Control and Prevention. Neither funder was involved in decisions regarding design, analysis, or interpretation of study results. NR 30 TC 16 Z9 16 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD SEP PY 2013 VL 132 IS 3 BP E604 EP E611 DI 10.1542/peds.2013-1002 PG 8 WC Pediatrics SC Pediatrics GA 226ZX UT WOS:000325077800005 PM 23940249 ER PT J AU Peterson, C Grosse, SD Oster, ME Olney, RS Cassell, CH AF Peterson, Cora Grosse, Scott D. Oster, Matthew E. Olney, Richard S. Cassell, Cynthia H. TI Cost-Effectiveness of Routine Screening for Critical Congenital Heart Disease in US Newborns SO PEDIATRICS LA English DT Article DE congenital heart defects; neonatal screening; costs and cost analysis ID PULSE OXIMETRY; DEFECTS; FEASIBILITY; STRATEGIES AB OBJECTIVES: Clinical evidence indicates newborn critical congenital heart disease (CCHD) screening through pulse oximetry is lifesaving. In 2011, CCHD was added to the US Recommended Uniform Screening Panel for newborns. Several states have implemented or are considering screening mandates. This study aimed to estimate the cost-effectiveness of routine screening among US newborns unsuspected of having CCHD. METHODS: We developed a cohort model with a time horizon of infancy to estimate the inpatient medical costs and health benefits of CCHD screening. Model inputs were derived from new estimates of hospital screening costs and inpatient care for infants with late-detected CCHD, defined as no diagnosis at the birth hospital. We estimated the number of newborns with CCHD detected at birth hospitals and life-years saved with routine screening compared with no screening. RESULTS: Screening was estimated to incur an additional cost of $6.28 per newborn, with incremental costs of $20 862 per newborn with CCHD detected at birth hospitals and $40 385 per life-year gained (2011 US dollars). We estimated 1189 more newborns with CCHD would be identified at birth hospitals and 20 infant deaths averted annually with screening. Another 1975 false-positive results not associated with CCHD were estimated to occur, although these results had a minimal impact on total estimated costs. CONCLUSIONS: This study provides the first US cost-effectiveness analysis of CCHD screening in the United States could be reasonably cost-effective. We anticipate data from states that have recently approved or initiated CCHD screening will become available over the next few years to refine these projections. C1 [Peterson, Cora; Grosse, Scott D.; Oster, Matthew E.; Olney, Richard S.; Cassell, Cynthia H.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Oster, Matthew E.] Emory Univ, Sibley Heart Ctr Childrens Healthcare Atlanta, Atlanta, GA 30322 USA. RP Peterson, C (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30333 USA. EM cora.peterson@cdc.hhs.gov OI Peterson, Cora/0000-0001-7955-0977 FU Intramural CDC HHS [CC999999] NR 24 TC 29 Z9 30 U1 0 U2 11 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD SEP PY 2013 VL 132 IS 3 BP E595 EP E603 DI 10.1542/peds.2013-0332 PG 9 WC Pediatrics SC Pediatrics GA 226ZX UT WOS:000325077800004 PM 23918890 ER PT J AU Allison, MA Dunne, EF Markowitz, LE O'Leary, ST Crane, LA Hurley, LP Stokley, S Babbel, CI Brtnikova, M Beaty, BL Kempe, A AF Allison, Mandy A. Dunne, Eileen F. Markowitz, Lauri E. O'Leary, Sean T. Crane, Lori A. Hurley, Laura P. Stokley, Shannon Babbel, Christine I. Brtnikova, Michaela Beaty, Brenda L. Kempe, Allison TI HPV Vaccination of Boys in Primary Care Practices SO ACADEMIC PEDIATRICS LA English DT Article DE BPV vaccine; immunization; physician attitudes ID HUMAN-PAPILLOMAVIRUS VACCINATION; ADOLESCENT IMMUNIZATIONS; PEDIATRICIANS INTENTION; DECISION-MAKING; VISIT PATTERNS; UNITED-STATES; MEN; ATTITUDES; PHYSICIANS; VACCINES AB OBJECTIVE: In October 2011, the Advisory Committee on Immunization Practices (ACIP) recommended the quadrivalent human papillomavirus vaccine (HPV4) for the routine immunization schedule for 11- to 12-year-old boys. Before October 2011, HPV4 was permissively recommended for boys. We conducted a study in 2010 to provide data that could guide efforts to implement routine HPV4 immunization in boys. Our objectives were to describe primary care physicians': 1) knowledge and attitudes about human papillomavirus (BPV)-related disease and HPV4, 2) recommendation and administration practices regarding HPV vaccine in boys compared to girls, 3) perceived bathers to HPV4 administration in boys, and 4) personal and practice characteristics associated with recommending HPV4 to boys. METHODS: We conducted a mail and Internet survey in a nationally representative sample of pediatricians and family medicine physicians from July 2010 to September 2010. RESULTS: The response rate was 72% (609 of 842). Most physicians thought that the routine use of HPV4 in boys was justified. Although it was permissively recommended, 33% recommended HPV4 to 11- to 12-year-old boys and recommended it more strongly to older male adolescents. The most common bathers to HPV4 administration were related to vaccine financing. Physicians who reported recommending HPV4 for 11- to 12-year-old boys were more likely to be from urban locations, perceive that HPV4 is efficacious, perceive that HPV-related disease is severe, and routinely discuss sexual health with 11- to 12-year-olds. CONCLUSIONS; Although most physicians support HPV4 for boys, physician education and evidence-based tools are needed to improve implementation of a vaccination program for males in primary care settings. C1 [Allison, Mandy A.; O'Leary, Sean T.; Crane, Lori A.; Hurley, Laura P.; Babbel, Christine I.; Brtnikova, Michaela; Beaty, Brenda L.; Kempe, Allison] Childrens Hosp Colorado, Childrens Outcomes Res Program, Aurora, CO USA. [Allison, Mandy A.; O'Leary, Sean T.; Kempe, Allison] Univ Colorado, Dept Pediat, Aurora, CO USA. [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO USA. [Beaty, Brenda L.; Kempe, Allison] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO USA. [Dunne, Eileen F.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO USA. RP Allison, MA (reprint author), Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM mandy.allison@ucdenver.edu FU Centers for Disease Control and Prevention PEP through the Association of American Medical Colleges, Washington, DC. [MM-1040-08/08] FX We thank Lynn Olson, PhD, and Karen O'Connor from the Department of Research, AAP, Herbert Young, MD, and Bellinda Schoof, MHA, at the AAFP, and the leaders of the AAP and AAFP for collaborating in the establishment of the sentinel networks in pediatrics and FM. We also thank all pediatricians and FM physicians in the networks for participating and responding to this survey. Supported in part by a grant from the Centers for Disease Control and Prevention PEP (MM-1040-08/08) through the Association of American Medical Colleges, Washington, DC. Presented in part at the Advisory Committee on Immunization Practices meeting, October 27,2010; Pediatric Academic Societies Annual Meeting, April 30,2011; and at the National Immunization Conference, Washington, DC, March 30,2011. NR 51 TC 17 Z9 17 U1 4 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD SEP-OCT PY 2013 VL 13 IS 5 BP 466 EP 474 PG 9 WC Pediatrics SC Pediatrics GA 223WQ UT WOS:000324843600011 PM 24011749 ER PT J AU Cogswell, ME Elliott, P Wang, CY Rhodes, DG Pfeiffer, CM Loria, CM AF Cogswell, Mary E. Elliott, Paul Wang, Chia-Yih Rhodes, Donna G. Pfeiffer, Christine M. Loria, Catherine M. TI Assessing US Sodium Intake through Dietary Data and Urine Biomarkers SO ADVANCES IN NUTRITION LA English DT Editorial Material ID POTASSIUM EXCRETION; SPECIMEN; ADULTS AB Sodium intake is related to blood pressure, an established risk factor for heart disease and stroke. Reducing intake may save billions in United States health care dollars annually. Efforts targeting sodium reductions make accurate monitoring vital, yet limited information exists on the accuracy of the current data to assess sodium intake in the United States population. In this symposium, new findings were presented on the accuracy of estimating population 24-h urinary excretion of sodium from spot urine specimens or sodium intake from 24-h dietary recalls. Differences in accuracy by sex, BMI, and race were apparent as well as by timing of spot urine collections. Although some published equations appear promising for estimating group means, others are biased. Individual estimates of sodium intake were highly variable and adjustment for within-individual variation in intake is required for estimating population prevalence or percentiles. Estimates indicated United States sodium intake remains high. C1 [Cogswell, Mary E.; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Elliott, Paul] Univ London Imperial Coll Sci Technol & Med, London, England. [Wang, Chia-Yih] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Rhodes, Donna G.] USDA, Beltsville, MD 20705 USA. [Loria, Catherine M.] NIH, Bethesda, MD 20892 USA. RP Cogswell, ME (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM mcogswell@cdc.gov FU ASN; U.S. Department of Health and Human Services; USDA; CDC [200-2010-43842]; National Institute for Health Research (NIHR) Biomedical Research Centre at Imperial College Healthcare National Health Service (NHS) Trust and Imperial College FX This article is a summary of the symposium "Assessing U.S. Sodium Intake Through Dietary Data and Urine Biomarkers" held April 24, 2013 at the ASN Scientific Sessions and Annual Meeting at Experimental Biology 2013 in Boson, MA. The symposium was sponsored by the ASN and endorsed by ASN the Medical Nutrition Council.; Supported by the U.S. Department of Health and Human Services and USDA. Dr. Elliot's work supported by CDC contract no. 200-2010-43842. Dr. Elliott also acknowledges support from the National Institute for Health Research (NIHR) Biomedical Research Centre at Imperial College Healthcare National Health Service (NHS) Trust and Imperial College. He is an NIHR Senior Investigator. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC nor those of the NHS, the NIHR or the Department of Health, UK. NR 5 TC 5 Z9 6 U1 0 U2 7 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 2161-8313 EI 2156-5376 J9 ADV NUTR JI Adv. Nutr. PD SEP PY 2013 VL 4 IS 5 BP 560 EP 562 DI 10.3945/an.113.004309 PG 3 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 217KH UT WOS:000324357900017 PM 24038257 ER PT J AU Reidy, DE Kearns, MC DeGue, S AF Reidy, Dennis E. Kearns, Megan C. DeGue, Sarah TI Reducing psychopathic violence: A review of the treatment literature SO AGGRESSION AND VIOLENT BEHAVIOR LA English DT Review DE Psychopathy; Violence; Aggression; Recidivism; Treatment ID SEX OFFENDER TREATMENT; COGNITIVE NEUROSCIENCE PERSPECTIVE; MENTALLY DISORDERED OFFENDERS; ADOLESCENT OFFENDERS; NONPSYCHOPATHIC OFFENDERS; PROACTIVE AGGRESSION; REACTIVE AGGRESSION; TREATMENT RESPONSE; TREATMENT BEHAVIOR; GENDER-DIFFERENCES AB Psychopathy reflects a pathological form of personality that predisposes individuals to risk for perpetration of chronic and severe violence across their lifespan. The violence attributable to psychopathic persons constitutes a substantial portion of the societal burden to the public health and criminal justice systems and thus necessitates significant attention by prevention experts. However, there is a relatively nascent literature that has examined psychopathic persons' response to treatment, especially considering violence as an outcome. Nevertheless, there have been repeated averments about the amenability (or lack thereof) of psychopathy to treatment. In the present paper, we attempt to provide a comprehensive review of studies assessing the relation of psychopathy to violence outcomes following intervention. Our review of studies suggests there is reason to suspect that specific and tailored interventions which take into consideration psychopathic persons' unique patterns of behavioral conditioning and predispositions may have the potential to reduce violence. However, equally important, certain interventions may potentially exacerbate these persons' violent behavior. The nature of the outcomes is likely highly dependent on the specific components of the intervention itself. We conclude that future research should increase methodological rigor by striving to include treatment control groups and increasing the transparency of the implemented interventions. Published by Elsevier Ltd. C1 [Reidy, Dennis E.; Kearns, Megan C.; DeGue, Sarah] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. EM dreidy@cdc.gov NR 119 TC 5 Z9 5 U1 12 U2 69 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-1789 J9 AGGRESS VIOLENT BEH JI Aggress. Violent Behav. PD SEP-OCT PY 2013 VL 18 IS 5 SI SI BP 527 EP 538 DI 10.1016/j.avb.2013.07.008 PG 12 WC Criminology & Penology; Psychology, Multidisciplinary SC Criminology & Penology; Psychology GA 218SK UT WOS:000324452600010 ER PT J AU Tsai, V Hall, R Conover, C Black, S Herwaldt, B AF Tsai, Victoria Hall, Rebecca Conover, Craig Black, Stephanie Herwaldt, Barbara TI International Notification of Cases of Cyclosporiasis (Call us, maybe?) SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID CAYETANENSIS C1 [Tsai, Victoria; Conover, Craig] Illinois Dept Publ Hlth, Chicago, IL 60603 USA. [Hall, Rebecca; Herwaldt, Barbara] Ctr Dis Control & Prevent, Atlanta, GA USA. [Black, Stephanie] Chicago Dept Publ Hlth, Chicago, IL USA. RP Tsai, V (reprint author), Illinois Dept Publ Hlth, 122 South Michigan Ave,7th Floor, Chicago, IL 60603 USA. EM Victoria.Tsai@Illinois.gov NR 4 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD SEP PY 2013 VL 108 IS 9 BP 1536 EP 1536 DI 10.1038/ajg.2013.136 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 222CV UT WOS:000324708500023 PM 24005356 ER PT J AU Modarai, F Mack, K Hicks, P Benoit, S Park, S Jones, C Proescholdbell, S Ising, A Paulozzi, L AF Modarai, F. Mack, K. Hicks, P. Benoit, S. Park, S. Jones, C. Proescholdbell, S. Ising, A. Paulozzi, L. TI Relationship of opioid prescription sales and overdoses, North Carolina SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Drug; Overdoses; Opiates; Prescription drugs; Opiods; North Carolina ID CHRONIC NONCANCER PAIN; EMERGENCY-DEPARTMENT VISITS; UNITED-STATES; MEDICAL USE; MONITORING PROGRAMS; DRUG OVERDOSE; ABUSE; ANALGESICS; ASSOCIATION; DEATHS AB Background: In the United States, fatal drug overdoses have tripled since 1991. This escalation in deaths is believed to be driven primarily by prescription opioid medications. This investigation compared trends and patterns in sales of opioids, opioid drug overdoses treated in emergency departments (EDs), and unintentional overdose deaths in North Carolina (NC). Methods: Our ecological study compared rates of opioid sales, opioid related ED overdoses, and unintentional drug overdose deaths in NC. Annual sales data, provided by the Drug Enforcement Administration, for select opioids were converted into morphine equivalents and aggregated by zip code. These opioid drug sales rates were trended from 1997 to 2010. In addition, opioid sales were correlated and compared to opioid related ED visits, which came from a Centers for Disease Control and Prevention syndromic surveillance system, and unintentional overdose deaths, which came from NC Vital Statistics, from 2008 to 2010. Finally, spatial cluster analysis was performed and rates were mapped by zip code in 2010. Results: Opioid sales increased substantially from 1997 to 2010. From 2008 to 2010, the quarterly rates of opioid drug overdoses treated in EDs and opioid sales correlated (r = 0.68, p = 0.02). Specific regions of the state, particularly in the southern and western corners, had both high rates of prescription opioid sales and overdoses. Conclusions: Temporal trends in sales of prescription opioids correlate with trends in opioid related ED visits. The spatial correlation of opioid sales with ED visit rates shows that opioid sales data may be a timely way to identify high-risk communities in the absence of timely ED data. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Modarai, F.; Mack, K.; Jones, C.; Paulozzi, L.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. [Hicks, P.; Benoit, S.; Park, S.] Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. [Proescholdbell, S.] North Carolina Div Publ Hlth, Chron Dis & Injury Sect, Injury & Violence Prevent Branch, Raleigh, NC 27609 USA. [Ising, A.] Univ N Carolina, Dept Emergency Med, Carolina Ctr Hlth Informat, Chapel Hill, NC 27599 USA. [Park, S.] McKing Consulting Corp, Fairfax, VA 22031 USA. RP Modarai, F (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Hwy,Mailstop F-62, Atlanta, GA 30341 USA. EM vqy8@cdc.gov RI Mack, Karin/A-3263-2012 OI Mack, Karin/0000-0001-9274-3001 FU External Medical Affairs, Pfizer, Inc. FX The authors disclose that Mr. Modarai's CDC Experience Applied Epidemiology Fellowship at the Centers for Disease Control and Prevention was funded by a grant to the CDC Foundation by External Medical Affairs, Pfizer, Inc. NR 39 TC 26 Z9 26 U1 6 U2 25 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD SEP 1 PY 2013 VL 132 IS 1-2 BP 81 EP 86 DI 10.1016/j.drugalcdep.2013.01.006 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 216KE UT WOS:000324281400011 PM 23399467 ER PT J AU Jones, CM AF Jones, Christopher M. TI Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010 SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Heroin; Prescription opioid use; Prescription opioids; NSDUM; National Survey on Drug Use and Health ID HEPATITIS-C VIRUS; METHADONE-MAINTENANCE TREATMENT; PATIENTS SEEKING TREATMENT; YOUNG-ADULTS; DRUG-USERS; ABUSE; DEPENDENCE; MISUSE; INFECTIONS; PREVALENCE AB Background: Heroin use and overdose deaths have increased in recent years. Emerging information suggests this is the result of increases in nonmedical use of opioid pain relievers and nonmedical users transitioning to heroin use. Understanding this relationship is critically important for the development of public health interventions. Methods: Combined data from the 2002-2004 National Surveys on Drug Use and Health were compared to the 2008-2010 surveys to examine patterns of heroin use and risk behaviors among past year nonmedical users of opioid pain relievers. Results: Between 2002-2004 and 2008-2010, past year heroin use increased among people reporting past year nonmedical use (PYNMU) of opioid pain relievers (p < 0.01), but not among those reporting no PYNMU. Frequent nonmedical users - people reporting 100-365 days of PYNMU - had the highest rate of past year heroin use and were at increased risk for ever injecting heroin (aOR 43, 95% CI 2.5-7.3) and past year heroin abuse or dependence (aOR 7.8, 95% CI 4.7-12.8) compared to infrequent nonmedical users (1-29 days of PYNMU). In 2008-2010, 82.6% of frequent nonmedical users who used heroin in the past year reported nonmedical use of opioid pain relievers prior to heroin initiation compared to 64.1% in 2002-2004. Conclusions: Heroin use among nonmedical users of opioid pain relievers increased between 2002-2004 and 2008-2010, with most reporting nonmedical use of opioid pain relievers before initiating heroin. Interventions to prevent nonmedical use of these drugs are needed and should focus on high-risk groups such as frequent nonmedical users of opioids. Published by Elsevier Ireland Ltd. C1 Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. RP Jones, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA. EM cjones@cdc.gov FU CDC FX All work for this manuscript was funded by the CDC. NR 36 TC 90 Z9 90 U1 5 U2 21 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD SEP 1 PY 2013 VL 132 IS 1-2 BP 95 EP 100 DI 10.1016/j.drugalcdep.2013.01.007 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 216KE UT WOS:000324281400013 PM 23410617 ER PT J AU Dietz, WH AF Dietz, William H. TI New Strategies To Improve Food Marketing To Children SO HEALTH AFFAIRS LA English DT Article ID UNITED-STATES; OBESITY; ADOLESCENTS; WEIGHT; HEALTH; YOUTH AB Federal efforts to address the impact of food marketing on children began more than thirty years ago, when the Federal Trade Commission sought comment on strategies to reduce young children's exposure to food advertising. The food, advertising, and television industries mounted a virulent response, and Congress withdrew the commission's authority to regulate unfair advertising to children. The same industries and Congress responded equally aggressively to the proposed nutrition criteria for food products marketed to children drafted by a working group of federal agencies in 2011. Although federal efforts over the past thirty years have led to modest improvements in food quality and marketing practices, commercial interests have consistently overridden the health concerns of children. Mobilization of parents as a political force to improve standards for food marketed to children, use of social media for counteradvertising, and the development of new technologies to decrease exposure to food advertisements could reduce the impact of food marketing to children. C1 [Dietz, William H.] Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA. EM dietzwcd4@gmail.com FU Institute of Medicine; Robert Wood Johnson Foundation FX William Dietz is a consultant to the Institute of Medicine and a senior adviser to the Robert Wood Johnson Foundation. Neither of these organizations provided financial support for this article, but both organizations have undertaken studies related to food marketing to children. NR 38 TC 13 Z9 13 U1 2 U2 33 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD SEP PY 2013 VL 32 IS 9 BP 1652 EP 1658 DI 10.1377/hlthaff.2012.1294 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 221TG UT WOS:000324681500020 PM 24019372 ER PT J AU Feikin, DR Kagucia, EW Loo, JD Link-Gelles, R Puhan, MA Cherian, T Levine, OS Whitney, CG O'Brien, KL Moore, MR AF Feikin, Daniel R. Kagucia, Eunice W. Loo, Jennifer D. Link-Gelles, Ruth Puhan, Milo A. Cherian, Thomas Levine, Orin S. Whitney, Cynthia G. O'Brien, Katherine L. Moore, Matthew R. CA Serotype Replacement Study Grp TI Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites SO PLOS MEDICINE LA English DT Article ID ACUTE OTITIS-MEDIA; STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; TEMPORAL TRENDS; CHILDREN; POPULATION; ERA; EPIDEMIOLOGY; INFECTIONS; IMMUNIZATION AB Background: Vaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined substantially following introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into national immunization programs. Increases in non-vaccineserotype (NVT) IPD rates occurred in some sites, presumably representing serotype replacement. We used a standardized approach to describe serotype-specific IPD changes among multiple sites after PCV7 introduction. Methods and Findings: Of 32 IPD surveillance datasets received, we identified 21 eligible databases with rate data >= 2 years before and >= 1 year after PCV7 introduction. Expected annual rates of IPD absent PCV7 introduction were estimated by extrapolation using either Poisson regression modeling of pre-PCV7 rates or averaging pre-PCV7 rates. To estimate whether changes in rates had occurred following PCV7 introduction, we calculated site specific rate ratios by dividing observed by expected IPD rates for each post-PCV7 year. We calculated summary rate ratios (RRs) using random effects meta-analysis. For children,5 years old, overall IPD decreased by year 1 post-PCV7 (RR 0.55, 95% CI 0.46-0.65) and remained relatively stable through year 7 (RR 0.49, 95% CI 0.35-0.68). Point estimates for VT IPD decreased annually through year 7 (RR 0? 03, 95% CI 0.01-0.10), while NVT IPD increased (year 7 RR 2.81, 95% CI 2.12-3.71). Among adults, decreases in overall IPD also occurred but were smaller and more variable by site than among children. At year 7 after introduction, significant reductions were observed (18-49 year-olds [RR 0.52, 95% CI 0.29-0.91], 50-64 year-olds [RR 0.84, 95% CI 0.77-0.93], and >= 65 year-olds [RR 0.74, 95% CI 0.58-0.95]). Conclusions: Consistent and significant decreases in both overall and VT IPD in children occurred quickly and were sustained for 7 years after PCV7 introduction, supporting use of PCVs. Increases in NVT IPD occurred in most sites, with variable magnitude. These findings may not represent the experience in low-income countries or the effects after introduction of higher valency PCVs. High-quality, population-based surveillance of serotype-specific IPD rates is needed to monitor vaccine impact as more countries, including low-income countries, introduce PCVs and as higher valency PCVs are used. C1 [Feikin, Daniel R.; Kagucia, Eunice W.; Puhan, Milo A.; Levine, Orin S.; O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot & Infect Dis, Atlanta, GA USA. [Loo, Jennifer D.; Link-Gelles, Ruth; Whitney, Cynthia G.; Moore, Matthew R.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Cherian, Thomas] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. RP Feikin, DR (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. EM dfeikin@jhsph.edu RI van der Linden, Mark/B-9305-2009; Garcia-Garcia, Juan Jose/J-5295-2014; Mintegi, Santiago/G-8252-2011; Munoz-Almagro, Carmen/N-7248-2015; Krizova, Pavla/M-6120-2015; Gomez, Borja/G-8669-2011; Park, Daniel/R-5604-2016; Sa-Leao, Raquel/A-9341-2011; Benito, Javier/G-9198-2011; Munoz-Almagro, Carmen/B-4308-2015; Pediatric Emergency, Cruces Univ Hospital/A-9127-2012 OI Lambertsen, Lotte/0000-0001-6409-6337; Camou, Teresa/0000-0002-9304-5683; Moulton, Lawrence/0000-0001-7041-7387; Byington, Carrie/0000-0002-7350-9495; Hilty, Markus/0000-0002-2418-6474; Sanyal, Abanti/0000-0003-0674-3617; Lipsitch, Marc/0000-0003-1504-9213; van der Linden, Mark/0000-0002-6574-4313; Garcia-Garcia, Juan Jose/0000-0002-3483-528X; Mintegi, Santiago/0000-0002-2342-8881; Munoz-Almagro, Carmen/0000-0001-5586-404X; Park, Daniel/0000-0001-5139-5397; Sa-Leao, Raquel/0000-0001-9804-827X; Munoz-Almagro, Carmen/0000-0001-5586-404X; FU Bill & Melinda Gates Foundation [OPP1020720] FX The study was supported by grant ID# OPP1020720 from the Bill & Melinda Gates Foundation (http://www.gatesfoundation.org/Pages/home.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 59 TC 110 Z9 111 U1 3 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD SEP PY 2013 VL 10 IS 9 AR e1001517 DI 10.1371/journal.pmed.1001517 PG 28 WC Medicine, General & Internal SC General & Internal Medicine GA 224EA UT WOS:000324863700012 PM 24086113 ER PT J AU Freeman, MC Ogden, S Jacobson, J Abbott, D Addiss, DG Amnie, AG Beckwith, C Cairncross, S Callejas, R Colford, JM Emerson, PM Fenwick, A Fishman, R Gallo, K Grimes, J Karapetyan, G Keene, B Lammie, PJ MacArthur, C Lochery, P Petach, H Platt, J Prabasi, S Rosenboom, JW Roy, S Saywell, D Schechtman, L Tantri, A Velleman, Y Utzinger, J AF Freeman, Matthew C. Ogden, Stephanie Jacobson, Julie Abbott, Daniel Addiss, David G. Amnie, Asrat G. Beckwith, Colin Cairncross, Sandy Callejas, Rafael Colford, Jack M., Jr. Emerson, Paul M. Fenwick, Alan Fishman, Rebecca Gallo, Kerry Grimes, Jack Karapetyan, Gagik Keene, Brooks Lammie, Patrick J. MacArthur, Chad Lochery, Peter Petach, Helen Platt, Jennifer Prabasi, Sarina Rosenboom, Jan Willem Roy, Sharon Saywell, Darren Schechtman, Lisa Tantri, Anupama Velleman, Yael Utzinger, Juerg TI Integration of Water, Sanitation, and Hygiene for the Prevention and Control of Neglected Tropical Diseases: A Rationale for Inter-Sectoral Collaboration SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID HELMINTH INFECTIONS; NYANZA PROVINCE; SAFE STRATEGY; GUINEA WORM; PROGRAM; HEALTH; SCHISTOSOMIASIS; DRACUNCULIASIS; TRACHOMA; AFRICA AB Improvements of water, sanitation, and hygiene (WASH) infrastructure and appropriate health-seeking behavior are necessary for achieving sustained control, elimination, or eradication of many neglected tropical diseases (NTDs). Indeed, the global strategies to fight NTDs include provision of WASH, but few programs have specific WASH targets and approaches. Collaboration between disease control programs and stakeholders in WASH is a critical next step. A group of stakeholders from the NTD control, child health, and WASH sectors convened in late 2012 to discuss opportunities for, and barriers to, collaboration. The group agreed on a common vision, namely "Disease-free communities that have adequate and equitable access to water and sanitation, and that practice good hygiene." Four key areas of collaboration were identified, including (i) advocacy, policy, and communication; (ii) capacity building and training; (iii) mapping, data collection, and monitoring; and (iv) research. We discuss strategic opportunities and ways forward for enhanced collaboration between the WASH and the NTD sectors. C1 [Freeman, Matthew C.; Ogden, Stephanie] Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA. [Ogden, Stephanie; Addiss, David G.; Gallo, Kerry] Taskforce Global Hlth, Children Worms, Atlanta, GA USA. [Ogden, Stephanie; Beckwith, Colin] Taskforce Global Hlth, Int Trachoma Initiat, Atlanta, GA USA. [Jacobson, Julie; Rosenboom, Jan Willem] Bill & Melinda Gates Fdn, Seattle, WA USA. [Abbott, Daniel] Save Children, Washington, DC USA. [Amnie, Asrat G.] Emory Univ, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Cairncross, Sandy] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England. [Callejas, Rafael] Millennium Water Alliance, Washington, DC USA. [Colford, Jack M., Jr.] Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA. [Emerson, Paul M.] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Fenwick, Alan; Grimes, Jack] Univ London Imperial Coll Sci Technol & Med, Schistosomiasis Control Initiat, London, England. [Fishman, Rebecca; Platt, Jennifer] WASH Advocates, Washington, DC USA. [Grimes, Jack] Univ London Imperial Coll Sci Technol & Med, Dept Civil & Environm Engn, London, England. [Karapetyan, Gagik] World Vis, Washington, DC USA. [Keene, Brooks; Lochery, Peter] CARE Int, Atlanta, GA USA. [Lammie, Patrick J.] Taskforce Global Hlth, Atlanta, GA USA. [Lammie, Patrick J.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [MacArthur, Chad] Helen Keller Int, New York, NY USA. [Petach, Helen] US Agcy Int Dev, Washington, DC 20523 USA. [Prabasi, Sarina] ORBIS Int, New York, NY USA. [Roy, Sharon] US Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA USA. [Saywell, Darren] Plan Int, Washington, DC USA. [Schechtman, Lisa] WaterAid Amer, Washington, DC USA. [Tantri, Anupama] Sabin Vaccine Inst, Washington, DC USA. [Velleman, Yael] WaterAid UK, London, England. [Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Utzinger, Juerg] Univ Basel, Basel, Switzerland. RP Freeman, MC (reprint author), Emory Univ, Dept Environm Hlth, Atlanta, GA 30322 USA. EM mcfreem@emory.edu OI Grimes, Jack/0000-0002-9001-446X FU Bill & Melinda Gates Foundation FX The meeting that led to the current policy platform was funded by the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 36 TC 47 Z9 47 U1 2 U2 29 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2013 VL 7 IS 9 AR e2439 DI 10.1371/journal.pntd.0002439 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 224WA UT WOS:000324920800044 PM 24086781 ER PT J AU Grisales, N Poupardin, R Gomez, S Fonseca-Gonzalez, I Ranson, H Lenhart, A AF Grisales, Nelson Poupardin, Rodolphe Gomez, Santiago Fonseca-Gonzalez, Idalyd Ranson, Hilary Lenhart, Audrey TI Temephos Resistance in Aedes aegypti in Colombia Compromises Dengue Vector Control SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID AMINO-ACID SUBSTITUTION; CONFERS INSECTICIDE RESISTANCE; ORGANOPHOSPHATE RESISTANCE; DIPTERA-CULICIDAE; SMALL PORTIONS; MOSQUITO; ACETYLCHOLINESTERASE; GENE; CARBOXYLESTERASES; MECHANISMS AB Background: Control and prevention of dengue relies heavily on the application of insecticides to control dengue vector mosquitoes. In Colombia, application of the larvicide temephos to the aquatic breeding sites of Aedes aegypti is a key part of the dengue control strategy. Resistance to temephos was recently detected in the dengue-endemic city of Cucuta, leading to questions about its efficacy as a control tool. Here, we characterize the underlying mechanisms and estimate the operational impact of this resistance. Methodology/Principal Findings: Larval bioassays of Ae. aegypti larvae from Cucuta determined the temephos LC50 to be 0.066 ppm (95% CI 0.06-0.074), approximately 15x higher than the value obtained from a susceptible laboratory colony. The efficacy of the field dose of temephos at killing this resistant Cucuta population was greatly reduced, with mortality rates <80% two weeks after application and <50% after 4 weeks. Neither biochemical assays nor partial sequencing of the ace-1 gene implicated target site resistance as the primary resistance mechanism. Synergism assays and microarray analysis suggested that metabolic mechanisms were most likely responsible for the temephos resistance. Interestingly, although the greatest synergism was observed with the carboxylesterase inhibitor, DEF, the primary candidate genes from the microarray analysis, and confirmed by quantitative PCR, were cytochrome P450 oxidases, notably CYP6N12, CYP6F3 and CYP6M11. Conclusions/Significance: In Colombia, resistance to temephos in Ae. aegypti compromises the duration of its effect as a vector control tool. Several candidate genes potentially responsible for metabolic resistance to temephos were identified. Given the limited number of insecticides that are approved for vector control, future chemical-based control strategies should take into account the mechanisms underlying the resistance to discern which insecticides would likely lead to the greatest control efficacy while minimizing further selection of resistant phenotypes. C1 [Grisales, Nelson; Poupardin, Rodolphe; Ranson, Hilary; Lenhart, Audrey] Univ Liverpool, Liverpool Sch Trop Med, Dept Vector Biol, Liverpool L3 5QA, Merseyside, England. [Grisales, Nelson] Univ Antioquia, Grp Biol & Control Enfermedades Infecciosas, Medellin, Colombia. [Gomez, Santiago; Fonseca-Gonzalez, Idalyd] Univ Antioquia, Inst Biol, Medellin, Colombia. [Lenhart, Audrey] Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Grisales, N (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Dept Vector Biol, Liverpool L3 5QA, Merseyside, England. EM ajl8@cdc.gov RI Poupardin, Rodolphe/K-3138-2014; OI Poupardin, Rodolphe/0000-0001-5195-5155; Ranson, Hilary/0000-0003-2332-8247 FU Wellcome Trust [090679/Z/09/Z] FX This work was funded by The Wellcome Trust as part of a Master's Training Fellowship in Public Health and Tropical Medicine for NG, grant number 090679/Z/09/Z. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 21 Z9 23 U1 4 U2 20 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2013 VL 7 IS 9 AR e2438 DI 10.1371/journal.pntd.0002438 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 224WA UT WOS:000324920800043 PM 24069492 ER PT J AU Torresi, J Tapia-Conyer, R Margolis, H AF Torresi, Joseph Tapia-Conyer, Roberto Margolis, Harold TI Preparing for Dengue Vaccine Introduction: Recommendations from the 1st Dengue v2V International Meeting SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID VIRUS-INFECTION; BLOOD-SAMPLES; ASIA-PACIFIC; AMERICA; SURVEILLANCE; COUNTRIES C1 [Torresi, Joseph] Austin Hlth, Heidelberg, Vic, Australia. [Torresi, Joseph] Univ Melbourne, Melbourne, Vic 3010, Australia. [Tapia-Conyer, Roberto] Carlos Slim Hlth Inst, Mexico City, DF, Mexico. [Margolis, Harold] Ctr Dis Control & Prevent, San Juan, PR USA. RP Torresi, J (reprint author), Austin Hlth, Heidelberg, Vic, Australia. EM josepht@unimelb.edu.au OI Torresi, Joseph/0000-0002-8212-0887 FU Sanofi Pasteur FX Dengue v2V is supported by an unrestricted educational grant from Sanofi Pasteur. The findings reported here are those of the meeting attendees who also made the decision to publish. Sanofi Pasteur participated in the critical review of the manuscript. NR 21 TC 10 Z9 10 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2013 VL 7 IS 9 AR e2261 DI 10.1371/journal.pntd.0002261 PG 5 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 224WA UT WOS:000324920800004 PM 24086776 ER PT J AU Wang, L Xiao, LH Duan, LP Ye, JB Guo, YQ Guo, MJ Liu, LL Feng, YY AF Wang, Lin Xiao, Lihua Duan, Liping Ye, Jianbin Guo, Yaqiong Guo, Meijin Liu, Lili Feng, Yaoyu TI Concurrent Infections of Giardia duodenalis, Enterocytozoon bieneusi, and Clostridium difficile in Children during a Cryptosporidiosis Outbreak in a Pediatric Hospital in China SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID TOXIN-B; DISEASE; GASTROENTERITIS; IDENTIFICATION; TRANSMISSION; SEQUENCE; HUMANS; SPP. AB Background: Over 200 cryptosporidiosis outbreaks have been reported, but little is known if other enteric pathogens were also involved in some of these outbreaks. Recently, an outbreak of cryptosporidiosis linked to poor hygiene by two Cryptosporidium hominis subtypes occurred in a pediatric hospital ward (Ward A) in China, lasting for more than 14 months. In this study, the concurrence during the outbreak of three other enteric pathogens with a similar transmission route, Giardia duodenalis, Enterocytozoon bieneusi, and Clostridium difficile, was assessed. Methods/Principal Findings: The occurrence of G. duodenalis, E. bieneusi, and C. difficile in 78 inpatients from Ward A and 283 and 216 inpatients from two control wards (Wards C and D) in the same hospital was examined using molecular diagnostic tools. Significantly higher infection rates were found in children in Ward A for all study pathogens than in Wards C and D (P<0.01): 9.5% versus 1.4% and 0% for G. duodenalis, 10.8% versus 2.8% and 3.7% for E. bieneusi, and 60.8% versus 37.8% and 27.8% for C. difficile, respectively. These differences were mostly seen in children <= 12 months. Enteric pathogen-positive children in Ward A (31/58 or 53.4%) were more likely to have mixed infections than those in Ward C (4/119 or 3.4%) or D (5/68, 7.4%; P<0.01). Having cryptosporidiosis was a risk factor for G. duodenalis (OR = 4.3; P = 0.08), E. bieneusi (OR = 3.1; P = 0.04), and C. difficile (OR = 4.7; P<0.01) infection. In addition, a lower diversity of G. duodenalis, E. bieneusi, and C. difficile genotypes/subtypes was observed in Ward A. Conclusions/Significance: Data from this study suggest that multiple pathogens were concurrently present during the previous cryptosporidiosis outbreak. Examination of multiple enteric pathogens should be conducted when poor hygiene is the likely cause of outbreaks of diarrhea. C1 [Wang, Lin; Ye, Jianbin; Guo, Yaqiong; Guo, Meijin; Liu, Lili; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Xiao, Lihua; Duan, Liping; Ye, Jianbin; Guo, Yaqiong] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Wang, L (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014; Yaqiong, Guo/N-4927-2015 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31110103901, 31229005, 41001316]; National Basic Research Program of China (973 Project) [2011CB200903]; Fundamental Research Funds for the Central Universities, China FX This work was supported by the National Natural Science Foundation of China (No. 31110103901, 31229005, 41001316); the National Basic Research Program of China (973 Project No. 2011CB200903); and Fundamental Research Funds for the Central Universities, China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 35 TC 54 Z9 56 U1 0 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2013 VL 7 IS 9 AR e2437 DI 10.1371/journal.pntd.0002437 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 224WA UT WOS:000324920800042 PM 24069491 ER PT J AU Zapata, JC Carrion, R Patterson, JL Crasta, O Zhang, Y Mani, S Jett, M Poonia, B Djavani, M White, DM Lukashevich, IS Salvato, MS AF Zapata, Juan Carlos Carrion, Ricardo, Jr. Patterson, Jean L. Crasta, Oswald Zhang, Yan Mani, Sachin Jett, Marti Poonia, Bhawna Djavani, Mahmoud White, David M. Lukashevich, Igor S. Salvato, Maria S. TI Transcriptome Analysis of Human Peripheral Blood Mononuclear Cells Exposed to Lassa Virus and to the Attenuated Mopeia/Lassa Reassortant 29 (ML29), a Vaccine Candidate SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID HEPARIN-BINDING EGF; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; ARENAVIRUS HEMORRHAGIC FEVERS; HUMAN DENDRITIC CELLS; NF-KAPPA-B; GENE-EXPRESSION; GROWTH-FACTOR; RHESUS MACAQUES; CHEMOTACTIC PROTEIN-2; HUMAN CYTOMEGALOVIRUS AB Lassa virus (LASV) is the causative agent of Lassa Fever and is responsible for several hundred thousand infections and thousands of deaths annually in West Africa. LASV and the non-pathogenic Mopeia virus (MOPV) are both rodent-borne African arenaviruses. A live attenuated reassortant of MOPV and LASV, designated ML29, protects rodents and primates from LASV challenge and appears to be more attenuated than MOPV. To gain better insight into LASV-induced pathology and mechanism of attenuation we performed gene expression profiling in human peripheral blood mononuclear cells (PBMC) exposed to LASV and the vaccine candidate ML29. PBMC from healthy human subjects were exposed to either LASV or ML29. Although most PBMC are non-permissive for virus replication, they remain susceptible to signal transduction by virus particles. Total RNA was extracted and global gene expression was evaluated during the first 24 hours using high-density microarrays. Results were validated using RT-PCR, flow cytometry and ELISA. LASV and ML29 elicited differential expression of interferon-stimulated genes (ISG), as well as genes involved in apoptosis, NF-kB signaling and the coagulation pathways. These genes could eventually serve as biomarkers to predict disease outcomes. The remarkable differential expression of thrombomodulin, a key regulator of inflammation and coagulation, suggests its involvement with vascular abnormalities and mortality in Lassa fever disease. C1 [Zapata, Juan Carlos; Poonia, Bhawna; Djavani, Mahmoud; Lukashevich, Igor S.; Salvato, Maria S.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. [Carrion, Ricardo, Jr.; Patterson, Jean L.] Texas Biomed Res Inst, San Antonio, TX USA. [Crasta, Oswald; Zhang, Yan] Virginia Tech, Virginia Bioinformat Inst, Blacksburg, VA USA. [Mani, Sachin; Jett, Marti] Walter Reed Army Inst Res, Silver Spring, MD USA. [White, David M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Zapata, JC (reprint author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. EM jczapata@ihv.umaryland.edu FU National Institutes of Health; Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases Research, MARCE [U54 AI057168]; WRCE [U54 AI057156]; NIH [AI053620, AI053619]; US-CDC FX This work was supported by funding from the National Institutes of Health and by the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases Research, MARCE (U54 AI057168, subcontracts to MSS and to ISL) and WRCE (U54 AI057156, subcontract to JLP and RC). Funding for microarray studies was from NIH grants AI053620 and AI053619 (to MSS). DC infections with LASV and ELISA conducted at the USCDC BSL-4 facilities by DMW were supported by the US-CDC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 99 TC 9 Z9 9 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD SEP PY 2013 VL 7 IS 9 AR e2406 DI 10.1371/journal.pntd.0002406 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 224WA UT WOS:000324920800015 PM 24069471 ER PT J AU Ozbay, F Heyde, TAD Reissman, D Sharma, V AF Ozbay, Fatih Heyde, Tanja Auf Der Reissman, Dori Sharma, Vansh TI The Enduring Mental Health Impact of the September 11th Terrorist Attacks Challenges and Lessons Learned SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE World Trade Center; Disaster response; Crisis counseling; Barriers to care; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; BORDERLINE PERSONALITY-DISORDER; NEW-YORK-CITY; TRADE-CENTER RESCUE; RECOVERY WORKERS; PROJECT-LIBERTY; REGISTRY ENROLLEES; CENTER DISASTER; RISK-FACTORS; CARE AB The authors review the existing literature on the mental health impact of the September 11th attacks and the implications for disaster mental health clinicians and policy makers. The authors discuss the demographic characteristics of those affected and the state of mental health needs and existing mental health delivery services; the nature of the disaster and primary impacts on lives, infrastructure, and socioeconomic factors; the acute aftermath in the days and weeks after the attacks; the persistent mental health impact and evolution of services of the postacute aftermath; and the implications for future disaster mental health practitioners and policy makers. C1 [Ozbay, Fatih] Icahn Sch Med Mt Sinai, WTC Mental Hlth Program, New York, NY USA. [Ozbay, Fatih; Heyde, Tanja Auf Der; Sharma, Vansh] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. [Ozbay, Fatih] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA. [Reissman, Dori] Natl Inst Occupat Hlth & Safety, WTC Hlth Program, Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ozbay, F (reprint author), Icahn Sch Med Mt Sinai, WTC Mental Hlth Program, New York, NY USA. EM fatih.ozbay@mssm.edu NR 53 TC 4 Z9 5 U1 5 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD SEP PY 2013 VL 36 IS 3 BP 417 EP + DI 10.1016/j.psc.2013.05.011 PG 15 WC Psychiatry SC Psychiatry GA 223XW UT WOS:000324846800009 PM 23954056 ER PT J AU Ridderhof, JC Wilcke, BW AF Ridderhof, John C. Wilcke, Burton W., Jr. TI PUBLIC HEALTH LABORATORY SYSTEMS: AT THE CROSSROADS SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID FUTURE C1 [Ridderhof, John C.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Lab Sci Policy & Practice Program Off, Atlanta, GA 30333 USA. [Wilcke, Burton W., Jr.] Univ Vermont, Coll Nursing & Hlth Sci, Dept Med Lab & Radiat Sci, Burlington, VT USA. RP Ridderhof, JC (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Lab Sci Policy & Practice Program Off, 1600 Clifton Rd NE,MS E94, Atlanta, GA 30333 USA. EM jridderhof@cdc.gov NR 31 TC 0 Z9 0 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2013 VL 128 SU 2 BP 1 EP 6 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 218PE UT WOS:000324443800001 PM 23997296 ER PT J AU Caggana, M Jones, EA Shahied, SI Tanksley, S Hermerath, CA Lubin, IM AF Caggana, Michele Jones, Elizabeth A. Shahied, S. I. Tanksley, Susan Hermerath, Cheryl A. Lubin, Ira M. TI Newborn Screening: From Guthrie to Whole Genome Sequencing SO PUBLIC HEALTH REPORTS LA English DT Editorial Material ID TANDEM MASS-SPECTROMETRY; PUBLIC-HEALTH; UNITED-STATES; PROGRAM; PHENYLKETONURIA; RECOMMENDATIONS; TECHNOLOGY; SPECIMENS; RETENTION C1 [Caggana, Michele] New York State Dept Hlth, Albany, NY USA. [Jones, Elizabeth A.] Assoc Publ Hlth Labs, Silver Spring, MD 20910 USA. [Shahied, S. I.] Penn Dept Hlth, Exton, PA USA. [Tanksley, Susan] Texas Dept State Hlth Serv, Austin, TX USA. [Hermerath, Cheryl A.] Oregon State Publ Hlth Lab, Hillsboro, OR USA. [Lubin, Ira M.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA USA. RP Jones, EA (reprint author), Assoc Publ Hlth Labs, 8515 Georgia Ave,Ste 700, Silver Spring, MD 20910 USA. EM elizabeth.jones@aphl.org FU NCHM CDC HHS [U60 HM000803, #U60HM000803] NR 34 TC 8 Z9 9 U1 0 U2 5 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2013 VL 128 SU 2 BP 14 EP 19 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 218PE UT WOS:000324443800004 PM 23997299 ER PT J AU Ridderhof, JC Moulton, AD Ned, RM Nicholson, JKA Chu, MC Becker, SJ Blank, EC Breckenridge, KJ Waddell, V Brokopp, C AF Ridderhof, John C. Moulton, Anthony D. Ned, Renee M. Nicholson, Janet K. A. Chu, May C. Becker, Scott J. Blank, Eric C. Breckenridge, Karen J. Waddell, Victor Brokopp, Charles TI The Laboratory Efficiencies Initiative: Partnership for Building a Sustainable National Public Health Laboratory System SO PUBLIC HEALTH REPORTS LA English DT Article ID SERVICES AB Beginning in early 2011, the Centers for Disease Control and Prevention and the Association of Public Health Laboratories launched the Laboratory Efficiencies Initiative (LEI) to help public health laboratories (PHLs) and the nation's entire PHL system achieve and maintain sustainability to continue to conduct vital services in the face of unprecedented financial and other pressures. The LEI focuses on stimulating substantial gains in laboratories' operating efficiency and cost efficiency through the adoption of proven and promising management practices. In its first year, the LEI generated a strategic plan and a number of resources that PHL directors can use toward achieving LEI goals. Additionally, the first year saw the formation of a dynamic community of practitioners committed to implementing the LEI strategic plan in coordination with state and local public health executives, program officials, foundations, and other key partners. C1 [Ridderhof, John C.; Moulton, Anthony D.; Ned, Renee M.; Chu, May C.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Lab Sci Policy & Practice Program Off, Atlanta, GA 30333 USA. [Nicholson, Janet K. A.] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA 30333 USA. [Becker, Scott J.; Blank, Eric C.; Breckenridge, Karen J.] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Waddell, Victor] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Brokopp, Charles] Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA. RP Ridderhof, JC (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Lab Sci Policy & Practice Program Off, 1600 Clifton Rd NE,MS E94, Atlanta, GA 30333 USA. EM jridderhof@cdc.gov FU CDC [U60HM000803] FX This article was supported by Cooperative Agreement #U60HM000803 from CDC and/or the Assistant Secretary for Preparedness and Response. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of APHL, CDC, and/or the Assistant Secretary for Preparedness and Response. The Laboratory Efficiencies Initiative project was 100% funded from federal funds, with a budget of $721,559. NR 29 TC 3 Z9 3 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2013 VL 128 SU 2 BP 20 EP 33 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 218PE UT WOS:000324443800005 PM 23997300 ER PT J AU Berkery, MR Penn, MS AF Berkery, Molly R. Penn, Matthew S. TI Legal Considerations in Cross-Jurisdictional Sharing of Public Health Laboratory Services SO PUBLIC HEALTH REPORTS LA English DT Article AB The Centers for Disease Control and Prevention and the Association of Public Health Laboratories initiated the Laboratory Efficiencies Initiative in 2011 to help address issues related to public health laboratory (PHL) capacity to perform critically needed tests and services. One approach to improving capacity and efficiency is sharing PHL services with other states or jurisdictions. Cross-jurisdictional sharing implicates numerous federal and state laws, including federal and state privacy laws, laboratory certifications, packaging and shipping requirements for laboratory specimens, and state laws regarding fees and revenue. While federal laws generally do not present insurmountable barriers to sharing PHL services, state laws vary greatly, even within the same region of the country. This article summarizes some of the potentially relevant federal and state legal issues related to cross-jurisdictional sharing. It is important that states interested in cross-jurisdictional sharing consider all relevant laws, potential conflicts of law, as well as inconsistencies with agreements already in place among health departments and laboratories. C1 [Berkery, Molly R.; Penn, Matthew S.] Ctr Dis Control & Prevent, Off State Tribal Local & Territorial Support, Publ Hlth Law Program, Atlanta, GA 30341 USA. RP Berkery, MR (reprint author), Ctr Dis Control & Prevent, Off State Tribal Local & Territorial Support, Publ Hlth Law Program, 4770 Buford Hwy NE,MS E-70, Atlanta, GA 30341 USA. EM mberkery@cdc.gov NR 4 TC 4 Z9 4 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2013 VL 128 SU 2 BP 70 EP 74 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 218PE UT WOS:000324443800011 PM 23997306 ER PT J AU Baur, C Brach, C AF Baur, Cynthia Brach, Cindy TI Pharmacy research on health literacy can contribute to national goals and health care system improvements SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Editorial Material C1 [Baur, Cynthia] Ctr Dis Control & Prevent, Off Associate Director Commun, US Dept HHS, Atlanta, GA 30333 USA. RP Baur, C (reprint author), Ctr Dis Control & Prevent, Off Associate Director Commun, US Dept HHS, 1600 Clifton Rd MS E21, Atlanta, GA 30333 USA. EM Cynthia.baur@cdc.hhs.gov FU Intramural AHRQ HHS [HS999999] NR 19 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD SEP-OCT PY 2013 VL 9 IS 5 BP 498 EP 502 DI 10.1016/j.sapharm.2013.06.012 PG 5 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 222RZ UT WOS:000324750100002 PM 23953981 ER PT J AU Menon, M Graves, L McCombs, K Hise, K Silk, B Kuehnert, M Lynch, M AF Menon, Manoj Graves, Lewis McCombs, Katherine Hise, Kelly Silk, Benjamin Kuehnert, Matthew Lynch, Michael TI Listeria monocytogenes in donated platelets: a potential transfusion-transmitted pathogen intercepted through screening SO TRANSFUSION LA English DT Article ID BACTERIAL-CONTAMINATION; SALMONELLA SEPTICEMIA; BLOOD-TRANSFUSION; RESIDUAL RISK; UNITED-STATES; INTERVENTIONS; PREVALENCE; EXPERIENCE; COMPONENTS; INFECTION AB Background: Bacterial contamination of blood components is a potentially life-threatening complication of transfusions. In October 2005, the Centers for Disease Control and Prevention (CDC) noted four Listeria monocytogenes (Lm) isolates cultured from four different units of donated apheresis platelets (PLTs) among Lm isolates sent to the CDC National Listeria Reference Laboratory for subtyping as part of routine surveillance activities. Study Design and Methods: We describe an investigation to determine possible common sources of infection among donors or factors associated with PLT collection or storage and to determine whether human transfusion-associated listeriosis cases had been reported. We also reviewed all isolates with PLTs as a source sent to the CDC National ListeriaReference Laboratory between November 1, 2005, and December 31, 2011. Results: Each PLT donor-associated isolate had a distinct pulsed-field gel electrophoresis pattern combination. Other than these four cases, no other cases of Lm-contaminated PLTs were identified by the American Red Cross or by CDC during 2005. However, two additional cases of Lm isolated from donated PLTs were detected, one in 2008 and one in 2011. Conclusion: Although the source of contamination for these PLT units is unclear, and a source common to all units was not identified, this investigation underscores the value of screening for bacterial contaminants of PLTs. C1 Ctr Dis Control & Prevent, Atlanta, GA USA. Florida Dept Hlth, Jacksonville, FL USA. RP Menon, M (reprint author), 1600 Clifton Rd,Mail Stop C-09, Atlanta, GA 30333 USA. EM manoj@u.washington.edu NR 22 TC 1 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD SEP PY 2013 VL 53 IS 9 BP 1974 EP 1978 DI 10.1111/trf.12097 PG 5 WC Hematology SC Hematology GA 213KG UT WOS:000324055200016 PM 23362824 ER PT J AU Meyers, AR Pinkerton, LE Hein, MJ AF Meyers, Alysha R. Pinkerton, Lynne E. Hein, Misty J. TI Cohort mortality study of garment industry workers exposed to formaldehyde: Update and internal comparisons SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE formaldehyde; cohort studies; occupational exposure; retrospective studies; leukemia ID TABLE ANALYSIS SYSTEM; OCCUPATIONAL-EXPOSURE; LEUKEMIA MORTALITY; IONIZING-RADIATION; FOLLOW-UP; RISK; CANCER; METAANALYSIS; ASSOCIATION; EMBALMERS AB Background To further evaluate the association between formaldehyde and leukemia, we extended follow-up through 2008 for a cohort mortality study of 11,043 US formaldehyde-exposed garment workers. Methods We computed standardized mortality ratios and standardized rate ratios stratified by year of first exposure, exposure duration, and time since first exposure. Associations between exposure duration and rates of leukemia and myeloid leukemia were further examined using Poisson regression models. Results Compared to the US population, myeloid leukemia mortality was elevated but overall leukemia mortality was not. In internal analyses, overall leukemia mortality increased with increasing exposure duration and this trend was statistically significant. Conclusions We continue to see limited evidence of an association between formaldehyde and leukemia. However, the extended follow-up did not strengthen previously observed associations. In addition to continued epidemiologic research, we recommend further research to evaluate the biological plausibility of a causal relation between formaldehyde and leukemia. Am. J. Ind. Med. 56:1027-1039, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Meyers, Alysha R.; Pinkerton, Lynne E.; Hein, Misty J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, Cincinnati, OH 45226 USA. [Meyers, Alysha R.] Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. RP Meyers, AR (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Industrywide Studies Branch, 4676 Columbia Pkwy,R-15, Cincinnati, OH 45226 USA. EM armeyers@cdc.gov OI Meyers, Alysha/0000-0002-6402-0145 NR 45 TC 8 Z9 8 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD SEP PY 2013 VL 56 IS 9 BP 1027 EP 1039 DI 10.1002/ajim.22199 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 200XX UT WOS:000323106000005 PM 23788124 ER PT J AU Stansbury, RC Beeckman-Wagner, LAF Wang, ML Hogg, JP Petsonk, EL AF Stansbury, Robert C. Beeckman-Wagner, Lu-Ann F. Wang, Mei-Lin Hogg, Jeffery P. Petsonk, Edward L. TI Rapid decline in lung function in coal miners: Evidence of disease in small airways SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE small airway disease; pneumoconiosis; spirometry; obstructive lung disease; coal mining; bronchial hyperreactivity ID DUST EXPOSURE; UNITED-STATES; EMPHYSEMA; WORKERS; PNEUMOCONIOSIS; MECHANICS; SMOKING; FEV1 AB Background Coal mine dust exposure can cause both pneumoconiosis and chronic airflow limitation. The contributions of various pathophysiologic mechanisms to dust-related lung function decrements remain unclear. Methods Clinical and physiological findings were assessed for 15 underground coal miners who had demonstrated accelerated FEV1 losses (decliners) over 6-18 years. Decliners' findings were evaluated in comparison to a group of 11 miners who had shown relatively stable lung function (referents) during the same period. Results At follow-up examination, the decliners showed significantly greater mean airway resistance (10.47 vs. 6.78cmH(2)O/L/s; P=0.05) and more air trapping (RV/TLC=37.5 vs. 29.1%; P<0.01) compared to the referents. Decliners also demonstrated more evidence of small airways dysfunction and tended to have more bronchospasm than the referent group. Total lung capacity, lung compliance, diffusing capacity, and chest radiography did not differ significantly between the two groups. After cessation of mine dust exposures, the decliners' mean rate of FEV1 loss normalized. Conclusion In a series of working coal miners, accelerated lung function declines were associated with air trapping and evidence of small airways dysfunction. A preventive benefit from controlling dust exposures was suggested. Am. J. Ind. Med. 56:1107-1112, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Stansbury, Robert C.; Petsonk, Edward L.] W Virginia Univ, Sch Med, Sect Pulm & Crit Care Med, Morgantown, WV 26505 USA. [Beeckman-Wagner, Lu-Ann F.; Wang, Mei-Lin] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, US Dept HHS, Morgantown, WV USA. [Hogg, Jeffery P.] W Virginia Univ, Sch Med, Dept Radiol, Morgantown, WV 26505 USA. RP Stansbury, RC (reprint author), W Virginia Univ, Sch Med, Sect Pulm & Crit Care Med, 4075A Hlth Sci Ctr North, Morgantown, WV 26505 USA. EM rstansbury@hsc.wvu.edu FU National Institute for Occupational Safety and Health FX Contract grant sponsor: National Institute for Occupational Safety and Health. NR 26 TC 7 Z9 7 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD SEP PY 2013 VL 56 IS 9 BP 1107 EP 1112 DI 10.1002/ajim.22211 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 200XX UT WOS:000323106000012 PM 23737372 ER PT J AU Parker, SE Yazdy, MM Tinker, SC Mitchell, AA Werler, MM AF Parker, Samantha E. Yazdy, Mahsa M. Tinker, Sarah C. Mitchell, Allen A. Werler, Martha M. TI The impact of folic acid intake on the association among diabetes mellitus, obesity, and spina bifida SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE folic acid; obesity; preexisting diabetes mellitus; pregnancy; spina bifida ID NEURAL-TUBE DEFECTS; BIRTH-DEFECTS; PREPREGNANCY OBESITY; MATERNAL OBESITY; UNITED-STATES; RISK; PREVENTION; PREGNANCY; WOMEN; OUTCOMES AB OBJECTIVE: The purpose of this study was to investigate the relationship between spina bifida and 2 established risk factors (pregestational diabetes mellitus and obesity) in both the presence and absence of the recommended daily folic acid intake in the periconceptional period. STUDY DESIGN: Cases of spina bifida (n = 1154) and control subjects (n = 9439) from the Slone Epidemiology Center Birth Defects Study (1976-2011) were included. Information on preexisting diabetes mellitus (collected 1976-2011) and obesity (collected 1993-2011), defined as a body mass index of >= 30 kg/m(2), was collected through interviews that were conducted within 6 months of delivery. Periconceptional folic acid intake was calculated with both dietary and supplement information. Mothers were classified as consuming more or less than 400 mu g/day of folic acid; food folate was included at a 30% discount for its lower bioavailability. Logistic regression models that were adjusted for maternal age, race, education, and study site were used to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for the joint effects of low folic acid intake coupled with diabetes mellitus or obesity. RESULTS: Case mothers were more likely to have diabetes mellitus or be obese (0.7% and 19.0%, respectively) than control mothers (0.4% and 10.8%, respectively). The joint effect of diabetes mellitus and lower folic acid intake on spina bifida was larger (aOR, 3.95; 95% CI, 1.56-10.00) than that of diabetes mellitus and higher folic acid intake (aOR, 1.31; 95% CI, 0.17-10.30). Folic acid intake made little difference on the association between obesity and spina bifida. CONCLUSION: Our findings suggest that folic acid further attenuates, although does not eliminate, the risk of spina bifida that is associated with diabetes mellitus than the risk with obesity. C1 [Parker, Samantha E.; Yazdy, Mahsa M.; Mitchell, Allen A.; Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Tinker, Sarah C.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Parker, SE (reprint author), Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA. EM separker@bu.edu OI Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814; Yazdy, Mahsa/0000-0002-7415-5350; /0000-0002-7193-077X FU Centers for Disease Control and Prevention [DD000697]; [NIH T32 HD052458] FX Supported in part by the Centers for Disease Control and Prevention (DD000697) and a predoctoral trainee grant number NIH T32 HD052458 to the Reproductive, Perinatal, and Pediatric Epidemiology training program, Boston University (S.E.P.). NR 37 TC 6 Z9 7 U1 1 U2 28 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD SEP PY 2013 VL 209 IS 3 AR 239.e1 DI 10.1016/j.ajog.2013.05.047 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 207OH UT WOS:000323610600024 PM 23711668 ER PT J AU Dowling, EC Chawla, N Forsythe, LP de Moor, J McNeel, T Rozjabek, HM Ekwueme, DU Yabroff, KR AF Dowling, Emily C. Chawla, Neetu Forsythe, Laura P. de Moor, Janet McNeel, Timothy Rozjabek, Heather M. Ekwueme, Donatus U. Yabroff, K. Robin TI Lost productivity and burden of illness in cancer survivors with and without other chronic conditions SO CANCER LA English DT Article DE MEPS; quality of life; cancer survivors; chronic conditions; comorbidities ID MENTAL-HEALTH STATUS; QUALITY-OF-LIFE; CARE; LIMITATIONS; RECORDS; AGE AB BACKGROUND Cancer survivors may experience long-term and late effects from treatment that adversely affect health and limit functioning. Few studies examine lost productivity and disease burden in cancer survivors compared with individuals who have other chronic conditions or by cancer type. METHODS We identified 4960 cancer survivors and 64,431 other individuals from the 2008-2010 Medical Expenditure Panel Survey and compared multiple measures of disease burden, including health status and lost productivity, between conditions and by cancer site for cancer survivors. All analyses controlled for the effects of age, sex, race/ethnicity, and number of comorbid conditions. RESULTS Overall, in adjusted analyses in multiple models, cancer survivors with another chronic disease (heart disease or diabetes) experienced higher levels of burden compared with individuals with a history of cancer only, chronic disease only, and neither cancer, heart disease, nor diabetes across multiple measures (P<.05). Among cancer survivors, individuals with short survival cancers and multiple cancers consistently had the highest levels of burden across multiple measures (P<.0001). CONCLUSIONS Cancer survivors who have another chronic disease experience more limitations and higher levels of burden across multiple measures. Limitations are particularly severe in cancer survivors with short survival cancer and multiple cancers. Cancer 2013;119:3393-401. (c) 2013 American Cancer Society. C1 [Dowling, Emily C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Chawla, Neetu; Forsythe, Laura P.; de Moor, Janet; Rozjabek, Heather M.; Yabroff, K. Robin] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [McNeel, Timothy] Informat Management Serv Inc, Rockville, MD USA. [Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Dowling, EC (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA. EM edowling@mgh-ita.org OI Yabroff, K. Robin/0000-0003-0644-5572 NR 27 TC 14 Z9 14 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD SEP PY 2013 VL 119 IS 18 BP 3393 EP 3401 DI 10.1002/cncr.28214 PG 9 WC Oncology SC Oncology GA 211EN UT WOS:000323887900021 PM 23794146 ER PT J AU MacCannell, D AF MacCannell, Duncan TI Bacterial Strain Typing SO CLINICS IN LABORATORY MEDICINE LA English DT Article DE Bacterial typing techniques; Molecular epidemiology; Multilocus sequence typing; DNA sequence analysis; Pulsed-field gel electrophoresis; Genomics ID FIELD GEL-ELECTROPHORESIS; RESISTANT STAPHYLOCOCCUS-AUREUS; MYCOBACTERIUM-TUBERCULOSIS; ESCHERICHIA-COLI; VARIABLE-NUMBER; CLOSTRIDIUM-DIFFICILE; PCR; PULSENET; LOCUS; REPEATS AB Over the course of the past several,decades, rapid advancements in molecular technologies have revolutionized the practice of public health microbiology, and have fundamentally changed the nature, accuracy, and timeliness of laboratory data for outbreak investigation and response. Whole-genome sequencing, in particular, is becoming an increasingly feasible and cost-effective approach for near real-time high-resolution strain typing, genomic characterization, and comparative analyses. This review discusses the current state of the art in bacterial strain typing for outbreak investigation and infectious disease surveillance, and the impact of emerging genomic technologies on the field of public health microbiology. C1 Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP MacCannell, D (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd Northeast,MS C12, Atlanta, GA 30333 USA. EM dmaccannell@cdc.gov NR 59 TC 9 Z9 10 U1 3 U2 22 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-2712 J9 CLIN LAB MED JI Clin. Lab. Med. PD SEP PY 2013 VL 33 IS 3 BP 629 EP + DI 10.1016/j.cll.2013.03.005 PG 23 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 215PB UT WOS:000324221600011 PM 23931842 ER PT J AU Kissin, DM Crawford, S Boulet, SL AF Kissin, Dmitry M. Crawford, Sara Boulet, Sheree L. TI The status of public reporting of clinical outcomes in assisted reproductive technology SO FERTILITY AND STERILITY LA English DT Letter C1 [Kissin, Dmitry M.; Crawford, Sara; Boulet, Sheree L.] Ctr Dis Control & Prevent, Natl ART Surveillance Syst NASS Grp, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Kissin, DM (reprint author), Ctr Dis Control & Prevent, Natl ART Surveillance Syst NASS Grp, Div Reprod Hlth, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 4 TC 4 Z9 4 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2013 VL 100 IS 3 BP E16 EP E17 DI 10.1016/j.fertnstert.2013.07.199 PG 2 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 215UA UT WOS:000324234900006 PM 23928256 ER PT J AU Buffet, JP Kosoy, M Vayssier-Taussat, M AF Buffet, Jean-Philippe Kosoy, Michael Vayssier-Taussat, Muriel TI Natural history of Bartonella-infecting rodents in light of new knowledge on genomics, diversity and evolution SO FUTURE MICROBIOLOGY LA English DT Review DE adaptation; arthropod vectors; Bartonella; diversity; geographical distribution; rodents ID VINSONII SUBSP ARUPENSIS; CITRATE SYNTHASE GENE; SMALL MAMMALS; SP-NOV; RATTUS-NORVEGICUS; WILD RODENTS; BANK VOLES; PHYLOGENETIC ANALYSIS; BORRELIA-BURGDORFERI; MOLECULAR-DETECTION AB Among the 33 confirmed Bartonella species to date, more than half are hosted by rodent species, and at least five of them have been involved in human illness causing diverse symptoms including fever, myocarditis, endocarditis, lymphadenitis and hepatitis. In almost all countries, wild rodents are infected by extremely diverse Bartonella strains with a high prevalence. In the present paper, in light of new knowledge on rodent-adapted Bartonella species genomics, we bring together knowledge gained in recent years to have an overview of the impact of rodent-adapted Bartonella infection on humans and to determine how diversity of Bartonella helps to understand their mechanisms of adaptation to rodents and the consequences on human health. C1 [Buffet, Jean-Philippe; Vayssier-Taussat, Muriel] Anses, INRA, USC Bipar Bartonella & Tiques, F-94700 Maisons Alfort, France. [Kosoy, Michael] Ctr Dis Control & Prevent, Div Vector Borne Infect, Ft Collins, CO 80521 USA. RP Vayssier-Taussat, M (reprint author), Anses, INRA, USC Bipar Bartonella & Tiques, 23 Ave Gen Gaulle, F-94700 Maisons Alfort, France. EM mvayssier@vet-alfort.fr FU Ile de France Region; Animal Health department of the French National Institute for Agricultural Research; EU [FP7-261504 EDE Next] FX This work was partially funded by the Ile de France Region, the Animal Health department of the French National Institute for Agricultural Research and by EU grant FP7-261504 EDE Next and is catalogued by the EDE Next Steering Committee as EDENext 117 (www.edenext.eu). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 84 TC 17 Z9 17 U1 0 U2 16 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1746-0913 J9 FUTURE MICROBIOL JI Future Microbiol. PD SEP PY 2013 VL 8 IS 9 BP 1117 EP 1128 DI 10.2217/fmb.13.77 PG 12 WC Microbiology SC Microbiology GA 213YJ UT WOS:000324096300015 PM 24020740 ER PT J AU Hunter, JE Allen, EG Shin, M Bean, LJH Correa, A Druschel, C Hobbs, CA O'Leary, LA Romitti, PA Royle, MH Torfs, CP Freeman, SB Sherman, SL AF Hunter, Jessica Ezzell Allen, Emily Graves Shin, Mikyong Bean, Lora J. H. Correa, Adolfo Druschel, Charlotte Hobbs, Charlotte A. O'Leary, Leslie A. Romitti, Paul A. Royle, Marjorie H. Torfs, Claudine P. Freeman, Sallie B. Sherman, Stephanie L. TI The association of low socioeconomic status and the risk of having a child with Down syndrome: a report from the National Down Syndrome Project SO GENETICS IN MEDICINE LA English DT Article DE chromosome nondisjunction; Down syndrome; risk factors; socioeconomic status; trisomy 21 ID MATERNAL AGE; MEIOTIC STAGE; HUMAN OOCYTES; CHROMOSOME-21 NONDISJUNCTION; DNA HYPOMETHYLATION; TRISOMY FORMATION; PARENTAL ORIGIN; MEIOSIS-II; ANEUPLOIDY; RECOMBINATION AB Purpose: Advanced maternal age and altered recombination are known risk factors for Down syndrome cases due to maternal nondisjunction of chromosome 21, whereas the impact of other environmental and genetic factors is unclear. The aim of this study was to investigate an association between low maternal socioeconomic status and chromosome 21 nondisjunction. Methods: Data from 714 case and 977 control families were used to assess chromosome 21 meiosis I and meiosis II nondisjunction errors in the presence of three low socioeconomic status factors: (i) both parents had not completed high school, (ii) both maternal grandparents had not completed high school, and (iii) an annual household income of <$25,000. We applied logistic regression models and adjusted for covariates, including maternal age and race/ethnicity. Results: As compared with mothers of controls (n = 977), mothers with meiosis II chromosome 21 nondisjunction (n = 182) were more likely to have a history of one low socioeconomic status factor (odds ratio = 1.81; 95% confidence interval = 1.07-3.05) and >= 2 low socioeconomic status factors (odds ratio = 2.17; 95% confidence interval = 1.02-4.63). This association was driven primarily by having a low household income (odds ratio = 1.79; 95% confidence interval = 1.14-2.73). The same statistically significant association was not detected among maternal meiosis I errors (odds ratio = 1.31; 95% confidence interval = 0.81-2.10), in spite of having a larger sample size (n = 532). Conclusion: We detected a significant association between low maternal socioeconomic status and meiosis II chromosome 21 nondisjunction. Further studies are warranted to explore which aspects of low maternal socioeconomic status, such as environmental exposures or poor nutrition, may account for these results. C1 [Hunter, Jessica Ezzell; Allen, Emily Graves; Bean, Lora J. H.; Freeman, Sallie B.; Sherman, Stephanie L.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. [Shin, Mikyong; Correa, Adolfo; O'Leary, Leslie A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Shin, Mikyong] Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Jackson Heart Study, Jackson, MS 39216 USA. [Druschel, Charlotte] New York State Dept Hlth, Bureau Environm & Occupat Epidemiol, Albany, NY USA. [Hobbs, Charlotte A.] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA. [Romitti, Paul A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Royle, Marjorie H.] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [Torfs, Claudine P.] Inst Publ Hlth, Oakland, CA USA. RP Hunter, JE (reprint author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. EM jhunte4@emory.edu OI Hunter, Jessica/0000-0002-1117-1097 FU NIH [R01 HD38979] FX The authors thank Rupa Masse, Maneesha Yadav-Shaw, and Weiya He for their laboratory assistance. They also thank all personnel at each NDSP site. A very special thanks go to the families whose participation made this study possible. This work was supported by NIH R01 HD38979. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 40 TC 4 Z9 4 U1 0 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD SEP PY 2013 VL 15 IS 9 BP 698 EP 705 DI 10.1038/gim.2013.34 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 214XN UT WOS:000324172000005 PM 23558253 ER PT J AU Bruce, MG Bruden, D Morris, J Reasonover, A Sacco, F Hurlburt, D Hennessy, T Gove, J Parkinson, A Sahagun, G Davis, P Klejka, J McMahon, B AF Bruce, M. G. Bruden, D. Morris, J. Reasonover, A. Sacco, F. Hurlburt, D. Hennessy, T. Gove, J. Parkinson, A. Sahagun, G. Davis, P. Klejka, J. McMahon, B. TI REINFECTION AFTER SUCCESSFUL ERADICATION OF HELICOBACTER PYLORI IN THREE DIFFERENT POPULATIONS IN ALASKA SO HELICOBACTER LA English DT Meeting Abstract CT 26th International Workshop on Helicobacter and Related Bacteria in Chronic Digestive Inflammation and Gastric Cancer CY SEP 12-14, 2013 CL Madrid, SPAIN SP European Helicobacter Study Grp C1 [Bruce, M. G.; Bruden, D.; Morris, J.; Reasonover, A.; Hurlburt, D.; Hennessy, T.; Parkinson, A.] Ctr Dis Control & Prevent, Anchorage, AK USA. [Sacco, F.; Davis, P.] Alaska Native Med Ctr, Anchorage, AK USA. [Gove, J.] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK USA. [Sahagun, G.] Internal Med Associate INC, Anchorage, AK USA. [Klejka, J.] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. [McMahon, B.] Div Community Hlth Serv, Liver Dis & Hepatitis Program, Anchorage, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD SEP PY 2013 VL 18 SU 1 SI SI BP 81 EP 81 PG 1 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 213HT UT WOS:000324047300022 ER PT J AU Lee, J Johnson, C Rice, J Warren, CW Chen, T AF Lee, Joann Johnson, Carolyn Rice, Janet Warren, C. Wick Chen, Ted TI Smoking Beliefs and Behavior Among Youth in South Korea, Taiwan, and Thailand SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE LA English DT Article DE Adolescents; Tobacco use; Cigarettes; Smoking ID ADOLESCENT SMOKING; TOBACCO USE; CESSATION; BENEFITS; RISKS AB Beliefs about smoking are important predictors of smoking behavior among adolescents, and adolescents who hold positive beliefs about the benefits of smoking are at an increased risk of smoking initiation. An alarming fact is the rising smoking prevalence in Asian countries, particularly the increasing trend in smoking during adolescence. This cross-sectional study examined smoking beliefs and behavior among a nationally representative sample of youth in South Korea, Taiwan, and Thailand. Descriptive statistics, linear regression, and logistic regression methods were used to analyze data from 13-15-year-old adolescents who participated in the 2005 Global Youth Tobacco Survey (GYTS) in South Korea (N = 4,765) and Thailand (N = 15,420) and the 2007 GYTS in Taiwan (N = 3,955). The rate of ever smoking among youth was similar in all three countries and ranged from 26.7 to 28.0 %. The prevalence of current smoking among youth in Thailand (11.4 %) was nearly double the prevalence in South Korea (6.6 %) and Taiwan (6.5 %). Pro-tobacco advertising exposure, as well as older ages, was a positive and significant predictor of positive beliefs about smoking among youth in all three countries. Additionally, youth who reported increased positive smoking-related beliefs, greater pro-tobacco advertising exposure, and were male were more likely to be current smokers in all three countries. Results suggest that greater attention be directed to understanding beliefs and attitudes about smoking among youth. Exploring the relationship between these factors and smoking behavior can provide a strong starting point in the development of effective smoking prevention interventions and tobacco control policies in this region. C1 [Lee, Joann] Univ Calif San Francisco, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA. [Johnson, Carolyn; Chen, Ted] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Community Hlth Sci, New Orleans, LA 70112 USA. [Rice, Janet] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA. [Warren, C. Wick] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Chen, T (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Community Hlth Sci, 1440 Canal St,Suite 2301, New Orleans, LA 70112 USA. EM tchen@tulane.edu NR 21 TC 1 Z9 1 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1070-5503 J9 INT J BEHAV MED JI Int. J. Behav. Med. PD SEP PY 2013 VL 20 IS 3 BP 319 EP 326 DI 10.1007/s12529-012-9236-3 PG 8 WC Psychology, Clinical SC Psychology GA 214FC UT WOS:000324115700001 PM 22592594 ER PT J AU Williams, JL Mersereau, PW Ruch-Ross, H Zapata, LB Ruhl, C AF Williams, Jennifer L. Mersereau, Patricia W. Ruch-Ross, Holly Zapata, Lauren B. Ruhl, Catherine TI Influenza Infection Control Practices in Labor and Delivery Units During the 2009 H1N1 Influenza Pandemic SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING LA English DT Article DE infection control; 2009 H1N1 pandemic; maternal and infant precautions; AWHONN ID PREGNANT-WOMEN; IMPACT AB Objective: To assess the presence and usefulness of written policies and practices on infection control consistent with the Center for Disease Control and Prevention's (CDC) guidance in hospital labor and delivery (L&D) units during the 2009 H1N1 influenza pandemic. Setting: Online survey. Participants: Of 11,845 eligible nurses, 2,641 (22%) participated. This analysis includes a subset of 1,866 nurses who worked exclusively in L&D units. Methods: A cross-sectional descriptive evaluation was sent to 12,612 members from the Association of Women's Health, Obstetric, and Neonatal Nurses (AWHONN) who reported working in labor, delivery, postpartum, or newborn care settings during the 2009 H1N1 influenza pandemic. Results: Respondents (73.8%) reported that CDC guidance was very useful for infection control in L&D settings during the pandemic. We assessed the presence of the following infection control written policies, consistent with CDC's guidance in hospital L&D units, during the 2009 H1N1 influenza pandemic and their rate of implementation most of the time: questioning women upon arrival about recent flu-like symptoms (89.4%, 89.9%), immediate initiation of antiviral medicines if flu suspected or confirmed (65.2%, 49%), isolating ill women from healthy women immediately (90.7%, 84.7%), ask ill women to wear masks during L&D (67%, 57.7%), immediately separating healthy newborns from ill mothers (50.9%, 42.4%), and bathing healthy infants when stable (58.4%, 56.9%). Reported written policies for five of the six practices increased during the pandemic. Five of six written policies remained above baseline after the pandemic. Conclusions: Respondents considered CDC guidance very useful. The presence of written policies is important for the implementation of infection control practices by L&D nurses. C1 [Williams, Jennifer L.; Mersereau, Patricia W.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Zapata, Lauren B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Ruhl, Catherine] Womens Hlth Programs Assoc Womens Hlth Obstet & N, Washington, DC USA. RP Williams, JL (reprint author), 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30333 USA. EM znv8@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 2 Z9 2 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-2175 J9 JOGNN-J OBST GYN NEO JI JOGNN PD SEP PY 2013 VL 42 IS 5 BP 527 EP 540 DI 10.1111/1552-6909.12243 PG 14 WC Nursing; Obstetrics & Gynecology SC Nursing; Obstetrics & Gynecology GA 213YP UT WOS:000324096900007 PM 24020478 ER PT J AU Stabler, ME Giacobbi, PR Fekedulegn, DB AF Stabler, Meagan E. Giacobbi, Peter R., Jr. Fekedulegn, Desta B. TI Association of Television Viewing Time With Overweight/Obesity Independent of Meeting Physical Activity Guidelines: Do Joint Exposures Yield Independence? SO JOURNAL OF EPIDEMIOLOGY LA English DT Letter C1 [Stabler, Meagan E.] W Virginia Univ, Sch Publ Hlth, Dept Epidemiol, Morgantown, WV 26506 USA. [Giacobbi, Peter R., Jr.] W Virginia Univ, Sch Publ Hlth, Dept Epidemiol, Dept Sport Sci, Morgantown, WV 26506 USA. [Fekedulegn, Desta B.] Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV USA. RP Stabler, ME (reprint author), W Virginia Univ, Sch Publ Hlth, Dept Epidemiol, POB 9190,Med Ctr Dr, Morgantown, WV 26506 USA. EM mstabler@hsc.wvu.edu NR 3 TC 1 Z9 1 U1 0 U2 4 PU JAPAN EPIDEMIOLOGICAL ASSOC PI TOKYO PA C/O UNIBO PRESS, HONGO MT BLDG 4F, 7-2-2 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN SN 0917-5040 J9 J EPIDEMIOL JI J. Epidemiol. PD SEP PY 2013 VL 23 IS 5 BP 396 EP 397 DI 10.2188/jea.JE20130073 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 214PO UT WOS:000324146500012 PM 23933619 ER PT J AU Tapia, JL Torres, BN Visvesvara, GS AF Tapia, Jose L. Nogueda Torres, Benjamin Visvesvara, Govinda S. TI Balamuthia mandrillaris: In Vitro Interactions with Selected Protozoa and Algae SO JOURNAL OF EUKARYOTIC MICROBIOLOGY LA English DT Article DE Acanthamoeba; food preferences; Giardia intestinalis; Naegleria; Paramecium; tachyzoites; Toxoplasma; Trypanosoma cruzi ID AMEBIC MENINGOENCEPHALITIS; NAEGLERIA-FOWLERI; ANIMALS; HUMANS; AGENT; CELLS; PCR AB Although Balamuthia mandrillaris was identified more than two decades ago as an agent of fatal granulomatous encephalitis in humans and other animals, little is known about its ecological niche, biological behavior in the environment, food preferences and predators, if any. When infecting humans or other animals, Balamuthia feeds on tissues; and in vitro culture, it feeds on mammalian cells (monkey kidney cells, human lung fibroblasts, and human microvascular endothelial cells). According to recent reports, it is believed that Balamuthia feeds on small amebae, for example, Acanthamoeba that are present in its ecological niche. To test this hypothesis, we associated Balamuthia on a one-on-one basis with selected protozoa and algae. We videotaped the behavior of Balamuthia in the presence of a potential prey, its ability to hunt and attack its food, and the time required to eat and cause damage to the target cell by direct contact. We found that B. mandrillaris ingested trophozoites of Naegleria fowleri, Naegleria gruberi, Acanthamoeba spp., Trypanosoma cruzi epimastigotes, Toxoplasma gondii tachyzoites, and Giardia. However, it did not feed on Acanthamoeba cysts or algae. Balamuthia caused cytolysis of T. cruzi epimastigotes and T. gondii tachyzoites by direct contact. Balamuthia trophozoites and cysts were, however, eaten by Paramecium sp. C1 [Tapia, Jose L.] Inst Diagnost & Referencia Epidemiol, Protozool Lab, Mexico City 11340, DF, Mexico. [Nogueda Torres, Benjamin] Escuela Nacl Ciencias Biol, Helminthol Lab, Mexico City 11340, DF, Mexico. [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Tapia, JL (reprint author), Inst Diagnost & Referencia Epidemiol, Dept Parasitol, Prolongac Carpio 470, Mexico City 11340, DF, Mexico. EM jltapiaunam76@hotmail.es NR 21 TC 4 Z9 4 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5234 J9 J EUKARYOT MICROBIOL JI J. Eukaryot. Microbiol. PD SEP PY 2013 VL 60 IS 5 BP 448 EP 454 DI 10.1111/jeu.12052 PG 7 WC Microbiology SC Microbiology GA 213XT UT WOS:000324094600002 PM 23790262 ER PT J AU Kjos, SA Marcet, PL Yabsley, MJ Kitron, U Snowden, KF Logan, KS Barnes, JC Dotson, EM AF Kjos, Sonia A. Marcet, Paula L. Yabsley, Michael J. Kitron, Uriel Snowden, Karen F. Logan, Kathleen S. Barnes, John C. Dotson, Ellen M. TI Identification of Bloodmeal Sources and Trypanosoma cruzi Infection in Triatomine Bugs (Hemiptera: Reduviidae) From Residential Settings in Texas, the United States SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE triatomine; Trypanosoma cruzi; host association; bloodmeal analysis ID POLYMERASE-CHAIN-REACTION; CHAGAS-DISEASE VECTORS; HOST-FEEDING PATTERNS; WEST-NILE-VIRUS; RURAL NORTHWESTERN ARGENTINA; CYTOCHROME-B GENE; MOLECULAR-IDENTIFICATION; AMERICAN TRYPANOSOMIASIS; AUTOCHTHONOUS TRANSMISSION; NATURAL-POPULATIONS AB The host-vector-parasite interactions in Chagas disease peridomestic transmission cycles in the United States are not yet well understood. Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae) infection prevalence and bloodmeal sources were determined for adult and immature triatomine (Hemiptera: Reduviidae) specimens collected from residential settings in central Texas. Sequenced cytochrome b DNA segments obtained from triatomine digestive tract identified nine vertebrate hosts and one invertebrate host in four triatomine species (Triatoma gerstaeckeri, Triatoma indictiva, Triatoma protracta, and Triatoma sanguisuga). The broad range of wild and domestic host species detected in triatomine specimens collected from residential sites indicates high host diversity and potential movement between the sylvatic and peridomestic settings. Domestic dogs appear to be key in the maintenance of the peridomestic transmission cycle as both a blood host for the triatomine vectors and a potential reservoir for the parasite. The high rate of T. cruzi infection among triatomine specimens that were collected from inside houses, outside houses, and dog kennels (69, 81, and 82%, respectively) suggests a current risk for Chagas disease vector-borne transmission for humans and domestic animals in residential settings in Texas because of overlap with the sylvatic cycle. C1 [Kjos, Sonia A.; Marcet, Paula L.; Dotson, Ellen M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA 30329 USA. [Yabsley, Michael J.] Univ Georgia, Coll Vet Med, Southeastern Cooperat Wildlife Dis Study, Dept Populat Hlth, Athens, GA 30602 USA. [Yabsley, Michael J.] Univ Georgia, Daniel B Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA. [Kitron, Uriel] Emory Clin, Dept Environm Studies, Atlanta, GA 30322 USA. [Snowden, Karen F.; Logan, Kathleen S.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA. [Barnes, John C.] Southwest Texas Vet Med Ctr, Uvalde, TX 78801 USA. RP Kjos, SA (reprint author), Univ Minnesota, Dept Biol, 207 Swenson Sci Bldg,1035 Kirby Dr, Duluth, MN 55812 USA. EM kjosx006@d.umn.edu OI Marcet, Paula/0000-0002-0676-3020 FU American Society for Microbiology/CDC postdoctoral fellowship; National Institutes of Health [R15 AI067304-02] FX We thank Jillian Gembler for help with field collections and the many Texas residents who submitted specimens or permitted access to their properties for sampling. We also thank Gena Lawrence for assistance with bloodmeal PCR assay optimization and the Centers for Disease Control and Prevention (CDC) Biotechnical Core Facility for providing the oligonucleotides. Funding for S. A. K. was provided through an American Society for Microbiology/CDC post-doctoral fellowship. Support for M.J.Y. was provided by National Institutes of Health (R15 AI067304-02). Use of trade names is for identification purposes only and does not imply endorsement of the Centers for Disease Control and Prevention, the Public Health Service, or the U.S. Health and Human Services. NR 90 TC 21 Z9 22 U1 2 U2 32 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 J9 J MED ENTOMOL JI J. Med. Entomol. PD SEP PY 2013 VL 50 IS 5 BP 1126 EP 1139 DI 10.1603/ME12242 PG 14 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 217QI UT WOS:000324374100024 PM 24180119 ER PT J AU Wethington, H Maynard, LM Blanck, HM AF Wethington, H. Maynard, L. M. Blanck, H. M. TI Use of calorie information at fast food and chain restaurants among US youth aged 918 years, 2010 SO JOURNAL OF PUBLIC HEALTH LA English DT Article DE children; food and nutrition; individual behaviour ID EXPANDING PORTION SIZES; NEW-YORK-CITY; ADOLESCENTS; PURCHASES; CHILDREN; OBESITY; IMPACT AB To examine whether youth use calorie information when it is available at fast food/chain restaurants and what factors are associated with using this information to make their food selection. A cross-sectional analysis was conducted on a sample of 721 youth (918 years) using the 2010 YouthStyles and HealthStyles surveys. The outcome measure was reported use of calorie information at fast food/chain restaurants. Multivariable logistic regression was used to examine the associations between sociodemographic variables and the use of calorie information at fast food/chain restaurants. Of those who visited fast food/chain restaurants, 42.4 reported using calorie information at least sometimes. Girls were more likely than boys (adjusted odds ratio (aOR) 1.8, 95 confidence interval (CI) 1.22.5) and youth who were obese were more likely than those at a healthy weight (aOR 1.7, 95 CI 1.042.9) to use calorie information, and youth eating at a fast food/chain restaurant twice a week or more versus once a week or less were half as likely to report using calorie information (aOR 0.5, 95 CI 0.40.8). Public health education efforts can benefit from research to determine how to increase usage among youth so that their food choices are appropriate for their caloric needs. C1 [Wethington, H.; Maynard, L. M.; Blanck, H. M.] CDC, NCCPHP, Div Nutr Phys Act & Obes, Obes Prevent & Control Branch, Atlanta, GA 30341 USA. RP Wethington, H (reprint author), CDC, NCCPHP, Div Nutr Phys Act & Obes, Obes Prevent & Control Branch, Atlanta, GA 30341 USA. EM hwethington@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 4 Z9 4 U1 0 U2 18 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-3842 J9 J PUBLIC HEALTH-UK JI J. Public Health PD SEP PY 2013 VL 35 IS 3 BP 354 EP 360 DI 10.1093/pubmed/fdt049 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 212FF UT WOS:000323967200002 PM 23697388 ER PT J AU Eaton, DK Olsen, EO Brener, ND Scanlon, KS Kim, SA Demissie, Z Yaroch, AL AF Eaton, Danice K. Olsen, Emily O'Malley Brener, Nancy D. Scanlon, Kelley S. Kim, Sonia A. Demissie, Zewditu Yaroch, Amy Lazarus TI A Comparison of Fruit and Vegetable Intake Estimates from Three Survey Question Sets to Estimates from 24-Hour Dietary Recall Interviews SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Fruit; Vegetable; Dietary assessment; Validity; Adolescents ID CANCER PREVENTION; PHYSICAL-ACTIVITY; CONSUMPTION; RISK; RELIABILITY; NUTRITION; VALIDITY; ADULTS; FOODS; US AB Background Fruit and vegetable (F/V) intake surveillance can provide information critical to the design and evaluation of interventions and the assessment of progress toward national intake objectives. The CDC's Youth Risk Behavior Surveillance System (YRBSS) assesses F/V intake among high school students using six questions about the frequency of intake in times per day. It is not known whether F/V intake frequency in times per day can be used as a proxy for intake in servings per day. Objective To compare F/V intake estimates based on responses to three sets of survey questions, including the standard set of six YRBSS questions, with criterion F/V intake in servings per day based on data from 24-hour dietary recall interviews. Participants/setting Study participants were 610 high school students who completed an in-class questionnaire and three telephone-administered 24-hour dietary recall interviews. The questionnaire asked students how many times they consumed 100% fruit juice and ate fruit, carrots, potatoes, green salad, and other vegetables during the "past 7 days" (set 1), the number of times they did so "yesterday" (set 2), and the number of cup-equivalents of fruits and vegetables they consumed per day (set 3). Main outcome measure Mean estimated F/V intake either as "times/day" or "servings/day" and the percentage of students whose estimated F/V intake was >= 1, >= 2, and >= 3 times/day or servings/day. Statistical analyses performed t tests and corrected Pearson correlations were used to compare F/V intake estimates based on survey question responses with estimates based on responses to the 24-hour dietary recall interview. Results Mean F/V intake estimates (in times/day or servings/day) based on responses to all sets of survey questions were significantly more than servings/day estimates based on responses to the 24-hour dietary recall interviews, and the percentages of students meeting each intake cutpoint were also more. Of the three sets of survey questions, the standard YRBSS questions produced estimates and percentages that were most consistently closest to 24-hour dietary recall interview estimates. Conclusions For brief self-administered questionnaires of high school students, the current,YRBSS questions are recommended for monitoring F/V intake even though mean intake estimates in times/day will likely be higher than, and are not a proxy for, mean intake estimates in servings/day. C1 [Eaton, Danice K.; Olsen, Emily O'Malley; Brener, Nancy D.; Scanlon, Kelley S.; Kim, Sonia A.; Demissie, Zewditu] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Yaroch, Amy Lazarus] Gretchen Swanson Ctr Nutr, Omaha, NE USA. RP Eaton, DK (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-92, Atlanta, GA 30333 USA. EM dhe0@cdc.gov FU Intramural CDC HHS [CC999999] NR 23 TC 12 Z9 12 U1 2 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD SEP PY 2013 VL 113 IS 9 BP 1165 EP 1174 DI 10.1016/j.jand.2013.05.013 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 217GK UT WOS:000324347400006 PM 23871104 ER PT J AU Barrera, R Mackay, AJ Amador, M AF Barrera, Roberto Mackay, Andrew J. Amador, Manuel TI A NOVEL AUTOCIDAL OVITRAP FOR THE SURVEILLANCE AND CONTROL OF AEDES AEGYPTI SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE Aedes aegypti; autocidal ovitrap; vector; surveillance; control ID PUERTO-RICO; SAN-JUAN; DENGUE; STICKY AB We describe an inexpensive autocidal ovitrap for Aedes aegypti that uses cross-linked polyacrylamide (PAM) gel as the oviposition substrate. Aedes aegypti females readily laid eggs on PAM gel that had been hydrated with either hay infusion or water. Aedes aegypti larvae that hatched from their eggs desiccated on the surface of the PAM gel. We tested the effects of gel hydration, texture, and type of attractant on trap performance, and compared the capture rates of standard ovitraps with those of PAM gel ovitraps in the field. The results showed that the number of eggs did not vary over a range of gel hydration levels (40-100%) and that more eggs were recovered from ovitraps containing coarse gel than from those containing homogenized gel. The PAM gel hydrated with hay infusion was more attractive to gravid female mosquitoes than gel hydrated with water. In the field, the number of eggs recovered from autocidal ovitraps with PAM gel was similar to that recovered from standard ovitraps with hay infusion. C1 [Barrera, Roberto; Mackay, Andrew J.; Amador, Manuel] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00920 USA. RP Barrera, R (reprint author), Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. NR 11 TC 1 Z9 1 U1 2 U2 16 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2013 VL 29 IS 3 BP 293 EP 296 DI 10.2987/13-6345R.1 PG 4 WC Entomology SC Entomology GA 217SJ UT WOS:000324380600012 PM 24199506 ER PT J AU Comer, JA AF Comer, James A. TI ROY WILLIAM CHAMBERLAIN 1916-2013 OBITUARY SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Biographical-Item C1 Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. RP Comer, JA (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD SEP PY 2013 VL 29 IS 3 BP 309 EP 311 DI 10.2987/13-6357.1 PG 3 WC Entomology SC Entomology GA 217SJ UT WOS:000324380600016 ER PT J AU Smith, JL Wilson, KM Orians, CE Byrd, TL AF Smith, Judith Lee Wilson, Katherine M. Orians, Carlyn E. Byrd, Theresa L. TI AMIGAS: Building a Cervical Cancer Screening Intervention for Public Health Practice SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HISPANIC WOMEN; PREVENTIVE SERVICES; UNITED-STATES; BREAST; LITERACY; LANGUAGE; PROGRAM AB Background: Many barriers to cervical cancer screening for Hispanic women have been documented, but few effective interventions exist. The Community Preventive Services Task Force recommends increasing cervical cancer screening through various methods. Building on this evidence, the Centers for Disease Control and Prevention funded the research and testing phases for an evidence-based and theoretically grounded intervention designed to increase cervical cancer screening among never and rarely screened Hispanic women of Mexican descent. In this article, we describe the development process of the AMIGAS (Ayudando a las Mujeres con Informacion,Guia, y Amor para su Salud) intervention, highlight the integration of scientific evidence and community-based participatory research principles, and identify opportunities for dissemination, adaptation, and implementation of this intervention. Methods: The AMIGAS team was a collaboration among researchers, promotoras (community health workers), and program administrators. The multiyear, multiphase project was conducted in Houston, Texas; El Paso, Texas; and Yakima, Washington. The team completed several rounds of formative research, designed intervention materials and methodology, conducted a randomized controlled trial, created a guide for program administrators, and developed an intervention dissemination plan. Results: Trial results demonstrated that AMIGAS was successful in increasing cervical cancer screening among Hispanic women. Adaptation of AMIGAS showed minimal reduction of outcomes. Dissemination efforts are underway to make AMIGAS available in a downloadable format via the Internet. Conclusions: Developing a community-based intervention that is evidence-based and theoretically grounded is challenging, time-intensive, and requires collaboration among multiple disciplines. Inclusion of key stakeholdersin particular program deliverers and administratorsand planning for dissemination and translation to practice are integral components of successful intervention design. By providing explicit directions for adaptation for program deliverers, relevant information for program administrators, and access to the intervention via the Internet, AMIGAS is available to help increase cervical cancer screening among Hispanic women and other women disproportionately affected by cervical cancer. C1 [Smith, Judith Lee] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Wilson, Katherine M.] Ctr Dis Control & Prevent, Epidemiol & Anal Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. [Orians, Carlyn E.] Battelle Publ Hlth & Stat, Seattle, WA USA. [Byrd, Theresa L.] Texas Tech Univ, Paul L Foster Sch Med, El Paso, TX USA. RP Smith, JL (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Highway NE,Mail Stop K-55, Atlanta, GA 30341 USA. EM JLeeSmith@cdc.gov FU Centers for Disease Control and Prevention [S1166-19/21, U48-DP000057, 200-98-0102, 200-2002-00573, 200-2008-27956] FX Research for this publication was supported by Centers for Disease Control and Prevention Cooperative Agreements # S1166-19/21 and U48-DP000057 and Contracts # 200-98-0102, 200-2002-00573, and 200-2008-27956. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 42 TC 2 Z9 2 U1 1 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD SEP 1 PY 2013 VL 22 IS 9 BP 718 EP 723 DI 10.1089/jwh.2013.4467 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 211UA UT WOS:000323935400002 PM 23930983 ER PT J AU Wittenborn, JS Zhang, XZ Feagan, CW Crouse, WL Shrestha, S Kemper, AR Hoerger, TJ Saaddine, JB AF Wittenborn, John S. Zhang, Xinzhi Feagan, Charles W. Crouse, Wesley L. Shrestha, Sundar Kemper, Alex R. Hoerger, Thomas J. Saaddine, Jinan B. CA Vision Cost-Effectiveness Study TI The Economic Burden of Vision Loss and Eye Disorders among the United States Population Younger than 40 Years SO OPHTHALMOLOGY LA English DT Article ID VISUAL IMPAIRMENT; COST; BLINDNESS; PREVALENCE; CHILDREN; MODELS; IMPACT; LIFE; UK AB Objective: To estimate the economic burden of vision loss and eye disorders in the United States population younger than 40 years in 2012. Design: Econometric and statistical analysis of survey, commercial claims, and census data. Participants: The United States population younger than 40 years in 2012. Methods: We categorized costs based on consensus guidelines. We estimated medical costs attributable to diagnosed eye-related disorders, undiagnosed vision loss, and medical vision aids using Medical Expenditure Panel Survey and MarketScan data. The prevalence of vision impairment and blindness were estimated using National Health and Nutrition Examination Survey data. We estimated costs from lost productivity using Survey of Income and Program Participation. We estimated costs of informal care, low vision aids, special education, school screening, government spending, and transfer payments based on published estimates and federal budgets. We estimated quality-adjusted life years (QALYs) lost based on published utility values. Main Outcome Measures: Costs and QALYs lost in 2012. Results: The economic burden of vision loss and eye disorders among the United States population younger than 40 years was $27.5 billion in 2012 (95% confidence interval, $21.5-$37.2 billion), including $5.9 billion for children and $21.6 billion for adults 18 to 39 years of age. Direct costs were $14.5 billion, including $7.3 billion in medical costs for diagnosed disorders, $4.9 billion in refraction correction, $0.5 billion in medical costs for undiagnosed vision loss, and $1.8 billion in other direct costs. Indirect costs were $13 billion, primarily because of $12.2 billion in productivity losses. In addition, vision loss cost society 215 000 QALYs. Conclusions: We found a substantial burden resulting from vision loss and eye disorders in the United States population younger than 40 years, a population excluded from previous studies. Monetizing quality-of-life losses at $50 000 per QALY would add $10.8 billion in additional costs, indicating a total economic burden of $38.2 billion. Relative to previously reported estimates for the population 40 years of age and older, more than one third of the total cost of vision loss and eye disorders may be incurred by persons younger than 40 years. (C) 2013 by the American Academy of Ophthalmology. C1 [Wittenborn, John S.] Univ Chicago, Natl Opin Res Ctr, Dept Publ Hlth Res, Morrisville, NC 27560 USA. [Zhang, Xinzhi; Shrestha, Sundar; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Feagan, Charles W.; Crouse, Wesley L.; Hoerger, Thomas J.] RTI Int, Publ Hlth Econ Program, Res Triangle Pk, NC USA. [Kemper, Alex R.] Duke Univ, Dept Pediat, Durham, NC 27706 USA. RP Wittenborn, JS (reprint author), Univ Chicago, Natl Opin Res Ctr, 1981 Grace Point Rd, Morrisville, NC 27560 USA. EM wittenborn-john@norc.org OI Klein, Ronald/0000-0002-4428-6237 FU Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia [200-2008-27958] FX Supported by the Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia (grant no.: 200-2008-27958). The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the National Opinion Research Center at the University of Chicago, RTI International, or Duke University. NR 23 TC 12 Z9 12 U1 3 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 J9 OPHTHALMOLOGY JI Ophthalmology PD SEP PY 2013 VL 120 IS 9 BP 1728 EP 1735 DI 10.1016/j.ophtha.2013.01.068 PG 8 WC Ophthalmology SC Ophthalmology GA 213HG UT WOS:000324045800023 PM 23631946 ER PT J AU Roldos, M Noonan, R Beattie, L AF Roldos, Maria Noonan, Rita Beattie, Lynn TI Strengthening the role of caregivers in promoting fall-risk screening for older adults during the annual wellness visit SO PERSPECTIVES IN PUBLIC HEALTH LA English DT Article C1 [Roldos, Maria] Univ San Francisco Quito, San Francisco, CA USA. [Noonan, Rita] Ctr Dis Control & Prevent, Atlanta, GA USA. [Beattie, Lynn] Ctr Hlth Aging, Washington, DC USA. RP Roldos, M (reprint author), Univ San Francisco Quito, San Francisco, CA USA. NR 8 TC 0 Z9 0 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1757-9139 J9 PERSPECT PUBLIC HEAL JI Perspect. Public Health PD SEP PY 2013 VL 133 IS 5 BP 246 EP 247 DI 10.1177/1757913913484872 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 214AK UT WOS:000324102100020 ER PT J AU Samoff, E Fangman, MT Fleischauer, AT Waller, AE MacDonald, PDM AF Samoff, Erika Fangman, Mary T. Fleischauer, Aaron T. Waller, Anna E. MacDonald, Pia D. M. TI Improvements in Timeliness Resulting from Implementation of Electronic Laboratory Reporting and an Electronic Disease Surveillance System SO PUBLIC HEALTH REPORTS LA English DT Article AB Objectives. Electronic laboratory reporting (ELR) reduces the time between communicable disease diagnosis and case reporting to local health departments (LHDs). However, it also imposes burdens on public health agencies, such as increases in the number of unique and duplicate case reports. We assessed how ELR affects the timeliness and accuracy of case report processing within public health agencies. Methods. Using data from May-August 2010 and January-March 2012, we assessed timeliness by calculating the time between receiving a case at the LHD and reporting the case to the state (first stage of reporting) and between submitting the report to the state and submitting it to the Centers for Disease Control and Prevention (second stage of reporting). We assessed accuracy by calculating the proportion of cases returned to the LHD for changes or additional information. We compared timeliness and accuracy for ELR and non-ELR cases. Results. ELR was associated with decreases in case processing time (median = 40 days for ELR cases vs. 52 days for non-ELR cases in 2010; median = 20 days for ELR cases vs. 25 days for non-ELR cases in 2012; both p<0.001). ELR also allowed time to reduce the backlog of unreported cases. Finally, ELR was associated with higher case reporting accuracy (in 2010, 2% of ELR case reports vs. 8% of non-ELR case reports were returned; in 2012, 2% of ELR case reports vs. 6% of non-ELR case reports were returned; both p<0.001). Conclusion. The overall impact of increased ELR is more efficient case processing at both local and state levels. C1 [Samoff, Erika; Fangman, Mary T.; MacDonald, Pia D. M.] Univ N Carolina, Gillings Sch Global Publ Hlth, North Carolina Inst Publ Hlth, Chapel Hill, NC USA. [Fleischauer, Aaron T.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Fleischauer, Aaron T.] North Carolina Div Publ Hlth, Raleigh, NC USA. [Waller, Anna E.] Univ N Carolina, Dept Emergency Med, Carolina Ctr Hlth Informat, Chapel Hill, NC USA. [MacDonald, Pia D. M.] Social & Sci Syst Inc, Durham, NC USA. RP Samoff, E (reprint author), Durham Cty Dept Publ Hlth, 414 E Main St, Durham, NC 27701 USA. EM esamoff@dconc.gov FU Centers for Disease Control and Prevention (CDC) [1PO1 TP 000296] FX The authors thank Lauren DiBiase of the University of North Carolina (UNC) and Robert G. Pace of the North Carolina Division of Public Health for their valuable insight on these data. This research was carried out by the North Carolina Preparedness and Emergency Response Research Center (NCPERRC), which is part of the UNC Center for Public Health Preparedness at the UNGChapel Hill Gillings School of Global Public Health and was supported by the Centers for Disease Control and Prevention (CDC) grant #1PO1 TP 000296. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of CDC. Additional information can be found at http://cphp.sph.unc.edu/ncperrc. NR 11 TC 1 Z9 1 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD SEP-OCT PY 2013 VL 128 IS 5 BP 51 EP 56 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 218PC UT WOS:000324443600010 ER PT J AU Kaur, H Long, J van Wyk, A Malik, N Mamadu, I Allan, L Yeung, S Fadei, I Green, M Fernandez, F AF Kaur, H. Long, J. van Wyk, A. Malik, N. Mamadu, I. Allan, L. Yeung, S. Fadei, I. Green, M. Fernandez, F. TI Assessing the quality of artemisinin combination therapies from Sub Saharan Africa and Cambodia, using analytical techniques SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Kaur, H.; Long, J.; van Wyk, A.; Malik, N.; Mamadu, I.; Allan, L.; Yeung, S.; Fadei, I.] London Sch Hyg & Trop Med, London, England. [Green, M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Fernandez, F.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2013 VL 18 SU 1 SI SI BP 21 EP 21 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213BS UT WOS:000324029000049 ER PT J AU Sejvar, J AF Sejvar, J. TI The evolving global epidemiology of encephalitis SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Sejvar, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2013 VL 18 SU 1 SI SI BP 28 EP 28 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213BS UT WOS:000324029000069 ER PT J AU Ustrup, M Ngwira, B Stockman, LJ Deming, M Nyasulu, P Bowie, C Msyamboza, K Meyrowitsch, DW Cunliffe, NA Bresee, J Fischer, TK AF Ustrup, M. Ngwira, B. Stockman, L. J. Deming, M. Nyasulu, P. Bowie, C. Msyamboza, K. Meyrowitsch, D. W. Cunliffe, N. A. Bresee, J. Fischer, T. K. TI Potential barriers to healthcare in Malawi for children under 5 years of age with cough and fever: a national household survey SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Ustrup, M.; Meyrowitsch, D. W.] Univ Copenhagen, Dept Publ Hlth, Fac Hlth Sci, Copenhagen, Denmark. [Ngwira, B.; Bowie, C.; Msyamboza, K.] Univ Malawi, Dept Community Hlth, Coll Med, Blantyre, Malawi. [Stockman, L. J.; Deming, M.; Fischer, T. K.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Nyasulu, P.] Univ Witwatersrand, Div Epidemiol & Biostat, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa. [Cunliffe, N. A.] Univ Liverpool, Dept Clin Infect Microbiol & Immunol, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Bresee, J.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2013 VL 18 SU 1 SI SI BP 76 EP 76 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213BS UT WOS:000324029000197 ER PT J AU Flevaud, L Sanchez, CL Albajar-Vinas, CP Wilkins, P Nieto, J Leyby, D Paris, L Scollo, K Guzman, C Luquetti, A Calvo, N Florez, C AF Flevaud, L. Sanchez, C. L. Albajar-Vinas, C. P. Wilkins, P. Nieto, J. Leyby, D. Paris, L. Scollo, K. Guzman, C. Luquetti, A. Calvo, N. Florez, C. TI Performance of rapid serological diagnostic tests for infection with Trypanosoma cruzi with serum/plasma/whole blood in Chagas disease endemic and non-endemic countries SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Sanchez, C. L.; Calvo, N.] Univ Antonio Narino, Bogota, Colombia. [Albajar-Vinas, C. P.; Calvo, N.] WHO Dept Control Neglected Trop Dis, Program Control Chagas Dis, Zurich, Switzerland. [Wilkins, P.; Calvo, N.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Leyby, D.; Calvo, N.] Amer Red Cross, Washington, DC 20006 USA. [Paris, L.; Calvo, N.] Hop La Pitie Salpetriere, Paris, France. [Scollo, K.; Calvo, N.] Inst Nacl Parasitol Dr Mario Fatala Chaben, Dept Diagnost, Buenos Aires, DF, Argentina. [Guzman, C.; Calvo, N.] Ctr Nacl Vigilancia Epidemiol & Control Enfermeda, Mexico City, DF, Mexico. [Luquetti, A.; Calvo, N.; Florez, C.] Univ Fed Goias, Hosp Clin, Goiania, Go, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2013 VL 18 SU 1 SI SI BP 91 EP 91 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213BS UT WOS:000324029000239 ER PT J AU Esquivel, CP Astete, H Lenhart, A Rio, RD Miquel, M Miranda, MA AF Esquivel, C. P. Astete, H. Lenhart, A. Rio, R. D. Miquel, M. Miranda, M. A. TI Residual effect of pyrethroids used in vector control on different house materials in the Peruvian Amazon SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Esquivel, C. P.; Rio, R. D.; Miquel, M.; Miranda, M. A.] Univ Balearic Isl, Palma De Mallorca, Spain. [Astete, H.] Hosp Ctr Med Naval, Dept Virol, US Naval Med Res Unit 6, Lima, Peru. [Lenhart, A.] Ctr Dis Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2013 VL 18 SU 1 SI SI BP 120 EP 120 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213BS UT WOS:000324029000323 ER PT J AU Wangroongsarb, P Satimai, W Khamsiriwatchara, A Thwing, J Eliades, JM Kaewkungwal, J Delacollette, C AF Wangroongsarb, P. Satimai, W. Khamsiriwatchara, A. Thwing, J. Eliades, J. M. Kaewkungwal, J. Delacollette, C. TI Respondent-driven sampling on the Thailand-Cambodia border. II. Knowledge, perception, practice and treatment-seeking behaviour of migrants in malaria endemic zones SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Meeting Abstract C1 [Wangroongsarb, P.; Satimai, W.] Minist Publ Hlth, Bur Vector Borne Dis, Bangkok, Thailand. [Khamsiriwatchara, A.; Kaewkungwal, J.] Ctr Excellence Biomed & Publ Hlth Informat BIOPHI, Bangkok, Thailand. [Thwing, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Eliades, J. M.; Delacollette, C.] World Hlth Org, Mekong Malaria Programme, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD SEP PY 2013 VL 18 SU 1 SI SI BP 155 EP 155 PG 1 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 213BS UT WOS:000324029000421 ER PT J AU Ritter, JM Muehlenbachs, A Blau, DM Paddock, CD Shieh, WJ Drew, CP Batten, BC Bartlett, JH Metcalfe, MG Pham, CD Lockhart, SR Patel, M Liu, L Jones, TL Greer, PW Montague, JL White, E Rollin, DC Seales, C Stewart, D Deming, MV Brandt, ME Zaki, SR AF Ritter, Jana M. Muehlenbachs, Atis Blau, Dianna M. Paddock, Christopher D. Shieh, Wun-Ju Drew, Clifton P. Batten, Brigid C. Bartlett, Jeanine H. Metcalfe, Maureen G. Pham, Cau D. Lockhart, Shawn R. Patel, Mitesh Liu, Lindy Jones, Tara L. Greer, Patricia W. Montague, Jeltley L. White, Elizabeth Rollin, Dominique C. Seales, Cynthia Stewart, Donna Deming, Mark V. Brandt, Mary E. Zaki, Sherif R. CA Exserohilum Infections Working Grp TI Exserohilum Infections Associated with Contaminated Steroid Injections A Clinicopathologic Review of 40 Cases SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID PAIN MANAGEMENT PROCEDURES; ASPERGILLUS MENINGITIS; MULTISTATE OUTBREAK; SERRATIA-MARCESCENS; FUNGAL MENINGITIS; APLASTIC-ANEMIA; UNITED-STATES; PHEOHYPHOMYCOSIS; PATIENT; TISSUE AB September 2012 marked the beginning of the Largest reported outbreak of infections associated with epidural and intra-articular injections. Contamination of methylprednisolone acetate with the black mold, Exserohilum rostratum, was the primary cause of the outbreak, with >13,000 persons exposed to the potentially contaminated drug, 741 confirmed drug-related infections, and 55 deaths. Fatal meningitis and localized epidural, paraspinal, and peripheral joint infections occurred. Tissues from 40 laboratory-confirmed cases representing these various clinical entities were evaluated by histopathological analysis, special stains, and IHC to characterize the pathological features and investigate the pathogenesis of infection, and to evaluate methods for detection of Exserohilum in formal:in-fixed, paraffin-embedded (FFPE) tissues. Fatal cases had necrosuppurative to granulomatous meningitis and vasculitis, with thrombi and abundant angioinvasive fungi, with extensive involvement of the basilar arterial circulation of the brain. IHC was a highly sensitive method for detection of fungus in FFPE tissues, demonstrating both hyphal forms and granular fungal antigens, and PCR identified Exserohilum in FFPE and fresh tissues. Our findings suggest a pathogenesis for meningitis involving fungal penetration into the cerebrospinal fluid at the injection site, with transport through cerebrospinal fluid to the basal cisterns and subsequent invasion of the basilar arteries. Further studies are needed to characterize Exserohilum and investigate the potential effects of underlying host factors and steroid administration on the pathogenesis of infection. C1 [Ritter, Jana M.; Muehlenbachs, Atis; Blau, Dianna M.; Paddock, Christopher D.; Shieh, Wun-Ju; Drew, Clifton P.; Batten, Brigid C.; Bartlett, Jeanine H.; Metcalfe, Maureen G.; Patel, Mitesh; Liu, Lindy; Jones, Tara L.; Greer, Patricia W.; Montague, Jeltley L.; White, Elizabeth; Rollin, Dominique C.; Seales, Cynthia; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Pham, Cau D.; Lockhart, Shawn R.; Brandt, Mary E.] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Stewart, Donna] Off Chief Med Examiner, Louisville, KY USA. [Deming, Mark V.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. RP Ritter, JM (reprint author), Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Mailstop G-32,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jritter@cdc.gov NR 45 TC 17 Z9 17 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 J9 AM J PATHOL JI Am. J. Pathol. PD SEP PY 2013 VL 183 IS 3 BP 881 EP 892 DI 10.1016/j.ajpath.2013.05.007 PG 12 WC Pathology SC Pathology GA 210WP UT WOS:000323866000022 PM 23809916 ER PT J AU Wang, LP He, XQ Szklarz, GD Bi, YY Rojanasakul, Y Ma, Q AF Wang, Liping He, Xiaoqing Szklarz, Grazyna D. Bi, Yongyi Rojanasakul, Yon Ma, Qiang TI The aryl hydrocarbon receptor interacts with nuclear factor erythroid 2-related factor 2 to mediate induction of NAD(P)H: quinoneoxidoreductase 1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE Ah receptor; Nrf2; NQO1; TCDD; ARE; Cross-interaction ID ANTIOXIDANT RESPONSE ELEMENT; DRUG-METABOLIZING-ENZYMES; AH RECEPTOR; NAD(P)H-QUINONE OXIDOREDUCTASE; TRANSCRIPTIONAL REGULATION; QUINONE REDUCTASE; GENE-EXPRESSION; DNA-BINDING; IN-VIVO; NRF2 AB NAD(P)H:quinoneoxidoreductase 1 (NQO1) belongs to a group of the aryl hydrocarbon receptor (AhR) battery of drug-metabolizing enzymes that are characteristically induced by both AhR agonists and nuclear factor erythroid 2-related factor 2 (Nrf2) activators. We have previously reported that induction of Nqo1 by the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in hepa1c1c7 cells involves Nrf2 (Ma et al., Biochem J 377, 205-213, 2004). Here we analyzed the molecular mechanism of induction. Induction required AhR and its DNA-binding partner Arnt because induction was not observed in AhR or Arnt-defective cells, but induction was restored upon reconstitution of the variant cells with functional AhR or Arnt. Induction also required Nrf2, as induction by benzo[a]pyrene was lost in the liver of Nrf2 knockout mice similarly to induction by butyl hydroxyanisol, demonstrating a cross-interaction between the AhR and Nrf2 pathways for induction in vivo. TCDD increased the protein level and induced the nuclear accumulation of Nrf2 with a delayed kinetics compared with activation of AhR. Chromatin immunoprecipitation revealed that TCDD recruited both AhR and Nrf2 to the Nqo1 promoter enhancer region containing a ORE and an ARE in time-dependent manners. Co-immunoprecipitation experiments revealed that, in addition to AhR-Arnt binding, TCDD induced an interaction between AhR and Nrf2 as well as Keap1. The findings reveal that TCDD induces multi protein complexes to mediate cross-interaction between the AhR and Nrf2 pathways, uncovering a novel mechanistic aspect of gene regulation by environmental chemicals through AhR and Nrf2. (C) 2013 Elsevier Inc. All rights reserved. C1 [Wang, Liping; Bi, Yongyi] Wuhan Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan 430071, Peoples R China. [Wang, Liping; Szklarz, Grazyna D.; Rojanasakul, Yon] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA. [He, Xiaoqing; Ma, Qiang] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Wang, LP (reprint author), 185 Donghu Rd, Wuhan 430071, Hubei, Peoples R China. EM may21thwlp@163.com; qam1@cdc.gov OI Rojanasakul, Yon/0000-0002-8839-6462 FU National Institute for Occupational Safety and Health USA [939ZXFF]; National Nature Science Foundation China [810772276] FX The study was supported in part by a grant from the National Institute for Occupational Safety and Health USA (939ZXFF) to Q. Ma and by a grant from the National Nature Science Foundation China (810772276) to Y. Bi. NR 29 TC 17 Z9 17 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD SEP 1 PY 2013 VL 537 IS 1 BP 31 EP 38 DI 10.1016/j.abb.2013.06.001 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 210DE UT WOS:000323808700005 PM 23800876 ER PT J AU Hernaez, R McLean, J Lazo, M Brancati, FL Hirschhorn, JN Borecki, IB Harris, TB Nguyen, T Kamel, IR Bonekamp, S Eberhardt, MS Clark, JM Kao, WHL Speliotes, EK AF Hernaez, Ruben McLean, Jody Lazo, Mariana Brancati, Frederick L. Hirschhorn, Joel N. Borecki, Ingrid B. Harris, Tamara B. Thutrang Nguyen Kamel, Ihab R. Bonekamp, Susanne Eberhardt, Mark S. Clark, Jeanne M. Kao, Wen Hong Linda Speliotes, Elizabeth K. CA Genetics Obesity-Related Liver Dis TI Association Between Variants in or Near PNPLA3, GCKR, and PPP1R3B With Ultrasound-Defined Steatosis Based on Data From the Third National Health and Nutrition Examination Survey SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Nonalcoholic Fatty Liver Disease; Replication; Candidate Gene Study; Genome-wide Association Study; SNP ID FATTY LIVER-DISEASE; GENOME-WIDE ASSOCIATION; US ADULTS; SUSCEPTIBILITY LOCI; METABOLIC SYNDROME; FASTING GLUCOSE; IDENTIFIES LOCI; PREVALENCE; METAANALYSIS; GLYCOGEN AB BACKGROUND & AIMS: A genome-wide association study associated 5 genetic variants with hepatic steatosis (identified by computerized tomography) in individuals of European ancestry. We investigated whether these variants were associated with measures of hepatic steatosis (HS) in non-Hispanic white (NHW), non-Hispanic black, and Mexican American (MA) participants in the US population-based National Health and Nutrition Examination Survey III, phase 2. METHODS: We analyzed data from 4804 adults (1825 NHW, 1442 non-Hispanic black, and 1537 MA; 51.7% women; mean age at examination, 42.5 y); the weighted prevalence of HS was 37.3%. We investigated whether ultrasound-measured HS, with and without increased levels of alanine aminotransferase (ALT), or level of ALT alone, was associated with rs738409 (patatin-like phospholipase domain-containing protein 3 [PNPLA3]), rs2228603 (neurocan [NCAN]), rs12137855 (lysophospholipase-like 1), rs780094 (glucokinase regulatory protein [GCKR]), and rs4240624 (protein phosphatase 1, regulatory subunit 3b [PPP1R3B]) using regression modeling in an additive genetic model, controlling for age, age-squared, sex, and alcohol consumption. RESULTS: The G allele of rs738409 (PNPLA3) and the T allele of rs780094 (GCKR) were associated with HS with a high level of ALT (odds ratio [OR], 1.36; P = .01; and OR, 1.30; P = .03, respectively). The A allele of rs4240624 (PPP1R3B) and the T allele of rs2228603 (NCAN) were associated with HS (OR, 1.28; P = .03; and OR, 1.40; P = .04, respectively). Variants of PNPLA3 and NCAN were associated with ALT level among all 3 ancestries. Some single-nucleotide polymorphisms were associated with particular races or ethnicities: variants in PNPLA3, NCAN, GCKR, and PPP1R3B were associated with NHW and variants in PNPLA3 were associated with MA. No variants were associated with NHB. CONCLUSIONS: We used data from the National Health and Nutrition Examination Survey III to validate the association between rs738409 (PNPLA3), rs780094 (GCKR), and rs4240624 (PPP1R3B) with HS, with or without increased levels of ALT, among 3 different ancestries. Some, but not all, associations between variants in NCAN, lysophospholipase-like 1, GCKR, and PPP1R3B with HS (with and without increased ALT level) were significant within subpopulations. C1 [Hernaez, Ruben; Lazo, Mariana; Brancati, Frederick L.; Clark, Jeanne M.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Kamel, Ihab R.; Bonekamp, Susanne] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA. [Hernaez, Ruben; Lazo, Mariana; Brancati, Frederick L.; Clark, Jeanne M.; Kao, Wen Hong Linda] Johns Hopkins Univ, Dept Epidemiol, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Brancati, Frederick L.; Clark, Jeanne M.; Kao, Wen Hong Linda] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. [Hernaez, Ruben] Georgetown Univ Hosp, Washington Hosp Ctr, Dept Med, Washington, DC 20007 USA. [McLean, Jody] NOVA Res Co, Bethesda, MD USA. [Hirschhorn, Joel N.; Thutrang Nguyen] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Hirschhorn, Joel N.; Thutrang Nguyen] Childrens Hosp, Div Genet, Boston, MA 02115 USA. [Hirschhorn, Joel N.; Thutrang Nguyen] Childrens Hosp, Program Genom, Boston, MA 02115 USA. [Hirschhorn, Joel N.; Thutrang Nguyen; Speliotes, Elizabeth K.] Broad Inst, Cambridge, MA USA. [Hirschhorn, Joel N.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA. [Harris, Tamara B.] NIH, Natl Inst Aging, Intramural Res Program, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA. [Eberhardt, Mark S.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Speliotes, Elizabeth K.] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA. [Speliotes, Elizabeth K.] Univ Michigan, Ctr Computat Med & Bioinformat, Ann Arbor, MI 48109 USA. RP Speliotes, EK (reprint author), Univ Michigan, 6520 MSRBI,SPC 5682,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA. EM espeliot@med.umich.edu RI Hernaez, Ruben/C-4039-2014; OI Hernaez, Ruben/0000-0002-1518-4020; Bonekamp, Susanne/0000-0001-5847-5656 FU American Diabetes Association [7-07-MN-08]; Doris Duke Medical Foundation; National Institutes of Health [K23DK080145-01, R01DK075787, 5R01DK075681, R01 DK083393] FX Supported by the American Diabetes Association Mentor-Based Fellowship Program 7-07-MN-08 (R.H., M.L., F.L.B.), Doris Duke Medical Foundation (E.K.S.), National Institutes of Health grants K23DK080145-01 (E.K.S.), R01DK075787 (J.N.H.), 5R01DK075681 (I.B.B.), and R01 DK083393 (J.M.C., R.H., M.L., F.L.B., I.R.H., S.B., W.H.L.K.). NR 32 TC 35 Z9 37 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD SEP PY 2013 VL 11 IS 9 BP 1183 EP U203 DI 10.1016/j.cgh.2013.02.011 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 210FU UT WOS:000323816100027 PM 23416328 ER PT J AU Tollefson, D Bloss, E Fanning, A Redd, JT Barker, K McCray, E AF Tollefson, D. Bloss, E. Fanning, A. Redd, J. T. Barker, K. McCray, E. TI Burden of tuberculosis in indigenous peoples globally: a systematic review SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Review DE tuberculosis; indigenous; surveillance; global ID FAR NORTH QUEENSLAND; PULMONARY TUBERCULOSIS; UNITED-STATES; CENTRAL INDIA; TRIBAL POPULATION; MADHYA-PRADESH; RISK-FACTORS; NEW-ZEALAND; PEDIATRIC TUBERCULOSIS; CLINICAL-FEATURES AB BACKGROUND: The burden of tuberculosis (TB) in the estimated 370 million indigenous peoples worldwide is unknown. OBJECTIVE: To conduct a literature review to summarize the TB burden in indigenous peoples, identify gaps in current knowledge, and provide the foundation for a research agenda prioritizing indigenous health within TB control. METHODS: A systematic literature review identified articles published between January 1990 and November 2011 quantifying TB disease burden in indigenous populations worldwide. RESULTS: Among the 91 articles from 19 countries included in the review, only 56 were from outside Australia, Canada, New Zealand and the United States. The majority of the studies showed higher TB rates among indigenous groups than non-indigenous groups. Studies from the Amazon generally reported the highest TB prevalence and incidence, but select populations from South-East Asia and Africa were found to have similarly high rates of TB. In North America, the Inuit had the highest reported TB incidence (156/100000), whereas the Metis of Canada and American Indians/Alaska Natives experienced rates of <10/100000. New Zealand's Maori and Pacific Islanders had higher TB incidence rates than Australian Aborigines, but all were at greater risk of developing TB than non-indigenous groups. CONCLUSION: Where data exist, indigenous peoples were generally found to have higher rates of TB disease than non-indigenous peoples; however, this burden varied greatly. The paucity of published information on TB burden among indigenous peoples highlights the need to implement and improve TB surveillance to better measure and understand global disparities in TB rates. C1 [Tollefson, D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Bloss, E.; McCray, E.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Fanning, A.] Univ Alberta, Edmonton, AB T6G 2M7, Canada. [Redd, J. T.] US Indian Hlth Serv, Santa Fe, NM USA. [Barker, K.] Univ Toronto, Toronto, ON, Canada. RP Bloss, E (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Int Res & Programs Branch, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM dpu2@cdc.gov NR 103 TC 14 Z9 14 U1 2 U2 24 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD SEP PY 2013 VL 17 IS 9 BP 1139 EP 1150 DI 10.5588/ijtld.12.0385 PG 12 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 210BN UT WOS:000323804400005 PM 23823137 ER PT J AU Prandini, THR Theodoro, RC Bruder-Nascimento, ACMO Scheel, CM Bagagli, E AF Rocha Prandini, Tamara Heloisa Theodoro, Raquel Cordeiro Bruder-Nascimento, Ariane C. M. O. Scheel, Christina M. Bagagli, Eduardo TI Analysis of Inteins in the Candida parapsilosis Complex for Simple and Accurate Species Identification SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID BLOOD-STREAM INFECTIONS; POPULATION-BASED SURVEILLANCE; INTERNAL TRANSCRIBED SPACER; MOLECULAR EPIDEMIOLOGY; MAXIMUM-LIKELIHOOD; PARACOCCIDIOIDES-BRASILIENSIS; ANTIFUNGAL SUSCEPTIBILITY; PHYLOGENETIC ANALYSIS; BIOFILM PRODUCTION; SENSU-LATO AB Inteins are coding sequences that are transcribed and translated with flanking sequences and then are excised by an autocatalytic process. There are two types of inteins in fungi, mini-inteins and full-length inteins, both of which present a splicing domain containing well-conserved amino acid sequences. Full-length inteins also present a homing endonuclease domain that makes the intein a mobile genetic element. These parasitic genetic elements are located in highly conserved genes and may allow for the differentiation of closely related species of the Candida parapsilosis (psilosis) complex. The correct identification of the three psilosis complex species C. parapsilosis, Candida metapsilosis, and Candida orthopsilosis is very important in the clinical setting for improving antifungal therapy and patient care. In this work, we analyzed inteins that are present in the vacuolar ATPase gene VMA and in the threonyl-tRNA synthetase gene ThrRS in 85 strains of the Candida psilosis complex (46 C. parapsilosis, 17 C. metapsilosis, and 22 C. orthopsilosis). Here, we describe an accessible and accurate technique based on a single PCR that is able to differentiate the psilosis complex based on the VMA intein. Although the ThrRS intein does not distinguish the three species of the psilosis complex by PCR product size, it can differentiate them by sequencing and phylogenetic analysis. Furthermore, this intein is unusually present as both mini-and full-length forms in C. orthopsilosis. Additional population studies should be performed to address whether this represents a common intraspecific variability or the presence of subspecies within C. orthopsilosis. C1 [Rocha Prandini, Tamara Heloisa; Bruder-Nascimento, Ariane C. M. O.; Bagagli, Eduardo] UNESP, Inst Biosci, Dept Microbiol & Immunol, Botucatu, SP, Brazil. [Theodoro, Raquel Cordeiro] Univ Fed Rio Grande do Norte, Rio Grande Do Norte, Brazil. [Scheel, Christina M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Bagagli, E (reprint author), UNESP, Inst Biosci, Dept Microbiol & Immunol, Botucatu, SP, Brazil. EM bagagli@ibb.unesp.br FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/04003-1, 2012/07741-3] FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) grants no. 2012/04003-1 and 2012/07741-3. NR 61 TC 8 Z9 8 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2013 VL 51 IS 9 BP 2830 EP 2836 DI 10.1128/JCM.00981-13 PG 7 WC Microbiology SC Microbiology GA 202KL UT WOS:000323214200005 PM 23784117 ER PT J AU Mijatovic-Rustempasic, S Tam, KI Kerin, TK Lewis, JM Gautam, R Quaye, O Gentsch, JR Bowen, MD AF Mijatovic-Rustempasic, Slavica Tam, Ka Ian Kerin, Tara K. Lewis, Jamie M. Gautam, Rashi Quaye, Osbourne Gentsch, Jon R. Bowen, Michael D. TI Sensitive and Specific Quantitative Detection of Rotavirus A by One-Step Real-Time Reverse Transcription-PCR Assay without Antecedent Double-Stranded-RNA Denaturation SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID POLYMERASE-CHAIN-REACTION; GROUP-A ROTAVIRUS; RT-PCR; UNITED-STATES; ACUTE GASTROENTERITIS; ENZYME IMMUNOASSAYS; VIRUS-REPLICATION; STOOL SPECIMENS; FECAL SPECIMENS; CELL-CULTURE AB A real-time quantitative reverse transcription-PCR (qRT-PCR) assay using the recombinant thermostable Thermus thermophilus (rTth) enzyme was developed to detect and quantify rotavirus A (RVA). By using rTth polymerase, significant improvement was achieved over the existing real-time RT-PCR assays, which require denaturation of the RVA double-stranded RNA (dsRNA) prior to assay setup. Using a dsRNA transcript for segment 7, which encodes the assay target NSP3 gene, the limit of detection for the improved assay was calculated to be approximately 1 genome copy per reaction. The NSP3 qRT-PCR assay was validated using a panel of 1,906 stool samples, 23 reference RVA strains, and 14 nontarget enteric virus samples. The assay detected a diverse number of RVA genotypes and did not detect other enteric viruses, demonstrating analytical sensitivity and specificity for RVA in testing stool samples. A XenoRNA internal process control was introduced and detected in a multiplexed qRT-PCR format. Because it does not require an antecedent dsRNA denaturation step, this assay reduces the possibility of sample cross-contamination and requires less hands-on time than other published qRT-PCR protocols for RVA detection. C1 [Mijatovic-Rustempasic, Slavica; Tam, Ka Ian; Kerin, Tara K.; Lewis, Jamie M.; Gautam, Rashi; Quaye, Osbourne; Gentsch, Jon R.; Bowen, Michael D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM mkb6@cdc.gov NR 54 TC 15 Z9 15 U1 0 U2 18 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2013 VL 51 IS 9 BP 3047 EP 3054 DI 10.1128/JCM.01192-13 PG 8 WC Microbiology SC Microbiology GA 202KL UT WOS:000323214200037 PM 23850952 ER PT J AU Traxler, RM Lehman, MW Bosserman, EA Guerra, MA Smith, TL AF Traxler, Rita M. Lehman, Mark W. Bosserman, Elizabeth A. Guerra, Marta A. Smith, Theresa L. TI A Literature Review of Laboratory-Acquired Brucellosis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Review ID BRITISH CLINICAL LABORATORIES; OCCUPATIONAL HAZARD; INFECTIONS; MELITENSIS; OUTBREAK; TRANSMISSION; WORKERS; PREVENTION; EXPOSURE; ABORTUS AB Brucellosis is a bacterial zoonotic disease which has been associated with laboratory-acquired infections. No recent reviews have addressed the characteristics of laboratory-acquired brucellosis (LAB). English-language literature was reviewed to identify reports of laboratory exposures to Brucella spp. and LAB cases between 1982 and 2007. Evaluation of 28 case reports identified 167 potentially exposed laboratory workers, of whom 71 had LAB. Nine reports were identified that summarized an additional 186 cases of LAB. Only 18 (11%) exposures were due to laboratory accidents, 147 (88%) exposures were due to aerosolization of organisms during routine identification activities, and the circumstances of 2 (1%) exposures were unknown. Brucella melitensis was the causative agent in 80% (135/167) of the exposures. Workers with high-risk exposures were 9.3 times more likely to develop LAB than workers with low-risk exposures (95% confidence interval [CI], 3.0 to 38.6; P < 0.0001); they were also 0.009 times likelier to develop LAB if they took antimicrobial PEP than if they did not (95% CI, 0 to 0.042; P < 0.0001). The median incubation period in case and summary reports was 8 weeks (range 1 to 40 weeks). Antimicrobial PEP is effective in preventing LAB. The incubation period may be used to identify appropriate serological and symptom surveillance time frames for exposed laboratory workers. C1 [Traxler, Rita M.; Lehman, Mark W.; Bosserman, Elizabeth A.; Guerra, Marta A.; Smith, Theresa L.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Lehman, Mark W.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Traxler, RM (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. EM RTraxler@cdc.gov NR 77 TC 18 Z9 21 U1 0 U2 13 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2013 VL 51 IS 9 BP 3055 EP 3062 DI 10.1128/JCM.00135-13 PG 8 WC Microbiology SC Microbiology GA 202KL UT WOS:000323214200038 PM 23824774 ER PT J AU Traxler, RM Guerra, MA Morrow, MG Haupt, T Morrison, J Saah, JR Smith, CG Williams, C Fleischauer, AT Lee, PA Stanek, D Trevino-Garrison, I Franklin, P Oakes, P Hand, S Shadomy, SV Blaney, DD Lehman, MW Benoit, TJ Stoddard, RA Tiller, RV De, BK Bower, W Smith, TL AF Traxler, R. M. Guerra, M. A. Morrow, M. G. Haupt, T. Morrison, J. Saah, J. R. Smith, C. G. Williams, C. Fleischauer, A. T. Lee, P. A. Stanek, D. Trevino-Garrison, I. Franklin, P. Oakes, P. Hand, S. Shadomy, S. V. Blaney, D. D. Lehman, M. W. Benoit, T. J. Stoddard, R. A. Tiller, R. V. De, B. K. Bower, W. Smith, T. L. TI Review of Brucellosis Cases from Laboratory Exposures in the United States in 2008 to 2011 and Improved Strategies for Disease Prevention SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MELITENSIS; INFECTION; WORKERS; STRAIN AB Five laboratory-acquired brucellosis (LAB) cases that occurred in the United States between 2008 and 2011 are presented. The Centers for Disease Control and Prevention (CDC) reviewed the recommendations published in 2008 and the published literature to identify strategies to further prevent LAB. The improved prevention strategies are described. C1 [Traxler, R. M.; Guerra, M. A.; Morrow, M. G.; Fleischauer, A. T.; Shadomy, S. V.; Blaney, D. D.; Lehman, M. W.; Benoit, T. J.; Stoddard, R. A.; Tiller, R. V.; De, B. K.; Bower, W.; Smith, T. L.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Haupt, T.] Wisconsin Dept Hlth Serv, Madison, WI USA. [Morrison, J.] Univ Wisconsin, Madison, WI USA. [Saah, J. R.; Smith, C. G.; Williams, C.; Fleischauer, A. T.] North Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Lee, P. A.] Bur Publ Hlth Labs, Florida Dept Hlth, Jacksonville, FL USA. [Stanek, D.] Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. [Trevino-Garrison, I.] Kansas Dept Hlth & Environm, Topeka, KS USA. [Franklin, P.] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. [Oakes, P.; Hand, S.] Mississippi Dept Hlth, Jackson, MS USA. [Lehman, M. W.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Traxler, RM (reprint author), Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. EM RTraxler@cdc.gov NR 31 TC 10 Z9 11 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD SEP PY 2013 VL 51 IS 9 BP 3132 EP 3136 DI 10.1128/JCM.00813-13 PG 5 WC Microbiology SC Microbiology GA 202KL UT WOS:000323214200058 PM 23824776 ER PT J AU Forbi, JC Ben-Ayed, Y Xia, GL Vaughan, G Drobeniuc, J Switzer, WM Khudyakov, YE AF Forbi, Joseph C. Ben-Ayed, Yousr Xia, Guo-liang Vaughan, Gilberto Drobeniuc, Jan Switzer, William M. Khudyakov, Yury E. TI Disparate distribution of hepatitis B virus genotypes in four sub-Saharan African countries SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Hepatitis B virus; Phylogenetic analysis; Genotypes; Subgenotypes; Sub-Saharan Africa ID GENETIC DIVERSITY; SURFACE-ANTIGEN; BLOOD-DONORS; WEST-AFRICA; MOLECULAR CHARACTERIZATION; PHYLOGENETIC ANALYSIS; SOUTH-AFRICA; SUBGENOTYPE; HIV; EPIDEMIOLOGY AB Background: Hepatitis B virus (HBV) places a substantial health burden on Africa. Here, we investigated genetic diversity of HBV variants circulating in 4 countries of sub-Saharan Africa using archived samples. In total, 1492 plasma samples were tested from HIV-infected individuals and pregnant women, among which 143 (9.6%) were PCR-positive for HBV DNA (Cote d'Ivoire, 70/608 [11.5%]; Ghana, 13/444 [2.9%]; Cameroon, 33/303 [10.9%]; and Uganda, 27/137 [19.7%]). Study design/results: Phylogenetic analysis of the S-gene sequences identified HBV genotypes E (HBV/E, n=96) and A (HBV/A, n=47) distributed as follows: 87% of HBV/E and 13% of HBV/A in Cote d'Ivoire; 100% of HBV/E in Ghana; 67% of HBV/E and 33% of HBV/A in Cameroon; and 100% of HBV/A in Uganda. The average and maximal nucleotide distances among HBV/E sequences were 1.9% and 6.4%, respectively, suggesting a greater genetic diversity for this genotype than previously reported (p<0.001). HBV/A strains were classified into subgenotypes HBV/A1, HBV/A2 and HBV/A3. In Uganda, 93% of HBV/A strains belonged to HBV/A1 whereas HBV/A3 was the only subgenotype of HBV/A found in Cameroon. In Cote d'Ivoire, HBV/A strains were classified as HBV/A1 (11.1%), HBV/A2 (33.3%) and HBV/A3 (55.6%). Phylogeographic analysis of the sequences available from Africa supported earlier suggestions on the origin of HBV/A1, HBV/A2 and HBV/A3 in East, South and West/Central Africa, respectively. Using predicted amino acid sequences, hepatitis B surface antigen (HBsAg) was classified into serotype ayw4 in 93% of HBV/E strains and adw2 in 68% of HBV/A strains. Also, 7.7% of the sequences carried substitutions in HBsAg associated with immune escape. Conclusions: The observations of pan-African and global dissemination of HBV/A1 and HBV/A2, and the circulation of HBV/E and HBV/A3 almost exclusively in West and Central Africa suggest a more recent increase in prevalence in Africa of HBV/E and HBV/A3 compared to HBV/A1 and HBV/A2. The broad genetic heterogeneity of HBsAg detected here may impact the efficacy of prevention and control efforts in sub-Saharan Africa. Published by Elsevier B.V. C1 [Forbi, Joseph C.; Ben-Ayed, Yousr; Xia, Guo-liang; Vaughan, Gilberto; Drobeniuc, Jan; Khudyakov, Yury E.] Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Forbi, JC (reprint author), Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM JForbi@cdc.gov FU Laboratory Branch, Division of Viral Hepatitis, CDC, Atlanta, GA, USA FX Laboratory Branch, Division of Viral Hepatitis, CDC, Atlanta, GA, USA. NR 59 TC 9 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2013 VL 58 IS 1 BP 59 EP 66 DI 10.1016/j.jcv.2013.06.028 PG 8 WC Virology SC Virology GA 206ZB UT WOS:000323564500011 PM 23871163 ER PT J AU Hernandez, BY Wilkens, LR Unger, ER Steinau, M Markowitz, L Garvin, K Thompson, PJ Shvetsov, YB O'Dillon, K Dunne, EF AF Hernandez, Brenda Y. Wilkens, Lynne R. Unger, Elizabeth R. Steinau, Martin Markowitz, Lauri Garvin, Keiko Thompson, Pamela J. Shvetsov, Yurii B. O'Dillon, Kristen Dunne, Eileen F. TI Evaluation of genital self-sampling methods for HPV detection in males SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Genital; Self-sampling; HPV; Males ID HUMAN-PAPILLOMAVIRUS INFECTION; UNITED-STATES; SEX PARTNERS; RISK-FACTORS; MEN; PREVALENCE; SITES; DNA; CIRCUMCISION; COHORT AB Background: There are no population-based HPV prevalence estimates in males because optimal sampling methods are unclear. Objectives: To evaluate the acceptability, feasibility, and validity of different male genital self-sampling methods for HPV detection. Study design: A total of 450 males, 14-59 years old, were randomly assigned to one of three genital sampling methods: (1) dry polyester-tipped swab; (2) dry foam swab; and (3) emery paper and wetted polyester-tipped swab. Samples were both self-collected and collected by a clinician. Subjects were queried on the acceptability of sampling methods. HPV was genotyped using an L1 consensus PCR assay. Results: Specimen adequacy (92-96%, p = 0.28) and HPV detection (44-49%, p = 0.68) were comparable across the three methods. Concordance for HPV detection was observed between self-and clinician-collected specimen pairs for all methods (kappa = 0.70-0.80). The collection procedure was reported to be very easy by 69% of dry polyester-tipped swab users and 64% of dry foam swab users compared to 48% of emery-wet swab users (p = 0.004). Similarly, 43-44% of dry swab and foam users reported the collection to be very comfortable compared to 24% of emery-wet swab users (p = 0.002). Pain was reported by 10% of emery-wet swab users compared to 3% and 5% of dry swab and foam users, respectively (p = 0.03). Self-collection by the emery-wet swab method required an average of 6 min compared to 3.3-3.5 min for the two dry methods (p < 0.0001). Conclusions: The dry collection methods are optimal for use in large epidemiologic studies or surveillance efforts based on their acceptability and feasibility. (C) 2013 Elsevier B. V. All rights reserved. C1 [Hernandez, Brenda Y.; Wilkens, Lynne R.; Garvin, Keiko; Thompson, Pamela J.; Shvetsov, Yurii B.] Univ Hawaii, Ctr Canc, Honolulu, HI 96813 USA. [Unger, Elizabeth R.; Steinau, Martin; Markowitz, Lauri; Dunne, Eileen F.] Ctr Dis Control & Prevent, Atlanta, GA USA. [O'Dillon, Kristen] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. RP Hernandez, BY (reprint author), Univ Hawaii, Ctr Canc, 701 Ilalo St, Honolulu, HI 96813 USA. EM brenda@cc.hawaii.edu OI Unger, Elizabeth/0000-0002-2925-5635 FU American Association of Medical Colleges [MM-1132]; Centers for Disease Control and Prevention FX This work was supported by grant # MM-1132 from the American Association of Medical Colleges and the Centers for Disease Control and Prevention. NR 23 TC 2 Z9 2 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2013 VL 58 IS 1 BP 168 EP 175 DI 10.1016/j.jcv.2013.06.032 PG 8 WC Virology SC Virology GA 206ZB UT WOS:000323564500029 PM 23880161 ER PT J AU Bankamp, B Byrd-Leotis, LA Lopareva, EN Woo, GKS Liu, CY Jee, Y Ahmed, H Lim, WW Ramamurty, N Mulders, MN Featherstone, D Bellini, WJ Rota, PA AF Bankamp, Bettina Byrd-Leotis, Lauren A. Lopareva, Elena N. Woo, Gibson K. S. Liu, Chunyu Jee, Youngmee Ahmed, Hinda Lim, Wilina W. Ramamurty, Nalini Mulders, Mick N. Featherstone, David Bellini, William J. Rota, Paul A. TI Improving molecular tools for global surveillance of measles virus SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Measles; Molecular diagnostics; FTA (R) cards; Genotyping ID AVIAN INFLUENZA-VIRUS; FTA(R) FILTER-PAPER; TIME RT-PCR; GEOGRAPHICAL-DISTRIBUTION; GENETIC-VARIABILITY; DISEASE VIRUS; EPIDEMIOLOGY; GENOTYPES; IDENTIFICATION; CARDS AB Background: The genetic characterization of wild-type measles viruses plays an important role in the description of viral transmission pathways and the verification of measles elimination. The 450 nucleotides that encode the carboxyl-terminus of the nucleoprotein (N-450) are routinely sequenced for genotype analysis. Objectives: The objectives of this study were to develop improved primers and controls for RT-PCR reactions used for genotyping of measles samples and to develop a method to provide a convenient, safe, and inexpensive means to distribute measles RNA for RT-PCR assays and practice panels. Study design: A newly designed, genetically defined synthetic RNA and RNA isolated from cells infected with currently circulating genotypes were used to compare the sensitivity of primer pairs in RT-PCR and nested PCR. FTA (R) cards loaded with lysates of measles infected cells were tested for their ability to preserve viral RNA and destroy virus infectivity. Results: A new primer pair, MeV216/MeV214, was able to amplify N-450 from viruses representing 10 currently circulating genotypes and a genotype A vaccine strain and demonstrated 100-fold increased sensitivity compared to the previously used primer set. A nested PCR assay further increased the sensitivity of detection from patient samples. A synthetic positive control RNA was developed that produced PCR products that are distinguishable by size from PCR products amplified from clinical samples. FTA (R) cards completely inactivated measles virus and stabilized RNA for at least six months. Conclusions: These improved molecular tools will advance molecular characterization of circulating measles viruses globally and provide enhanced quality control measures. Published by Elsevier B.V. C1 [Bankamp, Bettina; Byrd-Leotis, Lauren A.; Lopareva, Elena N.; Liu, Chunyu; Bellini, William J.; Rota, Paul A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Div Viral Dis, Atlanta, GA 30333 USA. [Woo, Gibson K. S.; Lim, Wilina W.] Ctr Hlth Protect, Dept Hlth, Publ Hlth Lab Serv Branch, Kowloon, Hong Kong, Peoples R China. [Jee, Youngmee] World Hlth Org, Reg Off Western Pacific, Manila, Philippines. [Ahmed, Hinda] World Hlth Org, Reg Off Eastern Mediterranean, Cairo, Egypt. [Ramamurty, Nalini] World Hlth Org, Reg Off South East Asia, New Delhi, India. [Mulders, Mick N.; Featherstone, David] World Hlth Org, Dept Immunizat Vaccines & Biol, Geneva, Switzerland. RP Bankamp, B (reprint author), Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Div Viral Dis, MS C-22,1600 Clifton Rd, Atlanta, GA 30333 USA. EM bbankamp@cdc.gov FU WHO FX LabNet regional reference laboratories are supported in part by WHO. NR 43 TC 14 Z9 16 U1 0 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2013 VL 58 IS 1 BP 176 EP 182 DI 10.1016/j.jcv.2013.05.018 PG 7 WC Virology SC Virology GA 206ZB UT WOS:000323564500030 PM 23806666 ER PT J AU Wesolowski, LG Delaney, KP Meyer, WA Blatt, AJ Bennett, B Chavez, P Granade, TC Owen, M AF Wesolowski, Laura G. Delaney, Kevin P. Meyer, William A., III Blatt, Amy J. Bennett, Berry Chavez, Pollyanna Granade, Timothy C. Owen, Michele TI Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blot SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HIV; Diagnosis; Algorithm; Rapid test; Western blot ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; INFECTION; DIAGNOSIS; TYPE-2; RNA; PERFORMANCE; ANTIBODIES; ALGORITHM; PLASMA AB Background: An alternate HIV testing algorithm has been proposed which includes a fourth-generation immunoassay followed by an HIV-1/HIV-2 antibody differentiation supplemental test for reactive specimens and a nucleic acid test (NAT) for specimens with discordant results. Objective: To evaluate the performance of five rapid tests (Alere Clearview, Bio-Rad Multispot, OraSure OraQuick, MedMira Reveal, and Trinity Biotech Unigold) as the supplemental antibody assay in the algorithm. Study design: A total of 3273 serum and plasma specimens that were third-generation immunoassay repeatedly reactive and Western blot (WB) negative or indeterminate were tested with rapid tests and NAT. Specimens were classified by NAT: (1) HIV-1 infected (NAT-reactive; n = 184, 5.6%), (2) HIV-status unknown (NAT nonreactive; n = 3078, 94.2%) or by Multispot, (3) HIV-2 positive (n = 5), and (4) HIV-1 and HIV-2 positive (n = 6). Excluding HIV-2 positive specimens, we calculated the proportion of reactive rapid tests among specimens with reactive and nonreactive NAT. Results: The proportion of infected specimens with reactive rapid test results and negative or indeterminate WB ranged from 30.4% (56) to 47.8% (88) depending on the rapid test. From 1% to 2% of NAT-negative specimens had reactive rapid test results. Conclusions: In these diagnostically challenging specimens, all rapid tests identified infections that were missed by the Western blot, but only Multispot could differentiate HIV-1 from HIV-2. Regardless of which rapid test is used as a supplemental test in the alternative algorithm, false-positive algorithm results (i.e., reactive screening and rapid test in uninfected person) may occur, which will need to be resolved during the baseline medical evaluation. Published by Elsevier B.V. C1 [Wesolowski, Laura G.; Delaney, Kevin P.; Chavez, Pollyanna; Granade, Timothy C.; Owen, Michele] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Meyer, William A., III] Quest Diagnost, Baltimore, MD 21227 USA. [Blatt, Amy J.] Quest Diagnost, West Norriton, PA 19403 USA. [Bennett, Berry] Florida Bur Labs, Jacksonville, FL 32202 USA. RP Wesolowski, LG (reprint author), Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS E46, Atlanta, GA 30333 USA. EM lig7@cdc.gov FU Centers for Disease Control and Prevention FX This project was funded by the Centers for Disease Control and Prevention. NR 31 TC 4 Z9 4 U1 0 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2013 VL 58 IS 1 BP 240 EP 244 DI 10.1016/j.jcv.2013.06.019 PG 5 WC Virology SC Virology GA 206ZB UT WOS:000323564500041 PM 23838670 ER PT J AU Gautam, R Lyde, F Esona, MD Quaye, O Bowen, MD AF Gautam, Rashi Lyde, Freda Esona, Mathew D. Quaye, Osbourne Bowen, Michael D. TI Comparison of Premier (TM) Rotaclone (R), ProSpecT (TM), and RIDASCREEN (R) rotavirus enzyme immunoassay kits for detection of rotavirus antigen in stool specimens SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Rotavirus; EIA; Comparison; RT-PCR; Sensitivity; Specificity ID POLYMERASE CHAIN-REACTION; CHILDREN AB Background: Rotaviruses are the major cause of severe dehydrating diarrhea in children throughout the world. Enzyme immunoassays (EIAs) have been the standard method for detection of rotavirus in stool specimens since the 1980s. The World Health Organization (WHO) Rotavirus Surveillance Network has proposed including three EIA kits in the WHO-GSM (Global Management System/Systeme Mondial de Gestion) catalog for easy procurement of EIA kits by participating rotavirus surveillance network laboratories. Objectives: In this study, we conducted a comparative analysis of 3 commercially available enzyme immunoassay kits: Premier (TM) Rotaclone (R) (Meridian Bioscience, Inc.), ProSpecT (TM) (Oxoid, Ltd.) and RIDASCREEN (R) (R-biopharm AG) for rotavirus diagnostics. Study design: Using reverse-transcriptase-PCR (RT-PCR) as the gold standard, the 3 EIA kits were evaluated by testing a stool panel consisting of 56 rotavirus-positive and 54 rotavirus negative samples. Results: The sensitivities of the Premier (TM) Rotaclone (R), ProSpecT (TM) and RIDASCREEN (R) kits were 76.8%, 75% and 82.1%, respectively, but did not differ significantly. The specificity of all the 3 kits was 100%. The use of RT-PCR as a gold standard lowered the observed sensitivity of all 3 EIA kits but helps to reduce equivocal results that can be seen when another EIA or other non-molecular methods are used as the reference assay in comparison studies. Conclusion: Our study found that all three kits are suitable for use by rotavirus surveillance programs. Published by Elsevier B.V. C1 [Gautam, Rashi; Lyde, Freda; Esona, Mathew D.; Quaye, Osbourne; Bowen, Michael D.] Ctr Dis Control & Prevent, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA 30333 USA. [Quaye, Osbourne] Univ Ghana, Dept Biochem Cell & Mol Biol, Legon, Accra, Ghana. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, DVD, NCIRD, 1600 Clifton Rd NE,Mailstop G04, Atlanta, GA 30333 USA. EM MKB6@CDC.GOV FU WHO; CDC FX Funding was provided by WHO and CDC. NR 9 TC 19 Z9 20 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD SEP PY 2013 VL 58 IS 1 BP 292 EP 294 DI 10.1016/j.jcv.2013.06.022 PG 3 WC Virology SC Virology GA 206ZB UT WOS:000323564500055 PM 23850415 ER PT J AU Shults, RA Williams, AF AF Shults, Ruth A. Williams, Allan F. TI Trends in driver licensing status and driving among high school seniors in the United States, 1996-2010 SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Adolescent; Teenagers; Motor vehicles; Automobile driving; Licensure AB Introduction: Understanding the reasons for fluctuations in teenage driver crashes over time in the United States is clouded by the lack of information on licensure rates and driving exposure. Methods: We examined results from the Monitoring the Future survey to estimate the proportion of high school seniors who possessed a driver's license and the proportion of seniors who did not drive "during an average week" during the 15-year period of 1996-2010. Results: During 1996-2010, the proportion of high school seniors in United States who reported having a driver's license declined by 12 percentage points (14%) from 85% to 73%. Two-thirds of the decline (8 percentage points) occurred during 2006-2010. During the same 15-year period, the proportion of high school seniors who did not drive during an average week increased by 7 percentage points (47%) from 15% in 1996 to 22% in 2010, with essentially all of the increase occurring during 2006-2009. Discussion: Findings in this report suggest that the economic recession in recent years has reduced rates of licensure and driving among high school seniors. National Safety Council and Elsevier Ltd. All rights reserved. C1 [Shults, Ruth A.] CDC, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. RP Shults, RA (reprint author), CDC, Div Unintent Injury Prevent, 4770 Buford Hwy NE,MS F-62, Atlanta, GA 30341 USA. EM rshults@cdc.gov NR 10 TC 15 Z9 15 U1 0 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD SEP PY 2013 VL 46 BP 167 EP 170 DI 10.1016/j.jsr.2013.04.003 PG 4 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 210ZQ UT WOS:000323874300019 PM 23932698 ER PT J AU Creanga, A Nguyen, DT Gerloff, N Do, HT Balish, A Nguyen, HD Jang, Y Dam, VT Thor, S Jones, J Simpson, N Shu, B Emery, S Berman, L Nguyen, HT Bryant, JE Lindstrom, S Klimov, A Donis, RO Davis, CT Nguyen, T AF Creanga, Adrian Diep Thi Nguyen Gerloff, Nancy Hoa Thi Do Balish, Amanda Hoang Dang Nguyen Jang, Yunho Vui Thi Dam Thor, Sharmi Jones, Joyce Simpson, Natosha Shu, Bo Emery, Shannon Berman, LaShondra Nguyen, Ha T. Bryant, Juliet E. Lindstrom, Steve Klimov, Alexander Donis, Ruben O. Davis, C. Todd Tung Nguyen TI Emergence of multiple clade 2.3.2.1 influenza A (H5N1) virus subgroups in Vietnam and detection of novel reassortants SO VIROLOGY LA English DT Article DE Orthomyxovirus; Highly pathogenic avian influenza virus; Phylogenetics; Geographic distribution; H5N1; Evolution; Reassortment ID PATHOGENIC AVIAN INFLUENZA; LIVE POULTRY MARKETS; EVOLUTION; INFECTION; CHICKENS; GENETICS; JAPAN; BIRDS AB Phylogenetic analyses of 169 influenza A(H5N1) virus genomes were conducted for samples collected through active surveillance and outbreak responses in Vietnam between September 2010 and September 2012. While clade 1.1 viruses persisted in southern regions, three genetically distinct subgroups of clade 2.3.2.1 were found in northern and central Vietnam. The identification of each subgroup corresponded with detection of novel reassortants, likely due to their overlapping circulation throughout the country. While the previously identified clade 1.1 and A/Hubei/1/2010-like 2.3.2.1 genotypes remained the predominant viruses detected, four viruses were found to be reassortants between A/Hubei/1/2010-like (HA, NA, PB2, PB1, PA, NP) and A/duck/Vietnam/NCVD-885/2010-like (M, NS) viruses and one virus was identified as having A/duck/Vietnam/NCVD-885/2010-like HA, NA, PB1, and NP with A/Hubei/1/2010-like PB2 and PA genes. Additionally, clade 23.2.1 A/Hong Kong/6841/2010-like viruses, first detected in mid-2012, were identified as reassortants comprised of A/Hubei/1/2010-like PB2 and PA and A/duck/Vietnam/NCVD-885/2010-like PB1, NP, NA, M, NS genes. Published by Elsevier Inc. C1 [Creanga, Adrian; Gerloff, Nancy; Balish, Amanda; Jang, Yunho; Thor, Sharmi; Jones, Joyce; Simpson, Natosha; Shu, Bo; Emery, Shannon; Berman, LaShondra; Nguyen, Ha T.; Lindstrom, Steve; Klimov, Alexander; Donis, Ruben O.; Davis, C. Todd] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Creanga, Adrian; Nguyen, Ha T.] Battelle Mem Inst, Atlanta, GA USA. [Diep Thi Nguyen; Hoa Thi Do; Hoang Dang Nguyen; Vui Thi Dam; Tung Nguyen] Natl Ctr Vet Diagnost, Dept Anim Hlth, Hanoi, Vietnam. [Diep Thi Nguyen; Bryant, Juliet E.] Univ Oxford, Hosp Trop Dis, Clin Res Unit, Ho Chi Minh City, Vietnam. [Diep Thi Nguyen; Bryant, Juliet E.] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England. [Tung Nguyen] Hanoi Univ Agr, Grad Sch, Hanoi, Vietnam. RP Davis, CT (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM ctdavis@cdc.gov; nguyentungncvd@hotmail.com RI Gerloff, Nancy/C-8955-2015 OI Gerloff, Nancy/0000-0001-5696-8318 FU Wellcome Trust [093724] NR 28 TC 19 Z9 19 U1 0 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD SEP PY 2013 VL 444 IS 1-2 BP 12 EP 20 DI 10.1016/j.virol.2013.06.005 PG 9 WC Virology SC Virology GA 210ZJ UT WOS:000323873600002 PM 23849789 ER PT J AU Lanciotti, RS Kosoy, OI Bosco-Lauth, AM Pohl, J Stuchlik, O Reed, M Lambert, AJ AF Lanciotti, Robert S. Kosoy, Olga I. Bosco-Lauth, Angela M. Pohl, Jan Stuchlik, Olga Reed, Matthew Lambert, Amy J. TI Isolation of a novel orthobunyavirus (Brazoran virus) with a 1.7 kb S segment that encodes a unique nucleocapsid protein possessing two putative functional domains SO VIROLOGY LA English DT Article DE Arbovirus; Mosquito; Orthobunyavirus; Phylogeny; Nucleocapsid ID FAMILY BUNYAVIRIDAE; INFECTED MOSQUITOS; HEMORRHAGIC-FEVER; NSS COUNTERACTS; REASSORTMENT; INTERFERON; PHLEBOVIRUS; INDUCTION; OUTBREAKS; AFRICA AB In July, 2012 three isolations were made from mosquitoes collected in Brazoria, Orange and Montgomery counties, Texas, USA. Data from immunofluorescence testing suggested that these isolates are members of the genus Orthobunyavirus. Expanded analyses confirmed that these isolates comprise three independent isolations of the same virus; a novel orthobunyavirus. The genetic organization of the M and L segments of this virus is similar to that of other orthobunyaviruses. However, the S segment (similar to 1.7 kb) is nearly twice the length of known orthobunyavirus S segments, encoding a significantly larger nucleocapsid, N (similar to 50 kDa) and putative non-structural NSs (similar to 20 kDa) proteins in a novel strategy by which the NSs ORF precedes the N ORF. The N protein appears to consist of two functional domains; an amino portion that possesses motifs similar to other orthobunyavirus N proteins and a carboxyl portion that possesses a glutamine-rich domain with no known homologue among Bunyaviridae. Published by Elsevier Inc. C1 [Lanciotti, Robert S.; Kosoy, Olga I.; Bosco-Lauth, Angela M.; Lambert, Amy J.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Publ Hlth Serv,US Dept HHS, Ft Collins, CO 80521 USA. [Pohl, Jan; Stuchlik, Olga; Reed, Matthew] Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Lanciotti, RS (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Publ Hlth Serv,US Dept HHS, Ft Collins, CO 80521 USA. EM rslanciotti@cdc.gov NR 24 TC 6 Z9 6 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD SEP PY 2013 VL 444 IS 1-2 BP 55 EP 63 DI 10.1016/j.virol.2013.05.031 PG 9 WC Virology SC Virology GA 210ZJ UT WOS:000323873600008 PM 23791018 ER PT J AU Wang, S Cheng, XF Dai, X Dong, C Xu, MJ Liang, JH Dong, M Purdy, MA Meng, JH AF Wang, Song Cheng, Xianfeng Dai, Xing Dong, Chen Xu, Mingjie Liang, Jiuhong Dong, Min Purdy, Michael A. Meng, Jihong TI Rabbit and human hepatitis E virus strains belong to a single serotype SO VIRUS RESEARCH LA English DT Article DE Hepatitis E virus; Rabbit; Serotype; Cross-challenge; Neutralization ID CROSS-SPECIES INFECTION; UNITED-STATES; HUMAN HEV; SWINE; IDENTIFICATION; GENOTYPE; PIGS; SEQUENCE; REPLICATION; CHALLENGE AB Hepatitis E virus (HEV) is a zoonotic pathogen and-all four established genotypes of HEV belong to a single serotype. The recently identified rabbit HEV is antigenically and genetically related to human HEV. It is unclear whether rabbit HEV belongs to the same serotype as human HEV. The purpose of this study was to determine the serotypic relationship between rabbit and human HEVs. HEV ORF2 recombinant capsid protein p166 (amino acids 452-617) of four known HEV genotypes and rabbit HEV were used to induce immune serum, which were evaluated for their ability to neutralize human HEV genotype 1, 4, and rabbit HEV strains by an in vitro PCR-based HEV neutralization assay. Immune sera of five kinds of p166 proteins were all found to neutralize or cross-neutralize the three different HEV strains, suggesting a common neutralization epitope(s) existing between human and rabbit HEV. Rabbit models of a second-passage rabbit HEV strain, JS204-2, and a genotype 4 human HEV strain, NJ703, were established as evidenced by fecal virus shedding, viremia and anti-HEV IgG seroconversion. Six rabbits, recovered from JS204 infection, were challenged with NJ703, and another six recovered from NJ703 infection were challenged with JS204-2. After challenge, viremia was not detected, shorter fecal virus shedding durations and obvious early stage declines in anti-HEV IgG values were observed. The results from this study indicate that rabbit HEV belongs to the same serotype as human HEV. (C) 2013 Elsevier B.V. All rights reserved. C1 [Wang, Song; Meng, Jihong] Southeast Univ, Sch Med, Affiliated Zhongda Hosp, Dept Internal Med, Nanjing 210009, Jiangsu, Peoples R China. [Cheng, Xianfeng; Dong, Chen; Xu, Mingjie; Liang, Jiuhong; Dong, Min; Meng, Jihong] Southeast Univ, Sch Med, Dept Microbiol & Immunol, Nanjing 210009, Jiangsu, Peoples R China. [Dai, Xing] Southeast Univ, Sch Med, Affiliated Zhongda Hosp, Dept Dermatol, Nanjing 210009, Jiangsu, Peoples R China. [Purdy, Michael A.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Meng, JH (reprint author), Southeast Univ, Sch Med, Nanjing 210009, Jiangsu, Peoples R China. EM jihongmeng@163.com FU National Natural Science Foundation of China [30271231, 30671858]; National High Technology Research and Development Program of China (863 Program) [2006AA02A235] FX This work was supported by the National Natural Science Foundation of China (Nos. 30271231 and 30671858) and the National High Technology Research and Development Program of China (863 Program, 2006AA02A235). NR 45 TC 6 Z9 7 U1 0 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1702 J9 VIRUS RES JI Virus Res. PD SEP PY 2013 VL 176 IS 1-2 BP 101 EP 106 DI 10.1016/j.virusres.2013.05.013 PG 6 WC Virology SC Virology GA 210TV UT WOS:000323858500012 PM 23742853 ER PT J AU Bowman, BA Pfeiffer, CM Barfield, WD AF Bowman, Barbara A. Pfeiffer, Christine M. Barfield, Wanda D. TI Thiamine deficiency, beriberi, and maternal and child health: why pharmacokinetics matter SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Editorial Material ID INFANTS; BLOOD C1 [Bowman, Barbara A.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA 30333 USA. [Barfield, Wanda D.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Nutr Biomarkers Branch, Atlanta, GA USA. RP Bowman, BA (reprint author), CDC, 4770 Buford Highway,MS F72, Chamblee, GA 30341 USA. EM bbowman@cdc.gov FU Intramural CDC HHS [CC999999] NR 14 TC 0 Z9 0 U1 1 U2 9 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD SEP PY 2013 VL 98 IS 3 BP 635 EP 636 DI 10.3945/ajcn.113.069419 PG 2 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 206OT UT WOS:000323532700002 PM 23902781 ER PT J AU Duffy, J Dumyati, G Bulens, S Namburi, S Gellert, A Fridkin, SK Lessa, FC AF Duffy, Jonathan Dumyati, Ghinwa Bulens, Sandra Namburi, Swathi Gellert, Anita Fridkin, Scott K. Lessa, Fernanda C. TI Community-onset invasive methicillin-resistant Staphylococcus aureus infections following hospital discharge SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Epidemiology; Bacteremia; Risk factors ID BLOOD-STREAM INFECTIONS; TERM-CARE FACILITIES; RISK-FACTORS; UNITED-STATES; DISEASE; COLONIZATION; DEFINITION; BACTEREMIA; DIALYSIS; ADULTS AB Background: The majority of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections in the United States are community-onset and occur in persons with recent health care exposure. Methods: We performed a matched case-control study to identify risk factors for invasive MRSA infection among recently discharged patients. Cases had MRSA cultured from a normally sterile body site within 100 days following hospital discharge. Controls were matched on hospital, week of admission, and age. Results: Among 77 cases, the most common types of invasive MRSA infection were bloodstream infection and osteomyelitis. Independent risk factors were a history of a MRSA-positive clinical culture from a superficial body site in the 12 months preceding the invasive infection (matched odds ratio [mOR], 23; 95% confidence interval [CI]: 3.7-142), hemodialysis (mOR, 21; 95% CI: 1.7-257), prior hospitalization length of stay >5 days (mOR, 4.5; 95% CI: 1.6-12), and male sex (mOR, 2.9; 95% CI: 1.1-7.9). Conclusion: Risk factors for postdischarge invasive MRSA infections can be identified prior to discharge and remain with the patient after the hospitalization ends. Measures to prevent community-onset invasive MRSA infections might start in the hospital but should also be evaluated in postdischarge settings. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Duffy, Jonathan; Bulens, Sandra; Fridkin, Scott K.; Lessa, Fernanda C.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Duffy, Jonathan] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Dumyati, Ghinwa; Gellert, Anita] Univ Rochester, Rochester, NY USA. [Namburi, Swathi] Ctr Dis Control & Prevent, Epidemiol Elect Program, Atlanta, GA 30333 USA. RP Duffy, J (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS D26, Atlanta, GA 30333 USA. EM jduffy@cdc.gov FU Centers for Disease Control and Prevention; CDC's Emerging Infections Program [5-U01-CI000311-05] FX Supported by the Centers for Disease Control and Prevention; ABCs MRSA surveillance is funded through the CDC's Emerging Infections Program cooperative agreement No. 5-U01-CI000311-05. NR 28 TC 8 Z9 8 U1 0 U2 13 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD SEP PY 2013 VL 41 IS 9 BP 782 EP 786 DI 10.1016/j.ajic.2012.10.020 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 207LE UT WOS:000323599600010 PM 23394888 ER PT J AU Kumar, D Unger, ER Panicker, G Medvedev, P Wilson, L Humar, A AF Kumar, D. Unger, E. R. Panicker, G. Medvedev, P. Wilson, L. Humar, A. TI Immunogenicity of Quadrivalent Human Papillomavirus Vaccine in Organ Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Cervical cancer; HPV; immunocompromised; SOT ID GRADE CERVICAL LESIONS; HIV-INFECTED CHILDREN; AGED 18-45 YEARS; HPV INFECTION; WOMEN; CANCER; SAFETY; EFFICACY; UPDATE AB Solid organ transplant recipients are at risk of morbidity from human papillomavirus (HPV)-related diseases. Quadrivalent HPV vaccine is recommended for posttransplant patients but there are no data on vaccine immunogenicity. We determined the immunogenicity of HPV vaccine in a cohort of young adult transplant patients. Patients were immunized with three doses of quadrivalent HPV vaccine containing viral types 6, 11, 16 and 18. Immunogenicity was determined by type-specific viral-like protein ELISA. Four weeks after the last dose of vaccine, a vaccine response was seen in 63.2%, 68.4%, 63.2% and 52.6% for HPV 6, 11, 16 and 18, respectively. Factors that led to reduced immunogenicity were vaccination early after transplant (p=0.019), having a lung transplant (p=0.007) and having higher tacrolimus levels (p=0.048). At 12 months, there were significant declines in antibody titer for all HPV types although the number of patients who remained seropositive did not significantly differ. The vaccine was safe and well tolerated. We show suboptimal immunogenicity of HPV vaccine in transplant patients. This is important for counseling patients who choose to receive this vaccine. Further studies are needed to determine an optimal HPV vaccine type and schedule for this population. C1 [Kumar, D.; Medvedev, P.; Wilson, L.; Humar, A.] Univ Alberta, Alberta Transplant Inst, Edmonton, AB, Canada. [Unger, E. R.; Panicker, G.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Atlanta, GA USA. RP Kumar, D (reprint author), Univ Alberta, Alberta Transplant Inst, Edmonton, AB, Canada. EM deepali.kumar@ualberta.ca OI Unger, Elizabeth/0000-0002-2925-5635 FU Hoffmann-LaRoche FX D. K. has received honoraria from Merck Vaccines and Pfizer; research support from Hoffmann-LaRoche; A. H. has received honoraria from Pfizer; research support from Hoffmann-LaRoche. The remaining authors have no conflict of interest as defined by the American Journal of Transplantation. NR 28 TC 23 Z9 23 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD SEP PY 2013 VL 13 IS 9 BP 2411 EP 2417 DI 10.1111/ajt.12329 PG 7 WC Surgery; Transplantation SC Surgery; Transplantation GA 208KS UT WOS:000323678200022 PM 23837399 ER PT J AU Huprikar, S Bosserman, E Patel, G Moore, A Pinney, S Anyanwu, A Neofytos, D Ketterer, D Striker, R Silveira, F Qvarnstrom, Y Steurer, F Herwaldt, B Montgomery, S AF Huprikar, S. Bosserman, E. Patel, G. Moore, A. Pinney, S. Anyanwu, A. Neofytos, D. Ketterer, D. Striker, R. Silveira, F. Qvarnstrom, Y. Steurer, F. Herwaldt, B. Montgomery, S. TI Donor-Derived Trypanosoma cruzi Infection in Solid Organ Recipients in the United States, 2001-2011 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Chagas; donor; transplantation; transmission ID CHAGAS-DISEASE; LIVER-TRANSPLANTATION; TRANSMISSION; DNA AB Although Trypanosoma cruzi, the parasite that causes Chagas disease, can be transmitted via organ transplantation, liver and kidney transplantation from infected donors may be feasible. We describe the outcomes of 32 transplant recipients who received organs from 14 T. cruzi seropositive donors in the United States from 2001 to 2011. Transmission was confirmed in 9 recipients from 6 donors, including 3 of 4 (75%) heart transplant recipients, 2 of 10 (20%) liver recipients and 2 of 15 (13%) kidney recipients. Recommended monitoring posttransplant consisted of regular testing by PCR, hemoculture, and serology. Thirteen recipients had no or incomplete monitoring; transmission was confirmed in five of these recipients. Four of the five recipients had symptomatic disease and all four died although death was directly related to Chagas disease in only one. Nineteen recipients had partial or complete monitoring for T. cruzi infection with weekly testing by PCR, hemoculture and serology; transmission was confirmed in 4 of 19 recipients with no cases of symptomatic disease. Our results suggest that liver and kidney transplantation from T. cruzi seropositive donors may be feasible when the recommended monitoring schedule for T. cruzi infection is followed and prompt therapy with benznidazole can be administered. C1 [Huprikar, S.; Patel, G.; Pinney, S.; Anyanwu, A.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Bosserman, E.; Moore, A.; Qvarnstrom, Y.; Steurer, F.; Herwaldt, B.; Montgomery, S.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Neofytos, D.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Ketterer, D.] Methodist Healthcare Univ Hosp, Memphis, TN USA. [Striker, R.] Univ Wisconsin Med, Madison, WI USA. [Silveira, F.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RP Huprikar, S (reprint author), Mt Sinai Med Ctr, New York, NY 10029 USA. EM shirish.huprikar@mssm.edu NR 20 TC 16 Z9 16 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD SEP PY 2013 VL 13 IS 9 BP 2418 EP 2425 DI 10.1111/ajt.12340 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA 208KS UT WOS:000323678200023 PM 23837488 ER PT J AU Gastanaduy, PA AF Gastanaduy, Paul A. TI Update: Severe Respiratory Illness Associated With Middle East Respiratory Syndrome Coronavirus (MERS-CoV)Worldwide, 2012-2013 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID SAUDI-ARABIA AB A novel coronavirus has been reported as a cause of severe respiratory illness in patients in the Middle East. The implications for transplant patients are unknown but donors and recipients with unexplained severe respiratory illness and travel to the Arabian peninsula may be infected with this virus. RP Gastanaduy, PA (reprint author), CDC, Atlanta, GA 30333 USA. EM eocreport@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD SEP PY 2013 VL 13 IS 9 BP 2492 EP 2495 DI 10.1111/ajt.12456 PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA 208KS UT WOS:000323678200035 ER PT J AU Wiggins, LD Robins, DL Yeargin-Allsopp, M AF Wiggins, Lisa D. Robins, Diana L. Yeargin-Allsopp, Marshalyn TI Short report: Improving record-review surveillance of young children with an autism spectrum disorder SO AUTISM LA English DT Review DE autism spectrum disorder; early identification; surveillance ID PERVASIVE DEVELOPMENTAL DISORDERS AB Introduction: Records-based autism spectrum disorder surveillance developed at the Centers for Disease Control and Prevention has been extended to younger cohorts, although the utility of additional record sources has not been examined. We therefore conducted a pilot project to describe whether Centers for Disease Control and Prevention surveillance could identify younger children with an autism spectrum disorder evaluated as part of an ongoing screening study at Georgia State University. Methods: In all, 31 families of children who screened positive for autism spectrum disorder and received a clinical evaluation at Georgia State University agreed to participate in the project. Of these, 10 children lived inside the surveillance area and had records abstracted and reviewed for this project. Centers for Disease Control and Prevention surveillance results (i.e. autism spectrum disorder or non-autism spectrum disorder) were compared with Georgia State University evaluation results (i.e. autism spectrum disorder or non-autism spectrum disorder). Results: In all, 4 of the 10 children were diagnosed with an autism spectrum disorder after the Georgia State University evaluation. None of the 4 children with an autism spectrum disorder were identified by current Centers for Disease Control and Prevention surveillance methods but all 4 children were identified by Centers for Disease Control and Prevention surveillance methods when additional record sources were included (i.e. records from the statewide early intervention program and Georgia State University evaluation). Conclusion: These findings suggest that partnering with early intervention programs and encouraging early autism spectrum disorder screening might improve autism spectrum disorder surveillance among young children. C1 [Wiggins, Lisa D.; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Robins, Diana L.] Georgia State Univ, Atlanta, GA 30303 USA. RP Wiggins, LD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM lwiggins@cdc.gov FU Intramural CDC HHS [CC999999] NR 15 TC 1 Z9 1 U1 0 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1362-3613 J9 AUTISM JI Autism PD SEP PY 2013 VL 17 IS 5 BP 623 EP 629 DI 10.1177/1362361312452161 PG 7 WC Psychology, Developmental SC Psychology GA 207ZW UT WOS:000323644900010 PM 22987886 ER PT J AU Snead, MC Kourtis, AP Black, CM Mauck, CK Brown, TM Penman-Aguilar, A Melendez, JH Gallo, MF Jamieson, DJ Macaluso, M AF Snead, Margaret C. Kourtis, Athena P. Black, Carolyn M. Mauck, Christine K. Brown, Teresa M. Penman-Aguilar, Ana Melendez, Johan H. Gallo, Maria F. Jamieson, Denise J. Macaluso, Maurizio TI Effect of topical vaginal products on the detection of prostate-specific antigen, a biomarker of semen exposure, using ABAcards SO CONTRACEPTION LA English DT Article DE Vaginal products; PSA; Semen; Biomarker; ABAcard; Lubricants; Spermicide ID LINKED-IMMUNOSORBENT-ASSAY; PSA MEMBRANE TEST; FEMALE CONDOM; IDENTIFICATION; INTERCOURSE; FLUID AB Background: Prostate-specific antigen (PSA) is a biomarker of recent semen exposure. There is currently only limited information on whether topical vaginal products affect PSA assays. We investigated this question using various dilutions of several vaginal products (lubricants and spermicides) and the Abacus ABAcard for PSA detection. Study Design: Pooled semen controls and various dilutions of nonoxynol-9 (N9), carboxymethyl cellulose (CMC), Replens, Gynol 2, K-Y jelly, Astroglide, Surgilube, combined with pooled semen dilutions, were tested for PSA using the Abacus ABAcard. Results: N9 (2% with saline) and CMC did not appear to affect the results of testing with the ABAcard, but not all semen dilutions were tested. The other products (including Replens and Gynol, which is 2% N9 with propylene glycol, K-Y, Astroglide and Surgilube) at some of the dilutions tested either affected or gave invalid results with PSA testing using the ABAcard. Both Gynol 2 and K-Y at 1:10 dilution gave false-positive results. Conclusions: Some vaginal products affect PSA results obtained by using the semiquantitative ABAcard. In vivo confirmation is necessary to further optimize PSA detection when topical vaginal products are present. (C) 2013 Elsevier Inc. All rights reserved. C1 [Snead, Margaret C.; Kourtis, Athena P.; Black, Carolyn M.; Brown, Teresa M.; Penman-Aguilar, Ana; Gallo, Maria F.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. [Snead, Margaret C.; Kourtis, Athena P.; Black, Carolyn M.; Brown, Teresa M.; Penman-Aguilar, Ana; Gallo, Maria F.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Sci Resources, Atlanta, GA 30341 USA. [Mauck, Christine K.] Eastern Virginia Med Sch, CONRAD, Norfolk, VA 23501 USA. [Melendez, Johan H.] Johns Hopkins Univ, Dept Infect Dis, Baltimore, MD 21224 USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. RP Snead, MC (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. EM msnead@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU Intramural CDC HHS [CC999999] NR 24 TC 4 Z9 4 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD SEP PY 2013 VL 88 IS 3 BP 382 EP 386 DI 10.1016/j.contraception.2012.10.034 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 207FZ UT WOS:000323585600012 PM 23218862 ER PT J AU Wang, GJ Bowman, BA AF Wang, Guijing Bowman, Barbara A. TI Recent Economic Evaluations of Interventions to Prevent Cardiovascular Disease by Reducing Sodium Intake SO CURRENT ATHEROSCLEROSIS REPORTS LA English DT Article DE Salt intake; Sodium; Cardiovascular disease; Costs; Hypertension; Interventions ID AMERICAN-HEART-ASSOCIATION; SALT INTAKE; BLOOD-PRESSURE; COST-EFFECTIVENESS; URINARY SODIUM; SATURATED FAT; POPULATION; REDUCTION; STROKE; RISK AB Excess intake of sodium, a common problem worldwide, is associated with hypertension and cardiovascular disease (CVD), and hypertension is a major risk factor for CVD. Population-wide efforts to reduce sodium intake have been identified as a promising strategy for preventing hypertension and CVD, and such initiatives are currently recommended by a variety of scientific and public health organizations. By reviewing the literature published from January 2011 to March 2013, we summarized recent economic analyses of interventions to reduce sodium intake. The evidence, derived from estimates of resultant blood pressure decreases and thus decreases in the incidence of CVD events, supports population-wide interventions for reducing sodium intake. Both lowering the salt content in manufactured foods and conducting mass media campaigns at the national level are estimated to be cost-effective in preventing CVD. Although better data on the cost of interventions are needed for rigorous economic evaluations, population-wide sodium intake reduction can be a promising approach for containing the growing health and economic burden associated with hypertension and its sequelae. C1 [Wang, Guijing; Bowman, Barbara A.] Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Wang, GJ (reprint author), Ctr Dis Control & Prevent CDC, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy,MS F-72, Atlanta, GA 30341 USA. EM Gbw9@cdc.gov FU Intramural CDC HHS [CC999999] NR 52 TC 6 Z9 6 U1 2 U2 29 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1523-3804 J9 CURR ATHEROSCLER REP JI Curr. Atheroscleros. Rep. PD SEP PY 2013 VL 15 IS 9 AR 349 DI 10.1007/s11883-013-0349-1 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 206DI UT WOS:000323497200002 PM 23881545 ER PT J AU Bardenheier, BH Bullard, KM Caspersen, CJ Cheng, YLJ Gregg, EW Geiss, LS AF Bardenheier, Barbara H. Bullard, Kai McKeever Caspersen, Carl J. Cheng, Yiling J. Gregg, Edward W. Geiss, Linda S. TI A Novel Use of Structural Equation Models to Examine Factors Associated With Prediabetes Among Adults Aged 50 Years and Older: National Health and Nutrition Examination Survey 2001-2006 SO DIABETES CARE LA English DT Article ID INSULIN-RESISTANCE; DIABETES RISK; TYPE-2; DYSLIPIDEMIA; HYPERTENSION; REDUCTION; PREHYPERTENSION; INDIVIDUALS; PROGRESSION; PREVALENCE AB OBJECTIVE To use structural modeling to test a hypothesized model of causal pathways related with prediabetes among older adults in the U.S.RESEARCH DESIGN AND METHODS Cross-sectional study of 2,230 older adults (50 years) without diabetes included in the morning fasting sample of the 2001-2006 National Health and Nutrition Examination Surveys. Demographic data included age, income, marital status, race/ethnicity, and education. Behavioral data included physical activity (metabolic equivalent hours per week for vigorous or moderate muscle strengthening, walking/biking, and house/yard work), and poor diet (refined grains, red meat, added sugars, solid fats, and high-fat dairy). Structural-equation modeling was performed to examine the interrelationships among these variables with family history of diabetes, high blood pressure, BMI, large waist (waist circumference: women, 35 inches; men, 40 inches), triglycerides 200 mg/dL, and total and HDL (60 mg/dL) cholesterol.RESULTS After dropping BMI and total cholesterol, our best-fit model included three single factors: socioeconomic position (SEP), physical activity, and poor diet. Large waist had the strongest direct effect on prediabetes (0.279), followed by male sex (0.270), SEP (-0.157), high blood pressure (0.122), family history of diabetes (0.070), and age (0.033). Physical activity had direct effects on HDL (0.137), triglycerides (-0.136), high blood pressure (-0.132), and large waist (-0.067); poor diet had direct effects on large waist (0.146) and triglycerides (0.148).CONCLUSIONS Our results confirmed that, while including factors known to be associated with high risk of developing prediabetes, large waist circumference had the strongest direct effect. The direct effect of SEP on prediabetes suggests mediation by some unmeasured factor(s). C1 [Bardenheier, Barbara H.; Bullard, Kai McKeever; Caspersen, Carl J.; Cheng, Yiling J.; Gregg, Edward W.; Geiss, Linda S.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Bardenheier, BH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. EM bfb7@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 9 Z9 9 U1 1 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2013 VL 36 IS 9 BP 2655 EP 2662 DI 10.2337/dc12-2608 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 205CZ UT WOS:000323420200053 PM 23649617 ER PT J AU Cheng, YLJ Imperatore, G Geiss, LS Wang, J Saydah, SH Cowie, CC Gregg, EW AF Cheng, Yiling J. Imperatore, Giuseppina Geiss, Linda S. Wang, Jing Saydah, Sharon H. Cowie, Catherine C. Gregg, Edward W. TI Secular Changes in the Age-Specific Prevalence of Diabetes Among US Adults: 1988-2010 SO DIABETES CARE LA English DT Article ID BODY-MASS INDEX; TO-HEIGHT RATIO; WAIST CIRCUMFERENCE; CARDIOMETABOLIC RISK; EXPERT COMMITTEE; UNITED-STATES; TRENDS; OBESITY; POPULATION; MORTALITY AB OBJECTIVE To examine the age-specific changes of prevalence of diabetes among U.S. adults during the past 2 decades.RESEARCH DESIGN AND METHODS This study included 22,586 adults sampled in three periods of the National Health and Nutrition Examination Survey (1988-1994, 1999-2004, and 2005-2010). Diabetes was defined as having self-reported diagnosed diabetes or having a fasting plasma glucose level 126 mg/dL or HbA(1c) 6.5% (48 mmol/mol).RESULTS The number of adults with diabetes increased by 75% from 1988-1994 to 2005-2010. After adjusting for sex, race/ethnicity, and education level, the prevalence of diabetes increased over the two decades across all age-groups. Younger adults (20-34 years of age) had the lowest absolute increase in diabetes prevalence of 1.0%, followed by middle-aged adults (35-64) at 2.7% and older adults (65) at 10.0% (all P < 0.001). Comparing 2005-2010 with 1988-1994, the adjusted prevalence ratios (PRs) by age-group were 2.3, 1.3, and 1.5 for younger, middle-aged, and older adults, respectively (all P < 0.05). After additional adjustment for body mass index (BMI), waist-to-height ratio (WHtR), or waist circumference (WC), the adjusted PR remained statistically significant only for adults 65 years of age.CONCLUSIONS During the past two decades, the prevalence of diabetes increased across all age-groups, but adults 65 years of age experienced the largest increase in absolute change. Obesity, as measured by BMI, WHtR, or WC, was strongly associated with the increase in diabetes prevalence, especially in adults <65. C1 [Cheng, Yiling J.; Imperatore, Giuseppina; Geiss, Linda S.; Wang, Jing; Saydah, Sharon H.; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Cowie, Catherine C.] NIDDK, NIH, Bethesda, MD USA. RP Cheng, YLJ (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ycheng@cdc.gov NR 38 TC 74 Z9 74 U1 0 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD SEP PY 2013 VL 36 IS 9 BP 2690 EP 2696 DI 10.2337/dc12-2074 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 205CZ UT WOS:000323420200058 PM 23637354 ER PT J AU Sangaramoorthy, T Kroeger, K AF Sangaramoorthy, Thurka Kroeger, Karen TI Mobility, Latino Migrants, and the Geography of Sex Work: Using Ethnography in Public Health Assessments SO HUMAN ORGANIZATION LA English DT Article DE mobility; migrant health; sex work; applied public health; HIV/AIDS; sexually transmitted disease ID UNITED-STATES; RAPID ASSESSMENT; NORTH-CAROLINA; COMMERCIAL SEX; EMBODIED VULNERABILITY; HISPANIC MIGRANTS; MEXICAN MIGRANTS; SOUTH-AFRICA; HIV; RISK AB Recent studies have documented frequent use of female sex workers among Latino migrant men in the southeastern United States, yet little is known about the context in which sex work takes place or the women who provide these services. As anthropologists working in applied public health, we use rapid ethnographic assessment as a technical assistance tool to document local understandings of the organization and typology of sex work and patterns of mobility among sex workers and their Latino migrant clients. By incorporating ethnographic methods in traditional public health needs assessments, we were able to highlight the diversity of migrant experiences and better understand the health needs of mobile populations more broadly. We discuss the findings in terms of their practical implications for HIV/STD prevention and call on public health practitioners to incorporate the concept of mobility as an organizing principle for the delivery of health care services. C1 [Sangaramoorthy, Thurka] Univ Maryland, College Pk, MD 20742 USA. [Kroeger, Karen] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Sangaramoorthy, T (reprint author), Univ Maryland, College Pk, MD 20742 USA. NR 72 TC 1 Z9 1 U1 1 U2 9 PU SOC APPLIED ANTHROPOLOGY PI OKLAHOMA CITY PA 3000 UNITED FOUNDERS BLVD, STE 148, OKLAHOMA CITY, OK 73112 USA SN 0018-7259 J9 HUM ORGAN JI Hum. Organ. PD FAL PY 2013 VL 72 IS 3 BP 263 EP 272 PG 10 WC Anthropology; Social Sciences, Interdisciplinary SC Anthropology; Social Sciences - Other Topics GA 206WM UT WOS:000323556100009 ER PT J AU Waters, KP Zuber, A Willy, RM Kiriinya, RN Waudo, AN Oluoch, T Kimani, FM Riley, PL AF Waters, Keith P. Zuber, Alexandra Willy, Rankesh M. Kiriinya, Rose N. Waudo, Agnes N. Oluoch, Tom Kimani, Francis M. Riley, Patricia L. TI Kenya's Health Workforce Information System: A model of impact on strategic human resources policy, planning and management SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Article DE Nursing informatics; Medical informatics; Human resources information system (HRIS); Human resources for health (HRH); Workforce surveillance; Global health AB Objective: Countries worldwide are challenged by health worker shortages, skill mix imbalances, and maldistribution. Human resources information systems (HRIS) are used to monitor and address these health workforce issues, but global understanding of such systems is minimal and baseline information regarding their scope and capability is practically non-existent. The Kenya Health Workforce Information System (KHWIS) has been identified as a promising example of a functioning HRIS. The objective of this paper is to document the impact of KHWIS data on human resources policy, planning and management. Methods: Sources for this study included semi-structured interviews with senior officials at Kenya's Ministry of Medical Services (MOMS), Ministry of Public Health and Sanitation (MOPHS), the Department of Nursing within MOMS, the Nursing Council of Kenya, Kenya Medical Practitioners and Dentists Board, Kenya's Clinical Officers Council, and Kenya Medical Laboratory Technicians and Technologists Board. Additionally, quantitative data were extracted from KHWIS databases to supplement the interviews. Health sector policy documents were retrieved from MOMS and MOPHS websites, and reviewed to assess whether they documented any changes to policy and practice as having been impacted by KHWIS data. Results: Interviews with Kenyan government and regulatory officials cited health workforce data provided by KHWIS influenced policy, regulation, and management. Policy changes include extension of Kenya's age of mandatory civil service retirement from 55 to 60 years. Data retrieved from KHWIS document increased relicensing of professional nurses, midwives, medical practitioners and dentists, and interviewees reported this improved compliance raised professional regulatory body revenues. The review of Government records revealed few references to KHWIS; however, documentation specifically cited the KHWIS as having improved the availability of human resources for health information regarding workforce planning, management, and development. Conclusion: KHWIS data have impacted a range of improvements in health worker regulation, human resources management, and workforce policy and planning at Kenya's ministries of health. Published by Elsevier Ireland Ltd C1 [Waters, Keith P.; Zuber, Alexandra; Riley, Patricia L.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Willy, Rankesh M.; Kimani, Francis M.] Minist Med Serv, Nairobi, Kenya. [Kiriinya, Rose N.; Waudo, Agnes N.] Kenya Hlth Work Force Project, Nairobi, Kenya. [Oluoch, Tom] Ctr Dis Control & Prevent, Nairobi, Kenya. RP Waters, KP (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, 1600 Clifton Rd,MS-E41, Atlanta, GA 30333 USA. EM kpwaters@cdc.gov OI Oluoch, Tom/0000-0001-9621-5900 NR 21 TC 5 Z9 5 U1 0 U2 58 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 J9 INT J MED INFORM JI Int. J. Med. Inform. PD SEP PY 2013 VL 82 IS 9 BP 895 EP 902 DI 10.1016/j.ijmedinf.2013.06.004 PG 8 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA 207FQ UT WOS:000323584700015 PM 23871121 ER PT J AU Moonan, PK Teeter, LD Salcedo, K Ghosh, S Ahuja, SD Flood, J Graviss, EA AF Moonan, Patrick K. Teeter, Larry D. Salcedo, Katya Ghosh, Smita Ahuja, Shama D. Flood, Jennifer Graviss, Edward A. TI Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study SO LANCET INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; LATENT TUBERCULOSIS; OUTBREAK; EPIDEMIOLOGY; PYRAZINAMIDE; MANAGEMENT; INFECTION; DRUGS; RISK; HOPE AB Background Multidrug-resistant (MDR) tuberculosis is a potential threat to tuberculosis elimination, but the extent of MDR tuberculosis disease in the USA that is attributable to transmission within the country is unknown. We assessed transmission of MDR tuberculosis and potential contributing factors in the USA. Methods In a cross-sectional study, clinical, demographic, epidemiological, and Mycobacterium tuberculosis genotype data were obtained during routine surveillance of all verified cases of MDR tuberculosis reported from eight states in the USA (California from Jan 1, 2007, to Dec 31, 2009; Texas from Jan 1, 2007, to March 31, 2009; and the states of Colorado, Maryland, Massachusetts, New York, Tennessee, and Washington from Jan 1, 2007 to Dec 31, 2008). In-depth interviews and health-record abstraction were done for all who consented to ascertain potential interpersonal connections. Findings 168 cases of MDR tuberculosis were reported in the eight states during our study period. 92 individuals (55%) consented to in-depth interview. 20 (22%) of these individuals developed MDR tuberculosis as a result of transmission in the USA; a source case was identified for eight of them (9%). 20 individuals (22%) had imported active tuberculosis (ie, culture-confirmed disease within 3 months of entry into the USA). 38 (41%) were deemed to have reactivation of disease, of whom 14 (15%) had a known previous episode of tuberculosis outside the USA. Five individuals (5%) had documented treatment of a previous episode in the USA, and so were deemed to have relapsed. For nine cases (10%), insufficient evidence was available to definitively classify reason for presentation. Interpretation About a fifth of cases of MDR tuberculosis in the USA can be linked to transmission within the country. Many individuals acquire MDR tuberculosis before entry into the USA. MDR tuberculosis needs to be diagnosed rapidly to reduce potential infectious periods, and clinicians should consider latent tuberculosis infection treatment-tailored to the results of drug susceptibility testing of the putative source case-for exposed individuals. C1 [Moonan, Patrick K.; Ghosh, Smita] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Teeter, Larry D.; Graviss, Edward A.] Methodist Hosp, Dept Pathol & Genom Med, Res Inst, Houston, TX 77030 USA. [Salcedo, Katya; Flood, Jennifer] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, Richmond, CA USA. [Ahuja, Shama D.] New York City Dept Hlth & Mental Hyg, Bur TB Control, New York, NY USA. RP Moonan, PK (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,Mailstop E-10, Atlanta, GA 30333 USA. EM pmoonan@cdc.gov RI Moonan, Patrick/F-4307-2014; OI Moonan, Patrick/0000-0002-3550-2065 FU CDC FX This study was funded by the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. We thank Melissa Valdez for her early work in the organisation and management of logistical aspects of protocol development and initial enrolment; the TBESC sites that participated in data collection, health-record abstraction, and interviews with patients (California Department of Public Health: Ed Desmond, Dayani Nualles, Peter Oh, Alicia Rodriguez, Lisa Pascopella; Denver Public Health and Hospitals Authority: Kirsten Wall, Randall Reves; Maryland Department of Health and Mental Hygiene: Wendy Cronin, Heather Rutz; Massachusetts Department of Public Health: Sue Etldnd, C Robert Horsburgh Jr, Sharon Sharnprapai; New York City Department of Health and Mental Hygiene: Holly Anger, Bianca Perri; New York State Department of Health, Health Research: Wilson P Miranda, Stephen Hughes, Margaret J Oxtoby; Tennessee State Health Department: Tamara Chavez-Lindell, Fernanda Maururi, Jon Warkentin; Texas Department of State Health Services: Denise Dunbar, Nicole Evert, Ken Jost Jr, Charles Wallace, Pandora Williams, Frank Valdez; Seattle-King County Department of Public Health: Masa Narita, Jenny Pang; University of North Texas Health Science Center at Fort Worth: Gerry Drewyer, Thad Miller, Guadalupe Munguia, Le Turk, Stephen Weis); staff from the National Tuberculctsis Genotyping Service contract laboratories, local and state public health laboratories, and local and state health departments who collected data included in these analyses; Barbara Seaworth and John Oeltmann for critically reading and commenting on the draft report; and Kashef Ijaz and Thomas Navin for contributions to the analytical approach. NR 40 TC 13 Z9 14 U1 0 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD SEP PY 2013 VL 13 IS 9 BP 777 EP 784 DI 10.1016/S1473-3099(13)70128-2 PG 8 WC Infectious Diseases SC Infectious Diseases GA 205SU UT WOS:000323465900023 PM 23759447 ER PT J AU Munoz-Price, LS Poirel, L Bonomo, RA Schwaber, MJ Daikos, GL Cormican, M Cornaglia, G Garau, J Gniadkowski, M Hayden, MK Kumarasamy, K Livermore, DM Maya, JJ Nordmann, P Patel, JB Paterson, DL Pitout, J Villegas, MV Wang, H Woodford, N Quinn, JP AF Munoz-Price, L. Silvia Poirel, Laurent Bonomo, Robert A. Schwaber, Mitchell J. Daikos, George L. Cormican, Martin Cornaglia, Giuseppe Garau, Javier Gniadkowski, Marek Hayden, Mary K. Kumarasamy, Karthikeyan Livermore, David M. Maya, Juan J. Nordmann, Patrice Patel, Jean B. Paterson, David L. Pitout, Johann Villegas, Maria Virginia Wang, Hui Woodford, Neil Quinn, John P. TI Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases SO LANCET INFECTIOUS DISEASES LA English DT Review ID HYDROLYZING BETA-LACTAMASE; KPC-PRODUCING ENTEROBACTERIACEAE; GRAM-NEGATIVE BACILLI; ACUTE-CARE FACILITIES; NEW-YORK-CITY; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; RESISTANT ENTEROBACTERIACEAE; K.-PNEUMONIAE; UNITED-STATES AB Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile beta-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now. C1 [Munoz-Price, L. Silvia] Univ Miami, Miller Sch Med, Dept Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. [Munoz-Price, L. Silvia] Univ Miami, Miller Sch Med, Dept Anesthesiol, Miami, FL 33136 USA. [Munoz-Price, L. Silvia] Jackson Mem Hosp, Dept Infect Control, Miami, FL 33136 USA. [Poirel, Laurent; Nordmann, Patrice] Hop Bicetre, AP HP, Serv Bacteriol Virol, INSERM Emerging Resistance Antibiot U914,Fac Med, K Bicetre, France. [Poirel, Laurent; Nordmann, Patrice] Univ Paris Sud, K Bicetre, France. [Bonomo, Robert A.] Louis Stokes Cleveland Dept Vet Affairs, Res Serv, Cleveland, OH USA. [Bonomo, Robert A.] Case Western Reserve Univ, Dept Med Pharmacol, Dept Mol Biol, Cleveland, OH 44106 USA. [Bonomo, Robert A.] Case Western Reserve Univ, Dept Microbiol, Cleveland, OH 44106 USA. [Schwaber, Mitchell J.] Israel Minist Hlth, Natl Ctr Infect Control, Tel Aviv, Israel. [Daikos, George L.] Univ Athens, Sch Med, Dept Propaedeut Med, GR-11527 Athens, Greece. [Cormican, Martin] Natl Univ Ireland Galway, Sch Med, Antimicrobial Resistance & Microbial Ecol ARME Gr, Galway, Ireland. [Cornaglia, Giuseppe] Univ Verona, Dept Pathol & Diagnost, I-37100 Verona, Italy. [Garau, Javier] Univ Barcelona, Infect Dis Unit, Hosp Univ Mutua Terrassa, Barcelona, Spain. [Gniadkowski, Marek] Natl Med Inst, Dept Mol Microbiol, Warsaw, Poland. [Hayden, Mary K.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA. [Hayden, Mary K.] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL 60612 USA. [Kumarasamy, Karthikeyan] Univ Madras, Dept Microbiol, Dr ALM PG IBMS, Madras, Tamil Nadu, India. [Livermore, David M.] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England. [Livermore, David M.; Woodford, Neil] Publ Hlth England, Antimicrobial Resistance & Healthcare Assoc Infec, London, England. [Maya, Juan J.; Villegas, Maria Virginia] Int Ctr Med Res andTraining CIDEIM, Cali, Colombia. [Patel, Jean B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Paterson, David L.] Univ Queensland, Clin Res Ctr, Royal Brisbane & Womens Hosp, Herston, Qld, Australia. [Pitout, Johann] Calgary Lab Serv, Div Microbiol, Calgary, AB, Canada. [Pitout, Johann] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada. [Wang, Hui] Peking Univ Peoples Hosp, Dept Clin Lab, Beijing, Peoples R China. [Quinn, John P.] AstraZeneca, Waltham, MA USA. RP Munoz-Price, LS (reprint author), Univ Miami, Miller Sch Med, Dept Med, Dept Publ Hlth Sci, PPW L-302,1611 NW 12th Ave, Miami, FL 33136 USA. EM smunozprice@med.miami.edu RI Staves, Peter/C-8219-2014; OI GARAU, JAVIER/0000-0001-7867-5911 FU Sage and Steris; Merck; grant Narodowy Program Ochrony Antybiotykow (NPOA) from the Polish Ministry of Health; grant SPUB MIKROBANK from the Polish Ministry of Science and Higher Education; Pfizer; Novartis; AstraZeneca; Astellas; Merck Sharp Dohme; Pfizer SA; Janssen-Cilag SA; Merck Colombia; AstraZeneca Colombia SA; bioMerieux Colombia SAS; Colciencias FX has received speaking fees from Sage and Steris. LP and PN have received research funds from Merck. MG's work was partially financed by the grant Narodowy Program Ochrony Antybiotykow (NPOA) from the Polish Ministry of Health, and the grant SPUB MIKROBANK from the Polish Ministry of Science and Higher Education. DML has shareholdings in Dechra, Eco Animal Health, Merck, and Pfizer; has accepted grants, speaking invitations, and conference invitations from Pfizer, Novartis, AstraZeneca, and Astellas; and has advisory or consultancy relationships with Achaogen, AstraZeneca, Basilea, Bayer, Cubist, Curetis, Discuva, GlaxoSmithKline, Kalidex, McKinsey, Meiji, Pfizer, Roche, Tetraphase, Theravance, and Wockhardt JP has received research funds from Merck and AstraZeneca. MVV has received research grants from Merck Sharp & Dohme, Pfizer SA, Janssen-Cilag SA, Novartis, Merck Colombia, AstraZeneca Colombia SA, bioMerieux Colombia SAS, and Colciencias. JPQ is an employee and potential shareholder in AstraZeneca. All other authors declare that they have no conflicts of interest. NR 134 TC 336 Z9 356 U1 14 U2 83 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD SEP PY 2013 VL 13 IS 9 BP 785 EP 796 DI 10.1016/S1473-3099(13)70190-7 PG 12 WC Infectious Diseases SC Infectious Diseases GA 205SU UT WOS:000323465900024 PM 23969216 ER PT J AU Polis, CB Curtis, KM AF Polis, Chelsea B. Curtis, Kathryn M. TI Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence SO LANCET INFECTIOUS DISEASES LA English DT Review ID SEXUALLY-TRANSMITTED INFECTIONS; IMMUNODEFICIENCY-VIRUS TYPE-1; MARGINAL STRUCTURAL MODELS; CONSISTENT CONDOM USE; SOUTH-AFRICA; SEX WORKERS; PROSPECTIVE COHORT; COMPETING RISKS; TRANSMISSION; UGANDA AB Whether or not the use of hormonal contraception affects risk of HIV acquisition is an important question for public health. We did a systematic review, searching PubMed and Embase, aiming to explore the possibility of an association between various forms of hormonal contraception and risk of HIV acquisition. We identified 20 relevant prospective studies, eight of which met our minimum quality criteria. Of these eight, all reported findings for progestin-only injectables, and seven also reported findings for oral contraceptive pills. Most of the studies that assessed the use of oral contraceptive pills showed no significant association with HIV acquisition. None of the three studies that assessed the use of injectable norethisterone enanthate showed a significant association with HIV acquisition. Studies that assessed the use of depot-medroxyprogesterone acetate (DMPA) or non-specified injectable contraceptives had heterogeneous methods and mixed results, with some investigators noting a 1.5-2.2 times increased risk of HIV acquisition, and others reporting no association. Thus, some, but not all, observational data raise concern about a potential association between use of DMPA and risk of HIV acquisition. More definitive evidence for the existence and size of any potential effect could inform appropriate counselling and policy responses in countries with varied profiles of HIV risk, maternal mortality, and access to contraceptive services. C1 [Polis, Chelsea B.] US Agcy Int Dev, Off Populat & Reprod Hlth, Washington, DC 20004 USA. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Polis, CB (reprint author), US Agcy Int Dev, Bur Global Hlth, Off Populat & Reprod Hlth, Res Technol & Utilizat Div, Suite 315,1201 Penn Ave NW, Washington, DC 20004 USA. EM cpolis@usaid.gov OI Polis, Chelsea/0000-0002-1031-7074 NR 68 TC 75 Z9 75 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD SEP PY 2013 VL 13 IS 9 BP 797 EP 808 DI 10.1016/S1473-3099(13)70155-5 PG 12 WC Infectious Diseases SC Infectious Diseases GA 205SU UT WOS:000323465900025 PM 23871397 ER PT J AU Morassutti, AL Perelygin, A De Carvalho, MO Lemos, LN Pinto, PM Frace, M Wilkins, PP Graeff-Teixeira, C Da Silva, AJ AF Morassutti, Alessandra L. Perelygin, Andrey De Carvalho, Marcos O. Lemos, Leandro Nascimento Pinto, Paulo Marcos Frace, Mike Wilkins, Patricia P. Graeff-Teixeira, Carlos Da Silva, Alexandre J. TI High throughput sequencing of the Angiostrongylus cantonensis genome: a parasite spreading worldwide SO PARASITOLOGY LA English DT Article DE Angiostrongylus cantonensis; genome sequencing; diagnostic targets ID 1ST REPORT; PEPTIDE IDENTIFICATION; PROTEINS; METASTRONGYLIDAE; COSTARICENSIS; NEMATODA; ANTIGEN; BRAZIL AB Angiostrongylus cantonensis is a parasitic nematode of rodents and a leading aetiological agent of eosinophilic meningitis in humans. Definitive diagnosis is difficult, often relying on immunodiagnostic methods which utilize crude antigens. New immunodiagnostic methods based on recombinant proteins are being developed, and ideally these methods would be made available worldwide. Identification of diagnostic targets, as well as studies on the biology of the parasite, are limited by a lack of molecular information on Angiostrongylus spp. available in databases. In this study we present data collected from DNA random high-throughput sequencing together with proteomic analyses and a cDNA walking methodology to identify and obtain the nucleotide or amino acid sequences of unknown immunoreactive proteins. 28 080 putative ORFs were obtained, of which 3371 had homology to other deposited protein sequences. Using the A. cantonensis genomic sequences, 156 putative ORFs, matching peptide sequences obtained from previous proteomic studies, were considered novel, with no homology to existing sequences. Full-length coding sequences of eight antigenic target proteins were obtained. In this study we generated not only the complete nucleotide sequences of the antigenic protein targets but also a large amount of genomic data which may help facilitate future genomic, proteomic, transcriptomic or metabolomic studies on Angiostrongylus. C1 [Morassutti, Alessandra L.; Graeff-Teixeira, Carlos] Pontificia Univ Rio Grande Sul PUCRS, Fac Biociencias, Lab Biol Parasitaria, BR-90690900 Porto Alegre, RS, Brazil. [Morassutti, Alessandra L.; Graeff-Teixeira, Carlos] Pontificia Univ Rio Grande Sul PUCRS, Inst Pesquisas Biomed, Lab Parasitol Mol, BR-90690900 Porto Alegre, RS, Brazil. [Perelygin, Andrey; Frace, Mike; Wilkins, Patricia P.; Da Silva, Alexandre J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [De Carvalho, Marcos O.] Univ Fed Rio Grande do Sul, Programa Posgrad Genet & Biol Mol, Porto Alegre, RS, Brazil. [Lemos, Leandro Nascimento; Pinto, Paulo Marcos] Univ Fed Pampa, BR-97300000 Sao Gabriel, RS, Brazil. RP Morassutti, AL (reprint author), Pontificia Univ Catolica Rio Grande do Sul, Inst Pesquisas Biomed, Ave Ipiranga 6690,2 Andar,Sala 20, BR-90690900 Porto Alegre, RS, Brazil. EM almorassutti@gmail.com RI Nascimento Lemos, Leandro/D-1094-2012; Pinto, Paulo/K-6921-2014; Morassutti, Alessandra/E-1046-2015 OI Pinto, Paulo/0000-0002-8513-0335; Morassutti, Alessandra/0000-0002-8142-1055 FU CNPq [201760/2009-6]; US Food Safety Initiative; CDC; APHL-USA; [300456/2007-7]; [477260/2007-1] FX Financial support was provided by Brazilian agencies: CNPq (scholarship 201760/2009-6) and US Food Safety Initiative, CDC and APHL-USA. C. Graeff-Teixeira is a recipient of a CNPq PQ 1D fellowship and of grants 300456/2007-7 and 477260/2007-1. NR 28 TC 4 Z9 4 U1 1 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0031-1820 J9 PARASITOLOGY JI Parasitology PD SEP PY 2013 VL 140 IS 10 BP 1304 EP 1309 DI 10.1017/S0031182013000656 PG 6 WC Parasitology SC Parasitology GA 204QH UT WOS:000323382500013 PM 23863082 ER PT J AU Goodhew, EB Secor, WE AF Goodhew, E. Brook Secor, W. Evan TI Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article DE Trichomonas; Resistance; Screening; Metronidazole ID 2-ACETYLAMINO-5-NITROTHIAZOLE; NIFURATEL; STRAINS AB Objectives Metronidazole and tinidazole are effective treatments for most patients with trichomoniasis but not for individuals who are infected with very resistant strains of Trichomonas vaginalis or persons with hypersensitivity to the 5-nitroimidazole drugs. Thus, there is a need for additional oral therapies to treat trichomoniasis. Methods We screened the US Drug Collection Library against metronidazole-susceptible and resistant strains of T vaginalis. Activity was measured by incubating parasites and drugs for 48 h in the presence of tritiated thymidine. Growth inhibition was determined by the reduction of incorporated radioactivity by compounds at 20 mu M in comparison to media control. Drugs that showed good initial activity were further tested to calculate IC50 values. Drugs with the most promise were tested together with metronidazole to see if there was any combinatorial effect. Results Of the 1040 drugs in the library, 83 (8%) reduced growth of a metronidazole-susceptible T vaginalis strain by at least 20%. Of these, IC50 values were calculated for 27 compounds and 8 drugs were evaluated in combination with metronidazole. Disulfiram and nithiamide were non-5-nitroimidazole drugs that showed the best activity against parasites when used alone. Albendazole and coenzyme B12 were the most promising compounds to boost the efficacy of metronidazole. Conclusions No one drug was as effective as any of the 5-nitroimidazole compounds. However, disulfiram and nithiamide may be useful to treat individuals with hypersensitivity to 5-nitroimidazole drugs and albendazole and coenzyme B12 may be helpful in combination with metronidazole or tinidazole for treatment of persons with highly resistant T vaginalis infections. C1 [Goodhew, E. Brook; Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop D-65, Atlanta, GA 30329 USA. EM was4@cdc.gov NR 20 TC 12 Z9 12 U1 2 U2 10 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD SEP PY 2013 VL 89 IS 6 SI SI BP 479 EP 484 DI 10.1136/sextrans-2013-051032 PG 6 WC Infectious Diseases SC Infectious Diseases GA 203UF UT WOS:000323318500015 PM 23794105 ER PT J AU Bristow, CC Dilraj, A Margot, B Podewils, LJ AF Bristow, Claire C. Dilraj, Athmanundh Margot, Bruce Podewils, Laura Jean TI Lack of patient registration in the electronic TB register for sputum smear-positive patients in KwaZulu-Natal, South Africa SO TUBERCULOSIS LA English DT Article DE Tuberculosis; Surveillance; Case finding; Sputum smear AB Analysis of diagnostic smear positive records from the laboratory from KwaZulu-Natal in South Africa shows that not all patients are counted in surveillance efforts. However, review of paper-based patient records suggests the majority of identified TB patients are being treated. Directly linking laboratory and clinical records would enhance surveillance information. (c) 2013 Elsevier Ltd. All rights reserved. C1 [Margot, Bruce] KwaZulu Natal, Republ South Africa Prov Dept Hlth, TB Control & Management, Durban, South Africa. [Podewils, Laura Jean] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. EM ccbristow@gmail.com FU Centers for Disease Control and Prevention South Africa Global AIDS Program; South African Medical Research Council [5 U51 PS000729-05, PA PS07-006] FX Evaluation of the project was made possible through the support of the Centers for Disease Control and Prevention South Africa Global AIDS Program, and through funding and collaboration with the South African Medical Research Council (Cooperative Agreement 5 U51 PS000729-05, PA PS07-006). NR 3 TC 3 Z9 3 U1 0 U2 2 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD SEP PY 2013 VL 93 IS 5 BP 567 EP 568 DI 10.1016/j.tube.2013.05.001 PG 2 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA 206TQ UT WOS:000323546200014 PM 23769141 ER PT J AU Montealegre, JR Johnston, LG Murrill, C Monterroso, E AF Montealegre, Jane R. Johnston, Lisa G. Murrill, Christopher Monterroso, Edgar TI Respondent Driven Sampling for HIV Biological and Behavioral Surveillance in Latin America and the Caribbean SO AIDS AND BEHAVIOR LA English DT Review DE HIV/AIDS; Respondent driven sampling; Surveillance; Latin America; Caribbean; Key populations at risk ID FEMALE SEX WORKERS; INJECTION-DRUG USERS; 10 BRAZILIAN CITIES; HIDDEN POPULATIONS; INTERNATIONAL SETTINGS; RISK BEHAVIORS; MEN; PREVALENCE; METHODOLOGY; IMPLEMENTATION AB Since 2005, respondent driven sampling (RDS) has been widely used for HIV biological and behavioral surveillance surveys (BBSS) in Latin America and the Caribbean (LAC). In this manuscript, we provide a focused review of RDS among hard-to-reach high-risk populations in LAC and describe their principal operational, design, and analytical considerations. We reviewed published and unpublished reports, protocols, and manuscripts for RDS studies conducted in LAC between January 1, 2005 and December 31, 2011. We abstracted key operational information and generated summary statistics across all studies. Between 2005 and 2011, 87 RDS studies were conducted in 15 countries in LAC (68 % in South America, 18 % in Mexico and Central America, and 14 % in the Caribbean). The target populations were primarily men who have sex with men (43 %), sex workers (29 %), and drug users (26 %). Study considerations included establishing clear eligibility criteria, measuring social network sizes, collecting specimens for biological testing, among others. Most of the reviewed studies are the first in their respective countries to collect data on hard-to-reach populations and the first attempt to use a probability-based sampling method. These RDS studies allowed researchers and public health practitioners in LAC to access hard-to-reach HIV high-risk populations and collect valuable data on the prevalence of HIV and other infections, as well as related risk behaviors. C1 [Montealegre, Jane R.] Univ Texas Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA. [Montealegre, Jane R.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Johnston, Lisa G.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70112 USA. [Johnston, Lisa G.] Univ Calif San Francisco, San Francisco, CA 94105 USA. [Murrill, Christopher; Monterroso, Edgar] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. RP Johnston, LG (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Community Hlth & Behav Sci, 1440 Canal St Ste 1191, New Orleans, LA 70112 USA. EM lsjohnston.global@gmail.com NR 37 TC 12 Z9 12 U1 0 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD SEP PY 2013 VL 17 IS 7 BP 2313 EP 2340 DI 10.1007/s10461-013-0466-4 PG 28 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 202UY UT WOS:000323246500004 PM 23568227 ER PT J AU Nasrullah, M Oraka, E Breiding, MJ Chavez, PR AF Nasrullah, Muazzam Oraka, Emeka Breiding, Mathew J. Chavez, Pollyanna R. TI HIV Testing and Intimate Partner Violence Among Non-Pregnant Women in 15 US States/Territories: Findings from Behavioral Risk Factor Surveillance System Survey Data SO AIDS AND BEHAVIOR LA English DT Article DE HIV/AIDS; HIV test; Violence; Women ID DOMESTIC VIOLENCE; INFECTION; CARE; NOTIFICATION; ADOLESCENTS; HIV/AIDS; ABUSE AB Intimate partner violence (IPV) has been shown to be associated with higher rates of HIV infection among women, underscoring the importance of encouraging IPV victims to receive HIV testing. However, we do not know how much HIV testing behavior is influenced by IPV victimization. The current study characterized the association between individual types of IPV and HIV testing in a large sample of non-pregnant women in 15 US states/territories. The 2005 Behavioral Risk Factor Surveillance System data were analyzed after restricting the sample to non-pregnant women. The dependent variable, whether a woman ever had an HIV test, was examined in relation to individual types of IPV victimization (threatened physical violence; attempted physical violence; completed physical violence; and unwanted sex). Associations between HIV testing and types of IPV were assessed using adjusted risk ratios (aRR) that controlled for demographics and HIV-related risk factors (intravenous drug use, sexually transmitted diseases, exchange sex, unprotected anal sex). Approximately 28.6 % of women reported ever having experienced IPV, and 52.8 % of these women reported being tested for HIV. Among women who had not experienced IPV, 32.9 % reported ever having been tested for HIV. HIV testing was associated with lifetime experience of threatened violence (aRR = 1.43; 95 % CI = 1.24-1.65), attempted violence (aRR = 1.43; 95 % CI = 1.20-1.69), completed physical violence (aRR = 1.30; 95 % CI = 1.13-1.48), and unwanted sex (aRR = 1.66; 95 % CI = 1.48-1.86). Women who experienced each type of IPV were more likely to have been ever tested for HIV compared to women with no IPV history. However, nearly half of those reporting IPV, even though at greater risk for HIV infection, had never been tested. Additional efforts are needed to address barriers to testing in this group. C1 [Nasrullah, Muazzam; Chavez, Pollyanna R.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Oraka, Emeka] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, ICF Int, Atlanta, GA 30333 USA. [Breiding, Mathew J.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30333 USA. RP Nasrullah, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mailstop E46, Atlanta, GA 30333 USA. EM snasrullah@cdc.gov NR 34 TC 1 Z9 1 U1 0 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD SEP PY 2013 VL 17 IS 7 BP 2521 EP 2527 DI 10.1007/s10461-013-0493-1 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 202UY UT WOS:000323246500024 PM 23653090 ER PT J AU Ostchega, Y Berman, L Hughes, JP Chen, TC Chiappa, MM AF Ostchega, Yechiam Berman, Lewis Hughes, Jeffery P. Chen, Te-Ching Chiappa, Michele M. TI Home Blood Pressure Monitoring and Hypertension Status Among US Adults: The National Health and Nutrition Examination Survey (NHANES), 2009-2010 SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE blood pressure; home blood pressure monitoring; hypertension; NHANES ID SOCIETY AB BACKGROUND Currently, no national prevalence is available on home blood pressure monitoring (HBPM). METHODS This report is based on national-level, cross-sectional data for non-institutionalized US adults aged >= 18 years (n = 6,001 participants) from the National Health and Nutrition Examination Survey (NHANES), 2009-2010. RESULTS Overall, 21.7% of the population reported HBPM in the past year. Using 2010 Census data as a reference, approximately 33 million (14.5%) individuals engaged in monthly or more frequent HBPM. The frequency of HBPM increased with higher age, higher body mass index, higher family income-to-poverty ratio, and a higher number of health-care visits (all, P < 0.05). Adults with health-care coverage engaged in monthly or more frequent HBPM than adults without coverage (16.1% vs. 8.4%; P < 0.05). Among people with hypertension (blood pressure >= 140/90 mm Hg or currently taking medication), 36.6% engaged in monthly or more frequent HBPM. Of those with hypertension whom were aware, treated, and controlled, 41.9%, 43.5%, and 42.1%, respectively, engaged in monthly or more frequent HBPM. Adjusting for covariables, those who were aware of, treated for, and controlled their hypertension were more likely to have a higher frequency of HBPM than the reference: unaware, untreated, and uncontrolled (odds ratio (OR) = 3.59; OR = 3.96; and OR = 1.50, respectively). CONCLUSIONS Approximately 14.5% of adults engaged in monthly or more frequent HBPM. Being aware of hypertension, being pharmacologically treated, and being controlled were associated with an increased frequency of HBPM. Even among these categories of people with hypertension, <50% were using HBPM. C1 [Ostchega, Yechiam; Hughes, Jeffery P.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Berman, Lewis] ICF Int, Rockville, MD USA. [Chen, Te-Ching; Chiappa, Michele M.] Harris Corp, Melbourne, FL 32919 USA. RP Ostchega, Y (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. EM yxo1@cdc.gov NR 11 TC 12 Z9 12 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD SEP PY 2013 VL 26 IS 9 BP 1086 EP 1092 DI 10.1093/ajh/hpt054 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 203NB UT WOS:000323298800006 PM 23604493 ER PT J AU Zhuo, XH Zhang, P Hoerger, TJ AF Zhuo, Xiaohui Zhang, Ping Hoerger, Thomas J. TI Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; INTENSIVE GLYCEMIC CONTROL; CORONARY-HEART-DISEASE; UNITED-STATES; MELLITUS; STYLE; PREVENTION; CARE; METFORMIN; RISK AB Background: Lifetime direct medical cost of treating type 2 diabetes and diabetic complications in the U.S. is unknown. Purpose: This study provides nationally representative estimates of lifetime direct medical costs of treating type 2 diabetes and diabetic complications in people newly diagnosed with type 2 diabetes, by gender and by age at diagnosis. Methods: A type 2 diabetes simulation model was used to simulate the disease progression and direct medical costs among a cohort of newly diagnosed type 2 diabetes patients. The study sample used for the simulation was based on data from the 2009-2010 National Health and Nutritional Examination Survey. The costs of treating type 2 diabetes and diabetic complications were derived from published literature. Annual medical costs were accumulated over the life span of type 2 diabetes to determine the lifetime medical costs. All costs were calculated from a healthcare system perspective, and expressed in 2012 dollars. Results: In men diagnosed with type 2 diabetes at ages 25-44 years, 45-54 years, 55-64 years, and >= 65 years, the lifetime direct medical costs of treating type 2 diabetes and diabetic complications were $124,700, $106,200, $84,000, and $54,700, respectively. In women, the costs were $130,800, $110,400, $85,500, and $56,600, respectively. The age-gender weighted average of the lifetime medical costs was $85,200, of which 53% was due to treating diabetic complications. The cost of managing macrovascular complications accounted for 57% of the total complication cost. Conclusions: Over the lifetime, type 2 diabetes imposes a substantial economic burden on healthcare systems. Effective interventions that prevent or delay type 2 diabetes and diabetic complications might result in substantial long-term savings in healthcare costs. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Zhuo, Xiaohui; Zhang, Ping] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Hoerger, Thomas J.] Res Triangle Int, Res Triangle Pk, NC USA. RP Zhuo, XH (reprint author), CDC, Div Diabet Translat, 4770 Buford Highway,MS K-10, Atlanta, GA 30333 USA. EM xzhuo@cdc.gov NR 50 TC 47 Z9 47 U1 1 U2 41 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2013 VL 45 IS 3 BP 253 EP 261 DI 10.1016/j.amepre.2013.04.017 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 202CU UT WOS:000323191900001 PM 23953350 ER PT J AU Lindley, MC Lorick, SA Geevarughese, A Lee, SJ Makvandi, M Miller, BL Nace, DA Smith, C Ahmed, F AF Lindley, Megan C. Lorick, Suchita A. Geevarughese, Anita Lee, Soo-Jeong Makvandi, Monear Miller, Brady L. Nace, David A. Smith, Carmela Ahmed, Faruque TI Evaluating a Standardized Measure of Healthcare Personnel Influenza Vaccination SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID LONG-TERM-CARE; RANDOMIZED CONTROLLED-TRIAL; NOSOCOMIAL INFLUENZA; ELDERLY-PEOPLE; HOME STAFF; WORKERS; MORTALITY; RESIDENTS; OUTBREAK; RATES AB Background: Methods of measuring influenza vaccination of healthcare personnel (HCP) vary substantially, as do the groups of HCP that are included in any given set of measurements. Thus, comparison of vaccination rates across healthcare facilities is difficult. Purpose: The goal of the study was to determine the feasibility of implementing a standardized measure for reporting HCP influenza vaccination data in various types of healthcare facilities. Methods: A total of 318 facilities recruited in four U.S. jurisdictions agreed to participate in the evaluation, including hospitals, long-term care facilities, dialysis clinics, ambulatory surgery centers, and physician practices. HCP in participating facilities were categorized as employees, credentialed non-employees, or other non-employees using standard definitions. Data were gathered using cross-sectional web-based surveys completed at three intervals between October 2010 and May 2011; data were analyzed in February 2012. Results: 234 facilities (74%) completed all three surveys. Most facilities could report on-site employee vaccination; almost one third could not provide complete data on HCP vaccinated outside the facility, contraindications, or declinations, primarily due to missing non-employee data. Inability to determine vaccination status of credentialed and other non-employees was cited as a major barrier to measure implementation by 24% and 27% of respondents, respectively. Conclusions: Using the measure to report employee vaccination status was feasible for most facilities; tracking non-employee HCP was more challenging. Based on evaluation findings, the measure was revised to limit the types of non-employees included. Although the revised measure is less comprehensive, it is more likely to produce valid vaccination coverage estimates. Use of this standardized measure can inform quality improvement efforts and facilitate comparison of HCP influenza vaccination among facilities. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Lindley, Megan C.; Lorick, Suchita A.; Ahmed, Faruque] CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Geevarughese, Anita] New York City Dept Hlth & Mental Hyg, Bur Immunizat, New York, NY USA. [Lee, Soo-Jeong] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Makvandi, Monear] Sandia Natl Labs, Albuquerque, NM 87185 USA. [Miller, Brady L.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Nace, David A.] Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA USA. RP Lindley, MC (reprint author), Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30333 USA. EM MLindley@cdc.gov RI Nace, David/D-2638-2014 FU CDC FX This work was supported by the CDC. NR 40 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2013 VL 45 IS 3 BP 297 EP 303 DI 10.1016/j.amepre.2013.04.019 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 202CU UT WOS:000323191900007 PM 23953356 ER PT J AU Yabroff, KR Short, PF Machlin, S Dowling, E Rozjabek, H Li, CY McNeel, T Ekwueme, DU Virgo, KS AF Yabroff, K. Robin Short, Pamela F. Machlin, Steven Dowling, Emily Rozjabek, Heather Li, Chunyu McNeel, Timothy Ekwueme, Donatus U. Virgo, Katherine S. TI Access to Preventive Health Care for Cancer Survivors SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID 2ND PRIMARY CANCERS; UNITED-STATES; MEDICAL-CARE; BREAST; MAINTENANCE AB Background: Access to health care, particularly effective primary and secondary preventive care, is critical for cancer survivors, in order to minimize the adverse sequelae of cancer and its treatment. Purpose: The goal of the study was to evaluate the association between cancer survivorship and access to primary and preventive health care. Methods: Cancer survivors (n=4960) and individuals without a cancer history (n=64,431) aged >= 18 years, from the 2008-2010 Medical Expenditure Panel Survey (MEPS), were evaluated. Multiple measures of access and preventive services use were compared. The association between cancer survivorship and access and preventive services was evaluated with multivariate logistic regression models, stratified by age group (18-64 years and >= 65 years), controlling for the effects of age, gender, race/ethnicity, education, marital status, and comorbidities. Data were analyzed in 2013. Results: Cancer survivors aged >= 65 years had equivalent or greater access and preventive services use than individuals without a cancer history, in adjusted analyses. However, among those aged 18-64 years with private health insurance, cancer survivors were more likely than other individuals to have a usual source of care and to use preventive services, whereas uninsured or publicly insured cancer survivors were generally less likely to have a usual source of care and to use preventive services than were uninsured or publicly insured adults without a cancer history. Conclusions: Although access and preventive care use in cancer survivors is generally equivalent or greater compared to that of other individuals, disparities for uninsured and publicly insured cancer survivors aged 18-64 years suggest that improvements in survivor care are needed. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Yabroff, K. Robin; Rozjabek, Heather] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Machlin, Steven] Agcy Healthcare Res & Qual, Ctr Financing Access & Cost Trends, Rockville, MD USA. [McNeel, Timothy] Informat Management Serv Inc, Calverton, MD USA. [Short, Pamela F.] Penn State Univ, Ctr Hlth Care & Policy Res, University Pk, PA 16802 USA. [Dowling, Emily] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Li, Chunyu; Ekwueme, Donatus U.] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Virgo, Katherine S.] Intramural Res Dept, Hlth Serv Res Program, Amer Canc Soc, Natl Home Off, Atlanta, GA USA. RP Yabroff, KR (reprint author), NCI, Hlth Serv & Econ Branch, 9609 Med Ctr Dr,3E436, Rockville, MD 20850 USA. EM yabroffr@mail.nih.gov NR 28 TC 10 Z9 10 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD SEP PY 2013 VL 45 IS 3 BP 304 EP 312 DI 10.1016/j.amepre.2013.04.021 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 202CU UT WOS:000323191900008 ER PT J AU Dirac, MA Weigel, KM Yakrus, MA Becker, AL Chen, HL Fridley, G Sikora, A Speake, C Hilborn, ED Pfaller, S Cangelosi, GA AF Dirac, M. Ashworth Weigel, Kris M. Yakrus, Mitchell A. Becker, Annie L. Chen, Hui-Ling Fridley, Gina Sikora, Arthur Speake, Cate Hilborn, Elizabeth D. Pfaller, Stacy Cangelosi, Gerard A. TI Shared Mycobacterium avium Genotypes Observed among Unlinked Clinical and Environmental Isolates SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID FRAGMENT-LENGTH-POLYMORPHISM; NONTUBERCULOUS MYCOBACTERIA; SP-NOV.; INTRACELLULARE COMPLEX; SUBSP HOMINISSUIS; GENETIC VARIANT; STRAINS; IS1245; TUBERCULOSIS; INFECTION AB Our understanding of the sources of Mycobacterium avium infection is partially based on genotypic matching of pathogen isolates from cases and environmental sources. These approaches assume that genotypic identity is rare in isolates from unlinked cases or sources. To test this assumption, a high-resolution PCR-based genotyping approach, large-sequence polymorphism (LSP)-mycobacterial interspersed repetitive unit-variable-number tandem repeat (MIRU-VNTR), was selected and used to analyze clinical and environmental isolates of M. avium from geographically diverse sources. Among 127 clinical isolates from seven locations in North America, South America, and Europe, 42 genotypes were observed. Among 12 of these genotypes, matches were seen in isolates from apparently unlinked patients in two or more geographic locations. Six of the 12 were also observed in environmental isolates. A subset of these isolates was further analyzed by alternative strain genotyping methods, pulsed-field gel electrophoresis and MIRU-VNTR, which confirmed the existence of geographically dispersed strain genotypes. These results suggest that caution should be exercised in interpreting high-resolution genotypic matches as evidence for an acquisition event. C1 [Dirac, M. Ashworth; Weigel, Kris M.; Becker, Annie L.; Chen, Hui-Ling; Sikora, Arthur; Speake, Cate; Cangelosi, Gerard A.] Univ Washington, Seattle, WA 98195 USA. [Dirac, M. Ashworth; Weigel, Kris M.; Becker, Annie L.; Chen, Hui-Ling; Fridley, Gina; Sikora, Arthur; Speake, Cate; Cangelosi, Gerard A.] Seattle Biomed Res Inst, Seattle, WA 98109 USA. [Yakrus, Mitchell A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hilborn, Elizabeth D.] US EPA, Res Triangle Pk, NC 27711 USA. [Pfaller, Stacy] US EPA, Cincinnati, OH 45268 USA. RP Dirac, MA (reprint author), Univ Washington, Seattle, WA 98195 USA. EM madirac@uw.edu; gcang@uw.edu OI Weigel, Kris/0000-0003-3199-2148 FU U.S. Environmental Protection Agency [FP-91695601, 833030010]; Medical Scientist Training Program (National Research Service Award from the National Institute of General Medical Sciences) [T32 GM07266] FX This publication was developed under a STAR Research Assistance Agreement (no. FP-91695601) and a Collaborative Agreement (no. 833030010) awarded by the U.S. Environmental Protection Agency. Additional funding was provided to M. A. D. by the Medical Scientist Training Program (T32 GM07266, a National Research Service Award from the National Institute of General Medical Sciences). NR 45 TC 4 Z9 4 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD SEP PY 2013 VL 79 IS 18 BP 5601 EP 5607 DI 10.1128/AEM.01443-13 PG 7 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 205DO UT WOS:000323421900021 PM 23851084 ER PT J AU Weston, A AF Weston, A. TI Occupational Exposures to Silica Associated with Hydraulic Fracturing: National Institute for Occupational Safety and Health (NIOSH) Field Operations. SO ENVIRONMENTAL AND MOLECULAR MUTAGENESIS LA English DT Meeting Abstract CT 44th Annual Meeting of the Environmental-Mutagenesis-and-Genomics-Society (EMGS) CY SEP 21-25, 2013 CL Monterey, CA SP Environm Mutagenesis & Genom Soc (EMGS) C1 [Weston, A.] CDC, Natl Inst Occupat Safety & Hlth, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 1 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0893-6692 J9 ENVIRON MOL MUTAGEN JI Environ. Mol. Mutagen. PD SEP PY 2013 VL 54 SU 1 BP S14 EP S14 PG 1 WC Environmental Sciences; Genetics & Heredity; Toxicology SC Environmental Sciences & Ecology; Genetics & Heredity; Toxicology GA 205FV UT WOS:000323429400008 ER PT J AU Menke, A Orchard, TJ Imperatore, G Bullard, KM Mayer-Davis, E Cowie, CC AF Menke, Andy Orchard, Trevor J. Imperatore, Giuseppina Bullard, Kai McKeever Mayer-Davis, Elizabeth Cowie, Catherine C. TI The Prevalence of Type 1 Diabetes in the United States SO EPIDEMIOLOGY LA English DT Letter C1 [Menke, Andy] Social & Sci Syst Inc, Silver Spring, MD USA. [Orchard, Trevor J.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Imperatore, Giuseppina; Bullard, Kai McKeever] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA USA. [Mayer-Davis, Elizabeth] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Cowie, Catherine C.] NIDDK, NIH, Bethesda, MD USA. RP Menke, A (reprint author), Social & Sci Syst Inc, Silver Spring, MD USA. EM amenke@s-3.com OI orchard, trevor/0000-0001-9552-3215 FU Intramural CDC HHS [CC999999]; PHS HHS [GS10F0381L] NR 8 TC 15 Z9 15 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD SEP PY 2013 VL 24 IS 5 BP 773 EP 774 DI 10.1097/EDE.0b013e31829ef01a PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 200YL UT WOS:000323107600019 PM 23903880 ER PT J AU Nahar, N Mondal, UK Sultana, R Hossain, MJ Khan, MSU Gurley, ES Oliveras, E Luby, SP AF Nahar, Nazmun Mondal, Utpal Kumar Sultana, Rebeca Hossain, M. Jahangir Khan, M. Salah Uddin Gurley, Emily S. Oliveras, Elizabeth Luby, Stephen P. TI Piloting the use of indigenous methods to prevent Nipah virus infection by interrupting bats access to date palm sap in Bangladesh SO HEALTH PROMOTION INTERNATIONAL LA English DT Article DE public health intervention development; community-based intervention; Bangladesh ID FLYING-FOXES; TRANSMISSION; HEALTH; COMMUNITY; CAMBODIA; ECOLOGY AB People in Bangladeshfrequently drink fresh date palm sap. Fruit bats (Pteropus giganteus) also drink raw sap and may contaminate the sap by shedding Nipah virus through saliva and urine. In a previous study we identified two indigenous methods to prevent bats accessing the sap, bamboo skirts and lime (calcium carbonate). We conducted a pilot study to assess the acceptability of these two methods among sap harvesters. We used interactive community meetings and group discussions to encourage all the sap harvesters (n 12) from a village to use either bamboo skirts or lime smear that some of them (n 4) prepared and applied. We measured the preparation and application time and calculated the cost of bamboo skirts. We conducted interviews after the use of each method. The sap harvesters found skirts effective in preventing bats from accessing sap. They were sceptical that lime would be effective as the lime was washed away by the sap flow. Preparation of the skirt took 105 min. The application of each method took 1 min. The cost of the bamboo skirt is minimal because bamboo is widely available and they made the skirts with pieces of used bamboo. The bamboo skirt method appeared practical and affordable to the sap harvesters. Further studies should explore its ability to prevent bats from accessing date palm sap and assess if its use produces more or better quality sap, which would provide further incentives to make it more acceptable for its regular use. C1 [Nahar, Nazmun; Mondal, Utpal Kumar; Sultana, Rebeca; Hossain, M. Jahangir; Khan, M. Salah Uddin; Gurley, Emily S.; Oliveras, Elizabeth; Luby, Stephen P.] ICDDR B, Dhaka 1212, Bangladesh. [Luby, Stephen P.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Nahar, N (reprint author), ICDDR B, Post Box 128, Dhaka 1212, Bangladesh. EM nahar.nazmun@yahoo.com RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X FU NCPDCID CDC HHS [5-U01-CI000298-03] NR 27 TC 11 Z9 11 U1 0 U2 24 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0957-4824 J9 HEALTH PROMOT INT JI Health Promot. Int. PD SEP PY 2013 VL 28 IS 3 BP 378 EP 386 DI 10.1093/heapro/das020 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 199DP UT WOS:000322975000010 PM 22669914 ER PT J AU Smith, JL Pollack, LA Rodriguez, JL Hawkins, NA Smith, T Rechis, R Miller, A Willis, A Miller, H Hall, IJ Fairley, TL Stone-Wiggins, B AF Smith, Judith Lee Pollack, Lori A. Rodriguez, Juan L. Hawkins, Nikki A. Smith, Tenbroeck Rechis, Ruth Miller, Andy Willis, Anne Miller, Helen Hall, Ingrid J. Fairley, Temeika L. Stone-Wiggins, Brenda TI Assessment of the status of A National Action Plan for Cancer Survivorship in the USA SO JOURNAL OF CANCER SURVIVORSHIP LA English DT Article DE Cancer survivorship; National Action Plan for Cancer Survivorship; Public health; Assessment; Evaluation ID LONG-TERM CANCER; QUALITY-OF-LIFE; PROSTATE-CANCER; BREAST-CANCER; HEALTH; SOCIETY; RECOMMENDATIONS; BURDEN; ONCOLOGY; SURGERY AB There are currently more than 12 million cancer survivors in the USA. Survivors face many issues related to cancer and treatment that are outside the purview of the clinical care system. Therefore, understanding and providing for the evolving needs of cancer survivors offers challenges and opportunities for the public health system. In 2004, the Centers for Disease Control and Prevention and the Lance Armstrong Foundation, now the Livestrong Foundation, partnered with national cancer survivorship organizations to develop the National Action Plan for Cancer Survivorship (NAPCS). This plan outlines public health strategies to address the needs of cancer survivors. To date, no assessment of NAPCS strategies and their alignment with domestic cancer survivorship activities has been conducted. The activities of five national organizations with organized public health agendas about cancer survivorship were assessed qualitatively during 2003-2007. Using the NAPCS as an organizing framework, interviews were conducted with key informants from all participating organizations. Interview responses were supplemented with relevant materials from informants and reviews of the organizations' websites. Strategies associated with surveillance and applied research; communication, education, and training; and programs, policy, and infrastructure represent a large amount of the organizational efforts. However, there are gaps in research on preventive interventions, evaluation of implemented activities, and translation. Numerous NAPCS strategies have been implemented. Future efforts of national cancer survivorship organizations should include rigorous evaluation of implemented activities, increased translation of research to practice, and assessment of dissemination efforts. The results of this descriptive assessment provide cancer survivors, cancer survivorship organizations, researchers, providers, and policy makers with initial information about cancer survivorship public health efforts in the USA. Additionally, results suggest areas in need of further attention and next steps in advancing the national cancer survivorship public health agenda. C1 [Smith, Judith Lee; Pollack, Lori A.; Rodriguez, Juan L.; Hawkins, Nikki A.; Hall, Ingrid J.; Fairley, Temeika L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Smith, Tenbroeck] Amer Canc Soc, Behav Res Ctr, Intramural Res Dept, Atlanta, GA 30329 USA. [Rechis, Ruth; Miller, Andy] Livestrong Fdn, Austin, TX USA. [Willis, Anne] Natl Coalit Canc Survivorship, Silver Spring, MD USA. [Miller, Helen] CancerCare, New York, NY USA. [Stone-Wiggins, Brenda] RTI Int, Res Triangle Pk, NC USA. [Pollack, Lori A.] Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Atlanta, GA USA. RP Smith, JL (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,Mail Stop K-55, Atlanta, GA 30341 USA. EM JLeeSmith@cdc.gov FU Centers for Disease Control and Prevention [200-2002-00575] FX Lori A. Pollack is now with the Prevention and Response Branch, Division of Healthcare Quality Promotion, CDC. Anne Willis is now at the George Washington University Cancer Institute. Research for this publication was supported by Centers for Disease Control and Prevention Contract number 200-2002-00575. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors gratefully acknowledge the contributions of Diane Blum for her thoughtful comments on project-related materials and her support for the project during her tenure at CancerCare and Pamela Goetz for her support of this project during her tenure as Director of Survivorship Programs at the National Coalition for Cancer Survivorship. NR 35 TC 5 Z9 5 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD SEP PY 2013 VL 7 IS 3 BP 425 EP 438 DI 10.1007/s11764-013-0276-8 PG 14 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 197WM UT WOS:000322883100014 PM 23609522 ER PT J AU Blake, RG Braden, CR Brown, LG AF Blake, Robert G. Braden, Christopher R. Brown, Laura G. TI InFORM: An Innovative, Integrated Food Safety Meeting SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 [Blake, Robert G.] CDC, EHSB, Atlanta, GA 30333 USA. [Braden, Christopher R.] CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Brown, LG (reprint author), Ctr Dis Control & Prevent, Emergency Serv, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-58, Atlanta, GA 30341 USA. EM lrgreen@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 1 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD SEP PY 2013 VL 76 IS 2 BP 44 EP 45 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 205QW UT WOS:000323460700007 PM 24073489 ER PT J AU Magadan, JG Khurana, S Das, SR Frank, GM Stevens, J Golding, H Bennink, JR Yewdell, JW AF Magadan, Javier G. Khurana, Surender Das, Suman R. Frank, Gregory M. Stevens, James Golding, Hana Bennink, Jack R. Yewdell, Jonathan W. TI Influenza A Virus Hemagglutinin Trimerization Completes Monomer Folding and Antigenicity SO JOURNAL OF VIROLOGY LA English DT Article ID VIRAL MEMBRANE-PROTEINS; INTRACELLULAR-TRANSPORT; RECEPTOR-BINDING; MONOCLONAL-ANTIBODIES; NEUTRALIZING ANTIBODY; ENDOPLASMIC-RETICULUM; GOLGI-COMPLEX; FUSION; CELLS; SITE AB Influenza A virus (IAV) remains an important human pathogen largely because of antigenic drift, the rapid emergence of anti-body escape mutants that precludes durable vaccination. The most potent neutralizing antibodies interact with cognate epitopes in the globular "head" domain of hemagglutinin (HA), a homotrimeric glycoprotein. The H1 HA possesses five distinct regions defined by a large number of mouse monoclonal antibodies (MAbs), i.e., Ca1, Ca2, Cb, Sa, and Sb. Ca1-Ca2 sites require HA trimerization to attain full antigenicity, consistent with their locations on opposite sides of the trimer interface. Here, we show that full antigenicity of Cb and Sa sites also requires HA trimerization, as revealed by immunofluorescence microscopy of IAV-infected cells and biochemically by pulse-chase radiolabeling experiments. Surprisingly, epitope antigenicity acquired by HA trimerization persists following acid triggering of the globular domains dissociation and even after proteolytic release of monomeric heads from acid-treated HA. Thus, the requirement for HA trimerization by trimer-specific MAbs mapping to the Ca, Cb, and Sa sites is not dependent upon the bridging of adjacent monomers in the native HA trimer. Rather, complete antigenicity of HA (and, by inference, immunogenicity) requires a final folding step that accompanies its trimerization. Once this conformational change occurs, HA trimers themselves would not necessarily be required to induce a highly diverse neutralizing response to epitopes in the globular domain. C1 [Magadan, Javier G.; Das, Suman R.; Bennink, Jack R.; Yewdell, Jonathan W.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA. [Khurana, Surender; Frank, Gregory M.; Golding, Hana] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA. [Stevens, James] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Yewdell, JW (reprint author), NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA. EM jyewdell@niaid.nih.gov FU Division of Intramural Research of the National Institute of Allergy and Infectious Diseases FX This work was supported by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases. NR 47 TC 11 Z9 11 U1 1 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD SEP PY 2013 VL 87 IS 17 BP 9742 EP 9753 DI 10.1128/JVI.00471-13 PG 12 WC Virology SC Virology GA 201NO UT WOS:000323148500032 PM 23824811 ER PT J AU King, BA Alam, S Promoff, G Arrazola, R Dube, SR AF King, Brian A. Alam, Suhana Promoff, Gabbi Arrazola, Rene Dube, Shanta R. TI Awareness and Ever-Use of Electronic Cigarettes Among U.S. Adults, 2010-2011 SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID NICOTINE DELIVERY-SYSTEMS; TOBACCO; POLICY; SMOKE; RISE AB Introduction: Electronic cigarettes, or e-cigarettes, were introduced into the U.S. market in recent years. However, little is known about the health impact of the product or the extent of its use. This study assessed the prevalence and correlates of awareness and ever-use of e-cigarettes among U.S. adults during 2010-2011. Methods: Data were obtained from the HealthStyles survey, a national consumer-based survey of U.S. adults aged years old. In 2010, data collection for the HealthStyles survey was both mail-based (n = 4,184) and web-based (n = 2,505), and in 2011, web-based (n = 4,050) only. Estimates of awareness and ever-use of e-cigarettes were calculated overall and by sex, age, race/ethnicity, educational attainment, household income, region, and smoking status. Results: In 2010, overall awareness of e-cigarettes was 38.5% (mail survey) and 40.9% (web survey); in 2011, awareness was 57.9% (web survey). Ever-use of e-cigarettes among all respondents was 2.1% in the 2010 mail survey, 3.3% in the 2010 web survey, and 6.2% in the 2011 web survey. Ever-use of e-cigarettes was significantly higher among current smokers compared with both former and never-smokers, irrespective of survey method or year. During 2010-2011, ever-use increased among both sexes, those aged 45-54 years, non-Hispanic Whites, those living in the South, and current and former smokers. Conclusions: Awareness and ever-use of e-cigarettes increased among U.S. adults from 2010 to 2011. In 2011, approximately 1 in 5 current smokers reported having ever-used e-cigarettes. Continued surveillance of e-cigarettes is needed for public health planning. C1 [King, Brian A.; Alam, Suhana; Promoff, Gabbi; Arrazola, Rene; Dube, Shanta R.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [King, Brian A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. [Alam, Suhana] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K-50, Atlanta, GA 30341 USA. EM baking@cdc.gov FU U.S. Department of Energy; CDC [DE-AC05-06OR23100] FX This project was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC (Grant DE-AC05-06OR23100). NR 27 TC 201 Z9 203 U1 2 U2 52 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD SEP PY 2013 VL 15 IS 9 BP 1623 EP 1627 DI 10.1093/ntr/ntt013 PG 5 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 202CM UT WOS:000323191100018 PM 23449421 ER PT J AU Thorpe, PG Gilboa, SM Hernandez-Diaz, S Lind, J Cragan, JD Briggs, G Kweder, S Friedman, JM Mitchell, AA Honein, MA AF Thorpe, Phoebe G. Gilboa, Suzanne M. Hernandez-Diaz, Sonia Lind, Jennifer Cragan, Janet D. Briggs, Gerald Kweder, Sandra Friedman, Jan M. Mitchell, Allen A. Honein, Margaret A. CA Natl Birth Defects Prevention TI Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE medication; pregnancy; fetal risk; teratogen; pharmacoepidemiology ID TERATOGENICITY; WOMEN AB Purpose To determine which medications are most commonly used by women in the first trimester of pregnancy and identify the critical gaps in information about fetal risk for those medications. Methods Self-reported first-trimester medication use was assessed among women delivering liveborn infants without birth defects and serving as control mothers in two large case-control studies of major birth defects. The Teratology Information System (TERIS) expert Advisory Board ratings of quality and quantity of data available to assess fetal risk were reviewed to identify information gaps. Results Responses from 5381 mothers identified 54 different medication components used in the first trimester by at least 0.5% of pregnant women, including 31 prescription and 23 over-the-counter medications. The most commonly used prescription medication components reported were progestins from oral contraceptives, amoxicillin, progesterone, albuterol, promethazine, and estrogenic compounds. The most commonly used over-the-counter medication components reported were acetaminophen, ibuprofen, docusate, pseudoephedrine, aspirin, and naproxen. Among the 54 most commonly used medications, only two had Good to Excellent data available to assess teratogenic risk in humans, based on the TERIS review. Conclusions For most medications commonly used in pregnancy, there are insufficient data available to characterize the fetal risk fully, limiting the opportunity for informed clinical decisions about the best management of acute and chronic disorders during pregnancy. Future research efforts should be directed at these critical knowledge gaps. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Thorpe, Phoebe G.; Gilboa, Suzanne M.; Lind, Jennifer; Cragan, Janet D.; Honein, Margaret A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Briggs, Gerald] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Briggs, Gerald] Univ So Calif, Los Angeles, CA USA. [Briggs, Gerald] Washington State Univ, Spokane, WA USA. [Kweder, Sandra] US FDA, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Friedman, Jan M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Mitchell, Allen A.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. RP Thorpe, PG (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-E86, Atlanta, GA 30333 USA. EM pht1@cdc.gov OI Friedman, Jan/0000-0002-7482-9570 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R01 HD046595]; Centers for Disease Control and Prevention [U50/CCU113247, PA 96043, PA 02081, FOA DD09-001] FX Drs. Hernandez-Diaz and Mitchell were supported by grant R01 HD046595 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Dr. Mitchell also receives support through Cooperative Agreement no. U50/CCU113247 with the Centers for Disease Control and Prevention to the Slone Epidemiology Center through the Massachusetts Department of Public Health. This work was also supported through cooperative agreements under PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study. NR 13 TC 37 Z9 37 U1 1 U2 36 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD SEP PY 2013 VL 22 IS 9 BP 1013 EP 1018 DI 10.1002/pds.3495 PG 6 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 202WF UT WOS:000323250600012 PM 23893932 ER PT J AU Ishida, K Klevens, J Rivera-Garcia, B Mirabal, B AF Ishida, Kanako Klevens, Joanne Rivera-Garcia, Brenda Mirabal, Brenda TI Child Maltreatment in Puerto Rico: Findings from the 2010 National Child Abuse and Neglect Data System SO PUERTO RICO HEALTH SCIENCES JOURNAL LA English DT Article DE Child maltreatment; Child abuse; The National Child Abuse and Neglect Data System ID RISKY SEXUAL-BEHAVIOR; SUBSTANTIATION AB Objective: Child maltreatment can have long-term adverse effects. Quantifying the scope and characteristics of child maltreatment is necessary for effective prevention in Puerto Rico. Methods: The National Child Abuse and Neglect Data System Child File contains all the reports of child maltreatment from the United States (US) and Puerto Rico. A child maltreatment victim is defined as a child whose maltreatment was substantiated or indicated by the local child protective agency. We compared reporting and victimization rates and reporting sources in Puerto Rico, with those in the US and examined characteristics of child maltreatment in Puerto Rico. Results: During 2006-2010, a total of 31,849-40,712 cases of child maltreatment were reported annually in Puerto Rico. Victimization rates are consistently higher in Puerto Rico than in the US (10.7/1,000-14.8/1,000 in Puerto Rico vs. 10.1/1,00012.1/1,000 in the US), despite consistently lower reporting rates. In 2010, victimization rates were highest among children aged 1-6 years. In Puerto Rico, neglect is the most common form of maltreatment, followed by emotional abuse; however, the majority of victims suffered multiple types of abuse. Reporting was more commonly anonymous in Puerto Rico (29.8%) than in the US (9.4%) and less commonly provided by professionals in Puerto Rico (37.2%) than in the US (58.7%). Conclusion: We identified a high prevalence of child maltreatment in Puerto Rico. A lower reporting rate, higher victimization rate, and substantial percentage of anonymous reporting indicate potential underreporting of child maltreatment in Puerto Rico. Increasing the awareness and training professionals for improved child maltreatment identification could help alleviate the problem of underreporting. C1 [Ishida, Kanako] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ishida, Kanako; Rivera-Garcia, Brenda] Puerto Rico Dept Hlth, San Juan, PR USA. [Klevens, Joanne] Ctr Dis Control & Prevent, Div Violence Prevent, San Juan, PR USA. [Mirabal, Brenda] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA. RP Ishida, K (reprint author), Ctr Dis Control & Prevent, Div Appl Sci, Sci Educ & Profess Dev Program Off, 1600 Clifton Rd,E-92, Atlanta, GA 30333 USA. EM kanakoi@ucla.edu NR 27 TC 4 Z9 6 U1 4 U2 7 PU UNIV PUERTO RICO MEDICAL SCIENCES CAMPUS PI SAN JUAN PA OFFICE DEAN ACADEMIC AFFAIRS BOX 365067, SAN JUAN, PR 00936-5067 USA SN 0738-0658 J9 P R HEALTH SCI J JI P. R. Health Sci. J. PD SEP PY 2013 VL 32 IS 3 BP 124 EP 131 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 205EA UT WOS:000323423500002 PM 24133893 ER PT J AU Pearson, T Hornstra, HM Sahl, JW Schaack, S Schupp, JM Beckstrom-Sternberg, SM O'Neill, MW Priestley, RA Champion, MD Beckstrom-Sternberg, JS Kersh, GJ Samuel, JE Massung, RF Keim, P AF Pearson, Talima Hornstra, Heidie M. Sahl, Jason W. Schaack, Sarah Schupp, James M. Beckstrom-Sternberg, Stephen M. O'Neill, Matthew W. Priestley, Rachael A. Champion, Mia D. Beckstrom-Sternberg, James S. Kersh, Gilbert J. Samuel, James E. Massung, Robert F. Keim, Paul TI When Outgroups Fail; Phylogenomics of Rooting the Emerging Pathogen, Coxiella burnetii SO SYSTEMATIC BIOLOGY LA English DT Article DE Coxiella burnetii; paralog SNPs; pathogen evolution; phylogeny; recent radiation; root; rooting using duplicated genes ID Q-FEVER; PHYLOGENETIC TREES; GENOME REDUCTION; YERSINIA-PESTIS; OPEN SOFTWARE; EVOLUTION; GENES; DIVERSITY; SEQUENCE; DNA AB Rooting phylogenies is critical for understanding evolution, yet the importance, intricacies and difficulties of rooting are often overlooked. For rooting, polymorphic characters among the group of interest (ingroup) must be compared to those of a relative (outgroup) that diverged before the last common ancestor (LCA) of the ingroup. Problems arise if an outgroup does not exist, is unknown, or is so distant that few characters are shared, in which case duplicated genes originating before the LCA can be used as proxy outgroups to root diverse phylogenies. Here, we describe a genome-wide expansion of this technique that can be used to solve problems at the other end of the evolutionary scale: where ingroup individuals are all very closely related to each other, but the next closest relative is very distant. We used shared orthologous single nucleotide polymorphisms (SNPs) from 10 whole genome sequences of Coxiella burnetii, the causative agent of Q fever in humans, to create a robust, but unrooted phylogeny. To maximize the number of characters informative about the rooting, we searched entire genomes for polymorphic duplicated regions where orthologs of each paralog could be identified so that the paralogs could be used to root the tree. Recent radiations, such as those of emerging pathogens, often pose rooting challenges due to a lack of ingroup variation and large genomic differences with known outgroups. Using a phylogenomic approach, we created a robust, rooted phylogeny for C. burnetii. C1 [Pearson, Talima; Hornstra, Heidie M.; Sahl, Jason W.; Beckstrom-Sternberg, Stephen M.; O'Neill, Matthew W.; Champion, Mia D.; Beckstrom-Sternberg, James S.; Keim, Paul] No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA. [Sahl, Jason W.; Schupp, James M.; Beckstrom-Sternberg, Stephen M.; Champion, Mia D.; Keim, Paul] Reed Coll, Dept Biol, Portland, OR 97202 USA. [Schaack, Sarah] Translat Genom Res Inst, Pathogen Genom Div, Flagstaff, AZ USA. [Priestley, Rachael A.; Kersh, Gilbert J.; Massung, Robert F.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. [Samuel, James E.] Texas A&M Hlth Sci Ctr, Dept Microbial & Mol Pathogenesis, College Stn, TX USA. RP Pearson, T (reprint author), No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA. EM talima.pearson@nau.edu FU Department of Homeland Security [HSHQDC-10-C-00139] FX This work was supported by the Department of Homeland Security [HSHQDC-10-C-00139]. NR 60 TC 18 Z9 18 U1 0 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1063-5157 EI 1076-836X J9 SYST BIOL JI Syst. Biol. PD SEP PY 2013 VL 62 IS 5 BP 752 EP 762 DI 10.1093/sysbio/syt038 PG 11 WC Evolutionary Biology SC Evolutionary Biology GA 203MO UT WOS:000323297500008 PM 23736103 ER PT J AU Mehal, JM Holman, RC Schonberger, LB Sejvar, JJ AF Mehal, Jason M. Holman, Robert C. Schonberger, Lawrence B. Sejvar, James J. TI Amyotrophic lateral sclerosis/motor neuron disease deaths in the United States, 1999-2009 SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article DE Amyotrophic lateral sclerosis; motor neuron disease; mortality ID ALS; POPULATION; EPIDEMIOLOGY; MORTALITY; FRANCE; IDENTIFICATION; FREQUENCY; MINNESOTA; DIAGNOSIS; ACCURACY AB Our objective was to examine trends and epidemiology of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) associated deaths in the United States. ALS/MND associated death rates and trends in the United States for 1999-2009 were examined using the multiple cause-of-death mortality data. Age-specific and age-adjusted death rates were calculated. For 1999-2009, the average annual age-adjusted death rate was 2.17/100,000 persons. The age-specific rate increased with age until 75-79 years. Males experienced a higher death rate than females. There was no definitive trend in the annual ALS/MND associated death rate, although analyses suggested a possible decrease (p = 0.05); however, the rate increased for persons 20-49 years of age and declined for persons >= 65 years of age. The annual rate for males decreased whereas the rate for females showed no change. In conclusion, the suggested decreasing annual ALS/MND associated death rate for 1999-2009 contrasts with earlier reports indicating that the incidence and death rate of ALS were increasing. While the ALS/MND associated death rate slightly increased among adults 20-49 years of age, rates declined among two subpopulations at higher risk for ALS/MND - males and persons >= 65 years of age. Continued monitoring of ALS/MND mortality data and additional epidemiological studies will be important to further elucidate these epidemiological trends. C1 [Mehal, Jason M.; Holman, Robert C.; Schonberger, Lawrence B.; Sejvar, James J.] Ctr Dis Control & Prevent CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Mehal, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-30, Atlanta, GA 30333 USA. EM jmehal@cdc.gov NR 44 TC 8 Z9 8 U1 1 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 2167-8421 J9 AMYOTROPH LA SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD SEP PY 2013 VL 14 IS 5-6 BP 346 EP 352 DI 10.3109/21678421.2013.787629 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 196NR UT WOS:000322782800004 PM 23621426 ER PT J AU Pinkerton, LE Hein, MJ Meyers, A Kamel, F AF Pinkerton, Lynne E. Hein, Misty J. Meyers, Alysha Kamel, Freya TI Assessment of ALS mortality in a cohort of formaldehyde-exposed garment workers SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; SURVIVAL; UPDATE C1 [Pinkerton, Lynne E.; Hein, Misty J.; Meyers, Alysha] NIOSH, Industrywide Studies Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Kamel, Freya] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA. RP Pinkerton, LE (reprint author), NIOSH, Industrywide Studies Branch, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,R-15, Cincinnati, OH 45226 USA. EM lep5@cdc.gov OI Meyers, Alysha/0000-0002-6402-0145; Kamel, Freya/0000-0001-5052-6615 FU Intramural Research Program of the National Institute for Occupational Safety and Health; Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences FX This work was supported in part by the Intramural Research Program of the National Institute for Occupational Safety and Health and in part by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences. NR 14 TC 6 Z9 6 U1 0 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 2167-8421 J9 AMYOTROPH LA SCL FR JI Amyotroph. Lateral Scher. Frontotemp. Degenerat. PD SEP PY 2013 VL 14 IS 5-6 BP 353 EP 355 DI 10.3109/21678421.2013.778284 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 196NR UT WOS:000322782800005 PM 23570513 ER PT J AU Abbo, LM Cosgrove, SE Pottinger, PS Pereyra, M Sinkowitz-Cochran, R Srinivasan, A Webb, DJ Hooton, TM AF Abbo, Lilian M. Cosgrove, Sara E. Pottinger, Paul S. Pereyra, Margaret Sinkowitz-Cochran, Ronda Srinivasan, Arjun Webb, David J. Hooton, Thomas M. TI Medical Students' Perceptions and Knowledge About Antimicrobial Stewardship: How Are We Educating Our Future Prescribers? SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE antimicrobial stewardship; education; medical students ID ANTIBIOTIC-RESISTANCE; PHYSICIANS; ATTITUDES; BELIEFS; CLINICIAN; PATTERNS; PROGRAMS; SOCIETY; IMPACT; CARE AB Background. Better understanding of medical students' perceptions, attitudes, and knowledge about antimicrobial prescribing practices could facilitate more effective education of these future prescribers. Methods. A 24-item electronic survey on antimicrobial prescribing and education was administered to fourth-year medical students at the University of Miami, the Johns Hopkins University, and the University of Washington (January-March 2012). Results. Three hundred seventeen of 519 (61%) students completed the survey; 92% of respondents agreed that strong knowledge of antimicrobials is important in their careers, and 90% said that they would like more education on appropriate use of antimicrobials. Mean correct knowledge score (11 items) was 51%, with statistically significant differences between study sites and sources of information used to learn about antimicrobials. Only 15% had completed a clinical infectious diseases rotation during medical school; those who had done so rated the quality of their antimicrobial education significantly higher compared to those who had not (mean, 3.93 vs 3.44, on a 5-point scale; P = .0003). There were no statistically significant associations between knowledge scores and having had an infectious diseases clinical elective. Only one-third of respondents perceived their preparedness to be adequate in some fundamental principles of antimicrobial use. Conclusions. Differences exist between medical schools in educational resources used, perceived preparedness, and knowledge about antimicrobial use. Variability in formative education could frame behaviors and prescribing practices in future patient care. To help address the growing problem of antimicrobial resistance, efforts should be undertaken to ensure that our future doctors are well educated in the principles and practices of appropriate use of antibiotics and antimicrobial stewardship. C1 [Abbo, Lilian M.; Hooton, Thomas M.] Univ Miami, Miller Sch Med, Div Infect Dis, Dept Med, Miami, FL 33136 USA. [Cosgrove, Sara E.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA. [Pottinger, Paul S.] Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA. [Pereyra, Margaret] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA. [Sinkowitz-Cochran, Ronda; Srinivasan, Arjun] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Webb, David J.] Univ Edinburgh, Queens Med Res Inst, Edinburgh EH8 9YL, Midlothian, Scotland. RP Abbo, LM (reprint author), Univ Miami, Miller Sch Med, Div Infect Dis, 1120 NW 14th St,Ste 851, Miami, FL 33136 USA. EM labbo@med.miami.edu FU Centers for Disease Control and Prevention Foundation; Merck FX This work was supported by the Centers for Disease Control and Prevention Foundation in partnership with and grant support from Merck. NR 31 TC 34 Z9 35 U1 3 U2 20 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2013 VL 57 IS 5 BP 631 EP 638 DI 10.1093/cid/cit370 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 199DJ UT WOS:000322974400002 PM 23728148 ER PT J AU Conklin, L Adjemian, J Loo, J Mandal, S Davis, C Parks, S Parsons, T McDonough, B Partida, J Thurman, K Diaz, MH Benitez, A Pondo, T Whitney, CG Winchell, JM Kendig, N Van Beneden, C AF Conklin, Laura Adjemian, Jennifer Loo, Jennifer Mandal, Sema Davis, Carol Parks, Sharyn Parsons, Tina McDonough, Brian Partida, Jorge Thurman, Kathleen Diaz, Maureen H. Benitez, Alvaro Pondo, Tracy Whitney, Cynthia G. Winchell, Jonas M. Kendig, Newton Van Beneden, Chris TI Investigation of a Chlamydia pneumoniae Outbreak in a Federal Correctional Facility in Texas SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Chlamydia pneumoniae; Chlamydophila; atypical pneumonia; community-acquired pneumonia; prison ID COMMUNITY-ACQUIRED PNEUMONIA; REAL-TIME PCR; CHLAMYDOPHILA-PNEUMONIAE; MYCOPLASMA-PNEUMONIAE; INFECTIOUS OUTBREAKS; CARE FACILITIES; PREVALENCE; TRAINEES; EPIDEMIC; FINLAND AB Background. Chlamydia pneumoniae illness is poorly characterized, particularly as a sole causative pathogen. We investigated a C. pneumoniae outbreak at a federal correctional facility. Methods. We identified inmates with acute respiratory illness (ARI) from 1 November 2009 to 24 February 2010 through clinic self-referral and active case finding. We tested oropharyngeal and/or nasopharyngeal swabs for C. pneumoniae by real-time polymerase chain reaction (qPCR) and serum samples by microimmunofluorescence. Cases were inmates with ARI and radiologically confirmed pneumonia, positive qPCR, or serological evidence of recent infection. Swabs from 7 acutely ill inmates were tested for 18 respiratory pathogens using qPCR TaqMan Array Cards (TACs). Follow-up swabs from case patients were collected for up to 8 weeks. Results. Among 33 self-referred and 226 randomly selected inmates, 52 (20.1%) met the case definition; pneumonia was confirmed in 4 by radiology only, in 9 by qPCR only, in 17 by serology only, and in 22 by both qPCR and serology. The prison attack rate was 10.4% (95% confidence interval, 7.0%-13.8%). White inmates and residents of housing unit Y were at highest risk. TAC testing detected C. pneumoniae in 4 (57%) inmates; no other causative pathogens were identified. Among 40 inmates followed prospectively, C. pneumoniae was detected for up to 8 weeks. Thirteen (52%) of 25 inmates treated with azithromycin continued to be qPCR positive >2 weeks after treatment. Conclusions. Chlamydia pneumoniae was the causative pathogen of this outbreak. Higher risk among certain groups suggests that social interaction contributed to transmission. Persistence of C. pneumoniae in the oropharynx creates challenges for outbreak control measures. C1 [Conklin, Laura; Loo, Jennifer; Mandal, Sema; Thurman, Kathleen; Diaz, Maureen H.; Benitez, Alvaro; Pondo, Tracy; Whitney, Cynthia G.; Winchell, Jonas M.; Van Beneden, Chris] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA. [Adjemian, Jennifer; Parsons, Tina; McDonough, Brian; Partida, Jorge; Kendig, Newton] US Fed Bur Prisons, Washington, DC USA. [Davis, Carol; Parks, Sharyn] Texas Dept State Hlth Serv, Emerging & Acute Infect Dis Branch, Austin, TX USA. [Mandal, Sema; Parks, Sharyn] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. RP Conklin, L (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, 1600 Clifton Rd,MS C-25, Atlanta, GA 30333 USA. EM lconklin@cdc.gov FU Centers for Disease Control and Prevention FX This work was funded by the Centers for Disease Control and Prevention. NR 25 TC 6 Z9 6 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2013 VL 57 IS 5 BP 639 EP 647 DI 10.1093/cid/cit357 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 199DJ UT WOS:000322974400003 PM 23723194 ER PT J AU Kemble, SK Westbrook, A Lynfield, R Bogard, A Koktavy, N Gall, K Lappi, V DeVries, AS Kaplan, E Smith, KE AF Kemble, Sarah K. Westbrook, Amy Lynfield, Ruth Bogard, April Koktavy, Nicole Gall, Kelly Lappi, Victoria DeVries, Aaron S. Kaplan, Edward Smith, Kirk E. TI Foodborne Outbreak of Group A Streptococcus Pharyngitis Associated With a High School Dance Team Banquet-Minnesota, 2012 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Streptococcus pyogenes; pharyngitis; foodborne diseases; pulsed-field gel electrophoresis; social media ID MOLECULAR ANALYSIS; FOOD; DISEASE; INFECTION; TONSILLOPHARYNGITIS; CONTAMINATION; TONSILLITIS; PENICILLIN; FAILURE AB Background. On 20 March 2012, the Minnesota Department of Health (MDH) was notified of multiple Facebook postings suggestive of a foodborne outbreak of Group A Streptococcus (GAS) pharyngitis occurring among attendees of a high school dance team banquet. An investigation was initiated. Methods. Associations between GAS pharyngitis and specific food items were assessed among banquet attendees. Pharyngeal swabs were performed on attendees, household contacts, and food workers. Patient GAS isolates from clinical laboratories were also obtained. Pharyngeal and food specimens were cultured for GAS by the MDH Public Health Laboratory. Isolates were further characterized by pulsed-field gel electrophoresis (PFGE) and emm typing. Results. Among 63 persons who consumed banquet food, 18 primary illnesses occurred, yielding an attack rate of 29%. Although no food or beverage items were significantly associated with illness, pasta consumption yielded the highest relative risk (risk ratio, 3.56; 95% confidence interval,.25-50.6). GAS colonies with indistinguishable PFGE patterns corresponding to emm subtype 1.0 were isolated from 5 patients and from leftover pasta. The pasta was prepared at home by a dance team member parent; both parent and child reported GAS pharyngitis episodes 3 weeks before the banquet. Conclusions. In this foodborne outbreak of GAS pharyngitis, pasta was implicated as the vehicle. Recognition of foodborne GAS illness is challenging because transmission is typically assumed to occur by respiratory spread; foodborne transmission should be considered when clusters of GAS pharyngitis patients are encountered. DNA-based typing can reveal potentially epidemiologically related isolates during GAS disease outbreaks and facilitate understanding and control of GAS disease. C1 [Kemble, Sarah K.; Westbrook, Amy; Lynfield, Ruth; Bogard, April; Koktavy, Nicole; DeVries, Aaron S.; Smith, Kirk E.] Minnesota Dept Hlth, St Paul, MN USA. [Gall, Kelly; Lappi, Victoria] Minnesota Dept Hlth Publ Hlth Lab, St Paul, MN USA. [Kaplan, Edward] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA. [Kemble, Sarah K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Kemble, SK (reprint author), Rush Univ, Med Ctr, Div Infect Dis, 600 South Paulina St,Ste 140, Chicago, IL 60615 USA. EM sarah_kemble@rush.edu FU Emerging Infections Program, CDC [3U01CI000313-05] FX This work was supported in part by the Emerging Infections Program, CDC (3U01CI000313-05). NR 31 TC 4 Z9 5 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2013 VL 57 IS 5 BP 648 EP 654 DI 10.1093/cid/cit359 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 199DJ UT WOS:000322974400004 PM 23868521 ER PT J AU Roy, M Benedict, K Deak, E Kirby, MA McNiel, JT Sickler, CJ Eckardt, E Marx, RK Heffernan, RT Meece, JK Klein, BS Archer, JR Theurer, J Davis, JP Park, BJ AF Roy, Monika Benedict, Kaitlin Deak, Eszter Kirby, Miles A. McNiel, Jena T. Sickler, Carrie J. Eckardt, Eileen Marx, Ruth K. Heffernan, Richard T. Meece, Jennifer K. Klein, Bruce S. Archer, John R. Theurer, Joan Davis, Jeffrey P. Park, Benjamin J. TI A Large Community Outbreak of Blastomycosis in Wisconsin With Geographic and Ethnic Clustering SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE blastomycosis; outbreak; Wisconsin; Hmong ID PULMONARY BLASTOMYCOSIS; DERMATITIDIS; EPIDEMIOLOGY; SOIL AB Background. Blastomycosis is a potentially life-threatening infection caused by the soil-based dimorphic fungus Blastomyces dermatitidis, which is endemic throughout much of the Midwestern United States. We investigated an increase in reported cases of blastomycosis that occurred during 2009-2010 in Marathon County, Wisconsin. Methods. Case detection was conducted using the Wisconsin Electronic Disease Surveillance System (WEDSS). WEDSS data were used to compare demographic, clinical, and exposure characteristics between outbreak-related and historical case patients, and to calculate blastomycosis incidence rates. Because initial mapping of outbreak case patients' homes and recreational sites demonstrated unusual neighborhood and household case clustering, we conducted a 1: 3 matched case-control study to identify factors associated with being in a geographic cluster. Results. Among the 55 patients with outbreak-related cases, 33 (70%) were hospitalized, 2 (5%) died, 30 (55%) had cluster-related cases, and 20 (45%) were Hmong. The overall incidence increased significantly since 2005 (average 11% increase per year, P < .001), and incidence during 2005-2010 was significantly higher among Asians than non-Asians (2010 incidence: 168 vs 13 per 100 000 population). Thirty of the outbreak cases grouped into 5 residential clusters. Outdoor activities were not risk factors for blastomycosis among cluster case patients or when comparing outbreak cases to historical cases. Conclusions. This outbreak of blastomycosis, the largest ever reported, was characterized by unique household and neighborhood clustering likely related to multifocal environmental sources. The reasons for the large number of Hmong affected are unclear, but may involve genetic predisposition. C1 [Roy, Monika] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30307 USA. [Roy, Monika; Benedict, Kaitlin; Deak, Eszter; Park, Benjamin J.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30307 USA. [Kirby, Miles A.; Heffernan, Richard T.] Wisconsin Div Publ Hlth, Bur Environm & Occupat Hlth, Madison, WI USA. [McNiel, Jena T.; Archer, John R.; Davis, Jeffrey P.] Wisconsin Div Publ Hlth, Bur Communicable Dis & Emergency Response, Madison, WI USA. [Sickler, Carrie J.; Eckardt, Eileen; Marx, Ruth K.; Theurer, Joan] Marathon Cty Hlth Dept, Wausau, WI USA. [Klein, Bruce S.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA. RP Roy, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30307 USA. EM ige6@cdc.gov FU CDC FX This work was supported by the CDC. NR 20 TC 12 Z9 12 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2013 VL 57 IS 5 BP 655 EP 662 DI 10.1093/cid/cit366 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 199DJ UT WOS:000322974400005 PM 23735332 ER PT J AU Hao, RZ Zhang, YW Li, P Wang, Y Qiu, SF Li, ZJ Wang, LG Wu, ZH Lin, R Liu, N Yang, G Yang, CJ Klena, JD Song, HB AF Hao, Rongzhang Zhang, Yewu Li, Peng Wang, Yong Qiu, Shaofu Li, Zhenjun Wang, Ligui Wu, Zhihao Lin, Rui Liu, Nan Yang, Guang Yang, Chaojie Klena, John D. Song, Hongbin TI Occupational Distribution and Prevalence of Influenza, China, 2008-2012 SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID PANDEMIC INFLUENZA; RISK C1 [Hao, Rongzhang; Li, Peng; Wang, Yong; Qiu, Shaofu; Wang, Ligui; Wu, Zhihao; Lin, Rui; Liu, Nan; Yang, Guang; Yang, Chaojie; Song, Hongbin] Acad Mil Med Sci, Inst Dis Control & Prevent, Beijing 100071, Peoples R China. [Zhang, Yewu] Chinese Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Serv Ctr, Beijing, Peoples R China. [Li, Zhenjun] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Prevent & Control, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China. [Klena, John D.] Int Emerging Infect Program, US Ctr Dis Control & Prevent, Beijing, Peoples R China. [Hao, Rongzhang; Li, Peng; Wang, Yong; Qiu, Shaofu; Wang, Ligui; Wu, Zhihao; Lin, Rui; Liu, Nan; Yang, Guang; Yang, Chaojie; Song, Hongbin] Acad Mil Med Sci, Inst Dis Control & Prevent, Atlanta, GA USA. [Zhang, Yewu] Chinese Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Serv Ctr, Atlanta, GA USA. [Li, Zhenjun] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Prevent & Control, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Infect Dis Prevent & Control, Atlanta, GA USA. [Klena, John D.] Int Emerging Infect Program, US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Song, HB (reprint author), Acad Mil Med Sci, Inst Dis Control & Prevent, 20 Dongdajie St, Beijing 100071, Peoples R China. EM hongbinsong@263.net NR 10 TC 1 Z9 1 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD SEP 1 PY 2013 VL 57 IS 5 BP 776 EP 778 DI 10.1093/cid/cit364 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 199DJ UT WOS:000322974400029 PM 23723200 ER PT J AU Kuhar, DT Henderson, DK Struble, KA Heneine, W Thomas, V Cheever, LW Gomaa, A Panlilio, AL AF Kuhar, David T. Henderson, David K. Struble, Kimberly A. Heneine, Walid Thomas, Vasavi Cheever, Laura W. Gomaa, Ahmed Panlilio, Adelisa L. CA US Public Hlth Serv Working Grp TI Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID TO-CHILD TRANSMISSION; PRIOR ANTIRETROVIRAL THERAPY; CARE WORKERS; HIV-INFECTION; NEEDLESTICK INJURY; HUMAN BITE; TYPE-1 INFECTION; LACTIC-ACIDOSIS; PREGNANCY; RISK AB This report updates US Public Health Service recommendations for the management of healthcare personnel (HCP) who experience occupational exposure to blood and/or other body fluids that might contain human immunodeficiency virus (HIV). Although the principles of exposure management remain unchanged, recommended HIV postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated. This report emphasizes the importance of primary prevention strategies, the prompt reporting and management of occupational exposures, adherence to recommended HIV PEP regimens when indicated for an exposure, expert consultation in management of exposures, follow-up of exposed HCP to improve adherence to PEP, and careful monitoring for adverse events related to treatment, as well as for virologic, immunologic, and serologic signs of infection. To ensure timely postexposure management and administration of HIV PEP, clinicians should consider occupational exposures as urgent medical concerns, and institutions should take steps to ensure that staff are aware of both the importance of and the institutional mechanisms available for reporting and seeking care for such exposures. The following is a summary of recommendations: (1) PEP is recommended when occupational exposures to HIV occur; (2) the HIV status of the exposure source patient should be determined, if possible, to guide need for HIV PEP; (3) PEP medication regimens should be started as soon as possible after occupational exposure to HIV, and they should be continued for a 4-week duration; (4) new recommendationPEP medication regimens should contain 3 (or more) antiretroviral drugs (listed in Appendix A) for all occupational exposures to HIV; (5) expert consultation is recommended for any occupational exposures to HIV and at a minimum for situations described in Box 1; (6) close follow-up for exposed personnel (Box 2) should be provided that includes counseling, baseline and follow-up HIV testing, and monitoring for drug toxicity; follow-up appointments should begin within 72 hours of an HIV exposure; and (7) new recommendationif a newer fourth-generation combination HIV p24 antigen--HIV antibody test is utilized for follow-up HIV testing of exposed HCP, HIV testing may be concluded 4 months after exposure (Box 2); if a newer testing platform is not available, follow-up HIV testing is typically concluded 6 months after an HIV exposure. C1 [Kuhar, David T.; Panlilio, Adelisa L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Henderson, David K.] NIH, Off Deputy Director Clin Care, Ctr Clin, Bethesda, MD 20892 USA. [Struble, Kimberly A.] US FDA, Div Antiviral Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Heneine, Walid; Thomas, Vasavi] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Cheever, Laura W.] US Hlth Resources & Serv Adm, HIV AIDS Bur, Rockville, MD 20857 USA. [Gomaa, Ahmed] NIOSH, Div Surveillance Hazard Evaluat & Hlth Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Kuhar, DT (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. FU Bristol-Myers Squibb; Janssen; Merck; ViiV; GlaxoSmithKline; Gilead FX The expert panel consultants report the following competing interests: J.A. has a board membership with and has received funding from Bristol-Myers Squibb, Janssen, Merck, and ViiV; J.E. has consulted for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck, and ViiV and has received grant funding from Bristol-Myers Squibb, GlaxoSmithKline, Merck, and ViiV; M. S. S. has consulted for Bristol-Myers Squibb, Gilead, Janssen, Merck, and ViiV and has received grant funding from Bristol-Myers Squibb, Gilead, Merck, and ViiV; M. L. T. owns Merck stock. All other authors report no conflicts of interest relevant to this article. NR 76 TC 98 Z9 102 U1 2 U2 19 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP 1 PY 2013 VL 34 IS 9 BP 875 EP 892 DI 10.1086/672271 PG 18 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 195LD UT WOS:000322702900001 PM 23917901 ER PT J AU Fagan, RP Edwards, JR Park, BJ Fridkin, SK Magill, SS AF Fagan, Ryan P. Edwards, Jonathan R. Park, Benjamin J. Fridkin, Scott K. Magill, Shelley S. TI Incidence Trends in Pathogen-Specific Central Line-Associated Bloodstream Infections in US Intensive Care Units, 1990-2010 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID STAPHYLOCOCCUS-AUREUS; QUALITY IMPROVEMENT; PREVENTION; PATIENT AB Objective.To quantify historical trends in rates of central line--associated bloodstream infections (CLABSIs) in US intensive care units (ICUs) caused by major pathogen groups, including Candida spp., Enterococcus spp., specified gram-negative rods, and Staphylococcus aureus.Design.Active surveillance in a cohort of participating ICUs through the Centers for Disease Control and Prevention, the National Nosocomial Infections Surveillance system during 1990--2004, and the National Healthcare Safety Network during 2006--2010.Setting.ICUs.Participants.Patients who were admitted to participating ICUs.Results.The CLABSI incidence density rate for S. aureus decreased annually starting in 2002 and remained lower than for other pathogen groups. Since 2006, the annual decrease for S. aureus CLABSIs in nonpediatric ICU types was --18.3% (95% confidence interval [CI], --20.8% to --15.8%), whereas the incidence density rate for S. aureus among pediatric ICUs did not change. The annual decrease for all ICUs combined since 2006 was --17.8% (95% CI, --19.4% to --16.1%) for Enterococcus spp., --16.4% (95% CI, --18.2% to --14.7%) for gram-negative rods, and --13.5% (95% CI, --15.4% to --11.5%) for Candida spp.Conclusions.Patterns of ICU CLABSI incidence density rates among major pathogen groups have changed considerably during recent decades. CLABSI incidence declined steeply since 2006, except for CLABSI due to S. aureus in pediatric ICUs. There is a need to better understand CLABSIs that still do occur, on the basis of microbiological and patient characteristics. New prevention approaches may be needed in addition to central line insertion and maintenance practices. C1 [Fagan, Ryan P.; Edwards, Jonathan R.; Park, Benjamin J.; Fridkin, Scott K.; Magill, Shelley S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Fagan, RP (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM fev3@cdc.gov NR 24 TC 25 Z9 30 U1 0 U2 15 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP 1 PY 2013 VL 34 IS 9 BP 893 EP 899 DI 10.1086/671724 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 195LD UT WOS:000322702900002 PM 23917902 ER PT J AU Tosh, PK Agolory, S Strong, BL VerLee, K Finks, J Hayakawa, K Chopra, T Kaye, KS Gilpin, N Carpenter, CF Haque, NZ Lamarato, LE Zervos, MJ Albrecht, VS McAllister, SK Limbago, B MacCannell, DR McDougal, LK Kallen, AJ Guh, AY AF Tosh, Pritish K. Agolory, Simon Strong, Bethany L. VerLee, Kerrie Finks, Jennie Hayakawa, Kayoko Chopra, Teena Kaye, Keith S. Gilpin, Nicholas Carpenter, Christopher F. Haque, Nadia Z. Lamarato, Lois E. Zervos, Marcus J. Albrecht, Valerie S. McAllister, Sigrid K. Limbago, Brandi MacCannell, Duncan R. McDougal, Linda K. Kallen, Alexander J. Guh, Alice Y. TI Prevalence and Risk Factors Associated with Vancomycin-Resistant Staphylococcus aureus Precursor Organism Colonization among Patients with Chronic Lower-Extremity Wounds in Southeastern Michigan SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID INVASIVE DISEASE; UNITED-STATES; ENTEROCOCCI AB Background.Of the 13 US vancomycin-resistant Staphylococcus aureus (VRSA) cases, 8 were identified in southeastern Michigan, primarily in patients with chronic lower-extremity wounds. VRSA infections develop when the vanA gene from vancomycin-resistant enterococcus (VRE) transfers to S. aureus. Inc18-like plasmids in VRE and pSK41-like plasmids in S. aureus appear to be important precursors to this transfer.Objective.Identify the prevalence of VRSA precursor organisms.Design.Prospective cohort with embedded case-control study.Participants.Southeastern Michigan adults with chronic lower-extremity wounds.Methods.Adults presenting to 3 southeastern Michigan medical centers during the period February 15 through March 4, 2011, with chronic lower-extremity wounds had wound, nares, and perirectal swab specimens cultured for S. aureus and VRE, which were tested for pSK41-like and Inc18-like plasmids by polymerase chain reaction. We interviewed participants and reviewed clinical records. Risk factors for pSK41-positive S. aureus were assessed among all study participants (cohort analysis) and among only S. aureus--colonized participants (case-control analysis).Results.Of 179 participants with wound cultures, 26% were colonized with methicillin-susceptible S. aureus, 27% were colonized with methicillin-resistant S. aureus, and 4% were colonized with VRE, although only 17% consented to perirectal culture. Six participants (3%) had pSK41-positive S. aureus, and none had Inc18-positive VRE. Having chronic wounds for over 2 years was associated with pSK41-positive S. aureus colonization in both analyses.Conclusions.Colonization with VRSA precursor organisms was rare. Having long-standing chronic wounds was a risk factor for pSK41-positive S. aureus colonization. Additional investigation into the prevalence of VRSA precursors among a larger cohort of patients is warranted. C1 [Tosh, Pritish K.; Agolory, Simon] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Tosh, Pritish K.; Strong, Bethany L.; Albrecht, Valerie S.; McAllister, Sigrid K.; Limbago, Brandi; MacCannell, Duncan R.; McDougal, Linda K.; Kallen, Alexander J.; Guh, Alice Y.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Tosh, Pritish K.] Mayo Clin, Div Infect Dis, Rochester, MN 55901 USA. [Agolory, Simon] Ctr Dis Control & Prevent, Div Global AIDS Prevent, Atlanta, GA USA. [Strong, Bethany L.] Harvard Univ, Sch Med, Boston, MA USA. [VerLee, Kerrie; Finks, Jennie] Michigan Dept Community Hlth, Lansing, MI USA. [VerLee, Kerrie] Council State & Terr Epidemiologists, Atlanta, GA USA. [Hayakawa, Kayoko; Chopra, Teena; Kaye, Keith S.] Detroit Med Ctr, Div Infect Dis, Detroit, MI USA. [Gilpin, Nicholas; Carpenter, Christopher F.] William Beaumont Hosp, Div Infect Dis, Royal Oak, MI 48072 USA. [Haque, Nadia Z.; Zervos, Marcus J.] Henry Ford Hlth Syst, Div Infect Dis, Detroit, MI USA. [Lamarato, Lois E.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA. RP Tosh, PK (reprint author), Mayo Clin, Div Infect Dis, 200 1st St SW, Rochester, MN 55901 USA. EM tosh.pritish@mayo.edu OI Chopra, Teena/0000-0003-1185-4549; Hayakawa, Kayoko/0000-0002-5480-4405 FU Cubist FX M.J.Z. reports that he has received grant support from Cubist and has received speaker honorarium from Souvinon. All other authors report no conflicts of interest relevant to this article. All authors submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest, and the conflicts that the editors consider relevant to this article are disclosed here. NR 20 TC 7 Z9 8 U1 0 U2 28 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD SEP 1 PY 2013 VL 34 IS 9 BP 954 EP 960 DI 10.1086/671735 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 195LD UT WOS:000322702900010 PM 23917910 ER PT J AU Chhabra, P Payne, DC Szilagyi, PG Edwards, KM Staat, MA Shirley, SH Wikswo, M Nix, WA Lu, XY Parashar, UD Vinje, J AF Chhabra, Preeti Payne, Daniel C. Szilagyi, Peter G. Edwards, Kathryn M. Staat, Mary Allen Shirley, S. Hannah Wikswo, Mary Nix, W. Allan Lu, Xiaoyan Parashar, Umesh D. Vinje, Jan TI Etiology of Viral Gastroenteritis in Children < 5 Years of Age in the United States, 2008-2009 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE viral gastroenteritis; sapovirus; astrovirus; adenovirus; population-based surveillance ID POLYMERASE CHAIN-REACTION; STOOL SAMPLES; MOLECULAR CHARACTERIZATION; ROTAVIRUS-VACCINATION; HUMAN PARECHOVIRUS; ENTERIC VIRUSES; YOUNG-CHILDREN; AICHI VIRUSES; DIARRHEA; PREVALENCE AB Background. Although rotavirus and norovirus cause nearly 40% of severe endemic acute gastroenteritis (AGE) in children <5 years of age in the United States, there are limited data on the etiologic role of other enteric viruses in this age group. Methods. We conducted active population-based surveillance in children presenting with AGE to hospitals, emergency departments, and primary care clinics in 3 US counties. Stool specimens from these children and from age-matched healthy controls collected between October 2008 and September 2009 were tested for enteric adenovirus, astrovirus, sapovirus, parechovirus, bocavirus, and aichivirus. Typing was performed by sequencing and phylogenetic analysis. Results. Adenovirus, astrovirus, sapovirus, parechovirus, bocavirus, and aichivirus were detected in the stool specimens of 11.8%, 4.9%, 5.4%, 4.8%, 1.4%, and 0.2% of patients with AGE and 1.8%, 3.0%, 4.2%, 4.4%, 2.4%, and 0% of healthy controls, respectively. Adenovirus (type 41), astrovirus (types 1, 2, 3, 4, and 8), sapovirus (genogroups I and II), parechovirus (types 1, 3, 4, and 5), and bocavirus (types 1, 2, and 3) were found cocirculating. Conclusions. Adenovirus, astrovirus, and sapovirus infections were detected in 22.1% of the specimens from children <5 years of age who had medical visits for AGE and tested negative for rotavirus and norovirus. No causal role for parechovirus and bocavirus was found. C1 [Chhabra, Preeti; Shirley, S. Hannah; Lu, Xiaoyan; Vinje, Jan] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Payne, Daniel C.; Wikswo, Mary; Parashar, Umesh D.] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Nix, W. Allan] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Szilagyi, Peter G.] Univ Rochester, Dept Pediat, Sch Med & Dent, New York, NY USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Vanderbilt Vaccine Res Program, Nashville, TN 37232 USA. [Staat, Mary Allen] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45221 USA. RP Vinje, J (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 160 Clifton Rd, Atlanta, GA 30333 USA. EM jvinje@cdc.gov OI Vinje, Jan/0000-0002-1530-3675 FU Centers for Disease Control and Prevention as part of the New Vaccine Surveillance Network FX This work was funded by the Centers for Disease Control and Prevention as part of the New Vaccine Surveillance Network. NR 49 TC 45 Z9 48 U1 0 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD SEP 1 PY 2013 VL 208 IS 5 BP 790 EP 800 DI 10.1093/infdis/jit254 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 198YB UT WOS:000322958900011 PM 23757337 ER PT J AU Davidson, CS Green, CF Gibbs, SG Schmid, KK Panlilio, AL Jensen, PA Scarpino, PV AF Davidson, Craig S. Green, Christopher F. Gibbs, Shawn G. Schmid, Kendra K. Panlilio, Adelisa L. Jensen, Paul A. Scarpino, Pasquale V. TI Performance Evaluation of Selected N95 Respirators and Surgical Masks When Challenged with Aerosolized Endospores and Inert Particles SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE endospores; filtration efficiency; inert particles; N95; relative efficiency; surgical mask ID FILTERING-FACEPIECE RESPIRATORS; PROTECTION; MICROORGANISMS; EFFICIENCY; LEAKAGE; LEVEL AB The objective of this study was to assess how the relative efficiency of N95 respirators and surgical masks might vary with different challenge aerosols, utilizing a standardized manikin head form as a surrogate to human participation. A Collision nebulizer aerosolized B. anthracis Sterne strain endospores and polystyrene latex (PSL) particles to evaluate 11 models of N95 respirators and surgical masks. An automated breathing simulator, calibrated to normal tidal volume and active breathing rate, mimicked human respiration. A manikin head form with N95 respirators or surgical masks, and manikin head form without N95 respirators or surgical masks were placed in the bioaerosol chamber. An AGI-30 sampler filled with phosphate buffered water was fitted behind the mouth of each manikin head form to collect endospore bioaerosol samples. PSL aerosols concentrations were quantified by an ARTI Hand Held Particle Counter. Geometric Mean (GM) relative efficiency of N95 respirators and surgical masks challenged with endospore bioaerosol ranged from 34-65%. In PSL aerosol experiments, GM relative efficiency ranged from 35-64% for 1.3 m particles. GM filtration efficiency of all N95 and surgical N95 respirators filter media evaluated was 99% when challenged with particles 0.1 m. GM filtration efficiency of surgical mask filter media ranged from 70-83% with particles 0.1 m and 74-92% with 1.3 m PSL particles. Relative efficiencies of N95 respirators and surgical masks challenged with aerosolized B. anthracis endospores and PSL were similar. Relative efficiency was similar between N95 respirators and surgical masks on a manikin head form despite clear differences in filtration efficiency. This study further highlights the importance of face seal leakage in the respiratory protection provided by N95 respirators, and demonstrates it on a human surrogate. C1 [Davidson, Craig S.; Scarpino, Pasquale V.] Univ Cincinnati, Dept Civil & Environm Engn, Cincinnati, OH 45221 USA. [Green, Christopher F.] Univ Cincinnati, Clermont Coll, Sci Math & Engn Div, Batavia, OH USA. [Gibbs, Shawn G.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, Omaha, NE 68198 USA. [Schmid, Kendra K.] Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA. [Panlilio, Adelisa L.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA USA. [Jensen, Paul A.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Gibbs, SG (reprint author), Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Environm Agr & Occupat Hlth, 984355 Nebraska Med Ctr, Omaha, NE 68198 USA. EM sgibbs@unmc.edu FU Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) FX This work was supported financially by the Department of Health and Human Services, Centers for Disease Control and Prevention (CDC). Work was completed at the University of Cincinnati College of Engineering. NR 31 TC 4 Z9 4 U1 1 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD SEP 1 PY 2013 VL 10 IS 9 BP 461 EP 467 DI 10.1080/15459624.2013.818243 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 197QG UT WOS:000322865100004 PM 23915331 ER PT J AU Zhuang, ZQ Bergman, MS Eimer, BC Shaffer, RE AF Zhuang, Ziqing Bergman, Michael S. Eimer, Benjamin C. Shaffer, Ronald E. TI Laboratory Faceseal Leakage Evaluation of N95 Filtering Facepiece Respirators Against Nanoparticles and "All Size" Particles SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article DE nanoparticles; N95 filtering facepiece respirators; fit-test; fit factors ID FIT; PERFORMANCE; PENETRATION; IMPACT AB National Institute for Occupational Safety and Health (NIOSH)-certified N95 filtering facepiece respirators (FFRs) are used for respiratory protection in some workplaces handling engineered nanomaterials. Previous NIOSH research has focused on filtration performance against nanoparticles. This article is the first NIOSH study using human test subjects to compare N95 FFR faceseal leakage (FSL) performance against nanoparticles and all size particles. In this study, estimates of FSL were obtained from fit factor (FF) measurements from nine test subjects who participated in previous fit-test studies. These data were analyzed to compare values obtained by: 1) using the PortaCount Plus (8020A, TSI, Inc., MN, USA) alone (measureable particle size range 20nm to > 1,000nm, hereby referred to as the all size particles test), and 2) using the PortaCount Plus with N95-Companion(TM) accessory (8095, TSI, Inc., Minn.) accessory (negatively charged particles, size range approximate to 40 to 60nm, hereby referred to as the nanoparticles test). Log-transformed FF values were compared for the all size particles test and nanoparticles test using one-way analysis of variance tests (significant at P < 0.05). For individual FFR models, geometric mean (GM) FF using the nanoparticles test was the same or higher than the GM FFs using all size particles test. For all three FFR models combined, GM FF using the nanoparticles test was significantly higher than the GM FF using all size particles test (P < 0.05). These data suggest that FSL for negatively charged approximate to 40-60nm nanoparticles is not greater than the FSL for the larger distribution of charged and uncharged 20 to > 1,000nm particles. C1 [Zhuang, Ziqing; Bergman, Michael S.; Shaffer, Ronald E.] NIOSH, Natl Personal Protect Technol Lab, Pittsburgh, PA 15236 USA. [Eimer, Benjamin C.] URS Corp, Pittsburgh, PA USA. RP Zhuang, ZQ (reprint author), NIOSH, Technol Res Branch, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, 626 Cochrans Mill Rd,Bldg 13,POB 18070, Pittsburgh, PA 15236 USA. EM zaz3@cdc.gov RI Shaffer, Ronald/I-2134-2012; Zhuang, Ziqing/K-5462-2012 NR 29 TC 1 Z9 1 U1 0 U2 10 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD SEP 1 PY 2013 VL 10 IS 9 BP 496 EP 504 DI 10.1080/15459624.2013.818237 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 197QG UT WOS:000322865100008 PM 23927376 ER PT J AU Masho, SW Bishop, DL Keyser-Marcus, L Varner, SB White, S Svikis, D AF Masho, Saba W. Bishop, Diane L. Keyser-Marcus, Lori Varner, Sara B. White, Shannon Svikis, Dace TI Least Explored Factors Associated with Prenatal Smoking SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Smoking during pregnancy; Correlates of smoking; Criminal history; Social services; Preconception health ID PREGNANT-WOMEN; CIGARETTE-SMOKING; SUBSTANCE USE; RISK-FACTORS; DEPRESSIVE SYMPTOMS; NICOTINE DEPENDENCE; UNITED-STATES; PREVALENCE; HEALTH; EXPOSURE AB Poor pregnancy and birth outcomes are major problems in the United States, and maternal smoking during pregnancy has been identified as one of the most preventable risk factors associated with these outcomes. This study examines less explored risk factors of smoking among underserved African American pregnant women. A cross-sectional survey was conducted at an outpatient obstetrics-gynecology clinic of an inner-city university hospital in Virginia from March 2009 through January 2011 in which pregnant women (N = 902) were interviewed at their first prenatal care visit. Survey questions included items related to women's sociodemographic characteristics as well as their pregnancy history; criminal history; receipt of social services; child protective services involvement; insurance status; and history of substance abuse, domestic violence, and depression. Multiple logistic regression was conducted to calculate odds ratios and 95 % confidence intervals depicting the relationship between these factors and smoking during pregnancy. The analysis reported that maternal age [OR = 1.08, 95 % CI = 1.05-1.12], less than high school education [OR = 4.30, 95 % CI = 2.27-8.14], unemployed [OR = 2.33, 95 % CI = 1.35-4.04], criminal history [OR = 1.66, 95 % CI = 1.05-2.63], receipt of social services [OR = 2.26, 95 % CI = 1.35-3.79] alcohol use [OR = 2.73, 95 % CI = 1.65-4.51] and illicit drug use [OR = 1.97, 95 % CI = 1.04-3.74] during pregnancy were statistically significant risk factors associated with smoking during pregnancy. In addition to the well known risk factors, public health professionals should be aware that criminal history and receipt of social services are important factors associated with smoking during pregnancy. Social service providers such as WIC and prisons and jails may offer a unique opportunity for education and cessation interventions during the preconception or interconception period. C1 [Masho, Saba W.] Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth & Obstet & Gyneco, VCU Inst Womens Hlth, VCU Ctr Hlth Dispar, Richmond, VA 23298 USA. [Bishop, Diane L.] Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth, Richmond, VA 23298 USA. [Keyser-Marcus, Lori; Varner, Sara B.] Virginia Commonwealth Univ, Dept Psychiat, VCU Inst Womens Hlth, Richmond, VA 23298 USA. [White, Shannon] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Svikis, Dace] Virginia Commonwealth Univ, Dept Psychol Psychiat & Obstet & Gynecol, VCU Inst Womens Hlth, Richmond, VA 23298 USA. RP Masho, SW (reprint author), Virginia Commonwealth Univ, Dept Epidemiol & Community Hlth & Obstet & Gyneco, VCU Inst Womens Hlth, VCU Ctr Hlth Dispar, POB 980212, Richmond, VA 23298 USA. EM swmasho@vcu.edu FU NCCDPHP CDC HHS [5U58DP000983, U58 DP000983]; NIMHD NIH HHS [P60 MD002256, 5 P60 MD002256-03] NR 42 TC 7 Z9 7 U1 0 U2 23 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2013 VL 17 IS 7 BP 1167 EP 1174 DI 10.1007/s10995-012-1103-y PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 195VS UT WOS:000322732300001 PM 22903305 ER PT J AU Clark, SJ Cowan, AE Wortley, PM AF Clark, Sarah J. Cowan, Anne E. Wortley, Pascale M. TI Obstetricians and the 2009-2010 H1N1 Vaccination Effort: Implications for Future Pandemics SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE H1N1 virus; Influenza vaccine; Pandemic; Obstetricians ID INFLUENZA VACCINATION; PREGNANT-WOMEN; GYNECOLOGISTS; PREVENTION; INFECTION; ATTITUDES; COVERAGE; INFANTS; SEASON; STATES AB Our objective was to describe the experiences of obstetricians during the 2009-2010 H1N1 vaccination campaign in order to identify possible improvements for future pandemic situations. We conducted a cross-sectional mail survey of a national random sample of 4,000 obstetricians, fielded in Summer 2010. Survey items included availability, recommendation, and patient acceptance of H1N1 vaccine; prioritization of H1N1 vaccine when supply was limited; problems with H1N1 vaccination; and likelihood of providing vaccine during a future influenza pandemic. Response rate was 66 %. Obstetricians strongly recommended H1N1 vaccine during the second (85 %) and third (86 %) trimesters, and less often during the first trimester (71 %) or the immediate postpartum period (76 %); patient preferences followed a similar pattern. H1N1 vaccine was typically available in outpatient obstetrics clinics (80 %). Overall vaccine supply was a major problem for 30 % of obstetricians, but few rated lack of thimerosal-free vaccine as a major problem (12 %). Over half of obstetricians had no major problems with the H1N1 vaccine campaign. Based on this experience, 74 % would be "very likely" and 12 % "likely" to provide vaccine in the event of a future influenza pandemic. Most obstetricians strongly recommended H1N1 vaccine, had few logistical problems beyond limited vaccine supply, and are willing to vaccinate in a future pandemic. Addressing concerns about first-trimester vaccination, developing guidance for prioritization of vaccine in the event of severe supply constraints, and continued facilitation of the logistical aspects of vaccination should be emphasized in future influenza pandemics. C1 [Clark, Sarah J.; Cowan, Anne E.] Univ Michigan, Child Hlth Evaluat & Res CHEAR Unit, Ann Arbor, MI 48109 USA. [Wortley, Pascale M.] Ctr Dis Control & Prevent, Immunizat Serv Div, NCIRD, Atlanta, GA USA. RP Clark, SJ (reprint author), Univ Michigan, Child Hlth Evaluat & Res CHEAR Unit, 300 N Ingalls,Rm 6E06, Ann Arbor, MI 48109 USA. EM saclark@med.umich.edu NR 29 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2013 VL 17 IS 7 BP 1185 EP 1190 DI 10.1007/s10995-012-1104-x PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 195VS UT WOS:000322732300003 PM 22911451 ER PT J AU Uddin, SFG Simon, AE AF Uddin, Sayeedha F. G. Simon, Alan E. TI Rates and Success Rates of Trial of Labor After Cesarean Delivery in the United States, 1990-2009 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Trial of labor; Trial of labor success; Vaginal birth after Cesarean delivery; Cesarean section ID VAGINAL BIRTH; UTERINE RUPTURE; IDENTIFY INDICATIONS; SECTION; WOMEN; RISK; MULTICENTER; EXPERIENCE; PREGNANCY; MORBIDITY AB This study compares rates of trial of labor after Cesarean delivery (TOLAC) and rates of successful TOLAC between 1990 and 2009. Serial cross-sectional analyses were performed using the National Hospital Discharge Survey data to compare rates of TOLAC and TOLAC success between 1990 and 2009. Joinpoint regression was used to assess trends over time, and logistic regression with marginal effects was used to examine the unadjusted and adjusted significance and magnitude of trends. The rate of TOLAC reached a high of 51.8 % (95 % CI 47.8-55.8 %) in 1995 and a low of 15.9 % (95 % CI 13.8-18.0 %) in 2006, declined, on average, 4.2 (95 % CI -4.8 to -3.9) percentage points per year between 1996 and 2005. Rates increased significantly from 1990 to 1996 and 2005 to 2009. TOLAC success was at its highest rate in 2000, 69.8 % (95 % CI 65.2-74.3 %) and its lowest in 2008, 38.5 % (95 % CI 28.1-48.8 %). The rate of TOLAC success increased significantly between 1990 and 2000, but declined thereafter an average of 3.4 % points per year (95 % CI -4.3 to -2.5). The rate of TOLAC in the US decreased between 1996 and 2005 and the rate of successful TOLAC has declined from 2000 to 2009. C1 [Uddin, Sayeedha F. G.; Simon, Alan E.] Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Uddin, SFG (reprint author), Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6122, Hyattsville, MD 20782 USA. EM suddin@cdc.gov NR 40 TC 6 Z9 8 U1 0 U2 10 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2013 VL 17 IS 7 BP 1309 EP 1314 DI 10.1007/s10995-012-1132-6 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 195VS UT WOS:000322732300019 PM 22991012 ER PT J AU Martin, A Cox, S Jamieson, DJ Whiteman, MK Kulkarni, A Tepper, NK AF Martin, Angela Cox, Shanna Jamieson, Denise J. Whiteman, Maura K. Kulkarni, Aniket Tepper, Naomi K. TI Respiratory Illness Hospitalizations Among Pregnant Women During Influenza Season, 1998-2008 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Health care burden; High risk condition; Influenza; Pregnancy; Respiratory illness ID IMMUNIZATION; IMPACT AB To examine health care burden, pregnancy outcomes and impact of high risk medical conditions among pregnancy hospitalizations during influenza season. Length of stay, hospitalization charges, and delivery complications were compared between hospitalizations with and without respiratory illness and compared by presence of high risk medical conditions. Length of stay and hospital charges were significantly increased among respiratory illness hospitalizations versus non-respiratory hospitalizations. Among respiratory illness hospitalization, the odds of intrauterine fetal demise were increased (adjusted odds ratio (aOR) 2.50, 95 % confidence interval (CI) 1.97-3.18). Among live births, there were higher odds of preterm delivery (aOR 3.82, 95 % CI 3.53-4.14), cesarean delivery (aOR 3.47, 95 % CI 3.22-3.74), and fetal distress (aOR 2.33, 95 % CI 2.15-2.52). The presence of high risk medical conditions did not impact pregnancy outcomes. Among pregnant women hospitalized during influenza season, those with respiratory illness were more likely than those without respiratory illness to have poor perinatal outcomes, regardless of the presence of high risk conditions. Efforts to minimize influenza morbidity, including universal vaccination and early antiviral therapy should be promoted among all pregnant women. C1 [Martin, Angela] Emory Univ, Dept Gynecol & Obstet, Atlanta, GA 30322 USA. [Cox, Shanna; Jamieson, Denise J.; Whiteman, Maura K.; Kulkarni, Aniket; Tepper, Naomi K.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Martin, A (reprint author), Emory Univ, Dept Gynecol & Obstet, 1648 Pierce Dr, Atlanta, GA 30322 USA. EM amatlac@emory.edu NR 24 TC 12 Z9 12 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD SEP PY 2013 VL 17 IS 7 BP 1325 EP 1331 DI 10.1007/s10995-012-1135-3 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 195VS UT WOS:000322732300021 PM 23001819 ER PT J AU Kramer, MS Abenhaim, H Dahhou, M Rouleau, J Berg, C AF Kramer, Michael S. Abenhaim, Haim Dahhou, Mourad Rouleau, Jocelyn Berg, Cynthia TI Incidence, Risk Factors, and Consequences of Amniotic Fluid Embolism SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE amniotic fluid embolism; labour induction; caesarean delivery; maternal mortality ID POPULATION-BASED COHORT; UNITED-STATES; MORTALITY AB Background: Amniotic fluid embolism (AFE) is a rare but serious cause of maternal mortality whose aetiology remains obscure. Previous population-based studies have reported associations with labour induction and caesarean delivery. Methods: We updated a previous analysis based on the US Nationwide Inpatient Sample from 1999 to 2008. We adapted a diagnostic validation algorithm to minimise false-positive diagnoses, along with statistical methods that account for the stratified random sampling design. Results: Of the 8 571 209 deliveries recorded in the database, 276 met our case definition of AFE, of which 62 (22.9% of the 274 with known vital status) were fatal. Significant associations with AFE were observed for medical induction {adjusted odds ratio [aOR] = 1.7 [95% confidence interval (CI) 1.2, 2.5]}, caesarean delivery [aOR = 15.0; 95% CI 9.4, 23.9], instrumental vaginal delivery [aOR = 6.6; 95% CI 4.0, 11.1], and cervical/uterine trauma [aOR = 7.4; 95% CI 3.6, 14.9]. AFE was associated with increases in risk of stillbirth, hysterectomy, maternal death, and prolonged maternal length of delivery hospital stay. Conclusions: AFE remains an extremely serious obstetric complication with high risks of maternal and fetal mortality. The increased risks of AFE associated with labour induction and caesarean delivery have implications for elective use of these interventions. C1 [Kramer, Michael S.; Dahhou, Mourad] McGill Univ, Dept Pediat, Fac Med, Montreal, PQ H3A 2T5, Canada. [Kramer, Michael S.] McGill Univ, Fac Med, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada. [Abenhaim, Haim] McGill Univ, Dept Obstet & Gynecol, Fac Med, Montreal, PQ H3A 2T5, Canada. [Rouleau, Jocelyn] Publ Hlth Agcy Canada, Maternal & Infant Hlth Sect, Div Surveillance & Epidemiol, Ottawa, ON, Canada. [Berg, Cynthia] Ctr Dis Control & Prevent CDC, Div Reprod Hlth, Atlanta, GA USA. RP Kramer, MS (reprint author), Montreal Childrens Hosp, 2300 Tupper St Les Tourelles, Montreal, PQ H3H 1P3, Canada. EM michael.kramer@mcgill.ca FU Canadian Institutes of Health Research FX Our study is supported by a grant from the Canadian Institutes of Health Research. None of the authors has a conflict of interest. NR 18 TC 13 Z9 15 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD SEP PY 2013 VL 27 IS 5 BP 436 EP 441 DI 10.1111/ppe.12066 PG 6 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 198IA UT WOS:000322914700002 PM 23930779 ER PT J AU Carroll, DS Olson, VA Smith, SK Braden, ZH Patel, N Abel, J Li, Y Damon, IK Karem, KL AF Carroll, Darin S. Olson, Victoria A. Smith, Scott K. Braden, Zach H. Patel, Nishi Abel, Jason Li, Yu Damon, Inger K. Karem, Kevin L. TI Orthopoxvirus variola infection of Cynomys ludovicianus (North American Black tailed prairie dog) SO VIROLOGY LA English DT Article DE Variola; Smallpox; Immunity; Infection; Orthopoxvirus; Prairie dog; Animal model ID MACACA-IRUS; MONKEYPOX; VIRUS; SMALLPOX; STRAINS; CONGO; FLEAS; MODEL AB Since the eradication of Smallpox, researchers have attempted to study Orthopoxvirus pathogenesis and immunity in animal models in order to correlate results human smallpox. A solely human pathogen, Orthopoxvirus variola fails to produce authentic smallpox illness in any other animal species tested to date. In 2003, an outbreak in the USA of Orthopoxvirus monkeypox, revealed the susceptibility of the North American black-tailed prairie dog (Cynomys ludovicianus) to infection and fulminate disease. Prairie dogs infected with Orthopoxvirus monkeypox present with a clinical scenario similar to ordinary smallpox, including prodrome, rash, and high mortality. This study examines if Black-tailed prairie dogs can become infected with O. variola and serve as a surrogate model for the study of human smallpox disease. Substantive evidence of infection is found in immunological seroconversion of animals to either intranasal or intradermal challenges with O. variola, but in the absence of overt illness. Published by Elsevier Inc. C1 [Carroll, Darin S.; Olson, Victoria A.; Smith, Scott K.; Braden, Zach H.; Patel, Nishi; Abel, Jason; Li, Yu; Damon, Inger K.; Karem, Kevin L.] Ctr Dis Control & Prevent, Natl Ctr Zoonot & Vector Borne & Enter Dis, Div High Consequence Pathogens & Pathol, Poxvirus Program, Atlanta, GA USA. RP Karem, KL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Zoonot & Vector Borne & Enter Dis, Div High Consequence Pathogens & Pathol, Poxvirus Program, Atlanta, GA USA. EM kkarem@cdc.gov FU poxvirus program in the Centers for Disease Control and Prevention FX The authors would like to acknowledge the assistance of the following individuals in accomplishing this project: Allison Williams DVM and Eddie Jackson of the Roybal ARB staff for animal husbandry. This work was funded through program funds at the poxvirus program in the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 18 TC 0 Z9 0 U1 0 U2 15 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD SEP 1 PY 2013 VL 443 IS 2 BP 358 EP 362 DI 10.1016/j.virol.2013.05.029 PG 5 WC Virology SC Virology GA 195FC UT WOS:000322686700021 PM 23809939 ER PT J AU Walters, G Henneburger, P Moore, V McGrath, E Burge, S AF Walters, Gareth Henneburger, Paul Moore, Vicky McGrath, Emmet Burge, Sherwood TI Aetiology and trends in healthcare workers' occupational asthma SO EUROPEAN RESPIRATORY JOURNAL LA English DT Meeting Abstract DE Asthma - diagnosis; Occupation; Environment C1 [Walters, Gareth; Moore, Vicky; McGrath, Emmet; Burge, Sherwood] Birmingham Heartlands Hosp, Occupat Lung Dis Unit, Birmingham B93 0HJ, W Midlands, England. [Henneburger, Paul] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. EM gaxwalters@hotmail.com; pkh0@cdc.gov; v.c.moore@heartofengland.nhs.uk; e.e.mcgrath@bham.ac.uk; sherwood.burge@heartofengland.nhs.uk NR 0 TC 0 Z9 0 U1 0 U2 0 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD SEP 1 PY 2013 VL 42 SU 57 MA 191 PG 1 WC Respiratory System SC Respiratory System GA V38VH UT WOS:000209370401316 ER PT J AU Honein, MA Gilboa, SM Broussard, CS AF Honein, Margaret A. Gilboa, Suzanne M. Broussard, Cheryl S. TI The need for safer medication use in pregnancy SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY LA English DT Editorial Material C1 [Honein, Margaret A.; Gilboa, Suzanne M.; Broussard, Cheryl S.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Honein, MA (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, 1600 Clifton Rd,NE,Mailstop E-86, Atlanta, GA 30333 USA. EM mhonein@cdc.gov FU Intramural CDC HHS [CC999999] NR 18 TC 4 Z9 4 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1751-2433 EI 1751-2441 J9 EXPERT REV CLIN PHAR JI Expert Rev. Clin. Pharmacol. PD SEP PY 2013 VL 6 IS 5 BP 453 EP 455 DI 10.1586/17512433.2013.827401 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA V37SL UT WOS:000209295400001 PM 23971869 ER PT J AU Boulet, SL Cohen, B Bailey, M McKane, P Kissin, D AF Boulet, S. L. Cohen, B. Bailey, M. McKane, P. Kissin, D. CA StatesMonitoring ART SMART Collabo TI EMBRYO TRANSFER PRACTICES AND PERINATAL OUTCOMES BY INSURANCE MANDATE STATUS. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT International-Federation-of-Fertility-Societies 21st World Congress on Fertility and Sterility / 69th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 12-17, 2013 CL Boston, MA SP Int Federat Fertil Soc, Amer Soc Reprod Med C1 [Boulet, S. L.; Kissin, D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Cohen, B.] Massachusetts Dept Hlth, Boston, MA USA. [Bailey, M.] Florida Dept Hlth, Tallahassee, FL USA. [McKane, P.; StatesMonitoring ART SMART Collabo] Michigan Dept Community Hlth, Lansing, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2013 VL 100 IS 3 SU S MA O-303 BP S93 EP S93 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ1PY UT WOS:000342554500301 ER PT J AU Kawwass, JF Monsour, M Crawford, S Kissin, DM Session, DR Jamieson, DJ AF Kawwass, J. F. Monsour, M. Crawford, S. Kissin, D. M. Session, D. R. Jamieson, D. J. TI DONOR OOCYTE: TRENDS AND PREDICTORS OF GOOD PERINATAL OUTCOME. SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT International-Federation-of-Fertility-Societies 21st World Congress on Fertility and Sterility / 69th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 12-17, 2013 CL Boston, MA SP Int Federat Fertil Soc, Amer Soc Reprod Med C1 [Kawwass, J. F.; Session, D. R.; Jamieson, D. J.] Emory Univ, Atlanta, GA 30322 USA. [Kawwass, J. F.; Monsour, M.; Crawford, S.; Kissin, D. M.; Jamieson, D. J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2013 VL 100 IS 3 SU S MA P-1174 BP S486 EP S486 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ1PY UT WOS:000342554502184 ER PT J AU Kissin, DM Kulkarni, A Kushnir, VA Jamieson, DJ AF Kissin, D. M. Kulkarni, A. Kushnir, V. A. Jamieson, D. J. TI USING GOOD PERINATAL OUTCOME AS A MEASURE OF SUCCESS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART). SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT International-Federation-of-Fertility-Societies 21st World Congress on Fertility and Sterility / 69th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 12-17, 2013 CL Boston, MA SP Int Federat Fertil Soc, Amer Soc Reprod Med C1 [Kissin, D. M.; Kulkarni, A.; Jamieson, D. J.] Ctr Dis Control & Prevent CDC, Div Reprod Hlth, Atlanta, GA USA. [Kushnir, V. A.] Ctr Human Reprod, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2013 VL 100 IS 3 SU S MA P-1178 BP S487 EP S488 PG 3 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ1PY UT WOS:000342554502188 ER PT J AU Sunderam, S Kissin, DM Crawford, S Anderson, J Jamieson, DJ Barfield, WD AF Sunderam, S. Kissin, D. M. Crawford, S. Anderson, J. Jamieson, D. J. Barfield, W. D. TI CONTRIBUTION OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TO MULTIPLE BIRTHS, PRETERM, AND LOW BIRTH WEIGHT INFANTS, US, 2010 SO FERTILITY AND STERILITY LA English DT Meeting Abstract CT International-Federation-of-Fertility-Societies 21st World Congress on Fertility and Sterility / 69th Annual Meeting of the American-Society-for-Reproductive-Medicine CY OCT 12-17, 2013 CL Boston, MA SP Int Federat Fertil Soc, Amer Soc Reprod Med C1 [Sunderam, S.; Kissin, D. M.; Crawford, S.; Anderson, J.; Jamieson, D. J.; Barfield, W. D.] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD SEP PY 2013 VL 100 IS 3 SU S MA O-299 BP S91 EP S91 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA AQ1PY UT WOS:000342554500297 ER PT J AU Eke, PI AF Eke, Paul I. TI Probing Depth Is Not a Reliable Predictor for Changes in Periodontitis SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Eke, PI (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS 45, Atlanta, GA 30341 USA. EM peke@cdc.gov NR 0 TC 3 Z9 3 U1 1 U2 1 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-3382 J9 J EVID-BASED DENT PR JI J. Evid.-Based Dent. Pract. PD SEP PY 2013 VL 13 IS 3 BP 107 EP 108 DI 10.1016/j.jebdp.2013.07.009 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA V37RX UT WOS:000209294000010 PM 24011007 ER PT J AU Griffin, SO Jones, K AF Griffin, Susan O. Jones, Kari TI Quality of Reporting in Economic Evaluations of Interventions to Prevent Dental Caries Needs Improvement SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE LA English DT Editorial Material C1 [Griffin, Susan O.] Ctr Dis Control & Prevent, Div Oral Hlth, Chamblee, GA 30341 USA. [Jones, Kari] Univ S Florida, Morsani Coll Med, Tampa, FL 33620 USA. RP Griffin, SO (reprint author), Ctr Dis Control & Prevent, Div Oral Hlth, 4770 Buford Highway MF F80, Chamblee, GA 30341 USA. EM sig1@cdc.gov; Kari.Jones@lvhn.org NR 6 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-3382 J9 J EVID-BASED DENT PR JI J. Evid.-Based Dent. Pract. PD SEP PY 2013 VL 13 IS 3 BP 109 EP 110 DI 10.1016/j.jebdp.2013.07.010 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA V37RX UT WOS:000209294000011 PM 24011008 ER PT J AU Coller-Monarez, S Groseclose, SL Kurilla, MG Berg, JM AF Coller-Monarez, Susan Groseclose, Samuel L. Kurilla, Michael G. Berg, Jeremy M. TI High Priority Preparedness Research and Its Support SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Editorial Material DE federal support; Centers for Disease Control and Prevention; National Institutes of Health; preparedness; Department of Homeland Security AB The US Federal Government has considerable interest in supporting research into preparedness. Because of the diverse nature of possible threats and the responsibilities of different agencies, a number of different programs have been developed. Perspectives from representatives from 3 of the leading agencies; the Department of Homeland Security, the Centers from Disease Control and Prevention, and the National Institutes of Health, are described herein. C1 [Coller-Monarez, Susan] Dept Homeland Secur, Threat Characterizat & Attribut Branch, Chem & Biol Def Div, Sci & Technol Directorate, Alexandria, VA USA. [Groseclose, Samuel L.] Ctr Dis Control & Prevent, Sci & Policy Hlth Practice, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Kurilla, Michael G.] NIAID, Off Biodef Res Resources & Translat Res, NIH, Bethesda, MD 20892 USA. [Kurilla, Michael G.] NIAID, Biodef Product Dev, Div Microbiol & Infect Dis, NIH, Bethesda, MD 20892 USA. [Berg, Jeremy M.] Univ Pittsburgh, Sci Strategy & Planning Hlth Sci, Pittsburgh, PA 15213 USA. [Berg, Jeremy M.] Univ Pittsburgh, Dept Computat & Syst Biol, 3550 Terrace St, Pittsburgh, PA USA. RP Berg, JM (reprint author), Univ Pittsburgh, Dept Computat & Syst Biol, 3550 Terrace St, Pittsburgh, PA USA. EM jberg@pitt.edu OI Berg, Jeremy/0000-0003-3022-0963 NR 4 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD SEP-OCT PY 2013 VL 19 SU 2 BP S9 EP S11 DI 10.1097/PHH.0b013e3182972287 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V43KM UT WOS:000209680300004 PM 23903401 ER PT J AU Belser, JA Tumpey, TM AF Belser, Jessica A. Tumpey, Terrence M. TI Tropism of H7N9 influenza viruses in the human respiratory tract SO LANCET RESPIRATORY MEDICINE LA English DT Editorial Material ID RECEPTOR-BINDING; TRANSMISSION; INFECTION; FERRETS C1 [Belser, Jessica A.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Belser, JA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jbelser@cdc.gov NR 11 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD SEP PY 2013 VL 1 IS 7 BP 501 EP 502 DI 10.1016/S2213-2600(13)70161-9 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AQ3KA UT WOS:000342690100005 PM 24461601 ER PT J AU Izadnegahdar, R Cohen, AL Klugman, KP Qazi, SA AF Izadnegahdar, Rasa Cohen, Adam L. Klugman, Keith P. Qazi, Shamim A. TI Childhood pneumonia in developing countries SO LANCET RESPIRATORY MEDICINE LA English DT Review ID AGED 2-59 MONTHS; PNEUMOCOCCAL CONJUGATE VACCINE; PEDIATRIC EMERGENCY-DEPARTMENT; COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE; ORAL AMOXICILLIN; CASE-MANAGEMENT AB Pneumonia is a widespread and common infectious lung disease that causes inflammation, which can lead to reduced oxygenation, shortness of breath, and death. An estimated nearly 1.2 million children younger than 5 years died in 2011 from pneumonia. Most of these deaths occured in developing countries where access to care is limited and interventions that have improved care in developed countries are scarce. Despite substantial increases in our understanding of the clinical syndrome of pneumonia and its aetiologies, its accurate diagnosis is challenging when clinical indicators are relied on, and improves only modestly with addition of laboratory, microbiological, or radiographical tests. Prevention programmes and treatment guidelines have led to impressive reductions in disease, but children remain at risk of misdiagnosis and inadequate treatment. Research to address challenges in the aetiological diagnosis of pneumonia and widespread implementation of treatment interventions beyond vaccines and antibiotics are necessary to mitigate the burden of pneumonia and improve child survival. C1 [Izadnegahdar, Rasa] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02118 USA. [Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa. [Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Klugman, Keith P.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Klugman, Keith P.] Univ Witwatersrand, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Qazi, Shamim A.] WHO, Dept Maternal Newborn Child & Adolescent Hlth, CH-1211 Geneva, Switzerland. RP Izadnegahdar, R (reprint author), Boston Univ, Ctr Global Hlth & Dev, Crosstown Ctr, 3rd Floor,801 Massachusetts Ave, Boston, MA 02118 USA. EM rasa@bu.edu NR 88 TC 8 Z9 10 U1 3 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-2600 J9 LANCET RESP MED JI Lancet Resp. Med. PD SEP PY 2013 VL 1 IS 7 BP 574 EP 584 DI 10.1016/S2213-2600(13)70075-4 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA AQ3KA UT WOS:000342690100022 PM 24461618 ER PT J AU Zaric, GS Lasry, A AF Zaric, Gregory S. Lasry, Arielle TI Foreword SO SOCIO-ECONOMIC PLANNING SCIENCES LA English DT Editorial Material C1 [Zaric, Gregory S.] Western Univ, Ivey Business Sch, London, ON, Canada. [Lasry, Arielle] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Lasry, A (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ftn9@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0038-0121 J9 SOCIO-ECON PLAN SCI JI Socio-Econ. Plan. Sci. PD SEP PY 2013 VL 47 IS 3 BP 157 EP 157 DI 10.1016/j.seps.2013.07.001 PG 1 WC Economics; Management; Operations Research & Management Science SC Business & Economics; Operations Research & Management Science GA V41GV UT WOS:000209535600001 ER PT J AU Linkins, RW Chonwattana, W Holtz, TH Wasinrapee, P Chaikummao, S Varangrat, A Tongtoyai, J Mock, PA Curlin, ME Sirivongrangson, P van Griensven, F McNicholl, JM AF Linkins, Robert W. Chonwattana, Wannee Holtz, Timothy H. Wasinrapee, Punneeporn Chaikummao, Supaporn Varangrat, Anchalee Tongtoyai, Jaray Mock, Philip A. Curlin, Marcel E. Sirivongrangson, Pachara van Griensven, Frits McNicholl, Janet M. TI Hepatitis A and hepatitis B infection prevalence and associated risk factors in men who have sex with men, Bangkok, 2006-2008 SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE hepatitis A; hepatitis B; prevalence; risk factors; immunization; homosexual men; Thailand ID HOMOSEXUAL-MEN; TRANSMISSION; THAILAND; SEROPREVALENCE; EFFICACY; OUTBREAK; ANTIBODY; VACCINE; TRIAL; VIRUS AB Despite the availability of safe and effective vaccines, little is known about prevalence and risk factors for hepatitis A (HAV) and hepatitis B virus (HBV) infection among Thai men who have sex with men. The prevalence of HAV and HBV infection among men who have sex with men cohort in Bangkok was assessed. Baseline blood specimens were drawn and demographic and behavioral data were collected. Bivariate and multivariate logistic regression analysis was used to analyze risk factors for prevalent HAV and HBV infection. One thousand two hundred ninety-nine Thai men who have sex with men 18 years and older were enrolled. Among those with results, 349/1,291 (27.0%) had evidence of past or current hepatitis A infection. Of the 1,117 (86.5%) men with unambiguous HBV test results, 442 (39.6%) had serologic evidence of past/current infection, 103 (9.2%) were immune due to hepatitis B vaccination, 572 (51.2%) had no evidence of immunological exposure to HBV or vaccine. Of those with past/current HBV infection, 130 (29.4%) were HIV positive. Age >35 years was independently associated with both HAV and HBV infection. University education was protective against both HAV and HBV infection. Increased alcohol consumption, number of lifetime male sexual partners 10, and prevalent HIV infection were also independently associated with HBV infection. The prevalence of past/current HAV and HBV infection was high in Bangkok men who have sex with men. Age-cohorts with a higher prevalence of hepatitis B vaccine induced immunity may be expected in the future. Hepatitis A and B vaccination is recommended. J. Med. Virol. 85:1499-1505, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Linkins, Robert W.; Holtz, Timothy H.; Curlin, Marcel E.; van Griensven, Frits; McNicholl, Janet M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Linkins, Robert W.; Chonwattana, Wannee; Holtz, Timothy H.; Wasinrapee, Punneeporn; Chaikummao, Supaporn; Varangrat, Anchalee; Tongtoyai, Jaray; Mock, Philip A.; Curlin, Marcel E.; van Griensven, Frits; McNicholl, Janet M.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [Sirivongrangson, Pachara] Minist Publ, Bur AIDS TB & STI, Nonthaburi, Thailand. RP Holtz, TH (reprint author), MPH Thailand MOPH US CDC Collaborat, Minist Publ Hlth, DDC 7 Bldg,4th Floor,Soi 4, Nonthaburi 11000, Thailand. EM tkh3@th.cdc.gov RI van Griensven, Frits/G-4719-2013 OI van Griensven, Frits/0000-0002-0971-2843 FU U.S. Centers for Disease Control and Prevention FX Grant sponsor: U.S. Centers for Disease Control and Prevention NR 30 TC 7 Z9 7 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 J9 J MED VIROL JI J. Med. Virol. PD SEP PY 2013 VL 85 IS 9 BP 1499 EP 1505 DI 10.1002/jmv.23637 PG 7 WC Virology SC Virology GA 181WD UT WOS:000321699700001 PM 23797893 ER PT J AU Meites, E Lin, C Unger, ER Steinau, M Patel, S Markowitz, LE Hariri, S AF Meites, Elissa Lin, Carol Unger, Elizabeth R. Steinau, Martin Patel, Sonya Markowitz, Lauri E. Hariri, Susan TI Can clinical tests help monitor human papillomavirus vaccine impact? SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE papillomavirus infections; population surveillance; papillomavirus vaccines; DNA probes; HPV; laboratories; epidemiology ID NUTRITION EXAMINATION SURVEY; STATES-NATIONAL-HEALTH; UNITED-STATES; CERVICAL-CANCER; LINEAR-ARRAY; HPV VACCINE; DNA TEST; WOMEN; ASSAY; HYBRID-CAPTURE-2 AB As immunization programs for human papillomavirus (HPV) are implemented more widely around the world, interest is increasing in measuring their impact. One early measurable impact of HPV vaccine is on the prevalence of specific HPV types in a population. In low-resource settings, a potentially attractive strategy would be to monitor HPV prevalence using clinical cervical cancer screening test results to triage specimens for HPV typing. We assessed this approach in a nationally representative population of U.S. females aged 14-59 years. Using self-collected cervico-vaginal swab specimens from 4,150 women participating in the National Health and Nutrition Examination Survey during 2003-2006, we evaluated type-specific HPV prevalence detected by the Roche linear array (LA) research test on all specimens, compared with type-specific HPV prevalence detected by LA conducted only on specimens positive by the digene hybrid capture 2 (HC-2) clinical test. We calculated weighted prevalence estimates and their 95% confidence intervals (CIs), and examined relative type-specific HPV prevalence according to the two testing approaches. The population prevalence of oncogenic HPV vaccine types 16/18 was 6.2% (CI:5.4-7.1) by LA if all specimens were tested, and 2.4% (CI:1.9-3.0) if restricted to positive HC-2. Relative prevalence of individual HPV types was similar for both approaches. Compared with typing all specimens, a triage approach would require testing fewer specimens, but a greater reduction in HPV prevalence or a larger group of specimens would be needed to detect vaccine impact. Further investigation is warranted to inform type-specific HPV monitoring approaches around the world. C1 [Meites, Elissa; Lin, Carol; Markowitz, Lauri E.; Hariri, Susan] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Unger, Elizabeth R.; Steinau, Martin; Patel, Sonya] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Meites, E (reprint author), 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM emeites@cdc.gov OI Meites, Elissa/0000-0002-0077-2591 FU Centers for Disease Control and Prevention FX Grant sponsor: Centers for Disease Control and Prevention NR 24 TC 3 Z9 3 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD SEP 1 PY 2013 VL 133 IS 5 BP 1101 EP 1106 DI 10.1002/ijc.28115 PG 6 WC Oncology SC Oncology GA 166MT UT WOS:000320559600009 PM 23420411 ER PT J AU Florindo, AA Mielke, GI Gomes, GAD Ramos, LR Bracco, MM Parra, DC Simoes, EJ Lobelo, F Hallal, PC AF Florindo, Alex Antonio Mielke, Gregore Iven de Oliveira Gomes, Grace Angelica Ramos, Luiz Roberto Bracco, Mario Maia Parra, Diana C. Simoes, Eduardo J. Lobelo, Felipe Hallal, Pedro Curi TI Physical activity counseling in primary health care in Brazil: a national study on prevalence and associated factors SO BMC PUBLIC HEALTH LA English DT Article DE Physical activity promotion; Physical activity counseling; Primary health care; Physicians; Nurses; Knowledge; Associated factors ID RANDOMIZED CONTROLLED-TRIAL; ACTIVITY PROMOTION PROGRAM; LIFE-STYLE; EXERCISE; ADVICE; PRESCRIPTION; DOCTORS; PROJECT; COST AB Background: The aim of this study was to determine the prevalence and correlates of physical activity counseling among physicians and nurses working in primary health care in Brazil. Methods: A phone survey was carried out in 2011 with professionals working in primary health care in Brazil. The target sample consisted of 1,600 randomly selected primary care units covering all regions of the country. We successfully interviewed 529 professionals within the sampled units; 182 physicians and 347 nurses. The overall response rate was 49.6%. Multivariable logistic regression was used to estimate correlates of counseling in the whole sample and separately for physicians and nurses. Results: The prevalence of regular physical activity counseling for at least six months was 68.9% (95% CI 64.9; 72.8) and was significantly higher among physicians compared to nurses (p < 0.05). Most professionals (93.2%) interviewed were unfamiliar with current physical activity recommendations for health. In the adjusted analysis, physical activity counseling was more frequent among those who report assessing patient's physical activity (OR = 2.16; 95% CI 1.41; 3.29), those reporting that lack of time was not a barrier for counseling (OR = 0.62 95% CI 0.42-0.93), those who felt prepared to provide physical activity counseling (OR = 2.34; 95% CI 1.50-3.66), and those working at primary care units offering physical activity programs for patients (OR = 2.06; 95% CI 1.33-3.20). In the stratified analysis, only assessing patient's physical activity was a significant correlate among physicians whereas assessing patient's physical activity, feeling prepared to provide counseling and working in units with physical activity interventions were significant correlates among nurses. Conclusions: Physicians and nurses deemed physical activity counseling of great importance in primary health care in Brazil. However, in order to increase the quality of counseling and the number of professionals engaging in this activity, these health teams require greater knowledge about physical activity (global recommendations for health) as well as training on the application of instruments for assessing physical activity. Moreover, sufficient time must be allowed during consultations for the counseling process, and physical activity promotion programs should be implemented within the primary health care units. C1 [Florindo, Alex Antonio] Univ Sao Paulo, Sch Arts Sci & Humanities, Sao Paulo, Brazil. [Mielke, Gregore Iven; Hallal, Pedro Curi] Univ Fed Pelotas, Postgrad Program Epidemiol, Pelotas, RS, Brazil. [de Oliveira Gomes, Grace Angelica] Univ Fed Sao Carlos, Gerontol Dept, BR-13560 Sao Carlos, SP, Brazil. [Ramos, Luiz Roberto] Univ Fed Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil. [Bracco, Mario Maia] Hosp Israelita Albert Einstein, Sao Paulo, Brazil. [Parra, Diana C.] Washington Univ, George Warren Brown Sch Social Work, Prevent Res Ctr St Louis, St Louis, MO 63130 USA. [Simoes, Eduardo J.] Univ Missouri, Sch Med, Dept Hlth Management & Informat, Columbia, MO USA. [Lobelo, Felipe] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Hallal, Pedro Curi] Univ Fed Pelotas, Sch Phys Educ, Pelotas, RS, Brazil. RP Florindo, AA (reprint author), Univ Sao Paulo, Sch Arts Sci & Humanities, Sao Paulo, Brazil. EM aflorind@usp.br RI Hallal, Pedro/A-3249-2011; Parra, Diana/B-7761-2015; Mielke, Gregore/E-2141-2014; OI Hallal, Pedro/0000-0003-1470-6461; Parra, Diana/0000-0002-9797-6231; Mielke, Gregore/0000-0002-3043-2715; Lobelo, Felipe/0000-0003-4185-7193; Simoes, Eduardo/0000-0003-4371-4305 FU Centers for Disease Control and Prevention's Prevention Research Centers Program [U48/DP001903] FX The authors wish to thank all members of the GUIA team. This study was funded through the Centers for Disease Control and Prevention's Prevention Research Centers Program special interest project U48/DP001903 (Applying Evidence-Physical Activity Recommendations in Brazil). NR 38 TC 9 Z9 11 U1 1 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD AUG 31 PY 2013 VL 13 AR 794 DI 10.1186/1471-2458-13-794 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 213NV UT WOS:000324065400001 PM 24005006 ER PT J AU Griffing, SM Gamboa, D Udhayakumar, V AF Griffing, Sean M. Gamboa, Dionicia Udhayakumar, Venkatachalam TI The history of 20th century malaria control in Peru SO MALARIA JOURNAL LA English DT Review DE Latin America; Malaria; Peru; Public health; Plasmodium; Vivax; Falciparum; Disease; Malaria control; Malaria eradication; Drug resistance; Pesticide resistance; Habitat change ID PLASMODIUM-VIVAX-MALARIA; FALCIPARUM DRUG-RESISTANCE; SULFADOXINE-PYRIMETHAMINE; ANOPHELES-DARLINGI; AMAZON REGION; TREATMENT POLICY; INFECTIONS; DEFORESTATION; SURVEILLANCE; CHLOROQUINE AB Malaria has been part of Peruvian life since at least the 1500s. While Peru gave the world quinine, one of the first treatments for malaria, its history is pockmarked with endemic malaria and occasional epidemics. In this review, major increases in Peruvian malaria incidence over the past hundred years are described, as well as the human factors that have facilitated these events, and concerted private and governmental efforts to control malaria. Political support for malaria control has varied and unexpected events like vector and parasite resistance have adversely impacted morbidity and mortality. Though the ready availability of novel insecticides like DDT and efficacious medications reduced malaria to very low levels for a decade after the post eradication era, malaria reemerged as an important modern day challenge to Peruvian public health. Its reemergence sparked collaboration between domestic and international partners towards the elimination of malaria in Peru. C1 [Griffing, Sean M.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Griffing, Sean M.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Dept Bioquim, Lima, Peru. [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Fac Ciencias & Filosofia, Dept Ciencias Celulares & Mol, Lima, Peru. RP Griffing, SM (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Ctr Global Hlth, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30329 USA. EM Sean.Griffing@gmail.com FU Antimicrobial Drug Resistance Working Group; Centers for Disease Control and Prevention; Atlanta Research and Education Foundation, Atlanta VA Medical Center; National Science Foundation Graduate Research Fellowship FX The work was supported in part by the Antimicrobial Drug Resistance Working Group, the Centers for Disease Control and Prevention, and the Atlanta Research and Education Foundation, Atlanta VA Medical Center. S. M. Griffing was supported under a National Science Foundation Graduate Research Fellowship. The authors appreciate the support and comments of Dr. William Ward. NR 46 TC 4 Z9 4 U1 3 U2 34 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD AUG 30 PY 2013 VL 12 AR 303 DI 10.1186/1475-2875-12-303 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 211RU UT WOS:000323928700001 PM 24001096 ER PT J AU Curtis, CR Yankey, D Jeyarajah, J Dorell, C Stokley, S MacNeil, J Hariri, S AF Curtis, C. Robinette Yankey, David Jeyarajah, Jenny Dorell, Christina Stokley, Shannon MacNeil, Jessica Hariri, Susan TI National and State Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Hariri, Susan] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Sexually Transmitted Dis, Atlanta, GA 30333 USA. EM rcurtis@cdc.gov NR 10 TC 125 Z9 125 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 30 PY 2013 VL 62 IS 34 BP 685 EP 693 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 211DS UT WOS:000323885600001 ER PT J AU Benjamin, G Mitra, M Graham, C Krahn, G Luce, S Fox, M Hootman, J Ghiya, N Popovic, T AF Benjamin, Georges Mitra, Monika Graham, Catherine Krahn, Gloria Luce, Stephen Fox, Michael Hootman, Jennifer Ghiya, Neelam Popovic, Tanja TI CDC Grand Rounds: Public Health Practices to Include Persons with Disabilities SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; ADULTS; VIOLENCE; ARTHRITIS; PREVALENCE; STUDENTS; ABUSE; RISK; CARE C1 [Mitra, Monika] Univ Massachusetts, Amherst, MA 01003 USA. [Graham, Catherine] Univ S Carolina, Sch Med, Columbia, SC 29208 USA. [Krahn, Gloria; Luce, Stephen; Fox, Michael] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. EM mhfox@cdc.gov NR 28 TC 7 Z9 7 U1 1 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 30 PY 2013 VL 62 IS 34 BP 697 EP 701 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 211DS UT WOS:000323885600003 ER PT J AU Weltman, A Longenberger, AH Moll, M Johnson, L Martin, J Beaudoin, A AF Weltman, Andre Longenberger, Allison H. Moll, Maria Johnson, Lydia Martin, Judy Beaudoin, Amanda TI Recurrent Outbreak of Campylobacter jejuni Infections Associated with a Raw Milk Dairy - Pennsylvania, April-May 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID STATES C1 [Weltman, Andre; Longenberger, Allison H.; Moll, Maria] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Beaudoin, Amanda] CDC, Atlanta, GA 30333 USA. RP Beaudoin, A (reprint author), CDC, Atlanta, GA 30333 USA. EM whz0@cdc.gov NR 3 TC 7 Z9 7 U1 1 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 30 PY 2013 VL 62 IS 34 BP 702 EP 702 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 211DS UT WOS:000323885600004 ER PT J AU Ogilvie, L Stanley, C Lewis, L Boyd, M Lozier, M AF Ogilvie, Laurie Stanley, Christina Lewis, Lauren Boyd, Molly Lozier, Matthew TI Acetyl Fentanyl Overdose Fatalities - Rhode Island, March-May 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ogilvie, Laurie] Rhode Isl State Hlth Lab, Providence, RI USA. [Stanley, Christina] Rhode Isl Off State Med Examiners, Providence, RI USA. [Lozier, Matthew] CDC, Atlanta, GA 30333 USA. RP Lozier, M (reprint author), CDC, Atlanta, GA 30333 USA. EM mlozier@cdc.gov NR 4 TC 30 Z9 31 U1 0 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 30 PY 2013 VL 62 IS 34 BP 703 EP 704 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 211DS UT WOS:000323885600005 ER PT J AU Reiter, PL Katz, ML Ruffin, MT Hade, EM DeGraffenreid, CR Patel, DA Paskett, ED Unger, ER AF Reiter, Paul L. Katz, Mira L. Ruffin, Mack T. Hade, Erinn M. DeGraffenreid, Cecilia R. Patel, Divya A. Paskett, Electra D. Unger, Elizabeth R. TI HPV Prevalence among Women from Appalachia: Results from the CARE Project SO PLOS ONE LA English DT Article ID HUMAN-PAPILLOMAVIRUS VACCINE; NUTRITION EXAMINATION SURVEY; CERVICAL-CANCER; UNITED-STATES; ADOLESCENT FEMALES; NATIONAL-HEALTH; INFECTION; RECOMMENDATIONS; PREVENTION; COVERAGE AB Background: Cervical cancer incidence and mortality rates are high among women from Appalachia, yet data do not exist on human papillomavirus (HPV) prevalence among these women. We examined the prevalence of genital HPV among Appalachian women and identified correlates of HPV detection. Methods: We report data from a case-control study conducted between January 2006 and December 2008 as part of the Community Awareness, Resources, and Education (CARE) Project. We examined HPV prevalence among 1116 women (278 women with abnormal Pap tests at study entry [cases], 838 women with normal Pap tests [controls]) from Appalachian Ohio. Analyses used multivariable logistic regression to identify correlates of HPV detection. Results: The prevalence of HPV was 43.1% for any HPV type, 33.5% for high-risk HPV types, 23.4% for low-risk HPV types, and 12.5% for vaccine-preventable HPV types. Detection of any HPV type was more common among women who were ages 18-26 (OR = 2.09, 95% CI: 1.26-3.50), current smokers (OR = 1.86, 95% CI: 1.26-2.73), had at least five male sexual partners during their lifetime (OR = 2.28, 95% CI: 1.56-3.33), or had multiple male sexual partners during the last year (OR = 1.98, 95% CI: 1.25-3.14). Similar correlates were identified for detection of a high-risk HPV type. Conclusions: HPV was prevalent among Appalachian women, with many women having a high-risk HPV type detected. Results may help explain the high cervical cancer rates observed among Appalachian women and can help inform future cervical cancer prevention efforts in this geographic region. C1 [Reiter, Paul L.; Katz, Mira L.; Paskett, Electra D.] Ohio State Univ, Coll Med, Div Canc Prevent & Control, Columbus, OH 43210 USA. [Reiter, Paul L.; Katz, Mira L.; DeGraffenreid, Cecilia R.; Paskett, Electra D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Reiter, Paul L.; Katz, Mira L.; Paskett, Electra D.] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA. [Ruffin, Mack T.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Hade, Erinn M.] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA. [Patel, Divya A.] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA. [Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Ruffin, MT (reprint author), Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. EM mruffin@med.umich.edu OI Ruffin, Mack/0000-0001-8336-478X; Unger, Elizabeth/0000-0002-2925-5635 FU National Cancer Institute at the National Institutes of Health [P50CA105632, P30CA016058] FX This study was supported by the National Cancer Institute at the National Institutes of Health (P50CA105632 and P30CA016058). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agencies. NR 33 TC 4 Z9 4 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 30 PY 2013 VL 8 IS 8 AR e74276 DI 10.1371/journal.pone.0074276 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 211BX UT WOS:000323880200098 PM 24023700 ER PT J AU Nadon, CA Trees, E Ng, LK Nielsen, EM Reimer, A Maxwell, N Kubota, KA Gerner-Smidt, P AF Nadon, C. A. Trees, E. Ng, L. K. Nielsen, E. Moller Reimer, A. Maxwell, N. Kubota, K. A. Gerner-Smidt, P. CA MLVA Harmonization Working Grp TI Development and application of MLVA methods as a tool for inter-laboratory surveillance SO EUROSURVEILLANCE LA English DT Review ID TANDEM REPEAT ANALYSIS; MULTILOCUS VARIABLE-NUMBER; ESCHERICHIA-COLI O157-H7; ENTERICA SEROTYPE ENTERITIDIS; FIELD GEL-ELECTROPHORESIS; COMPLETE GENOME SEQUENCE; CAPILLARY-ELECTROPHORESIS; SEROVAR TYPHIMURIUM; TYPING METHODS; PCR AB Multiple-locus variable-number of tandem-repeats analysis (MLVA) has emerged as a valuable method for subtyping bacterial pathogens and has been adopted in many countries as a critical component of their laboratory-based surveillance. Lack of harmonisation and standardisation of the method, however, has made comparison of results generated in different laboratories difficult, if not impossible, and has therefore hampered its use in international surveillance. This paper proposes an international consensus on the development, validation, nomenclature and quality control for MLVA used for molecular surveillance and outbreak detection based on a review of the current state of knowledge. C1 [Nadon, C. A.; Ng, L. K.; Reimer, A.] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. [Trees, E.; Maxwell, N.; Gerner-Smidt, P.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Nielsen, E. Moller] Statens Serum Inst, Unit Gastrointestinal Infect, DK-2300 Copenhagen, Denmark. [Kubota, K. A.] Assoc Publ Hlth Labs, Silver Spring, MD USA. RP Nadon, CA (reprint author), Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB, Canada. EM plg5@cdc.gov RI Nielsen, Eva Moller/B-9157-2011; Wain, John/B-3446-2013 OI Nielsen, Eva Moller/0000-0002-5349-7802; Wain, John/0000-0002-1257-1148 NR 35 TC 21 Z9 21 U1 3 U2 17 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD AUG 29 PY 2013 VL 18 IS 35 BP 10 EP 19 AR UNSP 20565 PG 10 WC Infectious Diseases SC Infectious Diseases GA 208US UT WOS:000323706700004 PM 24008231 ER PT J AU Madhi, SA Dangor, Z Heath, PT Schrag, S Izu, A Sobanjo-ter Meulen, A Dull, PM AF Madhi, Shabir A. Dangor, Ziyaad Heath, Paul T. Schrag, Stephanie Izu, Alaine Sobanjo-ter Meulen, Ajoke Dull, Peter M. TI Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants SO VACCINE LA English DT Review DE Group B streptococcus; Conjugate vaccine; Pregnant women ID INFLUENZA IMMUNIZATION; NEONATAL SEPSIS; IGG ANTIBODY; QUANTITATIVE-DETERMINATION; CAPSULAR POLYSACCHARIDE; VERTICAL TRANSMISSION; DEVELOPING-COUNTRIES; INFECTION; LEVEL; ERA AB In 2010, an estimated 393,000 infection-related neonatal deaths occurred worldwide with Group B streptococcus (GBS) being a leading cause. Prevention of early-onset disease (0-6 days; EOD) is currently focused on intra-partum antibiotic prophylaxis to mothers identified as being at risk; such strategies reduce EOD by 75-80% but are resource-intensive and logistically-difficult to implement in developing countries. Vaccination of pregnant women is an alternate strategy for preventing both EOD and late-onset disease (7-89 days; LOD). A trivalent GBS polysaccharide-protein conjugate vaccine (GBS-CV) composed of capsular epitopes from serotypes Ia, Ib and III is undergoing phase-II evaluation among pregnant women in Europe, North America and Africa. These serotypes cause 70-80% of all invasive GBS disease in early-infancy. Maternal anti-GBS antibodies are associated with protection from EOD, however, since a correlate of efficacy has not been defined, a phase III efficacy trial may be required for licensure. Criteria for selecting appropriate sites include sufficiently high GBS incidence in large birth cohorts, as well as adequate clinical and microbiological diagnostic skills and capacities. Alternate pathways to licensure should be explored, e.g. identification of serological correlates of protection with subsequent phase IV studies establishing vaccine-effectiveness against invasive GBS disease. Conducting a randomized, placebo-controlled efficacy trial, however, has the additional advantage of also being able to evaluate the role of GBS contributing to neonatal culture-negative sepsis, stillbirths, prematurity and low-birth weight. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Madhi, Shabir A.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Vaccines & Immunol, ZA-2131 Johannesburg, Gauteng, South Africa. [Madhi, Shabir A.; Dangor, Ziyaad; Izu, Alaine] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci, Fac Hlth Sci, Johannesburg, South Africa. [Madhi, Shabir A.; Dangor, Ziyaad; Izu, Alaine] MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Heath, Paul T.] Univ London, Vaccine Inst, London, England. [Schrag, Stephanie] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sobanjo-ter Meulen, Ajoke; Dull, Peter M.] Novartis Vaccines & Diagnost, Cambridge, MA USA. RP Madhi, SA (reprint author), Natl Hlth Lab Serv, Natl Inst Communicable Dis, 1 Modderfontein Rd, ZA-2131 Johannesburg, Gauteng, South Africa. EM madhis@rmpru.co.za FU US Centers for Disease Control and Prevention; Novartis FX Novartis: Receipt of research funding, investigator on research studies, received honoraria and consultancy (SAM). PTH is an investigator for research studies done on behalf of St Georges, University of London and funded by Novartis vaccines and serves as a consultant to Novartis vaccines. ASM and PAD are employees of Novartis. The gathering of the expert-group was sponsored by Novartis. SJS is solely funded by the US Centers for Disease Control and Prevention and received no Novartis funds NR 47 TC 37 Z9 39 U1 3 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 28 PY 2013 VL 31 SU 4 BP D52 EP D57 DI 10.1016/j.vaccine.2013.02.029 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 219MJ UT WOS:000324510800010 PM 23973347 ER PT J AU Schrag, SJ Verani, JR AF Schrag, Stephanie J. Verani, Jennifer R. TI Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: Experience in the United States and implications for a potential group B streptococcal vaccine SO VACCINE LA English DT Review DE Neonatal sepsis; Group B streptococcus; Intrapartum antibiotic prophylaxis; Maternal immunization ID ONSET NEONATAL SEPSIS; ESCHERICHIA-COLI; REVISED GUIDELINES; GBS INFECTION; RISK-FACTORS; INFANTS; CHEMOPROPHYLAXIS; SUSCEPTIBILITY; AMPICILLIN; PREGNANCY AB Group B Streptococcus (GBS) emerged as the leading cause of newborn infection in the United States in the 1970s. In the 1980s clinical trials demonstrated that giving intrapartum intravenous ampicillin or penicillin to mothers at risk was highly effective at preventing invasive GBS disease in the first week of life (early-onset). In 1996, the first national guidelines for the prevention of perinatal GBS disease were issued; these recommended either antenatal screening for GBS colonization and intrapartum antimicrobial prophylaxis (IAP) to colonized women, or targeting IAP to women with certain obstetric risk factors during labor. In 2002, revised guidelines recommended universal antenatal GBS screning. A multistate population-based review of labor and delivery records in 2003-2004 found 85% of women had documented antenatal GBS screening; 98% of screened women had a colonization result available at labor. However, missed opportunities for prevention were identified among women delivering preterm and among those with penicillin allergy, and more false negative GBS screening results were observed than expected. The incidence of invasive early-onset GBS disease decreased by more than 80% from 1.8 cases/1000 live births in the early 1990s to 0.26 cases/1000 live births in 2010; from 1994 to 2010 we estimate that over 70,000 cases of EOGBS invasive disease were prevented in the United States. IAP effectiveness is similar and high among term (91%) and preterm (86%) infants when first line therapy is received for at least 4 h. However, early-onset disease incidence among preterm infants remains twice that of term infants; moreover disease among infants after the first week of life (late-onset disease) has not been impacted by IAP. The US experience demonstrates that universal screening and IAP for GBS-colonized women comprise a highly effective strategy against early-onset GBS infections. Maximizing adherence to recommended practices holds promise to further reduce the burden of early-onset GBS disease. Yet there are also inherent limitations to universal screening and IAP. Some of these could potentially be addressed by an efficacious maternal GBS vaccine. Published by Elsevier Ltd. C1 [Schrag, Stephanie J.; Verani, Jennifer R.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Schrag, SJ (reprint author), Ctr Dis Control & Prevent, MS C25,1600 Clifton Rd, Atlanta, GA 30333 USA. EM zha6@cdc.gov FU Centers for Disease Control and Prevention FX This work was funded solely by the Centers for Disease Control and Prevention. NR 42 TC 48 Z9 49 U1 6 U2 20 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 28 PY 2013 VL 31 SU 4 BP D20 EP D26 DI 10.1016/j.vaccine.2012.11.056 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 219MJ UT WOS:000324510800005 PM 23219695 ER PT J AU Gastanaduy, PA Curns, AT Parashar, UD Lopman, BA AF Gastanaduy, Paul A. Curns, Aaron T. Parashar, Umesh D. Lopman, Ben A. TI Gastroenteritis Hospitalizations in Older Children and Adults in the United States Before and After Implementation of Infant Rotavirus Vaccination SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID INDIRECT PROTECTION; NOROVIRUS C1 [Gastanaduy, Paul A.; Curns, Aaron T.; Parashar, Umesh D.; Lopman, Ben A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. RP Gastanaduy, PA (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,Mailstop A-47, Atlanta, GA 30333 USA. EM vid7@cdc.gov NR 6 TC 31 Z9 31 U1 0 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 28 PY 2013 VL 310 IS 8 BP 851 EP 853 DI 10.1001/jama.2013.170800 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 206YA UT WOS:000323561400026 PM 23982372 ER PT J AU Jorgensen, P Wasley, A Mereckiene, J Cotter, S Weber, JT Brown, CS AF Jorgensen, Pernille Wasley, Annemarie Mereckiene, Jolita Cotter, Suzanne Weber, J. Todd Brown, Caroline Sarah TI Unequal access to vaccines in the WHO European Region during the A(H1N1) influenza pandemic in 2009 SO VACCINE LA English DT Article DE Influenza; Pandemic; Vaccines; A(H1N1)pdm09 ID PRODUCTION CAPACITY; VIRUS AB In a severe pandemic, rapid production and deployment of vaccines will potentially be critical in mitigating the impact on populations and essential services. We compared access to vaccines and timing of delivery relative to identification of A(H1N1)pdm09 and the geographic progression of the pandemic in the WHO European Region in order to identify gaps in provision. Information on vaccine procurement and donations was collected through a web-based survey conducted in all 53 member states of the Region. Among the 51 countries responding to the survey, the majority (84%) implemented vaccination campaigns against A(H1N1)pdm09. However, time of vaccine receipt and number of doses varied substantially across the region, with delayed access in many countries especially in those in the lowest income range. Improving access to influenza vaccines in low resource countries and solving issues of product liability should help reduce inequalities and operational challenges arising during a future public health crisis. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Jorgensen, Pernille; Wasley, Annemarie; Brown, Caroline Sarah] WHO Reg Off Europe, DK-2100 Copenhagen O, Denmark. [Mereckiene, Jolita; Cotter, Suzanne] Hlth Protect Surveillance Ctr, Dublin, Ireland. [Weber, J. Todd] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Jorgensen, P (reprint author), WHO Reg Off Europe, UN City, Marmorvej 51, DK-2100 Copenhagen O, Denmark. EM pej@euro.who.int NR 21 TC 2 Z9 2 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 28 PY 2013 VL 31 IS 38 BP 4060 EP 4062 DI 10.1016/j.vaccine.2013.06.082 PG 3 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 207IF UT WOS:000323591400003 PM 23845820 ER PT J AU Kilgore, A Donauer, S Edwards, KM Weinberg, GA Payne, DC Szilagyi, PG Rice, M Cassedy, A Ortega-Sanchez, IR Parashar, UD Staat, MA AF Kilgore, April Donauer, Stephanie Edwards, Kathryn M. Weinberg, Geoffrey A. Payne, Daniel C. Szilagyi, Peter G. Rice, Marilyn Cassedy, Amy Ortega-Sanchez, Ismael R. Parashar, Umesh D. Staat, Mary Allen TI Rotavirus-associated hospitalization and emergency department costs and rotavirus vaccine program impact SO VACCINE LA English DT Article DE Rotavirus; Medical costs; Hospitalizations; Emergency department visits; NVSN ID UNITED-STATES; US CHILDREN; DIARRHEA; GASTROENTERITIS; SURVEILLANCE; DISEASE; BURDEN; POPULATION; MORBIDITY; INFECTION AB Objectives: To determine the medical costs of laboratory-confirmed rotavirus hospitalizations and emergency department (ED) visits and estimate the economic impact of the rotavirus vaccine program. Patients and methods: During 4 rotavirus seasons (2006-2009), children <3 years of age hospitalized or seen in the ED with laboratory-confirmed rotavirus were identified through active population-based rotavirus surveillance in three US counties. Medical costs were obtained from hospital and physician billing data, and factors associated with increased costs were examined. Annual national costs were estimated using rotavirus hospitalization and ED visit rates and medical costs for rotavirus hospitalizations and ED visits from our surveillance program for pre- (2006-2007) and post-vaccine (2008-2009) time periods. Results: Pre-vaccine, for hospitalizations, the median medical cost per child was $3581, the rotavirus hospitalization rate was 22.1/10,000, with an estimated annual national cost of $91 million. Post-vaccine, the median medical cost was $4304, the hospitalization rate was 6.3/10,000 and the estimated annual national cost was $31 million. Increased costs were associated with study site, age <3 months, underlying medical conditions and an atypical acute gastroenteritis presentation. For ED visits, the pre-vaccine median medical cost per child was $574, the ED visit rate was 291/10,000 resulting in an estimated annual national cost of $192 million. Post-vaccine, the median medical cost was $794, the ED visit rate was 71/10,000 with an estimated annual national cost of $65 million. Conclusions: After implementation of rotavirus immunization, the total annual medical costs decreased from $283 million to $96 million, an annual reduction of $187 million (C) 2013 Elsevier Ltd. All rights reserved. C1 [Kilgore, April; Rice, Marilyn; Staat, Mary Allen] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Infect Dis, Cincinnati, OH 45229 USA. [Donauer, Stephanie; Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Dept Pediat, Div Infect Dis, Nashville, TN USA. [Weinberg, Geoffrey A.; Szilagyi, Peter G.] Univ Rochester, Sch Med & Dent, Rochester, NY USA. [Payne, Daniel C.; Ortega-Sanchez, Ismael R.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Donauer, S (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA. EM stephanie.donauer@cchmc.org FU Intramural CDC HHS [CC999999] NR 29 TC 11 Z9 11 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 28 PY 2013 VL 31 IS 38 BP 4164 EP 4171 DI 10.1016/j.vaccine.2013.06.085 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 207IF UT WOS:000323591400018 PM 23845802 ER PT J AU Wright, N Jackson, FR Niezgoda, M Ellison, JA Rupprecht, CE Nel, LH AF Wright, N. Jackson, F. R. Niezgoda, M. Ellison, J. A. Rupprecht, C. E. Nel, L. H. TI High prevalence of antibodies against canine adenovirus (CAV) type 2 in domestic dog populations in South Africa precludes the use of CAV-based recombinant rabies vaccines SO VACCINE LA English DT Article DE Canine adenovirus; Rabies; South Africa; Oral vaccines ID RACCOONS PROCYON-LOTOR; DISTEMPER VIRUS; ORAL IMMUNIZATION; VULPES-VULPES; UNITED-STATES; VACCINATION; EFFICACY; IMMUNITY; INFECTION; SAFETY AB Rabies in dogs can be controlled through mass vaccination. Oral vaccination of domestic dogs would be useful in the developing world, where greater vaccination coverage is needed especially in inaccessible areas or places with large numbers of free-roaming dogs. From this perspective, recent research has focused on development of new recombinant vaccines that can be administered orally in a bait to be used as adjunct for parenteral vaccination. One such candidate, a recombinant canine adenovirus type 2 vaccine expressing the rabies virus glycoprotein (CAV2-RG), is considered a promising option for dogs, given host specificity and safety. To assess the potential use of this vaccine in domestic dog populations, we investigated the prevalence of antibodies against canine adenovirus type 2 in South African dogs. Blood was collected from 241 dogs from the Gauteng and KwaZulu-Natal provinces. Sampled dogs had not previously been vaccinated against canine adenovirus type 1 (CAV1) or canine adenovirus type 2 (CAV2). Animals from both provinces had a high percentage of seropositivity (45% and 62%), suggesting that CAV2 circulates extensively among domestic dog populations in South Africa. Given this finding, we evaluated the effect of pre-existing CAV-specific antibodies on the efficacy of the CAV2-RG vaccine delivered via the oral route in dogs. Purpose-bred Beagle dogs, which received prior vaccination against canine parvovirus, canine distemper virus and CAV, were immunized by oral administration of CAV2-RG. After rabies virus (RABV) infection all animals, except one vaccinated dog, developed rabies. This study demonstrated that pre-existing antibodies against CAV, such as naturally occurs in South African dogs, inhibits the development of neutralizing antibodies against RABV when immunized with a CAV-based rabies recombinant vaccine. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Wright, N.; Nel, L. H.] Univ Pretoria, Dept Microbiol & Plant Pathol, Fac Nat & Agr Sci, ZA-0002 Pretoria, South Africa. [Jackson, F. R.; Niezgoda, M.; Ellison, J. A.; Rupprecht, C. E.] Ctr Dis Control & Prevent CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Wright, N (reprint author), Univ Pretoria, Dept Microbiol & Plant Pathol, Fac Nat & Agr Sci, Lynnwood Rd, ZA-0002 Pretoria, South Africa. EM nicolette.wright@up.ac.za OI Ellison, James/0000-0003-4492-4857 FU University of Pretoria; National Research Foundation; Poliomyelitis Research Foundation FX The authors acknowledge gratefully the University of Pretoria postgraduate student study abroad fund, the National Research Foundation and the Poliomyelitis Research Foundation for financial assistance. Kevin le Roux and Daniel Stewart kindly provided blood from KZN dogs. Blood for Gauteng dogs were kindly donated from a larger study by Dr Michelle Morters. Dr. Bernhard Dietzschold kindly provided the CAV 2 vaccine. NR 51 TC 2 Z9 3 U1 1 U2 35 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 28 PY 2013 VL 31 IS 38 BP 4177 EP 4182 DI 10.1016/j.vaccine.2013.06.089 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 207IF UT WOS:000323591400020 PM 23867013 ER PT J AU von Gottberg, A Cohen, C de Gouveia, L Meiring, S Quan, V Whitelaw, A Crowther-Gibson, P Madhi, SA Whitney, CG Klugman, KP AF von Gottberg, Anne Cohen, Cheryl de Gouveia, Linda Meiring, Susan Quan, Vanessa Whitelaw, Andrew Crowther-Gibson, Penny Madhi, Shabir A. Whitney, Cynthia G. Klugman, Keith P. TI Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008 SO VACCINE LA English DT Article DE Pneumococcal disease; Vaccine-preventable disease; Laboratory-based surveillance; Pneumococcus; Streptococcus pneumoniae; South Africa ID STREPTOCOCCUS-PNEUMONIAE; UNINFECTED CHILDREN; BACTEREMIA; SEROTYPES; BURDEN; SURVEILLANCE; MENINGITIS; SEROGROUPS; INFECTION; TRIAL AB Introduction: Dynamics of pneumococcal disease incidence and serotype distribution prior to introduction of pneumococcal conjugate vaccines (PCV) will assist in understanding effects of the vaccine over time and will be important in choosing the optimal PCV formulation. Methods: We conducted active, laboratory-based, national surveillance for invasive pneumococcal disease (IPD) through the Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA) from 2003 through 2008. Over 130 laboratories report to this system. Pneumococci were serotyped using Quellung and isolates screened for resistance by disk diffusion; minimum inhibitory concentrations were determined on potentially resistant isolates. We used univariate and multivariable multinomial regression models to assess differences between serotypes. Results: GERMS-SA identified 8674 cases among children <5 years. Overall, 58% (3849/6668), 65% (4314/6668), and 85% (5669/6668) of cases and 61% (455/751), 64% (482/751), 82% (616/751) of deaths were due to serotypes included in 7-valent PCV, 10-valent PCV and 13-valent PCV, respectively. Serotypes 6A and 19A accounted for 16% (527/3252) of penicillin non-susceptible disease. In 2008, reported incidence of IPD was 6-fold higher in children <1 compared to children 1-4 years of age: 87 per 100,000 population and 14/100,000, respectively. The relative risk of IPD was 21-fold (95% CI, 19-24) and 34-fold (29-41) greater in HIV-infected compared to HIV-uninfected children in the <1 year and 1-4-year-old age groups respectively. On multivariable analysis serotypes 6B (relative risk ratio (RRR) 0.7; confidence interval (Cl) 0.5-0.9), 18C (RRR 0.3; CI 0.1-0.5), 1 (RRR 0.2; CI 0.1-0.4) and 8 (RRR 0.2; CI 0.1-0.4) were significantly less common in HIV-infected individuals than serotype 14. Conclusions: All vaccine formulations have the potential to prevent most cases and deaths from IPD in children in South Africa. Vaccines with protection against 19A would be advantageous in South Africa. (C) 2013 Elsevier Ltd. All rights reserved. C1 [von Gottberg, Anne; Cohen, Cheryl; de Gouveia, Linda; Meiring, Susan; Quan, Vanessa; Crowther-Gibson, Penny; Madhi, Shabir A.; Klugman, Keith P.] NHLS, NICD, Johannesburg, South Africa. [von Gottberg, Anne; de Gouveia, Linda; Klugman, Keith P.] Univ Witwatersrand, Sch Pathol, Fac Hlth Sci, Johannesburg, South Africa. [von Gottberg, Anne; de Gouveia, Linda; Madhi, Shabir A.; Klugman, Keith P.] MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa. [Whitelaw, Andrew] Univ Cape Town, Dept Clin & Lab Sci, ZA-7925 Cape Town, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa. [Whitney, Cynthia G.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Klugman, Keith P.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Sch Med, Atlanta, GA USA. [Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. RP von Gottberg, A (reprint author), Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa. EM annev@nicd.ac.za OI de Gouveia, Linda/0000-0002-1418-8468 FU NICD/NHLS; United States Agency for International Development's Antimicrobial Resistance Initiative; Centers for Disease Control and Prevention (CDC), Atlanta, Georgia [U60/CCU022088]; CDC [U62/CCU022901] FX This study received funding from the NICD/NHLS and was supported in part by funds from the United States Agency for International Development's Antimicrobial Resistance Initiative, transferred via a cooperative agreement (number U60/CCU022088) from the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; and cooperative agreement U62/CCU022901 from the CDC. (The contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC.) NR 39 TC 19 Z9 19 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 28 PY 2013 VL 31 IS 38 BP 4200 EP 4208 DI 10.1016/j.vaccine.2013.04.077 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 207IF UT WOS:000323591400023 PM 23684826 ER PT J AU Kariuki, SK Njunge, J Muia, A Muluvi, G Gatei, W ter Kuile, F Terlouw, DJ Hawley, WA Phillips-Howard, PA Nahlen, BL Lindblade, KA Hamel, MJ Slutsker, L Shi, YP AF Kariuki, Simon K. Njunge, James Muia, Ann Muluvi, Geofrey Gatei, Wangeci ter Kuile, Feiko Terlouw, Dianne J. Hawley, William A. Phillips-Howard, Penelope A. Nahlen, Bernard L. Lindblade, Kim A. Hamel, Mary J. Slutsker, Laurence Shi, Ya Ping TI Effect of malaria transmission reduction by insecticide-treated bed nets (ITNs) on the genetic diversity of Plasmodium falciparum merozoite surface protein (MSP-1) and circumsporozoite (CSP) in western Kenya SO MALARIA JOURNAL LA English DT Article DE Malaria; Parasite diversity; MSP-1; CSP; Transmission; Bed nets ID RANDOMIZED CONTROLLED-TRIAL; VACCINE-CANDIDATE ANTIGENS; PAPUA-NEW-GUINEA; T-CELL EPITOPES; YOUNG-CHILDREN; MICROSATELLITE MARKERS; POPULATION STRUCTURES; SEQUENCE DIVERSITY; ALLELIC DIVERSITY; PHASE-3 TRIAL AB Background: Although several studies have investigated the impact of reduced malaria transmission due to insecticide-treated bed nets (ITNs) on the patterns of morbidity and mortality, there is limited information on their effect on parasite diversity. Methods: Sequencing was used to investigate the effect of ITNs on polymorphisms in two genes encoding leading Plasmodium falciparum vaccine candidate antigens, the 19 kilodalton blood stage merozoite surface protein-1 (MSP-1(19kDa)) and the Th2R and Th3R T-cell epitopes of the pre-erythrocytic stage circumsporozoite protein (CSP) in a large community-based ITN trial site in western Kenya. The number and frequency of haplotypes as well as nucleotide and haplotype diversity were compared among parasites obtained from children <5 years old prior to the introduction of ITNs (1996) and after 5 years of high coverage ITN use (2001). Results: A total of 12 MSP-1(19kDa) haplotypes were detected in 1996 and 2001. The Q-KSNG-L and E-KSNG-L haplotypes corresponding to the FVO and FUP strains of P. falciparum were the most prevalent (range 32-37%), with an overall haplotype diversity of > 0.7. No MSP-1(19kDa) 3D7 sequence-types were detected in 1996 and the frequency was less than 4% in 2001. The CSP Th2R and Th3R domains were highly polymorphic with a total of 26 and 14 haplotypes, respectively detected in 1996 and 34 and 13 haplotypes in 2001, with an overall haplotype diversity of > 0.9 and 0.75 respectively. The frequency of the most predominant Th2R and Th3R haplotypes was 14 and 36%, respectively. The frequency of Th2R and Th3R haplotypes corresponding to the 3D7 parasite strain was less than 4% at both time points. There was no significant difference in nucleotide and haplotype diversity in parasite isolates collected at both time points. Conclusion: High diversity in these two genes has been maintained overtime despite marked reductions in malaria transmission due to ITNs use. The frequency of 3D7 sequence-types was very low in this area. These findings provide information that could be useful in the design of future malaria vaccines for deployment in endemic areas with high ITN coverage and in interpretation of efficacy data for malaria vaccines based on 3D7 parasite strains. C1 [Kariuki, Simon K.] Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya. [Njunge, James; Muia, Ann; Muluvi, Geofrey] Kenyatta Univ, Dept Biochem & Biotechnol, Nairobi, Kenya. [Gatei, Wangeci] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Gatei, Wangeci; Hawley, William A.; Lindblade, Kim A.; Hamel, Mary J.; Slutsker, Laurence; Shi, Ya Ping] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. [ter Kuile, Feiko; Terlouw, Dianne J.; Phillips-Howard, Penelope A.] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L3 5QA, Merseyside, England. [Nahlen, Bernard L.] Presidents Malaria Initiat, Washington, DC USA. RP Kariuki, SK (reprint author), Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya. EM SKariuki@kemricdc.org OI Phillips-Howard, Penelope A/0000-0003-1018-116X; ter Kuile, Feiko/0000-0003-3663-5617 FU Multilateral Initiative on Malaria (MIM) Project through the UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) [A40046]; Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention (CDC) FX We thank all the people of Rarieda Division, the field workers and study supervisors. This investigation received financial support under the Multilateral Initiative on Malaria (MIM) Project A40046 through the UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR) and Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention (CDC). This paper is published with the permission of the Director KEMRI. NR 56 TC 3 Z9 3 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD AUG 27 PY 2013 VL 12 AR 295 DI 10.1186/1475-2875-12-295 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 209MA UT WOS:000323760500001 PM 23978002 ER PT J AU Akelo, V Girde, S Borkowf, CB Angira, F Achola, K Lando, R Mills, LA Thomas, TK Lecher, SL AF Akelo, Victor Girde, Sonali Borkowf, Craig B. Angira, Frank Achola, Kevin Lando, Richard Mills, Lisa A. Thomas, Timothy K. Lecher, Shirley Lee TI Attitudes toward Family Planning among HIV-Positive Pregnant Women Enrolled in a Prevention of Mother-To-Child Transmission Study in Kisumu, Kenya SO PLOS ONE LA English DT Article ID SUB-SAHARAN AFRICA; CONTRACEPTIVE USE; RURAL UGANDA; UNINTENDED PREGNANCIES; PROSPECTIVE COHORT; SOUTH-AFRICA; CONDOM USE; PREVALENCE; POSTPARTUM; INFECTION AB Background: Preventing unintended pregnancies among HIV-positive women through family planning (FP) reduces pregnancy-related morbidity and mortality, decreases the number of pediatric HIV infections, and has also proven to be a cost-effective way to prevent mother-to-child HIV transmission. A key element of a comprehensive HIV prevention agenda, aimed at avoiding unintended pregnancies, is recognizing the attitudes towards FP among HIV-positive women and their spouse or partner. In this study, we analyze FP attitudes among HIV-infected pregnant women enrolled in a PMTCT clinical trial in Western Kenya. Methods and Findings: Baseline data were collected on 522 HIV-positive pregnant women using structured questionnaires. Associations between demographic variables and the future intention to use FP were examined using Fisher's exact tests and permutation tests. Most participants (87%) indicated that they intended to use FP. However, only 8% indicated condoms as a preferred FP method, and 59% of current pregnancies were unintended. Factors associated with positive intentions to use FP were: marital status (p = 0.04), having talked to their spouse or partner about FP (p < 0.001), perceived spouse or partner approval of FP (p, 0.001), previous use of a FP method (p = 0.006), attitude toward the current pregnancy (p = 0.02), disclosure of a sexually transmitted infection (STI) diagnosis (p = 0.03) and ethnic group (p = 0.03). Conclusion: A significant gap exists between future FP intentions and current FP practices. Support and approval by the spouse or partner are key elements of FP intentions. Counseling services should be offered to both members of a couple to increase FP use, especially given the high number of unplanned pregnancies among HIV-positive women. Condoms should be promoted as part of a dual use method for HIV and STI prevention and for contraception. Integration of individual and couple FP services into routine HIV care, treatment and support services is needed in order to avoid unintended pregnancies and to prevent mother-to-child HIV transmission. C1 [Akelo, Victor; Angira, Frank; Achola, Kevin; Lando, Richard] Kenya Govt Med Res Ctr, Kisumu, Kenya. [Akelo, Victor; Girde, Sonali; Borkowf, Craig B.; Lecher, Shirley Lee] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Girde, Sonali] ICF Int, Atlanta, GA USA. [Mills, Lisa A.; Thomas, Timothy K.] US Ctr Dis Control & Prevent, HIV Res Branch, Atlanta, GA USA. RP Lecher, SL (reprint author), US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM gux5@cdc.gov FU Kenya Medical Research Institute (KEMRI) through the US Centers for Disease Control and Prevention (CDC) FX Funding for the study was provided by the Kenya Medical Research Institute (KEMRI) through a cooperative agreement with the US Centers for Disease Control and Prevention (CDC). The study design, data collection instruments, data collection, data analysis, decision to publish, and preparation of the manuscript were led by CDC and KEMRI staff based in Atlanta and at the KEMRI/CDC Field Station in Kisumu, Kenya. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC. NR 49 TC 9 Z9 9 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 26 PY 2013 VL 8 IS 8 AR e66593 DI 10.1371/journal.pone.0066593 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 215RU UT WOS:000324228800002 PM 23990868 ER PT J AU Althabe, F Aleman, A Mazzoni, A Berrueta, M Morello, P Colomar, M Ciganda, A Becu, A Gibbons, L Llambi, L Gonzalez, MGB Tong, VT Farr, SL Smith, RA Dietz, PM Johnson, C Buekens, P Belizan, JM AF Althabe, Fernando Aleman, Alicia Mazzoni, Agustina Berrueta, Mabel Morello, Paola Colomar, Mercedes Ciganda, Alvaro Becu, Ana Gibbons, Luz Llambi, Laura Bittar Gonzalez, Maria G. Tong, Van T. Farr, Sherry L. Smith, Ruben A. Dietz, Patricia M. Johnson, Carolyn Buekens, Pierre Belizan, Jose M. TI Tobacco cessation intervention for pregnant women in Argentina and Uruguay: study protocol SO REPRODUCTIVE HEALTH LA English DT Article DE Pregnancy; Smoking cessation; Guidelines ID RANDOMIZED CONTROLLED-TRIAL; SMOKING-CESSATION; ANTENATAL CARE; DISSEMINATION; PROGRAM; STRATEGIES; COUNTRIES; CLINICS AB Background: Argentina and Uruguay are among the countries with the highest proportion of pregnant women who smoke. The implementation of an effective smoking cessation intervention would have a significant impact on the health of mothers and infants. The "5 A's" (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider. The "5 A's" is considered the standard of care worldwide; however, it is under used in Argentina and Uruguay. Methods: We will conduct a two-arm, parallel cluster randomized controlled trial of an implementation intervention in 20 prenatal care settings in Argentina and Uruguay. Prenatal care settings will be randomly allocated to either an intervention or a control group after a baseline data collection period. Midwives' facilitators in the 10 intervention prenatal clinics (clusters) will be identified and trained to deliver the "5 A's" to pregnant women and will then disseminate and implement the program. The 10 clusters in the control group will continue with their standard in-service activities. The intervention will be tailored by formative research to be readily applicable to local prenatal care services at maternity hospitals and acceptable to local pregnant women and health providers. Our primary hypothesis is that the intervention is feasible in prenatal clinics in Argentina and Uruguay and will increase the frequency of women receiving tobacco use cessation counseling during pregnancy in the intervention clinics compared to the control clinics. Our secondary hypotheses are that the intervention will decrease the frequency of women who smoke by the end of pregnancy, and that the intervention will increase the attitudes and readiness of midwives towards providing counseling to women in the intervention clinics compared to the control clinics. C1 [Althabe, Fernando; Mazzoni, Agustina; Berrueta, Mabel; Morello, Paola; Becu, Ana; Gibbons, Luz; Belizan, Jose M.] Inst Clin Effectiveness & Hlth Policy IECS, Buenos Aires, DF, Argentina. [Aleman, Alicia; Colomar, Mercedes; Ciganda, Alvaro] Montevideo Clin & Epidemiol Res Unit UNICEM, Montevideo, Uruguay. [Llambi, Laura] Univ Republica, Fac Med, Hosp Clin, Clin Med A, Montevideo, Uruguay. [Llambi, Laura] Univ Republica, Fac Med, Hosp Clin, Tobacco Cessat Clin, Montevideo, Uruguay. [Bittar Gonzalez, Maria G.] Univ Republica, Fac Med, Dept Prevent Med, Montevideo, Uruguay. [Tong, Van T.; Farr, Sherry L.; Smith, Ruben A.; Dietz, Patricia M.] Ctr Dis Control & Prevent, CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Johnson, Carolyn; Buekens, Pierre] Tulane Sch Publ Hlth & Trop Med, Sch Publ Hlth, New Orleans, LA 70112 USA. RP Mazzoni, A (reprint author), Inst Clin Effectiveness & Hlth Policy IECS, Dr Emilio Ravignani 2024,C1414CPV, Buenos Aires, DF, Argentina. EM amazzoni@iecs.org.ar OI Tong, Van/0000-0002-3970-1440; Belizan, Jose/0000-0002-8412-3010 FU CDC [5U48DP001948-04 (SIP09-18)] FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of CDC. The study was supported through CDC cooperative agreement 5U48DP001948-04 (SIP09-18) to Tulane University. NR 43 TC 7 Z9 8 U1 2 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4755 J9 REPROD HEALTH JI Reprod. Health PD AUG 26 PY 2013 VL 10 AR 44 DI 10.1186/1742-4755-10-44 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 208LT UT WOS:000323681200001 PM 23971512 ER PT J AU Murnane, PM Celum, C Mugo, N Campbell, JD Donnell, D Bukusi, E Mujugira, A Tappero, J Kahle, EM Thomas, KK Baeten, JM AF Murnane, Pamela M. Celum, Connie Mugo, Nelly Campbell, James D. Donnell, Deborah Bukusi, Elizabeth Mujugira, Andrew Tappero, Jordan Kahle, Erin M. Thomas, Katherine K. Baeten, Jared M. CA Partners PrEP Study Team TI Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial SO AIDS LA English DT Article DE Africa; antiretroviral agents; HIV-1 acquisition; primary prevention; women ID TRANSMISSION; WOMEN AB Background:Daily oral antiretroviral preexposure prophylaxis (PrEP) is a promising strategy for prevention of HIV-1 acquisition. Three clinical trials demonstrated PrEP efficacy; however, two PrEP trials among women did not find protection against HIV-1. One hypothesis proposed for these divergent results is that PrEP efficacy may be reduced in populations with higher HIV-1 incidence.Methods:Using data from the Partners PrEP Study, a randomized, placebo-controlled trial of daily oral tenofovir (TDF) and emtricitabine/tenofovir (FTC/TDF) PrEP among heterosexual HIV-1 serodiscordant couples from Kenya and Uganda, we assessed PrEP efficacy among subgroups at higher risk for HIV-1 acquisition, including subgroups of women with high HIV-1 incidence.Results:The overall placebo arm HIV-1 incidence was 2.0 per 100 person-years. Among higher risk subgroups, placebo arm HIV-1 incidence ranged from 3.9 to 6.6 per 100 person-years. In all subgroups, PrEP was protective against HIV-1 acquisition, with efficacy point estimates ranging from 64 to 84%. Among subgroups of women with placebo-arm HIV-1 incidence more than 5.0, efficacy estimates ranged from 64 to 84%. Monthly visit attendance for PrEP refills and tenofovir detection in plasma were high.Conclusion:Among higher-risk subgroups in the Partners PrEP Study, including groups solely of higher-risk women, both TDF alone and combined FTC/TDF PrEP had consistently high efficacy for HIV-1 protection. PrEP, when used with high adherence, is a highly effective prevention strategy for higher risk heterosexuals. Prioritizing PrEP for persons at high risk of HIV-1 will maximize its prevention impact. C1 [Murnane, Pamela M.; Celum, Connie; Kahle, Erin M.; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA. [Murnane, Pamela M.; Celum, Connie; Mugo, Nelly; Donnell, Deborah; Bukusi, Elizabeth; Mujugira, Andrew; Kahle, Erin M.; Thomas, Katherine K.; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Seattle, WA 98104 USA. [Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Mugo, Nelly; Bukusi, Elizabeth] Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya. [Mugo, Nelly; Bukusi, Elizabeth] Kenyatta Natl Hosp, Dept Obstet & Gynaecol, Nairobi, Kenya. [Campbell, James D.] CDC Uganda, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Entebbe, Uganda. [Campbell, James D.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Div Infect Dis & Trop Pediat,Dept Pediat, Baltimore, MD 21201 USA. [Donnell, Deborah] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA. [Tappero, Jordan] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Baeten, JM (reprint author), Univ Washington, 325 9th Ave,UW Box 359927, Seattle, WA 98104 USA. EM jbaeten@uw.edu RI Hendrix, Craig/G-4182-2014; OI Hendrix, Craig/0000-0002-5696-8665; Donnell, Deborah/0000-0002-0587-7480 FU United States National Institutes of Health [R01MH095507]; Bill and Melinda Gates Foundation [OPP47674] FX the United States National Institutes of Health (grant R01MH095507) and the Bill and Melinda Gates Foundation (grant OPP47674) NR 13 TC 23 Z9 24 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD AUG 24 PY 2013 VL 27 IS 13 BP 2155 EP 2160 DI 10.1097/QAD.0b013e3283629037 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 248MG UT WOS:000326703500015 PM 24384592 ER PT J AU Mooney, A Kidanu, A Bradley, HM Kumoji, EK Kennedy, CE Kerrigan, D AF Mooney, Alyssa Kidanu, Aklilu Bradley, Heather M. Kumoji, Evelyn Kuor Kennedy, Caitlin E. Kerrigan, Deanna TI Work-related violence and inconsistent condom use with non-paying partners among female sex workers in Adama City, Ethiopia SO BMC PUBLIC HEALTH LA English DT Article DE Sex workers; HIV/AIDS; Ethiopia; Condom use; Violence; Alcohol abuse ID SEXUALLY-TRANSMITTED INFECTIONS; COMMERCIAL SEX; SOUTH-AFRICA; HIV-RISK; REGULAR PARTNERS; PROBLEM DRINKING; SUBSTANCE-ABUSE; ALCOHOL-USE; UNSAFE SEX; CLIENTS AB Background: Although reported condom use between female sex workers and their clients is high in Ethiopia, condom use with regular, non-paying partners remains low, posing a substantial risk of HIV infection to sex workers, their partners and the general population. Previous studies have identified the synergistic effects of substance abuse, violence and HIV risk, but few have examined these inter-relationships among female sex workers and their regular, non-paying partners. This study explored the associations between work-related violence, alcohol abuse and inconsistent condom use among establishment-based female sex workers and their regular, non-paying partners in Adama City, Ethiopia. Methods: A cross-sectional survey was conducted with 350 establishment-based female sex workers, aged 15-35, at 63 bars, hotels and nightclubs. Multivariate logistic regression analysis was conducted to test the association between work-related violence and condom use with regular, non-paying partners, controlling for age, overall income, education and sex workers' total number of sexual partners in the past week. Alcohol abuse was explored as an effect modifier. Results: Respondents reported a high prevalence of work-related violence (59%) and alcohol abuse (51%). Work-related violence was statistically significantly associated with unprotected sex with regular, non-paying partners among those who abused alcohol (OR: 6.34, 95% CI: 2.43-16.56) and among those who did not (OR: 2.98, 95% CI: 1.36-6.54). Alcohol abuse was not associated with inconsistent condom use within these partnerships, though it may strengthen the effect of work-related violence on unprotected sex. Conclusions: Findings suggest violence against establishment-based female sex workers is associated with HIV risk within regular, non-paying partnerships. Qualitative work is needed to better understand the links between a violent work environment and condom use with regular, non-paying partners and how interventions can be implemented in this context to prevent violence against sex workers and reduce HIV transmission. C1 [Mooney, Alyssa; Kennedy, Caitlin E.; Kerrigan, Deanna] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Kidanu, Aklilu] Miz Hasab Res Ctr, Addis Ababa, Ethiopia. [Bradley, Heather M.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Kumoji, Evelyn Kuor] Johns Hopkins Univ, Ctr Commun Programs, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Kennedy, CE (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 North Wolfe St, Baltimore, MD USA. EM ckennedy@jhsph.edu FU USAID\Project SEARCH [2]; US Agency for International Development [GHH-I-00-07-00032-00]; President's Emergency Plan for AIDS Relief FX The authors would like to thank the study participants, Miz-Hasab Research Center, the Research to Prevention management team, Health Communication Partnership and Elilta. This work was supported by USAID vertical bar Project SEARCH, Task Order No. 2, funded by the US Agency for International Development under Contract No. GHH-I-00-07-00032-00, beginning 30 September 2008, and supported by the President's Emergency Plan for AIDS Relief. NR 57 TC 11 Z9 11 U1 6 U2 14 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD AUG 23 PY 2013 VL 13 AR 771 DI 10.1186/1471-2458-13-771 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 210LV UT WOS:000323835900001 PM 23968148 ER PT J AU Pratt, SG Rodriguez-Acosta, RL AF Pratt, Stephanie G. Rodriguez-Acosta, Rosa L. TI Occupational Highway Transportation Deaths Among Workers Aged >= 55 Years - United States, 2003-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Pratt, Stephanie G.; Rodriguez-Acosta, Rosa L.] CDC, Div Safety Res, NIOSH, Atlanta, GA 30333 USA. RP Pratt, SG (reprint author), CDC, Div Safety Res, NIOSH, Atlanta, GA 30333 USA. EM spratt@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 23 PY 2013 VL 62 IS 33 BP 653 EP 657 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 204SH UT WOS:000323388700001 ER PT J AU Baig, S Fox, KK Jee, Y O'Connor, P Hombach, J Wang, SA Hyde, T Fischer, M Hills, SL AF Baig, Samir Fox, Kimberley K. Jee, Youngmee O'Connor, Patrick Hombach, Joachim Wang, Susan A. Hyde, Terri Fischer, Marc Hills, Susan L. TI Japanese Encephalitis Surveillance and Immunization - Asia and the Western Pacific, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Baig, Samir; Fox, Kimberley K.; Jee, Youngmee] CDC, Reg Off Western Pacific, Atlanta, GA 30333 USA. [O'Connor, Patrick] CDC, Reg Off South East Asia, Atlanta, GA 30333 USA. [Wang, Susan A.] CDC, WHO, Atlanta, GA 30333 USA. [Hyde, Terri] CDC, Ctr Global Hlth, Global Immunizat Div, Atlanta, GA 30333 USA. [Hills, Susan L.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Atlanta, GA 30333 USA. RP Hills, SL (reprint author), CDC, Reg Off Western Pacific, Atlanta, GA 30333 USA. EM shills@cdc.gov NR 10 TC 22 Z9 23 U1 1 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 23 PY 2013 VL 62 IS 33 BP 658 EP 662 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 204SH UT WOS:000323388700002 ER PT J AU Gidado, SO Nguku, PM Ohuabunwo, CJ Waziri, NE Etsano, A Mahmud, MZ Shuaib, FM Korir, CK Mkanda, P Bloland, PB Esapa, LE Kaplan, BC Mahoney, FJ Mast, EE Mba-Jonas, ACN Ogbuanu, IU Ruiz, AG Wassilak, SG Wiesen, ES AF Gidado, Saheed O. Nguku, Patrick M. Ohuabunwo, Chima J. Waziri, Ndadilnasiya E. Etsano, Andrew Mahmud, Mustapha Z. Shuaib, Faisal M. Korir, Charles K. Mkanda, Pascal Bloland, Peter B. Esapa, Lisa E. Kaplan, Brian C. Mahoney, Frank J. Mast, Eric E. Mba-Jonas, Adamma C. N. Ogbuanu, Ikechukwu U. Ruiz, Alicia G. Wassilak, Steve G. Wiesen, Eric S. TI Polio Field Census and Vaccination of Underserved Populations - Northern Nigeria, 2012-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POLIOMYELITIS ERADICATION; PROGRESS C1 [Bloland, Peter B.; Esapa, Lisa E.; Kaplan, Brian C.; Mahoney, Frank J.; Mast, Eric E.; Mba-Jonas, Adamma C. N.; Ogbuanu, Ikechukwu U.; Ruiz, Alicia G.; Wassilak, Steve G.; Wiesen, Eric S.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Mba-Jonas, ACN (reprint author), CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. EM Adamma.mba-jonas@fda.hhs.gov; iogbuanu@cdc.gov NR 6 TC 4 Z9 4 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 23 PY 2013 VL 62 IS 33 BP 663 EP 665 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 204SH UT WOS:000323388700003 ER PT J AU Cope, JR AF Cope, Jennifer R. TI Investigational Drug Available Directly from CDC for the Treatment of Infections with Free-Living Amebae SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Cope, JR (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM jcope@cdc.gov NR 2 TC 15 Z9 15 U1 0 U2 1 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 23 PY 2013 VL 62 IS 33 BP 666 EP 666 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 204SH UT WOS:000323388700004 ER PT J AU Cavicchia, PP Watkins, S Blackmore, C Matthias, J AF Cavicchia, Philip P. Watkins, Sharon Blackmore, Carina Matthias, James TI Eye Injuries Sustained at a Foam Party - Collier County, Florida 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Matthias, James] CDC, Atlanta, GA 30333 USA. EM philip_cavicchia@doh.state.fl.us NR 0 TC 0 Z9 0 U1 0 U2 0 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 23 PY 2013 VL 62 IS 33 BP 667 EP 668 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 204SH UT WOS:000323388700005 ER PT J AU Schleicher, RL McCoy, LF Powers, CD Sternberg, MR Pfeiffer, CM AF Schleicher, Rosemary L. McCoy, Leslie F. Powers, Carissa D. Sternberg, Maya R. Pfeiffer, Christine M. TI Serum concentrations of an aflatoxin-albumin adduct in the National Health and Nutrition Examination Survey (NHANES) 1999-2000 SO CLINICA CHIMICA ACTA LA English DT Article DE Aflatoxins; Biomarker; Mold; Population health; Human ID DILUTION MASS-SPECTROMETRY; DIETARY AFLATOXIN; GAMBIAN CHILDREN; FLUORESCENCE; PERFORMANCE; EXPOSURE AB Background: During 1998, weather conditions in the United States favored the growth of Aspergillus species leading to widespread contamination of Midwestern and Southern corn with hepatotoxic and hepatocarcinogenic aflatoxins. We designed a study to provide the first national prevalence estimate of aflatoxin exposure using the National Health and Nutrition Examination Survey (NHANES), a representative cross-sectional survey of the noninstitutionalized civilian population of the US. Methods: Isotope dilution liquid chromatography-tandem mass spectrometry was used to quantitate serum concentrations of aflatoxin B1-lysine in a one-third random subset of participants from NHANES 1999-2000. Results: About 1% of the US. population had detectable levels (>= 0.02 mu g/l) of aflatoxin B1-lysine. Of those with detectable levels, the geometric mean (95% confidence interval) was 0.038 (0.024-0.060) mu g/l (equivalent to 0.842 (0.530-134) pg/mg albumin). The highest value was 0.2 mu g/l (4.43 pg/mg albumin). Based on liver function bio-markers, there was no evidence of increased liver dysfunction in these persons. Conclusions: During a time when exposure to aflatoxins in food products might have been expected to be increased, we identified few exposed persons. Although none of the subgroup analyses provided reliable estimates due to high relative standard errors, they suggested that additional targeted surveillance may be warranted. Published by Elsevier B.V. C1 [Schleicher, Rosemary L.; Powers, Carissa D.; Sternberg, Maya R.; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Nutr Biomarkers Branch, Atlanta, GA 30341 USA. [McCoy, Leslie F.] Battelle Natl Labs, Columbus, OH USA. RP Schleicher, RL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Nutr Biomarkers Branch, Mailstop F55,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM Zwa5@cdc.gov NR 22 TC 5 Z9 5 U1 1 U2 21 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD AUG 23 PY 2013 VL 423 BP 46 EP 50 DI 10.1016/j.cca.2013.04.011 PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 172BY UT WOS:000320976100010 PM 23611894 ER PT J AU Wade, TJ Sams, EA Beach, MJ Collier, SA Dufour, AP AF Wade, Timothy J. Sams, Elizabeth A. Beach, Michael J. Collier, Sarah A. Dufour, Alfred P. TI The incidence and health burden of earaches attributable to recreational swimming in natural waters: a prospective cohort study SO ENVIRONMENTAL HEALTH LA English DT Article ID ACUTE OTITIS-EXTERNA; RAPIDLY MEASURED INDICATORS; PSEUDOMONAS-AERUGINOSA; CAUSAL INFERENCE; SWIMMERS EAR; QUALITY; ILLNESS AB Background: Earaches and outer ear infections are commonly associated with swimming. In this study, we estimated the excess risk and health burden of earaches due to swimming in natural fresh and marine waters using results from a survey of over 50,000 beachgoers at nine beaches across the United States. Methods: Prospective cohort studies were conducted at four freshwater and five marine sites in the United States and Puerto Rico. Beach visitors were enrolled on summer weekends and holidays. Ten to twelve days after the beach visit, respondents answered questions about health symptoms, including earaches or ear infections experienced since the beach visit. Economic and physical burdens were also obtained. Fixed slope, random intercept (beach site) multivariate logistic regression models were used to estimate the relationship between head immersion swimming exposure and earaches. Model results were used to calculate excess risk for earaches attributable to swimming. Results: The overall incidence of self-reported earache was 1.6% in the 10-12 days after the beach visit. Earaches were more frequent in head immersion swimmers compared to non-swimmers for all beach sites and age groups. Earaches were unassociated with water sample measures of fecal contamination and turbidity. After adjustment for covariates, we calculated 7.12 excess earaches among head immersion swimmers per 1,000 swimming events. Twenty-four percent of those with earache reported missing their regular activities; 28% visited a doctor; 4% visited the emergency room; and 31% and 40% used prescription and non-prescription medications, respectively. Conclusions: There are at least 128 million swimming events in natural waters annually. Such frequent exposures could result in 900,000 excess earaches, 260,000 visits to the doctor, 39,900 visits to the emergency room, nearly $4 million dollars in out-of-pocket expenditures on prescription and over-the-counter medications, and close to 75,000 hours of clinician time. More accurate estimates of swimming exposure are needed to improve population burden and associated cost estimates. C1 [Wade, Timothy J.; Sams, Elizabeth A.] US EPA, Off Res & Dev, Chapel Hill, NC USA. [Beach, Michael J.; Collier, Sarah A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dufour, Alfred P.] US EPA, Off Res & Dev, Cincinnati, OH 45268 USA. RP Wade, TJ (reprint author), US EPA, Off Res & Dev, Chapel Hill, NC USA. EM wade.tim@epa.gov NR 30 TC 4 Z9 4 U1 2 U2 12 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD AUG 21 PY 2013 VL 12 AR 67 DI 10.1186/1476-069X-12-67 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 208LP UT WOS:000323680800001 PM 23962340 ER PT J AU Kuklina, EV Hagen, EM AF Kuklina, Elena V. Hagen, Ellen Merete TI Link between cardiovascular disease and spinal cord injury New evidence and update SO NEUROLOGY LA English DT Editorial Material ID LEVEL C1 [Kuklina, Elena V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Hagen, Ellen Merete] Reg Hosp Viborg, Spinal Cord Injury Ctr Western Denmark, Dept Neurol, Viborg, Denmark. RP Kuklina, EV (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ekuklina@cdc.gov OI Hagen, Ellen Merete/0000-0002-6925-6747 FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD AUG 20 PY 2013 VL 81 IS 8 BP 700 EP 701 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 304JV UT WOS:000330743800005 PM 23884044 ER PT J AU Girard, MP Tam, JS Pervikov, Y Katz, JM AF Girard, Marc P. Tam, John S. Pervikov, Yuri Katz, Jacqueline M. TI Report on the first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses Hong Kong SAR, China, 24-26 January 2013 SO VACCINE LA English DT Article DE Universal influenza vaccines; Seasonal influenza vaccines; Pandemic influenza vaccines; Neutralizing antibodies; Live attenuated influenza vaccines; Inactivated influenza vaccines; Adjuvants ID VIRUS-LIKE PARTICLES; PHASE-I TRIAL; SEASONAL INFLUENZA; HEALTHY-ADULTS; CELL-CULTURE; DOUBLE-BLIND; CONSERVED EPITOPE; H5 HEMAGGLUTININ; YOUNG-CHILDREN; A VIRUSES AB On January 24-26, 2013, the World Health Organization convened the first integrated meeting on "The development and clinical trials of vaccines that induce broadly protective and long-lasting immune responses" to review the current status of development and clinical evaluation of novel influenza vaccines as well as strategies to produce and deliver vaccines in novel ways. Special attention was given to the development of possible universal influenza vaccines. Other topics that were addressed included an update on clinical trials of pandemic and seasonal influenza vaccines in high-risk groups and vaccine safety, as well as regulatory issues. C1 [Girard, Marc P.] Unvers Paris Diderot, French Natl Acad Med, F-75006 Paris, France. [Tam, John S.; Pervikov, Yuri] World Hlth Org, Initiat Vaccine Res Immunizat Vaccines & Biol, Geneva, Switzerland. [Katz, Jacqueline M.] Ctr Dis Control & Prevent CDC, Immunol & Pathogenesis Branch, Influenza Div, Atlanta, GA USA. RP Girard, MP (reprint author), Unvers Paris Diderot, French Natl Acad Med, 16 Rue Bonaparte, F-75006 Paris, France. EM marc.girard36@wanadoo.fr; TamS@who.int; pervikovy@sunrise.ch; Jkatz@cdc.gov FU Welcome Trust, London, United Kingdom; United States of America Centers for Disease Control and Prevention, Atlanta, GA [5U50C1000748, 49]; Institute of Creativity; Carter Center, Hong Kong Baptist University, China FX The assistance of Fred Hayden and Dominic Lam on the scientific and administrative organization was invaluable to the meeting. The financial support from the Institute of Creativity and the Carter Center, Hong Kong Baptist University, China, the Welcome Trust, London, United Kingdom, and the United States of America Centers for Disease Control and Prevention, Atlanta, GA (Grant 5U50C1000748 Project 49) are gratefully acknowledged. NR 70 TC 10 Z9 10 U1 1 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 20 PY 2013 VL 31 IS 37 BP 3766 EP 3771 DI 10.1016/j.vaccine.2013.06.047 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 218PI UT WOS:000324444200002 PM 23810374 ER PT J AU Wang, Z Yang, HL Li, KL Zhang, AH Feng, ZJ Seward, JF Bialek, SR Wang, CB AF Wang, Zhe Yang, Huili Li, Keli Zhang, Aihua Feng, Zijian Seward, Jane F. Bialek, Stephanie R. Wang, Chengbin TI Single-dose varicella vaccine effectiveness in school settings in China SO VACCINE LA English DT Article DE Chickenpox; Vaccine effectiveness; Vaccination coverage ID HEALTHY-CHILDREN; IMMUNIZATION; OUTBREAK; RECOMMENDATIONS; EPIDEMIOLOGY; PREVENTION AB Background: Varicella vaccine has been available in the private sector in China for a decade as a single-dose regimen, but varicella vaccine effectiveness (VE) has not been fully examined in school settings yet. Methods: A matched case-control study was carried out in elementary schools and daycares in Tai'an prefecture, Shandong province, China. Clinical diagnosis of varicella and breakthrough disease was used for this study. Four controls were randomly selected from classmates; two from classmates of the case and two from another class of the same grade without cases. Vaccination status, date of vaccination, and vaccine product received if vaccinated were collected from home and clinic immunization records. Vaccination status of all students in schools/daycares with varicella cases from home immunization records or parental recall was used to calculate vaccination coverage. Results: The overall varicella VE was 83.4% (95% confidence interval 71.4-90.3%). Receipt of varicella vaccine five years or more years before the outbreak was significantly associated with breakthrough varicella (odds ratio = 4.7, P<0.001), while age at vaccination (<15 vs. >= 15 months) was not (odds ratio = 1.5, P=0.62). Varicella vaccination coverage was 41% with substantial variation across schools (range of 0-93.8%). Conclusions: Single-dose varicella vaccine is highly effective in school settings. Maintaining limited vaccination coverage might shift varicella disease burden to older individuals, who are more prone to develop severe outcomes if varicella occurs. Published by Elsevier Ltd. C1 [Wang, Zhe; Li, Keli; Feng, Zijian] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China. [Yang, Huili; Zhang, Aihua] Taian Ctr Dis Control & Prevent, Tai An, Shandong, Peoples R China. [Seward, Jane F.; Bialek, Stephanie R.; Wang, Chengbin] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Wang, CB (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA. EM fengzj@chinacdc.cn; cwang1@cdc.gov FU Intramural CDC HHS [CC999999] NR 31 TC 9 Z9 12 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 20 PY 2013 VL 31 IS 37 BP 3834 EP 3838 DI 10.1016/j.vaccine.2013.06.075 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 218PI UT WOS:000324444200012 PM 23845816 ER PT J AU Chesson, HW Ekwueme, DU Saraiya, M Dunne, EF Markowitz, LE AF Chesson, Harrell W. Ekwueme, Donatus U. Saraiya, Mona Dunne, Eileen F. Markowitz, Lauri E. TI Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States SO VACCINE LA English DT Article DE Papillomavirus; Vaccination; Models; Cervical neoplasms; Genital warts ID COST-EFFECTIVENESS; QUADRIVALENT VACCINE; ECONOMIC-EVALUATION; YOUNG-WOMEN; PROGRAM; IMPACT; EFFICACY; CANCER; MODEL; AUSTRALIA AB Background: The objective of this study was to estimate the number of years after onset of a quadrivalent HPV vaccination program before notable reductions in genital warts and cervical intraepithelial neoplasia (CIN) will occur in teenagers and young adults in the United States. Methods: We applied a previously published model of HPV vaccination in the United States and focused on the timing of reductions in genital warts among both sexes and reductions in CIN 2/3 among females. Using different coverage scenarios, the lowest being consistent with current 3-dose coverage in the United States, we estimated the number of years before reductions of 10%, 25%, and 50% would be observed after onset of an HPV vaccination program for ages 12-26 years. Results: The model suggested female-only HPV vaccination in the intermediate coverage scenario will result in a 10% reduction in genital warts within 2-4 years for females aged 15-19 years and a 10% reduction in CIN 2/3 among females aged 20-29 years within 7-11 years. Coverage had a major impact on when reductions would be observed. For example, in the higher coverage scenario a 25% reduction in CIN2/3 would be observed with 8 years compared with 15 years in the lower coverage scenario. Conclusions: Our model provides estimates of the potential timing and magnitude of the impact of HPV vaccination on genital warts and CIN 2/3 at the population level in the United States. Notable, population-level impacts of HPV vaccination on genital warts and CIN 2/3 can occur within a few years after onset of vaccination, particularly among younger age groups. Our results are generally consistent with early reports of declines in genital warts among youth. Published by Elsevier Ltd. C1 [Chesson, Harrell W.; Dunne, Eileen F.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Ekwueme, Donatus U.; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Chesson, HW (reprint author), Ctr Dis Control & Prevent, Mail Stop E-80,1600 Clifton Rd, Atlanta, GA 30333 USA. EM HChesson@cdc.gov NR 36 TC 7 Z9 7 U1 1 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 20 PY 2013 VL 31 IS 37 BP 3899 EP 3905 DI 10.1016/j.vaccine.2013.06.050 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 218PI UT WOS:000324444200022 PM 23820080 ER PT J AU Thompson, MG McIntyre, AF Naleway, AL Black, C Kennedy, ED Ball, S Walker, DK Henkle, EM Gaglani, MJ AF Thompson, Mark G. McIntyre, Anne F. Naleway, Allison L. Black, Carla Kennedy, Erin D. Ball, Sarah Walker, Deborah Klein Henkle, Emily M. Gaglani, Manjusha J. TI Potential influence of seasonal influenza vaccination requirement versus traditional vaccine promotion strategies on unvaccinated healthcare personnel SO VACCINE LA English DT Article DE Health care personnel; Influenza vaccination; Mandate; Intervention ID PATIENT SAFETY; WORKERS; IMMUNIZATION; ATTITUDES; RATES; PHYSICIANS; PERCEPTIONS; PREVENTION AB In a prospective cohort study of 1670 healthcare personnel (HCP) providing direct patient care at Scott & White Healthcare in Texas and Kaiser Permanente Northwest in Oregon and Washington, we examined the potential impact of twelve vaccine promotion strategies on the likelihood of being vaccinated. Internet-based surveys were conducted at enrollment (Fall, 2010) and at post-season (Spring, 2011), which asked HCP whether twelve vaccination promotion strategies would make them "much less" to "much more" likely to be vaccinated next season (on a 5-point Likert scale). Overall, 366 of 1670 HCP (22%) were unvaccinated. Half (50%) of unvaccinated HCP self-reported that a vaccination requirement would make them more likely to be vaccinated and most (62%) identified at least one strategy other than a vaccination requirement that would make them more likely to be vaccinated. In sub-groups of unvaccinated HCPs with specific barriers to vaccination, about one in three (range = 27-35%) indicated that interventions targeting specific vaccination barrier would increase the likelihood they would be vaccinated. However, in all cases, significantly more unvaccinated HCP reported that a vaccination requirement would increase the likelihood of vaccination than reported a targeted intervention would have this effect (range in difference scores = +11-23%). Published by Elsevier Ltd. C1 [Thompson, Mark G.] Ctr Dis Control & Prevent CDC, Influenza Div, Atlanta, GA USA. [McIntyre, Anne F.; Black, Carla; Kennedy, Erin D.] Ctr Dis Control & Prevent CDC, Immunizat Serv Div, Atlanta, GA USA. [Naleway, Allison L.; Henkle, Emily M.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Ball, Sarah; Walker, Deborah Klein] ABT Associates Inc, Cambridge, MA 02138 USA. [Gaglani, Manjusha J.] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Scott & White Healthcare, Temple, TX 76508 USA. RP Thompson, MG (reprint author), Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, 1600 Clifton Rd,NE,Mailstop A-32, Atlanta, GA 30333 USA. EM isq8@cdc.gov OI Naleway, Allison/0000-0001-5747-4643 FU Centers for Disease Control and Prevention [200-2010-F-33396] FX Funding for this study was supported by the Centers for Disease Control and Prevention (contract 200-2010-F-33396 to Abt Associates Inc.). NR 39 TC 3 Z9 3 U1 2 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 20 PY 2013 VL 31 IS 37 BP 3915 EP 3921 DI 10.1016/j.vaccine.2013.06.045 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 218PI UT WOS:000324444200024 PM 23845807 ER PT J AU Rolnick, SJ Parker, ED Nordin, JD Hedblom, BD Wei, F Kerby, T Jackson, JM Crain, AL Euler, G AF Rolnick, S. J. Parker, E. D. Nordin, J. D. Hedblom, B. D. Wei, F. Kerby, T. Jackson, J. M. Crain, A. L. Euler, G. TI Self-report compared to electronic medical record across eight adult vaccines: Do results vary by demographic factors? SO VACCINE LA English DT Article DE Immunization; Vaccination surveillance; Self-report ID PNEUMOCOCCAL VACCINATION STATUS; INFLUENZA VACCINATION; ELDERLY OUTPATIENTS; HEALTH-SERVICES; UNITED-STATES; VALIDATION; ACCURACY; VALIDITY; COVERAGE; PROGRAM AB Immunizations are crucial to the prevention of disease, thus, having an accurate measure of vaccination status for a population is an important guide in targeting prevention efforts. In order to comprehensively assess the validity of self-reported adult vaccination status for the eight most common adult vaccines we conducted a survey of vaccination receipt and compared it to the electronic medical record (EMR), which was used as the criterion standard, in a population of community-dwelling patients in a large healthcare system. In addition, we assessed whether validity varied by demographic factors. The vaccines included: pneumococcal (PPSV), influenza (Flu), tetanus diphtheria (Td), tetanus diphtheria pertussis (Tdap), Human Papilloma Virus (HPV), hepatitis A (HepA), hepatitis B (HepB) and herpes zoster (shingles). Telephone surveys were conducted with 11,760 individuals, >= 18, half with documented receipt of vaccination and half without. We measured sensitivity, specificity, positive and negative predictive value, net bias and over- and under-reporting of vaccination. Variation was found across vaccines, however, sensitivity and specificity did not vary substantially by either age or race/ethnicity. Sensitivity ranged between 63% for HepA to over 90% (tetanus, HPV, shingles and Flu). Hispanics were 2.7 times more likely to claim receipt of vaccination compared to whites. For PPSV and Flu those 65+ had low specificity compared to patients of younger ages while those in the youngest age group had lowest specificity for HepA and HepB. In addition to racial/ethnic differences, over-reporting was more frequent in those retired and those with household income less than $75,000. Accurate information for vaccination surveillance is important to estimate progress toward vaccination coverage goals and ensure appropriate policy decisions and allocation of resources for public health. It was clear from our findings that EMR and self-report do not always agree. Finding approaches to improve both EMR data capture and patient awareness would be beneficial. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Rolnick, S. J.; Parker, E. D.; Hedblom, B. D.; Kerby, T.; Jackson, J. M.; Crain, A. L.] HealthPartners Inst Educ & Res, Minneapolis, MN 55420 USA. [Nordin, J. D.] HealthPartners Med Grp, St Paul, MN 55107 USA. [Wei, F.] Univ Arkansas Med Sci, Fay W Boozman Coll Publ, Dept Biostat, Little Rock, AR 72205 USA. [Euler, G.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Rolnick, SJ (reprint author), HealthPartners Inst Educ & Res, MS 21111R POB 1524, Minneapolis, MN 55420 USA. EM cheri.j.rolnick@healthpartners.com; emily.d.parker@healthpartners.com; jim.d.nordin@healthpartners.com; brita.d.hedblom@healthpartners.com; fwei@uams.edu; tessaj.kerby@healthpartners.com; jody.m.jackson@healthpartners.com; lauren.a.crain@healthpartners.com; cdceuler1@comcast.net FU Centers for Disease Control and Prevention (CDC) FX The authors wish to thank Colleen King, Manager, and David Butani, Research Study Coordinator, from the HealthPartners Institute for Education and Research Data Collection Center, who trained and monitored the numerous interviewers and oversaw the data collection for over 11,000 surveys. We also thank the Centers for Disease Control and Prevention (CDC) for funding of the study and James Singleton for his editorial comments. The authors wish to acknowledge Sandy De Quesada, BA, HealthPartners Institute for Education and Research, for her assistance in the preparation of this manuscript. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the CDC. NR 25 TC 48 Z9 48 U1 3 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 20 PY 2013 VL 31 IS 37 BP 3928 EP 3935 DI 10.1016/j.vaccine.2013.06.041 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 218PI UT WOS:000324444200026 PM 23806243 ER PT J AU Rosenberg, R Johansson, MA Powers, AM Miller, BR AF Rosenberg, Ronald Johansson, Michael A. Powers, Ann M. Miller, Barry R. TI Search strategy has influenced the discovery rate of human viruses SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE emerging diseases; zoonoses ID EMERGING INFECTIOUS-DISEASES; RNA VIRUSES; EMERGENCE; EVOLUTION; TRANSMISSION; REASSORTMENT; CHIKUNGUNYA; PATHOGENS; MOSQUITOS; TRENDS AB A widely held concern is that the pace of infectious disease emergence has been increasing. We have analyzed the rate of discovery of pathogenic viruses, the preeminent source of newly discovered causes of human disease, from 1897 through 2010. The rate was highest during 1950-1969, after which it moderated. This general picture masks two distinct trends: for arthropod-borne viruses, which comprised 39% of pathogenic viruses, the discovery rate peaked at three per year during 1960-1969, but subsequently fell nearly to zero by 1980; however, the rate of discovery of non-arboviruses remained stable at about two per year from 1950 through 2010. The period of highest arbovirus discovery coincided with a comprehensive program supported by The Rockefeller Foundation of isolating viruses from humans, animals, and arthropod vectors at field stations in Latin America, Africa, and India. The productivity of this strategy illustrates the importance of location, approach, long-term commitment, and sponsorship in the discovery of emerging pathogens. C1 [Rosenberg, Ronald; Johansson, Michael A.; Powers, Ann M.; Miller, Barry R.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Rosenberg, R (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. EM viruslist@cdc.gov NR 31 TC 13 Z9 14 U1 0 U2 15 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD AUG 20 PY 2013 VL 110 IS 34 BP 13961 EP 13964 DI 10.1073/pnas.1307243110 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 203DU UT WOS:000323271400065 PM 23918354 ER PT J AU De Cock, KM El-Sadr, WM AF De Cock, Kevin M. El-Sadr, Wafaa M. TI Clinical trials provide the evidence critical for patient empowerment SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Letter ID HIV-INFECTED ADULTS; ANTIRETROVIRAL THERAPY; AIDS-MORBIDITY; MORTALITY C1 [De Cock, Kevin M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [El-Sadr, Wafaa M.] Columbia Univ, ICAP, New York, NY 10032 USA. RP El-Sadr, WM (reprint author), Columbia Univ, ICAP, 722 West 168th St,Suite 1312, New York, NY 10032 USA. EM wme1@columbia.edu NR 17 TC 0 Z9 0 U1 2 U2 8 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD AUG 19 PY 2013 VL 16 AR 18811 DI 10.7448/IAS.16.1.18811 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 208TT UT WOS:000323703400001 PM 23962587 ER PT J AU Jancey, J Cooper, L Howat, P Meuleners, L Sleet, D Baldwin, G AF Jancey, Jonine Cooper, Lisa Howat, Peter Meuleners, Lynn Sleet, David Baldwin, Grant TI Pedestrian and Motorized Mobility Scooter Safety of Older People SO TRAFFIC INJURY PREVENTION LA English DT Article DE older adults; active transport; pedestrians; motorized mobility scooters; road safety ID CROSSWALK MARKINGS; VEHICLE COLLISIONS; INJURY; ADULTS; DRIVERS; MEDICATIONS; CRASHES; RISK AB Objectives: After driving, walking is older adults' second most preferred mode of transport and preferred recreational activity. This leads to greater exposure to traffic, increasing their risk of pedestrian-vehicle crashes, with older adults being more likely to die as a pedestrian compared to when using other modes of transport. However, less focus has been placed on this particularly vulnerable group. This review summarizes issues associated with older adult pedestrian and motorized mobility scooters (MMS) safety and interventions that have been conducted. Methods: A literature search was undertaken from PubMed, MUARC publications, the Curtin University Library Catalogue, and Google Scholar. Keywords included older pedestrians, older adult road injury, mobility scooter injury, and injury prevention. Publications from 2000 and later were used, unless an earlier publication had significant relevance and worth. Conclusion: Maintaining older adults' mobility and independence during a time of decreasing physical and mental capacity is a priority. Walking provides a key mode of transport that needs to be given higher priority within the road environment by policy makers, transport planners, and drivers. Therefore, governments need to consider appropriate and comprehensive urban planning and road safety policies that accommodate active aging to provide pedestrians and MMS users with environments that facilitate active living and safe transport. In addition, there is a need for community programs that raise awareness about safe road crossing for this growing vulnerable age group. Supplemental materials are available for this article. Go to the publisher's online edition of Traffic Injury Prevention to view the supplemental file. C1 [Jancey, Jonine; Cooper, Lisa; Howat, Peter] Curtin Univ, Western Australian Ctr Hlth Promot Res, Perth, WA 6845, Australia. [Jancey, Jonine; Howat, Peter] Curtin Univ, Ctr Behav Res Canc Control, Perth, WA 6845, Australia. [Meuleners, Lynn] Curtin Univ, Monash Univ Accid Res Ctr, Perth, WA 6845, Australia. [Sleet, David; Baldwin, Grant] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Jancey, J (reprint author), Curtin Univ, GPO Box U1987, Perth, WA 6845, Australia. EM j.jancey@curtin.edu.au FU Cancer Council of Western Australia (CCWA) FX The Centre for Behavioural Research in Cancer Control (CBRCC) receives funding support from the Cancer Council of Western Australia (CCWA). NR 66 TC 2 Z9 2 U1 7 U2 23 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1538-9588 EI 1538-957X J9 TRAFFIC INJ PREV JI Traffic Inj. Prev. PD AUG 18 PY 2013 VL 14 IS 6 BP 647 EP 653 DI 10.1080/15389588.2012.749465 PG 7 WC Public, Environmental & Occupational Health; Transportation SC Public, Environmental & Occupational Health; Transportation GA 187BN UT WOS:000322091800013 PM 23859228 ER PT J AU King, D Johnson, B Miller, D Landon, EM DeVries, A Fuller, S Ms, JH Lynfield, R Alelis, K High, P Wendolowski, J Rudowski, E Montana, B Wolf, B Efstathiou, M Doyle, T Schaefer, M Patel, P Erdman, D Lu, XY Schneider, E AF King, Diane Johnson, Barbara Miller, Darlene Landon, Emily M. DeVries, Aaron Fuller, Susan Harper, Jane Lynfield, Ruth Alelis, Karen High, Patricia Wendolowski, Joanne Rudowski, Ellen Montana, Barbara Wolf, Bruce Efstathiou, Mary Doyle, Timothy Schaefer, Melissa Patel, Priti Erdman, Dean Lu, Xiaoyan Schneider, Eileen TI Adenovirus-Associated Epidemic Keratoconjunctivitis Outbreaks - Four States, 2008-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DISINFECTION C1 [Miller, Darlene] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Coral Gables, FL 33124 USA. [Landon, Emily M.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [DeVries, Aaron; Fuller, Susan; Harper, Jane; Lynfield, Ruth] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Alelis, Karen] Bergen Cty Div Hlth Svcs, Bergen, Norway. [Wendolowski, Joanne] Hackensack Univ, Med Ctr, Hackensack, NJ USA. [Doyle, Timothy] Career Epidemiol Field Officer Program, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. [Erdman, Dean; Lu, Xiaoyan; Schneider, Eileen] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Schneider, E (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM eschneider@cdc.gov NR 10 TC 14 Z9 14 U1 0 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 16 PY 2013 VL 62 IS 32 BP 637 EP 641 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 203QS UT WOS:000323308300001 ER PT J AU Rupprecht, CE Brenner, E Cox, S Giurgiutiu, D Drociuk, D Blanton, JD Petersen, BW Lankau, EW Tack, DM AF Rupprecht, Charles E. Brenner, Eric Cox, Stephanie Giurgiutiu, Dana Drociuk, Dan Blanton, Jesse D. Petersen, Brett W. Lankau, Emily W. Tack, Danielle M. TI Human Rabies - South Carolina, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES C1 [Brenner, Eric; Cox, Stephanie; Giurgiutiu, Dana; Drociuk, Dan] S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA. [Lankau, Emily W.; Tack, Danielle M.] CDC, Atlanta, GA 30333 USA. RP Brenner, E (reprint author), S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA. EM brenneer@dhec.sc.gov RI Lankau, Emily/C-8057-2011 OI Lankau, Emily/0000-0002-7094-7780 NR 7 TC 5 Z9 5 U1 0 U2 5 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 16 PY 2013 VL 62 IS 32 BP 642 EP 644 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 203QS UT WOS:000323308300002 ER PT J AU Boscarino, JA Gordon, SC Rupp, LB Schmidt, MA Vijayadeva, V Moorman, A Xu, FJ Holmberg, SD Ko, SC AF Boscarino, Joseph A. Gordon, Stuart C. Rupp, Loralee B. Schmidt, Mark A. Vijayadeva, Vinutha Moorman, Anne Xu, Fujie Holmberg, Scott D. Ko, Stephen C. TI Locations and Reasons for Initial Testing for Hepatitis C Infection - Chronic Hepatitis Cohort Study, United States, 2006-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HCV INFECTION; CARE C1 [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Gordon, Stuart C.; Rupp, Loralee B.] Henry Ford Hlth Syst, Detroit, MI USA. [Schmidt, Mark A.] Permanente Northwest, Portland, OR USA. [Vijayadeva, Vinutha] Kaiser Permanente Hawaii, Honolulu, HI USA. [Ko, Stephen C.] CDC, Atlanta, GA 30333 USA. RP Ko, SC (reprint author), CDC, Atlanta, GA 30333 USA. EM stephenko@cdc.gov NR 10 TC 5 Z9 5 U1 0 U2 7 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 16 PY 2013 VL 62 IS 32 BP 645 EP 648 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 203QS UT WOS:000323308300003 ER PT J AU Chaulk, P Muvva, R Morgan, J Pearl, ML Matus, S Blythe, D Flynn, C Oster, AM Paz-Bailey, G Burnett, P Olthoff, G Hart-Cooper, G Cooley, LA Ross, C AF Chaulk, Patrick Muvva, Ravikiran Morgan, James Pearl, Marcia L. Matus, Sandra Blythe, David Flynn, Colin Oster, Alexandra M. Paz-Bailey, Gabriela Burnett, Phyllis Olthoff, Glen Hart-Cooper, Geoffrey Cooley, Laura A. Ross, Christine TI Repeat Syphilis Infection and HIV Coinfection Among Men Who Have Sex With Men - Baltimore, Maryland, 2010-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Chaulk, Patrick; Muvva, Ravikiran] Baltimore City Dept Hlth, Baltimore, MD USA. [Morgan, James] Baltimore Cty Dept Hlth & Human Svcs, Baltimore, MD USA. [Cooley, Laura A.; Ross, Christine] CDC, Atlanta, GA 30333 USA. RP Cooley, LA (reprint author), CDC, Atlanta, GA 30333 USA. EM lcooley@cdc.gov NR 3 TC 15 Z9 15 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 16 PY 2013 VL 62 IS 32 BP 649 EP 650 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 203QS UT WOS:000323308300004 ER PT J AU Jaffe, H Patterson, AP Lurie, N AF Jaffe, Harold Patterson, Amy P. Lurie, Nicole TI Extra Oversight for H7N9 Experiments SO SCIENCE LA English DT Letter C1 [Jaffe, Harold] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Patterson, Amy P.] NIH, Bethesda, MD 20852 USA. [Lurie, Nicole] Dept Hlth & Human Serv, Washington, DC 20201 USA. RP Patterson, AP (reprint author), NIH, Bethesda, MD 20852 USA. EM pattersa@od.nih.gov NR 3 TC 1 Z9 1 U1 1 U2 16 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD AUG 16 PY 2013 VL 341 IS 6147 BP 713 EP 714 DI 10.1126/science.1244158 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 201DZ UT WOS:000323122200017 PM 23926189 ER PT J AU Spiropoulou, CF Srikiatkhachorn, A AF Spiropoulou, Christina F. Srikiatkhachorn, Anon TI The role of endothelial activation in dengue hemorrhagic fever and hantavirus pulmonary syndrome SO VIRULENCE LA English DT Review DE viral hemorrhagic fevers; dengue; dengue hemorrhagic fever; hantavirus; hantavirus pulmonary syndrome ID CD8(+) T-CELLS; PUUMALA VIRUS-INFECTION; PREEXISTING ENHANCING ANTIBODIES; INDUCED LETHAL DISEASE; HUMAN DENDRITIC CELLS; ANDES VIRUS; CARDIOPULMONARY SYNDROME; SHOCK SYNDROME; VASCULAR-PERMEABILITY; ADHESION MOLECULES AB The loss of the endothelium barrier and vascular leakage play a central role in the pathogenesis of hemorrhagic fever viruses. This can be caused either directly by the viral infection and damage of the vascular endothelium, or indirectly by a dysregulated immune response resulting in an excessive activation of the endothelium. This article briefly reviews our knowledge of the importance of the disruption of the vascular endothelial barrier in two severe disease syndromes, dengue hemorrhagic fever and hantavirus pulmonary syndrome. Both viruses cause changes in vascular permeability without damaging the endothelium. Here we focus on our understanding of the virus interaction with the endothelium, the role of the endothelium in the induced pathogenesis, and the possible mechanisms by which each virus causes vascular leakage. Understanding the dynamics between viral infection and the dysregulation of the endothelial cell barrier will help us to define potential therapeutic targets for reducing disease severity. C1 [Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. [Srikiatkhachorn, Anon] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. EM ccs8@cdc.gov FU National Institutes of Health Grant [NIH-P01AI34533] FX The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. The authors thank Dr T Klimova and Dr In-Kyu Yoon for critical reading of the manuscript, and Craig Manning for help with the illustration. Part of this work was supported by National Institutes of Health Grant NIH-P01AI34533. The opinions or assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the view of the US Government. NR 169 TC 10 Z9 13 U1 0 U2 4 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2150-5594 EI 2150-5608 J9 VIRULENCE JI Virulence PD AUG 15 PY 2013 VL 4 IS 6 BP 525 EP 536 DI 10.4161/viru.25569 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 277IP UT WOS:000328812500017 PM 23841977 ER PT J AU Niccolai, LM Russ, C Julian, PJ Hariri, S Sinard, J Meek, JI McBride, V Markowitz, LE Unger, ER Hadler, JL Sosa, LE AF Niccolai, Linda M. Russ, Chelsea Julian, Pamela J. Hariri, Susan Sinard, John Meek, James I. McBride, Vanessa Markowitz, Lauri E. Unger, Elizabeth R. Hadler, James L. Sosa, Lynn E. TI Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty SO CANCER LA English DT Article DE human papillomavirus; human papillomavirus types; high-grade cervical lesions; health disparities; geocoding ID UNITED-STATES; SOCIOECONOMIC DISPARITIES; GEOCODING PROJECT; GENITAL WARTS; HPV VACCINE; CANCER; MORTALITY; ABNORMALITIES; INEQUALITIES; ATTRIBUTION AB BACKGROUND: Current vaccines protect against 2 human papillomavirus (HPV) types, HPV 16 and 18, which are associated with 70% of cervical cancers and 50% of high-grade cervical lesions. HPV type distribution was examined among women with high-grade lesions by individual and area-based measures of race, ethnicity, and poverty. METHODS: This analysis included 832 women aged 18 to 39 years reported to a surveillance registry in Connecticut during 2008 to 2010. Diagnostic specimens were obtained for HPV DNA testing. Individual measures were obtained from surveillance reports, medical records, and patient interviews. Cases were geo-coded to census tracts and linked to area-based measures of race, ethnicity, and poverty. Statistical analysis included use of generalized estimating equations. RESULTS: Overall, 44.8% of women had HPV 16/18. In a multivariate model controlled for confounding by age and diagnosis grade, black race (adjusted prevalence ratio [aPR] = 0.54, 95% confidence interval [CI] = 0.34-0.88), Hispanic ethnicity (aPR = 0.59, 95% CI = 0.40-0.88), and higher area-based poverty (aPR = 0.59, 95% CI = 0.40-0.87) were associated with a lower likelihood of HPV 16/18 positivity. Black and Hispanic women were less likely to have HPV 16/18 than white women across all levels of area-based measures. CONCLUSIONS: Black race, Hispanic ethnicity, and higher area-based poverty are salient predictors of lower HPV 16/18 positivity among women with high-grade cervical lesions. These data suggest that HPV vaccines might have lower impact among black and Hispanic women and those living in high poverty areas. These findings have implications for vaccine impact monitoring, vaccination programs, and new vaccine development. Cancer 2013; 119: 3052-8. (C) 2013 American Cancer Society. C1 [Niccolai, Linda M.; Russ, Chelsea; Julian, Pamela J.; Meek, James I.; McBride, Vanessa; Hadler, James L.] Connecticut Emerging Infect Program, New Haven, CT USA. [Niccolai, Linda M.; Russ, Chelsea; Julian, Pamela J.; Meek, James I.; McBride, Vanessa; Hadler, James L.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. [Hariri, Susan; Markowitz, Lauri E.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sinard, John] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA. [Sosa, Lynn E.] Connecticut Dept Publ Hlth, Hartford, CT USA. RP Niccolai, LM (reprint author), Yale Univ, Sch Publ Hlth, 60 Coll St, New Haven, CT 06520 USA. EM linda.niccolai@yale.edu OI Unger, Elizabeth/0000-0002-2925-5635 FU Centers for Disease Control and Prevention [CIU01000307] FX This work was funded by Cooperative Agreement CIU01000307 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. NR 31 TC 19 Z9 19 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD AUG 15 PY 2013 VL 119 IS 16 BP 3052 EP 3058 DI 10.1002/cncr.28038 PG 7 WC Oncology SC Oncology GA 194KQ UT WOS:000322632400018 PM 23661284 ER PT J AU Marks, SM Cronin, W Venkatappa, T Maltas, G Chon, S Sharnprapai, S Gaeddert, M Tapia, J Dorman, SE Etkind, S Crosby, C Blumberg, HM Bernardo, J AF Marks, Suzanne M. Cronin, Wendy Venkatappa, Thara Maltas, Gina Chon, Sandy Sharnprapai, Sharon Gaeddert, Mary Tapia, Jane Dorman, Susan E. Etkind, Sue Crosby, Claud Blumberg, Henry M. Bernardo, John TI The Health-System Benefits and Cost-effectiveness of Using Mycobacterium Tuberculosis Direct Nucleic Acid Amplification Testing to Diagnose Tuberculosis Disease in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE tuberculosis; diagnosis; molecular; cost; nucleic acid amplification AB Background. The utility of Mycobacterium tuberculosis direct nucleic acid amplification testing (MTD) for pulmonary tuberculosis disease diagnosis in the United States has not been well described. Methods. We analyzed a retrospective cohort of reported patients with suspected active pulmonary tuberculosis in 2008-2010 from Georgia, Hawaii, Maryland, and Massachusetts to assess MTD use, effectiveness, health-system benefits, and cost-effectiveness. Results. Among 2140 patients in whom pulmonary tuberculosis was suspected, 799 (37%) were M. tuberculosis-culture-positive. Eighty percent (680/848) of patients having acid-fast-bacilli-smear-positive specimens had MTD performed; MTD positive-predictive value (PPV) was 98% and negative-predictive value (NPV) was 94%. Nineteen percent (240/1292) of patients having smear-negative specimens had MTD; MTD PPV was 90% and NPV was 88%. Among patients suspected of tuberculosis but not having MTD, smear PPV for lab-confirmed tuberculosis was 77% and NPV 78%. Compared with no MTD, MTD significantly decreased time to diagnosis in patients with smear-positive/MTD-positive specimens, decreased respiratory isolation for patients having smear-positive/MTD-negative/culture-negative specimens, decreased outpatient days of unnecessary tuberculosis medications, and reduced resources expended on contact investigation. While MTD generally cost more than no MTD, incremental cost savings occurred in patients with human immunodeficiency virus (HIV) or homelessness to diagnose or to exclude tuberculosis, and in patients with substance abuse having smear-negative specimens to exclude tuberculosis. Conclusions. MTD improved diagnostic accuracy and timeliness and reduced unnecessary respiratory isolation, treatment, and contact investigations. It was cost saving in patients with HIV, homelessness, or substance abuse, but not in others. C1 [Marks, Suzanne M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Cronin, Wendy] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Venkatappa, Thara] State Hawaii Dept Hlth, Honolulu, HI USA. [Maltas, Gina; Chon, Sandy; Dorman, Susan E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Sharnprapai, Sharon; Gaeddert, Mary; Etkind, Sue; Bernardo, John] Massachusetts Dept Publ Hlth, Boston, MA USA. [Tapia, Jane; Crosby, Claud; Blumberg, Henry M.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA USA. RP Marks, SM (reprint author), Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA. EM smarks@cdc.gov OI Bernardo, John/0000-0002-3922-0559 FU Tuberculosis Epidemiologic Studies Consortium (TBESC) of the US Centers for Disease Control and Prevention FX This work was supported by the Tuberculosis Epidemiologic Studies Consortium (TBESC) of the US Centers for Disease Control and Prevention. The TBESC functions as an independent entity whose purpose is to conduct programmatically relevant tuberculosis research and evaluation and to strengthen tuberculosis public health infrastructure in the United States and Canada for the elimination of tuberculosis. NR 14 TC 13 Z9 13 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD AUG 15 PY 2013 VL 57 IS 4 BP 532 EP 542 DI 10.1093/cid/cit336 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 190LV UT WOS:000322342500016 PM 23697743 ER PT J AU Sable, SB AF Sable, Suraj B. TI Programmed Death 1 Lives Up to Its Reputation in Active Tuberculosis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material DE Mycobacterium tuberculosis; T-cell inhibition; T-cell exhaustion; biomarker; tuberculosis therapy ID T-CELLS; MYCOBACTERIUM-TUBERCULOSIS; PD-1 BLOCKADE; INFECTION; IMMUNITY; PATHWAY C1 [Sable, Suraj B.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Sable, SB (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div TB Eliminat, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM ssable@cdc.gov OI Sable, Suraj/0000-0001-8440-1693 NR 14 TC 6 Z9 6 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2013 VL 208 IS 4 BP 541 EP 543 DI 10.1093/infdis/jit211 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 191KO UT WOS:000322412100002 PM 23661796 ER PT J AU Kourtis, AP Ibegbu, CC Wiener, J King, CC Tegha, G Kamwendo, D Kumwenda, J Kaur, SP Flax, V Ellington, S Kacheche, Z Kayira, D Chasela, C van der Horst, C Jamieson, DJ AF Kourtis, Athena P. Ibegbu, Chris C. Wiener, Jeffrey King, Caroline C. Tegha, Gerald Kamwendo, Deborah Kumwenda, Jacob Kaur, Surinder P. Flax, Valerie Ellington, Sascha Kacheche, Zebrone Kayira, Dumbani Chasela, Charles van der Horst, Charles Jamieson, Denise J. TI Role of Intestinal Mucosal Integrity in HIV Transmission to Infants Through Breast-feeding: The BAN Study SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; infant; breast-feeding; microbial translocation; immune activation; intestinal permeability ID MICROBIAL TRANSLOCATION; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; INFECTED CHILDREN; GAMBIAN INFANTS; PERMEABILITY; GROWTH; ENDOTOXEMIA; PREVENTION; PROTECTION AB Background. Increased intestinal permeability may be one of the mechanisms of transmission of human immunodeficiency virus (HIV) to infants through breast-feeding. Intestinal permeability correlates with microbial translocation, which can be measured through quantification of bacterial lipopolysaccharide (LPS). Methods. We evaluated levels of plasma LPS (by the Limulus amebocyte lysate assay) and immune activation markers in serial specimens from infants exposed to but uninfected with HIV and infants infected with HIV from the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study. Results. Plasma LPS levels increased after infants in the BAN study were weaned from the breast, at 24 weeks of age. Cotrimoxazole prophylaxis was associated with higher plasma LPS levels (P = .004). Infants with HIV infection had higher LPS levels, compared with uninfected infants (P = .004). Higher preinfection plasma LPS levels were a significant predictor of infant HIV infection through breast-feeding (hazard ratio = 1.60 for every unit increase in plasma LPS level; P = .01) and of lower infant length-for-age z scores (P = .02). Conclusions. These findings suggest that disruption in intestinal integrity is a mechanism of HIV transmission to infants through breast-feeding. Weaning from breast milk and use of antibiotic prophylaxis was associated with increased levels of microbial translocation, which could facilitate HIV entry through the intestine. Complementary approaches to enhance intestinal mucosal integrity in the infant may further reduce breast-feeding transmission of HIV. C1 [Kourtis, Athena P.; Wiener, Jeffrey; King, Caroline C.; Ellington, Sascha; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, Atlanta, GA 30333 USA. [Ibegbu, Chris C.; Kaur, Surinder P.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Flax, Valerie; van der Horst, Charles] Univ N Carolina, Chapel Hill, NC USA. [Tegha, Gerald; Kamwendo, Deborah; Kumwenda, Jacob; Kacheche, Zebrone; Kayira, Dumbani; Chasela, Charles] UNC Project Malawi, Lilongwe, Malawi. RP Kourtis, AP (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM apk3@cdc.gov OI Flax, Valerie/0000-0003-0200-3355 FU Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944-01]; National Institute of Allergy and Infectious Diseases; University of North Carolina Center for AIDS Research [P30-AI50410]; NIH Fogarty AIDS International Training and Research Program [DHHS/NIH/FIC 2-D43 Tw01039-06, R24 Tw00798]; Emory University Center For AIDS Research Immunology Core [P30A01050409]; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; US Agency for International Development; NIH Fogarty AIDS International Training and Research Program (American Recovery and Reinvestment Act) FX This work was supported by the Prevention Research Centers Special Interest Project of the Centers for Disease Control and Prevention (grants SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944-01), the National Institute of Allergy and Infectious Diseases, the University of North Carolina Center for AIDS Research (grant P30-AI50410), the NIH Fogarty AIDS International Training and Research Program (grants DHHS/NIH/FIC 2-D43 Tw01039-06 and R24 Tw00798; the American Recovery and Reinvestment Act), and the Emory University Center For AIDS Research Immunology Core (grant P30A01050409). The antiretrovirals used in the BAN study were donated by Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, and Bristol-Myers Squibb. The Call to Action PMTCT program was supported by the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the US Agency for International Development. NR 33 TC 13 Z9 15 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2013 VL 208 IS 4 BP 653 EP 661 DI 10.1093/infdis/jit221 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 191KO UT WOS:000322412100015 PM 23687226 ER PT J AU Igietseme, JU Black, CM AF Igietseme, Joseph U. Black, Carolyn M. TI Toward Understanding Chlamydia Infection-Induced Infertility Caused by Dysfunctional Oviducts Reply SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID APOPTOSIS; CLEAVAGE; DICER; CELLS C1 [Igietseme, Joseph U.; Black, Carolyn M.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA USA. RP Igietseme, JU (reprint author), CDC, NCEZID, DSR, Mailstop G-36,1600 Clifton Rd, Atlanta, GA 30333 USA. EM jigietseme@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD AUG 15 PY 2013 VL 208 IS 4 BP 709 EP 710 DI 10.1093/infdis/jit217 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 191KO UT WOS:000322412100025 PM 23661795 ER PT J AU Hamelin, EI Bragg, W Shaner, RL Swaim, LL Johnson, RC AF Hamelin, Elizabeth I. Bragg, William Shaner, Rebecca L. Swaim, Leigh L. Johnson, Rudolph C. TI Comparison of high-resolution and tandem mass spectrometry for the analysis of nerve agent metabolites in urine SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY LA English DT Article ID ISOTOPE-DILUTION; QUANTITATION; QUANTIFICATION; ORBITRAP; PLASMA; SOMAN; SPECTROSCOPY; BIOANALYSIS; EXPOSURE; DRUGS AB RATIONALE Although use is prohibited, concerns remain for human exposure to nerve agents during decommissioning, research, and warfare. High-resolution mass spectrometry (HRMS) was compared to tandem mass spectrometry (MS/MS) analysis for the quantitation of five urinary metabolites specific to VX, Russian VX, soman, sarin and cyclosarin nerve agents. The HRMS method was further evaluated for qualitative screening of metabolites not included in the test panel. METHODS Nerve agent metabolites were extracted from urine using solid-phase extraction, separated using hydrophilic interaction chromatography and analyzed using both tandem and high-resolution mass spectrometry. MS/MS results were obtained using selected reaction monitoring with unit resolution; HRMS results were obtained using a mass extraction window of 10ppm at a mass resolution of 50 000. The benchtop Orbitrap HRMS instrument was operated in full scan mode, to measure the presence of unexpected nerve agent metabolites. RESULTS The assessment of two quality control samples demonstrated high accuracy (99.5-104%) and high precision (2-9%) for both HRMS and MS/MS. Sensitivity, as described by the limit of detection, was overlapping for both detectors (0.2-0.7ng/mL). Additionally, the HRMS method positively confirmed the presence of a nerve agent metabolite, not included in the test panel, using the accurate mass and relative retention time. CONCLUSIONS The precision, accuracy, and sensitivity were comparable between the current MS/MS method and this newly developed HRMS analysis for five nerve agent metabolites. HRMS showed additional capabilities beyond the current method by confirming the presence of a metabolite not included in the test panel. Published in 2013. This article is a U.S. Government work and is in the public domain in the USA. C1 [Hamelin, Elizabeth I.; Shaner, Rebecca L.; Swaim, Leigh L.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Emergency Response Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Bragg, William] Oak Ridge Inst Sci Educ, Oak Ridge, TN 37831 USA. RP Hamelin, EI (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F44, Atlanta, GA 30341 USA. EM ehamelin@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 6 Z9 6 U1 2 U2 37 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0951-4198 J9 RAPID COMMUN MASS SP JI Rapid Commun. Mass Spectrom. PD AUG 15 PY 2013 VL 27 IS 15 BP 1697 EP 1704 DI 10.1002/rcm.6621 PG 8 WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy GA 175BG UT WOS:000321203700004 PM 23821563 ER PT J AU Coyle, DR Murphy, MW Paskewitz, SM Orrock, JL Lee, X Murphy, RJ McGeehin, MA Raffa, KF AF Coyle, David R. Murphy, Matthew W. Paskewitz, Susan M. Orrock, John L. Lee, Xia Murphy, Robert J. McGeehin, Michael A. Raffa, Kenneth F. TI Belowground herbivory in red pine stands initiates a cascade that increases abundance of Lyme disease vectors SO FOREST ECOLOGY AND MANAGEMENT LA English DT Article DE Borrelia burgdorferi; Environmental precursor; Human disease; Pinus resinosa; Red pine pocket decline; Root herbivory ID IXODES-SCAPULARIS ACARI; BURGDORFERI SPIROCHAETALES-SPIROCHAETACEAE; INSECT-FUNGAL COMPLEX; UNITED-STATES; BORRELIA-BURGDORFERI; ANAPLASMA-PHAGOCYTOPHILUM; IXODIDAE; HABITAT; FOREST; DECLINE AB There is increasing recognition that infectious disease patterns are often driven by complex underlying ecological processes. In red pine plantations in the Great Lakes region of North America, feeding by rhizophagous insects triggers a cascade that ultimately results in higher densities of blacklegged ticks, Ixodes scapularis, which are the primary vector of the Lyme disease pathogen Borrelia burgdorferi. We sampled 31 plantations in Wisconsin, USA, that were diseased or asymptomatic for a previously described tree mortality syndrome that originates with root infestation. Understory vegetation was greater in diseased stands, as were the proportion of samples containing ticks and the number of ticks per sample. Infection rates with B. burgdorferi were consistent. Tick densities were identical between declining and healthy portions of symptomatic stands, suggesting stand-level factors are responsible, consistent with mammal movement. These results suggest that forest management practices that affect the dynamics of belowground food webs may have implications for human health. (C) 2013 Elsevier B.V. All rights reserved. C1 [Coyle, David R.; Paskewitz, Susan M.; Lee, Xia; Murphy, Robert J.; Raffa, Kenneth F.] Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA. [Murphy, Matthew W.; McGeehin, Michael A.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Orrock, John L.] Univ Wisconsin, Dept Zool, Madison, WI 53706 USA. [Murphy, Robert J.] Wisconsin Dept Nat Resources, Madison, WI 53707 USA. RP Coyle, DR (reprint author), Univ Georgia, DB Warnell Sch Forestry & Nat Resources, Bldg 4-434,180 E Green St, Athens, GA 30602 USA. EM drcoyle@uga.edu FU Centers for Disease Control and Prevention; University of Wisconsin-Madison College of Agricultural and Life Sciences; Wisconsin DNR FX We thank Charles Mason, Kirsten Martin, Justin Berg, Ace Lynn-Miller, and Robert Coyle for field assistance; Peter Crump and Rick Nordheim for statistical assistance; and valuable discussions with Ben Beard, Rebecca Eisen, and Joe Piesman. Thanks to Sandy Liebhold, and two anonymous reviewers, for valuable comments that improved our manuscript. We thank the Centers for Disease Control and Prevention and the University of Wisconsin-Madison College of Agricultural and Life Sciences for funding this work, and the Wisconsin DNR for project support. NR 47 TC 2 Z9 2 U1 5 U2 44 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1127 J9 FOREST ECOL MANAG JI For. Ecol. Manage. PD AUG 15 PY 2013 VL 302 BP 354 EP 362 DI 10.1016/j.foreco.2013.03.017 PG 9 WC Forestry SC Forestry GA 168XN UT WOS:000320741300037 ER PT J AU Woodhall, DM Wiegand, RE Wellman, M Matey, E Abudho, B Karanja, DMS Mwinzi, PMN Montgomery, SP Secor, WE AF Woodhall, Dana M. Wiegand, Ryan E. Wellman, Michael Matey, Elizabeth Abudho, Bernard Karanja, Diana M. S. Mwinzi, Pauline M. N. Montgomery, Susan P. Secor, W. Evan TI Use of Geospatial Modeling to Predict Schistosoma mansoni Prevalence in Nyanza Province, Kenya SO PLOS ONE LA English DT Article ID GENERALIZED LINEAR-MODELS; WESTERN KENYA; BIOMPHALARIA-PFEIFFERI; EPIDEMIOLOGY; TEMPERATURES; INFECTION; SNAILS AB Background: Schistosomiasis, a parasitic disease that affects over 200 million people, can lead to significant morbidity and mortality; distribution of single dose preventative chemotherapy significantly reduces disease burden. Implementation of control programs is dictated by disease prevalence rates, which are determined by costly and labor intensive screening of stool samples. Because ecological and human factors are known to contribute to the focal distribution of schistosomiasis, we sought to determine if specific environmental and geographic factors could be used to accurately predict Schistosoma mansoni prevalence in Nyanza Province, Kenya. Methodology/Principal Findings: A spatial mixed model was fit to assess associations with S. mansoni prevalence in schools. Data on S. mansoni prevalence and GPS location of the school were obtained from 457 primary schools. Environmental and geographic data layers were obtained from publicly available sources. Spatial models were constructed using ArcGIS 10 and R 2.13.0. Lower S. mansoni prevalence was associated with further distance (km) to Lake Victoria, higher day land surface temperature (LST), and higher monthly rainfall totals. Altitude, night LST, human influence index, normalized difference vegetation index, soil pH, soil texture, soil bulk density, soil water capacity, population, and land use variables were not significantly associated with S. mansoni prevalence. Conclusions: Our model suggests that there are specific environmental and geographic factors that influence S. mansoni prevalence rates in Nyanza Province, Kenya. Validation and use of schistosomiasis prevalence maps will allow control programs to plan and prioritize efficient control campaigns to decrease schistosomiasis burden. C1 [Woodhall, Dana M.; Wiegand, Ryan E.; Montgomery, Susan P.; Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Wellman, Michael] Ctr Dis Control & Prevent, Geospatial Res Anal & Serv Program, Atlanta, GA USA. [Matey, Elizabeth; Abudho, Bernard; Karanja, Diana M. S.; Mwinzi, Pauline M. N.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. RP Woodhall, DM (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. EM dqw6@cdc.gov FU Bill and Meilinda Gates grant FX This project was funded through a Bill and Meilinda Gates grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 5 Z9 7 U1 0 U2 17 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 14 PY 2013 VL 8 IS 8 AR e71635 DI 10.1371/journal.pone.0071635 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 202MQ UT WOS:000323221500093 PM 23977096 ER PT J AU Murray, CJL Abraham, J Ali, MK Alvarado, M Atkinson, C Baddour, LM Bartels, DH Benjamin, EJ Bhalla, K Birbeck, G Bolliger, I Burstein, R Carnahan, E Chen, HL Chou, D Chugh, SS Cohen, A Colson, KE Cooper, LT Couser, W Criqui, MH Dabhadkar, KC Dahodwala, N Danaei, G Dellavalle, RP Des Jarlais, DC Dicker, D Ding, EL Dorsey, R Duber, H Ebel, BE Engell, RE Ezzati, M Felson, DT Finucane, MM Flaxman, S Flaxman, AD Fleming, T Forouzanfar, MH Freedman, G Freeman, MK Gabriel, SE Gakidou, E Gillum, RF Gonzalez-Medina, D Gosselin, R Grant, B Gutierrez, HR Hagan, H Havmoeller, R Hoffman, H Jacobsen, KH James, SL Jasrasaria, R Jayaraman, S Johns, N Kassebaum, N Khatibzadeh, S Knowlton, LM Lan, Q Leasher, JL Lim, S Lin, JK Lipshultz, SE London, S Lozano, R Lu, Y MacIntyre, MF Mallinger, L McDermott, MM Meltzer, M Mensah, GA Michaud, C Miller, TR Mock, C Moffitt, TE Mokdad, AA Mokdad, AH Moran, AE Mozaffarian, D Murphy, T Naghavi, M Narayan, KMV Nelson, RG Olives, C Omer, SB Ortblad, K Ostro, B Pelizzari, PM Phillips, D Pope, CA Raju, M Ranganathan, D Razavi, H Ritz, B Rivara, FP Roberts, T Sacco, RL Salomon, JA Sampson, U Sanman, E Sapkota, A Schwebel, DC Shahraz, S Shibuya, K Shivakoti, R Silberberg, D Singh, GM Singh, D Singh, JA Sleet, DA Steenland, K Tavakkoli, M Taylor, JA Thurston, GD Towbin, JA Vavilala, MS Vos, T Wagner, GR Weinstock, MA Weisskopf, MG Wilkinson, JD Wulf, S Zabetian, A Lopez, AD AF Murray, Christopher J. L. Abraham, Jerry Ali, Mohammed K. Alvarado, Miriam Atkinson, Charles Baddour, Larry M. Bartels, David H. Benjamin, Emelia J. Bhalla, Kavi Birbeck, Gretchen Bolliger, Ian Burstein, Roy Carnahan, Emily Chen, Honglei Chou, David Chugh, Sumeet S. Cohen, Aaron Colson, K. Ellicott Cooper, Leslie T. Couser, William Criqui, Michael H. Dabhadkar, Kaustubh C. Dahodwala, Nabila Danaei, Goodarz Dellavalle, Robert P. Des Jarlais, Don C. Dicker, Daniel Ding, Eric L. Dorsey, Ray Duber, Herbert Ebel, Beth E. Engell, Rebecca E. Ezzati, Majid Felson, David T. Finucane, Mariel M. Flaxman, Seth Flaxman, Abraham D. Fleming, Thomas Forouzanfar, Mohammad H. Freedman, Greg Freeman, Michael K. Gabriel, Sherine E. Gakidou, Emmanuela Gillum, Richard F. Gonzalez-Medina, Diego Gosselin, Richard Grant, Bridget Gutierrez, Hialy R. Hagan, Holly Havmoeller, Rasmus Hoffman, Howard Jacobsen, Kathryn H. James, Spencer L. Jasrasaria, Rashmi Jayaraman, Sudha Johns, Nicole Kassebaum, Nicholas Khatibzadeh, Shahab Knowlton, Lisa Marie Lan, Qing Leasher, Janet L. Lim, Stephen Lin, John Kent Lipshultz, Steven E. London, Stephanie Lozano, Rafael Lu, Yuan MacIntyre, Michael F. Mallinger, Leslie McDermott, Mary M. Meltzer, Michele Mensah, George A. Michaud, Catherine Miller, Ted R. Mock, Charles Moffitt, Terrie E. Mokdad, Ali A. Mokdad, Ali H. Moran, Andrew E. Mozaffarian, Dariush Murphy, Tasha Naghavi, Mohsen Narayan, K. M. Venkat Nelson, Robert G. Olives, Casey Omer, Saad B. Ortblad, Katrina Ostro, Bart Pelizzari, Pamela M. Phillips, David Pope, C. Arden, III Raju, Murugesan Ranganathan, Dharani Razavi, Homie Ritz, Beate Rivara, Frederick P. Roberts, Thomas Sacco, Ralph L. Salomon, Joshua A. Sampson, Uchechukwu Sanman, Ella Sapkota, Amir Schwebel, David C. Shahraz, Saeid Shibuya, Kenji Shivakoti, Rupak Silberberg, Donald Singh, Gitanjali M. Singh, David Singh, Jasvinder A. Sleet, David A. Steenland, Kyle Tavakkoli, Mohammad Taylor, Jennifer A. Thurston, George D. Towbin, Jeffrey A. Vavilala, Monica S. Vos, Theo Wagner, Gregory R. Weinstock, Martin A. Weisskopf, Marc G. Wilkinson, James D. Wulf, Sarah Zabetian, Azadeh Lopez, Alan D. CA Us Burden Dis Collaborators TI The State of US Health, 1990-2010 Burden of Diseases, Injuries, and Risk Factors SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID BODY-MASS INDEX; ADJUSTED LIFE YEARS; GLOBAL BURDEN; SYSTEMATIC ANALYSIS; UNITED-STATES; PUBLIC-HEALTH; CARDIOVASCULAR-DISEASE; BUILT ENVIRONMENT; PHYSICAL-ACTIVITY; BLOOD-PRESSURE AB IMPORTANCE Understanding the major health problems in the United States and how they are changing over time is critical for informing national health policy. OBJECTIVES To measure the burden of diseases, injuries, and leading risk factors in the United States from 1990 to 2010 and to compare these measurements with those of the 34 countries in the Organisation for Economic Co-operation and Development (OECD) countries. DESIGN We used the systematic analysis of descriptive epidemiology of 291 diseases and injuries, 1160 sequelae of these diseases and injuries, and 67 risk factors or clusters of risk factors from 1990 to 2010 for 187 countries developed for the Global Burden of Disease 2010 Study to describe the health status of the United States and to compare US health outcomes with those of 34 OECD countries. Years of life lost due to premature mortality (YLLs) were computed by multiplying the number of deaths at each age by a reference life expectancy at that age. Years lived with disability (YLDs) were calculated by multiplying prevalence (based on systematic reviews) by the disability weight (based on population-based surveys) for each sequela; disability in this study refers to any short- or long-term loss of health. Disability-adjusted life-years (DALYs) were estimated as the sum of YLDs and YLLs. Deaths and DALYs related to risk factors were based on systematic reviews and meta-analyses of exposure data and relative risks for risk-outcome pairs. Healthy life expectancy (HALE) was used to summarize overall population health, accounting for both length of life and levels of ill health experienced at different ages. RESULTS US life expectancy for both sexes combined increased from 75.2 years in 1990 to 78.2 years in 2010; during the same period, HALE increased from 65.8 years to 68.1 years. The diseases and injuries with the largest number of YLLs in 2010 were ischemic heart disease, lung cancer, stroke, chronic obstructive pulmonary disease, and road injury. Age-standardized YLL rates increased for Alzheimer disease, drug use disorders, chronic kidney disease, kidney cancer, and falls. The diseases with the largest number of YLDs in 2010 were low back pain, major depressive disorder, other musculoskeletal disorders, neck pain, and anxiety disorders. As the US population has aged, YLDs have comprised a larger share of DALYs than have YLLs. The leading risk factors related to DALYs were dietary risks, tobacco smoking, high body mass index, high blood pressure, high fasting plasma glucose, physical inactivity, and alcohol use. Among 34 OECD countries between 1990 and 2010, the US rank for the age-standardized death rate changed from 18th to 27th, for the age-standardized YLL rate from 23rd to 28th, for the age-standardized YLD rate from 5th to 6th, for life expectancy at birth from 20th to 27th, and for HALE from 14th to 26th. CONCLUSIONS AND RELEVANCE From 1990 to 2010, the United States made substantial progress in improving health. Life expectancy at birth and HALE increased, all-cause death rates at all ages decreased, and age-specific rates of years lived with disability remained stable. However, morbidity and chronic disability now account for nearly half of the US health burden, and improvements in population health in the United States have not kept pace with advances in population health in other wealthy nations. C1 [Murray, Christopher J. L.; Alvarado, Miriam; Atkinson, Charles; Bolliger, Ian; Burstein, Roy; Carnahan, Emily; Chou, David; Colson, K. Ellicott; Dicker, Daniel; Duber, Herbert; Engell, Rebecca E.; Flaxman, Abraham D.; Gakidou, Emmanuela; Gonzalez-Medina, Diego; James, Spencer L.; Jasrasaria, Rashmi; Johns, Nicole; Lim, Stephen; MacIntyre, Michael F.; Mallinger, Leslie; Mokdad, Ali A.; Mokdad, Ali H.; Murphy, Tasha; Naghavi, Mohsen; Ortblad, Katrina; Phillips, David; Ranganathan, Dharani; Roberts, Thomas; Sanman, Ella; Vos, Theo; Wulf, Sarah] Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Couser, William; Ebel, Beth E.; Kassebaum, Nicholas; Mock, Charles; Olives, Casey; Rivara, Frederick P.; Vavilala, Monica S.] Univ Washington, Seattle, WA 98195 USA. [Abraham, Jerry] Univ Texas San Antonio, Sch Med, San Antonio, TX USA. [Omer, Saad B.; Steenland, Kyle] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Ali, Mohammed K.; Dabhadkar, Kaustubh C.; Narayan, K. M. Venkat; Zabetian, Azadeh] Emory Univ, Atlanta, GA 30322 USA. [Baddour, Larry M.; Gabriel, Sherine E.] Mayo Clin, Rochester, MN USA. [Danaei, Goodarz; Ding, Eric L.; Finucane, Mariel M.; Khatibzadeh, Shahab; Knowlton, Lisa Marie; Lin, John Kent; Lu, Yuan; Singh, Gitanjali M.; Tavakkoli, Mohammad; Weisskopf, Marc G.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Bartels, David H.; Jayaraman, Sudha; Mozaffarian, Dariush] Harvard Univ, Sch Med, Boston, MA USA. [Bhalla, Kavi] Harvard Univ, Boston, MA 02115 USA. [Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Felson, David T.] Boston Univ, Boston, MA 02215 USA. [Birbeck, Gretchen] Michigan State Univ, E Lansing, MI USA. [Chen, Honglei; London, Stephanie] NIEHS, Res Triangle Pk, NC 27709 USA. [Lan, Qing] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Grant, Bridget; Hoffman, Howard; Mensah, George A.] NIH, Bethesda, MD 20892 USA. [Nelson, Robert G.] Natl Inst Diabet & Digest & Kidney Dis, Bethesda, MD USA. [Wagner, Gregory R.] NIOSH, Baltimore, MD USA. [Chugh, Sumeet S.; Havmoeller, Rasmus] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Havmoeller, Rasmus] Karolinska Inst, Stockholm, Sweden. [Cohen, Aaron] Hlth Effects Inst, Boston, MA USA. [Cooper, Leslie T.] Loyola Univ, Sch Med, Chicago, IL 60611 USA. [Criqui, Michael H.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Dahodwala, Nabila; Silberberg, Donald] Univ Penn, Philadelphia, PA 19104 USA. [Dellavalle, Robert P.] Denver VA Med Ctr, Denver, CO USA. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Dorsey, Ray; Shivakoti, Rupak] Johns Hopkins Univ, Baltimore, MD USA. [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostatist, MRC HPA Ctr Environm & Hlth, London, England. [Flaxman, Seth] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Gillum, Richard F.] Howard Univ, Coll Med, Washington, DC USA. [Gosselin, Richard] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gutierrez, Hialy R.] Mailman Sch Publ Hlth, New York, NY USA. [Moran, Andrew E.] Columbia Univ, New York, NY USA. [Hagan, Holly; Thurston, George D.] NYU, New York, NY USA. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA 22030 USA. [Leasher, Janet L.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Lipshultz, Steven E.; Sacco, Ralph L.; Wilkinson, James D.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Lopez, Alan D.] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic, Australia. [Lozano, Rafael] Inst Nacl Salud Publ, Ctr Invest Sistemas Salud, Cuernavaca, Morelos, Mexico. [McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, Evanston, IL USA. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Michaud, Catherine] China Med Board, Boston, MA USA. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Moffitt, Terrie E.] Duke Univ, Durham, NC USA. [Mozaffarian, Dariush] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ostro, Bart] Calif Environm Protect Agcy, Sacramento, CA USA. [Pelizzari, Pamela M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Pope, C. Arden, III] Brigham Young Univ, Provo, UT 84602 USA. [Raju, Murugesan] Univ Missouri, Mason Eye Inst, Columbia, MO 65211 USA. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Ritz, Beate] Univ Calif Los Angeles, Los Angeles, CA USA. [Sampson, Uchechukwu] Vanderbilt Univ, Nashville, TN 37235 USA. [Sapkota, Amir] Univ Maryland, Sch Publ Hlth, College Pk, MD 20742 USA. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Shahraz, Saeid] Brandeis Univ, Waltham, MA USA. [Shibuya, Kenji] Univ Tokyo, Dept Global Hlth Policy, Tokyo, Japan. [Singh, David] Queens Med Ctr, Honolulu, HI USA. [Sleet, David A.] Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Taylor, Jennifer A.] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. [Towbin, Jeffrey A.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Weinstock, Martin A.] Brown Univ, Providence, RI 02912 USA. RP Murray, CJL (reprint author), Inst Hlth Metr & Evaluat, 2301 5th Ave,Ste 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI Lopez, Alan D/F-1487-2010; Dellavalle, Robert/L-2020-2013; Salomon, Joshua/D-3898-2009; Moffitt, Terrie/D-5295-2011; Narayan, K.M. Venkat /J-9819-2012; Ritz, Beate/E-3043-2015; Sapkota, Amir/A-5968-2011; Bolliger, Ian/C-4207-2016; Jacobsen, Kathryn/B-5857-2008 OI London, Stephanie/0000-0003-4911-5290; Chen, Honglei/0000-0003-3446-7779; Lopez, Alan D/0000-0001-5818-6512; Mock, Charles/0000-0002-0564-568X; Ding, Eric/0000-0002-5881-8097; singh, jasvinder/0000-0003-3485-0006; Johns, Nicole/0000-0003-4513-4582; Mensah, George/0000-0002-0387-5326; Benjamin, Emelia/0000-0003-4076-2336; Miller, Ted/0000-0002-0958-2639; Dellavalle, Robert/0000-0001-8132-088X; Salomon, Joshua/0000-0003-3929-5515; Pelizzari, Pamela/0000-0002-6992-9462; Ranganathan, Dharani/0000-0001-6506-2825; Moffitt, Terrie/0000-0002-8589-6760; Narayan, K.M. Venkat /0000-0001-8621-5405; Bolliger, Ian/0000-0001-8055-297X; Jacobsen, Kathryn/0000-0002-4198-6246 FU National Institutes of Health, the National Institute of Environmental Health Sciences; Bill and Melinda Gates Foundation FX This study is supported in part by the Intramural Program of the National Institutes of Health, the National Institute of Environmental Health Sciences, and in part by the Bill and Melinda Gates Foundation. NR 81 TC 551 Z9 556 U1 39 U2 250 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD AUG 14 PY 2013 VL 310 IS 6 BP 591 EP 608 DI 10.1001/jama.2013.13805 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 200HI UT WOS:000323058400015 PM 23842577 ER PT J AU Guo, W Bao, SL Lin, W Wu, GH Zhang, W Hladik, W Abdul-Quader, A Bulterys, M Fuller, S Wang, L AF Guo, Wei Bao, Shuilian Lin, Wen Wu, Guohui Zhang, Wei Hladik, Wolfgang Abdul-Quader, Abu Bulterys, Marc Fuller, Serena Wang, Lu TI Estimating the Size of HIV Key Affected Populations in Chongqing, China, Using the Network Scale-Up Method SO PLOS ONE LA English DT Article AB Objectives: To estimate the average social network size in the general population and the size of HIV key affected populations (KAPs) in Chongqing municipality using the network scale-up method (NSUM). Methods: A general population survey was conducted in 2011 through a multistage random sampling method. Participants aged between 18 and 60 years were recruited. The average social network size (c) was estimated and adjusted by known population method. The size of HIV KAP in Chongqing municipality was estimated using the adjusted c value with adjustment for the transmission effect using the scaled respect factor. Results: 3,026 inhabitants of Chongqing agreed to the survey, and 2,957 (97.7%) completed the questionnaire. The adjusted c value was 310. The estimated size of KAP was 28,418(95% Confidence Interval (CI): 26,636 similar to 30,201) for female sex workers (FSW), 163,199(95% CI: 156,490 similar to 169,908) for clients of FSW, 37,959(95% CI: 34,888 similar to 41,030) for drug users (DU), 14,975(95% CI: 13,047 similar to 16,904) for injecting drug users (IDU) and 16,767(95% CI: 14,602 similar to 18,932) for men who have sex with men (MSM). The ratio of clients to FSW was 5.74: 1, and IDU accounted for 39.5% of the DU population. The estimates suggest that FSW account for 0.37% of the female population aged 15-49 years in Chongqing, and clients of FSW and MSM represent 2.09% and 0.21% of the male population aged 15-49 years in the city, respectively. Conclusion: NSUM provides reasonable population size estimates for FSW, their clients, DU and IDU in Chongqing. However, it is likely to underestimate the population size of MSM even after adjusting for the transmission effect. C1 [Guo, Wei; Bao, Shuilian; Wang, Lu] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China. [Lin, Wen; Bulterys, Marc; Fuller, Serena] US Ctr Dis Control & Prevent, Global AIDS Program, Beijing Off, Beijing, Peoples R China. [Wu, Guohui; Zhang, Wei] Chongqing Ctr Dis Control & Prevent, Inst AIDS STD Control & Prevent, Chongqing, Peoples R China. [Hladik, Wolfgang; Abdul-Quader, Abu] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. RP Wang, L (reprint author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China. EM wanglu64@chinaaids.cn FU Young Scholar Scientific Research Foundation of China CDC [2011A104]; President's Emergency Plan for AIDS Relief from the HHS/Centers for Disease Control and Prevention (US CDC) [3U2GPS001188]; Global AIDS Program FX This publication was made possible by support from the Young Scholar Scientific Research Foundation of China CDC (2011A104 to WG, http://www.chinacdc.cn/) and the President's Emergency Plan for AIDS Relief through cooperative agreement (3U2GPS001188) from the HHS/Centers for Disease Control and Prevention (US CDC), Global AIDS Program (http://www.pepfar.gov and http://www.cdc.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 25 TC 7 Z9 7 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 13 PY 2013 VL 8 IS 8 AR e71796 DI 10.1371/journal.pone.0071796 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 201BN UT WOS:000323115800081 PM 23967246 ER PT J AU Liao, QH Bai, T Zhou, L Vong, S Guo, JQ Lv, W Dong, LB Xiang, NJ Li, Z Huai, Y Zhou, JF Li, XD Chen, RY Xu, Z Uyeki, TM Shu, YL Yu, H AF Liao, Qiaohong Bai, Tian Zhou, Lei Vong, Sirenda Guo, Junqiao Lv, Wei Dong, Libo Xiang, Nijuan Li, Zi Huai, Yang Zhou, Jianfang Li, Xiaodan Chen, Ray Y. Xu, Zhen Uyeki, Timothy M. Shu, Yuelong Yu, Hongjie TI Seroprevalence of Antibodies to Highly Pathogenic Avian Influenza A (H5N1) Virus among Close Contacts Exposed to H5N1 Cases, China, 2005-2008 SO PLOS ONE LA English DT Article AB To assess the extent of highly pathogenic avian influenza (HPAI) A (H5N1) virus transmission, we conducted sero-epidemiologic studies among close contacts exposed to H5N1 cases in mainland China during 2005-2008. Blood specimens were collected from 87 household members and 332 social contacts of 23 H5N1 index cases for HPAI H5N1 serological testing by modified horse red-blood-cell hemagglutinin inhibition and microneutralization assays. All participants were interviewed with a standardized questionnaire to collect information about the use of personal protective equipment, illness symptoms, exposure to an H5N1 case during the infectious period, and poultry exposures. Two (2.3%) household contacts tested positive for HPAI H5N1 virus antibody, and all social contacts tested negative. Both seropositive cases had prolonged, unprotected, close contact with a different H5N1 index case, including days of bed-care or sleeping together during the index case's infectious period, and did not develop any illness. None of the 419 close contacts used appropriate personal protective equipment including 17% who reported providing bedside care or having physical contact with an H5N1 case for at least 12 hours. Our findings suggest that HPAI H5N1 viruses that circulated among poultry in mainland China from 2005-2008 were not easily transmitted to close contacts of H5N1 cases. C1 [Liao, Qiaohong; Xu, Zhen; Yu, Hongjie] Chinese Ctr Dis Control & Prevent China CDC, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China. [Bai, Tian; Dong, Libo; Li, Zi; Zhou, Jianfang; Li, Xiaodan; Shu, Yuelong] Natl Hlth & Family Planning Commiss, Natl Inst Viral Dis Control & Prevent Chinese, Chinese Ctr Dis Control & Prevent, Key Lab Med Virol, Beijing, Peoples R China. [Zhou, Lei; Xiang, Nijuan] China CDC, Publ Hlth Emergency Ctr, Beijing, Peoples R China. [Vong, Sirenda] World Hlth Org WHO Beijing Off, Beijing, Peoples R China. [Guo, Junqiao] Liaoning Ctr Dis Control & Prevent, Shenyang, Liaoning, Peoples R China. [Lv, Wei] Guangxi Ctr Dis Control & Prevent, Nanning, Guangxi, Peoples R China. [Huai, Yang] US Ctr Dis Control & Prevent, Int Emerging Infect Program, Beijing, Peoples R China. [Chen, Ray Y.] NIAID, NIH, Bethesda, MD 20892 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Shu, YL (reprint author), Natl Hlth & Family Planning Commiss, Natl Inst Viral Dis Control & Prevent Chinese, Chinese Ctr Dis Control & Prevent, Key Lab Med Virol, Beijing, Peoples R China. EM yshu@cnic.org.cn; yuhj@chinacdc.cn OI Chen, Ray/0000-0001-6344-1442 FU National Institute of Allergy and Infectious Diseases (NIAID); U.S. National Institutes of Health [U19 AI51915]; Ministry of Science and Technology (MOST) of the People's Republic of China [2004BA519A71, 2006BAD06A02] FX This study was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (Comprehensive International Program for Research on AIDS grant U19 AI51915, http://www.niaid.nih.gov/Pages/default.aspx), and from the Ministry of Science and Technology (MOST) of the People's Republic of China (2004BA519A71 and 2006BAD06A02, http://www.most.gov.cn/). The NIAID was involved in the study design, data interpretation, and review and approval of the manuscript. The China MOST had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this study are those of the authors and do not represent the policy of their institutions. NR 45 TC 3 Z9 3 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 13 PY 2013 VL 8 IS 8 AR e71765 DI 10.1371/journal.pone.0071765 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 201BN UT WOS:000323115800078 PM 23967241 ER PT J AU Mahamud, A Masunu-Faleafaga, Y Walls, L Williams, N Garcia, P Teshale, E Williams, R Dulski, T Bellini, WJ Kutty, PK AF Mahamud, Abdirahman Masunu-Faleafaga, Yolanda Walls, Laura Williams, Nobia Garcia, Philip Teshale, Eyasu Williams, Roxanne Dulski, Theresa Bellini, William J. Kutty, Preeta K. TI Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination SO VACCINE LA English DT Article DE Seroprevalence; Measles; Mumps; Rubella; American Samoa ID MORTALITY; OUTBREAK; ISLANDS AB Introduction: In line with the global goals for measles elimination, countries in the West Pacific Region (WPR) have set a goal to eliminate measles by 2012. Due to its contagiousness, high population immunity is needed for achieving and documenting measles elimination. We assessed population immunity to measles, mumps and rubella among first grade children in American Samoa (AS) through a seroprevalance study. Methods: Using commercial indirect enzyme-linked immunosorbant IgG assays (Wampole Laboratories, Cranbury, NJ) we determined IgG antibodies against the measles, mumps, and rubella (MMR) viruses in sera collected from first grade students in AS in April-May 2011. Vaccination status was retrieved from the immunization cards. Factors associated with seropositivity of measles, mumps, and rubella were analyzed separately. Result: Among 509 first grade students, measles, mumps, and rubella seroprevalence were 92%, 90%, and 93%, respectively. The proportions of first grade students with documented one or two doses of MMR vaccine were 93% and 84%, respectively. The vaccination status of 6% of the first graders was unknown and 1% was unvaccinated. Receiving two-doses of MMR vaccines was associated with high measles and mumps seropositivity (p <0.01). Conclusion: The high measles seroprevalence among children shows the progress by American Samoa towards measles elimination. Achieving and maintaining high two-dose MMR vaccine coverage in all age groups will aid in attaining the measles elimination status and prevent transmission of measles from potential imported measles cases from other countries. Published by Elsevier Ltd. C1 [Mahamud, Abdirahman; Walls, Laura; Williams, Nobia; Garcia, Philip; Bellini, William J.; Kutty, Preeta K.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Mahamud, Abdirahman; Williams, Roxanne] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Masunu-Faleafaga, Yolanda] Amer Samoa Govt, Dept Hlth, Immunizat Program, Pago Pago, Assam, India. [Teshale, Eyasu; Williams, Roxanne] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Atlanta, GA USA. [Dulski, Theresa] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Mahamud, A (reprint author), 1600 Clifton Rd Ne,MS A-04, Atlanta, GA 30333 USA. EM Amahamud@cdc.gov NR 25 TC 1 Z9 1 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 12 PY 2013 VL 31 IS 36 BP 3683 EP 3687 DI 10.1016/j.vaccine.2013.05.102 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 204YT UT WOS:000323407900010 PM 23770334 ER PT J AU Kelly, S Le, TN Brown, JA Lawaczek, EW Kuehnert, M Rabe, IB Staples, JE Fischer, M AF Kelly, Sharon Le, Tuan N. Brown, Jennifer A. Lawaczek, Elisabeth W. Kuehnert, Matthew Rabe, Ingrid B. Staples, J. Erin Fischer, Marc TI Fatal West Nile Virus Infection After Probable Transfusion-Associated Transmission - Colorado, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID BLOOD-TRANSFUSION; UNITED-STATES; ASSAYS C1 [Kelly, Sharon] Presbyterian St Lukes Med Ctr, Denver, CO USA. [Le, Tuan N.] Bonfils Blood Ctr, Denver, CO USA. [Rabe, Ingrid B.; Staples, J. Erin; Fischer, Marc] CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Rabe, IB (reprint author), CDC, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM irabe@cdc.gov NR 10 TC 18 Z9 18 U1 0 U2 4 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 9 PY 2013 VL 62 IS 31 BP 622 EP 624 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 197SE UT WOS:000322870100002 ER PT J AU Barfield, W D'Angelo, D Moon, R Lu, M Wong, B Iskander, J AF Barfield, Wanda D'Angelo, Denise Moon, Rachel Lu, Michael Wong, Betty Iskander, John TI CDC Grand Rounds: Public Health Approaches to Reducing US Infant Mortality SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PRETERM BIRTH C1 [Barfield, Wanda; D'Angelo, Denise] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Wong, Betty; Iskander, John] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA. RP Barfield, W (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM wbarfield@cdc.gov NR 8 TC 12 Z9 12 U1 0 U2 6 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 9 PY 2013 VL 62 IS 31 BP 625 EP 628 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 197SE UT WOS:000322870100003 ER PT J AU May, AL Pan, LP Sherry, B Blanck, HM Galuska, D Dalenius, K Polhamus, B Kettel-Khan, L Grummer-Strawn, LM AF May, Ashleigh L. Pan, Liping Sherry, Bettylou Blanck, Heidi M. Galuska, Deborah Dalenius, Karen Polhamus, Barbara Kettel-Khan, Laura Grummer-Strawn, Laurence M. TI Vital Signs: Obesity Among Low-Income, Preschool-Aged Children - United States, 2008-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CHILDHOOD OBESITY; PREVALENCE; OVERWEIGHT; TRENDS AB Background: The prevalence of obesity among U. S. preschoolers has doubled in recent decades. Childhood obesity increases the risk for adult obesity and is associated with negative health consequences. Trends in the state-specific prevalence of obesity among low-income U. S. preschool children have not been examined since 2008. State-specific obesity prevalence surveillance helps determine the need for and impact of state and local obesity prevention strategies. Methods: Measured weight and height data from approximately 11.6 million low-income children aged 2-4 years from 40 states, the District of Columbia, and two U. S. territories who participated in the Pediatric Nutrition Surveillance System during 2008-2011 were used to estimate state obesity prevalence. Obesity was defined as having an age-and sex-specific body mass index >= 95th percentile, according to the 2000 CDC growth charts. Logistic regression models adjusted for age, sex, and race/ethnicity were used to examine trends in the state-specific obesity prevalence. Results: During 2008-2011, statistically significant downward trends in obesity prevalence were observed in 18 states and the U. S. Virgin Islands. Florida, Georgia, Missouri, New Jersey, South Dakota, and the U. S. Virgin Islands had the largest absolute decreases in obesity prevalence, each with a decrease of >= 1 percentage point. Twenty states and Puerto Rico experienced no significant change, and obesity prevalence increased significantly in three states. Conclusions and Implications for Public Health Practice: Small but significant declines in obesity among low-income preschoolers were observed in 19 of 43 states/territories examined. Continued prevention efforts are needed to sustain and expand the implementation and evaluation of population-level interventions to prevent childhood obesity. C1 [May, Ashleigh L.; Pan, Liping; Sherry, Bettylou; Blanck, Heidi M.; Galuska, Deborah; Dalenius, Karen; Polhamus, Barbara; Kettel-Khan, Laura; Grummer-Strawn, Laurence M.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP May, AL (reprint author), CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM amay@cdc.gov NR 19 TC 50 Z9 50 U1 2 U2 36 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 9 PY 2013 VL 62 IS 31 BP 629 EP 634 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 197SE UT WOS:000322870100004 ER PT J AU Jaffe, HW Patterson, AP Lurie, N AF Jaffe, Harold W. Patterson, Amy P. Lurie, Nicole TI Extra oversight for H7N9 experiments SO NATURE LA English DT Letter C1 [Jaffe, Harold W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Patterson, Amy P.] NIH, Bethesda, MD 20892 USA. [Lurie, Nicole] US Dept HHS, Washington, DC 20201 USA. RP Jaffe, HW (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM pattersa@od.nih.gov NR 1 TC 4 Z9 4 U1 0 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD AUG 8 PY 2013 VL 500 IS 7461 BP 151 EP 151 PG 1 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 197CH UT WOS:000322825500017 PM 23925232 ER PT J AU Mackay, AJ Amador, M Barrera, R AF Mackay, Andrew J. Amador, Manuel Barrera, Roberto TI An improved autocidal gravid ovitrap for the control and surveillance of Aedes aegypti SO PARASITES & VECTORS LA English DT Article DE Aedes aegypti; Oviposition; Sticky ovitraps; Vector surveillance; Puerto Rico ID CONTAINER-BREEDING MOSQUITOS; DENGUE-ENDEMIC AREA; LETHAL OVITRAP; POPULATION-DYNAMICS; DIPTERA-CULICIDAE; STICKY TRAP; PUERTO-RICO; OVIPOSITION BEHAVIOR; ALBOPICTUS DIPTERA; NORTH QUEENSLAND AB Background: Limited success has been achieved using traditional vector control methods to prevent the transmission of dengue viruses. Integrated control programs incorporating alternative tools, such as gravid ovitraps (lethal ovitraps and sticky ovitraps) may provide greater potential for monitoring and reducing vector populations and dengue virus transmission. We had developed an autocidal gravid ovitrap (AGO) as a simple, low-cost device for surveillance and control of Ae. aegypti without the use of pesticides that does not require servicing for an extended period of time. The purpose of our study was to improve the efficacy and efficiency of this device. Methods: Competitive assays were performed in the laboratory and an outdoor cage to evaluate whether modifications to the structure and appearance of our original trap design (AGO-A), and the addition of an olfactory bait (hay infusion), improve trap function. The performance of a modified trap design (AGO-B) was then assessed and compared with conventional ovitraps in a series of field tests in San Juan City, Puerto Rico. Generalized linear mixed models were used to analyze adult Ae. aegypti capture data from the laboratory, outdoor cage and field experiments. Results: Increasing the size of the trap entrance, altering the color of trap components, and increasing the volume/surface area of the aqueous bait significantly improved the performance of the AGO in the outdoor cage. In a subsequent field comparison, captures of Ae. aegypti females were 3.7 fold greater in the improved trap (AGO-B), compared with the original design (AGO-A). An infusion bait produced "in situ" significantly improved capture rates of the improved trap under both semi-natural and field conditions. Semi-weekly collections of Ae. aegypti females in the AGO-B were significantly correlated with cumulative rainfall 8 to 28 days prior to sampling, whereas egg collections in paired conventional ovitraps were not. When vector abundance was low, the AGO-B provided greater sensitivity and precision as a surveillance device, compared with paired conventional ovitraps. Conclusions: The AGO-B can be used to efficiently attract and capture gravid Ae. aegypti females for more than 8 weeks without the need for trap maintenance. C1 [Mackay, Andrew J.; Amador, Manuel; Barrera, Roberto] Ctr Dis Control & Prevent, Dengue Branch, San Juan, PR 00959 USA. [Mackay, Andrew J.] Univ Illinois, Dept Entomol, Urbana, IL 61801 USA. RP Mackay, AJ (reprint author), Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00959 USA. EM amackay@illinois.edu FU US Centers for Disease Control and Prevention (CDC) FX The authors declare that they have no competing interests. This research was fully funded by the US Centers for Disease Control and Prevention (CDC) which holds a provisional patent for the devices described in this manuscript (autocidal gravid ovitraps). NR 67 TC 19 Z9 20 U1 0 U2 31 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD AUG 6 PY 2013 VL 6 AR 225 DI 10.1186/1756-3305-6-225 PG 13 WC Parasitology SC Parasitology GA 201IR UT WOS:000323134400001 PM 23919568 ER PT J AU Hare, KM Singleton, RJ Grimwood, K Valery, PC Cheng, AC Morris, PS Leach, AJ Smith-Vaughan, HC Chatfield, M Redding, G Reasonover, AL McCallum, GB Chikoyak, L McDonald, MI Brown, N Torzillo, PJ Chang, AB AF Hare, Kim M. Singleton, Rosalyn J. Grimwood, Keith Valery, Patricia C. Cheng, Allen C. Morris, Peter S. Leach, Amanda J. Smith-Vaughan, Heidi C. Chatfield, Mark Redding, Greg Reasonover, Alisa L. McCallum, Gabrielle B. Chikoyak, Lori McDonald, Malcolm I. Brown, Ngiare Torzillo, Paul J. Chang, Anne B. TI Longitudinal Nasopharyngeal Carriage and Antibiotic Resistance of Respiratory Bacteria in Indigenous Australian and Alaska Native Children with Bronchiectasis SO PLOS ONE LA English DT Article ID CYSTIC FIBROSIS BRONCHIECTASIS; RANDOMIZED CONTROLLED-TRIAL; STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; HAEMOPHILUS-INFLUENZAE; MORAXELLA-CATARRHALIS; HEALTHY-CHILDREN; KILIFI DISTRICT; CO-COLONIZATION; DOUBLE-BLIND AB Background: Indigenous children in Australia and Alaska have very high rates of chronic suppurative lung disease (CSLD)/bronchiectasis. Antibiotics, including frequent or long-term azithromycin in Australia and short-term beta-lactam therapy in both countries, are often prescribed to treat these patients. In the Bronchiectasis Observational Study we examined over several years the nasopharyngeal carriage and antibiotic resistance of respiratory bacteria in these two PCV7-vaccinated populations. Methods: Indigenous children aged 0.5-8.9 years with CSLD/bronchiectasis from remote Australia (n = 79) and Alaska (n = 41) were enrolled in a prospective cohort study during 2004-8. At scheduled study visits until 2010 antibiotic use in the preceding 2-weeks was recorded and nasopharyngeal swabs collected for culture and antimicrobial susceptibility testing. Analysis of respiratory bacterial carriage and antibiotic resistance was by baseline and final swabs, and total swabs by year. Results: Streptococcus pneumoniae carriage changed little over time. In contrast, carriage of Haemophilus influenzae declined and Staphylococcus aureus increased (from 0% in 2005-6 to 23% in 2010 in Alaskan children); these changes were associated with increasing age. Moraxella catarrhalis carriage declined significantly in Australian, but not Alaskan, children (from 64% in 2004-6 to 11% in 2010). While beta-lactam antibiotic use was similar in the two cohorts, Australian children received more azithromycin. Macrolide resistance was significantly higher in Australian compared to Alaskan children, while H. influenzae beta-lactam resistance was higher in Alaskan children. Azithromycin use coincided significantly with reduced carriage of S. pneumoniae, H. influenzae and M. catarrhalis, but increased carriage of S. aureus and macrolide-resistant strains of S. pneumoniae and S. aureus (proportion of carriers and all swabs), in a 'cumulative dose-response' relationship. Conclusions: Over time, similar (possibly age-related) changes in nasopharyngeal bacterial carriage were observed in Australian and Alaskan children with CSLD/bronchiectasis. However, there were also significant frequency-dependent differences in carriage and antibiotic resistance that coincided with azithromycin use. C1 [Hare, Kim M.; Valery, Patricia C.; Morris, Peter S.; Leach, Amanda J.; Smith-Vaughan, Heidi C.; Chatfield, Mark; McCallum, Gabrielle B.; Chang, Anne B.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia. [Singleton, Rosalyn J.] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Singleton, Rosalyn J.; Reasonover, Alisa L.] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK USA. [Grimwood, Keith] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia. [Grimwood, Keith] Royal Childrens Hosp, Dept Infect Dis, Brisbane, Qld, Australia. [Cheng, Allen C.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Cheng, Allen C.] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia. [Morris, Peter S.] Royal Darwin Hosp, Darwin, NT, Australia. [Redding, Greg] Univ Washington, Sch Med, Seattle, WA USA. [Redding, Greg] Childrens Hosp & Reg Med Ctr, Div Pulm, Seattle, WA USA. [Chikoyak, Lori] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. [McDonald, Malcolm I.] James Cook Univ, Sch Med & Dent, Cairns, Qld, Australia. [Brown, Ngiare] Univ Wollongong, Wollongong, NSW, Australia. [Brown, Ngiare] Australian Indigenous Doctors Assoc, Parkes, ACT, Australia. [Torzillo, Paul J.] Nganampa Hlth Council, Alice Springs, NT, Australia. [Torzillo, Paul J.] Royal Prince Alfred Hosp, Sydney, NSW, Australia. [Torzillo, Paul J.] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia. [Chang, Anne B.] Royal Childrens Hosp, Queensland Childrens Med Res Inst, Dept Resp Med, Brisbane, Qld, Australia. RP Hare, KM (reprint author), Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia. EM kim.hare@menzies.edu.au RI VALERY, Patricia/G-6230-2013; Hare, Kim/N-2300-2013; Chatfield, Mark/N-2278-2013; OI VALERY, Patricia/0000-0002-8823-3006; Chatfield, Mark/0000-0002-0004-6274; Cheng, Allen/0000-0003-3152-116X FU National Health and Medical Research Council of Australia (National Health and Medical Research Council (NHMRC)) [389837]; National Health and Medical Research Council of Australia [545223]; National Health and Medical Research Council of Australia (Centre for Research Excellence in Lung Health of Aboriginal and Torres Strait Islanders) [1040830]; National Institutes of Health; National Heart Lung and Blood Institute [U26IHS3000001/01]; NHMRC [1038072, 1009945, 1024175, 545216, 1020561]; Australian Academy of Science's Douglas and Lola Douglas Scholarship; Australian Research Council [100100511] FX This work was supported by the National Health and Medical Research Council of Australia (http://www.nhmrc.gov.au/, National Health and Medical Research Council (NHMRC) project grants 389837 (clinical component) and 545223 (microbiology component), and Centre for Research Excellence in Lung Health of Aboriginal and Torres Strait Islanders grant 1040830). The Alaskan study site received funding from the National Institutes of Health (http://www.nih.gov/) and the National Heart Lung and Blood Institute (http://www.nhlbi.nih.gov/, No. U26IHS3000001/01). KMH is supported by the NHMRC Gustav Nossal Postgraduate Scholarship 1038072 and the Australian Academy of Science's (http://science.org.au/) Douglas and Lola Douglas Scholarship; PCV is supported by an Australian Research Council (http://www.arc.gov.au/) Future Fellowship No. 100100511; ACC and HSV are funded by NHMRC Career Development Fellowships 1009945 and 1024175; AJL is supported by the NHMRC Elizabeth Blackburn Research Fellowship 1020561; and ABC is supported by a NHMRC Practitioner Fellowship 545216. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 13 Z9 15 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 5 PY 2013 VL 8 IS 8 AR e70478 DI 10.1371/journal.pone.0070478 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 218XC UT WOS:000324465000076 PM 23940582 ER PT J AU Monteiro, FA Peretolchina, T Lazoski, C Harris, K Dotson, EM Abad-Franch, F Tamayo, E Pennington, PM Monroy, C Cordon-Rosales, C Salazar-Schettino, PM Gomez-Palacio, A Grijalva, MJ Beard, CB Marcet, PL AF Monteiro, Fernando A. Peretolchina, Tatiana Lazoski, Cristiano Harris, Kecia Dotson, Ellen M. Abad-Franch, Fernando Tamayo, Elsa Pennington, Pamela M. Monroy, Carlota Cordon-Rosales, Celia Maria Salazar-Schettino, Paz Gomez-Palacio, Andres Grijalva, Mario J. Beard, Charles B. Marcet, Paula L. TI Phylogeographic Pattern and Extensive Mitochondrial DNA Divergence Disclose a Species Complex within the Chagas Disease Vector Triatoma dimidiata SO PLOS ONE LA English DT Article ID MAXIMUM-LIKELIHOOD; PHYLOGENETIC-RELATIONSHIPS; EVOLUTIONARY RATES; TRYPANOSOMA-CRUZI; GENETIC-VARIATION; INSECT VECTORS; REDUVIIDAE; HEMIPTERA; POPULATIONS; GUATEMALA AB Background: Triatoma dimidiata is among the main vectors of Chagas disease in Latin America. However, and despite important advances, there is no consensus about the taxonomic status of phenotypically divergent T. dimidiata populations, which in most recent papers are regarded as subspecies. Methodology and Findings: A total of 126 cyt b sequences (621 bp long) were produced for specimens from across the species range. Forty-seven selected specimens representing the main cyt b clades observed (after a preliminary phylogenetic analysis) were also sequenced for an ND4 fragment (554 bp long) and concatenated with their respective cyt b sequences to produce a combined data set totalling 1175 bp/individual. Bayesian and Maximum-Likelihood phylogenetic analyses of both data sets (cyt b, and cyt b+ND4) disclosed four strongly divergent (all pairwise Kimura 2-parameter distances >0.08), monophyletic groups: Group I occurs from Southern Mexico through Central America into Colombia, with Ecuadorian specimens resembling Nicaraguan material; Group II includes samples from Western-Southwestern Mexico; Group III comprises specimens from the Yucatan peninsula; and Group IV consists of sylvatic samples from Belize. The closely-related, yet formally recognized species T. hegneri from the island of Cozumel falls within the divergence range of the T. dimidiata populations studied. Conclusions: We propose that Groups I-IV, as well as T. hegneri, should be regarded as separate species. In the Peten of Guatemala, representatives of Groups I, II, and III occur in sympatry; the absence of haplotypes with intermediate genetic distances, as shown by multimodal mismatch distribution plots, clearly indicates that reproductive barriers actively promote within-group cohesion. Some sylvatic specimens from Belize belong to a different species - likely the basal lineage of the T. dimidiata complex, originated similar to 8.25 Mya. The evidence presented here strongly supports the proposition that T. dimidiata is a complex of five cryptic species (Groups I-IV plus T. hegneri) that play different roles as vectors of Chagas disease in the region. C1 [Monteiro, Fernando A.] Fiocruz MS, Lab Epidemiol & Sistema Mol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil. [Peretolchina, Tatiana] Russian Acad Sci, Inst Limnol, Lab Mol Systemat, Siberian Branch, Irkutsk 664003, Russia. [Lazoski, Cristiano] Univ Fed Rio de Janeiro, Inst Biol, Rio De Janeiro, Brazil. [Harris, Kecia; Dotson, Ellen M.; Marcet, Paula L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA USA. [Abad-Franch, Fernando] Fiocruz Amazonia, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil. [Tamayo, Elsa] Univ Guadalajara, Area Entomol Med, Ctr Univ Sur, Ciudad Guzman, Mexico. [Pennington, Pamela M.] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Monroy, Carlota] Univ San Carlos, Fac Ciencias Quim & Farm, Lab Appl Entomol & Parasitol, Ciudad De Guatemala, Guatemala. [Maria Salazar-Schettino, Paz] Univ Nacl Autonoma Mexico, Lab Biol Parasitos, Dept Microbiol & Parasitol, Ciudad De Mexico, Mexico. [Gomez-Palacio, Andres] Univ Antioquia, Inst Biol, Grp Biol & Control Enfermedades Infecc, Medellin, Colombia. [Grijalva, Mario J.] Ohio Univ, Trop Dis Inst, Dept Biomed Sci, Heritage Coll Osteopath Med, Athens, OH 45701 USA. [Beard, Charles B.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. RP Monteiro, FA (reprint author), Fiocruz MS, Lab Epidemiol & Sistema Mol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil. EM fermonte@globo.com RI Lazoski, Cristiano/H-6192-2013; Abad-Franch, Fernando/L-4741-2013; OI Grijalva, Mario/0000-0003-1964-1425; Marcet, Paula/0000-0002-0676-3020; Gomez-Palacio, Andres/0000-0002-1069-9199 FU CODI-Universidad de Antioquia [CPT-0812]; COLCIENCIAS [111545921460]; Brazilian National Research Council, CNPq FX AGP received support from CODI-Universidad de Antioquia (project CPT-0812), and COLCIENCIAS (project #111545921460). This work received support from the Brazilian National Research Council, CNPq. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 21 Z9 21 U1 2 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 5 PY 2013 VL 8 IS 8 AR e70974 DI 10.1371/journal.pone.0070974 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 218XC UT WOS:000324465000166 PM 23940678 ER PT J AU Perelygina, L Zheng, Q Metcalfe, M Icenogle, J AF Perelygina, Ludmila Zheng, Qi Metcalfe, Maureen Icenogle, Joseph TI Persistent Infection of Human Fetal Endothelial Cells with Rubella Virus SO PLOS ONE LA English DT Article ID HEMODYNAMIC SHEAR-STRESS; CONGENITAL-RUBELLA; HUMAN CYTOMEGALOVIRUS; LYTIC INFECTION; MEASLES-VIRUS; KIDNEY CELLS; VERO CELLS; HOST-CELL; REPLICATION; PATHOLOGY AB Cardiovascular abnormalities are the leading cause of neonatal death among patients with congenital rubella syndrome (CRS). Although persistence of rubella virus (RV) in fetal endothelium has been repeatedly suggested as a possible cause of cardiovascular birth defects, evidence of the permissiveness of fetal endothelial cells to RV is lacking. In this study we evaluated the ability of RV to infect and persist in primary fetal endothelial cells derived from human umbilical vein (HUVEC). We found that wild type (wt) low passage clinical RV productively infected HUVEC cultures without producing cytopathology or ultrastructural changes. RV did not inhibit host cell protein synthesis, cell proliferation, or interfere with the cell cycle. Persistently infected cultures were easily established at low and high multiplicities of infection (MOI) with both laboratory and wt clinical RV strains. However, synchronous infections of entire HUVEC monolayers were only observed with clinical RV strains. The release of infectious virions into media remained at consistently high levels for several subcultures of infected HUVEC. The results indicate that macrovascular fetal endothelial cells are highly permissive to RV and allow slow persistent RV replication. The findings provide more evidence for the suggestion that vascular pathologies in CRS are triggered by persistent rubella virus infection of the endothelium. C1 [Perelygina, Ludmila; Zheng, Qi; Metcalfe, Maureen; Icenogle, Joseph] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Icenogle, J (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM jci1@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by core funding from the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 75 TC 3 Z9 3 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 5 PY 2013 VL 8 IS 8 AR e73014 DI 10.1371/journal.pone.0073014 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 218XC UT WOS:000324465000250 PM 23940821 ER PT J AU Zhu, J Wang, H Yang, S Guo, LQ Li, Z Wang, W Wang, SH Huang, WT Wang, LP Yang, T Ma, Q Bi, YY AF Zhu, Jie Wang, Hong Yang, Shuo Guo, Liqiao Li, Zhen Wang, Wei Wang, Suhan Huang, Wenting Wang, Liping Yang, Tan Ma, Qiang Bi, Yongyi TI Comparison of Toxicity of Benzene Metabolite Hydroquinone in Hematopoietic Stem Cells Derived from Murine Embryonic Yolk Sac and Adult Bone Marrow SO PLOS ONE LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE CATALYTIC SUBUNIT; PROGENITOR CELLS; CHILDHOOD-CANCER; PRENATAL ORIGIN; GENE-EXPRESSION; IN-VITRO; EXPOSURE; BLOOD; HEMATOTOXICITY AB Benzene is an occupational toxicant and an environmental pollutant that potentially causes hematotoxicity and leukemia in exposed populations. Epidemiological studies suggest an association between an increased incidence of childhood leukemia and benzene exposure during the early stages of pregnancy. However, experimental evidence supporting the association is lacking at the present time. It is believed that benzene and its metabolites target hematopoietic stem cells (HSCs) to cause toxicity and cancer in the hematopoietic system. In the current study, we compared the effects of hydroquinone (HQ), a major metabolite of benzene in humans and animals, on mouse embryonic yolk sac hematopoietic stem cells (YS-HSCs) and adult bone marrow hematopoietic stem cells (BM-HSCs). YS-HSCs and BM-HSCs were isolated and enriched, and were exposed to HQ at increasing concentrations. HQ reduced the proliferation and the differentiation and colony formation, but increased the apoptosis of both YS-HSCs and BM-HSCs. However, the cytotoxic and apoptotic effects of HQ were more apparent and reduction of colony formation by HQ was more severe in YS-HSCs than in BM-HSCs. Differences in gene expression profiles were observed in HQ-treated YS-HSCs and BM-HSCs. Cyp4f18 was induced by HQ both in YS-HSCs and BM-HSCs, whereas DNA-PKcs was induced in BM-HSCs only. The results revealed differential effects of benzene metabolites on embryonic and adult HSCs. The study established an experimental system for comparison of the hematopoietic toxicity and leukemogenicity of benzene and metabolites during mouse embryonic development and adulthood. C1 [Zhu, Jie; Wang, Hong; Yang, Shuo; Li, Zhen; Wang, Wei; Wang, Suhan; Huang, Wenting; Wang, Liping; Yang, Tan; Bi, Yongyi] Wuhan Univ, Sch Publ Hlth, Wuhan 430072, Hubei, Peoples R China. [Zhu, Jie; Wang, Hong; Yang, Shuo; Li, Zhen; Wang, Wei; Wang, Suhan; Huang, Wenting; Wang, Liping; Yang, Tan; Bi, Yongyi] Hubei Key Lab Allergy & Immune Related Dis, Wuhan, Hubei, Peoples R China. [Zhu, Jie; Wang, Hong; Yang, Shuo; Li, Zhen; Wang, Wei; Wang, Suhan; Huang, Wenting; Wang, Liping; Yang, Tan; Bi, Yongyi] Wuhan Univ, Hubei Biomass Resource Chem & Environm Biotechnol, Wuhan 430072, Hubei, Peoples R China. [Guo, Liqiao] China CDC XiAn City, Xian, Shanxi, Peoples R China. [Ma, Qiang] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Morgantown, WV USA. RP Bi, YY (reprint author), Wuhan Univ, Sch Publ Hlth, Wuhan 430072, Hubei, Peoples R China. EM yongyib@yahoo.com.cn FU Chinese National Natural Science Foundation [81072276, 81102104]; Self-research program for Doctoral Candidates of Wuhan University [2012305020203] FX The project was supported by Chinese National Natural Science Foundation to Y. Bi (Grant No. 81072276); Chinese National Natural Science Foundation to H. Wang (Grant No. 81102104), http://www.nsfc.gov.cn/Portal0/default166.htm; and Self-research program for Doctoral Candidates of Wuhan University (Grant No. 2012305020203), http://en.whu.edu.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 7 Z9 9 U1 1 U2 20 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD AUG 5 PY 2013 VL 8 IS 8 AR e71153 DI 10.1371/journal.pone.0071153 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 218XC UT WOS:000324465000185 PM 23940708 ER PT J AU Schoub, BD Gessner, BD Ampofo, W Cohen, AL Steffen, CA AF Schoub, Barry D. Gessner, Bradford D. Ampofo, William Cohen, Adam L. Steffen, Christoph A. TI Afriflu2-Second international workshop on influenza vaccination in the African continent-8 November 2012, Cape Town (South Africa) SO VACCINE LA English DT Article DE Conference report; Influenza; Africa; Illness burden; Vaccines; Priority groups; Vaccine security ID LABORATORY-CONFIRMED INFLUENZA; YOUNG-CHILDREN; RESPIRATORY ILLNESS; CONTROLLED-TRIAL; VIRAL ETIOLOGY; UNITED-STATES; DOUBLE-BLIND; SURVEILLANCE; MORTALITY; EFFICACY AB The second meeting of the Afriflu conferences took place in Cape Town, South Africa, with over 60 participants from 15 countries in Africa and also outside the continent. Significant progress in surveillance has been made in better understanding the illness burden of influenza on the continent, which limited evidence suggests is greater than that in the developed world. In southern Africa HIV and TB coinfections play a major role in increasing hospitalisation and mortality, while elsewhere in Africa other cofactors still need to be determined. There is currently no indigenous vaccine production in sub-Saharan Africa and only one facility, based in South Africa, capable of filling imported bulk. Innovative vaccine strategies will need to be explored, such as maternal immunisation, and also the possibility of other influenza vaccine options, such as live attenuated influenza vaccine for young children. Sustained indigenous vaccine production is essential for the continent to have vaccine security in the event of a pandemic even though establishing local production faces considerable challenges especially ensuring adequate markets on the continent. There is an urgent need to develop effective communication messages for decision makers as well as healthcare workers addressing the importance of influenza even in the face of the major competing health burdens of the continent. (c) 2013 The Authors. Published by Elsevier Ltd. All rights reserved. C1 [Schoub, Barry D.] Univ Witwatersrand, Dept Virol, Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Gessner, Bradford D.; Steffen, Christoph A.] Agence Med Prevent, F-01210 Ferney Voltaire, France. [Ampofo, William] Univ Ghana, Noguchi Mem Inst Med Res, Legon, Ghana. [Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Program, Pretoria, South Africa. [Cohen, Adam L.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Steffen, CA (reprint author), Agence Med Prevent, 13 Chemin Levant, F-01210 Ferney Voltaire, France. EM csteffen@aamp.org FU Sanofi Pasteur FX The 'Afriflu2' workshop was supported by Sanofi Pasteur. Sanofi Pasteur did not have any control over the conference agenda (which was determined by an Independent Scientific Committee) or the conference content (which was determined by the authors of the various presentations). Sanofi Pasteur did not have any editorial control over the contents of the current manuscript, which is solely the work of the authors. NR 37 TC 6 Z9 6 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 2 PY 2013 VL 31 IS 35 BP 3461 EP 3466 DI 10.1016/j.vaccine.2013.04.021 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 205PX UT WOS:000323457900001 PM 23602535 ER PT J AU Izurieta, HS Zuber, P Bonhoeffer, J Chen, RT Sankohg, O Laserson, KF Sturkenboom, M Loucq, C Weibel, D Dodd, C Black, S AF Izurieta, Hector S. Zuber, Patrick Bonhoeffer, Jan Chen, Robert T. Sankohg, Osman Laserson, Kayla F. Sturkenboom, Miriam Loucq, Christian Weibel, Daniel Dodd, Caitlin Black, Steve TI Roadmap for the international collaborative epidemiologic monitoring of safety and effectiveness of new high priority vaccines SO VACCINE LA English DT Article DE Vaccine; Safety; Effectiveness; Adverse events; Benefit-risk ID GUILLAIN-BARRE-SYNDROME; EVENT REPORTING SYSTEM; ROTAVIRUS VACCINATION; CASE SERIES; IMMUNIZATION; RISK; INTUSSUSCEPTION; CHILDREN; BENEFITS; PROGRAM AB With the advent of new vaccines targeted to highly endemic diseases in low- and middle-income countries (LMIC) and with the expansion of vaccine manufacturing globally, there is an urgent need to establish an infrastructure to evaluate the benefit-risk profiles of vaccines in LMIC. Fortunately the usual decade(s)-long time gap between introduction of new vaccines in high and low income countries is being significantly reduced or eliminated due to initiatives such as the Global Alliance for Vaccines and Immunizations (GAVI) and the Decade of Vaccines for the implementation of the Global Vaccine Action Plan. While hoping for more rapid disease control, this time shift may potentially add risk, unless appropriate capacity for reliable and timely evaluation of vaccine benefit-risk profiles in some LMIC's are developed with external assistance from regional or global level. An ideal vaccine safety and effectiveness monitoring system should be flexible and sustainable, able to quickly detect possible vaccine-associated events, distinguish them from programmatic errors, reliably and quickly evaluate the suspected event and its association with vaccination and, if associated, determine the benefit-risk of vaccines to inform appropriate action. Based upon the demonstrated feasibility of active surveillance in LMIC as shown by the Burkina Faso assessment of meningococcal A conjugate vaccine or that of rotavirus vaccine in Mexico and Brazil, and upon the proof of concept international GBS study, we suggest a sustainable, flexible, affordable and timely international collaborative vaccine safety monitoring approach for vaccines being newly introduced. While this paper discusses only the vaccine component, the same system could also be eventually used for monitoring drug effectiveness (including the use of substandard drugs) and drug safety. Published by Elsevier Ltd. C1 [Izurieta, Hector S.] US FDA, Rockville, MD 20852 USA. [Zuber, Patrick] WHO, CH-1211 Geneva, Switzerland. [Bonhoeffer, Jan] Brighton Collaborat Fdn, Basel, Switzerland. [Bonhoeffer, Jan] Univ Basel, Univ Childrens Hosp Basel, Basel, Switzerland. [Chen, Robert T.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Sankohg, Osman] INDEPTH Network, Accra, Ghana. [Sankohg, Osman] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Sankohg, Osman] Hanoi Med Sch, Hanoi, Vietnam. [Laserson, Kayla F.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. [Sturkenboom, Miriam; Weibel, Daniel] Erasmus Univ, Med Ctr, Rotterdam, Netherlands. [Loucq, Christian] Int Vaccine Inst, Seoul, South Korea. [Dodd, Caitlin; Black, Steve] Univ Cincinnati, Univ Childrens Hosp, Cincinnati, OH 45221 USA. RP Izurieta, HS (reprint author), US FDA, Immediate Off Director, OBE CBER, 1401 Rockville Pike,2nd Floor,Suite 200S,HFM-225, Rockville, MD 20852 USA. EM hector.izurieta@fda.hhs.gov RI Bonhoeffer, Jan/E-5903-2014 FU SIDA; Hewlett Foundation; Wellcome Trust; Gates Foundation FX Osman Sankoh is the Executive Director of the INDEPTH Network, funded by core support grants from SIDA, Hewlett Foundation, Wellcome Trust and the Gates Foundation. NR 33 TC 7 Z9 7 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD AUG 2 PY 2013 VL 31 IS 35 BP 3623 EP 3627 DI 10.1016/j.vaccine.2013.05.027 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 205PX UT WOS:000323457900022 PM 23707171 ER PT J AU Kristiansen, PA Ba, AK Sanou, I Ouedraogo, AS Ouedraogo, R Sangare, L Diomande, F Kandolo, D Thomas, JD Clark, TA LaForce, M Caugant, DA AF Kristiansen, Paul A. Ba, Absatou Ky Sanou, Idrissa Ouedraogo, Abdoul-Salam Ouedraogo, Rasmata Sangare, Lassana Diomande, Fabien Kandolo, Denis Thomas, Jennifer Dolan Clark, Thomas A. LaForce, Marc Caugant, Dominique A. TI Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine SO BMC INFECTIOUS DISEASES LA English DT Article DE Neisseria meningitidis; Carriage; Meningitis; Burkina Faso; Conjugate vaccine; MLST; Meningitis belt ID NEISSERIA-MENINGITIDIS; PHARYNGEAL CARRIAGE; CAPSULE REPLACEMENT; CLONAL EXPANSION; EPIDEMIC; AFRICA; W135; SURVEILLANCE; STRAINS; IDENTIFICATION AB Background: The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first introduced in mass vaccination campaigns of the 1-29-year-olds in Burkina Faso in 2010. The aim of this study was to genetically characterize meningococcal isolates circulating in Burkina Faso before and up to 13 months after MenAfriVac mass vaccination. Methods: A total of 1,659 meningococcal carriage isolates were collected in a repeated cross-sectional carriage study of the 1-29-year-olds in three districts of Burkina Faso in 2010 and 2011, before and up to 13 months after mass vaccination. Forty-two invasive isolates were collected through the national surveillance in Burkina Faso in the same period. All the invasive isolates and 817 carriage isolates were characterized by serogroup, multilocus sequence typing and porA-fetA sequencing. Results: Seven serogroup A isolates were identified, six in 2010, before vaccination (4 from carriers and 2 from patients), and one in 2011 from an unvaccinated patient; all were assigned to sequence type (ST)-2859 of the ST-5 clonal complex. No NmA carriage isolate and no ST-2859 isolate with another capsule were identified after vaccination. Serogroup X carriage and disease prevalence increased before vaccine introduction, due to the expansion of ST-181, which comprised 48.5% of all the characterized carriage isolates. The hypervirulent serogroup W ST-11 clone that was responsible for most of meningococcal disease in 2011 and 2012 was not observed in 2010; it appeared during the epidemic season of 2011, when it represented 40.6% of the serogroup W carriage isolates. Conclusions: Successive clonal waves of ST-181 and ST-11 may explain the changing epidemiology in Burkina Faso after the virtual disappearance of NmA disease and carriage. No ST-2859 strain of any serogroup was found after vaccination, suggesting that capsule switching of ST-2859 did not occur, at least not during the first 13 months after vaccination. C1 [Kristiansen, Paul A.; Caugant, Dominique A.] Norwegian Inst Publ Hlth, Oslo, Norway. [Ba, Absatou Ky] Lab Natl Sante Publ, Ouagadougou, Burkina Faso. [Sanou, Idrissa; Ouedraogo, Abdoul-Salam] Ctr Hosp Univ Souro Sanou, Bobo Dioulasso, Burkina Faso. [Sanou, Idrissa; Sangare, Lassana] Ctr Hosp Univ Yalgado, Ouagadougou, Burkina Faso. [Ouedraogo, Rasmata] Ctr Hosp Univ Pediat Charles de Gaulle Ouagadougo, Ouagadougou, Burkina Faso. [Diomande, Fabien; Kandolo, Denis] WHO Inter Country Support Team, Ouagadougou, Burkina Faso. [Diomande, Fabien; Thomas, Jennifer Dolan; Clark, Thomas A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [LaForce, Marc] Meningitis Vaccine Project, Ferney, France. [Caugant, Dominique A.] Univ Oslo, Fac Med, Oslo, Norway. RP Kristiansen, PA (reprint author), Norwegian Inst Publ Hlth, Oslo, Norway. EM paul.kristiansen@fhi.no FU Research Council of Norway [185784, 196327] FX The project was supported by the Research Council of Norway, grants no. 185784 and 196327 to D.A.C. NR 49 TC 7 Z9 7 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD AUG 2 PY 2013 VL 13 AR 363 DI 10.1186/1471-2334-13-363 PG 10 WC Infectious Diseases SC Infectious Diseases GA 199NP UT WOS:000323002000001 PM 23914778 ER PT J AU Kegler, SR Mercy, JA AF Kegler, Scott R. Mercy, James A. TI Firearm Homicides and Suicides in Major Metropolitan Areas - United States, 2006-2007 and 2009-2010 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Kegler, Scott R.] CDC, Div Anal Res & Practice Integrat, Atlanta, GA 30333 USA. [Mercy, James A.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Kegler, SR (reprint author), CDC, Div Anal Res & Practice Integrat, Atlanta, GA 30333 USA. EM skegler@cdc.gov NR 10 TC 4 Z9 4 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 2 PY 2013 VL 62 IS 30 BP 597 EP 602 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 194IR UT WOS:000322625700001 ER PT J AU Tobin-D'Angelo, M Martyn, A Moore, A Dishman, H Drenzek, C Turner, K Hicks, L Diaz, M Petrone, B Wolff, B Benitez, A Winchell, J Edison, L AF Tobin-D'Angelo, Melissa Martyn, Audrey Moore, Ashley Dishman, Hope Drenzek, Cherie Turner, Kim Hicks, Lauri Diaz, Maureen Petrone, Brianna Wolff, Bernard Benitez, Alvaro Winchell, Jonas Edison, Laura TI Mycoplasma pneumoniae Outbreak at a University - Georgia, 2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID REAL-TIME PCR; RESPIRATORY ILLNESS; STUDENTS C1 [Tobin-D'Angelo, Melissa; Martyn, Audrey; Moore, Ashley; Dishman, Hope; Drenzek, Cherie] CDC, Georgia Dept Publ Health, Atlanta, GA 30333 USA. [Turner, Kim] CDC, Fulton Cty Dept Hlth & Wellness, Atlanta, GA 30333 USA. [Hicks, Lauri; Diaz, Maureen; Petrone, Brianna; Wolff, Bernard; Benitez, Alvaro; Winchell, Jonas] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Edison, Laura] CDC, Atlanta, GA 30333 USA. RP Edison, L (reprint author), CDC, Atlanta, GA 30333 USA. EM laedison@dhr.state.ga.us NR 10 TC 9 Z9 9 U1 0 U2 3 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 2 PY 2013 VL 62 IS 30 BP 603 EP 606 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 194IR UT WOS:000322625700002 ER PT J AU Seither, R Shaw, L Knighton, CL Greby, SM Stokley, S AF Seither, Ranee Shaw, Lauren Knighton, Cynthia L. Greby, Stacie M. Stokley, Shannon TI Vaccination Coverage Among Children in Kindergarten - United States, 2012-13 School Year SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID NONMEDICAL EXEMPTIONS; IMMUNIZATION LAWS C1 [Seither, Ranee; Shaw, Lauren; Knighton, Cynthia L.; Greby, Stacie M.; Stokley, Shannon] CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Seither, R (reprint author), CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM rseither@cdc.gov NR 10 TC 20 Z9 20 U1 0 U2 2 PU CENTER DISEASE CONTROL & PREVENTION PI ATLANTA PA MAILSTOP E-90, ATLANTA, GA 30333 USA SN 0149-2195 J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD AUG 2 PY 2013 VL 62 IS 30 BP 607 EP 612 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 194IR UT WOS:000322625700003 ER PT J AU Flagg, EW Schwartz, R Weinstock, H AF Flagg, Elaine W. Schwartz, Robert Weinstock, Hillard TI Prevalence of Anogenital Warts Among Participants in Private Health Plans in the United States, 2003-2010: Potential Impact of Human Papillomavirus Vaccination SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID AGED 13-17 YEARS; SEXUAL MIXING PATTERNS; GENITAL WARTS; AMERICAN ADOLESCENTS; NATURAL-HISTORY; HPV VACCINATION; YOUNG-WOMEN; INFECTION; COVERAGE; SURVEILLANCE AB Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age group in a large US cohort with private insurance to detect potential decreases among people most likely to be affected by human papillomavirus (HPV) vaccination. Methods. We restricted health care claims to those from individuals aged 10 to 39 years with continuous insurance within a given year. We derived anogenital wart diagnoses from a diagnosis of condyloma acuminata, or either a less specific viral wart diagnosis or genital wart medication combined with either a benign anogenital neoplasm or destruction or excision of a noncervical anogenital lesion. Results. Prevalence increased slightly in 2003 to 2006, then significantly declined in 2007 to 2010 among girls aged 15 to 19 years; increased in 2003 to 2007, remained level through 2009, and declined in 2010 among women aged 20 to 24 years; and increased through 2009 but not in 2010 for women aged 25 to 39 years. For males aged 15 to 39 years, prevalence for each 5-year age group increased in 2003 to 2009, but no increases were observed for 2010. Conclusions. These data indicate reductions in anogenital warts among US females aged 15 to 24 years, the age group most likely to be affected by introduction of the HPV vaccine. C1 [Flagg, Elaine W.; Schwartz, Robert; Weinstock, Hillard] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Flagg, EW (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM eflagg@cdc.gov NR 51 TC 30 Z9 30 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2013 VL 103 IS 8 BP 1428 EP 1435 DI 10.2105/AJPH.2012.301182 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3MU UT WOS:000330997500032 PM 23763409 ER PT J AU Mahajan, R Liu, SJ Klevens, RM Holmberg, SD AF Mahajan, Reena Liu, Stephen J. Klevens, R. Monina Holmberg, Scott D. TI Indications for Testing Among Reported Cases of HCV Infection From Enhanced Hepatitis Surveillance Sites in the United States, 2004-2010 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID C VIRUS-INFECTION; RISK BEHAVIORS; DRUG-USERS; QUALITY; BURDEN; IDENTIFICATION; PREVALENCE; DISEASE AB Objectives. Centers for Disease Control and Prevention has recommended a 1-time HCV test for persons born from 1945 through 1965 to supplement current risk-based screening. We examined indications for testing by birth cohort (before 1945, 1945-1965, and after 1965) among persons with past or current HCV. Methods. Cases had positive HCV laboratory markers reported by 4 surveillance sites (Colorado, Connecticut, Minnesota, and New York) to health departments from 2004 to 2010. Health department staff abstracted demographics and indications for testing from cases' medical records and compiled this information into a surveillance database. Results. Of 110 223 cases of past or current HCV infection reported during 2004-2010, 74 578 (68%) were among persons born during 1945-1965. Testing indications were abstracted for 45 034 (41%) cases; of these, 29 544 (66%) identified at least 1 Centers for Disease Control and Prevention-recommended risk factor as a testing indication. Overall, 74% of reported cases were born from 1945 to 1965 or had an injection drug use history. Conclusions. These data support augmenting the current HCV risk-based screening recommendations by screening adults born from 1945 to 1965. C1 [Mahajan, Reena; Liu, Stephen J.; Klevens, R. Monina; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Mahajan, R (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM vif5@cdc.gov NR 36 TC 8 Z9 8 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2013 VL 103 IS 8 BP 1445 EP 1449 DI 10.2105/AJPH.2013.301211 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3MU UT WOS:000330997500034 PM 23763404 ER PT J AU Chiu, CH Schnall, AH Mertzlufft, CE Noe, RS Wolkin, AF Spears, J Casey-Lockyer, M Vagi, SJ AF Chiu, Cindy H. Schnall, Amy H. Mertzlufft, Caitlin E. Noe, Rebecca S. Wolkin, Amy F. Spears, Jeanne Casey-Lockyer, Mary Vagi, Sara J. TI Mortality From a Tornado Outbreak, Alabama, April 27, 2011 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; RISK-FACTORS; INJURIES; FATALITIES; DEATH AB Objectives. We describe the demographics of the decedents from the tornado outbreak in Alabama on April 27, 2011; examine the circumstances of death surrounding these fatalities; and identify measures to prevent future tornado-related fatalities. Methods. We collected information about the decedents from death certificates, disaster-related mortality surveillance, and interview data collected by American Red Cross volunteers from the decedent's families. We describe demographic characteristics, circumstances and causes of death, and sheltering behaviors before death. Results. Of the 247 fatalities, females and older adults were at highest risk for tornado-related deaths. Most deaths were directly related to the tornadoes, on scene, and trauma-related. The majority of the deceased were indoors in single-family homes. Word of mouth was the most common warning mechanism. Conclusions. This tornado event was the third deadliest in recent US history. Our findings support the need for local community shelters, enhanced messaging to inform the public of shelter locations, and encouragement of word-of-mouth warnings and personal and family preparedness planning, with a special focus on assisting vulnerable individuals in taking shelter. C1 [Chiu, Cindy H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Schnall, Amy H.; Noe, Rebecca S.; Wolkin, Amy F.; Vagi, Sara J.] Ctr Dis Control & Prevent, Hlth Studies Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Mertzlufft, Caitlin E.] Agcy Tox Subst & Dis Registry, Geospatial Res Anal & Serv Program, Atlanta, GA USA. [Spears, Jeanne; Casey-Lockyer, Mary] Amer Red Cross, Washington, DC 20006 USA. RP Chiu, CH (reprint author), Ctr Dis Control & Prevent, Hlth Studies Branch, Natl Ctr Environm Hlth, 4770 Buford Highway,Mailstop F-60, Atlanta, GA 30341 USA. EM cchiu@cdc.gov OI Chiu, Cindy H/0000-0003-2226-2776 NR 25 TC 4 Z9 4 U1 0 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD AUG PY 2013 VL 103 IS 8 BP E52 EP E58 DI 10.2105/AJPH.2013.301291 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA3MU UT WOS:000330997500015 PM 23763401 ER PT J AU Brown, DS Jia, HM Zack, MM Thompson, WW Haddix, AC Kaplan, RM AF Brown, Derek S. Jia, Haomiao Zack, Matthew M. Thompson, William W. Haddix, Anne C. Kaplan, Robert M. TI Using health-related quality of life and quality-adjusted life expectancy for effective public health surveillance and prevention SO EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH LA English DT Editorial Material DE chronic disease burden; life expectancy; prevention; quality of life; surveillance ID UNITED-STATES; SMOKING; SAMPLE C1 [Brown, Derek S.] Washington Univ, Inst Publ Hlth, St Louis, MO 63130 USA. [Jia, Haomiao] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10027 USA. [Jia, Haomiao] Columbia Univ, Sch Nursing, New York, NY 10027 USA. [Zack, Matthew M.; Thompson, William W.; Haddix, Anne C.] US Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Kaplan, Robert M.] NIH, Bethesda, MD USA. RP Brown, DS (reprint author), Washington Univ, Inst Publ Hlth, Campus Box 1196,One Brookings Dr, St Louis, MO 63130 USA. EM dereksbrown@wustl.edu RI Brown, Derek/J-3035-2013 OI Brown, Derek/0000-0001-9908-9882 NR 19 TC 7 Z9 7 U1 0 U2 2 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7167 EI 1744-8379 J9 EXPERT REV PHARM OUT JI Expert Rev. Pharmacoecon. Outcomes Res. PD AUG PY 2013 VL 13 IS 4 BP 425 EP 427 DI 10.1586/14737167.2013.818816 PG 3 WC Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA 301ME UT WOS:000330535600003 PM 23977969 ER PT J AU Santos, GM Coffin, PO Das, M Matheson, T DeMicco, E Raiford, JL Vittinghoff, E Dilley, JW Colfax, G Herbst, JH AF Santos, Glenn-Milo Coffin, Phillip O. Das, Moupali Matheson, Tim DeMicco, Erin Raiford, Jerris L. Vittinghoff, Eric Dilley, James W. Colfax, Grant Herbst, Jeffrey H. TI Dose-Response Associations Between Number and Frequency of Substance Use and High-Risk Sexual Behaviors Among HIV-Negative Substance-Using Men Who Have Sex With Men (SUMSM) in San Francisco SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; MSM; sexual risk behaviors; substance use; alcohol use; methamphetamine; cocaine; poppers ID DRUG-USE; BISEXUAL MEN; CLUB DRUGS; HEALTH; PREVENTION; INFECTION; ALCOHOL; LEVEL; GAY AB We evaluated the relationship between frequency and number of substances used and HIV risk [ie, serodiscordant unprotected anal intercourse (SDUAI)] among 3173 HIV-negative substance-using MSM. Compared with nonusers, the adjusted odds ratio (AOR) for SDUAI among episodic and at least weekly users, respectively, was 3.31 [95% confidence interval (CI), 2.55 to 4.28] and 5.46 (95% CI, 3.80 to 7.84) for methamphetamine, 1.86 (95% CI, 1.51 to 2.29) and 3.13 (95% CI, 2.12 to 4.63) for cocaine, and 2.08 (95% CI, 1.68 to 2.56) and 2.54 (95% CI, 1.85 to 3.48) for poppers. Heavy alcohol drinkers reported more SDUAI than moderate drinkers [AOR, 1.90 (95% CI, 1.43 to 2.51)]. Compared with nonusers, AORs for using 1, 2, and >= 3 substances were 16.81 (95% CI, 12.25 to 23.08), 27.31 (95% CI, 18.93 to 39.39), and 46.38 (95% CI, 30.65 to 70.19), respectively. High-risk sexual behaviors were strongly associated with frequency and number of substances used. C1 [Santos, Glenn-Milo; Coffin, Phillip O.; Das, Moupali; Matheson, Tim; DeMicco, Erin; Colfax, Grant] San Francisco Dept Publ Hlth, San Francisco, CA 94102 USA. [Santos, Glenn-Milo; Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Coffin, Phillip O.; Das, Moupali; Colfax, Grant] Univ Calif San Francisco, Div HIV AIDS, San Francisco, CA 94143 USA. [Dilley, James W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Raiford, Jerris L.; Herbst, Jeffrey H.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Santos, GM (reprint author), San Francisco Dept Publ Hlth, 25 Van Ness Ave,Suite 500, San Francisco, CA 94102 USA. EM glenn-milo.santos@sfdph.org OI Coffin, Phillip/0000-0002-3891-6570 FU Centers for Disease Control and Prevention [UR6PS000684] FX Supported by the Centers for Disease Control and Prevention, under cooperative agreement UR6PS000684 to Public Health Foundation Enterprises, City of Industry, CA. NR 24 TC 20 Z9 20 U1 3 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD AUG 1 PY 2013 VL 63 IS 4 BP 540 EP 544 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300FF UT WOS:000330449100021 PM 23572012 ER PT J AU Kirby, RS Marshall, J Tanner, JP Salemi, JL Feldkamp, ML Marengo, L Meyer, RE Druschel, CM Rickard, R Kucik, JE AF Kirby, Russell S. Marshall, Jennifer Tanner, Jean Paul Salemi, Jason L. Feldkamp, Marcia L. Marengo, Lisa Meyer, Robert E. Druschel, Charlotte M. Rickard, Russel Kucik, James E. CA Natl Birth Defects Prevention TI Prevalence and Correlates of Gastroschisis in 15 States, 1995 to 2005 SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID ABDOMINAL-WALL DEFECTS; BIRTH-DEFECTS; UNITED-STATES; RISK-FACTOR; OMPHALOCELE; EPIDEMIOLOGY; CLUSTER AB OBJECTIVE: To identify trends in the prevalence and epidemiologic correlates of gastroschisis using a large population-based sample with cases identified by the National Birth Defects Prevention Network over the course of an 11-year period. METHODS: This study examined 4,713 cases of gastroschisis occurring in 15 states during 1995-2005, using public use natality data sets for denominators. Multivariable Poisson regression was used to identify statistically significant risk factors, and Joinpoint regression analyses were conducted to assess temporal trends in gastroschisis prevalence by maternal age and race and ethnicity. RESULTS: Results show an increasing temporal trend for gastroschisis (from 2.32 per 10,000 to 4.42 per 10,000 live births). Increasing prevalence of gastroschisis has occurred primarily among younger mothers (11.45 per 10,000 live births among mothers younger than age 20 years compared with 5.35 per 10,000 among women aged 20 to 24 years). In the multivariable analysis, using non-Hispanic whites as the referent group, non-Hispanic black women had the lowest risk of having a gastroschisis-affected pregnancy (prevalence ratio 0.42, 95% confidence interval [CI] 0.37-0.48), followed by Hispanics (prevalence ratio 0.86, 95% CI 0.81-0.92). Gastroschisis prevalence did not differ by newborn sex. CONCLUSIONS: Our findings demonstrate that the prevalence of gastroschisis has been increasing since 1995 among 15 states in the United States, and that higher rates of gastroschisis are associated with non-Hispanic white maternal race and ethnicity, and maternal age younger than 25 years (particularly younger than 20 years of age). C1 Univ S Florida, Birth Defects Surveillance Program, Dept Community & Family Hlth, Tampa, FL 33612 USA. Univ S Florida, Dept Epidemiol & Biostat, Coll Publ Hlth, Tampa, FL 33612 USA. Univ Utah, Sch Med, Dept Pediat, Div Med Genet, Salt Lake City, UT USA. Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. North Carolina Div Publ Hlth, State Ctr Hlth Stat, North Carolina Birth Defects Monitoring Program, Raleigh, NC USA. New York State Dept Hlth, Troy, NY USA. Colorado Dept Publ Hlth & Environm, Denver, CO USA. Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA USA. RP Kirby, RS (reprint author), Univ S Florida, Birth Defects Surveillance Program, 13201 Bruce B Downs Blvd,MDC56, Tampa, FL 33612 USA. EM rkirby@health.usf.edu OI Salemi, Jason/0000-0002-0077-6023 FU Intramural CDC HHS [CC999999] NR 23 TC 41 Z9 43 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD AUG PY 2013 VL 122 IS 2 BP 275 EP 281 DI 10.1097/AOG.0b013e31829cbbb4 PN 1 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 301GL UT WOS:000330520700014 PM 23969795 ER PT J AU Moon, SS Tate, JE Ray, P Dennehy, PH Archary, D Coutsoudis, A Bland, R Newell, ML Glass, RI Parashar, U Jiang, BM AF Moon, Sung-Sil Tate, Jacqueline E. Ray, Pratima Dennehy, Penelope H. Archary, Derseree Coutsoudis, Anna Bland, Ruth Newell, Marie-Louise Glass, Roger I. Parashar, Umesh Jiang, Baoming TI Differential Profiles and Inhibitory Effect on Rotavirus Vaccines of Nonantibody Components in Breast Milk From Mothers in Developing and Developed Countries SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE rotavirus; breastmilk; lactoferrin; lactadherin; vaccine ID EFFICACY; INFANTS; IMMUNOGENICITY; SAFETY; INFECTION; CHILDREN; GASTROENTERITIS; METAANALYSIS; LACTOFERRIN; PROTECTION AB Background: Live oral rotavirus vaccines have been less immunogenic and efficacious for children of developing countries than for those in middle income and industrialized countries, and the basis for these differences is not fully understood. Recently, we demonstrated that breastmilk from mothers in India had significantly higher IgA and neutralizing activity against rotavirus that could reduce the effective titer of rotavirus vaccines reaching the gut when compared with that from mothers in the United States. We extended our study to understand the specific contribution of those nonantibody components in breastmilk to the neutralizing activity against rotavirus vaccine we observed. Methods: Breastmilk samples were collected from mothers of breast-feeding infants aged between 4 and 29 weeks (ie, vaccine eligible age) in India (N = 40), South Africa (N = 50) and the United States (N = 51). We examined breastmilk for lactoferrin, lactadherin, rotavirus-specific IgA and neutralizing activity against 3 rotavirus vaccine strains (Rotarix, RotaTeq G1 and 116E) using enzyme immunoassays, a plaque reduction assay or a microneutralization assay. Results: We observed higher levels of lactoferrin, lactadherin, IgA and neutralizing activity in breastmilk specimens from Indian and South African women than those from American women. We demonstrated positive associations between levels of lactoferrin or IgA and neutralizing activity in Indian and South African specimens, but not in American specimens. We demonstrated that the inhibitory effect of lactoferrin was dose- or species-dependent, as evidenced by greater reduction in titer of Rotarix and 116E by human lactoferrin. Lactadherin also exhibited inhibitory activity to rotavirus vaccines but appeared to be less effective. Conclusions: The lower immunogenicity and efficacy of rotavirus vaccines in developing countries could be explained, in part, by synergistic inhibitory effect of high levels of antibody and nonantibody components in breastmilk consumed by infants at the time of immunization. Therefore, there is a need for alternative rotavirus vaccine strategies in breast-feeding populations. C1 [Moon, Sung-Sil; Tate, Jacqueline E.; Parashar, Umesh; Jiang, Baoming] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Ray, Pratima] All India Inst Med Sci, Dept Pediat, Delhi, India. [Dennehy, Penelope H.] Rhode Isl Hosp, Dept Pediat, Providence, RI USA. [Archary, Derseree; Coutsoudis, Anna] Univ KwaZulu Natal, Dept Pediat & Child Hlth, Durban, South Africa. [Archary, Derseree] Univ KwaZulu Natal, Ctr AIDS Program Res South Africa, Durban, South Africa. [Bland, Ruth; Newell, Marie-Louise] Univ KwaZulu Natal, Africa Ctr Populat & Hlth Studies, Somkhele, South Africa. [Bland, Ruth] Univ Glasgow, Sch Med, Glasgow G12 8QQ, Lanark, Scotland. [Newell, Marie-Louise] UCL, Inst Child Hlth, London WC1E 6BT, England. [Glass, Roger I.] NIH, Fogarty Int Ctr, Rockville, MD USA. RP Jiang, BM (reprint author), Natl Ctr Immunizat & Resp Dis, Gastroenteritis & Resp Viruses Lab Branch, MS G04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM bxj4@cdc.gov OI Dennehy, Penelope/0000-0002-2259-5370; Ray, Pratima/0000-0002-2182-2279; Newell, Marie-Louise/0000-0002-1074-7699 FU Intramural CDC HHS [CC999999]; Wellcome Trust [097410] NR 31 TC 16 Z9 16 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD AUG PY 2013 VL 32 IS 8 BP 863 EP 870 DI 10.1097/INF.0b013e318290646d PG 8 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 301HT UT WOS:000330524100016 PM 23584581 ER PT J AU Lu, L Wang, CB Suo, LD Li, J Liu, WX Pang, XH Seward, JF AF Lu, Li Wang, Chengbin Suo, Luodan Li, Juan Liu, Weixiang Pang, Xinghuo Seward, Jane F. TI Varicella Disease in Beijing in the Era of Voluntary Vaccination, 2007 to 2010 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE chickenpox; varicella vaccine; outbreak ID ZOSTER-VIRUS-INFECTION; UNITED-STATES; IMPLEMENTATION; EPIDEMIOLOGY; PROGRAM; US AB Background: In China, varicella vaccine has been available in the private sector to children >= 12 months of age since 1998 with a single-dose indication. In December 2006, varicella became a notifiable disease in Beijing. We used surveillance data to describe varicella vaccine uptake from 2005 to 2010 and varicella epidemiology in Beijing from 2007 to 2010. Methods: Limited sociodemographic and clinical information was available from the passive surveillance system. Varicella vaccine coverage was estimated for each year for children born between 2004 and 2008 using the number of children in the immunization registry of each birth year as the denominator without adjustment for history of varicella. Results: Vaccine coverage increased within each birth cohort between 2005 and 2010. The coverage at 2 years of age increased from 62.4% in 2005 to 74.1% in 2010 and was 80.4% in children 3-6 years of age in 2010. Between 2007 and 2010, 15,544 to 18,256 varicella cases were reported annually with stable overall incidence (range: 1.0-1.1/1000 persons), but the incidence in children 1-4 years of age decreased significantly from 6.2 per 1000 children in 2007 to 4.4 per 1000 children in 2010 (P < 0.001). Among adults (>= 20 years of age), there were significant increases in the number and proportion of cases from 2557 (16.5%) in 2007 to 4277 (23.4%) in 2010 (P < 0.001). Conclusions: Moderately high 1-dose vaccine coverage in young children has been achieved with declining disease incidence, but varicella remains a common, seasonal disease in the population. Current epidemiology suggests that a government-funded varicella vaccine program that includes catch-up vaccination for older children, adolescents and adults needs consideration. C1 [Lu, Li; Suo, Luodan; Li, Juan; Liu, Weixiang; Pang, Xinghuo] Beijing Ctr Dis Control & Prevent, Beijing 100013, Peoples R China. [Wang, Chengbin; Seward, Jane F.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Wang, CB (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd MS A-34, Atlanta, GA 30333 USA. EM cwang1@cdc.gov; pxh17@sina.com FU Intramural CDC HHS [CC999999] NR 11 TC 5 Z9 5 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD AUG PY 2013 VL 32 IS 8 BP E314 EP E318 DI 10.1097/INF.0b013e31828d948b PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 301HT UT WOS:000330524100001 PM 23429564 ER PT J AU Le Moual, N Varraso, R Zock, JP Henneberger, P Speizer, FE Kauffmann, F Camargo, CA AF Le Moual, Nicole Varraso, Raphaelle Paul Zock, Jan Henneberger, Paul Speizer, Frank E. Kauffmann, Francine Camargo, Carlos A., Jr. TI Are Operating Room Nurses at Higher Risk of Severe Persistent Asthma? The Nurses' Health Study SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID IN-HOSPITAL WORKERS; OCCUPATIONAL EXPOSURES; GENERAL-POPULATION; CARE PROFESSIONALS; DISABILITY; COHORT; WOMEN; WORKFORCE; SYMPTOMS; OUTCOMES AB Objective: To assess the associations between operating room (OR) nursing, a category of health care workers at high risk of exposure to various inhaled agents, and asthma severity/control among women with asthma. Methods: The level of severity/control in nurses with prevalent doctor-diagnosed asthma in 1998/2000 was compared, using nominal logistic regression, in OR nursing (n = 69) and administrative nursing (n = 546) from the US Nurses' Health Study for whom detailed information on asthma and nursing employment status was available. Results: We observed a significant association between OR nursing, compared with administrative nursing, and severe persistent asthma (adjusted odds ratio, 2.48; 95% confidence interval, 1.06 to 5.77). Conclusions: Our findings suggest that nurses working in the OR are at a higher risk of severe persistent asthma. Further studies with detailed estimates of occupational exposures, especially to disinfectant/cleaning agents, are warranted. C1 [Le Moual, Nicole; Varraso, Raphaelle; Kauffmann, Francine] INSERM, Resp & Environm Epidemiol Team, Ctr Res Epidemiol & Populat Hlth, F-94807 Villejuif, France. [Le Moual, Nicole; Varraso, Raphaelle; Kauffmann, Francine] Univ Paris 11, Villejuif, France. [Paul Zock, Jan] Ctr Res Environm Epidemiol, Barcelona, Spain. [Paul Zock, Jan] Hosp del Mar, Res Inst, Barcelona, Spain. [Paul Zock, Jan] CIBER Epidemiol & Salud Publ, Barcelona, Spain. [Henneberger, Paul] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. [Speizer, Frank E.; Camargo, Carlos A., Jr.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. RP Le Moual, N (reprint author), INSERM, U1018, Ctr Res Epidemiol & Populat Hlth, Resp & Environm Epidemiol Team, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France. EM nicole.lemoual@inserm.fr RI Varraso, Raphaelle/R-8740-2016; LeMoual, Nicole/R-8976-2016 OI Varraso, Raphaelle/0000-0002-3338-7825; LeMoual, Nicole/0000-0002-2723-5569 FU National Institutes of Health (Bethesda, Maryland) [CA-87969, HL-63841, AI-52338] FX This study was funded by research grants CA-87969, HL-63841, and AI-52338 from the National Institutes of Health (Bethesda, Maryland). NR 32 TC 6 Z9 6 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD AUG PY 2013 VL 55 IS 8 BP 973 EP 977 DI 10.1097/JOM.0b013e318297325b PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 300EX UT WOS:000330448300019 PM 23887704 ER PT J AU Cramer, R Leichliter, JS Stenger, MR Loosier, PS Slive, L AF Cramer, Ryan Leichliter, Jami S. Stenger, Mark R. Loosier, Penny S. Slive, Lauren CA SSuN Working Grp TI The Legal Aspects of Expedited Partner Therapy Practice: Do State Laws and Policies Really Matter? SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID CONTROLLED-TRIAL; INFECTIONS; CHLAMYDIA; GONORRHEA; PROVIDERS AB Background: Expedited partner therapy (EPT) is a potential partner treatment strategy. Significant efforts have been devoted to policies intended to facilitate its practice. However, few studies have attempted to evaluate these policies. Methods: We used data on interviewed gonorrhea cases from 12 sites in the STD Surveillance Network in 2010 (n = 3404). Patients reported whether they had received EPT. We coded state laws relevant to EPT for gonorrhea using Westlaw legal research database and the general legal status of EPT in STD Surveillance Network sites from Centers for Disease Control and Prevention's Web site in 2010. We also coded policy statements by medical and other boards. We used chi(2) tests to compare receipt of EPT by legal/policy variables, patient characteristics, and provider type. Variables significant at P < 0.10 in bivariate analyses were included in a logistic regression model. Results: Overall, 9.5% of 2564 interviewed patients with gonorrhea reported receiving EPT for their partners. Receipt of EPT was significantly higher where laws and policies authorizing EPT existed. Where EPT laws for gonorrhea existed and EPT was permissible, 13.3% of patients reported receiving EPT as compared with 5.4% where there were no EPT laws and EPT was permissible, and 1.0% where there were no EPT laws and EPT was potentially allowable (P < 0.01). Expedited partner therapy was higher where professional boards had policy statements supporting EPT (P G 0.01). Receipt of EPT did not differ by most patient characteristics or provider type. Policy-related findings were similar in adjusted analyses. Conclusions: Expedited partner therapy laws and policies were associated with higher reports of receipt of EPT among interviewed gonorrhea cases. C1 [Cramer, Ryan; Leichliter, Jami S.; Stenger, Mark R.; Loosier, Penny S.; Slive, Lauren; SSuN Working Grp] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Cramer, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM rcramer@cdc.gov FU Centers for Disease Control and Prevention [PS08-865]; National Institutes of Health, National Institute of Allergy and Infectious Diseases [R01A068107] FX Supported by the Centers for Disease Control and Prevention (Cooperative Agreement No. PS08-865; data collection in Washington State also supported, in part, by National Institutes of Health, National Institute of Allergy and Infectious Diseases R01A068107). NR 16 TC 13 Z9 13 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2013 VL 40 IS 8 BP 657 EP 662 DI 10.1097/01.OLQ.0000431358.18959.d4 PG 6 WC Infectious Diseases SC Infectious Diseases GA 297FG UT WOS:000330240400016 PM 23859917 ER PT J AU Steiner, RJ Aquino, G Fenton, KA AF Steiner, Riley J. Aquino, Gustavo Fenton, Kevin A. TI Enhancing HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease, and Tuberculosis Prevention in the United States Through Program Collaboration and Service Integration: The Case for Broader Implementation SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID ONE-STOP SHOP; HEALTH-SERVICES; VIRUS-INFECTION; PUBLIC-HEALTH; SCALING-UP; HIV; COINFECTION; CARE; STD; PREVALENCE AB HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis in the United States remain major public health concerns. The current disease-specific prevention approach oftentimes has led to narrow success and missed opportunities for increasing program capacity, leveraging resources, addressing social and structural determinants, and accelerating health impact-suggesting a need for greater innovation to prevent related diseases. The National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention's Program Collaboration and Service Integration (PCSI) strategic priority aims to strengthen collaborative engagement across these disease areas and to integrate services at the client level. In this review, we articulate the 5 principles of PCSI-appropriateness, effectiveness, flexibility, accountability, and acceptability. Drawing upon these principles and published literature, we discuss the case for change that underlies PCSI, summarize advances in the field since 2007, and articulate key next steps. Although formal evaluation is needed to fully assess the health impact of PCSI, available evidence suggests that this approach is a promising tool to advance prevention goals. C1 [Steiner, Riley J.; Aquino, Gustavo; Fenton, Kevin A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Fenton, Kevin A.] Publ Hlth England, Hlth & Wellbeing Directorate, London, England. RP Fenton, KA (reprint author), 4th Floor,133-155 Wellington House,Waterloo Rd, London SE1 8UG, England. EM Kevin.Fenton@phe.gov.uk NR 46 TC 3 Z9 3 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2013 VL 40 IS 8 BP 663 EP 668 DI 10.1097/OLQ.0000000000000002 PG 6 WC Infectious Diseases SC Infectious Diseases GA 297FG UT WOS:000330240400017 PM 23859918 ER PT J AU Fenton, KA Steiner, RJ AF Fenton, Kevin A. Steiner, Riley J. TI Program Collaboration and Service Integration: Implementation Successes and Challenges SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material C1 [Fenton, Kevin A.] Publ Hlth England, Hlth & Wellbeing Directorate, London SE1 8UG, England. [Steiner, Riley J.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Fenton, KA (reprint author), Publ Hlth England, Wellington House,133-155Waterloo Rd, London SE1 8UG, England. EM Kevin.Fenton@phe.gov.uk NR 12 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD AUG PY 2013 VL 40 IS 8 BP 675 EP 677 DI 10.1097/OLQ.0000000000000003 PG 3 WC Infectious Diseases SC Infectious Diseases GA 297FG UT WOS:000330240400019 PM 23859919 ER PT J AU Minniear, TD McIntosh, EB Alexander, N Weidle, PJ Fulton, J AF Minniear, Timothy D. McIntosh, Emily B. Alexander, Nicole Weidle, Paul J. Fulton, John TI Using electronic surveys to gather information on physician practises during a response to a local epidemic-Rhode Island, 2011 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Physician's practice patterns; Survey methods; Data collection; Internet; Rhode Island ID MAIL SURVEYS; RATES AB Background: Electronic invitations may improve physician response rates to participate in internet surveys administered by public health agencies. Methods: Following an increase in reported HIV/syphilis co-infection diagnoses among men-who-have-sex-with-men in Rhode Island, we invited the state's 700 adult primary care and emergency medicine physicians via e-mail to participate in an online, multiple choice survey covering their knowledge, attitudes, and practices regarding sexually transmitted diseases and HIV testing and prevention. Survey invitations were released in three waves over 28 days, triggered by declining daily response rates. Results: Among 53% (n = 372) who agreed to participate, 68% (n = 252) completed all questions. Response was higher among internal medicine physicians than either family medicine or emergency medicine physicians (63% vs. 20% and 19%, respectively; P<0.0001). Daily response rates were highest in the first 48 hours after sending a reminder e-mail. Conclusion: This approach supported the Rhode Island Department of Health in rapidly gathering useful physician practice information during an outbreak. Internet-based survey tools coupled with increased prevalence of mobile communication devices and social media could greatly decrease the time and cost of shoe-leather epidemiology. (C) 2013 Elsevier Inc. All rights reserved. C1 [Minniear, Timothy D.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Minniear, Timothy D.; Weidle, Paul J.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [McIntosh, Emily B.] Emory Univ, Sch Med, Atlanta, GA USA. [Alexander, Nicole] Rhode Isl Dept Hlth, Off HIV AIDS & Viral Hepatitis, Providence, RI 02908 USA. [Fulton, John] Rhode Isl Dept Hlth, Div Dis Prevent & Control, Providence, RI 02908 USA. RP Minniear, TD (reprint author), 1600 Clifton Rd NE,MS E-45, Atlanta, GA 30333 USA. EM Timothy.Minniear@gmail.com NR 8 TC 2 Z9 2 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD AUG PY 2013 VL 23 IS 8 BP 521 EP 523 DI 10.1016/j.annepidem.2013.05.003 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 294AR UT WOS:000330015300010 PM 23830934 ER PT J AU Humiston, SG Serwint, JR Szilagyi, PG Vincelli, PA Dhepyasuwan, N Rand, CM Schaffer, SJ Blumkin, AK Curtis, CR AF Humiston, Sharon G. Serwint, Janet R. Szilagyi, Peter G. Vincelli, Phyllis A. Dhepyasuwan, Nui Rand, Cynthia M. Schaffer, Stanley J. Blumkin, Aaron K. Curtis, C. Robinette TI Increasing Adolescent Immunization Rates in Primary Care: Strategies Physicians Use and Would Consider Implementing SO CLINICAL PEDIATRICS LA English DT Article DE immunization; adolescent immunization; vaccination ID INFLUENZA VACCINATION; PREVENTIVE-SERVICES; HEALTH; REMINDER; DELIVERY; CHILDREN; CLINICS; TRIAL; COST; TOOL AB Strategies to increase adolescent immunization rates have been suggested, but little is documented about which strategies clinicians actually use or would consider. In spring 2010, we surveyed primary care physicians from 2 practice-based research networks (PBRNs): Greater Rochester PBRN (GR-PBRN) and national pediatric COntinuity Research NETwork (CORNET). Network clinicians received mailed or online surveys (response rate 76%, n = 148). The GR-PBRN patient population (51% suburban, 33% rural, and 16% urban) differed from that served by CORNET (85% urban). For nonseasonal vaccines recommended for adolescents, many GR-PBRN and CORNET practices reported using nurse prompts to providers at preventive visits (61% and 52%, respectively), physician education (53% and 53%), and scheduled vaccine-only visits (91% and 82%). Strategies not used that clinicians frequently indicated they would consider included patient reminder/recall and prompts to providers via nurses or electronic health records. As preventive visits and immunization recommendations grow more complex, using technology to support immunization delivery to adolescents might be effective. C1 [Humiston, Sharon G.] Childrens Mercy Hosp & Clin, Kansas City, MO 64108 USA. [Serwint, Janet R.] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA. [Serwint, Janet R.; Dhepyasuwan, Nui] Acad Pediat Assoc, Continu Res Network CORNET, Mclean, VA USA. [Szilagyi, Peter G.; Vincelli, Phyllis A.; Rand, Cynthia M.; Schaffer, Stanley J.; Blumkin, Aaron K.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Curtis, C. Robinette] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA. RP Humiston, SG (reprint author), Childrens Mercy Hosp & Clin, Div Emergency & Urgent Care, Dept Pediat, 2401 Gillham Rd, Kansas City, MO 64108 USA. EM sghumiston@cmh.edu OI Schaffer, Stanley/0000-0001-7993-1374 FU Centers for Disease Control and Prevention (CDC), National Center for Immunizations & Respiratory Diseases, Atlanta, GA [1U01P00012]; CTSI [UL RR024160] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Centers for Disease Control and Prevention (CDC), National Center for Immunizations & Respiratory Diseases, Atlanta, GA (Grant 1U01P00012), and the CTSI (Grant UL RR024160). NR 31 TC 6 Z9 7 U1 2 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 EI 1938-2707 J9 CLIN PEDIATR JI Clin. Pediatr. PD AUG PY 2013 VL 52 IS 8 BP 710 EP 720 DI 10.1177/0009922813483359 PG 11 WC Pediatrics SC Pediatrics GA 287WR UT WOS:000329573500004 PM 23580625 ER PT J AU Al-Nsour, M Zindah, M Belbeisi, A Rolle, IV Walke, H Strine, T Perry, GS Jarrar, B Mokdad, A AF Al-Nsour, Mohannad Zindah, Meyasser Belbeisi, Adel Rolle, Italia V. Walke, Henry Strine, Tara Perry, Geraldine S. Jarrar, Bassam Mokdad, Ali TI Frequent Mental Distress, Chronic Conditions, and Adverse Health Behaviors in the Behavioral Risk Factor Surveillance Survey, Jordan, 2007 SO PREVENTING CHRONIC DISEASE LA English DT Article ID QUALITY-OF-LIFE; HEART-DISEASE; ADULTS; DEPRESSION; ATTITUDES; OLDER AB Introduction Recent evidence indicates that chronic diseases and mental illness are associated. In the Middle Eastern country of Jordan, chronic diseases and frequent mental distress (FMD) are increasing; however, the capacity for mental health care is limited. The objective of this study was to determine the association between FMD, chronic conditions, and adverse health behaviors in Jordan. Methods The third cycle of the Jordan Behavioral Risk Factor Surveillance Survey (2007) served as the data source for this study. The sample consisted of 3,612 noninstitutionalized Jordanian adults aged 18 years or older. Logistic regression was used to obtain odds ratios for the association between chronic conditions, health behaviors, and FMD adjusted for age, sex, marital status, education, income, and employment. Results In the adjusted models, people with hypertension (adjusted odds ratio [AOR], 2.0; 95% confidence interval [CI], 1.6 2.7), high cholesterol (AOR, 2.3; 95% CI, 1.6-3.2), diabetes (AOR, 1.6; 95% CI, 1.1-2.4), and asthma (AOR, 2.2; 95% CI, 1.5-3.1) and smokers (AOR, 1.5; 95% CI, 1.1-2.0) were more likely to have FMD than people without each of these conditions. Adults who reported vigorous physical activity were less likely to have FMD (AOR, 0.6; 95% CI, 0.4-0.9) than their less active counterparts. Conclusions In Jordan, FMD was associated with several chronic conditions. As a result, we suggest additional research to examine the complex relationship between FMD and chronic conditions. More doctors in the primary health care system should be trained in mental health. C1 [Al-Nsour, Mohannad] Eastern Mediterranean Publ Hlth Network, Amman, Jordan. [Zindah, Meyasser; Belbeisi, Adel] Jordan Minist Hlth, Amman, Jordan. [Rolle, Italia V.; Walke, Henry; Strine, Tara; Perry, Geraldine S.; Jarrar, Bassam] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mokdad, Ali] Univ Washington, Seattle, WA 98195 USA. RP Al-Nsour, M (reprint author), Eastern Mediterranean Publ Hlth Network, Amman, Jordan. EM mohannadnsour973@yahoo.com NR 30 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2013 VL 10 AR UNSP 130030 DI 10.5888/pcd10.130030 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KJ UT WOS:000329392600014 ER PT J AU Anderson, LA Edwards, VJ Pearson, WS Talley, RC McGuire, LC Andresen, EM AF Anderson, Lynda A. Edwards, Valerie J. Pearson, William S. Talley, Ronda C. McGuire, Lisa C. Andresen, Elena M. TI Adult Caregivers in the United States: Characteristics and Differences in Well-being, by Caregiver Age and Caregiving Status SO PREVENTING CHRONIC DISEASE LA English DT Article ID FACTOR SURVEILLANCE SYSTEM; HEALTH AB We examined the characteristics of adults providing regular care or assistance to friends or family members who have health problems, long-term illnesses, or disabilities (ie, caregivers). We used data from the 2009 Behavioral Risk Factor Surveillance System (BRFSS) to examine caregiver characteristics, by age and caregiving status, and compare these characteristics with those of noncaregivers. Approximately 24.7% (95% confidence interval, 24.4%-25.0%) of respondents were caregivers. Compared with younger caregivers, older caregivers reported more fair or poor health and physical distress but more satisfaction with life and lower mental distress. Understanding the characteristics of caregivers can help enhance strategies that support their role in providing long-term care. C1 [Anderson, Lynda A.] Div Populat Hlth, Hlth Aging Program, Atlanta, GA 30341 USA. [Edwards, Valerie J.; Pearson, William S.; McGuire, Lisa C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Talley, Ronda C.] Western Kentucky Univ, Bowling Green, KY 42101 USA. [Andresen, Elena M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Anderson, LA (reprint author), Div Populat Hlth, Hlth Aging Program, Mailstop F78,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM laao@cdc.gov FU Centers for Disease Control and Prevention's Division of Population Health FX This work was supported with funds provided by the Centers for Disease Control and Prevention's Division of Population Health. NR 12 TC 3 Z9 3 U1 3 U2 16 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2013 VL 10 AR UNSP 130090 DI 10.5888/pcd10.130090 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KJ UT WOS:000329392600009 ER PT J AU May, AL Kim, SA Sherry, B Blanck, HM AF May, Ashleigh L. Kim, Sonia A. Sherry, Bettylou Blanck, Heidi M. TI Childhood Obesity Task Forces Established by State Legislatures, 2001-2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID UNITED-STATES; PHYSICAL-ACTIVITY; POLICY; CHILDREN; ADOLESCENTS; PREVALENCE; BEVERAGES; FOODS; RISK AB Introduction States and communities are considering policy and environmental strategies, including enacting legislation, to reduce and prevent childhood obesity. One legislative approach has been to create task forces to understand key issues and develop a course of action. The goal of this study was to describe state-level, childhood obesity task forces in the United States created by legislation from 2001 through 2010. Methods We used the Center for Disease Control and Prevention's Division of Nutrition, Physical Activity, and Obesity database to identify state-level childhood obesity task forces created through legislation from 2001 through 2010. Results We identified 21 states that had enacted legislation creating childhood obesity task forces of which 6 had created more than one task force. Most task forces were charged with both gathering and reviewing information and making recommendations for obesity-prevention actions in the state. Most legislation required that task forces include representation from the state legislature, state agencies, community organizations, and community members. Conclusion Evaluation of the effectiveness of obesity-prevention task forces and the primary components that contribute to their success may help to determine the advantages of the use of such strategies in obesity prevention. C1 [May, Ashleigh L.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Kim, Sonia A.; Sherry, Bettylou; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP May, AL (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,Mail Stop F-77, Atlanta, GA 30341 USA. EM amay@cdc.gov NR 34 TC 1 Z9 1 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2013 VL 10 AR UNSP 120153 DI 10.5888/pcd10.120153 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KJ UT WOS:000329392600018 ER PT J AU Neri, A Stewart, SL Angell, W AF Neri, Antonio Stewart, Sherri L. Angell, William TI Radon Control Activities for Lung Cancer Prevention in National Comprehensive Cancer Control Program Plans, 2005-2011 SO PREVENTING CHRONIC DISEASE LA English DT Article ID RESIDENTIAL RADON; UNITED-STATES; RISK-FACTORS; WEATHERIZATION; INTERVENTIONS AB Introduction Radon is the second leading cause of lung cancer among smokers and the leading cause among nonsmokers. The US Environmental Protection Agency recommends that every home be tested for radon. Comprehensive Cancer Control (CCC) programs develop cancer coalitions that coordinate funding and resources to focus on cancer activities that are recorded in cancer plans. Radon tests, remediation, and radon mitigation techniques are relatively inexpensive, but it is unclear whether coalitions recognize radon as an important carcinogen. Methods We reviewed 65 cancer plans created from 2005 through 2011 for the terms "radon," "radiation," or "lung." Plan activities were categorized as radon awareness, home testing, remediation, supporting radon policy activities, or policy evaluation. We also reviewed each CCC program's most recent progress report. Cancer plan content was reviewed to assess alignment with existing radon-specific policies in each state. Results Twenty-seven of the plans reviewed (42%) had radon-specific terminology. Improving awareness of radon was included in all 27 plans; also included were home testing (n = 21), remediation (n = 11) support radon policy activities (n = 13), and policy evaluation (n = 1). Three plans noted current engagement in radon activities. Thirty states had radon-specific laws; most (n = 21) were related to radon professional licensure. Eleven states had cancer plan activities that aligned with existing state radon laws. Conclusion Although several states have radon-specific policies, approximately half of cancer coalitions may not be aware of radon as a public health issue. CCC-developed cancer coalitions and plans should prioritize tobacco control to address lung cancer but should consider addressing radon through partnership with existing radon control programs. C1 [Neri, Antonio] Ctr Dis Control & Prevent, Comprehens Canc Control Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Publ Hlth Promot, Atlanta, GA 30341 USA. [Stewart, Sherri L.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Angell, William] Univ Minnesota, St Paul, MN 55108 USA. RP Neri, A (reprint author), Ctr Dis Control & Prevent, Comprehens Canc Control Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Publ Hlth Promot, 4770 Buford Hwy,MS K-57, Atlanta, GA 30341 USA. EM ANeri@cdc.gov NR 28 TC 7 Z9 7 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2013 VL 10 AR UNSP 120337 DI 10.5888/pcd10.120337 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KJ UT WOS:000329392600006 ER PT J AU Payne, GH Wethington, H Olsho, L Jernigan, J Farris, R Walker, DK AF Payne, Gayle Holmes Wethington, Holly Olsho, Lauren Jernigan, Jan Farris, Rosanne Walker, Deborah Klein TI Implementing a Farmers' Market Incentive Program: Perspectives on the New York City Health Bucks Program SO PREVENTING CHRONIC DISEASE LA English DT Article ID UNITED-STATES; FRUIT; INTERVENTION; OBESITY; VEGETABLES; WOMEN; RISK; FAT AB Introduction One strategy for lowering the prevalence of obesity is to increase access to and affordability of fruits and vegetables through farmers' markets. However, little has been documented in the literature on the implementation of such efforts. To address this gap, the Division of Nutrition, Physical Activity, and Obesity (DNPAO) sponsored an evaluation of the New York City Health Bucks program, a farmers' market coupon incentive program intended to increase access to fresh fruits and vegetables in underserved neighborhoods while supporting local farmers. Methods We conducted a process evaluation of Health Bucks program implementation. We interviewed 6 farmer/vendors, 3 market managers, and 4 program administrators, and collected data on site at 86 farmers' markets, including surveys of 81 managers and 141 farmer/vendors on their perspectives on promotion and redemption of the incentive coupons; knowledge and attitudes regarding the program; experiences with markets and products; and facilitators and barriers to program participation. Results Results indicate that respondents view Health Bucks as a positive program model. Farmers' market incentive coupon programs like Health Bucks are one strategy to address the problem of obesity and were associated with higher fruit and vegetable access and purchases in low-income communities. Conclusions This evaluation identified some areas for improving implementation of the Health Bucks program. Farmers' market incentive programs like Health Bucks may be one avenue to increase access to and affordability of fruits and vegetables among low-income persons. Further research is needed to assess the potential effects of these programs on access and health outcomes. C1 [Payne, Gayle Holmes; Wethington, Holly; Jernigan, Jan; Farris, Rosanne] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Wethington, Holly; Jernigan, Jan; Farris, Rosanne] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Olsho, Lauren; Walker, Deborah Klein] ABT Associates Inc, US Hlth Div, Cambridge, MA 02138 USA. RP Payne, GH (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F-77, Atlanta, GA 30341 USA. EM gpayne@cdc.gov NR 21 TC 6 Z9 6 U1 1 U2 17 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD AUG PY 2013 VL 10 AR UNSP 120285 DI 10.5888/pcd10.120285 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 285KJ UT WOS:000329392600019 PM 23987251 ER EF